<SEC-DOCUMENT>0000310158-20-000030.txt : 20201105
<SEC-HEADER>0000310158-20-000030.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105165558
ACCESSION NUMBER:		0000310158-20-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		201291337

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrk-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08,d:67ef4e29db364327800e42a94e43496a--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:mrk="http://www.merck.com/20200930" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM18zLTEtMS0xLTA_1db248f9-9364-4139-8ee7-d782b8b95bf2">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM180LTEtMS0xLTA_d28f6272-adc1-42dd-975a-e641db8399ec">2020</ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM181LTEtMS0xLTA_27361bd4-d0c7-4d97-9006-d9463f61c762">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM182LTEtMS0xLTA_669c10a8-98b1-482d-9759-f76a0bfb8a6a">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM183LTEtMS0xLTA_44c11b16-8771-44f8-a45d-e1a6d647b1e4">12/31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50285e1c6dd24576944ec0497f734115_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.125Notesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268c7fc26945402f9b563336318cd610_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if2b50aa67803469bbee45c3c944121ea_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1cde861334fc459fa80a684680fc7c3f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953cc45283754d089c0fca74403dda73_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0969664a04674af0b31c49bed8cbef6b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia308feb215e043c1ac8a269b649d7e2c_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia583d33831214bf4866a5542b0ff6a64_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320a221119db4c07bc18a27ee248eb45_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49be4558c154020a76d8aa7b2e8040b_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fca4df4602b4b828121637976fc9b3f_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ae7c8f36d1429f92d0302a0bd467cc_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f0266f7336448ca453ec3742701279_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i414ba63dcbe44cb0aabfd3725361a92d_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6780cf4bc91a4f248379b2621aca7281_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735e835c710c461daa6baff4b2c9daa6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0898439e84514304bb0e2daef6e908ba_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d789d97e6442d686b9da78d5403190_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4f7a3740f64b7abcdfd5b44d05ccef_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414e40bb67fd4c20b343d703df377db1_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43ede995e004eca8e478b1619a43970_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31320a95b2645eeaad75930b67cd813_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2237c4c6b34455a09bda4fbaa26b43_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c438f84c119401f80abdd10e94d725d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e81ff682db48488ca54b8292137c0f_D20200116-20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-16</xbrli:startDate><xbrli:endDate>2020-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17fd71a693f4aabb61654a6f056a503_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a7e2f30fbf4abfa7df8669c678d554_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9187aade515d4b17a57839461a710a17_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae34a9825984630b66dd918d954fcfc_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0baac3ebe43444669dc909ad981c9377_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5659ac2efe6a47eebd65404c8699603d_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84fda59fee3946e2ab4d84541f28495e_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea36cb2c86ec4304acd066b3b746ee37_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6ddf69451d477ab002e15190237eae_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaca125e93e984f7b91c7a53947611a63_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9c5cc14b4a4bd59f6fd4bca8f78bcb_D20190401-20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AntelliqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd675ee00e0c4fdda383d5adb62f0478_I20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074bf99e14004c60960bce1f01d121b3_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic574c26e06ba4bc7a5089ddc4873458d_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8dd786e26d1477aa8bd45ad2b6f3c5e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b4efb9755a49cfbb3e9ad58fc1264f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0cbbe2696d440b882b0f472d8d42ccd_D20170801-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b53eb43aee4f21bc681f524ea62b7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b40407b64e47609c2aa82a3959404e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65572a08fd174295982fa8fbf05e5d45_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4fc5d236d7843638ab3281a103c93b7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee9da70429aa4ac0ba5c6fc6bbe4b20c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a12f6da7654fefa46f0e8502eba97b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4306e1310aea4c4e8219428ac7a74614_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a49639fd9e44fc80d9d728cf4248ad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af7869909e242429c04502cbac1701d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89e4869799c4eddbb76087e4856f6e1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffbf0955eb8b4c4d98918582883b0e4a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d48c63441f485a81bc70510125df4a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc67ca1d79b4a9d9c65fbadafe2ed03_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8682bf21cbf4722b662136970328362_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8418200bd3474a8989d1feeaac0927f6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8baff54113d34962926404de668611aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b54f758421c483abea6109fc48d1294_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672e14c8326e49119792c5a739d15560_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff28471372f43c4aeca73d2b047bf8a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e7fffaaeaa473495ffacd2ac50867f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id915e0532c914695b005384447c665a1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a1dd31df764266bc67364b6f1a7916_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3121da41fc0647a98833a789f5fdd4ec_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6fe6accc36045aca588c404c0b2cd07_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40f44394c1e4c1bac21ea2a06244edd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d8f3b8efe9043f9aacc552835d92b46_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea90d2039c7141dca1496ccaa589ecc1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203c7a3ab0ea46d4a6dc810ea5880354_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i452c7b783504434287bc42a63fca472f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4812ae09bfa4ee1a36daa5fabe59052_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97f1dbf8ba2e4ace97a8ff751592fe5d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc77ff7d3d2418fa16f24a6c043ef75_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09080dd93c834c57b9ebff1a5663ec83_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09aa6a0b51c94fd996e7402de95de2be_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30c830280f947a689d5b271c94dc69a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a278d539314213bd6e5766dd997779_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355c8a370ea34624aebfc74a71246fae_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef5983f652b4f678745213cc80d39a2_D20180301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70a1af19330475d88753e88f14c38c2_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da39f245c784880b54370510f8d89b1_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba8f4a74d444bcd8400c0863cd3c92b_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f4566b3c6f4506b767bc5d2b892db8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f82b5879934498baf8420915f61a2a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3fbe331c8084a23bccb932806d23825_D20180401-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5002ac2a1b5410cb178591c19cc6f15_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245fd78ff94042f9bc0ed66ef072aafd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d59f0ea051148e99f9ddbfbb6a91314_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f502109a8d408591929847e1ec04c1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08506df034040a0a6bc566e66e0b025_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ff8630eade846b29dfa54f515c419a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ce8a9c45264255b55253efdffbee5a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd5ed28ae9c4290ae150fb16d9466fd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05babc5db48d458d8839840a56d0a9c1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d38eaf8021744fe8f4dfab94a5015fa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie29d30b68df740dfbc20eaab83dc5e38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7336913b5b4a20a439157fdc51f46f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc67bccad40d470c9949756b7eb748bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb427d5a13434a21a6ed491a4dd0e763_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9bee3c7f7024b5281e40456c78625e3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ff54672a98446994645788d1f59463_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida9b2e380dc5459f818bd1f423bdd1c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ab39e6826f45b7a3da069eaebd2a39_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734edac95cf34e8d8c5aa9e71b9f85ea_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f3d3057a1b74664bfffcee79d494ca8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f27f8096b5447d8aa97005ecfa5902_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3debc0d591324b7ea043d28f9093108a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3240881da60142e5953a1ec3857fb0d4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia949281fca194d51bc2b1de185ec698d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4715d086fff4408be90ea9d32249068_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ce31a9d972414f87e8b9b510ffd15f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f3cda8bb28a46d5bcadf58cfcbba40b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9bdb7de8f0e4a9593cf268c8664a7ab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idedcac7eb55940d8bf55d7f495fee349_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b439500c8b4e4db9be5c2fef7ba050_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c3eb857ced458dafba143b0afe517e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496aa343ecfe4651b28bd840131d00b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c74758a3e84c32b5a4934acd2a2e76_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3150bde02fd14893b33da1eeac0249de_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8461e98ecef64dbebc07597db5b84152_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id073b72dfd8d4b199dcc27df47315e69_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a955d765ba34e32bc493ef244feee8f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1082a8df5454aa3ad070d4a15057c2b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e2f7775e904a7b98b34ad10b77040a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991fd53b18024cf78c8d36aca923947e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ea86431ecd4511a44c25d8a18f135f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfdc92bf6c724ec79c32415e7d58a9c8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b86f1b1c991406c8b65e857fd90f944_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaef7e6bfd9d488cb6176aec4c7b915e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia602b90ebc2445e0b159157c4045d0a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416b15a8a7a9405fa9afdca4905b3480_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2305d63e914c5a801615d0a836fd82_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e55f5c070a64f55b6535d792904a04d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03df5735331c425896e06f66d7b5f298_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5366f568814c48f7b7b07bc4f56ba7d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e35b84854a44c8979089fcdc6b2904_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ef15a431a448c983ceb5183ff67376_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf78bc89101f49d49da83f8937116a1c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4a5bb3156148598a1e1f9ae18ef04f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe562f89249d4b43afbae31ab4ce846c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e10375bb6d64e70929401d584732bef_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fecd12fd431414ab4ca6f2ad011b352_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690cdcbbd385411cbf1ba1c4cd5fdb4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb0c8a5aab924e72ab1c5b49254dc12d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed7648249e34fcc824408b9de77708f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib983a94ca97d45f787f3cb16f067a659_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195c75449a61434aa05bc8da3256a067_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08999a59917842e88f521971cba054c2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bebe903b23d4dcbba8ed1365bd1e791_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3ad757a3474d31b0358ffd8bcf1d49_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9d1ae3982047b5add76445bf5210fc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia027800bf45f44df94cb3963582a6506_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070cc173e6a448f3a98d517737a45927_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55afe91875264dccbe9dfa4dc20872fa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae06c8a7ac2342d19a9a90933b904d07_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib375dc6a1ba24c1881cabe25f15d7706_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d0d80e338f41339faf6f80cc02c591_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i991711e49c2d4dd69b0c61a892af6fbe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8018c802ee402783f4d35dc51c8a4b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17880d14005f4047b6465ac23055841e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b8c757f331f461eab0d5987f837a626_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900f54b60fd94491a712d08a359324a3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e78a92e49843fbb9317beadc1eba25_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5d2c7cc4af4df5910fd6327736a5b6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e8aaa546894b88aacd797ac4581098_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82edc63f8c3749d78bc298cec6f0f96d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f385b2ccdba4576aedf43c72125dbbf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ee7a7c59a64fea97d7f02763d319bc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6098e7148348ea895e9410942d889e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11d46afe5bb4d4dbe9c00eaac1c3492_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472cfcc469764447a0758f2c876c9790_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3c8924793a4372a8741bdcfca35bf5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id249057c9eac47108ca7d3ebbb591f6f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae315aed51b4ef5ab252fc43e7d39c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad00d781aca4014ad7705b32c5aab4c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eda964c1d12432095177f2a403fe8bd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2cc47f55874d4da7e7cb748a8de516_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5ff6ca1aa444b5b1aca886da4f6507_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88c550ca65b41a2a95b1c07df1dfee2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5f714e7bf04709ab68bb6d0c04368c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57b2c9576daf42aaa97debb74c377ea1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4115454e07d24a8e9ac482d5f838c14d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5971c370c69444c08c083e89b5e5cd63_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46aa77d775fd4917ac86fb7ae4074f65_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf0c00a539540ffb0ff76746fc77f47_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461e55ad36644dcd801b1bc34ca7c5f5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i527fd9fd337149e19c3b0dcd8fab028a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9575da987aca4e06b7d8e7d64abdb71f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403aaeb86ea846378114a6861f297986_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6a58d8069f4937a5073e16850b6b61_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f29939fb6a4adc8144a86a1f1fa0a4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925511a1d07c420bb943ffad4efc7f06_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a15758d4a2849bb9a55611f14fff157_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ce36018a4a4b87beac4699cee74ff0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54180e23c792425c947ae0b2a21aed19_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23df0efd04e04b098e88861100d3586f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa78a4b6d7eb4b8cb4b91c89c4da9930_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37617f3467a144fb952951327ab34f7e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1dbaeb50ad4a1eac4d94e2a65c9d04_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839190f80323464f9bf5f1c57c708e99_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0622c35f09b249ecb7e04d44c43f9a29_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39f12905a33428bb5c546d1a6abec0d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie882429bc0d748c8a0b03fb32a34139c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a1493f82274c09859007cd79eacd11_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600eb20f2b2d4307b840f143cdefa814_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09cb0595ddce45a290d0d525d2a81f01_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0a355198574cf8a0944647df846e14_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i051031ffd19a4ba6b66f4482f9b16121_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cbdc10b57a2408d87748c99f6cc8658_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a928a5e815d4cabb958c8a84b7958ae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c0393b19a348d7aa690741b65c628e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309613a945a243f8881020b1a11c44c6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia319b8cd1cf240fc8cf6a6cf572ed109_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082ff741b7854aa59ffd11f6af0439fa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cffc90ec6148909d3599ea1d9df327_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b807ee322bd4ee9958bad75b8677e25_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa29d8b186047fc9548a924b7455a42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice720ee19510470cb2be22bfa752c7b3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8d2767b71a8465d8afd845a2deff157_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bafb9af91b4c66810b2658a0fb8100_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief51f272bb714d06bb4d146033290b24_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9862822be464d7590cac38e8a733045_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie877415544764c93a0e92480717fd720_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ac34bac82349ec87abc769df473091_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102e8398b68443efb7c670be371e221d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f7ee9e6e6f4549b1c06a6e2ee15ae2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="ie8db34a980b2470aaaff3a2d9dc09883_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174087d9f6454aebb32d8415fd4b71d8_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.85NotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd638b943ba14bbaa99c094906c46496_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia515ed5a6863469596b5d8b9a986ea6f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib089735791f34e7e946205004d6a744f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd8cd4de38943e2b14074d9417f6715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef73b3681a741db8a0d3055eb532b01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78266c2751d45698fdfe199e03b129d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1023089c2c54a80a18259c1511f87c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa826dff4de743c7acb6d521bd66ea9f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ec13cee627454ebf66f0d6ed39894a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21967f622cdb45cebad35ad052ece1de_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b48c75e8014c2382f84a5d33f0efe2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d507c1385a4984b104b15b14ad0b87_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebb8d0e743c4bc3aef276f00d195299_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d19d97eade44b698ef4d90c18cfb52_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb0bacacaba494588fdc16bec7aad2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a28e0e89eaa4a0381eb181749135076_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b722555bf44b6282741eb433c205bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4627226ed34963af481b31b209e7d1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c1b766e702403daadda490393c9ef9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4207f99483f4b8f940795c3f462096f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77b4c081c7234c27a717225ff5066862_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009ad414b39545bcb9714e42490d7cfe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f62a4056afb402185c1fd095207abdb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b237fa0466c445994cb3f605edb9744_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0afe3813f94b848a3beb92819435d7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7c81a6717548f3a8cb066f1d5113f1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ba62239ca44acebbb3f35490c6701e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3ca1373fb24ba68251d0301a10a20d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ea9d32cf204b73801d5f9d1325e43e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5e4820eed4496988270e13e3b094d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib552830a5da14067a97f6a37503c4784_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7e123c95db456a843cb9b4ea2ee304_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6199f48889a49748506a4b635c3bb86_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae423a542494b8d9adff25f3bf634fd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c5e6efb1434480a3a0aac64deb74fc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd5010fab09451c946ea37d93a410e6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e626082878b47229b64aad4223936be_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84727b70c6dd4761b253ea527ddd0887_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812ca05ea4394a4dac627795b29c49aa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e39e07079d24f1d97851dd0941257a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0874acdea1b94c23a104b3d79fa7bc54_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i924cd3c5889b4fa5a227f02451269580_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5f04d36a4044a793fc61d278bd3322_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46bd265492f54f4c8caf95f9c471e390_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6804bab188cb4e53b4fdd152aab4cfbf_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9334afd80f1c4e62b06c088ba45904e4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bcef7dcc6d49e88feb6e96d724788d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfcc3a06092c43dba855fc359441f405_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca8bb4bb8164a2a8869dee454cc4519_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49af6e85df0d44aab61037549d8b7ec7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85db4eee737467d84fa784c0406b915_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f31c0e3c79745898f6a563992c13494_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c141fe83ea54eb294e21e30b6d5921d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f79830cca114e6ba2294c2eb4be7851_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36602f32e5a74d8a81439836a90cda02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed394545474492aa72d62f2775bca14_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b74dc13822409f9caf279f6c6efb79_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0910059a35fa4db3a4f1688038846dcd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bcc86aa77164a2c9e420f79d5512eab_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460148134f8548f3b116acd07b6f4262_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c548bb51d534758a5b6a6644bb57312_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f28d45aab574360b168ce04f39ca7e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffe4cec0a0a437daa7a6c75edf5f759_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ab343a960448718c962d4ff1664ca7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50cee26c0cb24582a4fa7a23dab93ff8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b962ca0878246aea2caaba1e5068597_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12865349bba54bec9a0bc339687682cd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9c2404403b4dd19bf073d3fc40b18e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084046817ad547f0bf33554533117419_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3126ac40e55147ecad0cf2d7e7171a71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie381b020bc2d4cf48eefd6af3e63740a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edd3a5e5dbd40979d86029cf03f258d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id993747e094b4fd79654920246348cca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99eaa11a9d134c84aa9cfca643e17d0b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4c8e65bbc04387a96c107b13853bc9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809e8cb34704419bbc81bc11c64fce2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfd28bc6e0f42aaa81be96e54b6f594_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia932f1a4fb0744bc9993e55668e12ee7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21417c5ce10444faed848f53271d30e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f12d40a4894778869023a3c016eeb5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7a998c6b5342efb1a584d95ce95eda_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084814a830464e63ba5b40197d05e746_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a334d2c7f7f4c7ba7103637d1ec075c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8349cad8fb23464c808e9dda6e139864_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6faceee075314917b67b95d162851967_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1addd4cf0a714a1bb6df0443bd656292_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ab410ffa984d74b8491ca6135d2f49_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4220ee3541742be9a6a5b1189b6144f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4608091360a94197892bd6a3625a1eaf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i295721b3731942a08da7676215878345_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id54942bdb7d14f95b3cee4e66d8055b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1949445e84e744f29823c34223e1e913_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7932b106c7448daa2a3a55d1da0adfd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729ae19583c44de3bea4894565e3326e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b2c6ae9105493882fd7968a705b503_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3a6c594db44074808bec17ed6ec8b9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd21a1a7d51489a86f20b38a1d20755_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2583cf01e284ddcb2320ca55728a506_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7816629b0334d2aa6b53dc07c4e8faf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc955b1af87545599fdfcd8990fdedbd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia58a28f0d346460685afcc652227a9c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a1cbc1130ff48c682a122fa35090632_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9929f95c47e484fa82d3e06b0f0c945_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349b9790bbe54e36b0de77f50529bd5b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9014bc2ec9f4abeafcff803b0a03584_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ad7583f26b437581d137910e409b27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727ab934d22c4cfcbcec767507b45eeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1755cafcd4254c2e8aeb93f416956e53_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e30aabe97d4272be3e7e97eeff7de4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i827bb071fabb4cd1816ed87eba65624d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f5a8e02f1b1415090e676b983a40e37_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534176133b5e46268b75e8ee4783ef0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2257904af3c45abbfbf463b398101d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675ac0a159cc4cc691060e09552724bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdd387cfc074b9f95912bc5b38d09b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f98a00d9cb1469381ff2b85052e050d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id735af80d7e943a7b6cbff2ff9825cca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554c0786877949ee8178f77e6daab0f3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie26963a2ac324ba4a14e6c9468186690_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2c0faf9f814cdca31718d64e210291_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9553bd5ca6744da1b5727a32a9c9263b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8904871bd9ff4926abbade9d25474108_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5cb5301d76a4873b15a1335479d3c2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e635dc42c1b49bb99f084c0f6584807_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91862fa2efc447e29c59e61b626857ed_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81090f7e16204c969f9a89fd1d33cc95_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5599e985c1df48b8af48f1564e7b9e6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df4c3c188454c12a12d6adf310f9ac9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie262f30b95734e43832d8a9407f94eb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f22f3a8e434723aa4c8e677adcb774_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82319f76c8e24d55ad16cfbcb26dd55b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1b391a9730b4cf68a103be0f154b323_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ed48ae16f7483ab2c12115e9b3b1f8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic318e672eaab447c8135df89f679f16b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26fad08fdba44d0b82362dc57e0d7f8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6898b1302e46f2b14f135b0cf9ad8f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7943709a46a24d76a5bb3f5bcdd1ef43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc02a58f23874914ab829313aab4a522_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77b04eea3e5b4a1b849d4967371f9b86_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7573baa67fd4165af6f52acfff81eb1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e96a20a877543ee9ce8338ad2ef622f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cb59c697544159a4a94b077d73ed46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb4503c9509423bbee8e6c29bd5e78e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf8d0cc1ac8422fb6018bd01c7ffaa6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f17a0fdf894d27bdd29405d396934e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe06cede262f48698bafa7ad43037553_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1a6f29c939482d8e9f901e3e75b9db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20dc5a545bbb43b5b42188e27def9036_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i575af78c5c07443093cc857d1c99b8ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f10c43e33c64fccbb6f541ca846b3ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15622ac81bf64b6d8a631c6e28692012_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95e09f3059bd4468a374ad7a474b31ec_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica983717d6fb4ff095964b0c590cae02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6fe871055ff4f2c8a6464ebc3c894da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31e25b750ad407bbfe538ce6e4d1eba_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfc8aed4c32f4ba9bb8680a335959dec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5e55028bcf49d98bb89ed4e93e01ae_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f558a03fc74d9786822fef7d1da9ac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia564edcd14034ec790ba4a71ee6a8622_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.75notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic940ded1777647d7b1ecbaaef52763f0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.45notesdue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i111bb73a24814a3c8fff74bfc915fedd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35notesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037b1090dc53410598ac31bbb1af0ed8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.45notesdue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:Case</xbrli:measure></xbrli:unit><xbrli:context id="i2c65f9d30293433985417442b5f323df_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab048735a64c498682a6136168824f23_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-03-01</xbrli:startDate><xbrli:endDate>2014-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17584faa284b4b578d5ddb79fabaf164_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa614806e2ba4145bc4bcb5eccb090e5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:NewJerseyStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c548a060bf47df90e49186c4d38865_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:CaliforniaStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17f4cd39dcfa47ef9b2f783ce64bf95a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:Claim</xbrli:measure></xbrli:unit><xbrli:context id="ia0c76a997e6b436ba14ab8377850ad0d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed7a5d6344d40cb8f2f177240990f6b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i954b3ee345d542df871f572d67e9eb31_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fde4910e9b464480e8f2e6cbb3d025_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6549f2bd3da3405297ab00a3e9493624_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e3c82a44a84c4d9e95b408e7440546_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3bda94820614e02831a1a380b925d56_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ba186142fb49e1be6e39777874b85e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94d9d12af0d4d57bd9f39eda31326c2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1ea5618fc74137a1dd7d0a99fdc553_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661be48d847543a8a32ba2358107f61c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f65949371d5466d8d9c0005d5ea3e86_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f6eb6801e94b6aa490cf8461ca344d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b341ae138f41489d101f0152d09d24_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ac31ed97124e86a01cbe0bb15a0082_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fddb49b39a14e4c87423206f85f6bee_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61d77e3b21045fc893756b66fd2684b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i206b5fb493434864b42f3461b9ec4325_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532639a15db54349b73094a5ac53f994_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0577848ca68a405a9fd06758b4987ebe_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3eaa864f094450daf59663572c42e5f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58eff3e8192a44b392d66978e46f4f8e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729eb54219b048ff818ad6a1ac398d7c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida404da98be84835bb1bca80aa637c1e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55a6686f5d84014aaa7f5e1f1a99b12_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36f2245e6244cac86b52c10ca135b22_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2024d90064f04b119d58d93d92e8236d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7b18662e9547c19e8db82d3b49ad03_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68eb834fd2ba4689a131fc785fe1664a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2dbce2023d24bf7b14295815dc63340_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24296881407c49c4b8c78ad66fa3ad49_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1515e466edac46189d255abcb1355fd9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b0d790716bd451a9a48dc70ee90327e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aadea4a29ba4b14bb25f94d3779239f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242db40746324acea9058b979850563c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda54616745e475d9c94ff06081355b2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45834c2505094eeeb4eda66b2b373ec9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8db1c4585543f3813c30fd6dae8d64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6df4e6fd9a51492ca873f16e901201f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice9dc335efad486f8e04c605de2f04aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d6e7a2db2f477998a358afa23a3447_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8adcb6d851f94dc3a3fdea895e2d7460_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13c6933c3674a5181dbe15e12aaee8c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7179c9a592ed4b02a3c776ff0dd331b9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac567bcc7ca2418f86edba65970f34af_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9ad3599c3a84146ad4a9b8040fa9260_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69fee893e6cb48f090068514eaf1dca8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id990f16dcd334b06840813dd8a39b138_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3ff69e58674e75915bf501c2c193e4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db841c072d54fa6888133ec10cf2cc4_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6591fbc20c114de39653e3b19a29f103_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a6af2de3ce4f4a8efd8359eaeeb7bd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c230d35c63044149c73c8bb256576c8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8f30eb9789429a962564babf142645_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16aedbdec871407ea66e24efd83da330_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1878ab8ba71c4e20a87cd62012ad996e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ebcbbb713742d698719f2cb0caa991_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25f69cc39ada42e0b2aac3d80fa1092e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id791a906551f4c699ba3f0a28a87d3ae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93df020249f849fca4ee19c9749a68c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec46d9b67b440a8843d54b6ee61db1a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065889e51dbb442688e6ff3173a1e969_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cf5449d143444ea99ebf110cf6c87e2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454ba9cd9d334299a099d995c578d97c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia333381aeda74595900b302e6c11c47a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99ed860505e4c2a85a20cf2fdc2edef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97b428654714aed9ddab64e466a889f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed1325b520746ccbe6a911296faf7db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a46df96ea1b4b7db6f00fbe6c57fae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i217cd2a0efd84c7a9c2ef838da08a751_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31769e108011463f815d560721783429_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i734875f415f6427894327094cfdf75b7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i306fdc3327c343139058a1e912ec7a34_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1a45620d5740ef84279eefcdd52471_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b41de768cca43ae86a2b620ab7fd37a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf926c3546c74014b7e2f8860b5e44c2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f0231c8a1941c9a7f095b2dae733ac_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317ddaf4b00343c591e8949ca7d910a4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eff4fa2263b449ba4ad1953be6ba8f5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i547f0c973ddf4d25a0edb9aa55b1c990_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c49eca89b64ce683fdef4e64585ef6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib22b6772278549d3a7dc5725de45a549_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3906b3ace9b64befaf73a1adc407ae5b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc25861951e409b9bcaedf62ff4b291_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94fd4d2613b4279b09a4b269c9fa2e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1958e912e6ac404ab8549a9c645d5cc6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a4c78ade6e465c8ac9352f2745678f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea751a267ca49428fd752d3d82441bc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc329ef53f6466f8fd7202d74ce0a3c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7327daaa39b444129ac7963593aaf968_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93971dcba04a4a31bdce5505e25d2fe7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfca5975a1840b695feea389585ff70_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56ff7b0e8a54c8a8d4dfa5d57d82641_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec9add45dc0469788010c549ccbdb76_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51ef3c4eb03413ab36423e2fd771da8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf99264c8dcb454ea5e90380b2400b9e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca7a266855d4254a95f8178169a039e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc9b994e7da4fd19c71b16dd69ea18f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8717ca08a9d4379806fdd058d2feee8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i733c87bbcdae43878560a4ef5bdac803_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23398778be554bbf9ea4cac06d6173a0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe040aeeb11e449b8c5c18407e83aa44_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1453f6542194317be39084f21e53aed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef3169c86e54fc5ae677a048dc4eb96_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6829456a78436f98f59cc9fc651fee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553c60428afd4395aca8a65dc4d3d90c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92959775580548159c5b7ea24a92ea98_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if56024565ddb4465ab8bf341e3dd84c4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ddf16367e464e79a9f9c63e9ab32ce1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ecfc38e80742e18efb7ff88f14c004_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f067784d5e422c8ab4af07a2f8bcb9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172b683fbef54b37a292f3dfae49f813_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3c6f85819c4714b9885f8013fa08b1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i393c1adee8e84595bfe0acc21bf97c3d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia217fa4e279b4536b6b3f04c7fe81688_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0887d9184c47dfac2ce9c7bf039dec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5359f26b034c4f8b839c6f0b2177c80a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife80c9a9053e41bca34e6b7e6d9d4efa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9223587952c44aa0931adbd426c4f5e9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e280b6f3ee4222b4211f6c6344e7ce_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea870736ba5b42dd970e1c2e8cecd0a2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67048c78dc0b441b984b5eb1a80d4918_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708250723a2049d9b4354763f848521b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i979e50a4991d42aabb587279a1630515_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fdab53c5ca4fc7afb34303af488fe7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icefe099ec9f9447d89313fe5d966d097_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686f3ec310f8431aa70f7a29632549dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a7371dce5a4c7381c1ee54f2af4bba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66daa9001fc14740a44d38a81090f3aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce3f31aab04474a85482e57d7fe3b96_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414cc671cdbd4152bd1583dc67a4d839_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59138a1df4c34c0b8f31017c314ed9f4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3925c7ab1c44ef58b807944198fc32e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862f90ba138c4b01a609bfaec7fe9442_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf560762c004da7ab56bb4c5d6f3276_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44944b71a8804ac88c5e1188334b304d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac08e29232648c58d4d3e2b32573921_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e8855545fd4a67b2906f59348cf1cf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c793f46d7434d639f4b9af5a81dda9a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifae37299fa8e429c88f31b01349409ac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44abdfd9ef2340be84e53509a2ad1217_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38bc46dc41e4806b8a366f7c6a66444_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844c2dd9fe0b4d59b864cfc9dbeac1fd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaf14c7fbad4e81b02ee7ede86f6740_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1757a74efe45beab35e7c434a837d1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb7e9b25563d433abdc2de1fcc1cf790_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b874688aab4e3691b20bcb3c5dbeba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33106e55798a48b699ea798ff3d9c2c9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb60f686f644588a89cc8c7b689dd91_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b7cc10d3a44053975f929842e5c6f4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d7485ea0d844afb437a33a9c0c373b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3468a4ec91e4e0299f5e9d0627e20c0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14d6de6abd24d9487ccef62b379ddb5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63f20dcd0d3d4ee4add22bc0f3b7b2b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c865283192843a8b5c2910e9b0530bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e9b7bed9404b7fb7a2473c47829169_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e3e6fb55fb4477bd2e4344ba69226f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29681f0938a8432486e7449f7854b7b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1cba7975734d45833cda2fa2563bd7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f730dabc2740699bd827d675b983b2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27eb3d476c694f68abd9f5e5db26dcde_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c2064d607f4f06b74136bd86690a51_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i178d9b4b6cf34d169a02c96fa38dbaac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i235ae291edd64816acba0905d28cc37c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71afa28afc2b4c3bbe764e1563f8598f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9440d8597143a1b91e48f43b4b0bd4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3da5777cebc48a1ab0eb78234e6c524_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a0f69efec34219b126a5a5473b1670_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c189c6b947a49aa97d6dce2f79c6151_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4345b97e7f84437e9ba2ed7305654d4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4db3706ed6884db480687fa6df343826_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f4b0c199f44ad6bda16bdc1c99307b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ae2ba3b636440dbf51084099ea4e14_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b04d71a9794cad9297feb729f927f0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7ef7e87f1f6403786c8243b16effa57_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3da6673eab644f5ac8940187a307ab9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2737dd0c1b8c4fd6be8f3eb432e38a55_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5abdf92066496d90d2e3ed8f83f10c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf624a2fc58f4b8db74dc7ff1193332a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694a4dfc7d4f41fc9459a5328750c279_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6e1314672d458c80a6ea2181ccfefa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5204d5450def457b9bddb35e60c60d82_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d941127ebee46c6b3ca083a457c564a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367f009328af4f81970cfce2c888d476_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2772e763e8334f6a84b55704b593c8a1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b806fa3c4004464a6b42dc860d39e09_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac62401b132462a9e7d3e00f737696c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80b7f42ff4d40feb2b2ffee0f6914df_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72fdde8bfc914ac389b6d2024c9b1b2f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i351299226c1643e7ba68239fe2ba57a1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8aee6fbf35747b39ce2ad1ed1d54893_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec21e115e3a40838a098aa0894c0609_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417799794c1e4e23ae2b7e19043fcc61_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31a7bde573a847948f09da2562a0a446_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d9612c858e4a19b3a9c1ecc6f502a9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84a9822d9b040e1876a2c6879d001aa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73623d962db34390a9676bda7471397c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd9ef0920dbc496fbc1ef7fff281f68c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a9379092fd4fa5b67eb0c0899dc62d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc60755989b24bf88af02e4825aa9c3e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8062908fcb748948fa4b9408f90ea88_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341ee46b776246b09ef1d6d67599e9e2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47edc2dbd975482da465c5ac979419dd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e6a07eb2aa4e858f46dbb14ef8ced6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94548af382c74ea191084b248c9f2fa2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d18847d0eb4080984a7f92642b9c3f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dca799bf08b420b80463a36fb534945_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a1bc6f405f84099ab6dfd1b166d4a30_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702d3186e41442f7a78d814e62d3bd65_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a9f2da00d04e34a495294f13d301e8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33c89ea2353410a992159fd79ba7b27_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7537a2642ad14cc1b29e3fc7e39efdd1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708c24fc9863489497166c927cd80e26_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ac91c09eb64ca48bdfe2203abf90da_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b4250d2788459e8b5e2a862644234c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61152773c82437db2127adab1053a23_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d1e6a2e75a4c8eaff7e19133a84fe5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2671e945dfd43ed804f379d6b30ac92_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac2ca8f7efa4e3e8df4117cad2b06ed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fbe25f948d434ea8c2d71514c905b2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba671a135e142189f057be3fd5355bd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7426bb60d684ecc97eb4c32ab073460_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib178b02bf26e48b68748d2a55b2657c7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e7d2bc3a714126b66d4718cfa4a689_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39019f71db724d0388921c330404ac9d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if399ecbab7c147ff8c533bd49e5029dc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9c994a82754ec3bb4d67db85d4338a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i279d66dabd8340e4afb06b61ff1106da_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae82259b4751461ca0624752a35bce09_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77110243471455e93528fb60c32e34a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b27d7fd3224ed7a7515432a72d21c5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3d9fbef4a14ad188dd6c702f303d81_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd56b11ec30f439db004563892878a44_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7574915e7f9f45adb507296bad2d8acf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c4b2e42e50440983fdf402f1a3318b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0d8c1ce2404f1eb1853fea7819c9a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48a812f083634c0c918b8e40ac83a158_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7a2fc3636d4744a1e68680dd160a7d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf89995052242baaefbffc9a6c3d93f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f03323d756c4aaebedf7365c0c5f115_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6f397f156d434ba8c705812199c7b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b09565c92894fccad03d9a3f77269e3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776d8cffb24042c6bb2c4c3d914dff0a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i143736d83dd84805ba380c77aff27679_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i427aaa6059414501938b90f49d23d83f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54c2cf432c2492e881936280bb904f8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f165c4787b42588723ff48d0b6cf98_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e895a82c3e4ef3852770005b410b0b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06056e3d1fdd450fbaea2f8910ecf385_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ee3bcbe2894ccdb9103ea6acf2dc54_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3c12dc7fb64612938cc2e9c4345cca_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953896ac43dd4a4492bb05e6f55f1f63_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc471aad3c94e04a06f0fee9bd88cf3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2dc4f551874bdea08cc8b480c809b3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf3e6bdecc74c8db16756ad0211654b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea020ccf4a554e1b82196c6dd3816009_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81eb3b266055401489cbcc9e71b1b590_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1eaeca1be734efd9e7311afed56e4fd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a53f2d7fad41e399de72c840dc300a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id54a4864f2fc40e2af2de994c8aa8ab5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c982e709794dd68acadc44141524cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33aa602ccb9e44e7a7efcad8055fafa2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id881511a6cc84e72acb24c070e6797f5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3880d04cc6c346cbbb1fbaec73165ce3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe91553b040477b9005ed581ecac9d9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff55a2b1e45f483b908fa739760c0534_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5e5f802c454eb59aeab6da3df4da1d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id827b82628ce40ed984d4a930de9a590_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb446c3d46c4a828db42c890a42b26e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bebfe0a869441d786bd3a8fd4c62b20_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361cbe5c451845abb30a9a8f4f2e6455_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e8ccd8cde3495f9af0b571d95d1d00_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb936fd1c99f4c35801a4495e91bec73_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fe9b60ce0f449a99363f745dca6e96_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acb4cddc5604c7eb880aaa49a3e16f6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17701907ca0e47ba8fd1a971d48c2457_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73faba95052145acb3c26e84d3a4b602_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie736913c7dc4408abb11d1fbef1ce474_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec058f1ae0fc472090afafbd68d47461_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i989cab976f6448758df4479ff64c1fc5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261c4ce6a02a4800a83a51be1c99da21_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bf9eb755fc44eafa35a8b13e484061d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ba00bb057b41f5a6855415133e2535_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73eb6d53bbd4f5ba331d317ac2a8489_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac01653e21d0445aa0eee236c7ba741f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d4102e12044f109f6a5e7816007905_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i242aa19f5d014d05a2d3f4cd08cd39ba_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ff90a270f74713b7bcc28d52341906_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a7c01c0be3e49b5915a0dac164db1e4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7972da26546c42ac99a76ed6a9fd9ec2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb7005b439e4d31aef9325c0babf90e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993dd102bdca4431a2a35bc582ce9394_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3485a40e14d749c98847179c09c2bf32_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acb7f674c0e47aa9e58edfff2e3dbb9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf0a90d670947f2be36e5211d88cb00_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a7f87c772bb46ba90ef0bd0821eca8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04909af50dc845da9f9a8569bcf5eccb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26152f7f7b440fbb4cb9d200d2e7f77_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0931102ba1674080bf90d3330f7955d1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7670dc70afcd4b09937d261583e363d3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20fe0f50a9b4260b6c07bfa057998d1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i858538797815486f80a7414cb57358de_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a8339ae25046d28c34fe065d7fa146_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ff7e9937ea4f4d82b65c6fa6926786_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1700dc6b374b3aa45edfd416e35917_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9928d769c694dc2b2adfc1fb517f81b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0a0fa75bd64a7b8e10d99ff43623d5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1825f1272940bba1d0662fbbebe361_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4523ccacdb4f7f9000657e8e4309a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c9e9493f5641b8a375c87f2e0f240e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e423505d49f437db0eea268f1caec94_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b1c51d2fbf4f78a7e2768a8d38f881_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa4fa96062de49de83a4eec95e5f1c59_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebff762cc1db43248ab6ce27128b3ea1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35113cc0f784ea18a9ab80c7456f72f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0b5f18d0c94b499db52d87cb762e66_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623c2805c097460f9a7582db63744702_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96bb9a967fac42b0959e471029dd753d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b59bcf248242288925f9d29334b8a4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83851ea51a8b4f348c297fe9674a70b9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374d9072818a4be49130b74a30fab649_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb66d45ea6d43f891ac8d34790f596a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d20159069f44586beb2bd4d53b486fa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1589f85930c4c2490dbcd2bc2471fba_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d2b1a5d4e445afb22b111f115751ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2782b98a704284ac75156aa7888225_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28c15341c614ec3ab5f080633c0f9e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7892ccc679854d0f856e0d492c1d0dc2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454932685d7e4ec2b3f324fd851227e8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6b957265c64b67b737a553dc147e91_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if87992e546f14efb895456eb6a74307a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713d3719b5024faca7719a158e89109b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b7b30d595b4b568bf5d47c20418641_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a2b13d213f4580ade960efd7096274_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb922157dde34ceab969c20d2c593243_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e831ddc4674ba7a0e1d0b61409a910_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7c5a8d8197420585dca57047243f97_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938196e4279e4040b004c3a0e20fb083_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79705fd98c64c8e83345f5d01da64f7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f7c0c892af4ff1a708a6271afe4da7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f14a0f1d8c4abb8f6a1d03da5e0eae_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd47e42c1944c9c8213aa8f8808165f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d650ce0abb457d9453531cb7e334c7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c32b81ac1784ecf9a98aba06ce43e61_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de38a6154464d5695596fd542cd49e0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ab7aff39d449dcb43df1642f85616e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcbac2ba02f245f2bf19de7c0dda76b7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f6f5e968c5474488f0b232fe0e77e0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd98423d8c14073b9a11bd36db51615_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15d20ffb278846169ca7fdcd9df043c4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id028f116dd7b43eaa20b6e06ed2df1ac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50456612190942a080739275f8173a2e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c087cfa4f64c55b828f161589a223b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b39be43599c4cb7bf9bd31828ef9002_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99bcb57eb48d4c5598c716226714d7a3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05834b1651a949dc8f02f619c612749e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da82df886634a4fa849605c59fae2bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716c7e7fa0504751a650112eca041f5e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i318576a512024c6c81441fd12fd57fa1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cbee4cd8d004afe9a3ad3ed1829964e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i334447130bb944a993957aeaa20c39eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b78ab8426f34f24a032ff8f5061739f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8977d72497b74b1086d865c0aaaac8e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea630f933a7446e9a808f75d1870113b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5c211102c3f46678a682f40f99d407a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0d607a7351455a9f45abc4f86f952f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia279e76e54074dcaa5ac97de34e18efb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12096c3c413a49c898ae87d73a81726d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58002f53d69a46229000ce6d3360542b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e7b9d13ce74df1b09ad0cf151c9851_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92db4be05ab40318a94c027967ef6ad_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a231f98c7d149a490b785bad71e4496_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id303f0dee3b74b50b4a15ee325ebafa3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44bd2933ec84060aee7e36859962375_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i617676e5fd5247fa822d36489d37e0e4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d72700287de4fd4abc770a532f25f9c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c6b30dcffd403bb85af19b9d4165b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296ad230a93245ddbc5fd02cba30cc53_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88917ca1de89409e9f4b5b2c0fa57485_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebfa044147144425859e25282f0ef9bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i003abe7634514241b3a8d6350da515dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618a9be04c62409099b81b9ef1c5344d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a2abc9a0e534088b5e0fd5437f763c4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0be09895f8143679533f9a333f5a993_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93521f60ff59466495549fc41c457899_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5952b34144c141cda9875d2d182b3881_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5caa54b167f3434b80a36e8e76d7c6f5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651c70a05142434cbfb538a617b89007_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fcc4708c8eb4156b83f9055e325dac6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740e22d8434f4b8183f077a8a007e956_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640d595c82ce42e7a7c0fc6c0583bf14_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f141f8261348bca533b4aa5e20e68f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e53e8331413497ab9874b05911c0437_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68cf832a35a46ff8bdde3920247bd39_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f48e3aedc24f50b0808a4b79b5dc6f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6b9e3b829c4249bb4c0dd15118296b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d275d442cff4f52b27f27fd2a721187_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b693b792e3f4432bb82f7c6052c3ade_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226ad6cf1abd49039985c8760bfc48d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c690705a704872bb3bf8a6745a536b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ca2e5a714e482f8fdd4c3d12841689_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da7b1a0beca4bd29d8c4620041e50ef_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab88e6cb5824e4ea0470b131ece9e3d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6c90ac04b148ab96bd8f595258f46c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f486eea8904e70b20acef9a91c8270_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae7aa49415340d9869b132435677a23_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb42bbe4a18548f4a03796d68320493e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e9ec73128f4b998b320a2ff73af17e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c91d7cd6e084ae696ac51575ba5006a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13bbe57c7ef04ccab0073746177c2e21_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b0ecfa83ad149c5ad28f2a5c2bcba9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86aab60a014a46da930b6b4e9e51c7b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i101456f617a34e8f91f201fe318d9a1d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39e3340b0e647debae7f510c822e44a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6009d7735cd3433f9a820af8fb018481_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0257c158246c4e4dacbd738eee948877_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae95c10fc15484eb3969d05a0a65b4c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047053376fd540a295e977bc6188ab36_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09da9da15f049f18535de414de6ca38_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9106c5caf2b40498beb6bd13c71325c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42088e2a28144cd7873c943696f37b29_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0baa103cf7c4cac90311107a935dc92_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd842388eed64b3da555ffae75b7899f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda57adf0dc14c4d897dfd88fd256191_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c35e7bef0f74b0e9f2ad280b8c9d79a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe3d788155d4dcfa6d1bcf0849a7908_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf13f6a3f0b24f4692421a7f681056e2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823b7acf4af043c7bcfc682b9ea59b03_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i250b5ff269ea46b4bd2e15044f7e9e39_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816a6164517c4476bbb9046b7465a255_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bdf582fe7f04b6e84f53a13fdf085fd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabcb5052939546a08171746b38d9a959_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e1e1cd1ea5f45cb8b0d49ab5e325e7a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ee2df0e4d24ac49cecaf2f8612ac56_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8da3de0a1d54bb19a95bf565424fd8f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib197c58857094217ae70f45c5bba1512_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bf34d7c3de4b76b99865acb7b377fb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec190b0d42f42ba87646a7397218a62_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87932775cd94b648c1cddd6c945029d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida18cbb39b744ce7a0792eb9db392c68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7a1d7200fb43eaac711c3fce8929b7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5936f316e3b42a5bc7edc460c3d44d7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2c7223374443ddb83cddcd93f11059_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fc1591a9274ddf8df88b43546a8090_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e354e7391d543ed99baad3fb5dab811_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cbc9acc32f44e2806b5ff08ab4fe23_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4ad108871045beb3935eec15ecb68e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564e295cbae1431ea1342d1a6aeb2d66_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4cffe9e90bd459eaf7ef8497c5e3424_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d690c97e9cd4f4d9c35a892caaecac6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649cbc3cd44646e9a198d32f7491aaf6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc84657eb0946a79cc4a2c2d53f5f7c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c935c934b3455584cb3ada0f1e5c0b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80cc24848e04d269a3e8ae9c377edad_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77eee53991d46b5909d9edb93e5b74d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7f6840d5e34b2faca6d72b25845338_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id320e1dcac42446cbc9350d2c429f55c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f8b81383774d52a52223b7869349aa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b8498ad9774b9d82c1c33f73ed1085_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d53f4525194a86a9fea6c036af1d55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c38480569ad43bf8a8faaefe258752f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2661c49a72f4fa4b82bfea2d5eeafcf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba0bdb0d16143e98878115551e164fa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33caa9debafc499f9f035c363252e664_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70254c5658804d7db8c93d35ca1b2469_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f17b6e17a35418e8016b026c1f452a9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaf07528158c400fb9045d2904828cdc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6e2064c3ec4ee7bc561d67868ea2c2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29c1b123d68491cbc79c7aa181a889e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba270aaa589748cd947e1be8c444099d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia59bc2566f18462695b19da2c7e8857d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14f8fcbabb864499b102a4d91eb12390_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab058ed790442cf887ada3d278a7abe_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8878e9ea7e44254a65607e3a621ad36_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c96ed92bdc54f6dae73012eb2b0161a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8cfb19850424c50b34394d1394866d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8b9c2751764e1f8d74e88aaa332b62_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3220d799974f0eb91ea6a92667c1d5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8875e8b3d4847bf905c685aef59e0b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b57a142ee3a4ce9a28e2129619938b4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fcc4f2c591d42c2a24736d2c11c3061_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972845bfd88640bea722b70626571964_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe81fbfea644f74bfae5c97dafab313_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied38158acb5748a0a9a535f78ea93b3c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631b85d3d7a44f58b74177a695ee880f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e80c1e64b24bea81b052f8f6a31353_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1bb093533b64c6c9ff9dafcf60f4ee1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe47ce5722b844be8d813eb70e594427_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85247bb365e149738ac7c734ad073fcb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccdda557d4de4ed7b963da933bc6d89c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a45b54cb929479b91a5036c365ad2d1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf194fe2ef394a6d8fb6776943995e44_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd2fbab6f9043ddb7f5562393c06341_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1930b8b6109e4cea903f59042c7e749b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed7a671edaf49edad215de41a079a58_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a4a0980d7e40e4be58e702f91aab82_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief202939785e4d1fbd2e37bcca814959_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9f4d9097a44d18897c5e28a6e2be16_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic824da0674df49ef92b0f0f79ed94902_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ddc6db0368f41c29f507c8f2fe146ad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d21dbdf0f84c0d8dcbb85d77cda350_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb259bf8f6774eab95195ce94daa4d29_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60073e1f170740a18f008719f2754f25_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdf03e64d0c4fddbadaa8c893893a20_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b602e80983f48678ff06480b5a96fc6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i319f3974785d4167937eccdebe28675c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636d30541f2d41c1b70a178f58cf65e9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3add7668e892473ebd440941e4e6ff61_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4f8e164ae7418cb04b0ea9679efe3e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb109d299f6434dba3b52e63f9ea583_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd5b2fc3a6c4e7487aa809e527b4eb1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819e259a8f8545249f0f53c7bf645645_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id642fa8a9a20492f96aadcfe08e8c96b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a0a14797f94d938261561386085f3e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0134b6331943ce82d4a3f44a0afd52_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1618964a1d4460d94d2b4f7ca640620_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3af3901704424498cbb93a1bd47e45_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69b42b66ea64f81bc571b5e136a6b1e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a38b0abb2d475ea621d0cb55cade32_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf8ba8b236c94262b8730ba51f7dc42a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9728acb79d00420087a90f15524df617_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57045208e33461c96ad659d41f00462_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba969a5c23b6451cbeefa5426f1e393f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5946b43768450782f6246b122b119f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5473f1dea7542f691d2d95c97cad854_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8aaf2b2de2044518a3ec564ba88f75e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic94420b005aa4e66b856a2ff67bf8c89_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699b95b4f1f44764b9ba3bd58279cc61_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6dc35669ee24101a2c1185b33f55579_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ba7ff21103477bbabb92b26c7b3364_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a279b2b6514d2192430c67323a7e85_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5f9cabdb9941e7a863c97299c00368_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a57f86aa38f484f8aafcb6f09735cfe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eff7b7cb796442c9f4d72037c21fc95_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6983c97c98d42fb96684499a02a239b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754f6fc9ad27497fa0cd1510ac8e8907_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342f3ee0e5454000a23a20f0cd994598_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652d6027f193497da031fa27687560ae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d49a9dabac54fc597f022af9277e212_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3a784d71f1c4eefad36065887fc2930_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic534fa3517b64854a0401aca08abad91_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cc9e5ed0ff4a02b7d86616c322d0aa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9c7f8333b0450f87749a200192587e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a6c4a6b6894cda952479c46d393577_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3207dac346430d8a41e7dc3467d758_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd61a490327b40cfb9292092cfdc5ac4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeeb2222d43c4f96aa888a009b82082d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa7236576c74fcfb7383ec2acb28be4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe85f304c00147af96a365f14c8d9c30_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e40ead15e764c9889121bf33547189b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e37194dc584ce0b830f6a8b322858e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14106dbbbd7f48158d4a3e3068314a55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4011fe77ab4e7eaa38d98a880134fb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d0ea546af24a87a6255e69c9be826a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdba0b24408b477dbd1da28288ef0b28_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1ada048a5848499745516122810eab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc62432f3542449c81953affd9de22e1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bdebf9d8834484a80089286c5c652a8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0e6a497660484fb717730ec1682382_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6047455c7c64d9f874b87a52288b80e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dbedce779e14d0aa2f39e6a7b145b9d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898e69e9e3184245a88cddf0a47d6dc5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic000af4b0c4c4a2fadd5664d561dafbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09c33cccd764e8993469adf4635a214_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2365ecc7f5a942f28ba80cc309ae1981_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id893aa0127934f2d91eecbde06753def_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e15c24b2824478a886c6474a727dd9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2268e80ec95d4d869afeccbe9a5d42b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a5dbad6f9e4534bd2dae1d741c29b0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2d0f03f76040508bfb37e1f86e3a44_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d1cf04d3654121bb1372860aad23cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71294026dc2b41a6b110370ac311ccef_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf593e2d5525476f9946cba41a11778a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8dc8d4c2f684a0daf26c38edd0fc54e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie753576e2fbc401991ed4e99717613ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide9e8a73d73d4f3a9142b2330c6f27fe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4500010fb54d02ae13949698b9b8c4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a40509dbf045e4ada553d6fac4e6eb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i581246c6bfe2404db7120fbc4f4dee00_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89fb5894e97f4df3bc23850e83b77053_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1463025af91424094e317c427bd8c0a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0766d9bdbbc4e00bec07a37b42563bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6eae77f55e94cc2b2c83b0c7dc60c51_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c2c4a4b7be4001b1d581d890f1c1bc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be56294e35345518657c9cb1c795a55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5373290982d4d9790e6f6de2c301cb7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd74fd1d348488a9909e5be2e21240e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5968a3319d5e411c8e90433cc1e6dfee_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8a8038d02e4f88a246aa02f656695a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f058de6b2243f9becd32481d9afbbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia932a81be775481f98c6d46c74fc889e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb50c2f22f44b9c87ff52bc490d1857_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85051d25a924f2190907c50f47325ec_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313cf220e7c04c1a8ad44c9b6fdcbed0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a2befecfbb4aa5bc67a5cf1e38775f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b97ea09a131441e902cb9300382361f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d79fe35117f4651b248b578edc99dce_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd022943eb58411bbd1ed2c225198ac6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c4d3fc287a432a9fd94239cf8da2e4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1349039c214a1ab7b78b435fbbdb71_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a68094581a24c318a5e928a8ef2586d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9d51c6c5d64a0ba83ede5553c4da40_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6360f4861f46ebbb62566ea24fd0ea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100e2f176d6e43288c7996c8bb790ee0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7dcfda74e184dd19aa1034852473ac0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71cc45c9f8b14d8195ccd2d6963f6085_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1d1ba55c914a7b8e44658d9480b9dd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eee42c966664f4e9a6f8dda9caa4b70_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9af3f42bbe446f8bc0971d7ea5b622_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c2156786fb46cfa1e5ff1a41f7d595_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2a87acce6704921ba325076af735562_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i67ef4e29db364327800e42a94e43496a_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk0_9ee9068b-48c8-4a95-b106-57fe5f00e0f6">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6NWJmNTcyZDdkYzY0NDdmODliNDRmYTAzZDNhOGY0OWMvdGFibGVyYW5nZTo1YmY1NzJkN2RjNjQ0N2Y4OWI0NGZhMDNkM2E4ZjQ5Y18wLTAtMS0xLTA_72c52771-307f-4b3f-9cf7-1444b114ece8">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xNDE_2cd645e3-6a9d-4484-85c7-edc246bc1a4e">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6OWY3OTdhYzc3MDRhNDUwYzk1NGMxYTExNWM1N2YyMjgvdGFibGVyYW5nZTo5Zjc5N2FjNzcwNGE0NTBjOTU0YzFhMTE1YzU3ZjIyOF8wLTAtMS0xLTA_b7d2dcc3-521a-4cda-a296-412f849edbad">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk1_0e42add0-1904-45e8-8d46-56125760a4d1">1-6571</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk2_3e26cced-cf7a-43d4-b75e-302050750547">Merck&#160;&amp; Co., Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:41.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8wLTAtMS0xLTA_f7398a7f-fa88-4c1e-8ab2-2d4e5b358e8a">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8wLTEtMS0xLTA_6e3221a8-f7e0-4ade-84db-0382c283a17d">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8zLTAtMS0xLTA_6542fe7b-246d-4741-a3e5-bea4bef8fc8f">2000 Galloping Hill Road</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTAtMS0xLTA_41f85777-f2f8-40dc-ae3a-66bc67ae6ec5">Kenilworth</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTEtMS0xLTA_20b0ac7a-9640-46ed-92b1-f71deebef475">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTItMS0xLTA_ce0b63f7-e63d-4d72-afb3-bea6c70af550">07033</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices) (zip code)</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk3_6f57a33f-938e-480c-be51-ea9cf39d9bb4">(908)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk4_23a1b457-4d84-418a-b27c-6ece3141f249">740-4000</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:18.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report.)</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk5_91a487db-f02f-449a-9dd0-05e5540be77f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&#160;to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODky_974b9fc2-1c9e-428d-b559-9941771126f6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl8wLTAtMS0xLTA_90c2fa45-04e6-407b-9e58-1bf5c3cf4f76">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9744;</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#9744; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl8yLTMtMS0xLTA_30aa511c-408c-4837-8494-7332abfa3029">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl80LTMtMS0xLTA_1776075a-51c1-4a4f-8640-900e1321124f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODkz_9d5f98f3-1e67-4681-a915-06e05c04869e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#9746;</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:35.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTAtMS0xLTA_5c132516-3527-49f2-9b60-e04dbc11c84f">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTEtMS0xLTA_4175d09d-7c04-4ae5-8e98-2f2772383a3f">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTItMS0xLTA_fd1ee212-40a6-4656-9109-d87ef4b0a5bf">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTAtMS0xLTA_984ab766-33df-4689-b00a-ba95d5787a0a">1.125% Notes due 2021</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTEtMS0xLTA_04bc0d78-b62f-468a-8cd4-88f0d3256269">MRK/21</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTItMS0xLTA_4a8d0c17-f2d1-4f15-b43f-a7b799e1ff4a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTAtMS0xLTA_10d9be51-6253-49b0-a9da-1f577f051c51">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTEtMS0xLTA_436cebcb-ecf9-4ac0-948b-4e4780baca3a">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTItMS0xLTA_1fcb7e31-91e7-4f3b-b4f9-7b26aaa28775">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTAtMS0xLTA_fb946643-0969-4347-ac28-b27eddae1e14">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTEtMS0xLTA_2c1299f7-5206-4adf-84da-f141554c7880">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTItMS0xLTA_da5c4a56-b21e-4b86-9a57-ffbf15007c94">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTAtMS0xLTA_c23a1794-59dd-4954-98e9-ca63071d1465">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTEtMS0xLTA_997922f1-5f73-4e8b-96cb-e93221034c63">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTItMS0xLTA_0b534477-e05c-4133-8654-9bdcfbfae27d">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTAtMS0xLTA_0a36a174-3053-4002-881e-13a93384c7d6">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTEtMS0xLTA_ffcff42e-be65-4feb-aac7-c36fafb13851">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTItMS0xLTA_0ccb3e18-aff0-4724-a93a-74e9f5d392c1">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of the close of business on October&#160;31, 2020: <ix:nonFraction unitRef="shares" contextRef="if2b50aa67803469bbee45c3c944121ea_I20201031" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODg4_692eda74-ac78-457f-af28-b2e528c04a0e">2,530,034,437</ix:nonFraction></span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:13.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_16">Condensed Consolidated Statement of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_28">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_37">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_94">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_127">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_130">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_130">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_133">OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_133">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_136">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_136">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_139">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_139">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_1337">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_1337">52</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_142">53</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_145">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i67ef4e29db364327800e42a94e43496a_145">54</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Part I - Financial Information</span></div><div id="i67ef4e29db364327800e42a94e43496a_13"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1. Financial Statements</span></div><div id="i67ef4e29db364327800e42a94e43496a_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi0xLTEtMS0w_ed85604e-117e-4fd2-8523-1f6252bd9e23">12,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi0zLTEtMS0w_4d31f31c-fd68-4e14-b5cf-f8f924b82e37">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi01LTEtMS0w_c1689e55-137a-488f-8e8d-55d3fc63136b">35,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi03LTEtMS0w_e52688da-558c-48e0-8697-48b123dea50a">34,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC0xLTEtMS0w_712037f7-8f9e-4c06-a585-8ea19ccbd2ea">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC0zLTEtMS0w_44e85034-7b8f-4a81-935e-bb40460a71da">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC01LTEtMS0w_449a7c8d-76b8-4571-aa4d-a4b2b4d3c305">9,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC03LTEtMS0w_55b3e07c-2c6e-417c-aef7-d10863bd911d">10,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS0xLTEtMS0w_37adb5cc-d380-4ff7-9afe-f7e089b31fbe">2,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS0zLTEtMS0w_c4eee595-055c-4bfd-b9ad-fc2131972201">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS01LTEtMS0w_99ffad27-6fe9-4234-8b7d-47b58a45e7ec">7,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS03LTEtMS0w_15bc7fcf-415b-49b6-9de8-24f99d893445">7,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi0xLTEtMS0w_a4177cd6-9d4b-4f29-90c6-b3502d8abdfd">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi0zLTEtMS0w_06997abf-5ec9-4617-9133-ea855f939d63">3,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi01LTEtMS0w_15f0f30f-8990-44fc-b71d-e868d0bed995">7,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi03LTEtMS0w_923d0c60-1487-4aef-84a4-6de2f8dae295">7,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy0xLTEtMS0w_66dbd908-df75-49d6-b64b-709ebe314da8">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy0zLTEtMS0w_5aad937a-6413-4378-b7d2-1c7a67d4d0e5">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy01LTEtMS0w_5ffb0676-3a39-4b76-b707-20fc88a4f5d7">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy03LTEtMS0w_d61849a5-b520-4ee0-bb3d-f56e4bbc35da">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC0xLTEtMS0w_1ca7dab9-4229-4303-868b-ed6178ff538c">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC0zLTEtMS0w_0ebb5f88-477b-49e8-95f1-9f64109edde9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC01LTEtMS0w_22773d74-b9cb-4558-8fda-f853aacc6ad0">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC03LTEtMS0w_612a0cfe-3837-48fb-bf2b-943f9233c441">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS0xLTEtMS0w_e32f338c-f89d-4c13-852d-ca4fb3187411">9,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS0zLTEtMS0w_1952261c-41a2-4b1b-ad34-5c6b315b8936">10,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS01LTEtMS0w_0946ac5a-c923-4b97-9fad-4178d3da3717">24,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:CostsExpensesAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS03LTEtMS0w_0895201c-7c19-43e2-b8ff-004f430d752b">26,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtMS0xLTEtMA_d5d64c5d-cc71-4924-a954-cdfbe956f952">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtMy0xLTEtMA_b467d7a2-e307-4774-8aee-266daa348380">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtNS0xLTEtMA_d17af8d3-98d0-43c6-bb50-afe7cd8dee34">10,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtNy0xLTEtMA_5c044e34-9100-499c-8430-0a42d42abfff">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtMS0xLTEtMA_62169a99-4841-43bc-98ac-07dbefcb23ae">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtMy0xLTEtMA_b697756f-f373-4f54-a92f-745907c8e19f">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtNS0xLTEtMA_38afc057-cf10-424b-bdba-66e823813883">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtNy0xLTEtMA_0656763b-96d7-4610-a4c2-d128b010107e">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItMS0xLTEtMA_e9d08eae-d6b5-4423-81fb-c6edd00dbe68">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItMy0xLTEtMA_ab03fd9f-7a77-4e74-9983-454e229df189">1,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItNS0xLTEtMA_4ae7d4ed-5fad-48ae-994c-bb6c1d324d0a">9,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItNy0xLTEtMA_8045cbc1-c5b8-4a07-8304-2f8015628261">7,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net Income (Loss) Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtMS0xLTEtMA_88655bfb-c4f1-47e7-8a8b-ad1405cb4a5a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtMy0xLTEtMA_f106d29f-006e-4fb9-bde3-b1c2185857ae">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtNS0xLTEtMA_2b2c323a-059e-4452-ae19-af347cdb433f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtNy0xLTEtMA_203fa466-5666-40bd-a83d-98bb315ece52">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtMS0xLTEtMA_02623fc4-35bc-4848-a2a4-fa538594b78c">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtMy0xLTEtMA_22b4e31d-a11f-4a40-a139-94cac1df8572">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtNS0xLTEtMA_491c293b-e36f-4adc-af4b-05b1eb074a87">9,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtNy0xLTEtMA_b0297bdc-5c94-42e8-acc1-9431415420a6">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtMS0xLTEtMA_5aad267c-6997-4738-9b6f-ad0443578f79">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtMy0xLTEtMA_8076d4ad-0b24-439b-b6ae-1fe98bd63025">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtNS0xLTEtMA_8dbcc411-0715-48c4-920c-47f23eb476d2">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtNy0xLTEtMA_133d6867-4eb5-42d5-aabd-5ea9c3e26553">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtMS0xLTEtMA_6fc00e23-da7a-40e5-b501-3fe39fe5a68d">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtMy0xLTEtMA_a851888a-77e5-4742-aaa5-395a6b85dfb3">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtNS0xLTEtMA_b1040d4e-8c72-4902-809a-daea6c2d6c92">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtNy0xLTEtMA_733ee47a-4e27-4218-b779-cc55e3b86bf8">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i67ef4e29db364327800e42a94e43496a_19"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi0xLTEtMS0w_da639635-4cf1-45a8-bced-5e47b49e37fa">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi0zLTEtMS0w_e2b26c54-10ff-4a5e-b8b1-520dab8d6489">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi01LTEtMS0w_37991659-ec58-495c-8cb9-922e5e68faa1">9,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi03LTEtMS0w_7b77d21b-d6c4-4463-8eac-954574ac86da">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Comprehensive Income (Loss) Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC0xLTEtMS0w_2a6b70ac-4973-40f0-b224-a19f3909e53d">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC0zLTEtMS0w_4ffb2fec-022f-447c-8d9d-aa764118ee05">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC01LTEtMS0w_ed29f38e-1815-44e4-94cf-8ba9904f51ce">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC03LTEtMS0w_cab06857-041c-485f-8c60-16c56f9f0e86">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 15.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on investments, net of reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS0xLTEtMS0w_2b78c226-8f1a-49fc-8524-90e99a82bbce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS0zLTEtMS0w_9719f9c1-137f-457f-bfb8-d2fd17903348">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS01LTEtMS0w_f676bdbd-2b82-4873-ae50-aadada7eeff7">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS03LTEtMS0w_b44f8c25-7a10-40bc-bd5e-30051065d1e5">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plan net gain and prior service credit, net of amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi0xLTEtMS0w_28445e26-2f58-41bf-a0b8-39aa0469bded">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi0zLTEtMS0w_31b91b08-2219-44e1-a8b1-cef10f5b4125">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi01LTEtMS0w_a901c26a-7002-4881-aea9-a425fae6c7ec">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi03LTEtMS0w_07f8d12a-b3d4-4377-999b-2b454e341d54">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy0xLTEtMS0w_6c28e73b-e4f8-4645-9c86-9c4e711a3202">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy0zLTEtMS0w_ce1a4494-a392-4779-b0ec-b671f813123c">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy01LTEtMS0w_c9f4c18f-ff49-4d90-b68f-8294ff2103b3">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy03LTEtMS0w_4a23dc8c-39cf-4933-9a8f-775917fc40d8">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC0xLTEtMS0w_3ee0f61a-119a-4e07-aab4-8b0e5c38fb6f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC0zLTEtMS0w_f7480f06-e35b-4742-a6e8-f2686cbe75fe">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC01LTEtMS0w_68ab0fa1-c299-4ff5-a1e5-e2cc396f81c1">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC03LTEtMS0w_0c4f4124-bd51-477a-a6f4-8a304f53b89d">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS0xLTEtMS0w_ac78967d-1d4f-428b-b88b-72a29b6484aa">2,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS0zLTEtMS0w_ef77b8b7-922a-447e-9e22-3a1733b3d1df">1,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS01LTEtMS0w_6a9aeeec-61b3-455e-b6e6-f3658074c9d9">8,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS03LTEtMS0w_2a4dd5a4-afd2-4757-8481-fd5202729d6f">7,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 3 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMy0xLTEtMS0w_3361c358-983c-41cc-be29-5c92ba652205">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMy0zLTEtMS0w_408073f9-3661-4c8e-97d7-c8d92566d449">9,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNC0xLTEtMS0w_fc56a083-380f-4edd-8728-76a610a687aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNC0zLTEtMS0w_77fff40b-6226-45dd-9065-e528735b895f">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0wLTEtMS0wL3RleHRyZWdpb246NjcxYTVjM2NlODg1NDdiZjg4YmIwNWIxOGVjNzZhZWRfMjE5OTAyMzI1NTg1OQ_2db3eef0-02b4-4701-b8b3-56f1e669d673">89</ix:nonFraction> in 2020</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0wLTEtMS0wL3RleHRyZWdpb246NjcxYTVjM2NlODg1NDdiZjg4YmIwNWIxOGVjNzZhZWRfMjE5OTAyMzI1NTg3NQ_b4113599-2f23-4973-b6bb-8602b043aa16">86</ix:nonFraction> in 2019) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0xLTEtMS0w_b06fb974-e8ca-4db7-88a8-e5504214de4d">8,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0zLTEtMS0w_66baf9aa-1a93-4dca-b9a7-2c5d46a31f1b">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0wLTEtMS0wL3RleHRyZWdpb246Mzg5M2E1MzYzYmQyNDEzNDk0Njg2MGNhNzU4ZjMyNjdfMjE5OTAyMzI1NTY5NA_b699de2c-84f0-4c80-b05d-600dfb8b59fc">2,081</ix:nonFraction> in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0wLTEtMS0wL3RleHRyZWdpb246Mzg5M2E1MzYzYmQyNDEzNDk0Njg2MGNhNzU4ZjMyNjdfMjE5OTAyMzI1NTY4OA_6ee4213d-806e-48cb-82fc-7f6ac1c64dd6">1,480</ix:nonFraction> in 2019</span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0xLTEtMS0w_6b1ea8d4-fe80-4972-84d2-50042eea08f6">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0zLTEtMS0w_861656cc-c54b-4459-a019-777f31eb8f69">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNy0xLTEtMS0w_05760fde-c74f-4554-8b7a-d6cbf2241fe2">4,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNy0zLTEtMS0w_06bbefc0-48e3-4679-b47c-ec5f151b9cf9">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOC0xLTEtMS0w_5b8a63e5-08d0-47a2-bde4-d3b68769cb59">26,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOC0zLTEtMS0w_728edfe3-37f3-49d9-a4dc-fdd6600617ea">27,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOS0xLTEtMS0w_bc0329f9-8f6e-40af-a0fb-d13022078bb8">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOS0zLTEtMS0w_a6718b78-af6e-4ffd-8665-4679231aca93">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, Plant and Equipment, at cost, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjM2ODg4ZGVkMWE2NTQyOTBhYmMwNGU3ZmM5NDg1NzY1XzIxOTkwMjMyNTU2OTc_fac30a97-7e8a-4e99-b0e3-139f0d6686f9">18,572</ix:nonFraction></span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjM2ODg4ZGVkMWE2NTQyOTBhYmMwNGU3ZmM5NDg1NzY1XzIxOTkwMjMyNTU2OTI_025a504a-351c-458e-95d5-58ff651e5b27">17,686</ix:nonFraction> in 2019</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMS0xLTEtMA_bd9e329b-b064-4149-9081-fc1e55d24247">16,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMy0xLTEtMA_49333215-0c3f-4018-8eea-8de2ee3c518a">15,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTEtMS0xLTEtMA_45719962-78ba-4db9-8c8d-18dc66f72e02">20,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTEtMy0xLTEtMA_5566a877-30f1-4832-9a4a-50d5a0eaf768">19,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTItMS0xLTEtMA_6c9d6a15-86f6-4281-bb46-27c540583fd8">16,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTItMy0xLTEtMA_6b5dc6e4-43a6-42f0-8189-a864b610b1de">14,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTMtMS0xLTEtMA_7211219f-3d61-4f01-9636-fc142d228d6d">8,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTMtMy0xLTEtMA_2c378a05-19a1-462c-a2dd-a0d29a7f7da0">6,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTQtMS0xLTEtMA_70daadad-3bae-4268-9f08-3411b5d360bd">89,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTQtMy0xLTEtMA_28e77943-7cc0-42e5-bdf1-c647a4dc9d28">84,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTctMS0xLTEtMA_6af2f9fe-44bb-442a-bb4a-452229864a14">2,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTctMy0xLTEtMA_03a5555e-0a50-46f6-8ef2-b9e206c66d0b">3,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTgtMS0xLTEtMA_82b91c06-664d-43af-ba4f-c85b604e9271">3,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTgtMy0xLTEtMA_8a306f9b-bf40-4611-a133-03fd8bf0de88">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTktMS0xLTEtMA_0ec617bf-82fa-4826-89f2-811a9a99d8ff">11,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTktMy0xLTEtMA_cb90dd0b-a52d-4fa6-ae58-dd52bb026164">12,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjAtMS0xLTEtMA_b3075df8-476e-456f-a02f-5bf90bb7c0b2">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjAtMy0xLTEtMA_cbc8b6e0-881e-475b-8578-df5da09f21a3">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjEtMS0xLTEtMA_d5b777ea-6627-4952-9944-cfe73be861f3">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjEtMy0xLTEtMA_253b92c1-60c3-4919-90fc-e7558afbe059">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjItMS0xLTEtMA_13ed3e88-b517-468f-922d-8b7f8f8dcb0e">20,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjItMy0xLTEtMA_f446232c-c6e4-4c55-81a5-90a46b231590">22,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjMtMS0xLTEtMA_76bbd25a-6df0-4a28-bc56-70621e81faef">26,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjMtMy0xLTEtMA_6cd683de-1f24-4f8c-8dd2-3500af3d8360">22,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjQtMS0xLTEtMA_1a402e1d-b925-4897-ac08-3ff05253417f">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjQtMy0xLTEtMA_68aa41cb-8127-43bb-9852-b9e371db13f0">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjUtMS0xLTEtMA_1430817b-7b46-4cf4-b698-9e3ca6ae2fff">12,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjUtMy0xLTEtMA_c0743511-809d-4991-bf28-8dac0a0e2569">11,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2NzI_88f01d58-0c3b-448c-9f02-8a3b9755ba94"><ix:nonFraction unitRef="usdPerShare" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2NzI_ab7d7c2f-73ef-4ab0-bac1-b52cf815f34e">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2OTE_3177a118-537a-4595-b3f5-e46db8f34875"><ix:nonFraction unitRef="shares" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2OTE_e466ac5c-bcc2-493f-9945-0cbedbd3b876">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU3MDc_68870392-6230-408d-a4cb-36a01e4de746"><ix:nonFraction unitRef="shares" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU3MDc_b8277376-7fe0-4e87-b9bd-e2819f0311a9">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2020 and 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMS0xLTEtMA_1328d8ff-7b5c-4787-875a-6720797a99c3">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMy0xLTEtMA_5695f6ea-172d-400e-8191-40f69c5168a7">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjgtMS0xLTEtMA_43905fb4-a695-41d3-a44a-938606d8c4ae">39,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjgtMy0xLTEtMA_bed4486d-1ed4-4b42-8413-6ad51d027dce">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjktMS0xLTEtMA_73daea13-b38c-44d4-a554-990f15cee6c6">51,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjktMy0xLTEtMA_300a0625-b3fe-4b77-85a0-58b8d4cb1e61">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzAtMS0xLTEtMA_e985e81f-c235-4d49-9ff2-6bab74c9c43e">6,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzAtMy0xLTEtMA_4a3fa19b-bcbb-455a-a002-4770432d9c25">6,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzEtMS0xLTEtMA_ad94d5d0-78f4-48b2-82ba-0777e9a35843">86,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityBeforeTreasuryStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzEtMy0xLTEtMA_ad1c0b3b-4280-4292-a8f3-a708ad59b914">81,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmQ4ZGQxMWQ4ZGM3MTRlMTJiNTIwN2VmOTdmZmQwNDc3XzIxOTkwMjMyNTU3NTk_d01ffa77-4ac7-4e2c-93e9-07e2734a474e">1,047,343,390</ix:nonFraction> shares in 2020 and <ix:nonFraction unitRef="shares" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmQ4ZGQxMWQ4ZGM3MTRlMTJiNTIwN2VmOTdmZmQwNDc3XzIxOTkwMjMyNTU3NzU_ab10cb83-f73a-4990-a7d0-0cd46723c7df">1,038,087,496</ix:nonFraction> shares in 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMS0xLTEtMA_8f71fd54-c737-4111-9cce-39a0df502818">56,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMy0xLTEtMA_348d8d67-0d40-490b-9348-f2f2e81f7c3a">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzMtMS0xLTEtMA_4ee808ab-6e8a-4b37-b9c2-b4eb0e113a04">29,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzMtMy0xLTEtMA_d3bb6f6c-c49c-42d1-a2cd-af3e9167a9ff">25,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzQtMS0xLTEtMA_836ff8f4-1fa2-4c0a-bbee-88ac7547aa5e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzQtMy0xLTEtMA_9f2606b6-ff96-4657-b24a-a19e3c378023">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzUtMS0xLTEtMA_9576d43d-b8cc-4d92-86c2-2239e13a9e14">29,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzUtMy0xLTEtMA_6e62b257-fd1a-493f-8268-d744c086f0ec">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzYtMS0xLTEtMA_d7ab91c5-802b-4f0c-a905-be0c00475809">89,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzYtMy0xLTEtMA_473bcc54-edb7-4a90-9417-07d973698f43">84,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 4 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMy0xLTEtMS0w_7eb2758b-128e-4ad0-84bc-0a6bedac97ff">9,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMy0zLTEtMS0w_d7dcb3a6-afdb-422a-8e4a-24a4f92e1bc4">7,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNS0xLTEtMS0w_181a99bd-bf4f-4c16-a691-f21a6d786e7b">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNS0zLTEtMS0w_8b239bcd-da09-4ddd-b620-7d221334ed8c">2,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment charges</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNi0xLTEtMS0w_08e8dc7b-8b3d-441e-b6df-0c3942f6db5b">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNi0zLTEtMS0w_cd527c7f-75f6-42e1-bef4-68cc59ebf7dc">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge for acquisition of Peloton Therapeutics, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0xLTEtMS0xMDQ0_5ad2651b-c2e3-4d67-9429-d736e40f7dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0zLTEtMS0xMDQ0_11569774-f8fb-4a36-a3bc-b2dfa711b6f0">982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0xLTEtMS0w_9b600dbd-77f2-411e-80c2-be6a60c1c731">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0zLTEtMS0w_3aab500c-78ae-4c14-8522-3627b848d549">386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOC0xLTEtMS0w_15438552-0455-4ae7-8314-47417f755e31">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOC0zLTEtMS0w_d419ba42-3a25-42d9-a7e1-40ae25db277d">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOS0xLTEtMS0w_ad1b8ef1-badf-4c4e-bb6f-70e94aa1b511">445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOS0zLTEtMS0w_6c9aa356-f244-472b-be63-e0107df24c67">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTAtMS0xLTEtMA_e30aa00c-c26b-425b-9579-0e3c3140e707">5,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTAtMy0xLTEtMA_c094d06b-c30f-47d8-876e-a537768d3bbb">3,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTEtMS0xLTEtMA_9a39bdb4-8201-47b7-9435-3d9546b635be">6,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTEtMy0xLTEtMA_2ef27be1-8583-4b08-ab47-538333fa3d53">8,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTMtMS0xLTEtMA_f7fd725b-bfd3-4ed2-8c31-590884432b0f">3,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTMtMy0xLTEtMA_5bc17e3c-dcd0-4a77-91cc-ced8a4081b82">2,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTQtMS0xLTEtMA_20802a68-fa39-4dea-a4ef-2cce291e1248">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTQtMy0xLTEtMA_aa9b3b0a-facd-4f25-b5cc-acd9cd3c8fc4">2,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTUtMS0xLTEtMA_dc470111-407e-482e-95e1-acc1b0ffa82f">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTUtMy0xLTEtMA_442bd991-d72d-40be-aa8a-1d69a4ba6921">7,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of ArQule, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTYtMS0xLTEtMA_72dae676-6193-4930-a3dc-4cd651229b3b">2,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTYtMy0xLTEtMA_4ae1a900-142d-49d8-a503-cfdbf967a8ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Antelliq Corporation, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTctMS0xLTEtMA_4c87778d-403f-4d8b-94ca-8c71d8315e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTctMy0xLTEtMA_8e6be62f-e55d-49f3-999b-fcf0d69e530b">3,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMS0xLTEtMTA1MQ_604b6333-7611-4ffd-96a9-ea244be0da52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMy0xLTEtMTA1MQ_9558e96c-216b-463c-ae78-48c7cbb93368">1,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTgtMS0xLTEtMA_f652c4e1-cbde-4389-8a71-4a32a6b865d2">907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTgtMy0xLTEtMA_9a9240d9-a182-49de-8c81-c94cf6ed7748">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMS0xLTEtMA_1accf3cb-2192-4276-8ed3-f3f0e6f27047">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMy0xLTEtMA_b7658380-1e18-473d-8a93-bd5685be1794">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjAtMS0xLTEtMA_f061f4ed-4d64-4c3d-b03e-1fa36853b170">4,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjAtMy0xLTEtMA_fe04fb3a-319b-43db-8a42-349478b43b8f">1,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjItMS0xLTEtMA_00db15b1-f71d-4477-a0b5-80a2ac937fb2">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjItMy0xLTEtMA_849e25e9-73df-4ace-af25-b1f9d6e8ff4a">3,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjMtMS0xLTEtMA_6b82126a-86da-4978-ad13-f678a790e5a0">1,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjMtMy0xLTEtMA_eb9f3223-e062-405c-a483-bf5c00418ada">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjQtMS0xLTEtMA_16786b10-2359-41db-856f-26508d8a730b">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjQtMy0xLTEtMA_ea32884d-8d86-422a-bd5b-bce119706976">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjUtMS0xLTEtMA_e6364eb0-bfe7-49bb-a4b6-34d8e974ec05">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjUtMy0xLTEtMA_7a260b82-8893-43df-beb2-8ede71c62714">3,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjYtMS0xLTEtMA_fed17fc3-dc08-4b46-8e87-8083778f69ea">4,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjYtMy0xLTEtMA_ea1f63b2-313b-45b6-9d01-fd525c00b844">4,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjctMS0xLTEtMA_8a0e3e24-d8e8-43e5-bd86-46afbc6cc35e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjctMy0xLTEtMA_16eef22a-a7c6-418c-a806-d9ac83b5b7aa">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjgtMS0xLTEtMA_ebb5164b-b5a8-4cc1-a4dd-06cd3014d897">472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjgtMy0xLTEtMA_4c2ff995-b286-4000-b744-5a84a334e3a1">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjktMS0xLTEtMA_91831937-3963-448b-92af-d48d2d562269">4,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjktMy0xLTEtMA_5a8648ee-840e-435f-ba00-7946dea9550c">6,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzAtMS0xLTEtMA_27b32802-b2b3-43cf-b7f4-5e3108e543a9">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzAtMy0xLTEtMA_e2f8e5bf-e85d-4e06-9706-673ac63b0fe1">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Decrease in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzEtMS0xLTEtMA_23fbd30b-a34e-4831-8b2c-c56e65163013">2,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzEtMy0xLTEtMA_51a10ed1-f9e5-4fc5-87d1-50509291b369">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash of $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJjYzlhMjRhODU3NjRjNjhhMGNkZGQ0NzZiMzYyMzlkXzI3NDg3NzkwNjk2MjE_d649fb31-6c8c-4400-83bf-1641c9b56921">258</ix:nonFraction> at January 1, 2020 included in Other Assets)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMS0xLTEtMA_ae0cbfbb-0a36-46d4-8fe4-f20863b6733e">9,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMy0xLTEtMA_38b7e6bd-8e0e-4628-92a3-cfa65cc0c889">7,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjUyMWVjMjUzNTljMDQxYWQ4NzcxNDUzNmJkMmE3M2RiXzIxOTkwMjMyNTU3NDU_aeecbea0-bd91-45c4-89bc-663b0d09efa5">45</ix:nonFraction> at September 30, 2020 included in Other Assets)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMS0xLTEtMA_59193a2e-08ad-47d0-a60d-11bf84d22911">7,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMy0xLTEtMA_2042738d-009e-434f-9350-ae90e2ec30be">7,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 5 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div><span><br/></span></div><div id="i67ef4e29db364327800e42a94e43496a_37"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU3Ng_cb3ccc5b-25ff-404c-8db3-8d42999b08a1" continuedAt="i1834351d6c794189909eaa76e75f2b2f" escape="true"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU4NQ_78548442-2f5c-4be0-9dad-6fc759324ec9" continuedAt="ie9237882e23441acae8ba45df42919ec" escape="true">Basis of Presentation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ie9237882e23441acae8ba45df42919ec"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1834351d6c794189909eaa76e75f2b2f" continuedAt="i85fb30ddd3cc4ecfa295c0cdfbea5c0a">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;26, 2020.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85fb30ddd3cc4ecfa295c0cdfbea5c0a">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into New Company </span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ezetimibe and simvastatin), as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#8217;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#8217;s consolidated financial statements.</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU2Mg_f66e58fb-e587-4f5b-9fe4-d3b7126374da" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 6 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTYwMQ_693a8572-17e8-4aa5-bda5-a378873edc0e" continuedAt="i93385c6e0da14de4ae798c6a92bed4a3" escape="true">Acquisitions, Research Collaborations and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i93385c6e0da14de4ae798c6a92bed4a3" continuedAt="iae64a19dd8be4a04b0d6f08ec018ef25"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $<ix:nonFraction unitRef="usd" contextRef="ia308feb215e043c1ac8a269b649d7e2c_D20201101-20201130" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwNTYxNg_58b3628c-4358-4d7f-9cc8-7fc5bc1ebb63">2.75</ix:nonFraction>&#160;billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio&#8217;s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase&#160;1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTY4NQ_b518682a-7d9d-4a25-987e-858e86de0b0b">600</ix:nonFraction>&#160;million and a $<ix:nonFraction unitRef="usd" contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTcwNA_a993be34-121e-4c68-8a26-7a5c83fba235">1.0</ix:nonFraction>&#160;billion equity investment in <ix:nonFraction unitRef="shares" contextRef="ia583d33831214bf4866a5542b0ff6a64_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTcyMg_c5910466-cdca-41b8-8bb8-71e740ada762">5</ix:nonFraction>&#160;million shares of Seagen common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia583d33831214bf4866a5542b0ff6a64_I20200930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTczMw_dc598bb2-a8f3-4484-ba07-c8ce98420b85">200</ix:nonFraction> per share. Merck recorded $<ix:nonFraction unitRef="usd" contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjMzNQ_c55f52ea-1e3b-4cc5-9508-409016082cd5">622</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $<ix:nonFraction unitRef="usd" contextRef="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjI3OA_b81d4d26-f4fe-4347-9c1b-65670f848a9b">22</ix:nonFraction>&#160;million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $<ix:nonFraction unitRef="usd" contextRef="i320a221119db4c07bc18a27ee248eb45_D20201001-20201031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjI5MQ_3907dd07-1733-4857-badd-4933ab3d6619">6</ix:nonFraction>&#160;million reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc1MQ_d9d41f48-d8bb-41f6-8b66-f8d38e202235">2.6</ix:nonFraction>&#160;billion, including $<ix:nonFraction unitRef="usd" contextRef="ib49be4558c154020a76d8aa7b2e8040b_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc2Ng_f0c9f9db-983e-46f1-8b17-cceab207bc18">850</ix:nonFraction>&#160;million in development milestones and $<ix:nonFraction unitRef="usd" contextRef="i8fca4df4602b4b828121637976fc9b3f_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc4Mg_7c430e92-4c08-45ff-b1cd-d9cd87055c52">1.75</ix:nonFraction>&#160;billion in sales milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $<ix:nonFraction unitRef="usd" contextRef="ib0ae7c8f36d1429f92d0302a0bd467cc_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTgxMA_414d8d00-d7f7-4a42-96c0-0b74fd207263">210</ix:nonFraction>&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i79f0266f7336448ca453ec3742701279_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTgyNA_66af8d38-94b0-4d48-b68b-be7c0b20561b">65</ix:nonFraction>&#160;million and will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i414ba63dcbe44cb0aabfd3725361a92d_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjM0OQ_585f40fe-c50b-4c99-9070-647cc4790c21">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6780cf4bc91a4f248379b2621aca7281_D20200901-20200930" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjM1NA_f21c03f3-bf5c-4184-88e6-433a71e3e539">33</ix:nonFraction>% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;<ix:nonFraction unitRef="eur" contextRef="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODI5OQ_726af914-4558-4482-8a15-d860b5635a28">256</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk3MA_723d61ad-8f23-4a05-a80a-868c5dfa686d">302</ix:nonFraction>&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $<ix:nonFraction unitRef="usd" contextRef="i735e835c710c461daa6baff4b2c9daa6_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk0Mw_25120c77-0ca9-45f0-96d7-270a68b7bfad">289</ix:nonFraction>&#160;million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="i735e835c710c461daa6baff4b2c9daa6_I20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk1Nw_76d720f2-e5e9-45a2-b53f-8bd9168fe569">13</ix:nonFraction>&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $<ix:nonFraction unitRef="usd" contextRef="i0898439e84514304bb0e2daef6e908ba_D20200701-20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMTEwMQ_3aacfe17-c137-4e96-ba9b-14656734b5c7">410</ix:nonFraction> million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ic7d789d97e6442d686b9da78d5403190_D20200701-20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI5MDAzNA_b1be7c15-17ad-45ed-a0f9-d8fabf2d22cd">401</ix:nonFraction>&#160;million related to currently marketed products and inventory of $<ix:nonFraction unitRef="usd" contextRef="i5c4f7a3740f64b7abcdfd5b44d05ccef_I20200731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NjEzMg_8c344d13-76a0-4e2a-bbce-1e76fd4438ff">9</ix:nonFraction>&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of <ix:nonNumeric contextRef="i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI5MDA0MA_5e9ea53b-4d05-45e9-b2f3-fdc88caed6cc">15</ix:nonNumeric> years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 7 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="iae64a19dd8be4a04b0d6f08ec018ef25" continuedAt="ie257efd17a49491c95b02b833d97d10c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $<ix:nonFraction unitRef="usd" contextRef="i414e40bb67fd4c20b343d703df377db1_D20200601-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjM5MA_617ea163-115c-4f55-970e-caf669ab8604">366</ix:nonFraction> million. Merck may make additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjQ1Nw_d6be6a1e-c3c8-45c7-aeb7-e04b9f7d3890">740</ix:nonFraction> million, including up to $<ix:nonFraction unitRef="usd" contextRef="ie31320a95b2645eeaad75930b67cd813_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjQ3Nw_314978ce-ab80-433e-89c6-e7ee7bdca1ba">80</ix:nonFraction> million for development milestones, up to $<ix:nonFraction unitRef="usd" contextRef="i8a2237c4c6b34455a09bda4fbaa26b43_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjUxNA_44b953ce-73d0-4310-b438-a603942c1ef5">260</ix:nonFraction> million for regulatory approval milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i9c438f84c119401f80abdd10e94d725d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjU2Mw_4d4b15e9-3634-455d-891f-ec6b0111f0bf">400</ix:nonFraction> million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase&#160;1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzM2Nw_4b419222-4c48-410a-8081-1eb7ac0fea1a">97</ix:nonFraction> million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&amp;D) of $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzYzNg_d4659047-4321-4cd9-9d5b-8296ddb3388e">136</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzY0OA_077b3f06-f2e4-4bd6-9753-42ddf59bf986">59</ix:nonFraction> million, deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzY3NQ_94949fef-b2ae-43ad-a291-d6f1d9db7393">71</ix:nonFraction> million and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzcwNw_e64263b7-490b-4220-8e69-780422081b3e">32</ix:nonFraction> million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="ic43ede995e004eca8e478b1619a43970_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzgwMQ_83934c47-9ee8-41a5-a538-a82ed29df163">229</ix:nonFraction> million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties&#8217; commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck&#8217;s approved Ebola Zaire virus vaccine, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ervebo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNTA5Mg_f7f70679-4194-440c-b0ae-755289bf8d11">6.5</ix:nonFraction> million and may make additional contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNTE0OA_2960e3c5-9b6b-4cb3-acbd-8b5e4ca45bdb">100</ix:nonFraction> million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $<ix:nonFraction unitRef="usd" contextRef="i81e81ff682db48488ca54b8292137c0f_D20200116-20200116" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjIzNA_857969b5-cfcd-4784-a5c7-1d5c371c8f35">2.7</ix:nonFraction> billion included $<ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjI0Ng_de94cef6-7372-400d-9c64-31960bc3bbaf">138</ix:nonFraction> million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjQyNw_81ba330b-4811-4a4e-a036-813fdc254f58">95</ix:nonFraction> million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2020. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 8 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ie257efd17a49491c95b02b833d97d10c" continuedAt="idc86b45706f84f3c9f9eea3f1f01bcc9"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTYxOQ_45744391-1527-4141-bec1-a58352b74dff" continuedAt="i6659e69c4e024e65a0d4f700f635c32b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMi0xLTEtMS0w_49eba494-b74b-4731-aec4-41df9cbc136d">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMy0xLTEtMS0w_0aea5984-9169-4a63-aa91-ff5b7687856e">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNS0xLTEtMS0w_6e3b6920-1ec1-49ad-ba17-df3d12d0c034">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNi0xLTEtMS0w_ebc8521f-bc22-4503-ac03-43e0d25230ed">389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNy0xLTEtMS0w_425b9ddd-eabb-4dcc-abb4-007ab29b165f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfOC0xLTEtMS0w_83647a94-64de-4246-bf32-a969a9037b62">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfOS0xLTEtMS0w_69383923-6923-45c2-8f93-4ab8419dd048">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMTAtMS0xLTEtMA_cd158cd9-8b4c-4694-8930-06cec1f45d43">2,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="ia1a7e2f30fbf4abfa7df8669c678d554_I20200116" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzI4OQ_daf4e9ec-381e-40b1-8afc-499465ca318c">12.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#8217;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#945; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9187aade515d4b17a57839461a710a17_D20190701-20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkxMg_cd26bb50-e846-45ad-ad39-7d94195420b0">1.2</ix:nonFraction> billion; additionally, former Peloton shareholders will be eligible to receive $<ix:nonFraction unitRef="usd" contextRef="i5ae34a9825984630b66dd918d954fcfc_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkyMw_ff32b1a4-6e58-4f73-ab62-172b8cffa5b4">50</ix:nonFraction>&#160;million upon U.S. regulatory approval, $<ix:nonFraction unitRef="usd" contextRef="i0baac3ebe43444669dc909ad981c9377_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkzNg_e50bc0c4-24ac-4c8c-875f-f71f1fd51188">50</ix:nonFraction>&#160;million upon first commercial sale in the United States, and up to $<ix:nonFraction unitRef="usd" contextRef="i5659ac2efe6a47eebd65404c8699603d_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk0OQ_0f619edd-78ac-47c5-bc1a-aa1e3b8e9d85">1.05</ix:nonFraction>&#160;billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $<ix:nonFraction unitRef="usd" contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk3Ng_ec75f6ba-4f13-4172-8bf8-5b883f77004d">157</ix:nonFraction> million, deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODA2Ng_7af72bce-5c1b-47d3-a68e-db6f505518c0">64</ix:nonFraction> million, and other net liabilities of $<ix:nonFraction unitRef="usd" contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731" decimals="-6" format="ixt:numdotdecimal" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODA3OQ_47db99ba-5f97-4d33-9198-6207254c16d2">6</ix:nonFraction> million at the acquisition date and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i9187aade515d4b17a57839461a710a17_D20190701-20190731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk5MQ_9f39a261-4962-44f4-8988-4ae2080cb669">982</ix:nonFraction> million in the third quarter and first nine months of 2019 related to the transaction.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $<ix:nonFraction unitRef="usd" contextRef="iea36cb2c86ec4304acd066b3b746ee37_D20190401-20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzc2Nw_ec5360b4-b675-45fa-ad64-96a4f4cb4b9b">2.3</ix:nonFraction> billion to acquire all outstanding shares of Antelliq and spent $<ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzgyNg_fafba0b6-de4f-4c63-a05a-cfcce597da70">1.3</ix:nonFraction> billion to repay Antelliq&#8217;s debt. The transaction was accounted for as an acquisition of a business. </span></div><ix:continuation id="i6659e69c4e024e65a0d4f700f635c32b"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMi0xLTEtMS0w_a4ab11fb-d4f5-409f-a3d3-b3a9007ce3b1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMy0xLTEtMS0w_29f14165-6248-41e4-a1c1-df2fe4eea6b4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNC0xLTEtMS0w_bbb4a3c4-e5fd-4b77-9bd5-698f995a3d8b">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNS0xLTEtMS0w_8d4a1148-69be-4bda-9c4d-ae011f01d712">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from <ix:nonNumeric contextRef="iaca125e93e984f7b91c7a53947611a63_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0wLTEtMS0wL3RleHRyZWdpb246MWFkMWYwMmJkMjE3NDdlNGFkMzgwOTQxYzEyMzE0NmFfMjE5OTAyMzI1NTYzMw_3390e690-1cee-416b-90bb-d2eb90452eae">18</ix:nonNumeric>-<ix:nonNumeric contextRef="i1f9c5cc14b4a4bd59f6fd4bca8f78bcb_D20190401-20190401" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0wLTEtMS0wL3RleHRyZWdpb246MWFkMWYwMmJkMjE3NDdlNGFkMzgwOTQxYzEyMzE0NmFfMjE5OTAyMzI1NTYzOQ_f775b383-0650-451b-a161-cb61190d0f5c">24</ix:nonNumeric> years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0xLTEtMS0w_4f20b510-b803-4350-8cf1-fa28c3f7e3e6">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNy0xLTEtMS0w_77fc9eb6-03af-48b9-9ae6-b653b4220c27">589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" sign="-" name="mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfOC0xLTEtMS0w_bef8194f-0e47-4d12-be49-b8f37a147a5d">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfOS0xLTEtMS0w_c931fa19-7545-437b-b336-28d25dac186c">2,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMTAtMS0xLTEtMA_c4d044d7-e718-4cca-a025-801733032617">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMTEtMS0xLTEtMA_7246c37a-6fcb-46af-af11-9e7443554318">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="icd675ee00e0c4fdda383d5adb62f0478_I20190401" decimals="3" name="mrk:IntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfODI1Mg_f64c0b3e-b459-4085-ae12-794de02006cd">11.5</ix:nonFraction>%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfODY1Ng_c680db17-4827-4e8d-af59-88bb5d82d7f5">47</ix:nonFraction> million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approaches to enable the body&#8217;s immune system to fight disease, for $<ix:nonFraction unitRef="usd" contextRef="i074bf99e14004c60960bce1f01d121b3_D20190401-20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTA1Mw_6bf9e47f-d751-4013-8996-3e4fda58f5b4">301</ix:nonFraction> million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTE3MA_16d694c6-6006-4b00-a898-d764c72115a8">156</ix:nonFraction> million, cash of $<ix:nonFraction unitRef="usd" contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTE4Mg_3fb7278e-03f3-417a-a5c0-5299147b1a3d">83</ix:nonFraction> million and other net assets of $<ix:nonFraction unitRef="usd" contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTIwOQ_07c34679-02ac-4ae3-9066-1dc15a35cc34">42</ix:nonFraction> million. The excess of the consideration transferred over the fair value of net assets acquired of $<ix:nonFraction unitRef="usd" contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTMwMw_eaedb1f0-ce37-41c8-880c-477f0fb61108">20</ix:nonFraction> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 9 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idc86b45706f84f3c9f9eea3f1f01bcc9">million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.</ix:continuation> </span></div><div id="i67ef4e29db364327800e42a94e43496a_43"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTg3MQ_3f4bde70-7a4f-44b7-9a13-07f9823ecb1e" continuedAt="ic0681c2089cb4168949c9fbccbbfacd6" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="ic0681c2089cb4168949c9fbccbbfacd6" continuedAt="id16bd54efa0d479cacd1786a6de30344"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca&#8217;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca of $<ix:nonFraction unitRef="usd" contextRef="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731" decimals="-8" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMjc2Mg_3248d3fc-b237-4aad-848c-e6b789d64cca">1.6</ix:nonFraction> billion in 2017 and made payments of $<ix:nonFraction unitRef="usd" contextRef="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731" decimals="-6" format="ixt:numdotdecimal" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMjc5NA_2e51b875-5955-4f7a-a9d4-7ee509a4062b">750</ix:nonFraction> million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $<ix:nonFraction unitRef="usd" contextRef="id8dd786e26d1477aa8bd45ad2b6f3c5e_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzE0Mw_8fb88c0b-adb6-4201-97d6-43d3b5bd65d9">400</ix:nonFraction> million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="i96b4efb9755a49cfbb3e9ad58fc1264f_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzIzNw_4211c389-b3c6-4ab0-8af3-f5a86c730a5c">400</ix:nonFraction> million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="if0cbbe2696d440b882b0f472d8d42ccd_D20170801-20191231" decimals="-8" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzM5Ng_bc79b1ba-55c3-40c3-b3a9-160301852bf3">1.0</ix:nonFraction> billion related to Lynparza, of which $<ix:nonFraction unitRef="usd" contextRef="i36b53eb43aee4f21bc681f524ea62b7f_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQyOQ_7e07a524-2ba9-439c-b348-74408af5ab73">200</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i20b40407b64e47609c2aa82a3959404e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQzNg_9bbaa068-b357-4afe-988e-caf2b8d40fa7">250</ix:nonFraction> million was paid to AstraZeneca in 2019 and 2018, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i65572a08fd174295982fa8fbf05e5d45_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQ5OQ_95a7a97a-a4ca-4956-9513-1539f706adf2">250</ix:nonFraction> million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="if4fc5d236d7843638ab3281a103c93b7_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzU5NA_9a99d31e-9c41-48eb-86c4-85b3fb67a13f">2.7</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="iee9da70429aa4ac0ba5c6fc6bbe4b20c_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzgwNQ_4f52e4e7-3284-47f8-a2a9-c66a08b79100">135</ix:nonFraction> million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i39a12f6da7654fefa46f0e8502eba97b_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzkzNw_8b1e0541-f195-4314-af45-ab7eb1d0a34f">60</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4306e1310aea4c4e8219428ac7a74614_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzk0NA_b0a8c520-d958-4b63-b548-0ec5c87f88ab">140</ix:nonFraction> million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i26a49639fd9e44fc80d9d728cf4248ad_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNDA1Ng_8c38a3d6-ee99-4271-a383-ccf0a6c011ec">1.4</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i0af7869909e242429c04502cbac1701d_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNDIxNQ_55470778-6bc2-4a4a-9fae-94f0f0bd8fda">1.3</ix:nonFraction> billion at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 10 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id16bd54efa0d479cacd1786a6de30344" continuedAt="iae89be00097e4721b30522a0e4e4a9bb"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTg3NQ_5f12b1d1-6c65-45f0-88e9-e4fcae112071" continuedAt="i1b8f433ef72b436cb00857f23e1e5527" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89e4869799c4eddbb76087e4856f6e1_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi0xLTEtMS0w_f61a2fba-938f-4855-996a-51aa71a2a52b">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbf0955eb8b4c4d98918582883b0e4a_D20190701-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi0zLTEtMS0w_335ae0c3-96ce-4041-8eb7-a77d7138772b">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d48c63441f485a81bc70510125df4a_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi01LTEtMS0w_933e8cda-4f78-481e-9754-99584e4ef34d">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc67ca1d79b4a9d9c65fbadafe2ed03_D20190101-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi03LTEtMS0w_d3070641-e82d-4080-882c-18e841cfc945">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8682bf21cbf4722b662136970328362_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy0xLTEtMS0xNzY2_a07b09e5-3654-4062-ba6b-51befd0d86d4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8418200bd3474a8989d1feeaac0927f6_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy0zLTEtMS0xNzY2_f77c0835-c7fd-4165-aff6-1b3bcade5b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8baff54113d34962926404de668611aa_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy01LTEtMS0xNzY2_c490a06d-26cb-485e-8788-237874308b00">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b54f758421c483abea6109fc48d1294_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy03LTEtMS0xNzY2_a93ca814-c651-4e62-9464-9f4709bfa8bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672e14c8326e49119792c5a739d15560_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0xLTEtMS01Njg3_5286bf21-0e8e-4f5f-bce9-b4752c8e688a">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff28471372f43c4aeca73d2b047bf8a_D20190701-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0zLTEtMS01Njg3_b55b9fe1-48dc-4b9c-bf64-9e1ee7c5a5ba">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e7fffaaeaa473495ffacd2ac50867f_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC01LTEtMS01Njg3_71a5419a-fa63-4cba-8ffa-3c9bc043d25c">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id915e0532c914695b005384447c665a1_D20190101-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC03LTEtMS01Njg3_0f2ff944-58d0-48a7-8d46-3cab28306b15">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a1dd31df764266bc67364b6f1a7916_D20200701-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0xLTEtMS0w_07930633-7cac-4134-8d35-6bf30ef39e06">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3121da41fc0647a98833a789f5fdd4ec_D20190701-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0zLTEtMS0w_12071b2d-cdde-4a9c-961a-c49dd66495db">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6fe6accc36045aca588c404c0b2cd07_D20200101-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC01LTEtMS0w_076d12ff-f909-4fdd-a08e-aee9f9815ca7">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40f44394c1e4c1bac21ea2a06244edd_D20190101-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC03LTEtMS0w_fb2eaf86-49d6-491c-b674-ce58a499e18f">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8f3b8efe9043f9aacc552835d92b46_D20200701-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS0xLTEtMS0w_20008ee2-7859-48ef-9a21-6160a707095a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea90d2039c7141dca1496ccaa589ecc1_D20190701-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS0zLTEtMS0w_a06bb909-0da4-4e23-b4a1-2ebd0b0da5e3">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203c7a3ab0ea46d4a6dc810ea5880354_D20200101-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS01LTEtMS0w_338cb977-2521-453d-854d-ed59416b8189">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452c7b783504434287bc42a63fca472f_D20190101-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS03LTEtMS0w_56252b2a-2290-41d0-ae51-483e7843d023">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4812ae09bfa4ee1a36daa5fabe59052_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi0xLTEtMS0w_5f93ccc9-4511-47b3-8caf-af125263d8e8">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97f1dbf8ba2e4ace97a8ff751592fe5d_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi0zLTEtMS0w_02fa446d-c501-4662-877a-415a6ead5e84">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc77ff7d3d2418fa16f24a6c043ef75_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi01LTEtMS0w_369c2e10-a4b1-46f3-8f87-7cc2451d2896">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09080dd93c834c57b9ebff1a5663ec83_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi03LTEtMS0w_89ebbd00-cac6-4c22-a21b-da001ba1236b">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09aa6a0b51c94fd996e7402de95de2be_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfOS01LTEtMS0w_98958f2f-59a2-460a-bb34-8076a0d5f6d8">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30c830280f947a689d5b271c94dc69a_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfOS03LTEtMS0w_d764b6cf-b71e-47b5-b0e7-d19b0dfcc4a6">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTAtNS0xLTEtMA_92582369-2a9a-4c65-b8b4-6ddec25a20b6">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a278d539314213bd6e5766dd997779_I20191231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTAtNy0xLTEtMA_b6b0df51-f4d2-409e-8e13-34b8211138bd">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTEtNS0xLTEtMA_ebb77af5-de1c-42a1-a2f6-bce35d5c42d7">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a278d539314213bd6e5766dd997779_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTEtNy0xLTEtMA_754f8f56-2a33-4152-b408-4261af2ffbf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai of $<ix:nonFraction unitRef="usd" contextRef="i355c8a370ea34624aebfc74a71246fae_D20180301-20180331" decimals="-6" format="ixt:numdotdecimal" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTgyMg_7afa4f8d-fab7-4494-ad96-4d3a9f93ac90">750</ix:nonFraction> million and agreed to make payments of up to $<ix:nonFraction unitRef="usd" contextRef="i5ef5983f652b4f678745213cc80d39a2_D20180301-20210331" decimals="-6" format="ixt:numdotdecimal" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTg2Mg_11c4495c-1136-4dc4-b733-16ea5a7ef4b0">650</ix:nonFraction> million for certain option rights through 2021 (of which $<ix:nonFraction unitRef="usd" contextRef="ia70a1af19330475d88753e88f14c38c2_D20190301-20190331" decimals="-6" format="ixt:numdotdecimal" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTkxNA_70ffba83-bb84-406f-a7a8-6c493cc81c9d">325</ix:nonFraction> million was paid in March 2019, $<ix:nonFraction unitRef="usd" contextRef="i8da39f245c784880b54370510f8d89b1_D20200301-20200331" decimals="-6" format="ixt:numdotdecimal" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTk0MQ_8542a9a6-1fa0-4dcb-8a2b-7fc081e8c68c">200</ix:nonFraction> million was paid in March 2020 and $<ix:nonFraction unitRef="usd" contextRef="icba8f4a74d444bcd8400c0863cd3c92b_D20210301-20210331" decimals="-6" format="ixt:numdotdecimal" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTk3MQ_2cd36c30-9620-4445-9eb6-998e68e9c44a">125</ix:nonFraction> million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="if9f4566b3c6f4506b767bc5d2b892db8_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjM0Mg_21833d65-ac23-4007-a42a-4edc1840432c">370</ix:nonFraction> million from Merck to Eisai. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="if5f82b5879934498baf8420915f61a2a_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjM5Ng_d1fd80d5-861b-47e8-89c5-d1697afb161a">370</ix:nonFraction> million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $<ix:nonFraction unitRef="usd" contextRef="if3fbe331c8084a23bccb932806d23825_D20180401-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjU1NA_df270193-c5b7-4ef1-b1bb-260bac9b9d03">950</ix:nonFraction> million. Of these amounts, $<ix:nonFraction unitRef="usd" contextRef="id5002ac2a1b5410cb178591c19cc6f15_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjU3Ng_69de8e87-d8cc-4c9e-a029-db4387e635ff">50</ix:nonFraction> million&#160;was paid to Eisai in 2019 and an additional $<ix:nonFraction unitRef="usd" contextRef="i245fd78ff94042f9bc0ed66ef072aafd_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjYyMw_ab12bd4e-db4c-4c96-bdef-2110ba74356e">500</ix:nonFraction> million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i7d59f0ea051148e99f9ddbfbb6a91314_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjcxOA_fee9972b-9876-481e-be0c-d04482c9d16a">2.7</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id0f502109a8d408591929847e1ec04c1_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjkwNg_1964960a-445c-4c96-af63-c542aa4649bb">250</ix:nonFraction> million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ia08506df034040a0a6bc566e66e0b025_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjk5Nw_2053cb68-b734-4a45-8a1a-c3210f2343b6">135</ix:nonFraction> million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i0ff8630eade846b29dfa54f515c419a7_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNzE1NQ_d1a7e246-3428-470d-8cc0-abfa92b37921">1.1</ix:nonFraction> billion at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 11 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="iae89be00097e4721b30522a0e4e4a9bb"><ix:continuation id="i1b8f433ef72b436cb00857f23e1e5527" continuedAt="id0bc03216fd7439bad437b95bb026888"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ce8a9c45264255b55253efdffbee5a_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi0xLTEtMS0w_a3361e0a-7394-4630-b597-9d66531f329a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd5ed28ae9c4290ae150fb16d9466fd_D20190701-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi0zLTEtMS0w_1be8c3a5-3406-4141-a002-6438017e22e5">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05babc5db48d458d8839840a56d0a9c1_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi01LTEtMS0w_1320311b-c913-4314-9906-cf90f898298e">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d38eaf8021744fe8f4dfab94a5015fa_D20190101-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi03LTEtMS0w_8a880dc3-990b-40b5-9f49-33c76142a993">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29d30b68df740dfbc20eaab83dc5e38_D20200701-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC0xLTEtMS0w_99e03be5-9e99-40ae-8585-470e8a395de8">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7336913b5b4a20a439157fdc51f46f_D20190701-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC0zLTEtMS0w_eb81cf71-b5aa-4104-a22a-c600a928f695">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc67bccad40d470c9949756b7eb748bc_D20200101-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC01LTEtMS0w_1ef8f84b-732d-455c-b934-a490b1d376c7">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb427d5a13434a21a6ed491a4dd0e763_D20190101-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC03LTEtMS0w_d5363df5-e052-4cc5-be28-6dc7414711ec">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bee3c7f7024b5281e40456c78625e3_D20200701-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS0xLTEtMS0w_8cd0db59-9459-4c5d-8ad5-4a4e731ad4a3">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ff54672a98446994645788d1f59463_D20190701-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS0zLTEtMS0w_478ecab8-63e9-4422-8eb6-a9d6c258c8ef">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida9b2e380dc5459f818bd1f423bdd1c2_D20200101-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS01LTEtMS0w_4741426e-ec62-4f7c-b4b9-3a0ea2418a50">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ab39e6826f45b7a3da069eaebd2a39_D20190101-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS03LTEtMS0w_099af6e2-23b8-4223-bffa-a64734a30de0">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734edac95cf34e8d8c5aa9e71b9f85ea_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi0xLTEtMS0w_129e97a9-d877-4f15-8d05-31602db570cb">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3d3057a1b74664bfffcee79d494ca8_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi0zLTEtMS0w_26fa53b2-a803-458e-8b4c-368d06459c12">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f27f8096b5447d8aa97005ecfa5902_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi01LTEtMS0w_9bbdff76-c637-412d-9abc-3768786f135d">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3debc0d591324b7ea043d28f9093108a_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi03LTEtMS0w_1d51e378-668c-4010-8ff0-9dc3f6afa074">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3240881da60142e5953a1ec3857fb0d4_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfOS01LTEtMS0w_10fecbc0-3cc4-4fe3-b8f3-fb648e02dc66">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia949281fca194d51bc2b1de185ec698d_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfOS03LTEtMS0w_f68f6279-6d73-4ee7-b97c-e4e361e4ae8b">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4715d086fff4408be90ea9d32249068_I20200930" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTAtNS0xLTEtMA_b6278e58-d0f2-4e62-bda5-46f5bd481ac3">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ce31a9d972414f87e8b9b510ffd15f_I20191231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTAtNy0xLTEtMA_a8ba839c-4db7-41c5-94b2-b129ff2d68eb">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3cda8bb28a46d5bcadf58cfcbba40b_I20200930" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTEtNS0xLTEtMA_42c05789-0d7e-436e-aabc-85130bdc9e69">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9bdb7de8f0e4a9593cf268c8664a7ab_I20191231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTEtNy0xLTEtMA_991f5db2-b121-4591-a12b-38582020eb1f">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#8217;s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck&#8217;s share of profits from the sale of Adempas in Bayer&#8217;s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, Merck accrued&#160;$<ix:nonFraction unitRef="usd" contextRef="idedcac7eb55940d8bf55d7f495fee349_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTAyMw_79e63b1a-09c6-4e06-992b-04e63dce0909">725</ix:nonFraction> million&#160;of sales-based milestone payments for this collaboration, of which $<ix:nonFraction unitRef="usd" contextRef="i08b439500c8b4e4db9be5c2fef7ba050_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="mrk:MilestonePaymentsMadetoCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTA5Mw_db132591-340c-4efe-a5a4-2358d2aa0c55">350</ix:nonFraction> million was paid to Bayer in 2018. There is an additional $<ix:nonFraction unitRef="usd" contextRef="i43c3eb857ced458dafba143b0afe517e_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:ContingentPaymentsCollaborativeArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTE0Ng_6bff8867-688c-40df-a53c-6ad8858e3064">400</ix:nonFraction> million potential future sales-based milestone payment that&#160;has not yet been accrued as it is not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i496aa343ecfe4651b28bd840131d00b5_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTQ2Mw_6ad2fa9f-e99e-4781-8081-69a1475a8aae">838</ix:nonFraction> million at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="id0bc03216fd7439bad437b95bb026888"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi0xLTEtMS0w_b3082246-3e30-4590-9a34-5b0a9efba5ce">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi0zLTEtMS0w_29369201-9213-4a99-861b-313ef8a06ea9">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi01LTEtMS0w_e9617b70-f3c4-4b19-a9b6-c1f64b70276a">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi03LTEtMS0w_9cd1cd39-5c04-4a10-b427-cccba8c9cf5e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy0xLTEtMS0w_1a1b0728-80bf-4ddb-aee1-0d720acf9092">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy0zLTEtMS0w_48c7c382-730c-4131-8a29-f906f7aae061">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy01LTEtMS0w_c75c1269-4336-44ac-a7d0-0c47b2885f38">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy03LTEtMS0w_ff0f390c-291d-4552-91d5-96fd121f54c4">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC0xLTEtMS0w_29a7b169-829a-4b98-b6ef-3bbb1c58a573">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC0zLTEtMS0w_deac5859-b1a0-4ad9-aa80-7683d27aa81f">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC01LTEtMS0w_ff554bbf-730c-4050-87f3-de1a24a0fe3a">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC03LTEtMS0w_037a57f6-e7c2-4c71-87c6-63f4f13e62ab">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c74758a3e84c32b5a4934acd2a2e76_D20200701-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi0xLTEtMS0w_d893c0bb-5d66-4b9e-beab-40b2a5723fe6">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3150bde02fd14893b33da1eeac0249de_D20190701-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi0zLTEtMS0w_af1ad37d-e0f8-419d-b9ca-1db18810f34e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8461e98ecef64dbebc07597db5b84152_D20200101-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi01LTEtMS0w_c17cf2eb-44e3-46b0-9ee5-29083f0e86f2">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id073b72dfd8d4b199dcc27df47315e69_D20190101-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi03LTEtMS0w_498cacd9-e5ab-4109-b34f-fa33f5149b76">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a955d765ba34e32bc493ef244feee8f_D20200701-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy0xLTEtMS0w_c899081f-fa60-4eae-925f-f3817b3f5733">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1082a8df5454aa3ad070d4a15057c2b_D20190701-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy0zLTEtMS0w_2894d60a-7979-4650-8022-a2ced57c66fe">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e2f7775e904a7b98b34ad10b77040a_D20200101-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy01LTEtMS0w_6b72d925-b4f4-4c22-aef9-83d67caf9c29">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991fd53b18024cf78c8d36aca923947e_D20190101-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy03LTEtMS0w_9faa96d7-1113-40e0-8937-b22e29bd52b3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ea86431ecd4511a44c25d8a18f135f_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC0xLTEtMS0w_0232f5ed-df4e-4d37-91bd-25527e3f7b6e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfdc92bf6c724ec79c32415e7d58a9c8_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC0zLTEtMS0w_dc22a0b7-4cfe-442c-9cf3-51c22f97d69d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b86f1b1c991406c8b65e857fd90f944_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC01LTEtMS0w_6dedf595-b278-4d0f-8f1c-f7ff3ddac7a4">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaef7e6bfd9d488cb6176aec4c7b915e_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC03LTEtMS0w_c44489a4-9638-4a88-900a-0f2001082308">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia602b90ebc2445e0b159157c4045d0a6_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTEtNS0xLTEtMA_6eb64e61-648c-468c-a8ee-1b9d8cbdcfc1">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416b15a8a7a9405fa9afdca4905b3480_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTEtNy0xLTEtMA_13878d81-8645-470a-9340-8f653824cff5">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2305d63e914c5a801615d0a836fd82_I20200930" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTItNS0xLTEtMA_6d38e9fe-181f-49c8-866e-64b0b08b40a6">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e55f5c070a64f55b6535d792904a04d_I20191231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTItNy0xLTEtMA_3934e57e-5144-4d79-950f-8b0ada78f400">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 12 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzcxMg_42276795-58f8-4ea2-a137-4015ea08eb90" continuedAt="ibc2213ab1f3949f79e0595b91bce44dc" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="ibc2213ab1f3949f79e0595b91bce44dc" continuedAt="i4c78e2c595404babafce10b7d1c0d271"><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfOTI5_3e3f704b-121d-4d53-be1e-958054752a7a">2.5</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfOTc0_0600b708-4fd6-426e-a4e3-847b26b2550f">60</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTEzMA_9a2a6f36-9dfe-487d-b47a-e92a55af3c12">40</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i03df5735331c425896e06f66d7b5f298_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTMyOA_28dcc437-530a-4237-b0e8-ca1ca180e389">800</ix:nonFraction> million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTUwNg_392ddbca-8c6d-4303-a106-bc13729fa5a7">186</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTUxMw_0b538ff8-246d-4882-a7fb-7ab3e339f903">296</ix:nonFraction> million in the third quarter of 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTU2Ng_e9f28ddb-3c23-4216-a47f-964eae820e0e">504</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTU3Mw_d5e81c36-db80-4caa-964c-ee62185263e1">642</ix:nonFraction> million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2020, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTgwMQ_4753b5d0-d233-4735-8b1a-3b03b2595d7f">1.4</ix:nonFraction> billion. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzczNw_59f08bb9-2daf-47ac-ae89-c4662bcdd3a8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5366f568814c48f7b7b07bc4f56ba7d6_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xLTEtMS0w_33bf4439-5822-41e0-a1f4-92cbb8a40cb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e35b84854a44c8979089fcdc6b2904_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0zLTEtMS0w_ee469ff8-987d-4056-9aa2-dfb232137961">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ef15a431a448c983ceb5183ff67376_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi01LTEtMS0w_cd22a2c2-94b8-44ce-877d-bb771b5a48a6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi03LTEtMS0w_667ce273-fb20-4438-a5a9-afbcd378d667">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf78bc89101f49d49da83f8937116a1c_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi05LTEtMS0w_09d41b67-e9db-4289-9e04-0b8ba45f1851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica4a5bb3156148598a1e1f9ae18ef04f_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xMS0xLTEtMA_d08a267d-6c4b-4539-a5b6-e73c418c9dc4">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe562f89249d4b43afbae31ab4ce846c_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xMy0xLTEtMA_64e4b8b5-10eb-4b24-9e4b-46899b69294d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e10375bb6d64e70929401d584732bef_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xNS0xLTEtMA_af5572d5-18a4-4de1-b04c-37287da4dae7">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fecd12fd431414ab4ca6f2ad011b352_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xLTEtMS0w_a1788581-6846-4059-a91d-9f4b8156f1d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690cdcbbd385411cbf1ba1c4cd5fdb4a_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0zLTEtMS0w_e7433926-d8f4-4298-8546-e1b56577cc75">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb0c8a5aab924e72ab1c5b49254dc12d_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy01LTEtMS0w_d01efc7f-fa8b-47f9-be13-2a73cd4aa16b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed7648249e34fcc824408b9de77708f_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy03LTEtMS0w_d337e990-cf06-4631-afe3-3418ac5aad42">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib983a94ca97d45f787f3cb16f067a659_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy05LTEtMS0w_623437e9-3870-4ddf-9c74-eed089719ddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195c75449a61434aa05bc8da3256a067_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xMS0xLTEtMA_9d9318b1-3e90-42f1-8aaf-c556a010b585">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08999a59917842e88f521971cba054c2_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xMy0xLTEtMA_bac2dd1b-f551-400f-a7b3-3a17f6ff7eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bebe903b23d4dcbba8ed1365bd1e791_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xNS0xLTEtMA_95b3b392-3370-411a-80a3-019c526511ad">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3ad757a3474d31b0358ffd8bcf1d49_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xLTEtMS0w_b9da0f28-a3fd-4761-afed-e30f86566638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9d1ae3982047b5add76445bf5210fc_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0zLTEtMS0w_975336a6-06c0-4c25-96b0-6f9814beb248">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia027800bf45f44df94cb3963582a6506_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC01LTEtMS0w_1d838c0b-b8cf-4ae0-bd3a-f084af8672a5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i070cc173e6a448f3a98d517737a45927_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC03LTEtMS0w_ca770487-051d-4770-b98d-7001ad795a82">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55afe91875264dccbe9dfa4dc20872fa_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC05LTEtMS0w_583fe504-e1b9-4421-8e76-2c007596b9d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae06c8a7ac2342d19a9a90933b904d07_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xMS0xLTEtMA_34049407-1583-488b-8ead-d69de2e75ea1">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib375dc6a1ba24c1881cabe25f15d7706_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xMy0xLTEtMA_8b5e12d1-c356-43b5-8ceb-4d7a98d4470d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d0d80e338f41339faf6f80cc02c591_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xNS0xLTEtMA_638311bc-1b71-4a8a-b0a8-8220e017d248">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991711e49c2d4dd69b0c61a892af6fbe_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xLTEtMS0w_541d75e8-eac0-4e70-ab61-360aaa4cc770">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8018c802ee402783f4d35dc51c8a4b_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0zLTEtMS0w_0372de24-d2b2-469b-a0a5-aaf784ba7e15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17880d14005f4047b6465ac23055841e_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS01LTEtMS0w_332ed2f1-a6e7-4c1f-ad65-11f6cee8f8f5">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b8c757f331f461eab0d5987f837a626_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS03LTEtMS0w_b53fc92c-e817-460f-8341-6813921c6e22">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900f54b60fd94491a712d08a359324a3_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS05LTEtMS0w_cbe89a58-3207-401d-923f-4741bba86b25">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e78a92e49843fbb9317beadc1eba25_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xMS0xLTEtMA_b057e401-eaeb-4947-9362-b6c19a086f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5d2c7cc4af4df5910fd6327736a5b6_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xMy0xLTEtMA_49c23ea6-ffae-4ae3-b341-f4e02e1e2193">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e8aaa546894b88aacd797ac4581098_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xNS0xLTEtMA_e168cd3e-a643-4d19-ba60-7b0aa940b799">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82edc63f8c3749d78bc298cec6f0f96d_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xLTEtMS0w_4f888323-67eb-412d-bcf2-54ac8b83e474">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f385b2ccdba4576aedf43c72125dbbf_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0zLTEtMS0w_cedb0ea9-40b5-4bed-814a-a9b716cc0a1f">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ee7a7c59a64fea97d7f02763d319bc_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi01LTEtMS0w_b74d1fda-2f8a-4b8b-9582-6f0f5e61c050">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi03LTEtMS0w_2983ad8a-992c-4e92-883d-af0ace0621af">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi05LTEtMS0w_1253d582-3f75-49d4-a364-74f8335fb52f">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xMS0xLTEtMA_f0aab30d-8b04-4d05-8500-64ef91093197">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xMy0xLTEtMA_ac7e836b-c25b-4850-90a5-ec6ae398e1b0">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xNS0xLTEtMA_b8218a44-63b7-46cf-b03c-64c9805985f0">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6098e7148348ea895e9410942d889e_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xLTEtMS0w_0f8e6214-c89b-4eb6-beb9-8c109d6bd47b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11d46afe5bb4d4dbe9c00eaac1c3492_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0zLTEtMS0w_d8776eed-ab96-4cee-8d2f-ce247dc14e76">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i472cfcc469764447a0758f2c876c9790_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi01LTEtMS0w_c9999a82-bf41-4f3a-a96c-f791d0834932">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3c8924793a4372a8741bdcfca35bf5_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi03LTEtMS0w_7fa60e78-d123-425c-aa03-046d0c569626">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id249057c9eac47108ca7d3ebbb591f6f_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi05LTEtMS0w_ed330841-a39e-45bb-9a27-276d6e813679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ae315aed51b4ef5ab252fc43e7d39c8_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xMS0xLTEtMA_d7234b51-c5a8-499d-b511-8edc6fb29f20">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad00d781aca4014ad7705b32c5aab4c_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xMy0xLTEtMA_e56af9d5-a765-4459-92d4-22c21baef6be">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eda964c1d12432095177f2a403fe8bd_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xNS0xLTEtMA_1b41bbe7-0614-4eed-9e80-314c11eb0c2e">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2cc47f55874d4da7e7cb748a8de516_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xLTEtMS0w_ed8a4c68-9817-4516-8cb4-aedf4d76d2b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5ff6ca1aa444b5b1aca886da4f6507_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0zLTEtMS0w_75aded07-4afd-46d3-8289-33a65d1389ca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88c550ca65b41a2a95b1c07df1dfee2_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy01LTEtMS0w_77412aa7-88fc-474d-b75c-cd381e68e665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5f714e7bf04709ab68bb6d0c04368c_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy03LTEtMS0w_2888e192-de6a-4474-9eb7-b9b1abcfd44f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b2c9576daf42aaa97debb74c377ea1_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy05LTEtMS0w_a3f717d1-6b16-436e-a813-8daf7ae77e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4115454e07d24a8e9ac482d5f838c14d_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xMS0xLTEtMA_437f397a-be47-4b51-b362-fbb27f15ae9f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5971c370c69444c08c083e89b5e5cd63_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xMy0xLTEtMA_594612f7-1f96-4d70-be42-14fe7214fc99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aa77d775fd4917ac86fb7ae4074f65_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xNS0xLTEtMA_83037c64-26c6-4492-8be5-e67a5d2f427a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf0c00a539540ffb0ff76746fc77f47_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xLTEtMS0w_e8548952-31a2-4747-9033-7e44d288fc34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i461e55ad36644dcd801b1bc34ca7c5f5_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0zLTEtMS0w_717cd8e1-0c94-4752-af5a-0730c5c823ac">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i527fd9fd337149e19c3b0dcd8fab028a_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC01LTEtMS0w_ec9988ad-2205-472d-ae29-a3cc702bca6c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9575da987aca4e06b7d8e7d64abdb71f_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC03LTEtMS0w_3fdcd4e5-10d4-4866-8fd9-bb157e5bd9f8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403aaeb86ea846378114a6861f297986_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC05LTEtMS0w_4d2daa4f-9c41-4b1c-b9ad-32af2d7682f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6a58d8069f4937a5073e16850b6b61_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xMS0xLTEtMA_6be54221-972f-414e-a13a-0c2ef891268f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f29939fb6a4adc8144a86a1f1fa0a4_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xMy0xLTEtMA_f9ac1ce6-11a6-4a45-9e77-fae1883ea7e6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925511a1d07c420bb943ffad4efc7f06_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xNS0xLTEtMA_c79df1ce-de58-48d3-ba43-ca8dfaaf4d08">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a15758d4a2849bb9a55611f14fff157_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xLTEtMS0w_a69c2e58-df79-42fc-a3c2-ef8483d8ddf8">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ce36018a4a4b87beac4699cee74ff0_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0zLTEtMS0w_d07ebfbc-f4fe-43ea-b550-3c47bd14655e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54180e23c792425c947ae0b2a21aed19_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS01LTEtMS0w_7db608d2-17da-46f7-88bf-46d840fda83b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23df0efd04e04b098e88861100d3586f_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS03LTEtMS0w_554f8252-f237-4767-85aa-e646e783c04a">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa78a4b6d7eb4b8cb4b91c89c4da9930_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS05LTEtMS0w_954cdf75-ae24-41c3-8628-13824a346bb7">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37617f3467a144fb952951327ab34f7e_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xMS0xLTEtMA_004f8690-ad0d-4853-94a1-76a4d6e3f138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f1dbaeb50ad4a1eac4d94e2a65c9d04_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xMy0xLTEtMA_72bcac81-e50d-4bdc-8800-727a48eab15d">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839190f80323464f9bf5f1c57c708e99_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xNS0xLTEtMA_2ac9f457-7bc2-4b9a-8faa-424fdc32566e">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0622c35f09b249ecb7e04d44c43f9a29_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xLTEtMS0w_9dfe8447-32d9-42c9-a039-56bd8fb59904">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39f12905a33428bb5c546d1a6abec0d_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0zLTEtMS0w_8ee0909f-53ce-4cc2-917a-fdf8cb99f023">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie882429bc0d748c8a0b03fb32a34139c_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi01LTEtMS0w_0faf35c7-85f1-4263-bb91-e276f6c89c0a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi03LTEtMS0w_8f3f8d24-f410-4a85-b43b-4cd5f89313cf">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a1493f82274c09859007cd79eacd11_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi05LTEtMS0w_66417fae-9fce-4432-b49c-3100de2f6cdb">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i600eb20f2b2d4307b840f143cdefa814_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xMS0xLTEtMA_3fe7d6b2-e4d5-47bb-863a-a46dc9d77a3d">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cb0595ddce45a290d0d525d2a81f01_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xMy0xLTEtMA_998a5a70-47c3-4804-bfda-113f2fd3b5d4">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xNS0xLTEtMA_b59e7f6b-7250-4079-b63a-bc2f80a5ce3d">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 13 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4c78e2c595404babafce10b7d1c0d271" continuedAt="i0422ee289e6e4ebd84a29d42cb3dcec2"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzcxNQ_72c24008-f901-4e1a-90f6-148cca040619" continuedAt="i44ea251f66af40b5a7a1e7c41e816e59" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0a355198574cf8a0944647df846e14_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS0xLTEtMS0w_57edbd3f-d9c2-40ef-902e-84337757e6a3">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i051031ffd19a4ba6b66f4482f9b16121_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS0zLTEtMS0w_71e3777e-bdb4-4766-b4aa-cced9a40719e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbdc10b57a2408d87748c99f6cc8658_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS01LTEtMS0w_78e13b32-9d11-4e1a-903a-caa725563b42">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS03LTEtMS0w_ccd1b7a8-9fff-4671-a045-9682d2e8ac57">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi0xLTEtMS0w_0af8eb3d-6f13-443b-b83b-a8f2de0ab3d6">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi0zLTEtMS0w_ceacb71d-cb20-4214-9436-fb4f2fa70337">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi01LTEtMS0w_3b247626-9366-4301-8f16-62732c82f38e">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi03LTEtMS0w_1406fc56-56f3-4a13-902b-b3a2eb04eace">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy0xLTEtMS0w_b2aef363-84e9-4c54-a3a7-e0a487840ac2">395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy0zLTEtMS0w_57140155-92c0-4311-ac78-d8a22172cdf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy01LTEtMS0w_18080372-6d1a-49e0-8265-acaf69f2fbf6">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy03LTEtMS0w_32d54cf8-9a5a-4b04-ab69-eb8d26231123">632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC0xLTEtMS0w_fc3704d9-6db3-499f-90d4-810352e3fcc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC0zLTEtMS0w_12863d56-6406-4207-862e-237feb0692fa">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930" decimals="-6" sign="-" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC01LTEtMS0w_90bd895e-ab65-49df-b702-71fc9ba9ffbf">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="mrk:RestructuringReserveNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC03LTEtMS0w_235bc90e-9596-4716-bd61-93da31b476bc">153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a928a5e815d4cabb958c8a84b7958ae_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS0xLTEtMS0w_d44baf66-e6d6-43f6-9cbd-7b95ca4dfdf1">438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c0393b19a348d7aa690741b65c628e_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS0zLTEtMS0w_5bacd04e-5dee-4d7a-a8dd-9b11c29723bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309613a945a243f8881020b1a11c44c6_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS01LTEtMS0w_eee1bdbe-baa7-492e-bf80-1920cb9bd00f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS03LTEtMS0w_32366073-d53f-4fc7-82dd-8fd15935992a">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i0422ee289e6e4ebd84a29d42cb3dcec2" continuedAt="iad8d5a0224ef421da3ecd2d2b6d4d568"><ix:continuation id="i44ea251f66af40b5a7a1e7c41e816e59" continuedAt="i6c6c2dae9b7c4860b7b2449116f4e120">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:continuation id="iad8d5a0224ef421da3ecd2d2b6d4d568"><ix:continuation id="i6c6c2dae9b7c4860b7b2449116f4e120">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div><div id="i67ef4e29db364327800e42a94e43496a_49"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2OTU_388eec1b-eda3-4400-be0a-8f12750749ce" continuedAt="ibb15e84d3f45483da0b9b72f31a3f8db" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="ibb15e84d3f45483da0b9b72f31a3f8db" continuedAt="i6ab3f0952ad240b3b3a4dc3c1fd59f11"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="ia319b8cd1cf240fc8cf6a6cf572ed109_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:DerivativeAverageRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ4MQ_2b219f98-0cba-409c-9b10-9495c632a724">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 14 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i6ab3f0952ad240b3b3a4dc3c1fd59f11" continuedAt="i7b67522b6b4f49549e870304e445a25c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i082ff741b7854aa59ffd11f6af0439fa_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:DerivativeAverageRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNTAxMg_ff026d29-4570-4281-8ad9-425c153f7cd1">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NjQ_21e3237e-3b80-4f49-b0b7-9b45a270c244" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xLTEtMS0w_cf387c16-0748-4f02-b114-df1b174a722f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0zLTEtMS0w_d2220b78-fa16-4da5-ab63-ab5edca45f0e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC01LTEtMS0w_dbe0a796-6417-46c7-ab8e-85f101d923dc">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC03LTEtMS0w_90071c73-01c5-4e97-a8d8-80c0598b8253">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3cffc90ec6148909d3599ea1d9df327_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC05LTEtMS0w_82972282-b507-4fdc-a2a1-8120f47b3919">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b807ee322bd4ee9958bad75b8677e25_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xMS0xLTEtMA_2dbb3dd1-a406-4617-9fb2-585bd9aae343">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa29d8b186047fc9548a924b7455a42_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xMy0xLTEtMA_05e68b2d-f873-4772-9c10-07c73c1fa1b7">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice720ee19510470cb2be22bfa752c7b3_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xNS0xLTEtMA_ab29cc30-9a58-4f1e-9436-f0bb9d617e42">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d2767b71a8465d8afd845a2deff157_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xLTEtMS0w_5be1733b-f7de-4758-853d-99cb9c58280c">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48bafb9af91b4c66810b2658a0fb8100_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0zLTEtMS0w_5b5a04f6-8562-4af4-bbf9-ca04a3940f28">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief51f272bb714d06bb4d146033290b24_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS01LTEtMS0w_a1079143-6974-4777-b232-c0154a65d989">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9862822be464d7590cac38e8a733045_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS03LTEtMS0w_97f37f7e-bf0d-4441-bbdf-1e31dbfe1e9f">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie877415544764c93a0e92480717fd720_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS05LTEtMS0w_b3a0222d-491d-47c8-ba4f-37a374c373f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ac34bac82349ec87abc769df473091_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xMS0xLTEtMA_c793e09a-2743-4210-b3dd-bf979c80bd1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102e8398b68443efb7c670be371e221d_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xMy0xLTEtMA_d9fd5a56-0dec-46c3-a932-463ac17040ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f7ee9e6e6f4549b1c06a6e2ee15ae2_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xNS0xLTEtMA_1e644d7e-c278-4f8b-a722-bcb9d2404025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020,&#160;<ix:nonFraction unitRef="interest_rate_swap" contextRef="ie8db34a980b2470aaaff3a2d9dc09883_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzA4Nw_93df0738-f35a-4de2-807c-6f92aac61b58">five</ix:nonFraction>&#160;interest rate swaps with notional amounts of&#160;$<ix:nonFraction unitRef="usd" contextRef="ie8db34a980b2470aaaff3a2d9dc09883_I20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzEzNQ_ec202b68-2a0c-483b-87bd-d9a051d54c05">250</ix:nonFraction> million&#160;each matured. These swaps effectively converted the Company&#8217;s&#160;$<ix:nonFraction unitRef="usd" contextRef="i174087d9f6454aebb32d8415fd4b71d8_I20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzIwMA_5203146a-ee73-48bf-adaf-2d599e8ceed8">1.25</ix:nonFraction> billion,&#160;<ix:nonFraction unitRef="number" contextRef="i174087d9f6454aebb32d8415fd4b71d8_I20200229" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzIwNA_d3f9b8ed-b7eb-41fc-814c-61cb90ab5cee">1.85</ix:nonFraction>%&#160;fixed-rate notes due 2020 to variable rate debt.&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NDI_d0b8b5bf-4e78-4535-8ba8-f0bb6ef4f27a" continuedAt="ia084a3e09ca846e097b02c939d517c18" escape="true">At September&#160;30, 2020, the Company was a party to <ix:nonFraction unitRef="interest_rate_swap" contextRef="ibd638b943ba14bbaa99c094906c46496_I20200930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzI5MA_d67f6b80-a687-4e34-8274-32ba0d68e43a">14</ix:nonFraction> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ia084a3e09ca846e097b02c939d517c18"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0wLTEtMS0wL3RleHRyZWdpb246ZGQxZmI1ZGNiMDEyNDA1ZWFjZWVjZjI1M2YxY2NkOTNfMjE5OTAyMzI1NTU4Mw_b17e9853-8625-46ac-9af2-016c1e790ca9">3.875</ix:nonFraction>% notes due 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0xLTEtMS0w_08749588-4737-4a5e-bd01-9657409390f9">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0zLTEtMS0w_0536d06a-da88-4551-a182-119537b0586d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi01LTEtMS0w_095401ff-1202-48df-934c-6c97f984a5a5">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0wLTEtMS0wL3RleHRyZWdpb246MDAzZTIzYWJiNDNkNGEyY2E1ZGZlMWUyM2Y5NTJkMjlfMjE5OTAyMzI1NTU4MQ_15d83318-b027-4a66-bf7e-4412fd2a3e7b">2.40</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0xLTEtMS0w_68f1c600-9ed1-43b1-a400-082f05d7062d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0zLTEtMS0w_08522ffa-9f1f-442b-8e31-d2b5a45a2d92">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy01LTEtMS0w_c96615b1-c9a0-4332-b9dc-f93401c27e39">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib089735791f34e7e946205004d6a744f_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0wLTEtMS0wL3RleHRyZWdpb246YzVkNjI1NDdjZTdjNDdkMmI1YmE1Mzg2Y2ZjZTc0Y2RfMjE5OTAyMzI1NTU4MQ_3884f3a8-3671-461c-9a5c-f034df7a95ce">2.35</ix:nonFraction>% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib089735791f34e7e946205004d6a744f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0xLTEtMS0w_ca46ee7b-0795-4372-bb0b-c47a3d0e9689">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="interest_rate_swap" contextRef="ib089735791f34e7e946205004d6a744f_I20200930" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0zLTEtMS0w_a9841832-ec2c-458d-b35e-9c4ffce60edf">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib089735791f34e7e946205004d6a744f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC01LTEtMS0w_e9ee9835-a0c9-4586-abee-8187e9cb8c4d">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 15 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i7b67522b6b4f49549e870304e445a25c" continuedAt="i55f265c358ad4b2b874a1a5be35d489e"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NzI_f6548899-5669-48a3-92e1-508a178869f3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy0xLTEtMS0w_bdc1fe1b-48ca-41ed-8ec7-544f22851b21">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd8cd4de38943e2b14074d9417f6715_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy0zLTEtMS0w_556fcbf6-6d8b-4d51-87f3-f3b192d2fb91">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy01LTEtMS0w_d6228664-b101-4bef-8b45-25b2a69b2a46">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cd8cd4de38943e2b14074d9417f6715_I20191231" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy03LTEtMS0w_a250223e-e5e4-49cc-8936-4d1abdaf679e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC0xLTEtMS0w_50ec4dd6-978d-4d69-bcdb-ffdfdb60b3b5">2,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef73b3681a741db8a0d3055eb532b01_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC0zLTEtMS0w_468cdca1-def1-4af6-b7c3-0537cc5ee499">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC01LTEtMS0w_b5e078d7-a21b-4cda-8ab5-fe0e76ada5a0">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef73b3681a741db8a0d3055eb532b01_I20191231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC03LTEtMS0w_9ae05f96-461f-45c0-bccb-9f7477e24269">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NzQ_42261f15-556e-4e8e-8cde-75660085ec77" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:20.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78266c2751d45698fdfe199e03b129d_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC0yLTEtMS0w_88cdf284-0fd2-4355-bdc3-4e6233464ae2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78266c2751d45698fdfe199e03b129d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC02LTEtMS0w_d19b25b7-1597-4a5a-a250-7aec288ed84a">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1023089c2c54a80a18259c1511f87c3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC04LTEtMS0w_f816ca8c-8940-4b4b-a072-4e0f066cb42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1023089c2c54a80a18259c1511f87c3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC0xMi0xLTEtMA_06b231db-5480-4864-a410-427150a6f8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa826dff4de743c7acb6d521bd66ea9f_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS0yLTEtMS0w_33e7c33c-d22a-4b96-abe6-1ac8629eefe3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa826dff4de743c7acb6d521bd66ea9f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS02LTEtMS0w_5e5684ff-0cda-471b-8f37-1e05a741fef3">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ec13cee627454ebf66f0d6ed39894a_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS04LTEtMS0w_8435231a-dfd0-4db5-ae4b-f2b19c4e2ca9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ec13cee627454ebf66f0d6ed39894a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS0xMi0xLTEtMA_f4d5606f-74e0-485c-b9a9-68bf57df14c7">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21967f622cdb45cebad35ad052ece1de_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi00LTEtMS0w_c6428f2b-0285-453c-9367-0367e81b6b32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21967f622cdb45cebad35ad052ece1de_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi02LTEtMS0w_e91d5066-0eef-4890-89d2-89deb7622b2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b48c75e8014c2382f84a5d33f0efe2_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi0xMC0xLTEtMA_ab3c9473-7062-4be0-aa2d-2a683e16c697">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b48c75e8014c2382f84a5d33f0efe2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi0xMi0xLTEtMA_ba573339-4453-4522-9204-1d134da314d4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d507c1385a4984b104b15b14ad0b87_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy0yLTEtMS0w_31d9456c-596f-4cb3-b226-0578922fee57">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d507c1385a4984b104b15b14ad0b87_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy02LTEtMS0w_346e686d-6e93-4efc-8d90-9b3f8687a091">4,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebb8d0e743c4bc3aef276f00d195299_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy04LTEtMS0w_a0dc5bb9-37cf-4e6e-a910-05098bcd9646">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebb8d0e743c4bc3aef276f00d195299_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy0xMi0xLTEtMA_e138a279-673e-40ca-965e-a2cfc2ec6fce">6,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d19d97eade44b698ef4d90c18cfb52_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC0yLTEtMS0w_e0db0845-0058-4427-bf12-e586d9bf5b62">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d19d97eade44b698ef4d90c18cfb52_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC02LTEtMS0w_bf7bf5ae-5aa4-46d5-ae02-f493b974b3ee">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb0bacacaba494588fdc16bec7aad2b_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC04LTEtMS0w_236e46d7-6ed4-4ca2-97f9-aeb544a0fe40">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb0bacacaba494588fdc16bec7aad2b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC0xMi0xLTEtMA_36ca8070-47d3-4bb4-97ac-4d41c5440982">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a28e0e89eaa4a0381eb181749135076_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS00LTEtMS0w_38b7bf64-41bd-4a5b-a275-b3ebe4d850e0">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a28e0e89eaa4a0381eb181749135076_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS02LTEtMS0w_755ce991-fb95-4ab8-ab8a-320e411cbd45">3,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b722555bf44b6282741eb433c205bf_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS0xMC0xLTEtMA_1c7827df-ee4a-4c09-9749-eddd933e1c60">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b722555bf44b6282741eb433c205bf_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS0xMi0xLTEtMA_e0eef132-466f-4a8f-8678-0adf822f5707">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4627226ed34963af481b31b209e7d1_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtNC0xLTEtMA_fee39e62-51dc-4ecb-8f07-39059b93ef8e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4627226ed34963af481b31b209e7d1_I20200930" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtNi0xLTEtMA_a5a364e7-a1db-4af9-88d8-b6d1df546b4c">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c1b766e702403daadda490393c9ef9_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtMTAtMS0xLTA_1ffb09ee-8fc6-41cc-a80a-ca2fabb67244">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c1b766e702403daadda490393c9ef9_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtMTItMS0xLTA_41d19ad7-8096-4861-9de6-1497e86950f6">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMi0xLTEtMA_5b5ab74c-f379-4b9d-b1ad-b2683e16b2c6">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtNC0xLTEtMA_db08962d-7b7e-4f7a-b7d8-e2de7b2f61d4">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtNi0xLTEtMA_f037d46c-975b-4ee8-9e90-9ca712235ef1">12,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b4c081c7234c27a717225ff5066862_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtOC0xLTEtMA_d9d7056c-c404-4308-834e-b900bfc8a71b">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b4c081c7234c27a717225ff5066862_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMTAtMS0xLTA_0682e6e4-b0d8-4f71-a8c0-003a8c62f5a3">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b4c081c7234c27a717225ff5066862_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMTItMS0xLTA_5cc269cb-dd7f-4780-b983-3c29e7f8640b">14,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtMi0xLTEtMA_9ea6e315-2b10-4679-b231-20a172272fb9">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtNi0xLTEtMA_4319e297-e9e9-471c-a9ad-44b4a2f60fb4">5,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009ad414b39545bcb9714e42490d7cfe_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtOC0xLTEtMA_6effcc2a-4307-473a-bb08-14a957f610f5">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009ad414b39545bcb9714e42490d7cfe_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtMTItMS0xLTA_796527e6-95c6-4f77-a4a5-8a323e1be034">7,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f62a4056afb402185c1fd095207abdb_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtNC0xLTEtMA_ff6ef8c2-160a-46ce-bc2e-43a021f5b2f4">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f62a4056afb402185c1fd095207abdb_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtNi0xLTEtMA_f671a3b7-e14f-4b2b-b535-ef91f31ce942">8,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b237fa0466c445994cb3f605edb9744_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtMTAtMS0xLTA_80c9b522-4f31-4424-b402-18e35008d889">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b237fa0466c445994cb3f605edb9744_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtMTItMS0xLTA_db03db3b-1786-4e53-a4d5-a87b3620d3be">8,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0afe3813f94b848a3beb92819435d7_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNC0xLTEtNDc4NQ_13e84c55-46a7-44b6-a9d8-c33e5a11a51c">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf0afe3813f94b848a3beb92819435d7_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNi0xLTEtNDgyNQ_a180f513-be98-4bf0-a6f1-fcc6542bb6a9">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTAtMS0xLTQ3ODU_33f49db4-57b3-4b0b-adef-02d385a0f35a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTItMS0xLTQ3ODU_f3cef186-1724-4965-b3d0-a2a193476182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMi0xLTEtMA_302de65d-1d6d-4cdc-925c-f33698df8896">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNC0xLTEtMA_251c4d0a-601d-4a52-aae3-f8f0469e53ac">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNi0xLTEtMA_1a9940d4-38fa-44d7-b680-2a86e8b0ef28">14,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtOC0xLTEtMA_464a358f-98c8-4fe4-8991-83aaa4bdd3e1">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTAtMS0xLTA_98719d03-5215-4118-9218-a4649182eda1">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTItMS0xLTA_cdbc5790-4b23-45d8-926f-8a40f370838b">15,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMi0xLTEtMA_f27b34f3-b292-4196-9742-d6be2846cd22">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtNC0xLTEtMA_ca650909-2eee-4ad1-a27e-55743663cb52">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtNi0xLTEtMA_be559448-14ad-473f-9ffa-2fa1c6f8d277">27,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtOC0xLTEtMA_b07a8e97-61ae-4d9f-ada2-aba6d602ef40">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMTAtMS0xLTA_f8d03d74-8ca0-4124-867a-3538a4832cb4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMTItMS0xLTA_a501dbf0-43b3-4859-bba5-e876c07a99b7">30,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NDU_0a82f0aa-f5c1-4c05-9801-b1a00a7a33ac" continuedAt="i2101df0ac98f4458b32daa846ed3eceb" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i2101df0ac98f4458b32daa846ed3eceb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi0xLTEtMS0w_a3f59a9d-ad27-40fc-837e-418401f9e1ef">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi0zLTEtMS0w_d4f432ba-fb18-4cc1-ad48-2c5e59cd0cb3">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi01LTEtMS0w_74f11f9b-c623-4eec-96bb-fde008c71f0b">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi03LTEtMS0w_4d2a7f8b-b54a-4167-9404-34f6fb52e5aa">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy0xLTEtMS0w_3a5dc671-b20e-4c20-8efb-e92ec587a428">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy0zLTEtMS0w_abd0e2aa-d529-47dc-b6c5-43d1051c565a">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy01LTEtMS0w_7c0a0427-b6dd-44b9-a328-4705c26b7232">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy03LTEtMS0w_b9dcf4e3-ed29-4174-bd15-3c988d82480f">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC0xLTEtMS0w_b817e4ed-0295-482c-9035-bb89fe4b1604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC0zLTEtMS0w_f90f6d7e-0821-407e-b844-d6394eb61c51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC01LTEtMS0w_4b7bd622-7429-467d-9a07-acdd3a330f8e">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC03LTEtMS0w_f2259e19-341f-4e8b-ab38-ba0c4cd9de7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS0xLTEtMS0w_2ab8d516-0fd9-40d0-9107-c88700c335ca">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS0zLTEtMS0w_8c9fea14-55b8-4c46-a66a-a16d23ee85b0">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS01LTEtMS0w_e80e73a3-2098-4614-a1e3-84b835a0dab1">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS03LTEtMS0w_3f47536a-cd6a-4591-a43e-cbd9ad897ce5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 16 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i55f265c358ad4b2b874a1a5be35d489e" continuedAt="idf2460b182a3443c974fa1d88a2d03ef"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NTg_1e747659-ffb5-4f91-92f8-950f88b8b1a3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:17.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xLTEtMS0w_ed85604e-117e-4fd2-8523-1f6252bd9e23">12,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0zLTEtMS0w_4d31f31c-fd68-4e14-b5cf-f8f924b82e37">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy01LTEtMS0w_1ca7dab9-4229-4303-868b-ed6178ff538c">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy03LTEtMS0w_0ebb5f88-477b-49e8-95f1-9f64109edde9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy05LTEtMS0w_b3ae5699-819b-4d18-ba07-bcc92f43a019">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xMS0xLTEtMA_ab72d760-36aa-4f98-95cb-562f4c4e3ef6">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xMy0xLTEtMA_c1689e55-137a-488f-8e8d-55d3fc63136b">35,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xNS0xLTEtMA_e52688da-558c-48e0-8697-48b123dea50a">34,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xNy0xLTEtMA_22773d74-b9cb-4558-8fda-f853aacc6ad0">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xOS0xLTEtMA_612a0cfe-3837-48fb-bf2b-943f9233c441">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0yMS0xLTEtMA_68ab0fa1-c299-4ff5-a1e5-e2cc396f81c1">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0yMy0xLTEtMA_0c4f4124-bd51-477a-a6f4-8a304f53b89d">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi01LTEtMS0w_27e2efc5-7eb4-4cf8-b4cd-b339955d2faa">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi03LTEtMS0w_e131f0c9-853b-49c8-bbe3-b6e60cfefec5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi0xNy0xLTEtMA_d008b3c2-fe3e-485a-8851-c84fd38a3682">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi0xOS0xLTEtMA_300aa064-caed-468b-88ca-eb45c3b8529e">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy01LTEtMS0w_e28fda62-6054-4892-b8e2-6e50d546cc4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy03LTEtMS0w_ec59e1ce-ed1c-4af1-aef6-cac68c62971d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy0xNy0xLTEtMA_0d2d9b13-872a-47e3-8b26-2f9fe07f7e24">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy0xOS0xLTEtMA_77315abd-b999-43f5-a98c-984ba07ebb32">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtOS0xLTEtMA_617e9534-6bb3-4097-a1bb-bbe80124cf4a">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMTEtMS0xLTA_198943de-2adf-4935-ab78-098882d7b42b">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMjEtMS0xLTA_986ee591-4ff7-4663-a46f-497eea62293e">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMjMtMS0xLTA_2df73eed-b323-4626-bb8c-5c0881be92cb">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd3ca1373fb24ba68251d0301a10a20d_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMS0xLTEtMA_ba8831c2-f42d-487a-9338-e3d8780d113e">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ea9d32cf204b73801d5f9d1325e43e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMy0xLTEtMA_fceadae5-781f-4a39-acd2-e5dbc0e94c07">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtOS0xLTEtMA_cb6c44b7-b444-4c1c-b05d-41b36e3ff2f3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTEtMS0xLTA_adb4f772-5fe0-4996-9403-af72c2e3f368">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5e4820eed4496988270e13e3b094d0_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTMtMS0xLTA_50e262ec-a562-41f4-b5ee-b532074f9953">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib552830a5da14067a97f6a37503c4784_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTUtMS0xLTA_023428f5-6a0d-4411-bbaa-5714627b5cb2">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMjEtMS0xLTA_474a030a-28e7-4342-b9c9-e9fd1400be8b">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMjMtMS0xLTA_d2dbbc72-abdd-4b01-8c49-1e71983a2c7d">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtNS0xLTEtMA_dea86df9-e5c7-4426-aa2f-1b2a54516a74">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtNy0xLTEtMA_900ff081-0d44-4aba-821e-fdd514ac9b09">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtMTctMS0xLTA_682f9b63-f5dc-4317-be3a-cc7c30564361">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtMTktMS0xLTA_a31f3caa-127c-47eb-a250-144203472c68">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtOS0xLTEtMA_5ef644d4-61a9-4296-8f4e-110b40ef805c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e7e123c95db456a843cb9b4ea2ee304_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMTEtMS0xLTA_bc27ffbf-622e-4356-8f42-628abe7c4889">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6199f48889a49748506a4b635c3bb86_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMjEtMS0xLTA_030e5f7b-36e9-4e68-98ce-6c1ce744e640">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieae423a542494b8d9adff25f3bf634fd_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMjMtMS0xLTA_31a0b6b9-a1ac-4d27-bc40-3f9fb2b72662">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2ODU_86f06323-46ff-4879-ad57-a63c1aa51843" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:34.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC0zLTEtMS0w_c7671841-7352-460d-89e7-0da70ff38441">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c5e6efb1434480a3a0aac64deb74fc_D20190701-20190930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC01LTEtMS0w_17c85079-f592-4684-94b4-3d6d61565689">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fd5010fab09451c946ea37d93a410e6_D20200101-20200930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC03LTEtMS0w_d9728889-e3d1-4116-ba52-3e0d2f0ab93b">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e626082878b47229b64aad4223936be_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC05LTEtMS0w_3e93e764-3a19-47f3-9cf2-2ada2e4e0d1c">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84727b70c6dd4761b253ea527ddd0887_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS0zLTEtMS0w_62cf77a0-62b4-4d3c-b7b6-a20ed7d3a540">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i812ca05ea4394a4dac627795b29c49aa_D20190701-20190930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS01LTEtMS0w_84f16add-e8c0-4173-8cbd-ae72cbc1b6ef">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e39e07079d24f1d97851dd0941257a9_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS03LTEtMS0w_d5d05f39-61b1-4dab-8033-71998af5683c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0874acdea1b94c23a104b3d79fa7bc54_D20190101-20190930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS05LTEtMS0w_1fcdcd5f-b566-4029-95d6-62beb6532e99">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924cd3c5889b4fa5a227f02451269580_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi0zLTEtMS0w_7c980e3a-cbf3-4337-a26c-4b612294afeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5f04d36a4044a793fc61d278bd3322_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi01LTEtMS0w_3961da5b-c7a5-4227-b986-3efe806e7bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46bd265492f54f4c8caf95f9c471e390_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi03LTEtMS0w_ea6930ed-8a1b-4b53-b744-512aec260173">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6804bab188cb4e53b4fdd152aab4cfbf_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi05LTEtMS0w_fdf23704-234c-40cb-befd-593fc0abac99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy0zLTEtMS00ODAz_13530a0e-22fc-4acf-8215-5c19b04e3b36">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9334afd80f1c4e62b06c088ba45904e4_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy01LTEtMS00ODAz_b08b4cfc-8651-4291-b030-530b9a6fe861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bcef7dcc6d49e88feb6e96d724788d_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy03LTEtMS00ODAz_e2b10062-4753-437f-b58f-3583dc1ddfd1">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcc3a06092c43dba855fc359441f405_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy05LTEtMS00ODAz_1ad11ae0-0285-4776-a382-23d32422700f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfOTcxMw_42c947cc-08f8-4d40-bc92-51d531f393bf">155</ix:nonFraction> million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 17 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="idf2460b182a3443c974fa1d88a2d03ef" continuedAt="i32334c45c49743aa91d4db08282de299"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg3MTU_2c8402aa-a688-4dba-b222-71f8de0dbaea" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xLTEtMS0w_bbcbc0cf-ed91-4d8d-bfef-7554441e41d0">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0zLTEtMS0w_09eb3346-b16d-4b36-af66-d01ce6a9bcd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy01LTEtMS0w_3faca50d-64b3-460e-9339-9666e1c76098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy03LTEtMS0w_48f93b04-4600-495a-9954-9f68ce676d1c">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy05LTEtMS0w_6879a916-e76a-4c93-a4bf-db724925446f">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xMS0xLTEtMA_cf39d91e-25db-43f2-bb6e-caeda963f810">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xMy0xLTEtMA_2a5ce312-31c8-4376-a9d2-0da898f88f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xNS0xLTEtMA_4d8b3e02-0887-4ca4-b564-482fe3907667">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85db4eee737467d84fa784c0406b915_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xLTEtMS0w_22deca63-2044-492a-9a77-a14904d51e1d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85db4eee737467d84fa784c0406b915_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0zLTEtMS0w_6ca1c2fe-7177-44c6-b6b8-40889888b812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85db4eee737467d84fa784c0406b915_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC01LTEtMS0w_4446aee5-d2f5-4892-a03e-c7219da5b707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85db4eee737467d84fa784c0406b915_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC03LTEtMS0w_1d0d62b5-f772-4456-9f41-e559996ff8cd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC05LTEtMS0w_b9dac7c7-1237-406f-917f-309f8170b5bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xMS0xLTEtMA_29c4d1f3-0ed3-4703-9b22-7f0222f3b935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xMy0xLTEtMA_3b199a1a-2bd1-453e-ab60-1f902a4641e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xNS0xLTEtMA_23185d7e-2e14-40e9-a1f1-32239eb1f2c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xLTEtMS0w_8c2058da-d669-4e9c-8612-f1864d2ceea9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0zLTEtMS0w_9724e735-34df-4751-8614-f99442f278dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS01LTEtMS0w_0ca0a38a-5399-443e-8777-25cd1a676408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS03LTEtMS0w_10dd3c8b-0422-4e73-a4e1-07b72e4e4c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS05LTEtMS0w_7dc1cd13-ff42-408a-9a9d-85344d1b9cd5">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xMS0xLTEtMA_8c277058-0bd2-4e8f-849a-608f18d7f4c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xMy0xLTEtMA_147dc27e-aa4f-4316-9dce-d6d67526a2e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xNS0xLTEtMA_e6837c66-4f07-4779-9d3b-8d6834bc8e84">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xLTEtMS0w_d85c2b5b-0667-4133-9ac1-74e7387fca56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0zLTEtMS0w_7cd46d6a-3e8e-45e0-9f97-92738eb11bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi01LTEtMS0w_c3f784e4-ef50-4713-982d-0248c72a310e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi03LTEtMS0w_531a5847-1559-4951-b0cc-81e831a77709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi05LTEtMS0w_550c9b2e-f023-4955-96e1-ef1b87053ded">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xMS0xLTEtMA_525f2b67-98bb-4d1f-92b7-64c68bae60c4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xMy0xLTEtMA_0c6b01da-418a-4ecf-95db-69ebdeec23e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xNS0xLTEtMA_c9ad6348-548f-4ecd-a215-4bf33afdc358">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed394545474492aa72d62f2775bca14_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xLTEtMS0w_489e42d1-c5ae-4706-8b16-3751ca3e9e1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed394545474492aa72d62f2775bca14_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0zLTEtMS0w_9b1e1221-3534-43be-9a5e-a54b9ba58f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed394545474492aa72d62f2775bca14_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy01LTEtMS0w_3d72881a-e237-4977-862c-aa9093e61d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ed394545474492aa72d62f2775bca14_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy03LTEtMS0w_f0157f8c-a0b7-4436-8d94-7d5669d09e27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy05LTEtMS0w_7a5aae2d-3302-4527-ba16-02ecb59d16c3">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xMS0xLTEtMA_30c2cc14-aa4c-402c-8543-99c1d15167c6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xMy0xLTEtMA_2ca595ca-454a-4fb7-847a-153001a4448e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xNS0xLTEtMA_295d4f04-0000-4f5a-a6f1-2ba3f2ac8256">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xLTEtMS0w_b3185fe0-6a41-4875-8045-baf85753cd56">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0zLTEtMS0w_5b47b69a-f778-4b68-a159-0d730efe07b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC01LTEtMS0w_db29d2d8-f498-4c8c-a5c9-fe08f2bbdf92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC03LTEtMS0w_e83bb22c-dcd4-445e-82be-e3ebb1f2ac27">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC05LTEtMS0w_e01ffab8-b4da-47f7-9e9d-5f4a4ca979a5">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xMS0xLTEtMA_27531bb7-9078-4c2b-9418-aa4633d85178">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xMy0xLTEtMA_7f5813e1-a04b-49b6-a86b-0c16dba138a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xNS0xLTEtMA_63236252-9651-4df9-9678-9ef026d3650c">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOS03LTEtMS0w_e8c5b9ef-9a28-4ae9-9848-5a43342858ad">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOS0xNS0xLTEtMA_5d728b21-16a5-4454-a48e-3dcf69e1a7f8">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMTAtNy0xLTEtMA_2e44ee0d-bada-4e6c-b651-1279101ef43d">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMTAtMTUtMS0xLTA_b1f2a6bd-aab8-4444-8496-a406af7102b9">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net (gains) losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2020 were $(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTAzMjI_c4d1aef3-9a1a-478e-8fba-3d853b127265">43</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTAzMjk_196b4dec-5482-47a8-8c02-2a4d89fe3d8c">512</ix:nonFraction>) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA1MDY_6c94bc65-c935-4209-9f40-636e93399e46">25</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA1MTM_60939121-fc1a-4749-b6e8-fc87a58d5098">41</ix:nonFraction>) million in the third quarter and first nine months of 2019, respectively.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020 and September&#160;30, 2019, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA2MTA_84521a11-e639-45cb-82c4-14835b496631">508</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA2MTc_316f3d39-568a-4a8a-91b6-476adfbd514d">393</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEwNjQ_2940ed4f-cad3-4fda-99cf-19a8e8f0d9c6">21</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEwOTI_199a15a0-3fe2-4596-82fc-d19aaa19fc3c">3</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these equity investments held at September&#160;30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEyNTE_d47aacf1-739d-42a8-8ecc-3c34804ff2fa">4</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEyNzk_37f0d070-1b80-46fc-abcb-48e611cdaed2">12</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to these investments held at September&#160;30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTE1NTE_32425edf-ce84-4138-8834-81bc306ae277">128</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTE1NTg_65c80b08-b533-4bbf-b7a7-7aa4f459cc14">24</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 18 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i32334c45c49743aa91d4db08282de299" continuedAt="i648c5a837cb04c57a451a63008c8a453"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2OTg_b3147c3a-21d6-4b25-9f0f-96d6dfb5c2fb" escape="true"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:20.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b74dc13822409f9caf279f6c6efb79_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xLTEtMS0w_affb003e-01b0-4cb8-b5e6-adbf92f141a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0910059a35fa4db3a4f1688038846dcd_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0zLTEtMS0w_8fd55415-cb8b-41bb-99d3-a446081ee9f8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcc86aa77164a2c9e420f79d5512eab_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS01LTEtMS0w_4a271ef4-ea4c-48e0-a559-c0d8c2f270cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460148134f8548f3b116acd07b6f4262_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS03LTEtMS0w_3c1fd79c-f48e-46ae-b456-2f23a48b383c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c548bb51d534758a5b6a6644bb57312_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS05LTEtMS0w_007c03ee-8a29-4136-a667-0d77546ca501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f28d45aab574360b168ce04f39ca7e5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xMS0xLTEtMA_e6fcebf5-965d-493f-abed-12932641f8df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffe4cec0a0a437daa7a6c75edf5f759_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xMy0xLTEtMA_cc3ac52a-665c-4bba-ac7e-e0e8c9bf3300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8ab343a960448718c962d4ff1664ca7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xNS0xLTEtMA_8b0d7d2a-e9a6-4bb2-b1e5-7096e92a0a9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50cee26c0cb24582a4fa7a23dab93ff8_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xLTEtMS0w_99f1b585-5a77-4a78-ab58-9a26eaa649da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b962ca0878246aea2caaba1e5068597_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0zLTEtMS0w_1fd9deb2-d171-4b9e-aab2-f79eb9849d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12865349bba54bec9a0bc339687682cd_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi01LTEtMS0w_3f604a49-6ddd-4e1e-b7de-21beeb73aafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9c2404403b4dd19bf073d3fc40b18e_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi03LTEtMS0w_5d46b165-44da-4696-be06-b85cd9bfff85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084046817ad547f0bf33554533117419_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi05LTEtMS0w_28249556-1aca-4771-9ab4-b8803e68c6ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3126ac40e55147ecad0cf2d7e7171a71_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xMS0xLTEtMA_3a0a0f8d-a48e-4c6a-b4c5-d58f922411fd">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie381b020bc2d4cf48eefd6af3e63740a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xMy0xLTEtMA_65257a60-08cf-434f-bb29-5f5a02590cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edd3a5e5dbd40979d86029cf03f258d_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xNS0xLTEtMA_1f937cb0-4b15-424b-95b3-1d2817cb47b6">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id993747e094b4fd79654920246348cca_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xLTEtMS0w_783787eb-94cc-49c3-98b5-c4a163951c84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99eaa11a9d134c84aa9cfca643e17d0b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0zLTEtMS0w_c00d8f2e-0983-4634-a10f-4c03d84398dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4c8e65bbc04387a96c107b13853bc9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy01LTEtMS0w_836e303b-3cba-485e-95af-b009247e76c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809e8cb34704419bbc81bc11c64fce2d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy03LTEtMS0w_b4ccc02b-7987-48b2-84f3-dffacc4505ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfd28bc6e0f42aaa81be96e54b6f594_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy05LTEtMS0w_f1da1dfa-f462-45b1-bf1d-3ea1b328dc21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia932f1a4fb0744bc9993e55668e12ee7_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xMS0xLTEtMA_77be8fb2-ad6c-45ea-9968-3177b0db777f">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21417c5ce10444faed848f53271d30e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xMy0xLTEtMA_b20ca0e4-1211-4230-8a44-e9ef6915d323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f12d40a4894778869023a3c016eeb5_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xNS0xLTEtMA_bfcbce2f-2d56-40bc-8ee4-a7a91239bf50">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7a998c6b5342efb1a584d95ce95eda_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xLTEtMS0w_59a19d0d-df42-4f87-a3a8-4c6b3bfacbb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084814a830464e63ba5b40197d05e746_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0zLTEtMS0w_7dc7f158-5e47-4356-a2cc-0b48b4a2e5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a334d2c7f7f4c7ba7103637d1ec075c_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC01LTEtMS0w_d0c27b0e-445b-4bce-8b00-05d2eb01e9ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8349cad8fb23464c808e9dda6e139864_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC03LTEtMS0w_84720740-29fe-48c8-9901-f17b2259adec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6faceee075314917b67b95d162851967_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC05LTEtMS0w_6bca55ae-ffef-4679-985b-98f3fe29c537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1addd4cf0a714a1bb6df0443bd656292_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xMS0xLTEtMA_3edf2bce-2ed3-48b0-a348-1fcc32a0a981">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ab410ffa984d74b8491ca6135d2f49_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xMy0xLTEtMA_79b47484-dfb7-4571-910b-7f919db55da6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4220ee3541742be9a6a5b1189b6144f_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xNS0xLTEtMA_e68b9337-cee3-423d-a46b-263ff96bf76d">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4608091360a94197892bd6a3625a1eaf_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xLTEtMS0w_c87fb246-0e0a-447b-89e0-81111e49fb1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295721b3731942a08da7676215878345_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0zLTEtMS0w_4e358fc3-fea1-4cc3-b64c-4c6582676d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54942bdb7d14f95b3cee4e66d8055b5_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS01LTEtMS0w_f178aa26-18d6-4905-b0f6-ac0651ee2a4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1949445e84e744f29823c34223e1e913_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS03LTEtMS0w_9ddf45ea-b552-4bba-8c88-05fc61fcf26d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7932b106c7448daa2a3a55d1da0adfd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS05LTEtMS0w_4d45c86a-9086-443b-b94f-1e575d895a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xMS0xLTEtMA_2527dc3d-09a4-43be-9d24-b6eee76399b3">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729ae19583c44de3bea4894565e3326e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xMy0xLTEtMA_4c0d8e5c-6530-4ff1-af4e-dcdae3ada01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b2c6ae9105493882fd7968a705b503_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xNS0xLTEtMA_7e29148d-7892-483e-8bd0-289c47457f94">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMS0xLTEtMA_9310229e-a72f-47d3-a6e1-5c87b9175acf">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3a6c594db44074808bec17ed6ec8b9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMy0xLTEtMA_7d790117-3b53-48df-baf0-f238a8a72cf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd21a1a7d51489a86f20b38a1d20755_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtNS0xLTEtMA_f77bfb51-40fb-494c-b79c-06956fa69daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2583cf01e284ddcb2320ca55728a506_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtNy0xLTEtMA_7ca26656-f352-49a7-87fe-6cdbcf96536e">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7816629b0334d2aa6b53dc07c4e8faf_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtOS0xLTEtMA_ccca170d-a655-499f-a6be-be4129b7ea59">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc955b1af87545599fdfcd8990fdedbd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTEtMS0xLTA_89823ee0-b38b-483a-82ea-4663c7acb3fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58a28f0d346460685afcc652227a9c5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTMtMS0xLTA_2e0de33a-076d-4244-bd16-2edb079d0579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTUtMS0xLTA_831cfa84-9c36-4691-8cdb-9a4a2ec2cfe7">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMS0xLTEtMA_d63183ea-6dff-4770-be9a-23563a6d3382">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMy0xLTEtMA_12f6d789-33a1-4b51-a934-f9aa905bbc25">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtNS0xLTEtMA_5e2abf48-6bd3-422f-a0b5-55a97d214878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtNy0xLTEtMA_d28f8a3a-88fd-4d16-b528-0f7276e0f946">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtOS0xLTEtMA_fd9d5739-4787-422b-bd0d-14febdebec71">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTEtMS0xLTA_9a7f746e-bbc5-4b18-97ea-db51ca89312a">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTMtMS0xLTA_085b4835-c76c-40c3-a896-87bb99c416c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTUtMS0xLTA_8dcd47b7-0fde-4655-87d1-557f274327d7">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4608091360a94197892bd6a3625a1eaf_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMS0xLTEtMA_2ddeab0d-93bc-4f19-ae41-017a590cc9c8">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295721b3731942a08da7676215878345_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMy0xLTEtMA_ae39ce50-bdc8-4891-8d88-ca7ea3b56b83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54942bdb7d14f95b3cee4e66d8055b5_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtNS0xLTEtMA_6befd683-76b3-4563-98f7-b9f99f770532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1949445e84e744f29823c34223e1e913_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtNy0xLTEtMA_73f5779c-3b81-441c-80d1-b58934ea8a8e">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7932b106c7448daa2a3a55d1da0adfd_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtOS0xLTEtMA_7a9effa7-61b2-4f0f-8c84-8696b513612d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTEtMS0xLTA_b8c63101-9ce8-451c-b14c-ea59c9a5af11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729ae19583c44de3bea4894565e3326e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTMtMS0xLTA_23961dc0-1e12-4ba6-a04d-e01a492c7538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b2c6ae9105493882fd7968a705b503_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTUtMS0xLTA_f884a20c-3b55-456f-bc07-46a215889f32">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMS0xLTEtMA_a445e5b1-2a0c-43b5-907c-53c0543f3fba">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3a6c594db44074808bec17ed6ec8b9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMy0xLTEtMA_02ea12d2-d88d-4f27-8af0-e1b4114ef66b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd21a1a7d51489a86f20b38a1d20755_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtNS0xLTEtMA_da7c83e0-c2ff-4030-b71e-86bd177fab4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2583cf01e284ddcb2320ca55728a506_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtNy0xLTEtMA_4b7ea03f-be59-4adf-9679-f94ebae117c3">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7816629b0334d2aa6b53dc07c4e8faf_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtOS0xLTEtMA_d3b22e4d-8fa2-413c-8d7f-a9acaea6377c">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc955b1af87545599fdfcd8990fdedbd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTEtMS0xLTA_55828db2-8679-4d03-9dec-eed3a903bafc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58a28f0d346460685afcc652227a9c5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTMtMS0xLTA_b291da1b-3442-4f4c-b80b-25c8d345f375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTUtMS0xLTA_a23720dd-d429-47c6-bf13-d269a81f72f3">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMS0xLTEtMA_276cbf40-f50f-484d-ae11-84c526f088ae">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMy0xLTEtMA_9f2ef168-98e5-4b06-9d89-6b2978521d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtNS0xLTEtMA_95bf1ec8-94d2-4485-8109-2c77c9d5567a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtNy0xLTEtMA_c60bd584-5ee7-4164-bb50-6a65dacc7036">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtOS0xLTEtMA_a2d947b5-ac97-4f0c-a12e-38c68ee9e5e6">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTEtMS0xLTA_f1124a53-be3a-4750-afd4-10191d0b5a3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTMtMS0xLTA_27be1fd3-6e8e-48c6-a51c-eac754cfc64b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTUtMS0xLTA_66698dd3-d34f-4ef7-b277-7a11c6e598e9">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1755cafcd4254c2e8aeb93f416956e53_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMS0xLTEtMA_6fd313fe-b6aa-4340-ab03-b4fbe9b2a6c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e30aabe97d4272be3e7e97eeff7de4_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMy0xLTEtMA_a6438d03-da53-486e-9622-fe7c0f333634">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i827bb071fabb4cd1816ed87eba65624d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctNS0xLTEtMA_6ddfa8e4-ca60-4a70-9a95-d63b9e1e62b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5a8e02f1b1415090e676b983a40e37_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctNy0xLTEtMA_8b68afb5-ebd8-487c-9839-0c824b82d0a4">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534176133b5e46268b75e8ee4783ef0b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctOS0xLTEtMA_7b5d80d8-3499-4c54-9b14-2857b1011cac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2257904af3c45abbfbf463b398101d9_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTEtMS0xLTA_2921e534-47fe-4e47-b7de-515135179b95">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675ac0a159cc4cc691060e09552724bf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTMtMS0xLTA_4924144e-4a1b-4172-a810-71218c07ea32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdd387cfc074b9f95912bc5b38d09b3_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTUtMS0xLTA_092dc509-8007-48cd-b6b3-0a6bb73b717f">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f98a00d9cb1469381ff2b85052e050d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMS0xLTEtMzIzMA_1fdce328-cf21-45fb-89ce-4e6539d0e696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735af80d7e943a7b6cbff2ff9825cca_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMy0xLTEtMzIzMA_d01748bc-1d73-4f97-95bd-bd9413574fde">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554c0786877949ee8178f77e6daab0f3_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNS0xLTEtMzIzMA_b5705e19-640b-468f-8aa8-864c475922cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie26963a2ac324ba4a14e6c9468186690_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNy0xLTEtMzIzMA_4497e6a8-8f66-4c0f-a870-27fc22fefa26">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2c0faf9f814cdca31718d64e210291_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtOS0xLTEtMzIzMA_dc4ff84c-6585-408d-b737-37af216e5065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9553bd5ca6744da1b5727a32a9c9263b_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTEtMS0xLTMyMzA_303645e2-d499-4e55-bc8e-174721a14590">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8904871bd9ff4926abbade9d25474108_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTMtMS0xLTMyMzA_d88c69cc-a8cb-4022-aab9-8d2c4d711ba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cb5301d76a4873b15a1335479d3c2a_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTUtMS0xLTMyMzA_adcfd24a-2bc4-410c-bfb5-c88ee020e493">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e635dc42c1b49bb99f084c0f6584807_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMS0xLTEtMA_63ef88ef-14f1-4ea6-922c-ab8dfd942bb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMy0xLTEtMA_fdd1e5f3-9a83-41a0-ab53-d5a8180d18fb">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNS0xLTEtMA_7ca73bb8-a27a-4ba0-8225-695cf0283fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91862fa2efc447e29c59e61b626857ed_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNy0xLTEtMA_33188090-8394-4177-9a61-b3cf4275db68">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81090f7e16204c969f9a89fd1d33cc95_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtOS0xLTEtMA_137e3fc8-2847-45aa-b8d4-50b1b03661d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5599e985c1df48b8af48f1564e7b9e6d_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTEtMS0xLTA_2941df57-57c8-4e56-bff0-4624dea3773f">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df4c3c188454c12a12d6adf310f9ac9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTMtMS0xLTA_673c345b-c30e-445f-bb70-c60407b8a6cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie262f30b95734e43832d8a9407f94eb4_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTUtMS0xLTA_b331f99c-826a-40e7-b449-73f950075d36">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMS0xLTEtMA_79b8028e-9950-4a14-9150-b40adc5887c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMy0xLTEtMA_b8ea3702-088f-451a-b23d-4fcf8e158630">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtNS0xLTEtMA_d54976ac-2247-4128-9241-5294be73c02e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtNy0xLTEtMA_f9f8e744-4567-4e29-9194-4e5eee6704db">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtOS0xLTEtMA_94393098-16e4-43ca-b672-dadb8bc88981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTEtMS0xLTA_e99a703a-42ca-45a3-8d67-4926bbee4c52">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTMtMS0xLTA_a82e3d62-209b-4406-884a-5e63fbac5380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTUtMS0xLTA_979c7dc3-56d0-4e0d-affe-fe3b9a8c3acf">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMS0xLTEtMA_a9c6381d-10c5-42ee-b7cf-cb6b531ab834">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMy0xLTEtMA_dbee66e1-1923-4b85-b7ad-2902598a5695">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtNS0xLTEtMA_5471874e-83b7-4e1c-bd85-e28dd8a8d2d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtNy0xLTEtMA_07beea63-c085-45d5-8410-332ca0165016">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtOS0xLTEtMA_360b0e95-f38a-408a-9d18-39fcb51a90ff">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTEtMS0xLTA_0793048a-c4f4-4a6c-b159-90a4a6cc6c48">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTMtMS0xLTA_19dd85d2-1924-4cf9-aa9b-4c150ad0af54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTUtMS0xLTA_74645250-f8d7-4ad3-b0ed-24bcb2c89385">2,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMS0xLTEtMA_8f9795bd-a4a3-4ecc-9613-544f859055e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMy0xLTEtMA_068a1b60-e423-4377-8dbd-7ccea5ed43e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtNS0xLTEtMA_69baf17b-74e9-4299-aad2-b70012879391">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtNy0xLTEtMA_0ef2c76e-23e1-4b20-9572-421f0525ea48">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtOS0xLTEtMA_7a44ad3c-4341-4c6f-8485-ca0c340739ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTEtMS0xLTA_f779d6f6-1fb1-485b-ad3d-700cd99cb833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTMtMS0xLTA_88838856-7c2a-4a17-b9a6-ec668a3a3d23">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTUtMS0xLTA_7b20ff03-2d79-404b-9ab2-2418495d7b34">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1755cafcd4254c2e8aeb93f416956e53_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMS0xLTEtMA_2d2174da-e651-4867-aeed-4ba97fa3b39f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e30aabe97d4272be3e7e97eeff7de4_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMy0xLTEtMA_42d50455-a71c-40da-b471-97f804d445b2">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i827bb071fabb4cd1816ed87eba65624d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtNS0xLTEtMA_f2ea9963-1e8b-4d8e-b2e8-34f0c9af8317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5a8e02f1b1415090e676b983a40e37_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtNy0xLTEtMA_234c6419-fad3-4f76-ab6d-2a7da0fc67ff">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i534176133b5e46268b75e8ee4783ef0b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtOS0xLTEtMA_e01d4932-8297-43b7-85b1-b97bd5ff1f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2257904af3c45abbfbf463b398101d9_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTEtMS0xLTA_30246dc5-0787-42d8-8ea9-1c191a7a4e81">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675ac0a159cc4cc691060e09552724bf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTMtMS0xLTA_a59c49c9-7762-4097-95d1-411e5bb39fe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfdd387cfc074b9f95912bc5b38d09b3_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTUtMS0xLTA_67ff6d6b-0be6-4c31-9b27-e504cdbb771f">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f22f3a8e434723aa4c8e677adcb774_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMS0xLTEtNDgxMg_35433c85-ed4a-4e5d-b8d6-44095beea184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82319f76c8e24d55ad16cfbcb26dd55b_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMy0xLTEtNDgxMg_6993d52c-def7-411f-adbd-e478b1396873">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b391a9730b4cf68a103be0f154b323_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNS0xLTEtNDgxMg_777a9e45-55f6-47d8-841e-1ca8ac9fdb71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ed48ae16f7483ab2c12115e9b3b1f8_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNy0xLTEtNDgxMg_ce4ce63a-336f-439b-a4e4-94567c92d021">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic318e672eaab447c8135df89f679f16b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctOS0xLTEtNDgxMg_d8bd9245-990c-43b2-b47c-e7edeac6eaad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26fad08fdba44d0b82362dc57e0d7f8c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTEtMS0xLTQ4MTI_27775f42-4d21-4ef5-aeb1-6b28a21b7241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6898b1302e46f2b14f135b0cf9ad8f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTMtMS0xLTQ4MTI_296012fc-0c4e-4e99-9a02-37be5c1635d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7943709a46a24d76a5bb3f5bcdd1ef43_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTUtMS0xLTQ4MTI_73470396-5e94-43fb-95dc-d14c9b98cc43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e635dc42c1b49bb99f084c0f6584807_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMS0xLTEtMA_803621fe-5820-4287-87e1-9f10235d55b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMy0xLTEtMA_ab4e20b2-a97a-4986-9308-f8bbfc04a36d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNS0xLTEtMA_31a81d38-ad9a-468e-9591-e71455c8813d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91862fa2efc447e29c59e61b626857ed_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNy0xLTEtMA_68bdd203-eecb-4707-83b3-2e884e60e68d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81090f7e16204c969f9a89fd1d33cc95_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctOS0xLTEtMA_a044c1e0-13d6-410b-9070-c40d272586cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5599e985c1df48b8af48f1564e7b9e6d_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTEtMS0xLTA_0f8c6257-9045-47b2-a452-cb26caac635c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df4c3c188454c12a12d6adf310f9ac9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTMtMS0xLTA_ab5ce7a5-8e3f-4830-9032-49ba921d2555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie262f30b95734e43832d8a9407f94eb4_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTUtMS0xLTA_a1f52cbf-abae-422b-808f-f78894a7b230">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc02a58f23874914ab829313aab4a522_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMS0xLTEtMA_0a82e1ac-2782-456a-95ad-ea4c27226452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77b04eea3e5b4a1b849d4967371f9b86_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMy0xLTEtMA_bd0101d7-68b1-4018-9be5-7e1f91d38b1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7573baa67fd4165af6f52acfff81eb1_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtNS0xLTEtMA_ccc2fb1b-1e8b-4660-a86b-d04c40f90d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e96a20a877543ee9ce8338ad2ef622f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtNy0xLTEtMA_a8dc0c34-9723-4666-be97-0b93be09934f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cb59c697544159a4a94b077d73ed46_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtOS0xLTEtMA_bf73f93f-89ce-40fb-93af-07443506451b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb4503c9509423bbee8e6c29bd5e78e_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTEtMS0xLTA_4cf30f85-bf96-4b8b-ae81-28e0e1aacd80">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf8d0cc1ac8422fb6018bd01c7ffaa6_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTMtMS0xLTA_d872924e-868d-42ea-bbf2-39f4f5c5f8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f17a0fdf894d27bdd29405d396934e_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTUtMS0xLTA_fa83b1fa-2dba-4449-b033-6022a643499b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMS0xLTEtMA_de48751c-a534-4bff-84cd-e3a3757b17f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMy0xLTEtMA_2261c815-2f67-4bb3-a4cb-cace3c38f828">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktNS0xLTEtMA_6a8c7c8e-7c60-4d36-ae1b-9c4245d13830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktNy0xLTEtMA_2f4b377e-93e2-4c44-9635-6e6b1b5b9446">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktOS0xLTEtMA_50568762-8beb-452e-95bb-530f5f329624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTEtMS0xLTA_b40e4894-fe70-473f-813a-f1261ff019fc">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTMtMS0xLTA_b0fb59ed-a068-406f-a3f6-6501caea24db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTUtMS0xLTA_bf0ea8ce-d655-4039-9e01-4182038056fc">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMS0xLTEtMA_fc26b786-6efd-4c8a-80c9-7460ad1ca9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMy0xLTEtMA_de549842-6c9d-485f-9d66-4ab0c6fd2183">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtNS0xLTEtMA_1bb99810-638c-4536-94d2-2b05a88232f7">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtNy0xLTEtMA_97870dbb-1c05-42b5-b5eb-fdcb9d8e4e18">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtOS0xLTEtMA_3a058fb3-594e-481a-a1da-746f014e8dd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTEtMS0xLTA_52a28cd8-9e17-4d96-ae6a-44cf440684f6">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad7583f26b437581d137910e409b27_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTMtMS0xLTA_840d2337-4242-4879-8597-e3c345a306a1">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTUtMS0xLTA_e3eccde9-b94c-4cac-b86f-3093bb212b00">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily all of the asset-backed securities were highly rated (Standard&#160;&amp; Poor&#8217;s rating of AAA and Moody&#8217;s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily <ix:nonNumeric contextRef="ibe06cede262f48698bafa7ad43037553_D20200101-20200930" format="ixt-sec:duryear" name="mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM1ODM_57ddb5e8-2fd4-4c79-a0eb-e8eab0f99593">5</ix:nonNumeric> years or less. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $<ix:nonFraction unitRef="usd" contextRef="i8c1a6f29c939482d8e9f901e3e75b9db_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM5OTE_d0dde4a6-6119-43ed-b6c3-bf7aeec597e8">6.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i20dc5a545bbb43b5b42188e27def9036_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM5OTg_fd0dc5d4-b70d-4a25-8a0c-846c4dc983dd">8.9</ix:nonFraction> billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 19 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i648c5a837cb04c57a451a63008c8a453"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NjY_aed9069b-2baf-46cd-8391-76d5495dc819" escape="true"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMi0xLTEtMS0w_f7d6c3c6-3a3b-4061-bf85-8a48a3efff0d">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMi0zLTEtMS0w_b65c3f3d-3af3-4fde-ae4b-50635e1962b0">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMy0xLTEtMS0w_146cb649-b6c6-4294-a4e3-437f027fca74">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMy0zLTEtMS0w_2e2a66d1-03a9-4ba1-967a-455558b12d20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNC0xLTEtMS0w_cf2ee637-bab0-4c9a-9b8a-8878d2f06ae8">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNC0zLTEtMS0w_47371bef-c8eb-46d2-b837-3cd5b9be055a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNS0xLTEtMS0w_549b9c00-6478-47aa-9806-0cc1796572d5">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNS0zLTEtMS0w_3ff349eb-0bfd-4fbe-bea5-f3969fb1efce">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNi0xLTEtMS0w_becafca1-0f1d-47a7-b6b7-6ea3983a7e51">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNi0zLTEtMS0w_51201220-0769-44cf-944a-1edbf98a3863">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at September&#160;30, 2020 includes $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ0Mzc_efaf3d86-26c2-4c72-9a28-1a46e253a2bb">140</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At September&#160;30, 2020 and December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i575af78c5c07443093cc857d1c99b8ff_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ1NTA_d45eeb05-4de7-4384-910e-ab36250c9448">637</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f10c43e33c64fccbb6f541ca846b3ad_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ1NTc_5c9990ec-f232-4698-ba2b-7d43369738df">625</ix:nonFraction> million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="i575af78c5c07443093cc857d1c99b8ff_I20200930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ3NjY_ce9e0ef5-6e77-4e26-a252-f321381a9c0c">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i15622ac81bf64b6d8a631c6e28692012_I20200930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTUwMzA_32db07fa-cc98-4524-a878-8b57d11cff84">8</ix:nonFraction>% to present value the cash flows.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2020, was $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU2OTA_5c0cbc90-ad0f-44e6-9f51-55565f007952">32.6</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3Mjc_c3d73d29-eb11-48c9-a35e-2a31929b19a2">28.7</ix:nonFraction> billion and at December&#160;31, 2019, was $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3NDU_fefb63b7-5e25-4b67-bfc8-d67ca4918c0b">28.8</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3ODI_24b21a1a-5841-4e0c-935c-9d0d1d6cd472">26.3</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableSale" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTcxODI_19cedc35-e2f4-4368-87f6-383d15c7d5d9">2.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i95e09f3059bd4468a374ad7a474b31ec_D20191001-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableSale" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTcxODk_94a9a820-994f-4def-ab2d-dd16741d4f8e">2.7</ix:nonFraction> billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg0MzM_142d73ce-d850-44f7-833b-b1ae2861e7d3">34</ix:nonFraction> million at December&#160;31, 2019. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg1NTk_1c6aa14c-9d06-4e30-9267-453d1fb8b754"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg1NTk_a56ccebd-cc80-4202-a323-780132b8a3d5">No</ix:nonFraction></ix:nonFraction> cash collateral was advanced by the Company to counterparties as of September&#160;30, 2020 or December&#160;31, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 20 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfNDIy_94b52f9b-2bcb-4130-9e1d-a587209d34c9" continuedAt="ia359f73d71aa4f58acc2d0a9780bb767" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ia359f73d71aa4f58acc2d0a9780bb767"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfNDM0_8dc5a792-dd28-4bac-a81d-07f48884fb23" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMS0xLTEtMS0w_1fb8531a-6311-4c55-82a8-62023242553c">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMS0zLTEtMS0w_2d4bc6e1-f51a-4191-accd-8c295d3ebaea">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessAndRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMi0xLTEtMS0w_ff2a8479-3435-45fc-86b1-cb835450ee48">6,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessAndRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMi0zLTEtMS0w_2aa99040-ee7d-4005-acbf-b19f400e8e63">5,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMy0xLTEtMS0w_9de31cf8-214c-4a9e-869e-34bf7f49cac3">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMy0zLTEtMS0w_13bdfe72-e141-46da-9832-0970f3b8f2d1">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNC0xLTEtMS0w_4129902a-254a-4fd3-bf4c-dc77f2c3ab64">8,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNC0zLTEtMS0w_229f6b2b-3bac-4410-8801-b24b032577bb">7,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNS0xLTEtMS0w_a2302b72-c0c2-4231-8b4a-d39e7e85d266">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNS0zLTEtMS0w_859ba7bb-8aa3-4c2d-afa1-8528a7969a3e">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNi0xLTEtMS0w_62292ec0-fc44-4bce-91ba-07d39cda079d">8,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="mrk:InventoryNetAndInventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNi0zLTEtMS0w_888b63d5-beb5-49a2-a864-efe716050736">7,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOC0xLTEtMS0w_42c13af4-c776-4b0e-ae04-bb5751a77fa3">6,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOC0zLTEtMS0w_d3b3a3d1-4334-44e0-bf31-d460e93cdb78">5,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOS0xLTEtMS0w_50d2e896-b5d2-4cb6-b405-b3452c76b29d">2,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOS0zLTEtMS0w_8c05f32b-c7ee-48d0-af2a-6d40dd50b244">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2020 and December&#160;31, 2019, these amounts included $<ix:nonFraction unitRef="usd" contextRef="ica983717d6fb4ff095964b0c590cae02_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMjAx_f477e356-1f37-427f-adeb-acdd6c16ddb2">1.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib6fe871055ff4f2c8a6464ebc3c894da_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMjA4_d6176476-0377-459d-b15a-9b7847ab12df">1.3</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="ie31e25b750ad407bbfe538ce6e4d1eba_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMzE4_be8cdf45-8371-40e3-8f2c-a88ba10a8c05">288</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idfc8aed4c32f4ba9bb8680a335959dec_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMzI1_6c0c89f3-dc5c-4941-8890-712697ddcc5f">168</ix:nonFraction> million at September&#160;30, 2020 and December&#160;31, 2019, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_1296"></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTc2_ac15f1d8-7bf8-4ee6-8e99-79c82c8324f2" escape="true"><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Other Intangibles</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter and first nine months of 2019, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTMy_711be0aa-bab7-43e3-a158-7ef566954233">612</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTQ5_b0ec7d2c-9f2a-490b-a6de-24f42e45b992">693</ix:nonFraction> million, respectively, of intangible asset impairment charges related to marketed products within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the third quarter of 2019, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ice5e55028bcf49d98bb89ed4e93e01ae_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTcw_9072b7e6-296a-4d7c-bc7c-3de91c30001f">612</ix:nonFraction>&#160;million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div></ix:nonNumeric><div id="i67ef4e29db364327800e42a94e43496a_58"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfNDQx_0e2a1c27-ad78-417a-b43a-068e8fdd5484" continuedAt="i1222c5f2ae284cc4be8a0d82b02c8c45" escape="true">Long-Term Debt</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1222c5f2ae284cc4be8a0d82b02c8c45">In June 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i41f558a03fc74d9786822fef7d1da9ac_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfNTY_e0c190f1-6119-4bb9-a74b-89d0027f0ac6">4.5</ix:nonFraction> billion principal amount of senior unsecured notes consisting of $<ix:nonFraction unitRef="usd" contextRef="ia564edcd14034ec790ba4a71ee6a8622_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTE2_d307fee9-0a0f-4b5e-a34f-e27be1cdd954">1.0</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="ia564edcd14034ec790ba4a71ee6a8622_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTIy_ec041768-ee21-4c50-a9e4-b0cdc9872f1a">0.75</ix:nonFraction>% notes due 2026, $<ix:nonFraction unitRef="usd" contextRef="ic940ded1777647d7b1ecbaaef52763f0_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTQx_a3e2fffd-88c3-41f3-adbd-f06adcb8d131">1.25</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="ic940ded1777647d7b1ecbaaef52763f0_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTQ3_24b12f86-10ad-41d6-8a58-50eb722846e8">1.45</ix:nonFraction>% notes due 2030, $<ix:nonFraction unitRef="usd" contextRef="i111bb73a24814a3c8fff74bfc915fedd_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTY2_7f4566c7-3e91-498b-b784-f539702c5c22">1.0</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i111bb73a24814a3c8fff74bfc915fedd_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTcy_6f743638-7b7e-4c7b-a18d-13315665345e">2.35</ix:nonFraction>% notes due 2040 and $<ix:nonFraction unitRef="usd" contextRef="i037b1090dc53410598ac31bbb1af0ed8_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTk0_39864ed2-ac13-4549-a8fd-62ffb757ec81">1.25</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i037b1090dc53410598ac31bbb1af0ed8_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMjAw_f3f78bac-39a2-45ef-a6ec-213b16b53cb3">2.45</ix:nonFraction>% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.</ix:continuation> </span></div><div id="i67ef4e29db364327800e42a94e43496a_61"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTk4MjE_b6d13d6f-b2fd-4cd4-95c9-832a18fa495b" continuedAt="i3c45d88cf1eb4db491b673f5990625ae" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i3c45d88cf1eb4db491b673f5990625ae" continuedAt="id6e073608a194c50bf7f50bd209e96c8"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTk4MjY_813df34a-9769-4106-ab02-d40058b5603e" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 21 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id6e073608a194c50bf7f50bd209e96c8" continuedAt="i47540b31644e47b4b269455d1a427be6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Litigation). As of September&#160;30, 2020, approximately <ix:nonFraction unitRef="case" contextRef="i2c65f9d30293433985417442b5f323df_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMjQzNA_9ad613b6-ceef-4435-a610-5e4e4d766a9b">3,590</ix:nonFraction> cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck&#8217;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#8217;s motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff&#8217;s failure to warn claim was preempted by federal law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#8217;s preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately <ix:nonFraction unitRef="case" contextRef="iab048735a64c498682a6136168824f23_D20140301-20140331" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMzYzNA_0140e4c6-2ed8-4c8d-8400-12dd902c3774">650</ix:nonFraction> cases on preemption grounds. Plaintiffs in approximately <ix:nonFraction unitRef="case" contextRef="iab048735a64c498682a6136168824f23_D20140301-20140331" decimals="0" name="mrk:LossContingencyClaimsonAppealNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMzY5NA_4dd80ca7-29fe-4d42-9ffa-4399fd4806e9">515</ix:nonFraction> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, as of September&#160;30, 2020, approximately <ix:nonFraction unitRef="case" contextRef="i17584faa284b4b578d5ddb79fabaf164_I20200930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNDczOA_4ac3c37f-37bf-4b1f-a5fc-d3dbb9964ced">970</ix:nonFraction> cases were actively pending in the Femur Fracture MDL.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, approximately <ix:nonFraction unitRef="case" contextRef="iaa614806e2ba4145bc4bcb5eccb090e5_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNDgyMA_b2bb8a7b-291c-4034-ba06-d1432d58965d">2,340</ix:nonFraction> cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, approximately <ix:nonFraction unitRef="case" contextRef="i41c548a060bf47df90e49186c4d38865_I20200930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTEzNg_04e5cb6a-3bf5-4d07-a84b-645a898aa4f5">275</ix:nonFraction> cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are <ix:nonFraction unitRef="case" contextRef="i17f4cd39dcfa47ef9b2f783ce64bf95a_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTM5Mg_b2ca99a5-dccd-4217-a154-d85782e4d405">four</ix:nonFraction> Femur Fracture cases pending in other state courts.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of September&#160;30, 2020, Merck is aware of approximately <ix:nonFraction unitRef="claim" contextRef="ia0c76a997e6b436ba14ab8377850ad0d_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTc3OQ_3ab62644-0c17-41d3-962b-3b0fd7ecdea5">1,465</ix:nonFraction> product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the MDL and California State Court&#8211;in separate opinions&#8211;granted summary judgment to defendants on grounds of federal preemption.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 22 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i47540b31644e47b4b269455d1a427be6" continuedAt="ie73dbc2aa59f41e59ba7c3cc5fe3a61c"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motions. Under the stipulated case management schedule, the hearings for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and summary judgment motions took place on October 20, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, <ix:nonFraction unitRef="claim" contextRef="i8ed7a5d6344d40cb8f2f177240990f6b_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNzAyMw_7f274d3a-974e-4a46-9f89-0b727371399e">six</ix:nonFraction> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately <ix:nonFraction unitRef="claim" contextRef="i954b3ee345d542df871f572d67e9eb31_I20200930" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfODE4Ng_ffba3a8c-8bc6-46b1-9aef-75425213a065">50</ix:nonFraction> additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Antitrust Litigation</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers&#8217; motion for class certification and certify a class of <ix:nonFraction unitRef="claim" contextRef="i42fde4910e9b464480e8f2e6cbb3d025_I20200930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTI0MjI_9cace16b-e004-459a-a69a-365f5547b604">35</ix:nonFraction> direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants&#8217; motion for permission to appeal the district court&#8217;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 23 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ie73dbc2aa59f41e59ba7c3cc5fe3a61c" continuedAt="ice37709a1e8247ffa4ae830ed1080f59"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants.  The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.  All New Jersey actions against all defendants have been consolidated.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company&#8217;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonFraction unitRef="case" contextRef="i6549f2bd3da3405297ab00a3e9493624_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTY2NTE_4b0fd56a-f8fb-4e00-81a2-8487c64f7df2">five</ix:nonFraction> generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, <ix:nonFraction unitRef="case" contextRef="ic5e3c82a44a84c4d9e95b408e7440546_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTcyMzI_ee9dd72b-1343-48a3-b163-f80ad5e51add">three</ix:nonFraction> additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy&#8217;s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan&#8217;s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 24 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ice37709a1e8247ffa4ae830ed1080f59"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> could lose market exclusivity in Germany as early as July 2022. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SPC have also occurred in Portugal and Finland, and could occur in other European countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2020 and December&#160;31, 2019 of approximately $<ix:nonFraction unitRef="usd" contextRef="ie3bda94820614e02831a1a380b925d56_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTkxOTU_0e8b0e0c-de47-4820-8bb1-5885cc827632">255</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i76ba186142fb49e1be6e39777874b85e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTkyMDI_61bb7219-13ef-4065-b6c8-6733cf943a2b">240</ix:nonFraction> million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_64"></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RleHRyZWdpb246ZTJjMjY0MGE2YmM2NDI3MmExZDM3MjdkNmIwNjVmOTdfMzg_e25846b5-c46b-47f9-8344-19aaa3c2353b" continuedAt="i28cbec50d9f14b5288e75eb726657931" escape="true">Equity</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i28cbec50d9f14b5288e75eb726657931" continuedAt="ifb76ad4d6d864424a2424d0a426dce7d"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RleHRyZWdpb246ZTJjMjY0MGE2YmM2NDI3MmExZDM3MjdkNmIwNjVmOTdfMzk_a83e84a1-7951-4f86-9e9f-25c587f7d708" continuedAt="ib31f538ee9e74fb7a768cdb39514cb32" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0xLTEtMS0w_81a79cba-64fc-4ec6-bd4c-3b8bfeb38b7d">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0yLTEtMS0w_b20576ca-91cf-4553-a17d-c3fed4b46a49">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94d9d12af0d4d57bd9f39eda31326c2_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0zLTEtMS0w_f88c5f99-d829-4708-a557-273497040c14">39,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1ea5618fc74137a1dd7d0a99fdc553_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy00LTEtMS0w_51100110-41e7-4d71-b0ff-fcb482dcf097">45,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i661be48d847543a8a32ba2358107f61c_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy01LTEtMS0w_0774b876-4b99-41b4-adf9-0502f4e9ded1">5,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f65949371d5466d8d9c0005d5ea3e86_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy02LTEtMS0w_21b3c3d4-bd52-47c4-aff5-2d180de43cbf">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f65949371d5466d8d9c0005d5ea3e86_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy03LTEtMS0w_2cc0c7ec-3d14-4467-89db-b81063e4d386">53,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f6eb6801e94b6aa490cf8461ca344d_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy04LTEtMS0w_b507ca19-1fa2-42e6-8d30-6664b63ac892">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b341ae138f41489d101f0152d09d24_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy05LTEtMS0w_48945593-ba83-4ce6-a14a-182e6f37ea83">27,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNC00LTEtMS0w_118190cb-cb95-4daa-b8e3-3830b1dd5fb8">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNC05LTEtMS0w_23bbd56a-8db4-4920-aa37-89f1086a03c5">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20ac31ed97124e86a01cbe0bb15a0082_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNS01LTEtMS0w_1a2a26c1-e73a-42da-a837-a20550ec9305">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNS05LTEtMS0w_bae23a27-bdff-4f0d-bc54-a0cf690cda00">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi0wLTEtMS0zOTY2L3RleHRyZWdpb246MWY0MmExZTkxMDI2NDI3NWIyMDc5NjQxMWNlZGZkZDNfMjE5OTAyMzI1NTYxOQ_a38b9960-71c3-4098-99be-b1d54f9037d4">0.55</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi00LTEtMS0w_10c20963-5431-4851-8156-04b4550d626c">1,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi05LTEtMS0w_438ad856-58b3-43a4-a648-7225b5a12de0">1,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy02LTEtMS0w_33e6c712-b9d5-49d1-8656-a287c54d918b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy03LTEtMS0w_a36f63c5-63f7-4316-9cbe-e69275d8b10a">1,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy05LTEtMS0w_3b4d976d-38ac-4bda-9e3e-6380f6a3d821">1,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fddb49b39a14e4c87423206f85f6bee_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC0zLTEtMS0w_6223fdc2-0f72-4c05-93b6-1f4b65243c0e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC02LTEtMS0w_ff59491f-3874-440d-91a7-68f0ab87451b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC03LTEtMS0w_fece13ed-cec6-489c-9a78-57d20e296198">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC05LTEtMS0w_22d03c38-68dd-4647-8f14-0a3394bc3eba">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOS04LTEtMS0w_a90f3515-3005-4ef8-a4d0-bed9636644ab">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOS05LTEtMS0w_3ca2052c-2b27-4669-9eaa-b2b888695833">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTAtOC0xLTEtMA_b4ba137f-d793-4231-a65b-645395faabe9">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTAtOS0xLTEtMA_92af2458-304c-4474-a24a-68b862a9e432">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMS0xLTEtMA_29f87f6a-3f1d-40ee-8d66-7d420b7d57e4">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMi0xLTEtMA_1305022c-e774-4eb9-908b-ce02d37ddf42">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMy0xLTEtMA_333e997f-23c2-4972-910e-e8f6c2a702b0">39,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206b5fb493434864b42f3461b9ec4325_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNC0xLTEtMA_fd535ca5-53f5-46be-a29c-78c16c091230">45,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i532639a15db54349b73094a5ac53f994_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNS0xLTEtMA_182da3ba-9ee9-4cde-8d06-997cc7cbcc31">5,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNi0xLTEtMA_3e4184bd-35cb-420a-96dd-3a1740f9525f">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNy0xLTEtMA_45a26cd3-f2ad-487a-9ad5-721ac2fcef62">54,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtOC0xLTEtMA_87f6a539-f976-48c8-9528-f4ba144aadee">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtOS0xLTEtMA_ca5e0e7b-4f9c-4fe8-ad00-17bbc6e1c461">26,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3eaa864f094450daf59663572c42e5f_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMS0xLTEtMA_26aeab1a-66f6-492e-85a8-d9f2534ce932">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3eaa864f094450daf59663572c42e5f_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMi0xLTEtMA_f8ebadcb-3e77-4e19-854d-498271331f97">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58eff3e8192a44b392d66978e46f4f8e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMy0xLTEtMA_9c19fc54-85f8-4792-9c83-f140771e3d15">39,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eb54219b048ff818ad6a1ac398d7c_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNC0xLTEtMA_005114e8-a117-463d-bb7d-eeb96f64ec49">49,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNS0xLTEtMA_0c3f027d-6bad-4396-8e34-de88e37602ee">6,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNi0xLTEtMA_898688cb-a095-4a9c-9552-24fbe0ac52db">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNy0xLTEtMA_c13966e5-c283-4d51-a29f-ac5baba3b536">56,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida404da98be84835bb1bca80aa637c1e_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItOC0xLTEtMA_5393cb0a-01d9-4f91-b0ba-2ca2595f00a9">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f558a03fc74d9786822fef7d1da9ac_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItOS0xLTEtMA_f2e2de46-f78a-4044-9036-cb1d3b521b79">27,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTMtNC0xLTEtMA_5d5bbb1f-4520-4ce1-a5c8-a7573a9bb6f6">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTMtOS0xLTEtMA_566c5d48-3ed6-4bce-97d2-602dd8e0485a">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55a6686f5d84014aaa7f5e1f1a99b12_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTQtNS0xLTEtMA_3394c90e-03e7-4752-86df-779d3be030b8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTQtOS0xLTEtMA_defa963b-521f-4b3f-ae3f-57b3019cd873">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtMC0xLTEtMzk2My90ZXh0cmVnaW9uOjIxOWJkNDA4NmQxOTRhNzdhNWVjOWU0YWU2NDhiN2JmXzIxOTkwMjMyNTU2MTk_7a29e087-361d-419e-9338-ae4d4e71d48e">0.61</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtNC0xLTEtMA_f8067bbf-e688-4ad9-b115-9d1895ba2a74">1,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtOS0xLTEtMA_0243c2cf-e5ff-48f9-bf56-2a40f2bdffda">1,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36f2245e6244cac86b52c10ca135b22_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtMy0xLTEtMA_f074cecb-bc27-4ca5-8b66-01fb60de8d20">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtNi0xLTEtMA_094653f7-844d-4e17-9b64-ab3a3134173b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtNy0xLTEtMA_3e479ff2-68aa-49cf-90f6-5c6c8b57ad6b">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtOS0xLTEtMA_b02a48e7-6be2-45a0-bb46-fbd3e989004e">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTctOC0xLTEtMA_2696161f-b309-4e3c-86f7-7fa98bf473e6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTctOS0xLTEtMA_50003f1a-2265-4eb0-9f45-e89e6e1aa90e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTgtOC0xLTEtMA_00449ac3-a63b-41ee-ab1e-516b27eef400">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTgtOS0xLTEtMA_eb865eca-d1df-46b7-90c2-60d79efeed8a">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMS0xLTEtMA_e800521a-25fe-4260-a0a7-cc87d32467ed">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMi0xLTEtMA_ea259b56-78d0-44a5-9364-e26901413be9">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7b18662e9547c19e8db82d3b49ad03_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMy0xLTEtMA_a299f4ce-285b-4341-a1ee-4093f7a5b790">39,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68eb834fd2ba4689a131fc785fe1664a_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNC0xLTEtMA_d2742357-6b9f-4454-926c-920d1d990c03">51,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNS0xLTEtMA_59b9e109-bc3b-4c22-8be2-f0cd6254b306">6,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNi0xLTEtMA_a6d4f660-c60a-47f5-8961-5ae109cae5de">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNy0xLTEtMA_0587a1fc-9c65-4961-804d-a9d645a0ac18">56,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktOC0xLTEtMA_7e6e6f41-a084-4492-9880-4661274e3c24">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktOS0xLTEtMA_99364854-9124-4e70-970a-7fe9f1e9d380">29,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 25 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ifb76ad4d6d864424a2424d0a426dce7d"><ix:continuation id="ib31f538ee9e74fb7a768cdb39514cb32"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1515e466edac46189d255abcb1355fd9_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0xLTEtMS0w_2eb6c287-f296-4d8e-9777-fdda010d02de">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1515e466edac46189d255abcb1355fd9_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0yLTEtMS0w_cc7faf71-5bec-4225-9341-880535ef73b5">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0d790716bd451a9a48dc70ee90327e_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0zLTEtMS0w_16fce7cb-7a53-45dd-a42f-3dafd27b8679">38,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aadea4a29ba4b14bb25f94d3779239f_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy00LTEtMS0w_7adae252-38b1-4e79-a694-51241c1a1adb">42,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy01LTEtMS0w_8f55f206-3e0e-434a-a42f-d5bd15c6e48a">5,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy02LTEtMS0w_e46543fc-c92c-498a-b012-c751bedaab21">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy03LTEtMS0w_088efed7-1c01-4fd7-ba53-06e810e9d584">50,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242db40746324acea9058b979850563c_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy04LTEtMS0w_6b5885b8-a9e1-4be8-ad86-ce0d07add681">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy05LTEtMS0w_26dfd8c1-6109-4a0d-a78d-e3acf869548f">26,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNC00LTEtMS0w_f5d85f93-54f4-4538-9803-53a1fb501ca4">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNC05LTEtMS0w_db7df47b-ec14-4013-b4fb-cd1e265c15d3">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifda54616745e475d9c94ff06081355b2_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNS01LTEtMS0w_1caf6b73-f74c-4523-ad9c-6ad11b902889">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNS05LTEtMS0w_c0461465-d315-4c87-a92c-2fdcceab5142">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi0wLTEtMS0wL3RleHRyZWdpb246Y2Y2Y2FiNmEyMDJlNGExNTk0ZWJhNDgxOTliOTMyZTBfMjE5OTAyMzI1NTY4NA_4b1104ff-3a3e-440d-b645-e897ed03006d">1.65</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi00LTEtMS0w_631f5e1f-b238-48be-81d3-51969dd49a1f">4,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi05LTEtMS0w_2892d12d-1b75-4878-886b-96148cb4ad7a">4,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy0zLTEtMS0w_377bdd96-f662-48df-bc04-9d101073196b">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy02LTEtMS0w_692e5bba-bd76-417a-8fba-332d2d2d0ba6">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy03LTEtMS0w_a4039cd0-9c7e-446f-b97e-8d906eca59c6">4,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy05LTEtMS0w_3e6aca1e-3993-48d6-90cc-31d58e6a3450">3,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC0zLTEtMS0w_d8308c9e-6f96-4df6-b12b-6e1c1b8e09ab">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC02LTEtMS0w_3989c2d2-34eb-4e08-990b-31b46b19c543">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC03LTEtMS0w_21acc624-c816-4d69-9ab7-4d8ce79014f3">734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC05LTEtMS0w_4871876a-9a84-4ff3-9966-622ac3b29cf9">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOS04LTEtMS0w_43787fbe-f2bb-44f5-862f-19b245d2010f">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOS05LTEtMS0w_3b7b1a0e-bb2f-4921-b22a-b72d9b4836bd">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOC0xLTEtMjk0_4f508cb4-11f9-4099-820b-27eade8a6e6f">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOS0xLTEtMTA5MA_2b45d040-11dc-4b62-ba83-887f1d83e17d">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMS0xLTEtMA_dbec383a-3381-4f84-82d2-628f4a3e6425">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMi0xLTEtMA_ad41e5b8-8ae0-4197-a0d3-de549c1de04d">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMy0xLTEtMA_caca995c-7838-45b5-948c-57f1bb6460cb">39,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i206b5fb493434864b42f3461b9ec4325_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNC0xLTEtMA_392d3d98-5ded-4494-95a6-764bbaba3c79">45,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i532639a15db54349b73094a5ac53f994_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNS0xLTEtMA_b8ad1830-e0d2-4382-91cb-3c30ae7671bb">5,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNi0xLTEtMA_d8a35f1f-0f4f-4047-82de-51b41ffc44ba">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNy0xLTEtMA_3d52a111-3ea9-467f-a989-edf568afc422">54,925</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOC0xLTEtMA_c92343b8-7028-4b3f-b822-34206187823c">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOS0xLTEtMA_961d3d78-44a7-40c0-adf5-7e45d1a7d78c">26,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45834c2505094eeeb4eda66b2b373ec9_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMS0xLTEtMA_e1f28dd1-99c9-44be-b210-4ecf0cb6fa52">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45834c2505094eeeb4eda66b2b373ec9_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMi0xLTEtMA_b74862ad-761a-49bd-8798-b0799d60b511">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa8db1c4585543f3813c30fd6dae8d64_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMy0xLTEtMA_3dba8df2-e080-402e-a4a9-b8d1106a7f5b">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6df4e6fd9a51492ca873f16e901201f7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNC0xLTEtMA_a023b4c9-b864-4eff-a159-5854bb6e713f">46,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice9dc335efad486f8e04c605de2f04aa_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNS0xLTEtMA_9939e584-5bdd-43a3-91f4-6270d056f90d">6,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28d6e7a2db2f477998a358afa23a3447_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNi0xLTEtMA_e84bbfe5-1445-4854-8755-55481f7c3b85">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28d6e7a2db2f477998a358afa23a3447_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNy0xLTEtMA_93877869-2264-4d2e-86cb-72bb86e01618">55,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8adcb6d851f94dc3a3fdea895e2d7460_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtOC0xLTEtMA_bc4c4fa0-49a5-47ff-b59d-c634cf815115">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953cc45283754d089c0fca74403dda73_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtOS0xLTEtMA_1e84c098-f34f-4497-b42f-38ab0d8a57bc">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTItNC0xLTEtMA_a1a67050-10bf-412c-82d4-d0063880d12c">9,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTItOS0xLTEtMA_d79ab53e-4543-4547-bafd-053d7a16c44b">9,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib13c6933c3674a5181dbe15e12aaee8c_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTMtNS0xLTEtMA_b2875c75-6f60-4884-bca0-da6bebc9c6fa">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTMtOS0xLTEtMA_6746f828-97d5-4a0b-8ffa-00cab656424c">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtMC0xLTEtMzk2OS90ZXh0cmVnaW9uOjM1YWNmZmFmNmFhMTQwN2FhMzU3M2QzNDg3NmMzYjgyXzIxOTkwMjMyNTU2ODM_292a0597-3d4f-497c-82e2-3ae4b36f3059">1.83</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTQtNC0xLTEtMA_40183ff4-5aaf-4b37-bde3-1bff59b6ad42">4,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTQtOS0xLTEtMA_5ffc4118-b446-4c40-b050-2d796346175a">4,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtNi0xLTEtMA_aa3c24d6-acc8-478f-89ae-9e0704339844">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtNy0xLTEtMA_9a579328-24c9-4dfc-a8ba-dd39e3f5ef9d">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtOS0xLTEtMA_237f4683-af7c-4691-9fca-ff2a9f99b223">1,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7179c9a592ed4b02a3c776ff0dd331b9_D20200101-20200930" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtMy0xLTEtMA_da4f9367-0c8c-4369-8c32-3f74ce9a2a7a">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtNi0xLTEtMA_c7192410-c0c6-48ef-a52d-6f8969909193">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtNy0xLTEtMA_d75107f8-5870-4c3a-ba89-3ac7d5f56e0b">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtOS0xLTEtMA_013f79ed-8d2c-4705-8c93-a4b87bfe930e">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTctOC0xLTEtMA_03cf0b26-476d-4133-9aa0-18f9bbdd38d5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTctOS0xLTEtMA_d4d207d2-869d-4125-aebf-9e09d69cc85e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTktOC0xLTEtNDA4NA_9824ebab-640c-4623-8117-fc35500bcbbf">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTktOS0xLTEtNDA5OA_b5553cb6-dc35-42b2-8dad-a168f6a8ccb5">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMS0xLTEtMA_57e33d13-5956-49d0-886c-99c45a6cb97c">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMi0xLTEtMA_336be8a6-f13b-42a3-98a8-c5b72d70b886">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7b18662e9547c19e8db82d3b49ad03_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMy0xLTEtMA_1d3246ee-7519-4b2e-a535-6b98701327b7">39,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68eb834fd2ba4689a131fc785fe1664a_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNC0xLTEtMA_f4b3a38b-4c06-48c5-bb45-f313ab4d68ff">51,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNS0xLTEtMA_692bc384-3b90-414c-bae4-4b677d842ed3">6,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNi0xLTEtMA_9741447e-a976-4197-a952-cdc4121a71ea">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNy0xLTEtMA_1367acf4-d263-4a84-a0dd-4b4af61daef3">56,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtOC0xLTEtMA_5052dab6-2209-4e4c-a3b0-e9d03cad188a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtOS0xLTEtMA_a299a058-1b6e-42ca-9584-0d6ced0ba2b6">29,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i67ef4e29db364327800e42a94e43496a_70"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcwNw_418bc651-d6b3-4845-aa07-38bf4b45b3ba" continuedAt="i05a74330d68449b3a3188ecdb3528d7c" escape="true">Share-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="i05a74330d68449b3a3188ecdb3528d7c" continuedAt="i4c7585b65f1c4809bffc892bb77eb441"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.</span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcxOA_4767ff13-8aa1-40b1-8ab8-c62669b2ba43" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi0xLTEtMS0w_85d6d5bb-63e4-4398-935d-f307fbc9b488">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi0zLTEtMS0w_8ddf7c6d-c19f-40a9-8d3a-eaee6fc40c48">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi01LTEtMS0w_1e2d6aad-d4ce-4cef-a3a7-d414a0522203">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi03LTEtMS0w_055b9c54-7118-48b3-aadb-c962b240dea6">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy0xLTEtMS0w_50e9f12d-b6ab-483e-94af-2e8145472711">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy0zLTEtMS0w_0312e845-0d1f-4167-aa13-8af8d92c9208">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy01LTEtMS0w_02ee9bd4-6628-44ef-8869-5dc3c1f4f45f">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy03LTEtMS0w_4f95ec54-d5ec-4a2a-aafa-96b12927cdd9">42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC0xLTEtMS0w_3dee6ae9-423f-4405-8745-f9a9c020a056">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC0zLTEtMS0w_afd55487-28ae-443a-adf1-3196cb17efbf">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC01LTEtMS0w_f83bb032-a8ca-4e47-b677-6909fa5581a3">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC03LTEtMS0w_1ecd7def-c8e0-48fa-b379-a2d2edd5cf12">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNTc1_fe2e26cb-9205-461d-9db6-b735873a5340">7</ix:nonFraction> million RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNjMy_9c62e366-36cd-43b8-acf2-fd4e410819cb">77.83</ix:nonFraction> per RSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted <ix:nonFraction unitRef="shares" contextRef="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNjg4_b9ac8e6e-2ec3-4b28-918c-770494a9c92a">5</ix:nonFraction> million&#160;RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNzQ1_1df1353d-b8d3-4e43-9a58-23b535035a50">80.03</ix:nonFraction> per RSU. During the first nine months of 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfODEx_6314cf73-0b83-4585-b18f-10ea3a1f9363">773</ix:nonFraction> thousand PSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfODY4_2db68a8c-653f-417d-9005-d7e50c2dab7b">75.22</ix:nonFraction> per PSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted <ix:nonFraction unitRef="shares" contextRef="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfOTI0_8513cd63-08f7-4d98-a413-f264b59a77d6">609</ix:nonFraction> thousand&#160;PSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfOTgx_9ff9fd46-7cc0-49bd-8237-85bff511909a">90.50</ix:nonFraction> per PSU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcyMA_d7c75d55-db44-44d1-98ed-e64afe9be1ea" continuedAt="ib25ab8dffc764ea6af7772d9dd08a4ee" escape="true">During the first nine months of 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTA1MA_08dee29b-2324-4906-a20c-b033137faa77">4</ix:nonFraction> million stock options with a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTEwOQ_9e258628-cd69-4c79-bc1a-5d00e211bee4">77.67</ix:nonFraction> per option and during the first nine months of 2019 granted <ix:nonFraction unitRef="shares" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTE3MA_a7f9a5a3-3f34-4769-899b-9356cc0064f8">3</ix:nonFraction> million stock options with a weighted-average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTIyOQ_6b3492f5-e3a5-49cd-a7cc-69b3f2488a83">80.05</ix:nonFraction> per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTM0Mw_c3bf5a45-7fd0-447e-a632-acd3c222f948">9.93</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTM1MA_b1a4f1de-a5cc-4b2c-8d4b-97a8188b6d76">10.63</ix:nonFraction> per option, respectively, and was determined using the following assumptions:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 26 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4c7585b65f1c4809bffc892bb77eb441"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ib25ab8dffc764ea6af7772d9dd08a4ee"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMi0xLTEtMS0w_d70ba2d8-87bb-4597-aed0-e5aec9f1f62f">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMi0zLTEtMS0w_fb686066-9148-49aa-bd1f-8a24fa61ec47">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMy0xLTEtMS0w_6052c496-4ebd-49a7-8eb3-8d833e01b8b6">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMy0zLTEtMS0w_a3efc57f-9e81-4a70-b411-7d679709e507">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNC0xLTEtMS0w_bc16345a-6d07-443b-90cb-74ab66fe9126">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNC0zLTEtMS0w_022ddf7b-aac5-45aa-9f2c-f6abeb930bc4">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNS0xLTEtMS0w_56d3b029-872f-4494-b7a1-34a3e407ffc9">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNS0zLTEtMS0w_62a5afe5-1bd3-422d-b817-f0559340dbd4">5.9</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTQ1MA_ddd42205-8590-4697-9c18-18c4663ede12">800</ix:nonFraction> million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTYxNw_92a7de3f-4611-416e-86e7-a1af0f810916">2.1</ix:nonNumeric> years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_73"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUyNw_ce578795-87fc-402e-84f4-66c4f5bb000a" continuedAt="i41bb4fe24ab54cb48dd087b57bd49058" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i41bb4fe24ab54cb48dd087b57bd49058" continuedAt="i4bdcdb2de55c4f49aa28bc11be413e82"><ix:nonNumeric contextRef="i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUyMg_bbd2d5ab-5642-48d8-b9fb-d746042796cb" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xLTEtMS0w_de7597ed-4b35-4edf-9dcf-7c8ddb0591f5">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0zLTEtMS0w_bdff99b3-3d7a-4613-8ac9-2d123f87c2d8">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy01LTEtMS0w_343ca5bd-4203-4205-ab50-05c76cb86c9d">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy03LTEtMS0w_76261715-4089-4032-8225-066259a4339a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy05LTEtMS0w_18eb3d22-9443-4b27-9c53-bc8606e5a3fd">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xMS0xLTEtMA_e330d3bc-baef-41c0-a306-eea894999043">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xMy0xLTEtMA_cea4e784-58b5-45ba-804f-fcdb16d3e58d">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xNS0xLTEtMA_9a83e374-49c9-467a-a4bb-4f88d7a5f80d">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xLTEtMS0w_4f80da46-eb5e-4e8a-a4a1-7872c85e7b81">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0zLTEtMS0w_ed715080-05ad-4811-a012-c0a2b6a3f14c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC01LTEtMS0w_47de4108-3f64-49f0-80f5-7cc9d8945992">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC03LTEtMS0w_2a039a65-3249-48c0-9adc-65daebeb5d3b">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC05LTEtMS0w_fe41fe7d-fd73-40a4-b801-ab380b172c5f">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xMS0xLTEtMA_10dd36e9-9cd4-409d-97ed-70bf477f9453">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xMy0xLTEtMA_fe174d20-a82d-4bb6-9a4d-e9b798e77bee">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xNS0xLTEtMA_d57d99b4-7e31-44bd-963b-d93cf29d7115">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xLTEtMS0w_f546d859-9dfb-4e2f-bc18-9316f05ec88b">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0zLTEtMS0w_68c91a74-7f11-4ef5-8955-01f9030627a4">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS01LTEtMS0w_7533b37a-a30e-4985-860c-3696c93d78f9">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS03LTEtMS0w_a24ce3d7-4c01-4be0-8957-3b9f79ad4cf7">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS05LTEtMS0w_f1fc6b9f-6773-43eb-a06e-f964b44f74f9">581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xMS0xLTEtMA_4385a7dc-8e61-4a8e-9e7b-e59f1a5f7b52">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xMy0xLTEtMA_1adeb63a-92ca-4c59-9d8c-daf156015d76">613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xNS0xLTEtMA_b7c4dd8c-9232-48e7-b5e0-fcbcb835332d">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xLTEtMS0w_da73cf98-6a75-42fa-afff-9640efc461cc">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0zLTEtMS0w_14661dee-2a48-46d3-b691-f25d75a267c3">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi01LTEtMS0w_06739870-35ed-4c9a-9831-1f45f712b4a5">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi03LTEtMS0w_1d689fb5-2a55-4ff7-93ab-f7f9784846b9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi05LTEtMS0w_92586ee6-52dc-477e-9c7b-46b54bd283e4">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xMS0xLTEtMA_358254a2-ca83-4d96-a2e2-30ed8dc51c8e">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xMy0xLTEtMA_993137f6-80b4-40ec-aa50-76f5da797b0b">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xNS0xLTEtMA_14fb5caf-e603-4386-9715-bf97ac653503">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xLTEtMS0w_da5393d6-a353-4ea1-94ca-aaf4ee90f371">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0zLTEtMS0w_ae7d7c02-98a9-4244-9e60-e39efa8d2a43">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy01LTEtMS0w_8541a63d-dc70-40dd-81a8-5fce40de6bb0">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy03LTEtMS0w_82af2960-72ed-4484-b96c-5af4876b380e">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy05LTEtMS0w_886b23a6-df62-4066-9c7c-106e664dd7d5">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xMS0xLTEtMA_1fbac9ec-43b6-4c5f-9cb2-e7b965432667">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xMy0xLTEtMA_2de80ea7-be61-4acb-8fe6-462f84b39472">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xNS0xLTEtMA_e3d138b5-5ca1-4a4e-bb96-c71ece9b8bbe">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xLTEtMS0w_43f1b9d5-50d4-44d6-80ea-71bb951337e5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0zLTEtMS0w_4916dc88-6f6a-45a6-9414-d38a10ecba7d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC01LTEtMS0w_69b06cfa-756b-4243-ae7d-c3124071f31a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC03LTEtMS0w_ba1d390d-6155-4616-8f2c-17a08a6f090c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC05LTEtMS0w_6bbb1bf8-3d3d-45a9-9f35-40177f7f2e91">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xMS0xLTEtMA_f044dbe6-77cd-4a33-a43d-19931a705270">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xMy0xLTEtMA_b386d1d2-c587-4e47-95f2-58e0f31f0417">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xNS0xLTEtMA_8621e528-86c3-495b-9fd3-a8a8fbe6d4d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xLTEtMS0w_9f017947-6517-4aee-9a21-668c8e18d21b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0zLTEtMS0w_c4408257-c7bb-462d-8b89-8872867d235c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS01LTEtMS0w_6ba230f3-3a34-4fb0-8694-96402839db24">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS03LTEtMS0w_da21d740-ff83-4cb6-baca-70477d580d55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS05LTEtMS0w_6961fecd-8d7f-4d60-8bbf-2ac4cfbb2265">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xMS0xLTEtMA_c9bd1cb7-9a45-49e2-a058-a81ed90a2537">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xMy0xLTEtMA_c7d575fe-a6b0-4c72-a2ed-feda7af66269">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xNS0xLTEtMA_36a47aeb-0627-4987-b5b4-fbc72155106f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMS0xLTEtMA_a264c098-be48-4bfc-b296-94fc0a957905">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMy0xLTEtMA_fbedbb91-713b-4c62-a9b1-0572508aca63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtNS0xLTEtMA_a0869473-6893-4132-b4c8-5f24c0e1622d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtNy0xLTEtMA_96102e0f-d81b-4805-b14b-c2a35cb995cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtOS0xLTEtMA_88e18486-8b78-40af-86d6-cbf8bdce99ac">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTEtMS0xLTA_aba1718d-6609-4274-8947-70061a01fd06">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTMtMS0xLTA_932a32cf-da74-44f6-ba97-b8baea1eeda4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTUtMS0xLTA_8111f4b8-7f43-48e2-a946-16d14f79f69c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMS0xLTEtMA_96d6e8d6-87c1-4635-82d5-37a2c76a7b92">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMy0xLTEtMA_763cdf07-7a29-49d6-bd6a-c6eb7ce0984b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtNS0xLTEtMA_4739315f-4159-4a92-985b-6db8cd5a39bb">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtNy0xLTEtMA_08c7ca43-bdd0-41eb-a5a9-b051ead134b2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtOS0xLTEtMA_5aabf4e2-e9c3-45be-99a4-b247ba71a588">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTEtMS0xLTA_cfacce78-2acd-491b-9ce6-d03075f18b0e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTMtMS0xLTA_f2abd76e-894b-4a0c-9367-4dd5ec0850c3">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTUtMS0xLTA_102dd368-0218-4a94-addc-e07eaa67ab06">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that in 2020 it will contribute approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="iac567bcc7ca2418f86edba65970f34af_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMzQy_7d6e3c94-b4f0-48d7-8668-f0fe040ab0b6">200</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="if9ad3599c3a84146ad4a9b8040fa9260_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMjE5OTAyMzI1NzM2MQ_cc457578-5e78-4f43-a0be-ee8753bba5b0">375</ix:nonFraction>&#160;million to its U.S. and international pension plans, respectively, of which&#160;$<ix:nonFraction unitRef="usd" contextRef="i69fee893e6cb48f090068514eaf1dca8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMzg5_603d27c8-bcfe-43f4-b9a6-37b11587d9da">184</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="id990f16dcd334b06840813dd8a39b138_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMjE5OTAyMzI1NzM3NQ_34494b71-7cfb-4dac-a022-d17e75281d89">123</ix:nonFraction>&#160;million, respectively, was contributed in the first nine months of the year. </span></div><ix:nonNumeric contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUzMw_0b0cade2-ccbe-4f6e-8a78-a9acfb71b047" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi0xLTEtMS0w_bf551ede-e8d4-4eca-b6d8-c40291b29bd8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi0zLTEtMS0w_c88b2e1e-ddec-44b8-90c5-331d793bfe16">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi01LTEtMS0w_64d03f4c-47e3-45c4-884c-deb08547fa93">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi03LTEtMS0w_547405bf-2f1a-4e19-b4a2-bf2c8c6c82c6">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy0xLTEtMS0w_32cee2ea-4735-4560-945f-ab81cc0906c0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy0zLTEtMS0w_15407ae0-cdb6-4c3b-8a24-af0ddce3d7bc">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy01LTEtMS0w_3705e025-87b8-477a-b696-f44c74dd672a">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy03LTEtMS0w_f95de4ad-e518-4432-bad4-e8f85db87770">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC0xLTEtMS0w_6abcedf1-ec81-471c-83a8-20238af382ad">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC0zLTEtMS0w_1174eb36-5fff-414f-8e7b-7e6eb04f7e8a">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC01LTEtMS0w_83bc9846-3cfe-4628-9dbe-f241665ff8dd">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC03LTEtMS0w_d447a65a-416b-41b5-b4b8-ce172fab41e5">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS0xLTEtMS0w_21ef528d-a47d-47eb-bb61-24965d5345d5">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS0zLTEtMS0w_59464bbf-4893-4031-8cce-1721f731a25d">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS01LTEtMS0w_1dd5c037-4e18-4777-a84b-acfc9a1991f7">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS03LTEtMS0w_45c34aa9-e20a-47be-a8d0-62360b269c30">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0xLTEtMS0zMzU_3d884a47-9cb8-4356-b10d-ce7ce1dc99c8">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0zLTEtMS0zMzU_be41215b-dd1a-4398-96cc-3a33a0e8ba3b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi01LTEtMS0zMzU_cbc7a9b9-0355-4a28-8a13-663c023679a0">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi03LTEtMS0zMzU_87119675-aa2f-4281-ae4f-a720aba82b23">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0xLTEtMS0zMzk_b1bd964c-da7e-410e-8ae9-94314bad836c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0zLTEtMS0zMzk_19c82237-9282-4006-a17a-87849519ebe3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy01LTEtMS0zMzk_9a529734-bb1b-439f-b256-e8dc111516b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy03LTEtMS0zMzk_aecdcad2-eaa3-4931-b01b-fba8a405b8d3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0xLTEtMS0w_6b58aef4-5b3b-4d9b-a6fa-7332929ebe09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0zLTEtMS0w_553c1abf-2150-44f6-b50b-6ff436dc6bcf">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi01LTEtMS0w_553317a0-05ce-4197-8b85-92b1e60e616c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi03LTEtMS0w_2a48d23c-71a9-41d6-a949-7f1a794bb3ee">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0xLTEtMS0w_73d1931b-4051-467f-bab3-22be820bb10a">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0zLTEtMS0w_8400a90c-67aa-4a91-9724-43b10284a8dc">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy01LTEtMS0w_ef9a6e9d-ee9c-4e94-ae93-b7876c75115e">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy03LTEtMS0w_3f7a2fee-2426-4c71-9d4c-29409135f4b5">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 13), with the exception of certain amounts for termination benefits, curtailments and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 27 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4bdcdb2de55c4f49aa28bc11be413e82"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.</span></ix:continuation></div><div id="i67ef4e29db364327800e42a94e43496a_76"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ2NA_0fc2ebf4-ea74-4ff0-8c4c-f494220f52ba" continuedAt="i92a30c009fcc491da01d03cf36d5f744" escape="true">Other (Income) Expense, Net</ix:nonNumeric></span></div><ix:continuation id="i92a30c009fcc491da01d03cf36d5f744"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ4MQ_9811fb0d-dff6-4fdb-868b-a04b95971d0b" continuedAt="ibd466a8c00694742adf88e650de5797f" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi0xLTEtMS0w_69336933-989c-48b7-861f-ebfb7822b181">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi0zLTEtMS0w_cbca5c26-da67-42be-aadd-40dac05facf6">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi01LTEtMS0w_7c05d76b-6b71-4150-8d60-7e08a1264541">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi03LTEtMS0w_7692b491-6fd6-4050-b9b4-68d8e47d8959">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy0xLTEtMS0w_58a95ea8-c62a-4c87-869f-dc0708d16092">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy0zLTEtMS0w_2146d0cc-bb35-4a5e-a9c9-92e43757e006">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy01LTEtMS0w_b46a59d1-9dce-43ff-8576-68d468a5a514">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy03LTEtMS0w_cbed56f2-f294-4dfa-b0e2-dbd73e3e0700">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC0xLTEtMS0w_dd8bbb6a-4042-4ae3-bc5d-e1da7ae75df5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC0zLTEtMS0w_b5ec6bce-3e23-4a03-b6e5-fd6e01b793c6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC01LTEtMS0w_13511a78-3f3e-48ac-9e42-1ec25878a6db">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC03LTEtMS0w_f08b3255-ed7b-4290-b8ce-b8a2196a6bf9">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS0xLTEtMS0w_511eafdd-dadc-4439-8df1-ebf05078bee9">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS0zLTEtMS0w_9da0ed5b-f509-48c3-9e48-72f6723cac81">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS01LTEtMS0w_ee95c15f-43de-45a1-8c3d-2b4da536dd1b">964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS03LTEtMS0w_851d176c-5165-4917-9754-c5603daa0497">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi0xLTEtMS0w_4c4ecd23-634a-4053-9104-900a9d62843a">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi0zLTEtMS0w_a496c038-ed7e-4c5c-bf37-c9d2622947b2">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi01LTEtMS0w_f3817beb-db29-47f6-941b-7783cdd87e24">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi03LTEtMS0w_284d5a84-7c2f-4002-9d1c-f0bf18ddef39">409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy0xLTEtMS0w_78ff5a36-44e4-46aa-bff7-ec48ebb64d1a">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy0zLTEtMS0w_027e769a-97c5-4527-a42f-e2c088e329c7">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy01LTEtMS0w_ea13456b-21c7-4c8f-aba2-d30d8550c4a9">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy03LTEtMS0w_d9879b53-de4c-4fb3-b5de-a54c9bac20f2">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC0xLTEtMS0w_6e0468d9-27f7-4a81-b132-87b9e8bf3150">312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC0zLTEtMS0w_c6f52a82-4d80-4f6e-a935-d13492c6eb63">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC01LTEtMS0w_397e46c9-e90c-4de3-89d4-5a57bd7b697e">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC03LTEtMS0w_bba9b4c1-3fbb-480f-8eb9-099a23ef79ab">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ibd466a8c00694742adf88e650de5797f" continuedAt="i78d7b75cc6514811afc91df5445b2892">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i78d7b75cc6514811afc91df5445b2892">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first nine months of 2019 includes $<ix:nonFraction unitRef="usd" contextRef="iaa3ff69e58674e75915bf501c2c193e4_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTI3Mw_034b3c16-814c-4209-8fd2-f7ef7c01ed40">162</ix:nonFraction> million of goodwill impairment charges related to certain businesses in the Healthcare Services segment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September&#160;30, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ0MQ_62dbadfe-735d-4e08-843d-5dcd7455b202">605</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ0OA_437e3a6d-87d0-4301-93fa-e3d3c569ac5b">629</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_79"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTIxOA_1b82789e-3118-4262-9ac8-fb3e80033396" continuedAt="i32aea046a4c540d68150b199c5382e70" escape="true">Taxes on Income</ix:nonNumeric></span></div><ix:continuation id="i32aea046a4c540d68150b199c5382e70"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates of <ix:nonFraction unitRef="number" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNTk_b92a08f8-44fb-4f17-bbb6-843e834a772d">14.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNjY_395cc74f-ef14-400e-8a9c-d5fc3a279139">18.7</ix:nonFraction>% for the third quarter of 2020 and 2019, respectively, and <ix:nonFraction unitRef="number" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTIw_debba452-d18f-4b5c-b2c1-992de1fc1bff">14.9</ix:nonFraction>%  and <ix:nonFraction unitRef="number" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTI4_4a6a3d90-0c8d-4f0c-9a23-cd330422018b">14.5</ix:nonFraction>% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $<ix:nonFraction unitRef="usd" contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNDUw_025c777e-2cdc-4d5d-8805-511dbfb2023d">360</ix:nonFraction> million net tax benefit related to the settlement of certain federal income tax matters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonFraction unitRef="usd" contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNzQw_71705360-6b48-4cb1-89ea-16bfecacdc34">107</ix:nonFraction> million. The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfOTI3_025c777e-2cdc-4d5d-8805-511dbfb2023d">360</ix:nonFraction> million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_82"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 28 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfNDU1_01546a35-ea71-4e56-8caa-00882eab7215" continuedAt="i720d52e775454469873ab72973511da3" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i720d52e775454469873ab72973511da3" continuedAt="ida731e2ddf684132a20a194284b63409"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfNDYx_ca2e0f38-cd69-4652-86d8-40570f991e35" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:61.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi0xLTEtMS0w_fbf9f141-daec-4494-b054-3126a6913714">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi0zLTEtMS0w_6fcb48d5-18f5-40ad-a349-1364a5f1aa12">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi01LTEtMS0w_69e34e63-3f9c-457f-bb91-410da2c91db8">9,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi03LTEtMS0w_41c7fd79-72d9-40d8-8ac6-6c2bbbd1ecea">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy0xLTEtMS0w_3cb4006c-c90a-4848-829b-27cc43b855ee">2,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy0zLTEtMS0w_9e9f532c-6fc1-4d39-b3d1-c775326b5113">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy01LTEtMS0w_e264033f-1421-44e3-8e04-22620acf5fbe">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy03LTEtMS0w_59009b2e-a011-4e2a-8d39-badecdf2e902">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC0xLTEtMS0w_424aae64-855c-4f57-9cf5-0ff7e65397cc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC0zLTEtMS0w_813eb717-c38e-4b94-a2f1-37f9008f5a6e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC01LTEtMS0w_b61cc52b-9b1a-4bf5-9639-f4c942111301">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC03LTEtMS0w_d7899e79-ef84-4622-92b2-4737e26067d6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS0xLTEtMS0w_74429ead-87cc-41fb-a155-7ecf87ac08b5">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS0zLTEtMS0w_e7869ff5-0134-4e54-a9b4-cbc2a0386a78">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS01LTEtMS0w_f1bd8a39-3e77-4aa9-9701-28a2f4b6739f">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS03LTEtMS0w_e9cf312c-28c0-4910-b30a-8d38199186b6">2,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi0xLTEtMS0w_5ca2075b-7de6-41de-8cbd-d4e45bb29c91">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi0zLTEtMS0w_ab8ebda0-2585-402b-9e46-6ccc74440386">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi01LTEtMS0w_199157ff-3231-4755-ac6e-e17d2a96154a">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi03LTEtMS0w_0e7058ab-ce62-4e96-8543-051082d3d28f">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy0xLTEtMS0w_a5aaf7e8-3a0e-4651-9d27-f722caa97465">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy0zLTEtMS0w_228f0c22-a985-4b2f-9e9c-c22f7b78edbb">0.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy01LTEtMS0w_944457b6-cffa-41bc-bdba-bf2c03963f99">3.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy03LTEtMS0w_a2e565b6-9aa1-4e98-b424-503e7ac1ce64">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida731e2ddf684132a20a194284b63409">For the third quarter of 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMTc2_bbe85da9-eab9-470b-a368-9e36ac958df4">5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMTgz_80bf7842-9d6d-4163-80b9-939712604811">3</ix:nonFraction> million, respectively, and for the first nine months of 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMjc0ODc3OTA2OTk3OQ_c14f9b9e-1635-4687-9fba-c59df4611d81">5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMjUy_edb657e2-8b3b-4d38-9f0f-c9e7905f9dae">2</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div id="i67ef4e29db364327800e42a94e43496a_88"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RleHRyZWdpb246N2Q2ZDUwZWI0MzYzNDg4OWI2MmFmZjRjODQxMDhjYTBfNDgy_f2081598-63df-4359-881d-367da51b3d35" continuedAt="id19933d24bca4a95919d3a64823491e5" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="id19933d24bca4a95919d3a64823491e5" continuedAt="i0a2b594230f74b3faa42773b64041673"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RleHRyZWdpb246N2Q2ZDUwZWI0MzYzNDg4OWI2MmFmZjRjODQxMDhjYTBfNDg5_4ee6f1d0-7b12-48bd-8afb-7ced67bea518" continuedAt="ic13c89fbcb8e4d029e0ec025502f6222" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db841c072d54fa6888133ec10cf2cc4_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi0xLTEtMS0w_d811f1fe-e0a0-4a56-b9d8-3e85b7a31436">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6591fbc20c114de39653e3b19a29f103_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi0zLTEtMS0w_30b9855d-1298-4459-9315-4cf4ba4233dd">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1a6af2de3ce4f4a8efd8359eaeeb7bd_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi01LTEtMS0w_ee83934a-2620-4db3-b381-337d39d6da30">3,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c230d35c63044149c73c8bb256576c8_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi03LTEtMS0w_706009aa-e667-4b08-8be3-9b522cd5ec0c">1,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i661be48d847543a8a32ba2358107f61c_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi05LTEtMS0w_750efdb8-7a28-48b3-a23c-566c32b99990">5,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy0xLTEtMS0w_95c01562-85c7-4caa-be34-45d4defc0908">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy0zLTEtMS0w_5574f2e4-e5da-477a-94c7-851fd3041d71">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy01LTEtMS0w_f13dc1c1-3d02-4e45-ba51-33cd6aa0cb71">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy03LTEtMS0w_b9e5e0bd-69db-4233-81bb-f17d2e958a68">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy05LTEtMS0w_bb800d3e-4cd4-4d33-a27d-cac0377b40ca">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC0xLTEtMS0w_d464d49c-77f6-4133-bf16-43a524e819b7">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC0zLTEtMS0w_03b6f1b9-7be6-4b10-9357-883a6c0679e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC01LTEtMS0w_4e186a9b-f62b-435d-9ac4-625472bdc89a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC03LTEtMS0w_50d6f25d-39c7-4cdd-9d8c-0f461a5692d6">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC05LTEtMS0w_936626fb-a956-47b0-8f12-4dd11a30f1e1">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS0xLTEtMS0w_1674d66f-c525-4bc3-9121-4d6f5cdf5cf8">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS0zLTEtMS0w_24c690a2-2dc4-4833-8190-a0ecf5a465aa">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS01LTEtMS0w_73749cba-8298-4d68-a9a8-95e97ffef494">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS03LTEtMS0w_ac009da5-c4e7-4e9f-9a67-69c415f33ee4">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS05LTEtMS0w_a4543012-a899-4764-b119-eb9bc8349b1c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi0xLTEtMS0w_8eb5aab3-0991-48cd-a104-bc08c337d2be">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi0zLTEtMS0w_644582cb-ddff-499a-b202-29be1bd14c31">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi01LTEtMS0w_bb1e2919-4141-4af7-851f-e8c8bdaf3e59">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi03LTEtMS0w_ae75801a-eccc-4d33-b31c-f5f4743f8872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi05LTEtMS0w_4d23460d-e5f3-4e9f-b573-10980eb76353">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy0xLTEtMS0w_52425579-022f-421f-8740-4dd81b739a9b">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy0zLTEtMS0w_96bfcd2a-355f-4186-90eb-8a99986ff738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy01LTEtMS0w_84dce0d8-bfdd-4f38-8a07-cc32ddfef6ed">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy03LTEtMS0w_e14c4900-e940-4078-b6c6-98da24fad6cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy05LTEtMS0w_d406aaf1-3cc7-4f8b-88b6-35e8a90cc5ea">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC0xLTEtMS0w_7e47d879-876f-4de2-9fc8-2c6485fa2216">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC0zLTEtMS0w_b33b5427-69b6-4ec9-a65b-f4b332c2a354">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC01LTEtMS0w_ea9e48cb-da64-4a35-af29-f6dcd19a5290">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC03LTEtMS0w_ee29fc3f-290b-4ece-bd93-a561a1e15d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC05LTEtMS0w_90958d87-04fb-4a79-8a4d-a58a7b798821">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS0xLTEtMS0w_e611b9a4-0d21-402a-8c7d-b067ef6b39c0">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS0zLTEtMS0w_923e8e35-ca39-410d-9e9e-c5f05c4121ad">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS01LTEtMS0w_53caf26c-ee53-4736-b809-b763f94ff480">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS03LTEtMS0w_73b59732-75f4-4515-9ec9-c2fc87ec053c">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS05LTEtMS0w_beb1c55e-236c-4e9c-b20c-b790e67a3eb4">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8f30eb9789429a962564babf142645_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtMS0xLTEtMA_c954136e-2e4f-4ec1-954c-0080c65251c8">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16aedbdec871407ea66e24efd83da330_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtMy0xLTEtMA_ab7ec0f4-e3e5-4e90-9bf4-c0aa42c8a622">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1878ab8ba71c4e20a87cd62012ad996e_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtNS0xLTEtMA_6be21df7-7745-4728-9873-1d2501885a50">3,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ebcbbb713742d698719f2cb0caa991_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtNy0xLTEtMA_a78812db-e7f8-4564-bf04-69a2a5401476">2,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i532639a15db54349b73094a5ac53f994_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtOS0xLTEtMA_96140ef6-7fa3-4e6f-9472-1e684ce8c0ea">5,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25f69cc39ada42e0b2aac3d80fa1092e_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtMS0xLTEtMA_03260e8a-b47f-4cc8-b8a4-2c00d7d57bc8">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id791a906551f4c699ba3f0a28a87d3ae_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtMy0xLTEtMA_107ea382-d5f8-4fa1-80aa-ce46c8652afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93df020249f849fca4ee19c9749a68c7_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtNS0xLTEtMA_bf17b711-67ac-455f-86ea-40b6bb06f5e6">4,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifec46d9b67b440a8843d54b6ee61db1a_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtNy0xLTEtMA_2d52288f-8bbc-4906-b201-cb7119f3a646">2,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtOS0xLTEtMA_dc2adbe5-6683-4b3e-8857-48d6cf3cfdf1">6,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItMS0xLTEtMA_cd03a701-39fe-4e22-8661-47ce8887502b">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItMy0xLTEtMA_b57ecb07-b804-4027-b68e-a1c40f110859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItNS0xLTEtMA_d84a1536-b8ee-4cce-954f-5479ef36616d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItNy0xLTEtMA_6cb10b70-fd1a-484b-adf4-67f1ed8f52f0">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItOS0xLTEtMA_d3faec19-00bb-450a-8822-129bd48cc5fb">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtMS0xLTEtMA_fe490bb1-c1c5-4886-ab35-d4cd2962c662">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtMy0xLTEtMA_98fd608f-3858-472c-861f-474b612d3fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtNS0xLTEtMA_6d03bde2-0737-430a-9326-2bc5b6b2e67f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtNy0xLTEtMA_82f3bc9c-54bd-42f6-b993-a8f9d70f5ce0">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtOS0xLTEtMA_d11fdafa-dfe6-4f0c-bc8a-ff861b009550">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtMS0xLTEtMA_db3040fb-b0f9-41b0-9ffd-93ba658b1e67">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtMy0xLTEtMA_80efd1a0-c55c-4e10-b269-7fcbac59a17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtNS0xLTEtMA_f5f24045-554a-4b57-bbac-d10e2ff46710">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtNy0xLTEtMA_3abf755c-a3c6-4de6-a146-4e3fe48eaa88">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtOS0xLTEtMA_fa33ba7d-58d1-45c5-9a2c-a40d05ad7932">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtMS0xLTEtMA_18ea8dbc-5e5e-4ba1-970b-bdffafdfe3c6">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtMy0xLTEtMA_f766530a-711d-4362-8309-b865d12f7cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtNS0xLTEtMA_c1ae3d96-133c-420b-a3c8-02be62c0e3bd">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtNy0xLTEtMA_2f086194-b9fe-49b0-85ed-484cd0946572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtOS0xLTEtMA_7af632b5-ed73-48f1-a85b-13423c01e0fd">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtMS0xLTEtMA_7eb67ed9-68b1-4b76-a987-f35ab54b9428">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtMy0xLTEtMA_c6b1beb4-1ecd-4bde-8a00-876d82956b2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtNS0xLTEtMA_7460a85a-09f8-4f83-b200-c2a96dd18b52">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtNy0xLTEtMA_77698ef0-0d4a-4810-90f5-f502562ce267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtOS0xLTEtMA_24e580ca-42cd-4577-b2e4-feef443ef373">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctMS0xLTEtMA_56ee8109-bbe3-4d98-8325-096ed08df2aa">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctMy0xLTEtMA_28d7caf1-4288-4512-8de5-4526fcb41b10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctNS0xLTEtMA_b7ec2015-5bc8-43b8-990b-243f80e51700">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctNy0xLTEtMA_89f0183a-654e-4796-91fc-f0719070f88e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctOS0xLTEtMA_1eb3b4ca-0df3-4bbf-8a0e-878917a318ca">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtMS0xLTEtMA_efe2f068-d6a7-465d-bc30-7864fc989100">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtMy0xLTEtMA_e639016e-9a37-40f4-ae2b-076ff509813d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtNS0xLTEtMA_e0846bf8-45e2-4e92-b32c-60d59cb600e9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtNy0xLTEtMA_0a854630-9705-4ef0-911c-8d30e0a18e7c">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtOS0xLTEtMA_c8a4c856-2306-45c6-9e41-58c8541cc2cb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktMS0xLTEtMA_4012e411-6022-4e01-8ef4-3ac0ac7fad37">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065889e51dbb442688e6ff3173a1e969_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktMy0xLTEtMA_35a0195e-7863-4c9c-bb59-090615a61c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktNS0xLTEtMA_516585f1-589e-42e9-93a5-c33f0fa71071">4,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cf5449d143444ea99ebf110cf6c87e2_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktNy0xLTEtMA_904bf96f-e48e-499e-94f0-55acd413c166">2,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktOS0xLTEtMA_e3b7e2f6-32b1-4306-a479-38eb4cbdd27a">6,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 29 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i0a2b594230f74b3faa42773b64041673"><ix:continuation id="ic13c89fbcb8e4d029e0ec025502f6222"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454ba9cd9d334299a099d995c578d97c_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi0xLTEtMS0w_8a3b4d74-a15f-45da-9724-f1678aa31ed9">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia333381aeda74595900b302e6c11c47a_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi0zLTEtMS0w_3ab23bf2-813f-4cc7-add9-9622f7def42d">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia99ed860505e4c2a85a20cf2fdc2edef_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi01LTEtMS0w_a58ab893-56a7-4a57-8db7-ceab1e800ba9">3,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic97b428654714aed9ddab64e466a889f_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi03LTEtMS0w_51ecc5ea-9c4c-4da1-8072-3d8b16a078fb">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi05LTEtMS0w_5fcb60c4-2915-465c-bae4-7e45180141ea">5,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy0xLTEtMS0w_d56f98c1-1b69-41f7-b18f-2ac5622ab385">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy0zLTEtMS0w_99922875-a858-4be5-8a02-5c79b589d4c3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy01LTEtMS0w_fd508eef-ce0b-470e-8961-07f4e246a53b">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy03LTEtMS0w_d3a1fd0f-62a9-4c59-9c9c-712a7ea6da5b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy05LTEtMS0w_0b4f8a37-c3ef-428e-a0f5-4b844b89017d">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC0xLTEtMS0w_e2b1e35e-9db8-4219-b469-8efc744ca3d1">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC0zLTEtMS0w_34c552b3-4824-47f6-b9da-3fb309dbb96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC01LTEtMS0w_679ca7d2-717c-4839-96de-a264ea30b757">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC03LTEtMS0w_5f1edd8a-999d-49cc-8eb2-3723410e443f">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC05LTEtMS0w_56c22805-7626-4ddb-b2b4-ce9155a8c40d">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS0xLTEtMS0w_27b12085-3b6e-4191-8917-5f46d116dae6">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS0zLTEtMS0w_95926f19-7d68-4bcd-8798-8b6ef16b5be6">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS01LTEtMS0w_b7f0683a-ccee-4093-978e-1d69de63b42c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS03LTEtMS0w_683206ac-8638-4f9c-99a4-eb0e974dbf9b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS05LTEtMS0w_0963f890-5813-4cc7-a4c4-c78b7ff58f82">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi0xLTEtMS0w_c26ad490-ecde-47f3-af6b-1d316c6dd68e">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi0zLTEtMS0w_6af256e4-a18c-4af3-aeb2-8c57588dfc0c">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi01LTEtMS0w_5d36e1fd-76a3-4dc8-8a19-db12a32920d3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi03LTEtMS0w_b6564c74-fa1b-471f-ae5e-e37833a2af4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi05LTEtMS0w_cf49d365-4263-45d2-902b-88cb69da4614">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy0xLTEtMS0w_bff550fd-dfdf-4caa-a244-da041a666176">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy0zLTEtMS0w_13580073-4c50-4c60-b073-35ac5a192e89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy01LTEtMS0w_7f0e0d93-c8ed-4e36-9e4f-85bce6ac9381">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy03LTEtMS0w_5082e2e8-accf-489c-9f82-01c4f2f181a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy05LTEtMS0w_5e180bcc-0b5b-4b23-8a6d-5cca9a6e6e0c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC0xLTEtMS0w_cf19e4e1-1d31-4955-85c0-a961ae5fe83d">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC0zLTEtMS0w_bba42f29-9c6a-4e47-a793-cf043658a960">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC01LTEtMS0w_5303ff49-8357-4d09-bc44-f4bb117d90fa">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC03LTEtMS0w_48d0a959-593b-498a-800d-c19c1c1f60d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC05LTEtMS0w_80789eea-8e9b-4fbf-b070-b371ddde612f">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS0xLTEtMS0w_fe8cf79c-103a-4e6c-944a-0c6dfdda8226">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS0zLTEtMS0w_ef473624-8592-4cbc-b9e6-695d31bda35c">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS01LTEtMS0w_7a5ac5b8-925c-4651-8b07-bf8e54ae5a5e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS03LTEtMS0w_6fd274c3-6255-46d3-9ab3-cc79c8f66ef3">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS05LTEtMS0w_c677b6cc-dc48-4618-8acb-038c1c959810">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8f30eb9789429a962564babf142645_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtMS0xLTEtMA_ffc035ae-509a-455d-9972-ce2f19fbd5f9">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16aedbdec871407ea66e24efd83da330_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtMy0xLTEtMA_0bcc4997-9b0d-4fb4-8404-70930569388c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1878ab8ba71c4e20a87cd62012ad996e_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtNS0xLTEtMA_b62aa9b0-225b-42cb-8a05-dcef7f287b43">3,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ebcbbb713742d698719f2cb0caa991_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtNy0xLTEtMA_c8c7c431-3332-4dbf-896a-202f9651590b">2,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i532639a15db54349b73094a5ac53f994_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtOS0xLTEtMA_7c89e1ab-6934-4804-b360-bff4ae06e250">5,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed1325b520746ccbe6a911296faf7db_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtMS0xLTEtMA_4fc3487a-f53f-4946-8f95-17a1304eed53">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a46df96ea1b4b7db6f00fbe6c57fae1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtMy0xLTEtMA_0993254b-b804-4e84-ad59-2e3a63865910">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i217cd2a0efd84c7a9c2ef838da08a751_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtNS0xLTEtMA_8f59ff2b-eeef-45e4-a61c-9859b03988fd">4,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31769e108011463f815d560721783429_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtNy0xLTEtMA_b4714d90-71e6-4c64-8dc7-1487421180ab">1,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice9dc335efad486f8e04c605de2f04aa_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtOS0xLTEtMA_67f35c1a-2915-4451-8cb9-fa9c94a98907">6,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItMS0xLTEtMA_8cb8d051-e35f-43e8-adae-5c4c8de366f5">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItMy0xLTEtMA_726e985d-c306-44b6-a055-41c0321725a1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItNS0xLTEtMA_3cf5a4f3-e823-4802-8fad-c1abf2e1fd25">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItNy0xLTEtMA_58dca1fd-e8bf-4752-816b-c11c19eb7844">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItOS0xLTEtMA_1e03bcb1-bc9e-41e2-bd01-9374b9a0b220">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtMS0xLTEtMA_98aa91c3-27e0-44de-86af-ef2ae7c76927">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtMy0xLTEtMA_b4d857cb-92ef-43b1-8105-5c0998fc2aa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtNS0xLTEtMA_6220bef6-8821-4551-b280-4ff96446192e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtNy0xLTEtMA_244263be-fca5-43cc-9295-87d23a57584f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtOS0xLTEtMA_2292b410-584c-4d66-8723-df0dc6e3a088">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtMS0xLTEtMA_9cdf6efa-6984-4e3d-821b-0f2de8452918">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtMy0xLTEtMA_8403b4b9-7fd8-4103-a863-a37d6b5e9e32">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtNS0xLTEtMA_decb5640-1f22-4136-8434-bdcac47bf16b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtNy0xLTEtMA_9bf6c71c-1f5f-43f9-9225-67d7a42d973f">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtOS0xLTEtMA_f480282e-03a1-418f-bee9-70ab0a74b479">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtMS0xLTEtMA_1db576a2-e49a-4c8f-9de0-03138af73b9d">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtMy0xLTEtMA_f3613d38-678f-4c17-9d18-c82de0fe80d0">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtNS0xLTEtMA_9cc109c5-68c5-4006-a7e4-3c3abb62f652">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtNy0xLTEtMA_231582a2-094a-474d-8829-94d66ffa3e5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtOS0xLTEtMA_ff4569c7-8de1-4989-82fa-fcd379e11d46">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtMS0xLTEtMA_9d1bddc9-baef-468a-a465-3e9e3262a796">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtMy0xLTEtMA_e576b7c5-7c43-4a23-b52e-8a15e083a2e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtNS0xLTEtMA_6c2dfd07-74a2-40c8-9435-069fd0596bf0">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtNy0xLTEtMA_fb2f37be-cbb7-46c8-97c0-1693f9f7dd52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtOS0xLTEtMA_0bd35d95-efcb-4a56-a0fb-d1997506be10">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctMS0xLTEtMA_1e2038cb-ed90-40a3-b4b1-48c2db4b253a">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctMy0xLTEtMA_dfe06f33-a115-4f01-a892-7b9c8f3bbb9d">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctNS0xLTEtMA_932f1935-1d1f-410c-b67c-e2f74a5af5fd">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctNy0xLTEtMA_a128b5af-1dd0-4763-8620-fdc7f88dcc13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctOS0xLTEtMA_7dde9569-bf0e-4fd6-a09d-4ee2ec64a701">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtMS0xLTEtMA_502dad9e-8547-41c3-89ab-05f4710e7040">153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtMy0xLTEtMA_f4c4dafd-7daa-4b0d-8442-f46493cc9c4c">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtNS0xLTEtMA_3961949d-e340-461a-98ca-336989a554e8">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtNy0xLTEtMA_0e0f477a-1bef-47a0-acd0-4ee282f198ab">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtOS0xLTEtMA_106a798a-e7ed-4609-a9f9-3173d14a67b7">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktMS0xLTEtMA_97709374-e945-49c4-b3c5-e9dc06684007">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065889e51dbb442688e6ff3173a1e969_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktMy0xLTEtMA_e0e2edcd-393c-4fea-ad63-f03c09598204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktNS0xLTEtMA_f4f2ffdc-5416-4e68-910a-bcbefe235f9e">4,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cf5449d143444ea99ebf110cf6c87e2_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktNy0xLTEtMA_8b3c5232-3b0c-4203-b5c8-6924c8b68040">2,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktOS0xLTEtMA_e0412b2b-63fe-433a-85df-497e3118aafd">6,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).</span></div></ix:continuation></ix:continuation><div id="i67ef4e29db364327800e42a94e43496a_91"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTc5Ng_95a274ba-2d00-455f-b237-baed72026d56" continuedAt="iebc1c21890944373baeb3693b70ed3a0" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="iebc1c21890944373baeb3693b70ed3a0" continuedAt="ieb341ecdd6994820b5550074cd0828f9"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include <ix:nonFraction unitRef="segment" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMTA4_c9733d85-b1d2-4fb9-86da-e4a69a07fd7b">three</ix:nonFraction> operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 30 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ieb341ecdd6994820b5550074cd0828f9" continuedAt="if8f82c4fbf734ea49952a93e30061ddc"><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTgwNg_7928c675-3830-4575-a34e-1e6de908abea" continuedAt="i3ee43632127541ecab4f1f5c04255b11" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306fdc3327c343139058a1e912ec7a34_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xLTEtMS0w_75c9fda8-fd72-4ae0-b3ad-82eb0ad02334">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1a45620d5740ef84279eefcdd52471_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0zLTEtMS0w_1a2465fd-b658-40b6-88db-7678df4c7d5c">1,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b41de768cca43ae86a2b620ab7fd37a_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS01LTEtMS0w_ffbaf65d-58cd-4b76-bcb7-3253c489ec23">3,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf926c3546c74014b7e2f8860b5e44c2_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS03LTEtMS0w_0bae7d23-7fc1-4788-a95c-59e039748f44">1,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f0231c8a1941c9a7f095b2dae733ac_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS05LTEtMS0w_db27de1b-9d95-44d8-a874-12314ebf4a2a">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317ddaf4b00343c591e8949ca7d910a4_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xMS0xLTEtMA_8b102988-bf39-4979-8edd-990a45ea1eb8">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eff4fa2263b449ba4ad1953be6ba8f5_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xMy0xLTEtMA_1817680b-d2e1-4298-a87e-e7ad98a0b038">6,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i547f0c973ddf4d25a0edb9aa55b1c990_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xNS0xLTEtMA_507a78e2-9b0b-4239-97d4-d32c579b1136">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c49eca89b64ce683fdef4e64585ef6_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xNy0xLTEtMA_f54524e2-9971-4c7b-b1a9-56cb7696c23b">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib22b6772278549d3a7dc5725de45a549_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xOS0xLTEtMA_b8335144-e704-41d7-8402-65c07ccc8eea">4,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3906b3ace9b64befaf73a1adc407ae5b_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0yMS0xLTEtMA_3ed6d90e-f249-46f7-a86f-e21892c0e72e">3,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc25861951e409b9bcaedf62ff4b291_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0yMy0xLTEtMA_97ead5ed-d871-4a76-971f-2d23fb7dc839">7,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94fd4d2613b4279b09a4b269c9fa2e8_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xLTEtMS0w_9e9b1696-8878-4182-a169-6976b517300c">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1958e912e6ac404ab8549a9c645d5cc6_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0zLTEtMS0w_c57da9f0-9e61-43e1-9f16-00f768ada128">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a4c78ade6e465c8ac9352f2745678f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi01LTEtMS0w_30d6f575-f500-4bed-ae6c-255c3be05d17">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea751a267ca49428fd752d3d82441bc_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi03LTEtMS0w_5f2d25e3-e47d-47b6-b6c0-0091189939a1">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc329ef53f6466f8fd7202d74ce0a3c_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi05LTEtMS0w_4040a6d8-0364-4fe0-bcfa-189be2b1d854">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7327daaa39b444129ac7963593aaf968_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xMS0xLTEtMA_e9755826-d57b-41c5-b746-ef626a706f40">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93971dcba04a4a31bdce5505e25d2fe7_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xMy0xLTEtMA_aff62ab5-588f-46cb-9896-8a777497e23e">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfca5975a1840b695feea389585ff70_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xNS0xLTEtMA_1d59bc5a-cb91-47ea-bce6-70f6bfcec3b9">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56ff7b0e8a54c8a8d4dfa5d57d82641_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xNy0xLTEtMA_b85cd668-9b5b-4ad8-a128-d7621d759f1b">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec9add45dc0469788010c549ccbdb76_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xOS0xLTEtMA_e6f2d5b4-5ffd-4a28-a423-f9c6539c71b0">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia51ef3c4eb03413ab36423e2fd771da8_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0yMS0xLTEtMA_8affc4ad-fe16-4dc9-abf2-d4f5d1cf817d">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf99264c8dcb454ea5e90380b2400b9e_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0yMy0xLTEtMA_93e9ad94-ee63-4ff4-9f43-3adba336578f">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca7a266855d4254a95f8178169a039e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xLTEtMS0w_763c6c80-da87-40f0-ab70-166b45efea33">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc9b994e7da4fd19c71b16dd69ea18f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0zLTEtMS0w_70d943cb-3320-47f0-9d81-6fdab379fe2f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8717ca08a9d4379806fdd058d2feee8_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy01LTEtMS0w_00844b57-e7a3-4b68-ba87-3eea1a969f0a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733c87bbcdae43878560a4ef5bdac803_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy03LTEtMS0w_c1679217-aab1-4d84-a6a4-39896ec7c460">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23398778be554bbf9ea4cac06d6173a0_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy05LTEtMS0w_aa7779ae-c53b-4138-81a8-df46bfe28b80">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe040aeeb11e449b8c5c18407e83aa44_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xMS0xLTEtMA_23f97cd9-a314-4f69-bbe6-aa47d3e7affd">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1453f6542194317be39084f21e53aed_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xMy0xLTEtMA_0b07c731-20b0-42e6-a1a3-8c01c8861279">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef3169c86e54fc5ae677a048dc4eb96_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xNS0xLTEtMA_1d17f567-a44b-4302-9689-5a7d2049592e">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6829456a78436f98f59cc9fc651fee_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xNy0xLTEtMA_0a7a1881-36f7-4282-9c03-8803fc7a33d3">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i553c60428afd4395aca8a65dc4d3d90c_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xOS0xLTEtMA_a3821a08-081b-424e-ab9a-26568ad4d496">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92959775580548159c5b7ea24a92ea98_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0yMS0xLTEtMA_a7b83fc0-c4bc-4c4c-94f6-f0031c2851d0">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56024565ddb4465ab8bf341e3dd84c4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0yMy0xLTEtMA_45e5a44a-26c2-492e-8fe7-339c7500416d">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ddf16367e464e79a9f9c63e9ab32ce1_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xLTEtMS0w_419cd42d-5f25-4306-a396-505372ef531b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ecfc38e80742e18efb7ff88f14c004_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0zLTEtMS0w_f32d065d-bb4d-4e3e-b829-b71b3b26d5a4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f067784d5e422c8ab4af07a2f8bcb9_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC01LTEtMS0w_82d01628-4fbd-4f49-b384-68fa6f42d6a8">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172b683fbef54b37a292f3dfae49f813_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC03LTEtMS0w_a2c49dd9-db57-48fb-81c7-c22dc89a6548">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3c6f85819c4714b9885f8013fa08b1_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC05LTEtMS0w_b9a74ae0-28d5-4cd4-8847-13f3927ade85">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i393c1adee8e84595bfe0acc21bf97c3d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xMS0xLTEtMA_9a4e8e75-687e-4654-b0d1-96acdf9cb12a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia217fa4e279b4536b6b3f04c7fe81688_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xMy0xLTEtMA_dbb35be2-f916-4151-8c31-1ffd32b54d0e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0887d9184c47dfac2ce9c7bf039dec_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xNS0xLTEtMA_7953ec66-8d97-432b-86d4-3aec2a600958">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5359f26b034c4f8b839c6f0b2177c80a_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xNy0xLTEtMA_7072b022-bec7-4ba5-bf62-e006c51167ca">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife80c9a9053e41bca34e6b7e6d9d4efa_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xOS0xLTEtMA_ed21af3a-1e51-4f4e-be38-4379e4ee17c5">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9223587952c44aa0931adbd426c4f5e9_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0yMS0xLTEtMA_547625c4-fe86-4cdc-a4e7-4583931c15b7">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e280b6f3ee4222b4211f6c6344e7ce_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0yMy0xLTEtMA_0f710bab-072d-4508-b096-9c68cad364d1">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea870736ba5b42dd970e1c2e8cecd0a2_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMS0xLTEtMA_0983c088-af7a-40d1-8ae8-07eaa2c48882">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67048c78dc0b441b984b5eb1a80d4918_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMy0xLTEtMA_827d2182-5260-4416-8e65-f6ac257d0be5">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708250723a2049d9b4354763f848521b_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtNS0xLTEtMA_1c8595dc-f810-49a3-8830-cd6907d15a2f">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979e50a4991d42aabb587279a1630515_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtNy0xLTEtMA_71549ca7-ab60-4e58-9c12-3e1bb5dff53f">761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fdab53c5ca4fc7afb34303af488fe7_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtOS0xLTEtMA_ee381301-e066-45ca-8616-68785755db22">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icefe099ec9f9447d89313fe5d966d097_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTEtMS0xLTA_3831a4c0-0750-427c-98e8-ad558c303fb8">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686f3ec310f8431aa70f7a29632549dd_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTMtMS0xLTA_1c1f243e-47d5-42f2-a353-811de2763d98">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a7371dce5a4c7381c1ee54f2af4bba_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTUtMS0xLTA_a2aed7b2-8c68-4ac5-9639-8999d3517699">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66daa9001fc14740a44d38a81090f3aa_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTctMS0xLTA_03cd54b4-5392-4abb-941f-574563fe51e0">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce3f31aab04474a85482e57d7fe3b96_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTktMS0xLTA_c20ff632-54da-4b03-be54-8bc231dc7955">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414cc671cdbd4152bd1583dc67a4d839_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMjEtMS0xLTA_2a924ab2-51aa-48b7-9632-156a193ba123">1,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59138a1df4c34c0b8f31017c314ed9f4_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMjMtMS0xLTA_1334c439-3838-4348-9bb3-b9f6ed4d0a67">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3925c7ab1c44ef58b807944198fc32e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMS0xLTEtMA_58885fd3-1a35-4498-aef6-9b06d9d8dc3a">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862f90ba138c4b01a609bfaec7fe9442_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMy0xLTEtMA_08b78200-fb8e-4ebb-bea2-9ad1ac8851ba">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf560762c004da7ab56bb4c5d6f3276_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtNS0xLTEtMA_d8675808-3d0d-409f-bf35-683d4a1362f4">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44944b71a8804ac88c5e1188334b304d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtNy0xLTEtMA_3ddca079-1a90-488c-b844-41bf5f9c42ed">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac08e29232648c58d4d3e2b32573921_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtOS0xLTEtMA_5ba5e5f9-ed9e-44bd-af0c-1ae2dcf3804a">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e8855545fd4a67b2906f59348cf1cf_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTEtMS0xLTA_1c56e185-3edf-43d6-b0cd-3bdcc1252df4">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c793f46d7434d639f4b9af5a81dda9a_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTMtMS0xLTA_2711fc10-c413-4945-9e5f-29168c637a40">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae37299fa8e429c88f31b01349409ac_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTUtMS0xLTA_e76734e1-7579-4205-83cd-fcb5d8f134ff">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44abdfd9ef2340be84e53509a2ad1217_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTctMS0xLTA_1e809f0f-43ee-47c8-a0ac-df30dcdb5574">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38bc46dc41e4806b8a366f7c6a66444_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTktMS0xLTA_c3b15ee3-4031-4518-bd53-b4901ac11b03">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844c2dd9fe0b4d59b864cfc9dbeac1fd_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMjEtMS0xLTA_e575e127-f2a2-49ae-bbec-b175bf432d48">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aaf14c7fbad4e81b02ee7ede86f6740_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMjMtMS0xLTA_22099cc5-1870-44c6-b1a5-912f3561c007">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1757a74efe45beab35e7c434a837d1_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMS0xLTEtMjI4MQ_37d220c8-3ff5-4c3f-b8de-aa26a58265a0">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9b25563d433abdc2de1fcc1cf790_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMy0xLTEtMjI4MQ_c0716ab6-253e-49aa-bb7e-2e425572a80d">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b874688aab4e3691b20bcb3c5dbeba_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNS0xLTEtMjI4MQ_a276d7ea-449e-4a27-bf5e-6bab3c64aae7">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33106e55798a48b699ea798ff3d9c2c9_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNy0xLTEtMjI4MQ_d4a59453-7420-4c23-a06e-aa86e49b62f9">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb60f686f644588a89cc8c7b689dd91_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItOS0xLTEtMjI4MQ_b8250ed8-4576-4643-ac3b-80efbe0c2f3d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b7cc10d3a44053975f929842e5c6f4_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTEtMS0xLTIyODE_e649fd2a-0384-40d4-9370-82c72a59ff73">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d7485ea0d844afb437a33a9c0c373b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTMtMS0xLTIyODE_2af57c9b-9dcb-46d0-9cff-d78c0ac360d7">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3468a4ec91e4e0299f5e9d0627e20c0_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTUtMS0xLTIyODE_ec36f877-6fb4-4866-8ac2-592af87b9e01">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14d6de6abd24d9487ccef62b379ddb5_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTctMS0xLTIyODE_5e43b736-7499-478b-9b55-09771a6ed127">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63f20dcd0d3d4ee4add22bc0f3b7b2b1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTktMS0xLTIyODE_9a5c1924-e941-4eec-8c41-91ccd543a8a6">428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c865283192843a8b5c2910e9b0530bb_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjEtMS0xLTIyODE_1e76b9c4-29c1-486b-b451-150567f2975a">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e9b7bed9404b7fb7a2473c47829169_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjMtMS0xLTIyODE_f0f5d1af-e5bb-415d-85a7-d85fdd5e733d">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e3e6fb55fb4477bd2e4344ba69226f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMS0xLTEtMA_80a586c0-69f7-417a-b253-9b598179c24c">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29681f0938a8432486e7449f7854b7b0_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMy0xLTEtMA_67b92a3a-9cb7-46f7-a419-913f0444b9a9">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1cba7975734d45833cda2fa2563bd7_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNS0xLTEtMA_e4f88714-6871-4e91-9a27-a57e52d227f1">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f730dabc2740699bd827d675b983b2_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNy0xLTEtMA_e16721ea-dc47-4b7f-bd68-b1ba87bf72b5">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27eb3d476c694f68abd9f5e5db26dcde_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItOS0xLTEtMA_33c59d94-7a0a-4680-9fc4-26193561999f">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c2064d607f4f06b74136bd86690a51_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTEtMS0xLTA_bc6f13cd-1f27-4204-bd2b-c86f49f37d9c">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178d9b4b6cf34d169a02c96fa38dbaac_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTMtMS0xLTA_902f6d2b-05e1-4a32-97a1-b4e697adaa18">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235ae291edd64816acba0905d28cc37c_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTUtMS0xLTA_86d4039a-aeb5-4443-a311-a169d553a04f">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71afa28afc2b4c3bbe764e1563f8598f_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTctMS0xLTA_39956252-e31b-4176-87f9-a07881d1774f">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9440d8597143a1b91e48f43b4b0bd4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTktMS0xLTA_28d8cbd3-40e6-4450-8fe0-8476bbe46c38">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3da5777cebc48a1ab0eb78234e6c524_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjEtMS0xLTA_a254abab-a364-43b1-acd8-0b87aacb8ea1">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a0f69efec34219b126a5a5473b1670_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjMtMS0xLTA_735dcfc6-5b0b-4ddc-94c6-359292869b53">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c189c6b947a49aa97d6dce2f79c6151_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMS0xLTEtMA_32c89285-4eb3-4a60-9bf3-957cb6df27a1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4345b97e7f84437e9ba2ed7305654d4a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMy0xLTEtMA_d0b4270c-9ce8-440e-808d-a1633cb56893">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db3706ed6884db480687fa6df343826_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtNS0xLTEtMA_49c43d4c-c8b4-4ade-a92c-84931a3a7665">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f4b0c199f44ad6bda16bdc1c99307b_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtNy0xLTEtMA_af55b42b-34e2-4c26-9ed5-2ad1f88e6c5d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ae2ba3b636440dbf51084099ea4e14_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtOS0xLTEtMA_fe9ffe11-c632-44ed-8d7c-3961e12099ca">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b04d71a9794cad9297feb729f927f0_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTEtMS0xLTA_43df6cad-65c8-4ef4-8126-57d232ed7776">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ef7e87f1f6403786c8243b16effa57_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTMtMS0xLTA_898db642-6109-48dc-8e91-885e7879b7f5">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3da6673eab644f5ac8940187a307ab9_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTUtMS0xLTA_c6588f9b-314c-4b93-87e8-834a2bddab0c">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2737dd0c1b8c4fd6be8f3eb432e38a55_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTctMS0xLTA_d3c1a4be-e17c-4657-b636-2e2e8e8235b6">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5abdf92066496d90d2e3ed8f83f10c_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTktMS0xLTA_2b0eb2ba-7830-4abe-9f79-13544a42d475">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf624a2fc58f4b8db74dc7ff1193332a_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMjEtMS0xLTA_224bdfbd-0523-4636-8762-f4e0e58891dd">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694a4dfc7d4f41fc9459a5328750c279_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMjMtMS0xLTA_c5359f4f-8950-42cf-b993-198d6477d376">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb6e1314672d458c80a6ea2181ccfefa_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMS0xLTEtMA_5c3e47bf-3ba0-4010-babf-844972c7eac6">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5204d5450def457b9bddb35e60c60d82_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMy0xLTEtMA_8e4b416e-6c47-4343-afde-4bc47d5f8ecf">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d941127ebee46c6b3ca083a457c564a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtNS0xLTEtMA_67a00c52-486b-441f-a5c8-72243a1a2a56">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367f009328af4f81970cfce2c888d476_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtNy0xLTEtMA_5b8136c2-7ee7-49af-bf9a-4d44dfd77f02">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2772e763e8334f6a84b55704b593c8a1_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtOS0xLTEtMA_692fc5c6-d30b-4e22-b57e-c730af60952f">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b806fa3c4004464a6b42dc860d39e09_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTEtMS0xLTA_47220d8c-6f48-4bca-9813-68b61de2de80">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac62401b132462a9e7d3e00f737696c_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTMtMS0xLTA_5cbc97cc-a65d-4b31-8391-361aebc3e318">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b7f42ff4d40feb2b2ffee0f6914df_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTUtMS0xLTA_41b6bc55-38eb-4fdd-bf02-cfb3dbaa4520">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fdde8bfc914ac389b6d2024c9b1b2f_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTctMS0xLTA_7b77c2d0-2878-47b0-ba75-a2764ef8c7a8">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i351299226c1643e7ba68239fe2ba57a1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTktMS0xLTA_13bca52a-eb88-4a28-b148-a3964e128c9d">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8aee6fbf35747b39ce2ad1ed1d54893_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMjEtMS0xLTA_b259a680-b994-4703-bb1f-92489c6a5047">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec21e115e3a40838a098aa0894c0609_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMjMtMS0xLTA_9e83c475-38e8-4262-a7fe-ed66fd01bd3c">817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417799794c1e4e23ae2b7e19043fcc61_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMS0xLTEtMA_fe58c96c-3aa8-4cb7-b1f0-669a2d0d7c71">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a7bde573a847948f09da2562a0a446_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMy0xLTEtMA_c6d2f4ac-c3b4-4f72-8cae-2e0239500f7f">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d9612c858e4a19b3a9c1ecc6f502a9_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctNS0xLTEtMA_f58a6e7d-4991-4a51-ad3c-ade2c0670ef3">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84a9822d9b040e1876a2c6879d001aa_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctNy0xLTEtMA_c854374a-bb0a-483f-b1a6-6a10a7a94617">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73623d962db34390a9676bda7471397c_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctOS0xLTEtMA_18e04952-aef4-4e18-acb7-6413e1ae994a">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9ef0920dbc496fbc1ef7fff281f68c_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTEtMS0xLTA_d45955b9-2002-4125-b45b-d83eca69d6c0">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a9379092fd4fa5b67eb0c0899dc62d_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTMtMS0xLTA_23538fca-652b-4de0-90d6-10181165d788">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc60755989b24bf88af02e4825aa9c3e_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTUtMS0xLTA_f40b5659-1f17-4c2d-a3d8-68308b4e1534">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8062908fcb748948fa4b9408f90ea88_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTctMS0xLTA_8ccfc00d-0ad9-4e73-94ed-11f6af6603b2">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341ee46b776246b09ef1d6d67599e9e2_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTktMS0xLTA_3a5f2fdc-179f-47fe-a636-5574b2628bf1">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47edc2dbd975482da465c5ac979419dd_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMjEtMS0xLTA_c201ade1-f8ae-4221-a546-f611415b263e">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e6a07eb2aa4e858f46dbb14ef8ced6_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMjMtMS0xLTA_83a5df77-e9eb-41a5-8050-68f06a413c71">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94548af382c74ea191084b248c9f2fa2_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMS0xLTEtMA_65f35a10-55a3-42e8-af74-4f7e9c87c71c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d18847d0eb4080984a7f92642b9c3f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMy0xLTEtMA_879d08a5-0209-415f-84a8-19fd0216d01f">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dca799bf08b420b80463a36fb534945_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtNS0xLTEtMA_bdb0e657-435d-4527-a4c9-8b35ad8fc92e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a1bc6f405f84099ab6dfd1b166d4a30_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtNy0xLTEtMA_6bd84307-4278-42ac-8a50-042031887164">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702d3186e41442f7a78d814e62d3bd65_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtOS0xLTEtMA_de79516e-65d0-4127-bb28-e6f30d1f1975">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a9f2da00d04e34a495294f13d301e8_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTEtMS0xLTA_febf71f6-4492-435d-97a8-49284065ee3c">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33c89ea2353410a992159fd79ba7b27_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTMtMS0xLTA_1092bb99-6b15-41c0-ba3a-fa9912104ca8">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7537a2642ad14cc1b29e3fc7e39efdd1_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTUtMS0xLTA_7f2aa3c7-2d91-45c2-a31f-e96dae9d2117">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708c24fc9863489497166c927cd80e26_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTctMS0xLTA_f4a097b6-6a99-4d11-981e-8e7f7c9c1a0d">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ac91c09eb64ca48bdfe2203abf90da_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTktMS0xLTA_9edd15fc-85e1-4459-84ab-1ce347c09484">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b4250d2788459e8b5e2a862644234c_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMjEtMS0xLTA_76c3c9eb-9e3f-463f-997b-96253b1c5ef1">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia61152773c82437db2127adab1053a23_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMjMtMS0xLTA_c3152e2a-1f44-4d8b-805f-1a1920ded476">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d1e6a2e75a4c8eaff7e19133a84fe5_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMS0xLTEtMA_da197635-fa9d-4889-b116-10ff1e740c97">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2671e945dfd43ed804f379d6b30ac92_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMy0xLTEtMA_920842aa-9a34-4b32-905e-9e1a58c73cb4">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac2ca8f7efa4e3e8df4117cad2b06ed_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktNS0xLTEtMA_f2e7969f-3132-4502-b8ae-057f1cffbd87">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fbe25f948d434ea8c2d71514c905b2_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktNy0xLTEtMA_118fb620-29e7-4134-b629-620479a78da8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba671a135e142189f057be3fd5355bd_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktOS0xLTEtMA_4af24443-a0dd-45b4-b3d8-2cf9f8edb999">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7426bb60d684ecc97eb4c32ab073460_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTEtMS0xLTA_bf2336ee-4e28-4188-b470-0bef7da4020c">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib178b02bf26e48b68748d2a55b2657c7_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTMtMS0xLTA_1a9d1cee-6af7-48cd-b4c4-1e494385a85f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e7d2bc3a714126b66d4718cfa4a689_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTUtMS0xLTA_710aa3c7-e6a3-4454-bec7-74328de24da6">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39019f71db724d0388921c330404ac9d_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTctMS0xLTA_3eacf5c5-225c-4b81-ad06-0de7cc965377">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if399ecbab7c147ff8c533bd49e5029dc_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTktMS0xLTA_4d487405-f8cf-40a6-8d15-46fc980903cb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9c994a82754ec3bb4d67db85d4338a_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMjEtMS0xLTA_f357fca1-a4b8-4129-ad3a-4c4413af2a28">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279d66dabd8340e4afb06b61ff1106da_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMjMtMS0xLTA_e0f1bc68-3515-42bb-8fe9-238b8a58b647">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae82259b4751461ca0624752a35bce09_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMS0xLTEtMA_322e464b-87e1-4973-8833-3a5197233325">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77110243471455e93528fb60c32e34a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMy0xLTEtMA_9ff4d40a-8e5e-4dd0-840e-7f8d81546406">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b27d7fd3224ed7a7515432a72d21c5_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtNS0xLTEtMA_6baec709-58cc-472a-9a8f-9b751282147f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad3d9fbef4a14ad188dd6c702f303d81_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtNy0xLTEtMA_2d854df1-a05e-4c63-bb3a-f91020f49262">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd56b11ec30f439db004563892878a44_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtOS0xLTEtMA_3643af04-7df8-4668-a9a0-b81fe3dbee39">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7574915e7f9f45adb507296bad2d8acf_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTEtMS0xLTA_e770ced1-2d52-4ea0-8a5e-8e40d3bc345c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c4b2e42e50440983fdf402f1a3318b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTMtMS0xLTA_9de493a7-af18-4365-a8d1-2a41237749b7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d8c1ce2404f1eb1853fea7819c9a5_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTUtMS0xLTA_a01c481c-a4a3-4ce5-935d-0bc8beef0088">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a812f083634c0c918b8e40ac83a158_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTctMS0xLTA_b8d78458-fe39-472b-b13b-6e885899876e">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7a2fc3636d4744a1e68680dd160a7d_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTktMS0xLTA_17d8409e-f118-41ed-b61b-5c44be055d84">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf89995052242baaefbffc9a6c3d93f_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMjEtMS0xLTA_7d2a3557-3c2f-4197-9517-de3d0429976f">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f03323d756c4aaebedf7365c0c5f115_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMjMtMS0xLTA_06e4465e-a008-49de-85c8-90553c4b57ec">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6f397f156d434ba8c705812199c7b0_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMS0xLTEtMA_07fe2411-4e85-4fe6-841f-e6a868bf1f4c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b09565c92894fccad03d9a3f77269e3_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMy0xLTEtMA_c7c572b3-5322-416d-a0c0-72ef5b0fd5f3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776d8cffb24042c6bb2c4c3d914dff0a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtNS0xLTEtMA_7b6bb8ad-aa2d-410e-a080-739f0288bbd3">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143736d83dd84805ba380c77aff27679_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtNy0xLTEtMA_3d3dd576-62e9-4421-8438-d57e8ac440ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i427aaa6059414501938b90f49d23d83f_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtOS0xLTEtMA_10ba616f-7032-427a-b225-491cb033b7fe">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia54c2cf432c2492e881936280bb904f8_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTEtMS0xLTA_7b4c7bc0-e939-47d3-9259-869ca1610f61">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f165c4787b42588723ff48d0b6cf98_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTMtMS0xLTA_bf2c14b2-848a-4737-8a12-79f375d92353">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e895a82c3e4ef3852770005b410b0b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTUtMS0xLTA_a658c02e-0ba3-404a-a224-7dac3fc980f1">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06056e3d1fdd450fbaea2f8910ecf385_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTctMS0xLTA_949701d1-b624-4b43-ae3c-475a62a405b0">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ee3bcbe2894ccdb9103ea6acf2dc54_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTktMS0xLTA_0ac46d5b-3c25-47b6-85c0-5777aba5ef74">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3c12dc7fb64612938cc2e9c4345cca_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMjEtMS0xLTA_4b14fa9e-895c-45a5-bea8-d13e1fd989bf">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953896ac43dd4a4492bb05e6f55f1f63_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMjMtMS0xLTA_9a0a3155-7d51-4c57-8a7d-6d5fb7f1598d">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc471aad3c94e04a06f0fee9bd88cf3_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMS0xLTEtMA_07d0d6ea-d389-4c4e-9818-9c5cf6619466">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2dc4f551874bdea08cc8b480c809b3_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMy0xLTEtMA_3a257552-b2b5-4e65-84e5-f70d2544d921">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf3e6bdecc74c8db16756ad0211654b_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItNS0xLTEtMA_e2aff21a-215e-4cb7-b0d9-4dd7fbb04c44">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea020ccf4a554e1b82196c6dd3816009_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItNy0xLTEtMA_020f562c-5183-4a6f-b586-a0038b1b7f21">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81eb3b266055401489cbcc9e71b1b590_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItOS0xLTEtMA_a02d5db1-830d-4153-9481-baa1c7049a1f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1eaeca1be734efd9e7311afed56e4fd_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTEtMS0xLTA_c2e5bfba-8e8f-4c97-b317-a80039a0f2ef">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a53f2d7fad41e399de72c840dc300a_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTMtMS0xLTA_febc0de5-90cc-4616-95b3-d0748f911f9e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54a4864f2fc40e2af2de994c8aa8ab5_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTUtMS0xLTA_a06f1cdf-f731-4702-9c51-d9aa02c07ec0">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c982e709794dd68acadc44141524cd_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTctMS0xLTA_51de36f4-df1d-4415-abb5-1697f70612bb">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33aa602ccb9e44e7a7efcad8055fafa2_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTktMS0xLTA_561071b1-c77d-4842-acb9-fbdf36622057">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id881511a6cc84e72acb24c070e6797f5_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMjEtMS0xLTA_a5b4e232-2c47-4158-8f08-e8b63d8c82d0">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3880d04cc6c346cbbb1fbaec73165ce3_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMjMtMS0xLTA_83cf5112-fc0d-4350-88cd-f1991a45099d">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe91553b040477b9005ed581ecac9d9_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMS0xLTEtMA_dfa3ecc7-60b1-41e3-a15b-c00e54e73a6c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff55a2b1e45f483b908fa739760c0534_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMy0xLTEtMA_fcf8bd1c-9168-43e4-b16f-f02b28749ca7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5e5f802c454eb59aeab6da3df4da1d_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtNS0xLTEtMA_782106ed-bf3c-480c-b7e4-e1c54f637bbc">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id827b82628ce40ed984d4a930de9a590_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtNy0xLTEtMA_904fdf46-43f2-42ab-a33a-3ead26743178">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb446c3d46c4a828db42c890a42b26e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtOS0xLTEtMA_d55722c7-f4fc-41fe-9da4-fb3f4b0a090c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bebfe0a869441d786bd3a8fd4c62b20_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTEtMS0xLTA_f0063dbf-1c68-4f59-8af8-69c38d0421fa">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i361cbe5c451845abb30a9a8f4f2e6455_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTMtMS0xLTA_a89da5a3-ab69-4d87-af31-683fe4b14d21">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e8ccd8cde3495f9af0b571d95d1d00_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTUtMS0xLTA_369a6ab3-d2b7-49e9-b4e0-fad5b87f7022">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb936fd1c99f4c35801a4495e91bec73_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTctMS0xLTA_e62230ec-c0c4-483a-825d-78e169fbb08e">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fe9b60ce0f449a99363f745dca6e96_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTktMS0xLTA_cd755da7-5dd3-4f0c-8128-5d1b875d7362">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acb4cddc5604c7eb880aaa49a3e16f6_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMjEtMS0xLTA_13bd5ed8-fe60-4bd2-8a75-a594a4ce6045">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17701907ca0e47ba8fd1a971d48c2457_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMjMtMS0xLTA_25a72190-805f-4b20-aca4-2e15d48781fa">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73faba95052145acb3c26e84d3a4b602_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMS0xLTEtMA_c35822a1-a298-4c60-8b8a-401032ea87d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie736913c7dc4408abb11d1fbef1ce474_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMy0xLTEtMA_53fba6c0-f880-4c14-84df-cedc08ed63ac">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec058f1ae0fc472090afafbd68d47461_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtNS0xLTEtMA_34c1753f-681b-4d1d-bf0c-a9db00716d94">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989cab976f6448758df4479ff64c1fc5_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtNy0xLTEtMA_483df49b-4af8-46db-ba7e-044944cf254c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i261c4ce6a02a4800a83a51be1c99da21_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtOS0xLTEtMA_c2c0a61d-9891-4be9-a4a6-22af6d413128">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf9eb755fc44eafa35a8b13e484061d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTEtMS0xLTA_84fb0280-7312-47e2-8147-601febbdf5cd">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ba00bb057b41f5a6855415133e2535_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTMtMS0xLTA_4c4a53ff-046d-46b1-8f00-78076fc33b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73eb6d53bbd4f5ba331d317ac2a8489_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTUtMS0xLTA_c01d61f2-cd29-4432-ac71-2c649a7c6ae0">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac01653e21d0445aa0eee236c7ba741f_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTctMS0xLTA_04a1b148-c17f-47e6-9b2a-dcc88b0f6b52">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d4102e12044f109f6a5e7816007905_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTktMS0xLTA_442a4683-2859-43ee-a4e0-1eb621d8fe4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242aa19f5d014d05a2d3f4cd08cd39ba_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMjEtMS0xLTA_a814154b-9f79-489b-887c-bce07d469666">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ff90a270f74713b7bcc28d52341906_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMjMtMS0xLTA_ddd0fcc5-9acd-450b-bb8b-5689a70916be">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7c01c0be3e49b5915a0dac164db1e4_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMS0xLTEtMA_9902363b-1948-47ac-8388-e8b580c1dd17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7972da26546c42ac99a76ed6a9fd9ec2_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMy0xLTEtMA_0660ca0e-56b9-4dc0-9d9b-2cf3ef4cfd08">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb7005b439e4d31aef9325c0babf90e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtNS0xLTEtMA_c0e7c497-c2d0-4369-81d1-8e0ad4c8a576">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993dd102bdca4431a2a35bc582ce9394_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtNy0xLTEtMA_3ba1c532-1b47-4fb9-963c-7e5f86bf5838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3485a40e14d749c98847179c09c2bf32_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtOS0xLTEtMA_29413044-0315-439f-a76a-7c343134f7e6">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acb7f674c0e47aa9e58edfff2e3dbb9_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTEtMS0xLTA_ccaaad64-156d-45c8-8309-b75e85133a95">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf0a90d670947f2be36e5211d88cb00_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTMtMS0xLTA_179ee0b7-de9e-41b7-ae46-71200a99d170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a7f87c772bb46ba90ef0bd0821eca8f_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTUtMS0xLTA_a8dd9015-2a6c-4172-a0e5-171a1e9c52d8">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04909af50dc845da9f9a8569bcf5eccb_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTctMS0xLTA_aa777281-df15-48fd-9218-de7c7f861e98">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26152f7f7b440fbb4cb9d200d2e7f77_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTktMS0xLTA_9a4dfa0a-911e-4dab-833e-9671230aa6c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0931102ba1674080bf90d3330f7955d1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMjEtMS0xLTA_b54888a6-fdfc-435a-b3ca-d170f615b93a">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7670dc70afcd4b09937d261583e363d3_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMjMtMS0xLTA_ffe84bd9-dfa0-4e67-91b4-eef17cd748ac">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20fe0f50a9b4260b6c07bfa057998d1_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMS0xLTEtMA_b96a605f-66c0-457b-85c7-3a34e3573d38">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i858538797815486f80a7414cb57358de_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMy0xLTEtMA_ed0a2ee6-90cc-4e4c-ae54-ff10d6dc4456">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a8339ae25046d28c34fe065d7fa146_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtNS0xLTEtMA_550556bb-753f-426d-88b2-bc655c7b704e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ff7e9937ea4f4d82b65c6fa6926786_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtNy0xLTEtMA_d2e25f1f-b136-451c-ab5b-dfb752242d92">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1700dc6b374b3aa45edfd416e35917_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtOS0xLTEtMA_bff87fb9-17fe-47c7-9a63-75275b158862">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9928d769c694dc2b2adfc1fb517f81b_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTEtMS0xLTA_127596e5-70cc-41a0-adf3-512f60c77c83">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0a0fa75bd64a7b8e10d99ff43623d5_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTMtMS0xLTA_a805a523-eda7-4ac9-b50c-ad40581dc36b">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b1825f1272940bba1d0662fbbebe361_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTUtMS0xLTA_7a2a694a-4709-4471-8d2d-b78c00fc66b8">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4523ccacdb4f7f9000657e8e4309a8_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTctMS0xLTA_4f8f8869-5397-4a0f-8854-6046aea8cc86">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c9e9493f5641b8a375c87f2e0f240e_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTktMS0xLTA_b9e03884-74d1-46f7-9572-9e88d1e56a52">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e423505d49f437db0eea268f1caec94_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMjEtMS0xLTA_e9733fbc-f98e-4ae8-891f-3e621b8803e5">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b1c51d2fbf4f78a7e2768a8d38f881_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMjMtMS0xLTA_30b20737-ae84-4004-9afe-c7fbd3a00662">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4fa96062de49de83a4eec95e5f1c59_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMS0xLTEtMA_56076aa3-eb7d-4f88-b698-7af704de4a44">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebff762cc1db43248ab6ce27128b3ea1_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMy0xLTEtMA_470ea067-5f67-4a65-88c6-4dc30edda1cf">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35113cc0f784ea18a9ab80c7456f72f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtNS0xLTEtMA_6b1d4d34-d7fd-4400-97de-83c0ce4da007">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0b5f18d0c94b499db52d87cb762e66_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtNy0xLTEtMA_0002e971-dd3f-4243-95e7-789faab90bcf">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i623c2805c097460f9a7582db63744702_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtOS0xLTEtMA_6149c421-a3b7-4bbf-9760-1c8426b431a8">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bb9a967fac42b0959e471029dd753d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTEtMS0xLTA_fa0f5ab2-7ec7-49c1-80b2-367de4e7c5cf">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b59bcf248242288925f9d29334b8a4_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTMtMS0xLTA_0c6d9894-bf29-4a46-ad96-22084d2fee45">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83851ea51a8b4f348c297fe9674a70b9_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTUtMS0xLTA_f9c92099-219f-47ff-9413-b084ba8420ce">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374d9072818a4be49130b74a30fab649_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTctMS0xLTA_ef5f23dd-84da-469b-badc-6d220d4bc934">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb66d45ea6d43f891ac8d34790f596a_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTktMS0xLTA_ef29c3f4-b408-4e30-ac78-007811f64a22">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d20159069f44586beb2bd4d53b486fa_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMjEtMS0xLTA_886c6fcb-0225-466b-9c9b-757c3fddfa74">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1589f85930c4c2490dbcd2bc2471fba_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMjMtMS0xLTA_08fc681c-dfeb-4687-a5b0-d30c18209354">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d2b1a5d4e445afb22b111f115751ee_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMS0xLTEtMA_fcff4ad1-247e-4a4a-bf93-9a136161bf6f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2782b98a704284ac75156aa7888225_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMy0xLTEtMA_721a347c-eb18-4777-919d-7f5f2ed1d92f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28c15341c614ec3ab5f080633c0f9e8_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtNS0xLTEtMA_1c6eba7e-18dc-4c89-ad43-605230894de3">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7892ccc679854d0f856e0d492c1d0dc2_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtNy0xLTEtMA_7d725161-e713-42eb-8044-5f6c20ad82a9">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454932685d7e4ec2b3f324fd851227e8_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtOS0xLTEtMA_39dd675f-112e-4d51-96f3-0f66f849b6b7">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6b957265c64b67b737a553dc147e91_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTEtMS0xLTA_d0d3f82d-45d5-418e-9ef5-d369adafd524">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87992e546f14efb895456eb6a74307a_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTMtMS0xLTA_78cd50f3-e3a9-40d1-af79-327983a11d86">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713d3719b5024faca7719a158e89109b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTUtMS0xLTA_72259e31-49f2-409a-8744-f923bb5faf0e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b7b30d595b4b568bf5d47c20418641_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTctMS0xLTA_6d3ff7f4-f85d-4009-baed-462691524d7e">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a2b13d213f4580ade960efd7096274_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTktMS0xLTA_54496af9-8061-4138-8798-074af528ed68">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb922157dde34ceab969c20d2c593243_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMjEtMS0xLTA_8314cd56-af21-48c9-a8fb-037e6feefd43">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e831ddc4674ba7a0e1d0b61409a910_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMjMtMS0xLTA_154505fd-e3e2-4146-92fd-e3a03adb35f6">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c7c5a8d8197420585dca57047243f97_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMS0xLTEtMA_caff30f1-e8d2-4515-a25c-f645bc44a0a5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938196e4279e4040b004c3a0e20fb083_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMy0xLTEtMA_11a1db7e-441f-4493-b1a2-407d07aebd36">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79705fd98c64c8e83345f5d01da64f7_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtNS0xLTEtMA_db272ad1-b047-403a-a52c-b251ddfe898c">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f7c0c892af4ff1a708a6271afe4da7_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtNy0xLTEtMA_5db7b1f6-85b3-414d-a631-dd5846195b60">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f14a0f1d8c4abb8f6a1d03da5e0eae_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtOS0xLTEtMA_0abb6ce1-ded4-485e-a7a1-ff9800055832">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd47e42c1944c9c8213aa8f8808165f_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTEtMS0xLTA_a4bc72b3-4e58-41e3-a3ea-d616cf035067">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04d650ce0abb457d9453531cb7e334c7_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTMtMS0xLTA_a853ce30-61aa-454c-8d0b-e1a3418cbd6c">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c32b81ac1784ecf9a98aba06ce43e61_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTUtMS0xLTA_c0125933-6f70-4445-80c3-2a7bfcf447a3">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de38a6154464d5695596fd542cd49e0_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTctMS0xLTA_381c2fae-3a66-4fd5-89b3-4a4f928b16ff">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ab7aff39d449dcb43df1642f85616e_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTktMS0xLTA_d7a2cdd3-d0b1-4c61-b8d4-0ffa69feeabb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcbac2ba02f245f2bf19de7c0dda76b7_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMjEtMS0xLTA_44fb9b5b-7f02-40cc-8b87-5484330853cd">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f6f5e968c5474488f0b232fe0e77e0_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMjMtMS0xLTA_a71c8802-1889-4dd0-b751-93d4c641db8f">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd98423d8c14073b9a11bd36db51615_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMS0xLTEtMA_b2cd506c-e891-414f-83aa-5956705fdcd3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d20ffb278846169ca7fdcd9df043c4_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMy0xLTEtMA_821c1ff9-0a8b-4cdd-9db1-c0fd8311ca23">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id028f116dd7b43eaa20b6e06ed2df1ac_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtNS0xLTEtMA_7fdb8923-99da-4cf1-a22d-8a444853a24d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50456612190942a080739275f8173a2e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtNy0xLTEtMA_3909c590-a48e-4a94-ac32-dfa37e4ce34f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c087cfa4f64c55b828f161589a223b_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtOS0xLTEtMA_d5e1a73b-ccb6-4524-8b5b-d752a3705917">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b39be43599c4cb7bf9bd31828ef9002_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTEtMS0xLTA_bbbd6600-b5b8-461c-94a9-0eb430f2a936">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bcb57eb48d4c5598c716226714d7a3_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTMtMS0xLTA_bc411bee-273d-4d9c-bff9-2fe378a45079">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05834b1651a949dc8f02f619c612749e_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTUtMS0xLTA_53468d70-f1a6-48a3-b16c-43cfd8be426d">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da82df886634a4fa849605c59fae2bc_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTctMS0xLTA_fcd5dc68-4f36-4462-8d6c-c471f1d076c8">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716c7e7fa0504751a650112eca041f5e_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTktMS0xLTA_1510368f-24c0-42f9-8333-fd7090d2a83b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318576a512024c6c81441fd12fd57fa1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMjEtMS0xLTA_2760fab5-465f-451c-841d-c389d3bfed50">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbee4cd8d004afe9a3ad3ed1829964e_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMjMtMS0xLTA_1bd3c3dc-142a-4902-851f-3f07dbe35458">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334447130bb944a993957aeaa20c39eb_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMS0xLTEtMA_496a67ca-195a-4af8-863a-4d1bed05b586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b78ab8426f34f24a032ff8f5061739f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMy0xLTEtMA_e1adae83-d18e-44ba-be60-091dc0f3e04d">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8977d72497b74b1086d865c0aaaac8e8_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtNS0xLTEtMA_eb510b8c-ad07-45c3-92c2-a4474f320693">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea630f933a7446e9a808f75d1870113b_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtNy0xLTEtMA_2ddef571-ccad-4475-8381-7e042337d4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c211102c3f46678a682f40f99d407a_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtOS0xLTEtMA_e328f38b-e4fa-4d99-ae3e-e546b9ec5958">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0d607a7351455a9f45abc4f86f952f_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTEtMS0xLTA_e163acf3-9998-46b1-a1a8-ee95a27c8c03">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia279e76e54074dcaa5ac97de34e18efb_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTMtMS0xLTA_d4deedcc-19ff-4ebd-9f67-a0f40184f31d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12096c3c413a49c898ae87d73a81726d_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTUtMS0xLTA_f3a8bf17-4067-436e-92c0-80858cc3bdb4">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58002f53d69a46229000ce6d3360542b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTctMS0xLTA_5b53a379-536d-48cb-80b0-a0ec5ef9a445">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e7b9d13ce74df1b09ad0cf151c9851_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTktMS0xLTA_530f8074-3ac0-409c-9c50-d6d00c3114fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92db4be05ab40318a94c027967ef6ad_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMjEtMS0xLTA_b9f26dc0-30dd-4205-a00f-3504a1da37ba">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a231f98c7d149a490b785bad71e4496_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMjMtMS0xLTA_c381a758-8950-4bb7-b444-6621aa0e381b">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id303f0dee3b74b50b4a15ee325ebafa3_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMS0xLTEtMA_2f622d3c-a771-4163-8fc5-41b587c0552a">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bd2933ec84060aee7e36859962375_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMy0xLTEtMA_3ac0d1a9-7848-42b5-8adf-e94cc6b24f65">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617676e5fd5247fa822d36489d37e0e4_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtNS0xLTEtMA_db6216a7-a682-4d79-a805-d1fde4ec8ecc">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d72700287de4fd4abc770a532f25f9c_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtNy0xLTEtMA_6c3523c9-cce0-4a3c-bae4-405bc0f408aa">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c6b30dcffd403bb85af19b9d4165b3_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtOS0xLTEtMA_969b2fd6-1bc9-4273-bc8c-c075288b4a68">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296ad230a93245ddbc5fd02cba30cc53_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTEtMS0xLTA_78630c68-87b5-4c96-a6b6-0a133a89cec8">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88917ca1de89409e9f4b5b2c0fa57485_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTMtMS0xLTA_d02920f3-d2c4-415e-adf0-c16f42362692">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfa044147144425859e25282f0ef9bb_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTUtMS0xLTA_dc622d2a-1b8b-49ee-8fd3-c930e8dd2971">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003abe7634514241b3a8d6350da515dc_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTctMS0xLTA_ee92dbf9-c228-40b4-9209-77fda8a88956">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618a9be04c62409099b81b9ef1c5344d_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTktMS0xLTA_0adcefc5-fe93-4fe0-99d5-1c103acd5aaf">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a2abc9a0e534088b5e0fd5437f763c4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMjEtMS0xLTA_e2208944-607f-4397-b329-f81f973fd3eb">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0be09895f8143679533f9a333f5a993_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMjMtMS0xLTA_3c8e56a1-4ab4-4d23-b141-23aed2884fc9">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93521f60ff59466495549fc41c457899_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMS0xLTEtMA_3a5febcd-1347-48c0-97d0-1072ead9b7f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5952b34144c141cda9875d2d182b3881_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMy0xLTEtMA_313251fa-08ba-472e-9b84-cb0b7420bbf5">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5caa54b167f3434b80a36e8e76d7c6f5_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctNS0xLTEtMA_0a41222d-e3cc-4512-92d7-cb16e403e363">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i651c70a05142434cbfb538a617b89007_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctNy0xLTEtMA_93e6838e-b887-4a3b-a0a5-46ffa9897e56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcc4708c8eb4156b83f9055e325dac6_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctOS0xLTEtMA_b700693b-f285-4c8e-af7c-f44a8aff89a2">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740e22d8434f4b8183f077a8a007e956_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTEtMS0xLTA_2c70e80c-a88e-4164-9218-45d8aa8c6887">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640d595c82ce42e7a7c0fc6c0583bf14_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTMtMS0xLTA_7a6d2a8e-3444-451e-ad3b-7eb4b89de579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f141f8261348bca533b4aa5e20e68f_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTUtMS0xLTA_62ce34cd-a906-43b2-97b4-e316fd5cec83">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e53e8331413497ab9874b05911c0437_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTctMS0xLTA_2af836ec-78dc-4548-bb50-f6595b994134">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68cf832a35a46ff8bdde3920247bd39_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTktMS0xLTA_4c5280a7-8407-416d-bc4c-00762cf726dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f48e3aedc24f50b0808a4b79b5dc6f_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMjEtMS0xLTA_61a1e71f-3be1-46ff-b8d1-1a4bdb4238f0">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6b9e3b829c4249bb4c0dd15118296b_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMjMtMS0xLTA_8860f04d-c771-4df4-8369-f1e070b4caf4">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d275d442cff4f52b27f27fd2a721187_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMS0xLTEtMA_7dbe4764-bb62-4fad-923d-c30c5338c4df">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b693b792e3f4432bb82f7c6052c3ade_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMy0xLTEtMA_10266d65-7efb-41c0-85be-abcad806cc1e">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i226ad6cf1abd49039985c8760bfc48d0_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktNS0xLTEtMA_451c3510-fa31-4ea4-83a5-a8606cf0bf99">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c690705a704872bb3bf8a6745a536b_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktNy0xLTEtMA_afae78cc-59c9-4b51-a54e-8d650fea073f">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ca2e5a714e482f8fdd4c3d12841689_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktOS0xLTEtMA_e11493ad-07b1-4955-b031-c78e35be6216">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da7b1a0beca4bd29d8c4620041e50ef_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTEtMS0xLTA_d7e85659-8405-4e4a-a9ae-d33948133c7c">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab88e6cb5824e4ea0470b131ece9e3d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTMtMS0xLTA_4b3d6701-105a-49f2-bead-cf74350165ed">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6c90ac04b148ab96bd8f595258f46c_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTUtMS0xLTA_d2d07d4e-881c-4474-9a0d-bfc80ac32d10">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f486eea8904e70b20acef9a91c8270_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTctMS0xLTA_b1ee0ec5-8b18-4ee3-94f7-b8da861992ff">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae7aa49415340d9869b132435677a23_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTktMS0xLTA_2e551a46-5631-4f6d-888d-7022e861147f">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb42bbe4a18548f4a03796d68320493e_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMjEtMS0xLTA_b4e4afb0-d893-4525-af44-ee5cee162499">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e9ec73128f4b998b320a2ff73af17e_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMjMtMS0xLTA_03c5ab1d-7da5-4be1-a013-acd550a282c0">2,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c91d7cd6e084ae696ac51575ba5006a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMS0xLTEtMA_fbc57778-729b-4e54-ab68-12dfb31f28c5">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13bbe57c7ef04ccab0073746177c2e21_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMy0xLTEtMA_23400d8f-f91b-42b9-9a23-b1b5f7cd7bbc">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b0ecfa83ad149c5ad28f2a5c2bcba9a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtNS0xLTEtMA_41976bbf-98c7-443c-ac21-3ce5478e1aac">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86aab60a014a46da930b6b4e9e51c7b5_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtNy0xLTEtMA_0053067f-ddd8-4b19-8e8d-56f09c21e50f">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i101456f617a34e8f91f201fe318d9a1d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtOS0xLTEtMA_194ca180-34d5-4124-a5fb-eed6df01519f">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39e3340b0e647debae7f510c822e44a_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTEtMS0xLTA_af6ca839-38d3-43e9-9712-95c176ea3329">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6009d7735cd3433f9a820af8fb018481_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTMtMS0xLTA_a893560a-c722-4680-9a51-75c76ec35ab0">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0257c158246c4e4dacbd738eee948877_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTUtMS0xLTA_7b494c6e-467a-479d-ab41-db10a3fc6e0e">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae95c10fc15484eb3969d05a0a65b4c_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTctMS0xLTA_4ae5a5e4-3960-4383-a4c1-81b09daf6bee">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047053376fd540a295e977bc6188ab36_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTktMS0xLTA_83fbc125-7746-4cda-8199-0e95594d421e">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09da9da15f049f18535de414de6ca38_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMjEtMS0xLTA_b6b45008-aa64-4129-bb5e-588e17615c03">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9106c5caf2b40498beb6bd13c71325c_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMjMtMS0xLTA_ba730ff7-0605-47e0-b83f-7bd27bb28a6e">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42088e2a28144cd7873c943696f37b29_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMS0xLTEtMA_73cff51e-ad6d-4cc0-84bc-9a53339fb5d1">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0baa103cf7c4cac90311107a935dc92_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMy0xLTEtMA_4b95e457-e8ce-4dba-9d96-bc21c8dd0c65">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd842388eed64b3da555ffae75b7899f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItNS0xLTEtMA_71096e07-4938-47ae-b2ca-0192e41776fb">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda57adf0dc14c4d897dfd88fd256191_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItNy0xLTEtMA_a5f79758-237a-4490-8e1b-11d3387bb72b">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c35e7bef0f74b0e9f2ad280b8c9d79a_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItOS0xLTEtMA_2493bef9-c1ea-48d1-973e-e2eab4a9e60c">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe3d788155d4dcfa6d1bcf0849a7908_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTEtMS0xLTA_e73cde14-8868-404c-8e94-8c393b3c853b">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13f6a3f0b24f4692421a7f681056e2_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTMtMS0xLTA_41273afc-a9bc-48ae-9d4e-d0d31c36ad02">374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823b7acf4af043c7bcfc682b9ea59b03_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTUtMS0xLTA_0579c030-b15f-4610-b152-6173281080f9">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i250b5ff269ea46b4bd2e15044f7e9e39_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTctMS0xLTA_04bed983-b0c8-40e1-9d88-e1874501c717">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816a6164517c4476bbb9046b7465a255_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTktMS0xLTA_abdd9e00-fd54-487c-a8c1-9ca63fbd0068">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bdf582fe7f04b6e84f53a13fdf085fd_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMjEtMS0xLTA_e1db6a71-cbde-494f-8d67-8524a8bd442f">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabcb5052939546a08171746b38d9a959_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMjMtMS0xLTA_7869431e-88a4-420e-b64a-027ee7a5a0d1">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1e1cd1ea5f45cb8b0d49ab5e325e7a_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMS0xLTEtMA_cba81d36-5a86-4df2-a6cc-054bd9e0ec98">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ee2df0e4d24ac49cecaf2f8612ac56_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMy0xLTEtMA_7b1b09fa-f9a2-42e0-a6ea-4f95d803f1a9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8da3de0a1d54bb19a95bf565424fd8f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtNS0xLTEtMA_a8180399-4b22-43cb-b693-13478593303e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib197c58857094217ae70f45c5bba1512_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtNy0xLTEtMA_8ac96e38-e8a0-4097-8b2b-a51b4f092ba1">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65bf34d7c3de4b76b99865acb7b377fb_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtOS0xLTEtMA_09561301-e9fa-448a-beb1-597b7e7e4a6d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec190b0d42f42ba87646a7397218a62_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTEtMS0xLTA_f1b20b20-d4d6-403e-96d4-51440e006e99">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87932775cd94b648c1cddd6c945029d_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTMtMS0xLTA_c2561251-6a0f-42f4-aa9a-392c1941dc96">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida18cbb39b744ce7a0792eb9db392c68_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTUtMS0xLTA_8f659c67-41f8-4a66-98fb-967268ed5ffa">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida7a1d7200fb43eaac711c3fce8929b7_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTctMS0xLTA_3ee18bca-7749-413e-a993-4385f0bb8442">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5936f316e3b42a5bc7edc460c3d44d7_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTktMS0xLTA_7fb438e7-05c6-4733-a2d7-38f6934a5055">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2c7223374443ddb83cddcd93f11059_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMjEtMS0xLTA_e9bfb882-843f-4d61-b003-5659fbde7364">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fc1591a9274ddf8df88b43546a8090_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMjMtMS0xLTA_55ea3e6d-3d25-4363-a955-b7bbd5b4e6ec">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e354e7391d543ed99baad3fb5dab811_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMS0xLTEtMA_67fca2eb-a339-4b22-9a33-eef71c249f82">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79cbc9acc32f44e2806b5ff08ab4fe23_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMy0xLTEtMA_13c86d46-0633-4b35-88bc-44daf7b7e8de">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4ad108871045beb3935eec15ecb68e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtNS0xLTEtMA_6a92a79f-c775-4b60-89e9-053d9f84f9ce">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564e295cbae1431ea1342d1a6aeb2d66_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtNy0xLTEtMA_9db157d4-0ae1-4af9-b451-ed0a83659b9a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4cffe9e90bd459eaf7ef8497c5e3424_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtOS0xLTEtMA_0ff2077a-f47e-406a-baa9-dba51b789f4b">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d690c97e9cd4f4d9c35a892caaecac6_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTEtMS0xLTA_aee8cb8e-a8e9-4508-9b6b-196ca075270e">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i649cbc3cd44646e9a198d32f7491aaf6_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTMtMS0xLTA_14f17322-735e-477a-8857-c0a668f2f34a">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc84657eb0946a79cc4a2c2d53f5f7c_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTUtMS0xLTA_015ef5b1-b5a6-4305-8367-370ad43b7664">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c935c934b3455584cb3ada0f1e5c0b_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTctMS0xLTA_5e368aed-ecdf-4b15-81a3-3ef620de11f3">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80cc24848e04d269a3e8ae9c377edad_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTktMS0xLTA_81dcf365-8f5b-4563-9e6e-ccce40b8c225">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77eee53991d46b5909d9edb93e5b74d_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMjEtMS0xLTA_fd0b2e20-88fa-4a33-816b-a3d838d488c7">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7f6840d5e34b2faca6d72b25845338_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMjMtMS0xLTA_bd0fdde4-6bab-4d37-bd8b-54302b47d3eb">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id320e1dcac42446cbc9350d2c429f55c_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMS0xLTEtMA_d8803021-84a4-4af6-bd7f-81b1a655b7bd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f8b81383774d52a52223b7869349aa_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMy0xLTEtMA_4f54d61c-c6ba-4896-aa57-05c5d3d76496">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b8498ad9774b9d82c1c33f73ed1085_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtNS0xLTEtMA_b2414085-6714-4d52-95ad-810dc0bf6a6d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d53f4525194a86a9fea6c036af1d55_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtNy0xLTEtMA_d11ace1e-4a9c-4c32-9d9e-d8e16bee6afc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c38480569ad43bf8a8faaefe258752f_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtOS0xLTEtMA_dd2fb7a0-8086-4ce2-8a1d-bd3fdd51c2f4">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2661c49a72f4fa4b82bfea2d5eeafcf_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTEtMS0xLTA_5357bfd9-0cfa-440d-a5df-6a582cf5e07f">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba0bdb0d16143e98878115551e164fa_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTMtMS0xLTA_e6526b1f-1939-4a6a-8d12-96b1ed2fd617">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33caa9debafc499f9f035c363252e664_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTUtMS0xLTA_0759bd31-22e1-46ec-b03a-20dea8ba39f7">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70254c5658804d7db8c93d35ca1b2469_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTctMS0xLTA_6fb0f655-405c-408a-b624-c7a6a7a44df3">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f17b6e17a35418e8016b026c1f452a9_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTktMS0xLTA_b71977b7-9d9f-4dc5-9adf-91d2f3896cf8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf07528158c400fb9045d2904828cdc_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMjEtMS0xLTA_8c7e2cd2-7fcc-44af-b2e4-c1a2afb7b040">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6e2064c3ec4ee7bc561d67868ea2c2_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMjMtMS0xLTA_e81701d6-3fe6-447b-ba4a-453a5cdbed9e">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29c1b123d68491cbc79c7aa181a889e_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMS0xLTEtMA_73244c09-0bd6-4e26-a8ae-774e2dcd30c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba270aaa589748cd947e1be8c444099d_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMy0xLTEtMA_1ce181d4-4c93-4051-abe6-5408b415488e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59bc2566f18462695b19da2c7e8857d_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctNS0xLTEtMA_baa59b63-3fac-4c71-873c-22981ae7017a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f8fcbabb864499b102a4d91eb12390_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctNy0xLTEtMA_4bcf2d64-633c-45ae-acda-9a0aec0791fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab058ed790442cf887ada3d278a7abe_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctOS0xLTEtMA_b993f53f-8104-4a10-a52f-c7f4ad7317fa">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8878e9ea7e44254a65607e3a621ad36_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTEtMS0xLTA_2751177b-8d57-46e1-8b43-e378a46cacf0">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c96ed92bdc54f6dae73012eb2b0161a_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTMtMS0xLTA_a2bba2e2-8a64-4322-9f2d-a6f272bca109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8cfb19850424c50b34394d1394866d3_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTUtMS0xLTA_8403a10a-0965-4f5d-b2b3-024f490df0c9">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8b9c2751764e1f8d74e88aaa332b62_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTctMS0xLTA_27fcf636-08ca-472f-bcfd-f9cbe82d4d73">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3220d799974f0eb91ea6a92667c1d5_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTktMS0xLTA_9b895a4c-bf11-4935-b7ce-ebde72a69b12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8875e8b3d4847bf905c685aef59e0b5_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMjEtMS0xLTA_e451e73d-b58a-4d4b-940f-b070e4a43a8e">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b57a142ee3a4ce9a28e2129619938b4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMjMtMS0xLTA_90335673-9970-4c60-b0f6-7960c02ec1de">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fcc4f2c591d42c2a24736d2c11c3061_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMS0xLTEtMA_33fd9821-bfeb-4da3-936a-32fdfc15cac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972845bfd88640bea722b70626571964_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMy0xLTEtMA_072fddee-20ea-464b-b5e6-3038f527ef22">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe81fbfea644f74bfae5c97dafab313_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtNS0xLTEtMA_2c156b89-b475-4604-8efc-e4355af6528f">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied38158acb5748a0a9a535f78ea93b3c_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtNy0xLTEtMA_47336823-e999-4ce8-93c1-3350157f1709">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631b85d3d7a44f58b74177a695ee880f_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtOS0xLTEtMA_fd4c5d63-7ab7-4148-b27a-0ca7b53d270b">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e80c1e64b24bea81b052f8f6a31353_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTEtMS0xLTA_20e76143-2b2d-4ec1-ab4a-44bd3492f992">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1bb093533b64c6c9ff9dafcf60f4ee1_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTMtMS0xLTA_586b6705-bb7d-4acc-9953-94efa5a75192">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe47ce5722b844be8d813eb70e594427_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTUtMS0xLTA_e5abe198-beb0-4379-a769-8dffe1ce0162">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85247bb365e149738ac7c734ad073fcb_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTctMS0xLTA_ccb2117e-4182-4a11-9c40-3b72ed54a6e0">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccdda557d4de4ed7b963da933bc6d89c_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTktMS0xLTA_57e015f7-982e-4e45-82e5-3e474dd5de45">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a45b54cb929479b91a5036c365ad2d1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMjEtMS0xLTA_6ef1bf12-9a96-4414-bcdd-86289be623ff">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf194fe2ef394a6d8fb6776943995e44_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMjMtMS0xLTA_d2d80cad-0b33-4ca5-94c4-4c313c8bf926">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd2fbab6f9043ddb7f5562393c06341_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMS0xLTEtMA_d35602b1-1bf6-4089-9c7d-89c89b9c1e42">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1930b8b6109e4cea903f59042c7e749b_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMy0xLTEtMA_bdd047c2-0b3a-4922-a059-ded24ea393e7">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed7a671edaf49edad215de41a079a58_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktNS0xLTEtMA_e8ae2187-a4c3-4fdc-ba50-e6760ab85740">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a4a0980d7e40e4be58e702f91aab82_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktNy0xLTEtMA_6a67b379-2c5e-4345-8210-61c16518a084">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief202939785e4d1fbd2e37bcca814959_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktOS0xLTEtMA_7eb11ce3-e9c1-4a81-9625-39f292c5d056">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba9f4d9097a44d18897c5e28a6e2be16_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTEtMS0xLTA_0729d26a-a122-493b-aa9b-23526447029a">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic824da0674df49ef92b0f0f79ed94902_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTMtMS0xLTA_410c114b-3ef6-4798-be55-155e94d6b87e">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddc6db0368f41c29f507c8f2fe146ad_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTUtMS0xLTA_7cda9a6f-4545-4326-9d34-2384e0521671">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d21dbdf0f84c0d8dcbb85d77cda350_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTctMS0xLTA_bbf463d6-fd14-40b3-8312-9fa9be2ff1d7">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb259bf8f6774eab95195ce94daa4d29_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTktMS0xLTA_d7b50f49-81b0-4530-8e86-52f51c5ae679">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60073e1f170740a18f008719f2754f25_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMjEtMS0xLTA_944de955-a5ea-44f4-8c4a-b15a0c1f4d5c">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdf03e64d0c4fddbadaa8c893893a20_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMjMtMS0xLTA_8fe6f1f8-8ccc-48a7-acaa-94ffb858d137">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b602e80983f48678ff06480b5a96fc6_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMS0xLTEtMA_c6202e5a-4add-45f4-80ef-7dfa44f7dfba">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i319f3974785d4167937eccdebe28675c_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMy0xLTEtMA_3b7cc563-be5c-4fad-b894-028e3cf93096">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636d30541f2d41c1b70a178f58cf65e9_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtNS0xLTEtMA_a6cc989d-21dd-4922-82a2-c69acfdc822d">1,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3add7668e892473ebd440941e4e6ff61_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtNy0xLTEtMA_63347877-2263-43eb-a401-c1cf06735039">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4f8e164ae7418cb04b0ea9679efe3e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtOS0xLTEtMA_c0e470d3-1ddf-48a0-95fc-844cbf241704">804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb109d299f6434dba3b52e63f9ea583_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTEtMS0xLTA_ce6e322c-c5e0-4da2-adcb-f3f4ce9afa10">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd5b2fc3a6c4e7487aa809e527b4eb1_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTMtMS0xLTA_f3e76621-7b0b-446e-89ab-49fed3873633">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819e259a8f8545249f0f53c7bf645645_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTUtMS0xLTA_853a6b96-0918-4c45-82cd-ac2a3cb6de4a">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id642fa8a9a20492f96aadcfe08e8c96b_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTctMS0xLTA_4754fbf4-b1ef-4f0f-b6ab-2f85f0290749">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99a0a14797f94d938261561386085f3e_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTktMS0xLTA_c3632fbf-a7eb-4535-8e99-816f471b9bd2">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0134b6331943ce82d4a3f44a0afd52_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMjEtMS0xLTA_59bff052-e120-4db8-936d-9a6ee2d3c70e">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1618964a1d4460d94d2b4f7ca640620_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMjMtMS0xLTA_94bac946-4665-4de5-a344-c74f48cb9473">3,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3af3901704424498cbb93a1bd47e45_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMS0xLTEtMA_d314e0e6-2373-40a8-a82f-862ca3dfb62c">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69b42b66ea64f81bc571b5e136a6b1e_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMy0xLTEtMA_17021d8e-b82f-45e3-bb47-911af08a1560">6,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtNS0xLTEtMA_174ffd37-c856-47ce-9ba4-44ad81be0b1c">11,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a38b0abb2d475ea621d0cb55cade32_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtNy0xLTEtMA_6bb713a7-9ad5-484e-8438-d4aac33104ef">5,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf8ba8b236c94262b8730ba51f7dc42a_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtOS0xLTEtMA_b37352db-5cc2-49e4-832c-cdfebd90c0e5">5,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728acb79d00420087a90f15524df617_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTEtMS0xLTA_d30aa528-8b66-479e-b524-2d10739d2ef5">11,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57045208e33461c96ad659d41f00462_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTMtMS0xLTA_9cb003b1-c49a-4e48-9f61-b7a7e8d4c946">14,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba969a5c23b6451cbeefa5426f1e393f_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTUtMS0xLTA_2e4d5904-3b6e-452a-bc69-8e3216d60511">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTctMS0xLTA_84770b44-70bf-49a5-912e-1378a1f22bb7">31,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5946b43768450782f6246b122b119f_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTktMS0xLTA_c823fa19-9184-40fc-8d01-92f73160acf4">14,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5473f1dea7542f691d2d95c97cad854_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMjEtMS0xLTA_12175fed-ddca-4552-aca6-54b8f0b6c6a6">17,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMjMtMS0xLTA_1a0acf3e-ac0f-475c-8da7-d066431bb4fe">31,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8aaf2b2de2044518a3ec564ba88f75e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMS0xLTEtMA_3e8212af-0a4a-4b43-8e9b-4ffe3512af99">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94420b005aa4e66b856a2ff67bf8c89_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMy0xLTEtMA_8ad08e04-b156-48da-a6f0-8549737e6d77">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699b95b4f1f44764b9ba3bd58279cc61_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtNS0xLTEtMA_2b249f2f-7266-4bef-90b7-84acb0238e20">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dc35669ee24101a2c1185b33f55579_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtNy0xLTEtMA_cf57478a-b51b-49e5-a001-7867228d5a9c">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1ba7ff21103477bbabb92b26c7b3364_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtOS0xLTEtMA_6fe0b167-4312-4729-b786-072409653493">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a279b2b6514d2192430c67323a7e85_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTEtMS0xLTA_87d42971-cf1b-46c7-8bce-3d33628896d3">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b5f9cabdb9941e7a863c97299c00368_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTMtMS0xLTA_d2788443-e428-4023-94be-f27674d56f2d">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a57f86aa38f484f8aafcb6f09735cfe_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTUtMS0xLTA_1be3253b-bc93-44f8-a36c-8243e9c313e9">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eff7b7cb796442c9f4d72037c21fc95_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTctMS0xLTA_e263d73d-395b-4370-b532-baeea9e7c9f6">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6983c97c98d42fb96684499a02a239b_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTktMS0xLTA_4c74cf73-e953-4b5f-88d5-3817a974d92e">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754f6fc9ad27497fa0cd1510ac8e8907_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMjEtMS0xLTA_bfc7da9b-70bf-4e05-8d63-a19c1ab94e68">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f3ee0e5454000a23a20f0cd994598_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMjMtMS0xLTA_ee3d7884-6b66-481c-8ec4-3c264ab4debd">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d6027f193497da031fa27687560ae_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMS0xLTEtMA_34cc5a98-7174-4ef8-9fc5-a054bedf992f">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d49a9dabac54fc597f022af9277e212_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMy0xLTEtMA_20067a46-39cb-47e4-bb66-85dbe3affe5c">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3a784d71f1c4eefad36065887fc2930_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtNS0xLTEtMA_792a8dfa-20f4-419f-a188-aa54560b1e96">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic534fa3517b64854a0401aca08abad91_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtNy0xLTEtMA_e6a4e01e-89cb-4eca-9af4-fa5664c4b768">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cc9e5ed0ff4a02b7d86616c322d0aa_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtOS0xLTEtMA_d4659449-6ddd-4863-a231-82e72bca4b32">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9c7f8333b0450f87749a200192587e_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTEtMS0xLTA_dbe686a7-0f6d-48e8-9d2b-f7cbf380515e">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a6c4a6b6894cda952479c46d393577_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTMtMS0xLTA_386a091e-b7b8-42f3-9e3a-74c965b677cd">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3207dac346430d8a41e7dc3467d758_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTUtMS0xLTA_8e762d9b-d484-4812-8a2b-620e9b2d2c90">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd61a490327b40cfb9292092cfdc5ac4_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTctMS0xLTA_d922bd04-df90-4cd5-a726-3e5a69abd1a7">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeeb2222d43c4f96aa888a009b82082d_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTktMS0xLTA_8b6872f8-ba41-48f7-a78d-830f5a37cf85">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa7236576c74fcfb7383ec2acb28be4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMjEtMS0xLTA_f694e4c6-0458-479e-a24e-842e24faded6">704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe85f304c00147af96a365f14c8d9c30_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMjMtMS0xLTA_5766baac-620a-478f-b167-abba67fb9093">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e40ead15e764c9889121bf33547189b_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMS0xLTEtMA_856c10ce-5f0b-4ef1-987e-221ffbf44d99">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e37194dc584ce0b830f6a8b322858e_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMy0xLTEtMA_0c63db6b-163f-4eee-b61f-ed3dee4749fd">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtNS0xLTEtMA_4b718314-ff60-4c3f-b7a7-caf2645c3bfd">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14106dbbbd7f48158d4a3e3068314a55_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtNy0xLTEtMA_7db31a2e-cee0-44ec-9f5e-48f894d950a3">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae4011fe77ab4e7eaa38d98a880134fb_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtOS0xLTEtMA_11f67612-f352-4c3c-ac12-75c6ededd98e">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTEtMS0xLTA_c4087f50-560b-4b73-a722-8d8d5394f928">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d0ea546af24a87a6255e69c9be826a_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTMtMS0xLTA_dd08fe9d-8c0b-4dfe-82c0-59a58fca27a4">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdba0b24408b477dbd1da28288ef0b28_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTUtMS0xLTA_dc12d7fd-ff91-4a66-bf8f-41a6cfd16efe">2,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1ada048a5848499745516122810eab_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTctMS0xLTA_6f12b11c-6aaa-418f-a213-fe13dd0dd006">3,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc62432f3542449c81953affd9de22e1_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTktMS0xLTA_ab03b656-d254-4d91-be7c-d71cdf9b901b">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdebf9d8834484a80089286c5c652a8_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMjEtMS0xLTA_362546a6-5fba-4c4d-bff5-982943640493">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMjMtMS0xLTA_967e4665-d405-4fa0-a14a-7fd15f2c63b1">3,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0e6a497660484fb717730ec1682382_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMS0xLTEtMA_5a0aaad9-4a39-486d-8492-b531974bdbea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6047455c7c64d9f874b87a52288b80e_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMy0xLTEtMA_7bd9256a-4708-483b-bb03-5651af3a0a30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtNS0xLTEtMA_9e679b60-3955-4be3-95c0-2126515e2bb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbedce779e14d0aa2f39e6a7b145b9d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtNy0xLTEtMA_49fbc453-8bfb-4641-bfde-1e93752de38e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898e69e9e3184245a88cddf0a47d6dc5_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtOS0xLTEtMA_ef836a6a-162a-4603-adf9-688688da0158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTEtMS0xLTA_2923eb81-52bf-445d-9001-fc55e8ac15ce">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic000af4b0c4c4a2fadd5664d561dafbe_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTMtMS0xLTA_975eb257-58fc-4c88-a457-d258ac10e4f6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09c33cccd764e8993469adf4635a214_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTUtMS0xLTA_453d6b31-419a-4589-bacd-dce470b2a87b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTctMS0xLTA_a0c88cf6-d262-4af3-a9d9-5c673e48cc38">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2365ecc7f5a942f28ba80cc309ae1981_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTktMS0xLTA_8595d113-74ee-4e50-abf9-b03baccc5c43">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id893aa0127934f2d91eecbde06753def_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMjEtMS0xLTA_4a58c8a0-5f50-4cdb-b076-71a57c6ca263">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMjMtMS0xLTA_cc400680-b4a4-4ab6-ba64-457619465843">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e15c24b2824478a886c6474a727dd9_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMS0xLTEtMA_d1298c8a-ac65-4fbe-8875-a255d043b225">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2268e80ec95d4d869afeccbe9a5d42b5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMy0xLTEtMA_2e66778b-78bc-4780-8522-8d422729b703">6,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctNS0xLTEtMA_0e1d1727-fdca-494e-93f5-9745dc0847fe">12,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a5dbad6f9e4534bd2dae1d741c29b0_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctNy0xLTEtMA_7ebf606b-f8c8-4899-b2c6-4f470ea0c771">5,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2d0f03f76040508bfb37e1f86e3a44_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctOS0xLTEtMA_7a1692b9-7460-49d6-8d9f-9b62d9fa579e">6,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTEtMS0xLTA_fed8fa7a-3eff-4b29-8267-4d3c26f44608">12,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d1cf04d3654121bb1372860aad23cd_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTMtMS0xLTA_8b60a443-f9b1-47ec-b1ff-87f3324f9212">15,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71294026dc2b41a6b110370ac311ccef_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTUtMS0xLTA_c5abe353-0b07-44a2-8acb-3d45b8a0a82b">19,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTctMS0xLTA_b7a551b4-c4a1-4f5b-857b-102a5222399b">35,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf593e2d5525476f9946cba41a11778a_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTktMS0xLTA_e7a9a495-b631-4aa4-b8b0-93bbd5b9d4dc">15,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8d4c2f684a0daf26c38edd0fc54e_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMjEtMS0xLTA_30a986bb-b544-4c94-a3c4-c6b35fd34875">19,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMjMtMS0xLTA_9b1f16c0-4b5f-4650-a1fa-07c5c8575a65">34,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie753576e2fbc401991ed4e99717613ba_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMS0xLTEtMA_97511fa0-5848-42d0-a375-b64a6c79624c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide9e8a73d73d4f3a9142b2330c6f27fe_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMy0xLTEtMA_6aa777cb-34c7-4030-ba4a-8fcfa212263d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtNS0xLTEtMA_dbe01c1d-6342-4d17-bd6f-da46cea8f062">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4500010fb54d02ae13949698b9b8c4_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtNy0xLTEtMA_3a15beca-6b8e-4827-b0e8-61b345134ce9">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a40509dbf045e4ada553d6fac4e6eb_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtOS0xLTEtMA_e115a268-0fca-48ba-950a-e28d8dfdd7c1">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTEtMS0xLTA_c2de48e4-ef94-4c94-8c8b-6a603d5b425d">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i581246c6bfe2404db7120fbc4f4dee00_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTMtMS0xLTA_0ad8aebc-de46-422f-b8d5-50dadf1585f5">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fb5894e97f4df3bc23850e83b77053_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTUtMS0xLTA_6bf5326a-9b73-43ae-ac87-3510fa2b5d9f">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1463025af91424094e317c427bd8c0a_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTctMS0xLTA_0bb873d9-d654-4aeb-bf4d-deaf697f801e">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0766d9bdbbc4e00bec07a37b42563bb_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTktMS0xLTA_062a40bb-dbc4-4d50-9d17-539ed9618d5f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6eae77f55e94cc2b2c83b0c7dc60c51_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMjEtMS0xLTA_1f499fe8-137c-4ba3-91f5-91d9e726d956">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMjMtMS0xLTA_d28ad760-6981-4a19-bc8f-0b41ccd5e583">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMS0xLTEtMA_2c1d50ba-0e19-41ae-a1ba-85b98f88b206">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c2c4a4b7be4001b1d581d890f1c1bc_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMy0xLTEtMA_ff4d3c8e-1862-487b-ac65-5bb7150558ec">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktNS0xLTEtMA_e256ac33-007e-4e6b-a857-b514118a34f8">12,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be56294e35345518657c9cb1c795a55_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktNy0xLTEtMA_cdea033a-4be9-46ad-bb8a-5624033ad6a6">5,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5373290982d4d9790e6f6de2c301cb7_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktOS0xLTEtMA_1a02cf8a-21ac-4e2b-aa70-c8a3d4bf4f31">6,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTEtMS0xLTA_b411f332-1170-415c-82fa-120a17ef48ec">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTMtMS0xLTA_b4b1ce2c-fe11-438c-8fd5-57e22440b982">15,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd74fd1d348488a9909e5be2e21240e_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTUtMS0xLTA_8dd88ea1-2a60-41ad-a7cf-b0eb7f4345dc">20,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTctMS0xLTA_69656a90-cab1-4972-aa02-f10324f0570e">35,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTktMS0xLTA_0afb6dd5-6b68-478a-bfeb-24024b67f401">15,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968a3319d5e411c8e90433cc1e6dfee_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMjEtMS0xLTA_11e436b8-57dc-4971-a6c7-eb124f0a695d">19,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMjMtMS0xLTA_18c1827f-098d-4041-ac09-67d49689162e">34,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i3ee43632127541ecab4f1f5c04255b11" continuedAt="id194f8c74b21484a979da1a88bc6c37c">(5)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="id194f8c74b21484a979da1a88bc6c37c">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 31 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="if8f82c4fbf734ea49952a93e30061ddc"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $<ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzgyNQ_2acf2114-2be0-40ca-8919-fb275c9268d2">3.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzgzMg_e8b0f0a2-256d-46a2-8ee0-8155d2cec8d1">3.0</ix:nonFraction> billion for the three months ended September&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzg5MQ_b1c73561-2ab2-43ca-904c-46c09b952665">9.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-8" format="ixt:numdotdecimal" name="mrk:SalesDiscounts" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzg5OA_4d5396de-f969-44e6-a117-72844ac3459c">8.6</ix:nonFraction> billion for the nine months ended September&#160;30, 2020 and 2019, respectively. </span></div><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTc5OQ_b48886fd-b372-4642-a029-92b0810b1514" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi0xLTEtMS0w_50ddb4c3-7725-4664-9e0f-9d0e200eaa8d">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be56294e35345518657c9cb1c795a55_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi0zLTEtMS0w_3a51cb8b-22cc-49da-9bba-36e1c06e4e52">5,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi01LTEtMS0w_7662f4bb-91da-47cf-9acb-f8884325da71">15,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi03LTEtMS0w_893362a7-de20-4f62-9626-cb8113df0660">15,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy0xLTEtMS0w_47be21be-0fff-43de-b188-9235388d5601">3,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a8038d02e4f88a246aa02f656695a_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy0zLTEtMS0w_63a7b747-ac2f-470f-b946-653f9247d9eb">3,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f058de6b2243f9becd32481d9afbbe_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy01LTEtMS0w_dcc2c4e3-789f-42ec-8509-ee8540201d10">10,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia932a81be775481f98c6d46c74fc889e_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy03LTEtMS0w_6cbc687d-86fd-49aa-b3d0-599595112432">9,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb50c2f22f44b9c87ff52bc490d1857_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC0xLTEtMS0w_a0903f7f-51a3-484d-a0d2-bccb11980cbe">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85051d25a924f2190907c50f47325ec_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC0zLTEtMS0w_5deaf5b2-9a13-4c67-8539-59de0ed3085b">914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313cf220e7c04c1a8ad44c9b6fdcbed0_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC01LTEtMS0w_c3630dae-09c7-4613-8925-02655f42dd9a">2,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a2befecfbb4aa5bc67a5cf1e38775f_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC03LTEtMS0w_0165e1b2-b616-4070-82ed-638d3f6fef2c">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b97ea09a131441e902cb9300382361f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS0xLTEtMS0w_8dbc33c1-8cf1-408c-a108-53c5cfcad278">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d79fe35117f4651b248b578edc99dce_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS0zLTEtMS0w_44d5d855-7084-4099-a715-8c9812ec7b96">919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd022943eb58411bbd1ed2c225198ac6_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS01LTEtMS0w_6f7f9c3e-8fb8-4eec-9a07-ccbb5e656f62">2,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c4d3fc287a432a9fd94239cf8da2e4_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS03LTEtMS0w_b1d8c1d4-8fb5-4dc1-80b4-c630d14a8eb6">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1349039c214a1ab7b78b435fbbdb71_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi0xLTEtMS0w_c074d8fb-ed9c-4f25-81c1-43743995f953">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a68094581a24c318a5e928a8ef2586d_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi0zLTEtMS0w_d352dd64-d7c0-4f80-9750-31218a8b8b0a">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9d51c6c5d64a0ba83ede5553c4da40_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi01LTEtMS0w_13130b25-b079-4e12-84ed-0d4440120547">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6360f4861f46ebbb62566ea24fd0ea_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi03LTEtMS0w_d32477a4-916e-421d-8394-8b2d6f7c05d9">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100e2f176d6e43288c7996c8bb790ee0_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy0xLTEtMS0w_264f38ed-3344-42d0-94e2-4ee0131cae03">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7dcfda74e184dd19aa1034852473ac0_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy0zLTEtMS0w_92b54815-91ce-4e2f-83eb-cc5d763403ba">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71cc45c9f8b14d8195ccd2d6963f6085_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy01LTEtMS0w_f7ee51ef-c832-4dad-a4ab-294b3d9edc3f">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1d1ba55c914a7b8e44658d9480b9dd_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy03LTEtMS0w_ba007942-db46-4fb2-afbd-3ce02ec9e06f">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eee42c966664f4e9a6f8dda9caa4b70_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC0xLTEtMS0w_dad31403-3d63-4a35-aab4-8b6fa2456ea7">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c9af3f42bbe446f8bc0971d7ea5b622_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC0zLTEtMS0w_94eb4c17-1d46-4fb0-afad-d05b277d80ef">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c2156786fb46cfa1e5ff1a41f7d595_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC01LTEtMS0w_66226a1d-fd1d-4c76-b598-ff168cfeb604">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2a87acce6704921ba325076af735562_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC03LTEtMS0w_0bcccb1e-d170-4a5d-ad53-e9561a526949">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS0xLTEtMS0w_fcd771bf-69ac-4b0b-b070-152022500711">12,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS0zLTEtMS0w_d3f93934-1c3a-4551-8a6d-68bc2a15114a">12,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS01LTEtMS0w_13a3fe6a-ad6a-41e5-a534-57fc43a61620">35,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS03LTEtMS0w_7cdc3bc6-46e8-4015-a8e0-3943db2772e0">34,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTgzMA_34593baa-178f-42c6-be67-1137c285448f" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy0xLTEtMS0w_ca77c87f-7cf3-4164-a5ae-8c90d4c81b34">7,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9728acb79d00420087a90f15524df617_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy0zLTEtMS0w_a635d160-98eb-4e55-94fb-d7241ab8ad7f">7,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy01LTEtMS0w_929b375f-ea7a-45a7-891a-042c6be43865">22,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy03LTEtMS0w_8390832b-30b5-4337-942c-b9529b1e3b93">21,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC0xLTEtMS0w_3db362f7-03f9-4978-bee6-debd9b8a50e3">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC0zLTEtMS0w_9be7379d-770e-4ef9-9069-e95f3144d1ee">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1ada048a5848499745516122810eab_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC01LTEtMS0w_7b9019c8-f1e0-4a76-a6dd-8779272764e2">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC03LTEtMS0w_d51d494e-3ecc-4e79-b3ad-1f803713d467">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS0xLTEtMS0w_725dbead-9fa7-4eeb-9f7f-b0fe54adcbb0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS0zLTEtMS0w_596b4d35-ec9b-41d1-97ee-8ee6a7a86caf">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS01LTEtMS0w_6e555a35-b3dd-45ae-8749-21041904b880">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS03LTEtMS0w_323e6177-175a-40b7-9e41-fb31b4cd27b3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi0xLTEtMS0w_c719a1c8-9bf2-4fe7-b254-a53f0e248ffb">8,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi0zLTEtMS0w_804d86de-183a-40ca-b5df-6a29c63786a9">8,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi01LTEtMS0w_a24fb292-6ca5-435f-af1a-143c590b8e46">23,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi03LTEtMS0w_c9d57c0e-dce4-48ac-9008-e116ef6ed371">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy0xLTEtMS0w_d87de558-4f6f-4698-a37b-b15e674dd5f5">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy0zLTEtMS0w_663bbe2c-940a-4309-816f-0338abbcde12">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1463025af91424094e317c427bd8c0a_D20200101-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy01LTEtMS0w_c33ab30e-0579-4797-a5c5-c40e98ee7356">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy03LTEtMS0w_c7a8700b-6cf6-4604-825c-3764fbe49ad0">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS0xLTEtMS0w_d25fbec6-1d7d-45ef-adec-182a69f6a712">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS0zLTEtMS0w_46c79e96-6520-4f8d-80ee-7f981700f493">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS01LTEtMS0w_30ddcbae-33ea-4a20-b1eb-09e58b6bfc70">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS03LTEtMS0w_beace086-41b5-4b86-9ac1-a6748ad4c353">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtMS0xLTEtMA_1f4a8601-2f32-4e5f-a91e-b4ecd17e9be4">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtMy0xLTEtMA_8c20571b-c2b8-4d43-9916-59b2aef8da81">231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtNS0xLTEtMA_17675f14-2dd1-466c-9f1e-0f5e3c217d7f">624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtNy0xLTEtMA_09a8f69a-c975-4f3c-bc5d-1b56cad0d108">674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtMS0xLTEtMA_5e06c582-ef5b-4cfc-b4b9-21be813e0916">395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtMy0xLTEtMA_5394fcf8-c41a-4460-9856-6a413b6939e8">382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtNS0xLTEtMA_6faed7d9-505a-457d-b162-1a4f528823a6">1,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtNy0xLTEtMA_c65b9702-9d81-4c09-891e-23734c0e5c63">1,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItMS0xLTEtMA_e8c2a129-e0f8-4d66-9b77-bd0676d21f87">3,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItMy0xLTEtMA_0640ffb3-9361-49ee-8f77-3e09b1e951a2">3,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItNS0xLTEtMA_65e64747-9ab7-4cbf-8680-d4d6c5908b86">7,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItNy0xLTEtMA_d4b091bb-9441-44a2-b9ff-2ec98042df5e">7,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtMS0xLTEtMA_4217f026-b7f9-4d5a-99ce-e62406dbe60c">285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtMy0xLTEtMA_73378f90-e6d1-4211-a897-a1961400c74f">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtNS0xLTEtMA_10ee3f89-52b3-4558-8e55-1a9d8317ac1e">879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:AmortizationOfPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtNy0xLTEtMA_316697c1-b412-48b6-92bb-650070d6a735">1,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtMS0xLTEtMA_7d0d4f6d-e3c0-4086-a79c-e91733c9f586">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtMy0xLTEtMA_8b0458ec-891a-42cf-9bf8-4f455d031a74">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtNS0xLTEtMA_731b1983-6301-4ff1-9184-bf7daadc7442">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtNy0xLTEtMA_db40f91b-909f-4845-800b-b4acafa459c8">444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtMS0xLTEtMA_496c8bb3-4c3e-481d-83e2-e42a4879aed2">724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtMy0xLTEtMA_60bb5b69-73b7-49ab-b644-8e21e1a8f671">1,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtNS0xLTEtMA_fb7903c2-4508-45bd-a6dd-de4f33aa0f5d">2,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtNy0xLTEtMA_ad7b1ffa-d1f0-455f-917d-3c9f76f754c6">4,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtMS0xLTEtMA_e8252f5f-d25c-4db8-a97f-11dfac09a853">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtMy0xLTEtMA_15e9e88b-54c6-414b-801f-4968fffb1b15">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtNS0xLTEtMA_fd7f1c3a-7707-4621-88d9-fc4443a56c79">10,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtNy0xLTEtMA_1edac6c3-fdd9-4822-be3d-e8dbb2583dbb">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 32 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i67ef4e29db364327800e42a94e43496a_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into New Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ezetimibe and simvastatin), as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#8217;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#8217;s consolidated financial statements.</span></div><div id="i67ef4e29db364327800e42a94e43496a_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management </span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Merck announced that Dr. Roger M. Perlmutter will be retiring as Executive Vice President and President, Merck Research Laboratories (MRL). Dr. Perlmutter will be succeeded by Dr. Dean Y. Li, effective January 1, 2021. Dr. Perlmutter will remain as Non-Executive Chairman, MRL through June 30, 2021 to facilitate a seamless transition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of significant 2020 business development activity. See Note 2 to the condensed consolidated financial statements for additional information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio&#8217;s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase&#160;1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. The closing of the equity investment occurred in October 2020. Seagen is also eligible to receive future contingent milestone payments dependent upon the achievement of certain developmental and sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million. Seagen is also eligible to receive future contingent regulatory approval milestones and will receive tiered royalties on sales of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;256&#160;million ($302&#160;million). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 33 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments dependent upon the achievement of certain developmental, regulatory approval and commercial milestones. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19, which is currently in Phase 1 clinical development. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments dependent upon the achievement of certain sales-based milestones, as well as royalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, for total consideration of $2.7 billion. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Coronavirus Disease 2019 (COVID-19) Update</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of vaccine and antiviral approaches, and supporting health care providers and Merck&#8217;s communities. Although COVID-19-related disruptions to patients&#8217; ability to access health care providers negatively affected results for the third quarter and first nine months of 2020, Merck remains confident in the fundamental underlying demand for its products and its prospects for long-term growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, the negative impact of the COVID-19 pandemic to Merck&#8217;s Pharmaceutical sales was estimated to be approximately $475 million. The negative impact to Animal Health sales was immaterial. The negative impact to sales in the first nine months of 2020 was approximately $2.0 billion for the Pharmaceutical segment and $50 million for the Animal Health segment. Merck assumes that the majority of the negative impact from the COVID-19 pandemic occurred in the second quarter of 2020. However, the Company expects some residual negative impacts in the fourth quarter, largely in Europe and certain emerging markets. In addition, the phasing of the recovery of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9  (Human Papillomavirus 9-valent Vaccine, Recombinant) demand is slower than originally anticipated, in particular in the United States due to lower back-to-school demand. Accordingly, for the full-year 2020, including the impact for the first nine months, Merck expects an unfavorable impact to sales of approximately $2.35 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $2.3 billion for Pharmaceutical revenue and approximately $50 million for Animal Health revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roughly two-thirds of Merck&#8217;s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company&#8217;s human health products, in particular for its vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, as well as for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant). Access to healthcare providers remains reduced, although improved from the second quarter. Merck anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in elective surgeries negatively affected the demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection in the year-to-date period. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent) increased due to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were positively affected in the third quarter and first nine months of 2020 by approximately $115 million and $540 million, respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. For the full-year 2020, Merck expects a net favorable impact to operating expenses of approximately $625 million reflecting continued lower spending due to the COVID-19 pandemic, partially offset by spending on COVID-19-related antiviral and vaccine research programs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. In the United States, pricing pressure continues on many of the Company&#8217;s products. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s revenue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 34 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance in the first nine months of 2020 was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.</span></div><div id="i67ef4e29db364327800e42a94e43496a_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales were $12.6 billion and $35.5 billion for the third quarter and first nine months of 2020, respectively, representing growth of 1% compared with the same prior year periods. Sales growth in both periods was primarily driven by higher sales in the oncology franchise reflecting strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as increased alliance revenue from Lynparza (olaparib) and Lenvima (lenvatinib). Also contributing to revenue growth were higher sales of certain vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, and higher sales of certain hospital acute care products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(letermovir) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Higher sales of Animal Health products also contributed to revenue growth in the third quarter and first nine months of 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales growth in both periods was partially offset by the ongoing effects of generic competition for certain products including women&#8217;s health product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etonogestrel/ethinyl estradiol vaginal ring), hospital acute care product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (posaconazole), oncology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (aprepitant)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fosaprepitant dimeglumine) for Injection, cardiovascular products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as products within the diversified brands franchise. The diversified brands franchise includes certain products that are approaching the expiration of their marketing exclusivity or that are no longer protected by patents in developed markets. Lower sales of certain vaccines including human papillomavirus (HPV) vaccines </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6,11,16 and 18] Vaccine, Recombinant)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 and pediatric vaccines </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), as well as lower sales of virology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elbasvir and grazoprevir) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (raltegravir) also partially offset revenue growth in the third quarter and first nine months of 2020. As discussed above, the COVID-19 pandemic unfavorably affected sales in the third quarter and first nine months of 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the condensed consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="i67ef4e29db364327800e42a94e43496a_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lenvima </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, primary mediastinal large B-cell lymphoma (PMBCL), and urothelial carcinoma. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with axitinib for renal cell carcinoma (RCC), and in combination with Lenvima for endometrial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 35 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carcinoma. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types (see &#8220;Research and Development&#8221; below). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the U.S. Food and Drug Administration (FDA) approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of certain patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) based on the results of the KEYNOTE-057 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">across all adult indications, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg every three weeks (Q3W).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA granted accelerated approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) (&#8805;10 mutations/megabase) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options based in part on the results of the KEYNOTE-158 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2020, the FDA approved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy both for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation based on data from the Phase 2 KEYNOTE-629 trial and </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the first-line treatment of patients with unresectable or metastatic MSI-H or mismatch repair deficient colorectal cancer based on results from the Phase 3 KEYNOTE-177 trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved an expanded label for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy for the treatment of adult patients with relapsed or refractory cHL. The approval is based on results from the Phase 3 KEYNOTE-204 trial in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly reduced the risk of disease progression or death compared to brentuximab vedotin. The FDA also approved an updated pediatric indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of pediatric patients with refractory cHL or cHL that has relapsed after two or more lines of therapy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was previously approved under the FDA&#8217;s accelerated approval process for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy based on data from the KEYNOTE-087 trial. In accordance with accelerated approval regulations, continued approval was contingent upon verification and description of clinical benefit; these accelerated approval requirements have been fulfilled with the data from KEYNOTE-204.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the National Medical Products Administration (NMPA) in China as monotherapy for the second-line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (Combined Positive Score [CPS] &#8805;10). This indication was granted based on the Phase 3 KEYNOTE-181 trial, including data from an extension of the global study in Chinese patients. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) as monotherapy for the treatment of patients whose tumors are PD-L1-positive, and have radically unresectable, advanced or recurrent ESCC who have progressed after chemotherapy. The approval was based on results from the Phase 3 KEYNOTE-181 trial. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved by the Japan PMDA for use at an additional recommended dosage of 400 mg Q6W, including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg Q3W. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 21% and 30% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with multiple new indications globally, although the COVID-19 pandemic had a dampening effect on growing demand. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with uptake in the RCC, adjuvant melanoma, HNSCC, bladder cancer and endometrial carcinoma indications. Uptake of the Q6W dosing regimen in the United States benefited sales in 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in international markets was driven by continued uptake in approved indications, particularly in the European Union (EU). Sales growth in the third quarter and first nine months of 2020 was partially offset by declines in Japan due to pricing. Pursuant to a re-pricing rule, the Japanese government reduced the price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by 17.5% effective February 2020. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza increased 59% and 66% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was largely driven by continued uptake across the multiple approved indications in the United States, the EU and China. In May 2020, the FDA approved Lynparza in combination with bevacizumab as a first-line maintenance treatment of certain adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy based on the results from the Phase 3 PAOLA-1 trial. In November 2020, Lynparza was </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 36 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved in the EU for the maintenance treatment of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or parital response following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a breast cancer susceptibility gene 1/2 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2) mutation and/or genomic instability based on the results from the PAOLA-1 trial. Also in May 2020, the FDA approved Lynparza for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone based on positive results from the Phase 3 PROfound trial. In November 2020, Lynparza was approved in the EU as monotherapy for the treatment of adult patients with mCRPC and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2 mutations (germline and/or somatic) who have progressed following a prior therapy that included a new hormonal agent based on the PROfound trial. In July 2020, Lynparza was approved in the EU as a monotherapy for the maintenance treatment of adult patients with germline&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen based on the results from the Phase 3 POLO trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew 30% and 50% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was primarily due to higher demand in the United States, China and the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the prevention of chemotherapy-induced nausea and vomiting, declined 60% and 66% in the third quarter and first nine months of 2020, respectively. The sales declines were primarily driven by lower demand and pricing in the United States due to generic competition, including recent generic competition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection following U.S. patent expiry in September 2019. Also contributing to the sales declines in the third quarter and first nine months of 2020 was lower demand in the EU as a result of generic competition for the oral formulation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following loss of market exclusivity in May 2019. U.S. market exclusivity for the oral formulation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> previously expired in 2015. Generic competition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection in Japan following loss of exclusivity also contributed to the sales declines in the third quarter and first nine months of 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection lost market exclusivity in major European markets in August 2020.&#160;The Company anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Injection in these markets will decline significantly in future periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA approved Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI&#8217;s Center for Cancer Research, Pediatric Oncology Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil 9</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, declined 10% and 3% in the third quarter and first nine months of 2020, respectively, primarily due to lower demand in the United States and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic, partially offset by higher volumes in China and in the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that in the fourth quarter of 2020 it will replenish the doses of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 borrowed from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile in the fourth quarter of 2019. The replenishment will result in the recognition of approximately $120 million in sales and a reversal of the related liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved an expanded indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. The oropharyngeal and head and neck </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 37 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancer indication was approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Silgard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 aqueous suspension for intramuscular injection syringes (recombinant adsorbed 9-valent Human Papillomavirus virus-like particles vaccine) were approved for use in women and girls by the Ministry of Health, Labor and Welfare in Japan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, declined 6% and 14% in the third quarter and first nine months of 2020, respectively, primarily due to lower demand in the United States resulting from the COVID-19 pandemic, partially offset by higher pricing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M&#8209;M&#8209;R&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II, a vaccine to help protect against measles, mumps and rubella, declined 35% in the first nine months of 2020 primarily driven by lower demand in the United States resulting from fewer measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic, partially offset by higher pricing. Additionally, the sales decline in the first nine months of 2020 reflects lower demand in Brazil.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaccine to help prevent chickenpox (varicella), declined 10% and 22% in the third quarter and first nine months of 2020, respectively. The sales declines reflect lower demand in the United States resulting from the COVID-19 pandemic, partially offset by higher pricing. The sales decline in the first nine months of 2020 was also attributable to lower government tenders in Brazil. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, grew 58% and 26% in the third quarter and first nine months of 2020, respectively, primarily due to higher volumes in the United States and in the EU attributable in part to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season. Higher pricing in the United States also contributed to sales growth in the third quarter and first nine months of 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 13% and 3% in the third quarter and first nine months of 2020, respectively, primarily attributable to higher demand in the United States. Fewer elective surgeries as a result of the COVID-19 pandemic unfavorably affected demand in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the prevention of invasive fungal infections, declined 55% and 56% in the third quarter and first nine months of 2020, respectively, primarily due to generic competition in the United States and in the EU. The patents that provided U.S.&#160;market exclusivity for certain forms of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> representing the majority of U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales expired in July 2019. Additionally, the patent for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in a number of major European markets in December 2019. Accordingly, the Company is experiencing volume and pricing declines in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in these markets as a result of generic competition and expects the declines to continue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 72% and 74% in the third quarter and first nine months of 2020, respectively, due to continued uptake since launch in the EU and in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cubicin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(daptomycin for injection), an I.V. antibiotic for complicated skin and skin structure infections or bacteremia when caused by designated susceptible organisms, declined 26% and 44% in the third quarter and first nine months of 2020, respectively, primarily due to ongoing generic competition in the EU and in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA approved a supplemental New Drug Application (NDA) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recarbrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by certain susceptible Gram-negative microorganisms. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) is indicated for the treatment of HABP/VABP caused by certain susceptible Gram-negative microorganisms, and for the treatment of certain complicated urinary tract and intra-abdominal infections. The COVID-19 pandemic is unfavorably affecting sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, particularly in the United States. An increased focus on more stringent cleaning protocols at hospitals, along with visitor restrictions, have reduced patients&#8217; exposure to developing HABP/</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 38 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VABP, resulting in a smaller population of patients that need to be treated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These factors resulted in lower cash flow forecasts for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, which constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset for impairment. Although the &#8220;step one&#8221; impairment test that was performed indicated that the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remains recoverable, in the event that these trends depress sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to a greater extent than anticipated by the Company, or in the event other circumstances arise that further reduce global cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company may record an intangible asset impairment charge in the future and such charge could be material. The carrying value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $2.2 billion at September 30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simponi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 2% in the first nine month of 2020 primarily driven by lower demand in the EU due to the uptake of biosimilars for a competing product, partially offset by the timing of shipments in Russia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 19% and 25% in the third quarter and first nine months of 2020, respectively, driven by ongoing biosimilar competition in the Company&#8217;s marketing territories in Europe. The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remicade</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virology</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 18% and 14% in the third quarter and first nine months of 2020, respectively, primarily driven by competitive pressure in the United States and in the EU, as well as the timing of shipments in Brazil.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zepatier</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 67% and 60% in the third quarter and first nine months of 2020, respectively, driven by lower demand globally due to competition and declining patient volumes, coupled with the impact of the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zetia/Vytorin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rosuzet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (marketed in most countries outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (marketed outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), medicines for lowering LDL cholesterol, declined 27% in the third quarter of 2020, primarily due to lower sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan. The patent that provided market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan expired in September 2019 and generic competition began in June 2020. Accordingly, the Company is experiencing a rapid and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 39 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial decline in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in Japan and expects the decline to continue. Higher demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l in China partially offset the sales decline in the third quarter of 2020. Combined global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 22% in the first nine months of 2020 primarily due to generic competition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan. The EU patents for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inegy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in April 2018 and April 2019, respectively. The sales decline in the first nine months of 2020 was also attributable to lower pricing following loss of exclusivity in Australia in 2018. Higher demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ezetrol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China partially offset the sales decline in the first nine months of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Atozet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe and atorvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, grew 14% and 23% in the third quarter and first nine months of 2020, respectively, primarily due to higher demand in most markets, particularly in the EU, Japan and other countries in the Asia Pacific region.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 3 to the condensed consolidated financial statements). Revenue from Adempas includes Merck&#8217;s share of profits from the sale of Adempas in Bayer&#8217;s marketing territories, which grew 67% and 50% in the third quarter and first nine months of 2020, respectively, as well as sales in Merck&#8217;s marketing territories, which declined 5% in the third quarter and grew 6% in the first nine months of 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCl), medicines that help lower blood sugar levels in adults with type 2 diabetes, grew 1% in the third quarter of 2020 driven primarily by higher demand in certain international markets, particularly in China, partially offset by continued pricing pressure in the United States. Global combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> declined 4% in the first nine months of 2020. The decline was primarily due to continued pricing pressure in the United States and lower demand in the EU, partially offset by higher demand in certain international markets, particularly in China. The Company expects U.S. pricing pressure to continue. The patents that provide market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States expire in July 2022 (although six-month pediatric exclusivity may extend this date). The patent that provides market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU expires in July 2022 (although pediatric exclusivity has recently been granted which may extend this date to September 2022 and the Company is applying in individual countries for the extensions). The supplementary patent certificate that provides market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the EU expires in April 2023. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after these patent expiries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Women&#8217;s Health&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a single-rod subdermal contraceptive implant, declined 5% in the third quarter of 2020 primarily driven by lower demand in Latin America. Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">declined 11% in the first nine months of 2020 primarily due to lower demand in the United States and in the EU resulting from the COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaginal contraceptive product, declined 76% and 74% in the third quarter and first nine months of 2020, respectively, due to generic competition in the United States. The patent that provided U.S. market exclusivity for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expired in April 2018 and generic competition began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales and expects the decline to continue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biosimilars</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 40 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2 overexpressing gastric cancer; and Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of certain inflammatory diseases. Merck&#8217;s commercialization territories under the agreement vary by product. Sales of biosimilars grew 45% and 20% in the third quarter and first nine months of 2020, respectively, primarily due to the launch of Ontruzant in Brazil in August 2020 and continued post-launch uptake of Renflexis in the United States and Canada. Sales growth in the first nine months of 2020 was partially offset by lower sales of Brenzys in Brazil.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the EC granted marketing authorization for Aybintio (bevacizumab) for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, NSCLC, advanced and/or metastatic RCC, epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer. An application seeking approval of Aybintio in the United States was filed in September 2019. </span></div><div id="i67ef4e29db364327800e42a94e43496a_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.959%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of livestock products grew 5% and 7% in the third quarter and first nine months of 2020, respectively, primarily driven by higher demand for ruminant, swine and poultry products. Sales growth in the first nine months of 2020 was also driven by the April 2019 acquisition of Antelliq Corporation (Antelliq) (see Note 2 to the condensed consolidated financial statements). Sales of companion animal products grew 17% in the third quarter of 2020 and 10% in the first nine months of 2020 primarily driven by higher demand for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner) line of products, as well as higher demand for companion animal vaccines. </span></div><div id="i67ef4e29db364327800e42a94e43496a_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,952&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,050&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Greater than 100%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales declined 13% and 5% in the third quarter and first nine months of 2020, respectively. Cost of sales includes the amortization of intangible assets recorded in connection with business acquisitions, which totaled $270 million and $320 million in the third quarter of 2020 and 2019, respectively, and $843 million and $1.1 billion in the first nine months of 2020 and 2019, respectively. Cost of sales also includes the amortization of amounts capitalized in connection with collaborations of $117 million and $81 million in the third quarter of 2020 and 2019, respectively, and $509 million and $307 million in the first nine months of 2020 and 2019, respectively. Additionally, costs include intangible asset impairment charges of $612 million and $693 million in the third quarter and first nine months of 2019, respectively, related to marketed products. The Company may recognize additional impairment charges in the future related to intangible assets that were measured at fair value and capitalized in connection with business acquisitions and such charges could be material. Also included in cost of sales are expenses associated with restructuring activities which amounted to $38 million and $62 million in the third quarter of 2020 and 2019, respectively, and $131 million and $161 million in the first nine months of 2020 and 2019, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 41 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was 72.3% in the third quarter of 2020 compared with 67.8% in the third quarter of 2019. The gross margin improvement reflects lower intangible asset impairment charges (noted above), the favorable effect of product mix and lower restructuring costs, partially offset by the unfavorable effects of pricing pressure, inventory write-offs and foreign exchange. Gross margin was 71.9% in the first nine months of 2020 compared with 70.1% in the first nine months of 2019. The gross margin improvement was primarily driven by lower impairment charges and amortization related to intangible assets (noted above), as well as the favorable effect of product mix and lower restructuring costs, partially offset by the unfavorable effects of pricing pressure, royalties, manufacturing variances, and inventory write-offs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses declined 5% and 4% in the third quarter and first nine months of 2020, respectively, primarily due to lower administrative and selling costs, including reduced travel and fewer meetings, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange, partially offset by costs related to the planned spin-off of Organon. Transaction costs related to the acquisition of ArQule also partially offset the decline in SG&amp;A expenses in the first nine months of 2020 (see Note 2 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses grew 6% and 5% in the third quarter and first nine months of 2020, respectively, primarily driven by higher upfront payments related to collaborations and license agreements (see Note 2 to the condensed consolidated financial statements), increased clinical development, discovery research and early drug development spending, as well as higher restructuring costs, partially offset by a charge in 2019 for the acquisition of Peloton Therapeutics, Inc. (Peloton) (see Note 2 to the condensed consolidated financial statements), lower costs associated with the COVID-19 pandemic (net of spending on COVID-19-related vaccine and antiviral research programs), and the favorable effect of foreign exchange.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by MRL, the Company&#8217;s research and development division that focuses on human health-related activities, which were $1.6 billion in both the third quarter of 2020 and 2019, and $4.7 billion and $4.4 billion in the first nine months of 2020 and 2019, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $645 million and $655 million for the third quarter of 2020 and 2019, respectively, and were $1.9 billion in both the first nine months of 2020 and 2019. In addition, R&amp;D expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business acquisitions. The Company recorded a net reduction in expenses of $48 million and $36 million in the first nine months of 2020 and 2019, respectively, related to the changes in these estimates. R&amp;D expenses also reflect $19 million and $67 million of accelerated depreciation costs in connection with restructuring activities in the third quarter and first nine months of 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program to result in annual net cost savings of approximately $900 million by the end of 2023. Actions under previous global restructuring programs have been substantially completed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $114 million and $232 million for the third quarter of 2020 and 2019, respectively, and $269 million and $444 million in the first nine months of 2020 and 2019, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs. The Company recorded aggregate pretax costs of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 42 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million in the first nine months of 2020 and 2019, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details on the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> see Note 13 to the condensed consolidated financial statements. </span></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-reportable segment profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,996)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits grew 3% in both the third quarter and first nine months of 2020 driven primarily by higher sales, as well as lower administrative and selling costs. Animal Health segment profits grew 6% and 7% in the third quarter and first nine months of 2020, respectively, reflecting higher sales and lower promotional costs, partially offset by higher R&amp;D costs and the unfavorable effect of foreign exchange.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9% and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Attributable to Noncontrolling Interests</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interests of $73 million for the first nine months of 2019 includes the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that are attributable to noncontrolling interests.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 43 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income and Earnings per Common Share</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Merck&#160;&amp; Co., Inc. was $2.9 billion for the third quarter of 2020 compared with $1.9 billion for the third quarter of 2019 and was $9.2 billion for the first nine months of 2020 compared with $7.5 billion for the first nine months of 2019. Earnings per common share assuming dilution attributable to Merck&#160;&amp; Co., Inc. common shareholders (EPS) for the third quarter of 2020 were $1.16 compared with $0.74 in the third quarter of 2019 and were $3.61 for the first nine months of 2020 compared with $2.89 for the first nine months of 2019. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Income and Non-GAAP EPS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP&#160;EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP). </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges for collaborations and acquisitions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 15pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,904&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on income as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax charge related to finalization of treasury regulations for the Tax Cuts and Job Act of 2017</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP taxes on income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Acquisition and divestiture-related costs attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS assuming dilution as reported under GAAP</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes $832 million related to transactions with Seagen. Amount in 2019 represents a charge for the acquisition of Peloton. See Note 2 to the condensed consolidated financial statements.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 44 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with business acquisitions and divestitures. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2020 are upfront payments related to licensing arrangements and collaborations, including the transactions with Seagen (see Note 2 to the condensed consolidated financial statements), and an adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a charge for the acquisition of Peloton (see Note 2 to the condensed consolidated financial statements), a net tax benefit related to the settlement of certain federal income tax matters (see Note 14 to the condensed consolidated financial statements) and a tax charge related to the finalization of U.S. treasury regulations related to the Tax Cuts and Jobs Act of 2017. </span></div><div id="i67ef4e29db364327800e42a94e43496a_115"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA accepted for priority review the NDA for vericiguat, an orally administered sGC stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction, in combination with other heart failure therapies. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2021. Vericiguat is being jointly developed with Bayer (see Note 3 to the condensed consolidated financial statements). The application is based on results from the Phase 3 VICTORIA trial, which is the first contemporary outcomes study focused exclusively on a population with worsening chronic heart failure who are at high risk for cardiovascular mortality and repeated heart failure hospitalizations. Data from VICTORIA were presented at the virtual American College of Cardiology&#8217;s 69th&#160;Annual Scientific Session together with World Congress of Cardiology and published in&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Vericiguat is also under review in the EU and in Japan. Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Koselugo is under review in the EU for the treatment of pediatric patients two years of age and older with NF1 who have symptomatic, inoperable PN based on positive results from the NCI CTEP-sponsored Phase 2 SPRINT Stratum 1 trial. Koselugo was approved by the FDA in April 2020. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,300 clinical trials, including more than 900 trials that combine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, melanoma, mesothelioma, nasopharyngeal, non-small-cell lung, ovarian, prostate, renal, small-cell lung, triple-negative breast and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA accepted and granted Priority Review for a supplemental Biologics License Application (BLA) seeking accelerated approval for </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triple-negative breast cancer (</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TNBC) whose tumors express PD-L1 (CPS &#8805;10). The application was based on data from the KEYNOTE-355 trial in which </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients whose tumors expressed PD-L1 at CPS &#8805;10. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In patients whose tumors expressed PD-L1 with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 45 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CPS &#8805;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy improved PFS versus chemotherapy alone, however these results did not meet statistical significance. </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These data were presented at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. As previously announced, the trial will continue without changes to evaluate the other dual primary endpoint of overall survival (OS). The FDA set a PDUFA date of November 28, 2020. In October 2020, Merck announced the submission of KEYNOTE-355 to the Japan PMDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2020, the FDA accepted for standard review a supplemental BLA for </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of patients with high-risk, early-stage TNBC, in combination with chemotherapy as neoadjuvant treatment, and then as a single agent as adjuvant treatment after surgery. The application was based on data from the KEYNOTE-522 trial in which neoadjuvant </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy resulted in a statistically significant increase in pathologic complete response in patients with early-stage TNBC, regardless of PD-L1 expression. The </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regimen also demonstrated a favorable trend for the other dual primary endpoint of event-free survival. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis for this study was conducted by the Independent Data Monitoring Committee (DMC). Based on the recommendation of the DMC, the study continues to evaluate event-free survival. </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the KEYNOTE-522 trial were presented at the European Society for Medical Oncology 2019 Congress. As previously announced, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus chemotherapy was granted Breakthrough Therapy designation by the FDA in September 2019 for the neoadjuvant treatment of patients with high-risk, early-stage TNBC. The PDUFA date for this application is March 29, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee for Medicinal Products for Human Use&#160;(CHMP) of the European Medicines Agency (EMA) announced the start of a procedure to extend the currently approved therapeutic indication for the treatment of relapsed or refractory cHL in adults to an earlier line of therapy based on the pivotal Phase 3 KEYNOTE-204 trial, in which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> demonstrated a significant improvement in PFS compared to brentuximab vedotin (BV), a current standard of care in this patient population. Data from KEYNOTE-204 were presented during the virtual scientific program of the 2020 ASCO Annual Meeting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved for this indication by the FDA in October 2020. The procedure also seeks to extend the indication to include pediatric patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review in the EU and in Japan for the first-line treatment of patients with MSI-H or mismatch repair deficient unresectable or metastatic colorectal cancer based on the results from the Phase 3 KEYNOTE-177 trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved for this indication by the FDA in June 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Breakthrough Therapy designation from the FDA for the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with neoadjuvant chemotherapy for the treatment of high-risk, early-stage TNBC noted above, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also received Breakthrough Therapy designation from the FDA in February 2020 for the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with PADCEV (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The FDA&#8217;s Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction cancer. In the study,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy significantly improved OS and PFS versus chemotherapy in all randomized patients; it was demonstrated that the risk of death was reduced by 27% versus chemotherapy as first-line treatment for locally advanced or metastatic esophageal cancer. With these results, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first anti-PD-1 therapy in combination with chemotherapy to show superior OS, PFS and objective response rate (ORR) versus chemotherapy, the current standard of care, for these patients regardless of histology or PD-L1 expression status. These data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Merck will be sharing these data with regulatory authorities worldwide. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck announced that the Phase 3 KEYNOTE-361 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of OS or PFS, compared with standard of care chemotherapy. In the final analysis of the study, there was an improvement in OS and PFS for patients treated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy compared to chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The monotherapy arm of the study was not formally tested, since superiority was not reached for OS or PFS in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination arm. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has three FDA-approved bladder cancer indications across multiple stages of bladder cancer. Additionally, Merck has an extensive clinical development program in bladder cancer and is continuing to evaluate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as monotherapy and in combination with other anti-cancer therapies across several disease settings (i.e., metastatic, muscle invasive bladder cancer, and non-muscle invasive bladder cancer).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck announced positive results from two studies from the Company&#8217;s lung cancer research program. Initial results from the Phase 2 KEYNOTE-799 trial evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus concurrent chemoradiation therapy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 46 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstrated an ORR of 67.0% in Cohort A (squamous and nonsquamous NSCLC patients who received paclitaxel plus carboplatin) and 56.6% in Cohort B (nonsquamous NSCLC patients who received cisplatin plus pemetrexed) in untreated patients with unresectable, locally advanced stage III NSCLC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in May 2020, Merck and Eisai presented data from analyses of two trials evaluating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima at the 2020 ASCO Annual Meeting, in which the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination demonstrated clinically meaningful ORR:  the KEYNOTE-524/Study 116 trial in patients with unresectable HCC with no prior systemic therapy and the KEYNOTE-146/Study 111 trial in patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck and Eisai announced that the FDA issued a Complete Response Letter (CRL) regarding Merck&#8217;s and Eisai&#8217;s applications seeking accelerated approval of Keytruda plus Lenvima for the first-line treatment of patients with unresectable HCC based on data from the Phase 1b KEYNOTE-524/Study 116 trial, which showed clinically meaningful efficacy in the single-arm setting. These data supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Merck&#8217;s and Eisai&#8217;s applications, another combination therapy was approved based on a randomized, controlled trial that demonstrated improvement in OS versus standard-of-care treatment. Consequently, the CRL stated that Merck&#8217;s and Eisai&#8217;s applications do not provide evidence that Keytruda in combination with Lenvima represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for KEYNOTE-524/Study 116 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plus Lenvima combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the current approved indications for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or for Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA granted Breakthrough Therapy designation to the hypoxia-inducible factor-2 alpha (HIF-2&#945;) inhibitor MK-6482, a novel investigational</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidate for the treatment of patients with von Hippel-Lindau (VHL) disease-associated RCC with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required. The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with VHL-associated ccRCC, which were presented at the 2020 ASCO Annual Meeting. Additionally, Phase 2 data showing anti-tumor responses in VHL disease patients with ccRCC and other tumors were presented at the </span><span style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESMO Virtual Congress 2020</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen announced a collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Seagen also granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa (MK-7119), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. See Note 2 to the condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. NCI, were presented at the 2020 ASCO Annual Meeting. This follows the March 2020, Merck and AstraZeneca announcement of the high-level results from the Phase 3 GY004 trial that examined primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in PFS with cediranib in combination with Lynparza vs. platinum-based chemotherapy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck announced the results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. In these studies, adult patients treated with gefapixant 45 mg twice daily demonstrated a statistically significant reduction in 24-hour cough frequency versus placebo at 12 weeks (COUGH-1) and 24 weeks (COUGH-2). The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study. These results were presented at the Virtual European Respiratory Society International Congress 2020. Merck plans to share data from COUGH-1 and COUGH-2 with regulatory authorities worldwide.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 47 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Merck announced Week 96 data from the Phase 2b trial (NCT03272347) evaluating the efficacy and safety of islatravir, the company&#8217;s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pifeltro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in treatment-na&#239;ve adults with HIV-1 infection. Week 96 findings demonstrated that the combination of islatravir and doravirine maintained virologic suppression (as measured by the number of study participants achieving HIV-1 RNA levels &lt;50 copies/mL, similar to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delstrigo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (doravirine/lamivudine/tenofovir disoproxil fumarate)), and the findings were consistent with Week 48 results. Additional Week 96 data from the study show low rates of participants meeting the definition of protocol-defined virologic failure in both the islatravir plus doravirine and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Delstrigo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment arms, and no participants in either arm met the criteria for resistance testing. These data were presented at the virtual 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasglow).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Merck announced findings from two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the Company&#8217;s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age and older received V114 or PCV13 followed by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 one year later. Immune responses following vaccination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13, immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114 met their primary immunogenicity objectives. The pivotal PNEU-AGE (V114-019) study in healthy adults 50 years of age or older demonstrated that V114 is non-inferior to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 serotypes targeted by both vaccines and superior for serotypes 22F and 33F, the two serotypes targeted by V114 but not PCV13. The PNEU-AGE study also met the key secondary immunogenicity objective, demonstrating superiority of V114 compared to PCV13 for serotype 3, a leading cause of invasive pneumococcal disease globally. In another Phase 3 study, PNEU-TRUE (V114-020), in healthy adults 50 years of age or older, V114 met its primary immunogenicity objective demonstrating equivalent immune response across all 15 serotypes for three different lots of V114. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114. Results from the PNEU-WAY (V114-018) study in adults 18 years of age or older living with HIV showed that V114 elicited an immune response to all 15 serotypes included in the vaccine, including serotypes 22F and 33F. Results from the PNEU-FLU (V114-021) study in healthy adults 50 years of age or older showed that V114 can be given concomitantly with the quadrivalent influenza vaccine. These data were announced and published in the International Symposium on Pneumococci and Pneumococcal Diseases digital library in lieu of an in-person meeting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The V114 Phase 3 clinical development program is comprised of 16 trials investigating the safety, tolerability and immunogenicity of V114 in a variety of populations who are at increased risk for pneumococcal disease including both healthy older adult and healthy pediatric populations, as well as people who are immunocompromised or have certain chronic conditions. Findings from the V114 Phase 3 clinical program, including the studies above, will be presented at a future scientific congress and will form the basis for global regulatory licensure applications, beginning with the FDA before the end of the year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck and Pfizer Inc. announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated Steglatro (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in patients with type 2 diabetes and atherosclerotic CV disease. The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is a composite of CV death, nonfatal myocardial infarction or nonfatal stroke, compared to placebo. The key secondary endpoints of superiority for Steglatro versus placebo for time to the first occurrence of the composite of CV death or hospitalization for heart failure, time to CV death alone and time to the first occurrence of the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with Steglatro. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the FDA granted V181, the Company&#8217;s investigational dengue vaccine in Phase 1 development, Fast Track designation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below reflects the Company&#8217;s research pipeline as of November 2, 2020. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 48 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:233pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 (molnupiravir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1026 </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1454</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684 (vibostolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Melanoma </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary Tract</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Glioblastoma</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V937</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Chikungunya virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V184</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cytomegalovirus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V160</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Prevention</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591 (islatravir)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V116</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1654</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8189</span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary Tract (September 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast (October 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical (October 2018) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal (December 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Nasopharyngeal (April 2016)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017) (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6482</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (August 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Bladder (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial (June 2018) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (March 2018)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591A (doravirine/islatravir) (February 2020)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumoconjugate Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V114 (June 2018)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">New Molecular Entities/Vaccines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Heart Failure</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1242 (vericiguat)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (U.S.) (EU) (JPN)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pediatric Neurofibromatosis Type 1</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5618 (selumetinib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Metastatic Triple-Negative Breast Cancer </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-355) (U.S.) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Early-Stage Triple-Negative Breast Cancer </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-522) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Refractory Classical Hodgkin Lymphoma </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-204) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Unresectable or Metastatic MSI-H or dMMR Colorectal</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cancer (KEYNOTE-177) (EU) (JPN)</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Hepatocellular Carcinoma</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(KEYNOTE-524) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)(4)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#8226;    Thymic Carcinoma (NCCH1508/REMORA) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div></td></tr><tr style="height:204pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Being developed in a collaboration</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  Being developed in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  Being developed as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">  In July 2020, the FDA issued a CRL for Merck&#8217;s and Eisai&#8217;s applications. Merck and Eisai are reviewing the letter and will submit data to the FDA. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div><span><br/></span></div><div id="i67ef4e29db364327800e42a94e43496a_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities was $6.2 billion in the first nine months of 2020 compared with $8.6 billion in the first nine months of 2019. Cash provided by operating activities in the first nine months of 2020 includes $2.1 billion of payments related to collaborations compared with $505 million in the first nine months of 2019. Cash provided by operating activities continues to be the Company&#8217;s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and dividends paid to shareholders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $4.7 billion in the first nine months of 2020 compared with $1.9 billion in the first nine months of 2019. The increase was driven primarily by lower proceeds from sales of securities and other investments and higher capital expenditures, partially offset by lower purchases of securities and other investments and lower use of cash for acquisitions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 49 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was $4.2 billion in the first nine months of 2020 compared with $6.9 billion in the first nine months of 2019. The lower use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, as well as lower purchases of treasury stock, partially offset by higher payments on debt (see below), lower proceeds from the issuance of debt (see below), higher dividends paid to shareholders, and lower proceeds from the exercise of stock options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures totaled $3.2 billion and $2.3 billion for the first nine months of 2020 and 2019, respectively. The increased capital expenditures reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck&#8217;s key products, as well as the purchase of a manufacturing facility in Dunboyne, Ireland to support upcoming product launches (see Note 2 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to stockholders were $4.7 billion and $4.3 billion for the first nine months of 2020 and 2019, respectively.&#160;In May 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company&#8217;s common stock for the third quarter that was paid in July 2020. In July 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company&#8217;s common stock for the fourth quarter that was paid in October 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company&#8217;s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering of $5.0 billion for general corporate purposes, including the repayment of outstanding commercial paper borrowings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first nine months of 2020, the Company purchased $1.3 billion (16 million shares) of its common stock for its treasury under this share repurchase program. As of September&#160;30, 2020, the Company&#8217;s remaining share repurchase authorization was $5.9&#160;billion. In March 2020, the Company temporarily suspended its share repurchase program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div id="i67ef4e29db364327800e42a94e43496a_121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies, which include management&#8217;s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December&#160;31, 2019 included in Merck&#8217;s Form 10&#8209;K filed on February&#160;26, 2020. Certain of these accounting policies are considered critical as disclosed in the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in Merck&#8217;s Form 10-K because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates. There have been no significant changes in the Company&#8217;s critical accounting policies since December&#160;31, 2019. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2020.</span></div><div id="i67ef4e29db364327800e42a94e43496a_124"></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 50 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.</span></div><div id="i67ef4e29db364327800e42a94e43496a_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that as of September&#160;30, 2020, the Company&#8217;s disclosure controls and procedures are effective. For the third quarter of 2020, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i67ef4e29db364327800e42a94e43496a_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and other words of similar meaning, or negative variations of any of the foregoing. One can&#160;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product development, product approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including the impact of the global outbreak of COVID-19 and other risks and uncertainties some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of the Company&#8217;s Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2019, as filed on February&#160;26, 2020, in the Company&#8217;s Form 10-Q for the quarterly period ended March 31, 2020, as filed on May 6, 2020, in the Company&#8217;s Form 10-Q for the quarterly period ended June 30, 2020, as filed on August 5, 2020, and in this Form 10-Q, the Company discusses in&#160;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&#160;to be a&#160;complete statement of all potential risks or uncertainties.</span></div><div id="i67ef4e29db364327800e42a94e43496a_133"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PART II - Other Information</span></div><div id="i67ef4e29db364327800e42a94e43496a_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Note 9 included in Part I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Condensed Consolidated Financial Statements.</span></div><div id="i67ef4e29db364327800e42a94e43496a_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks that affect the Company&#8217;s business, please refer to Part I, Item IA, &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019.&#160;There have been no material changes to the risk factors as previously disclosed in the Company&#8217;s Annual Report on Form 10-K, except as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The global COVID-19 pandemic is having an adverse impact on the Company&#8217;s business, operations and financial performance. The Company is unable to predict the full extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial performance, results of operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business and financial results have been negatively impacted by the outbreak of&#160;Coronavirus Disease 2019 (COVID-19). The duration, spread and severity of the COVID-19&#160;pandemic is uncertain, rapidly changing and difficult to predict. The degree to which&#160;COVID-19&#160;impacts the Company&#8217;s results will depend on future developments, beyond the Company&#8217;s knowledge or control, including, but not limited to, the duration and spread of the outbreak, its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 51 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck assumes that the majority of the negative impact from the COVID-19 pandemic occurred in the second quarter of 2020. However, the Company expects some residual negative impacts in the fourth quarter, largely in Europe and certain emerging markets. In addition, the phasing of the recovery of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 demand is slower than originally anticipated, in particular in the United States due to lower back-to-school demand. To the extent these assumptions prove to be incorrect, the Company&#8217;s results may differ materially from the estimates set forth herein.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus far in 2020,&#160;the COVID-19&#160;pandemic has impacted the Company&#8217;s business and the Company continues to expect that it will impact the business in numerous ways, including but not limited to those outlined below: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, the negative impact of the COVID-19 pandemic to Merck&#8217;s Pharmaceutical sales was estimated to be approximately $475 million. The negative impact to Animal Health sales was immaterial. The negative impact to sales in the first nine months of 2020 was approximately $2.0 billion for the Pharmaceutical segment and $50 million for the Animal Health segment. For the full-year 2020, including the impact for the first nine months, Merck expects an unfavorable impact to sales of approximately $2.35 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $2.3 billion for Pharmaceutical revenue and approximately $50 million for Animal Health revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roughly two-thirds of Merck&#8217;s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company&#8217;s human health products, in particular for its vaccines, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), as well as for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon/Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant). Access to healthcare providers remains reduced, although improved from the second quarter. Merck anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in elective surgeries negatively affected the demand for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection in the year-to-date period. Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent) increased due to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses were positively affected in the third quarter and first nine months of 2020 by approximately $115 million and $540 million, respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. For the full-year 2020, Merck expects a net favorable impact to operating expenses of approximately $625 million reflecting continued lower spending due to the COVID-19 pandemic, partially offset by spending on COVID-19-related antiviral and vaccine research programs.</span></div><div id="i67ef4e29db364327800e42a94e43496a_1337"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended September&#160;30, 2020 were as follows:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1 - July 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1 - August 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1 - September 30</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,888</span></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The Company did not purchase any shares during the three months ended September&#160;30, 2020 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck&#8217;s common stock for its treasury.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 52 -</span></div></div></div><div id="i67ef4e29db364327800e42a94e43496a_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&#160;6. Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 6.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) &#8211; Incorporated by reference to Current Report on Form 8-K filed on November&#160;4, 2009 (No. 1-6571)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 6.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015815000048/exhibit32-byxlawsxmerckcoi.htm">By-Laws of Merck &amp; Co., Inc. (effective July 22, 2015) &#8211; Incorporated by reference to Current Report on Form 8-K filed on July 28, 2015 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-rule13ax14a.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-rule13ax14a.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-section1350.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-section1350.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 53 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i67ef4e29db364327800e42a94e43496a_145"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK &amp; CO., INC.</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rita A. Karachun</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 54 -</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-rule13ax14a.htm
<DESCRIPTION>EX-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO 3Q20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i51d297e83aaa4a11834e5e2dcf822e9d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth C. Frazier, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:45.614%"><tr><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER<br>Chairman, President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-rule13ax14a.htm
<DESCRIPTION>EX-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO 3Q20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i091368aa45a444189fd05f1a6e11ada6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;November&#160;5, 2020 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.345%"><tr><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Executive Vice President, Global Services<br>and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-section1350.htm
<DESCRIPTION>EX-32.1 SECTION 1350 CERTIFICATION OF CEO 3Q20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i285c8ef037874e4ab18b759776ee2ab8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.115%"><tr><td style="width:1.0%"></td><td style="width:50.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.407%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  November 5, 2020</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth C. Frazier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KENNETH C. FRAZIER<br>Chairman,&#160;President&#160;and&#160;Chief&#160;Executive&#160;Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-section1350.htm
<DESCRIPTION>EX-32.2 SECTION 1350 CERTIFICATION OF CFO 3Q20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3bab3462fb604fb190e7e65d9bd3275b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.983%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  November 5, 2020</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Executive Vice President, Global Services<br>and Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mrk-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEET" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.merck.com/role/BasisofPresentation">
        <link:definition>2101101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.merck.com/role/BasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreements" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements">
        <link:definition>2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsTables" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables">
        <link:definition>2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails">
        <link:definition>2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>2107103 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>2308302 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>2409403 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsScheduleofTransactionsDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails">
        <link:definition>2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>2111104 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>2312303 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>2413405 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails">
        <link:definition>2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails">
        <link:definition>2415407 - Disclosure - Restructuring - Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>2116105 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>2317304 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2418408 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails">
        <link:definition>2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails">
        <link:definition>2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
        <link:definition>2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
        <link:definition>2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>2129106 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>2330305 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails">
        <link:definition>2431419 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesInventoriesDetails_1" roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1">
        <link:definition>2431419 - Disclosure - Inventories - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>2432420 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibles" roleURI="http://www.merck.com/role/OtherIntangibles">
        <link:definition>2133107 - Disclosure - Other Intangibles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangiblesDetails" roleURI="http://www.merck.com/role/OtherIntangiblesDetails">
        <link:definition>2434421 - Disclosure - Other Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.merck.com/role/LongTermDebt">
        <link:definition>2135108 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNarrativeDetails" roleURI="http://www.merck.com/role/LongTermDebtNarrativeDetails">
        <link:definition>2436422 - Disclosure - Long-Term Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.merck.com/role/Contingencies">
        <link:definition>2137109 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesNarrativeDetails" roleURI="http://www.merck.com/role/ContingenciesNarrativeDetails">
        <link:definition>2438423 - Disclosure - Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>2139110 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>2340306 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityRollforwardReconciliationsDetails" roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails">
        <link:definition>2441424 - Disclosure - Equity - Rollforward Reconciliations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlans" roleURI="http://www.merck.com/role/ShareBasedCompensationPlans">
        <link:definition>2142111 - Disclosure - Share-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansTables" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables">
        <link:definition>2343307 - Disclosure - Share-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansExpenseAllocationsDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails">
        <link:definition>2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansNarrativeDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails">
        <link:definition>2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails">
        <link:definition>2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>2147112 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails">
        <link:definition>2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>2151113 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>2352309 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails">
        <link:definition>2453430 - Disclosure - Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails">
        <link:definition>2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>2155114 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDetails">
        <link:definition>2456432 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.merck.com/role/EarningsPerShare">
        <link:definition>2157115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.merck.com/role/EarningsPerShareTables">
        <link:definition>2358310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareDetails">
        <link:definition>2459433 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>2160116 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>2462434 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>2163117 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>2364312 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>2465435 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesofCompanysProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails">
        <link:definition>2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails">
        <link:definition>2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingProfitstoIncomeBeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails">
        <link:definition>2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.35NotesDue2022Member" abstract="true" name="A2.35NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SingulairMember" abstract="true" name="SingulairMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A0.75notesdue2026Member" abstract="true" name="A0.75notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ArcoxiaMember" abstract="true" name="ArcoxiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" abstract="true" name="PensionandOtherPostretirementBenefitPlansNarrativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ZetiaantitrustlitigationMember" abstract="true" name="ZetiaantitrustlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_VelosBioMember" abstract="true" name="VelosBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A3.875NotesDue2021Member" abstract="true" name="A3.875NotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="mrk_A2.40NotesDue2022Member" abstract="true" name="A2.40NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" abstract="false" name="Licenseoptionpaymentrelatedtocollaborativearrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CancidasMember" abstract="true" name="CancidasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_NasonexMember" abstract="true" name="NasonexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CozaarHyzaarMember" abstract="true" name="CozaarHyzaarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SeagenMember" abstract="true" name="SeagenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RestructuringReserveNoncashActivity" abstract="false" name="RestructuringReserveNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_VytorinMember" abstract="true" name="VytorinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CaliforniaStateCourtMember" abstract="true" name="CaliforniaStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CubicinMember" abstract="true" name="CubicinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FemurFractureLitigationMember" abstract="true" name="FemurFractureLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_NuvaringMember" abstract="true" name="NuvaringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ProbableContingentPaymentsCollaborativeArrangement" abstract="false" name="ProbableContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ZepatierMember" abstract="true" name="ZepatierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LongTermDebtExcludingCurrentMaturitiesMember" abstract="true" name="LongTermDebtExcludingCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.35notesdue2040Member" abstract="true" name="A2.35notesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SentinelMember" abstract="true" name="SentinelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.85NotesDue2020Member" abstract="true" name="A1.85NotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_HealthcareServicesSegmentMember" abstract="true" name="HealthcareServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FollistimAqMember" abstract="true" name="FollistimAqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" abstract="false" name="PaymentsToAcquireBusinessFourNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ZetiaMember" abstract="true" name="ZetiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasMember" abstract="true" name="AllianceRevenueAdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" abstract="false" name="InvestmentsPrimaryWeightedAverageLifeofCollateral" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SivextroMember" abstract="true" name="SivextroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ImmuneDesignMember" abstract="true" name="ImmuneDesignMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ThemisMember" abstract="true" name="ThemisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_TukysaMember" abstract="true" name="TukysaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ContingentPaymentsCollaborativeArrangement" abstract="false" name="ContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LossContingencyClaimsonAppealNumber" abstract="false" name="LossContingencyClaimsonAppealNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InvanzMember" abstract="true" name="InvanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_PelotonMember" abstract="true" name="PelotonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DunboyneMember" abstract="true" name="DunboyneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" abstract="true" name="CasesCompanyAgreedToTollStatuteOfLimitationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" abstract="true" name="ComponentofOtherIncomeExpenseofNonoperatingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_A1.125Notesdue2021Member" abstract="true" name="A1.125Notesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ImplanonNexplanonMember" abstract="true" name="ImplanonNexplanonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_A1.45notesdue2030Member" abstract="true" name="A1.45notesdue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_OtherStateCourtMember" abstract="true" name="OtherStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrk_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ArQuleMember" abstract="true" name="ArQuleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A2.45notesdue2050Member" abstract="true" name="A2.45notesdue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrk_AntelliqMember" abstract="true" name="AntelliqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_LongTermDebtCurrentMaturitiesMember" abstract="true" name="LongTermDebtCurrentMaturitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FosamaxMember" abstract="true" name="FosamaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AtozetMember" abstract="true" name="AtozetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_AmortizationOfPurchaseAccountingAdjustments" abstract="false" name="AmortizationOfPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_NewJerseyStateCourtMember" abstract="true" name="NewJerseyStateCourtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_EmendMember" abstract="true" name="EmendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_FederalMember" abstract="true" name="FederalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_CommercialMilestoneMember" abstract="true" name="CommercialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrk_IAVIMember" abstract="true" name="IAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mrk-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dfb8e1a3-d6df-4588-93c1-0de238847f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a197436e-d299-4bb0-b56c-340058ded1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dfb8e1a3-d6df-4588-93c1-0de238847f4f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a197436e-d299-4bb0-b56c-340058ded1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d3a91912-5699-4ed5-8862-113d0c7f87dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dfb8e1a3-d6df-4588-93c1-0de238847f4f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d3a91912-5699-4ed5-8862-113d0c7f87dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:href="mrk-20200930.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e2f72c53-83b0-4b90-b5da-160590b39bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e2f72c53-83b0-4b90-b5da-160590b39bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d84e6899-f64a-436f-9670-233acb6eb077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d84e6899-f64a-436f-9670-233acb6eb077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_43f1045c-e68c-4b37-b43e-5789a7e4b0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_43f1045c-e68c-4b37-b43e-5789a7e4b0d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f54a4bfd-3fa8-4822-9222-24e6433d65a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:to="loc_us-gaap_RestructuringCharges_f54a4bfd-3fa8-4822-9222-24e6433d65a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_74e03f1c-13e1-40c6-ae50-3900e787082b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_48d5e873-ac7c-4087-b797-8ba6cadecef4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_74e03f1c-13e1-40c6-ae50-3900e787082b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c139504b-df12-420d-afc1-955e14f203e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9030da57-d0ef-4a8f-acb8-87b850ef83fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c139504b-df12-420d-afc1-955e14f203e9" xlink:to="loc_us-gaap_ProfitLoss_9030da57-d0ef-4a8f-acb8-87b850ef83fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_17914e87-cd7d-4a98-a547-6ab51a246689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c139504b-df12-420d-afc1-955e14f203e9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_17914e87-cd7d-4a98-a547-6ab51a246689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96152ab3-fe55-40f2-a746-830320b47997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32daa799-13c0-486b-89d3-c4cb37fa8822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96152ab3-fe55-40f2-a746-830320b47997" xlink:to="loc_us-gaap_Revenues_32daa799-13c0-486b-89d3-c4cb37fa8822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_3adb5b14-5dd4-4310-a2f0-e9b76f690147" xlink:href="mrk-20200930.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96152ab3-fe55-40f2-a746-830320b47997" xlink:to="loc_mrk_CostsExpensesAndOther_3adb5b14-5dd4-4310-a2f0-e9b76f690147" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_eab4362c-f02c-4bdf-9db2-0318a03000ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f55762b4-bd15-42f3-8089-8b0241ec5816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_eab4362c-f02c-4bdf-9db2-0318a03000ae" xlink:to="loc_us-gaap_NetIncomeLoss_f55762b4-bd15-42f3-8089-8b0241ec5816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_48f7a5e4-fc22-436b-82dc-b2e14d95bc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_eab4362c-f02c-4bdf-9db2-0318a03000ae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_48f7a5e4-fc22-436b-82dc-b2e14d95bc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c226dd1-6f28-49c6-b034-dd8db8e7ee2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_04d88a67-e33e-4648-b416-b07b596726ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c226dd1-6f28-49c6-b034-dd8db8e7ee2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_04d88a67-e33e-4648-b416-b07b596726ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_97cc8d44-bf67-446e-b1bf-3c882655058e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c226dd1-6f28-49c6-b034-dd8db8e7ee2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_97cc8d44-bf67-446e-b1bf-3c882655058e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_89979310-86fe-42f5-90b0-9e6a6b356cea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c226dd1-6f28-49c6-b034-dd8db8e7ee2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_89979310-86fe-42f5-90b0-9e6a6b356cea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_16bd3765-c849-46a7-935b-689752dd781d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c226dd1-6f28-49c6-b034-dd8db8e7ee2d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_16bd3765-c849-46a7-935b-689752dd781d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_794a1952-93fe-4d89-84a7-147d51e866cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8bfde1b8-7dcd-456d-80ac-a04ae20934ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794a1952-93fe-4d89-84a7-147d51e866cd" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_8bfde1b8-7dcd-456d-80ac-a04ae20934ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d5aba32b-f1bb-48f2-8fb5-880192af6a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794a1952-93fe-4d89-84a7-147d51e866cd" xlink:to="loc_us-gaap_TreasuryStockValue_d5aba32b-f1bb-48f2-8fb5-880192af6a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f5ff365-fe5f-4769-8229-cde70aabcc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f5ff365-fe5f-4769-8229-cde70aabcc77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1b624425-f38f-4401-90a3-810a625296b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1b624425-f38f-4401-90a3-810a625296b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8b8e0c22-465f-40dd-8b16-2b9560264566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8b8e0c22-465f-40dd-8b16-2b9560264566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c6941f8e-dc82-431e-941b-21b1ea13814a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:to="loc_us-gaap_InventoryNet_c6941f8e-dc82-431e-941b-21b1ea13814a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_d214f9d0-49b3-4924-bab5-d6d24163c19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c9708280-81df-493c-8441-40ce4cf23eb5" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_d214f9d0-49b3-4924-bab5-d6d24163c19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_7781f04a-4aee-4cd7-b6c5-a1c39ec7ede6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:to="loc_us-gaap_DebtCurrent_7781f04a-4aee-4cd7-b6c5-a1c39ec7ede6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_865e9ba1-563d-4385-a743-2d3fc4df1ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:to="loc_us-gaap_AccountsPayableCurrent_865e9ba1-563d-4385-a743-2d3fc4df1ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_92324b12-13ad-460d-b002-45d67e9494a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_92324b12-13ad-460d-b002-45d67e9494a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_6ad4163e-3735-4001-94dc-45710a2289b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_6ad4163e-3735-4001-94dc-45710a2289b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_fba142a2-38e5-4e1c-9811-43d4eb4746f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3a30e973-9f8d-464b-af04-5a0f32ac5254" xlink:to="loc_us-gaap_DividendsPayableCurrent_fba142a2-38e5-4e1c-9811-43d4eb4746f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_64b81517-f2cd-49d1-8e09-c7e26a58624f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:to="loc_us-gaap_LiabilitiesCurrent_64b81517-f2cd-49d1-8e09-c7e26a58624f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d0950131-c16e-45ba-9cda-d15921b21a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d0950131-c16e-45ba-9cda-d15921b21a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_108ca4b6-a111-41b3-a2ac-a57e1db687b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_108ca4b6-a111-41b3-a2ac-a57e1db687b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6372e13a-f902-4f98-bd4e-40de2dfafc59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6372e13a-f902-4f98-bd4e-40de2dfafc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ec4ba3e-34c2-42cf-accc-1b91041536de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cac359d8-812a-4da7-8038-2572efb3b4d1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6ec4ba3e-34c2-42cf-accc-1b91041536de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6241a004-23fe-448a-8703-4a81dbf25737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_AssetsCurrent_6241a004-23fe-448a-8703-4a81dbf25737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_4ea19048-af0f-491f-a06a-fffc757db97e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_4ea19048-af0f-491f-a06a-fffc757db97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9471a6a8-a57a-43e5-b1ee-415bb79fa786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9471a6a8-a57a-43e5-b1ee-415bb79fa786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5db830b3-927e-425a-877f-ee525417a30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_Goodwill_5db830b3-927e-425a-877f-ee525417a30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe174407-205d-4831-b917-5a63e017c54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_fe174407-205d-4831-b917-5a63e017c54e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_b395408e-bdd1-48f9-9e63-02aefd081fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fa3dfbf4-5f71-4a28-afcb-fc5847a6060d" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_b395408e-bdd1-48f9-9e63-02aefd081fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c32e204c-a3ab-4ba1-b63d-3c5eccf38ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9cdd84a4-9e37-4b33-a988-9ee205eb7fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c32e204c-a3ab-4ba1-b63d-3c5eccf38ea3" xlink:to="loc_us-gaap_CommonStockValue_9cdd84a4-9e37-4b33-a988-9ee205eb7fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d4cd1b9-ef7f-4e48-b9bd-406175cc9496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c32e204c-a3ab-4ba1-b63d-3c5eccf38ea3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d4cd1b9-ef7f-4e48-b9bd-406175cc9496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71788fc8-4dfa-4db8-bac3-5a7ceea3b457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c32e204c-a3ab-4ba1-b63d-3c5eccf38ea3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71788fc8-4dfa-4db8-bac3-5a7ceea3b457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cf1f40c3-e1b2-4249-812e-2046936778e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c32e204c-a3ab-4ba1-b63d-3c5eccf38ea3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cf1f40c3-e1b2-4249-812e-2046936778e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_995a71eb-d67a-4bf8-81e3-82f36eca0296" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10d1262c-a6d8-4ef0-ad0c-cfa8d8daa861" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_995a71eb-d67a-4bf8-81e3-82f36eca0296" xlink:to="loc_us-gaap_StockholdersEquity_10d1262c-a6d8-4ef0-ad0c-cfa8d8daa861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f7ca0596-e40e-421f-86e3-1a4629cd66df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_995a71eb-d67a-4bf8-81e3-82f36eca0296" xlink:to="loc_us-gaap_MinorityInterest_f7ca0596-e40e-421f-86e3-1a4629cd66df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8aaccafe-156f-4b18-a6e4-d376866e8d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8aaccafe-156f-4b18-a6e4-d376866e8d8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_09508325-bebd-407f-b140-c69c2aa65b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_09508325-bebd-407f-b140-c69c2aa65b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_bca116a9-efac-4bdc-bd3d-4392568f5f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_bca116a9-efac-4bdc-bd3d-4392568f5f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88fb25cd-318d-491a-b572-67332829d1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88fb25cd-318d-491a-b572-67332829d1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_12b856df-851a-4b48-95f8-f01f249c885a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_12b856df-851a-4b48-95f8-f01f249c885a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_87ce2271-8e05-4d60-91cc-6e4e5ed5e0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_87ce2271-8e05-4d60-91cc-6e4e5ed5e0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f845981a-b344-4eef-baa1-f9c96665c742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9fb04860-c03d-4cae-9efd-d0e61024fccc" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f845981a-b344-4eef-baa1-f9c96665c742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_7556f812-b9c6-4085-a2db-e8d98b6e1a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_7556f812-b9c6-4085-a2db-e8d98b6e1a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89b3759c-c111-44f4-859c-25ead2f46d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_89b3759c-c111-44f4-859c-25ead2f46d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e03b81a9-ac7b-4cb9-81c2-e835aa022a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e03b81a9-ac7b-4cb9-81c2-e835aa022a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_3fbd77ec-7547-4ac9-ab80-ad4efaa9785a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_3fbd77ec-7547-4ac9-ab80-ad4efaa9785a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_dc525244-6d5a-4791-999b-8319f15b202b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_dc525244-6d5a-4791-999b-8319f15b202b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_21b43e17-83da-4d8e-bbc3-e248de26517f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_21b43e17-83da-4d8e-bbc3-e248de26517f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4d116592-d752-4752-b494-bfed369bd4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4d116592-d752-4752-b494-bfed369bd4f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_8a289e94-92c0-4e7e-aac4-94cbac60602e" xlink:href="mrk-20200930.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_382baeaa-7f79-45c4-8d49-469d94ac596c" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_8a289e94-92c0-4e7e-aac4-94cbac60602e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c7d9d12f-24d7-463b-b869-7c6da8670f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_ProfitLoss_c7d9d12f-24d7-463b-b869-7c6da8670f3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ea31a2d1-84cf-422e-8fb9-4af1b5fc3cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ea31a2d1-84cf-422e-8fb9-4af1b5fc3cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_0bc9a98a-609d-46f9-b881-414cfe1fb9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_0bc9a98a-609d-46f9-b881-414cfe1fb9fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_36e176d1-9981-4073-88e9-671e2dc7e6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_36e176d1-9981-4073-88e9-671e2dc7e6c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_535b5feb-ab9c-4368-8775-afee01dd3987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_ShareBasedCompensation_535b5feb-ab9c-4368-8775-afee01dd3987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_53e36ba8-f0ee-4332-b8c6-e37ba99f5e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_53e36ba8-f0ee-4332-b8c6-e37ba99f5e1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_dcd3b1c2-d3f5-4c15-99ed-ac62c107a4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5ccc9db2-8c4c-4691-91cf-eb395e7d6a4a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_dcd3b1c2-d3f5-4c15-99ed-ac62c107a4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd774a7-96d8-44ca-94f5-faaf062d4a16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_725b8ad0-00df-447c-b852-83b119a867ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd774a7-96d8-44ca-94f5-faaf062d4a16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_725b8ad0-00df-447c-b852-83b119a867ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c3f814f-bcb3-44dd-a842-641b768fb359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd774a7-96d8-44ca-94f5-faaf062d4a16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c3f814f-bcb3-44dd-a842-641b768fb359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad82a7c6-1107-4b6a-906f-6bdc34b35b73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd774a7-96d8-44ca-94f5-faaf062d4a16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad82a7c6-1107-4b6a-906f-6bdc34b35b73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f145ff7-56ff-494b-82a0-2ec24f3a2327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fd774a7-96d8-44ca-94f5-faaf062d4a16" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f145ff7-56ff-494b-82a0-2ec24f3a2327" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_764c34ed-bef0-4f58-9c8f-2e5c85812343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_764c34ed-bef0-4f58-9c8f-2e5c85812343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2eaf7f73-9883-4662-8400-1818e8a5495b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_ShareBasedCompensation_2eaf7f73-9883-4662-8400-1818e8a5495b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c7629b47-31df-42ec-989b-2caebfc9999a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c7629b47-31df-42ec-989b-2caebfc9999a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_37031f91-e5d1-45a3-82fb-f0150ffc58cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_ProfitLoss_37031f91-e5d1-45a3-82fb-f0150ffc58cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_bfbf3f43-8987-4125-ab68-f59b5bc78a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_bfbf3f43-8987-4125-ab68-f59b5bc78a09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c94c1fe-6e4b-4978-86f8-617054b37399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c94c1fe-6e4b-4978-86f8-617054b37399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f4387e2f-7041-4251-9915-a234bdbdacf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f4387e2f-7041-4251-9915-a234bdbdacf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_bde0c51b-6824-4c5f-9e4b-6829b4122ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24c678a0-a31e-409f-9ed3-3d6a8de1adab" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_bde0c51b-6824-4c5f-9e4b-6829b4122ce3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/BasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4e03a2d8-b492-4f57-90d4-f491289ede83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_4e03a2d8-b492-4f57-90d4-f491289ede83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5ba9b23c-e07a-4e9e-9379-5acb191683c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5ba9b23c-e07a-4e9e-9379-5acb191683c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2220cf80-2e7e-4fca-8505-4d4d9af95a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2220cf80-2e7e-4fca-8505-4d4d9af95a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ac06b9d4-489a-4ac2-b468-17beeeecf55b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ac06b9d4-489a-4ac2-b468-17beeeecf55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_42303589-d4e0-4338-a1e6-599b0ee76a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_42303589-d4e0-4338-a1e6-599b0ee76a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bf215a50-42f0-434d-a3c1-e76dbe906c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_bf215a50-42f0-434d-a3c1-e76dbe906c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_6ea5df4d-af21-42d7-a643-0a8a450416be" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_6ea5df4d-af21-42d7-a643-0a8a450416be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_68229f34-436b-43b0-bdb6-3b31d7082bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1c843545-61da-463f-b64e-eedae0edaf17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_68229f34-436b-43b0-bdb6-3b31d7082bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ae1509b5-82ab-4461-b519-9c7502cfc964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3f7bbdc1-0e2d-43f5-bbd9-573daf2f75ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ae1509b5-82ab-4461-b519-9c7502cfc964" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3f7bbdc1-0e2d-43f5-bbd9-573daf2f75ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1a78d3a8-cb48-4645-990e-6343755a5bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ae1509b5-82ab-4461-b519-9c7502cfc964" xlink:to="loc_us-gaap_Goodwill_1a78d3a8-cb48-4645-990e-6343755a5bd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangements"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsScheduleofTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20200930.xsd#Restructuring"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueHedgesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a985d9f6-1652-467d-903c-080a3b5d903e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d5b853ad-de48-42f7-918a-76b1dcd0643a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a985d9f6-1652-467d-903c-080a3b5d903e" xlink:to="loc_us-gaap_DerivativeLiabilities_d5b853ad-de48-42f7-918a-76b1dcd0643a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_25646cf2-b4d1-440b-83dd-21f4db922eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a985d9f6-1652-467d-903c-080a3b5d903e" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_25646cf2-b4d1-440b-83dd-21f4db922eaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_da362881-c0e5-441a-ba59-4f0326732156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a985d9f6-1652-467d-903c-080a3b5d903e" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_da362881-c0e5-441a-ba59-4f0326732156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7441ee01-1432-44cf-9516-69dc615d6ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_fd7c0750-396c-4c27-982d-b68c95c1e08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7441ee01-1432-44cf-9516-69dc615d6ebc" xlink:to="loc_us-gaap_DerivativeAssets_fd7c0750-396c-4c27-982d-b68c95c1e08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_e3abd81a-38b4-4977-81a9-130b2b3a2eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7441ee01-1432-44cf-9516-69dc615d6ebc" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_e3abd81a-38b4-4977-81a9-130b2b3a2eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_786a440f-45c2-4c0a-8df7-0288a7a4c5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7441ee01-1432-44cf-9516-69dc615d6ebc" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_786a440f-45c2-4c0a-8df7-0288a7a4c5d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_66e4896b-bc3e-4118-83f4-ef0fa680b580" xlink:href="mrk-20200930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89c38179-fb33-4ec3-bcf9-864e62eb8e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_66e4896b-bc3e-4118-83f4-ef0fa680b580" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89c38179-fb33-4ec3-bcf9-864e62eb8e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_580b43c5-91f0-4130-acd6-e68203cf3a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_66e4896b-bc3e-4118-83f4-ef0fa680b580" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_580b43c5-91f0-4130-acd6-e68203cf3a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d66f99bf-0a09-4d4b-abd4-980ab04b897f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e3ac5581-3051-4c2d-bda5-2fb9db57e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d66f99bf-0a09-4d4b-abd4-980ab04b897f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e3ac5581-3051-4c2d-bda5-2fb9db57e6f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db2fd6c0-6c49-47a0-96b5-6b9dc2aa0def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d66f99bf-0a09-4d4b-abd4-980ab04b897f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db2fd6c0-6c49-47a0-96b5-6b9dc2aa0def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ae8cc8c-cf28-4756-bbf6-f39128e34681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d66f99bf-0a09-4d4b-abd4-980ab04b897f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4ae8cc8c-cf28-4756-bbf6-f39128e34681" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_74f6d124-46a4-477a-acb0-0eaed4ce0ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53082228-5afb-4083-8701-afd734b3b926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_74f6d124-46a4-477a-acb0-0eaed4ce0ec9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_53082228-5afb-4083-8701-afd734b3b926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_91969205-5391-4c96-b5ae-e27904b23aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_74f6d124-46a4-477a-acb0-0eaed4ce0ec9" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_91969205-5391-4c96-b5ae-e27904b23aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_390a33fe-6bc1-409a-b1b2-59da1a6a459d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_815fc144-2d53-4bda-b8bd-b0c159d5f552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_390a33fe-6bc1-409a-b1b2-59da1a6a459d" xlink:to="loc_us-gaap_TradingSecurities_815fc144-2d53-4bda-b8bd-b0c159d5f552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9504fd0a-de4b-4425-94c8-00dd80964901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_390a33fe-6bc1-409a-b1b2-59da1a6a459d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9504fd0a-de4b-4425-94c8-00dd80964901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_456dda0c-b34a-495a-86c5-2bb4b7ae965b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_390a33fe-6bc1-409a-b1b2-59da1a6a459d" xlink:to="loc_us-gaap_DerivativeAssets_456dda0c-b34a-495a-86c5-2bb4b7ae965b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e3967182-ac54-4282-a9e3-d39f41f4c0da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_79c3d1db-9f4d-4acf-adac-cc99ec0c5b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e3967182-ac54-4282-a9e3-d39f41f4c0da" xlink:to="loc_us-gaap_DerivativeLiabilities_79c3d1db-9f4d-4acf-adac-cc99ec0c5b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5277233e-d95f-46ea-9cad-16e771a79727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e3967182-ac54-4282-a9e3-d39f41f4c0da" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5277233e-d95f-46ea-9cad-16e771a79727" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20200930.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_cb3e47fa-2780-4115-8cd1-707c31413bdc" xlink:href="mrk-20200930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fada776d-2f30-48d4-971b-3c108cc9a425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_cb3e47fa-2780-4115-8cd1-707c31413bdc" xlink:to="loc_us-gaap_InventoryNet_fada776d-2f30-48d4-971b-3c108cc9a425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_390171cf-b848-42c9-a6ab-9dac50c1c6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_cb3e47fa-2780-4115-8cd1-707c31413bdc" xlink:to="loc_us-gaap_InventoryNoncurrent_390171cf-b848-42c9-a6ab-9dac50c1c6eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_426af42b-f301-4637-ae15-7a365f0f3db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_78f759bd-a762-4106-83e6-396865fe62e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_426af42b-f301-4637-ae15-7a365f0f3db1" xlink:to="loc_us-gaap_InventoryFinishedGoods_78f759bd-a762-4106-83e6-396865fe62e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_4b01861f-6275-45b5-86be-9402396ffde4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_426af42b-f301-4637-ae15-7a365f0f3db1" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_4b01861f-6275-45b5-86be-9402396ffde4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_1f1b2a48-4f3c-47a8-a9b3-f128b48fcfe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_426af42b-f301-4637-ae15-7a365f0f3db1" xlink:to="loc_us-gaap_OtherInventorySupplies_1f1b2a48-4f3c-47a8-a9b3-f128b48fcfe9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_0cc9b75c-9901-44a9-a151-770f3b0325e5" xlink:href="mrk-20200930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_5866dc63-bf32-441b-9688-e3fa68a58962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_0cc9b75c-9901-44a9-a151-770f3b0325e5" xlink:to="loc_us-gaap_InventoryGross_5866dc63-bf32-441b-9688-e3fa68a58962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_bde19f7f-e530-4836-be08-76313a2f4c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_0cc9b75c-9901-44a9-a151-770f3b0325e5" xlink:to="loc_us-gaap_InventoryLIFOReserve_bde19f7f-e530-4836-be08-76313a2f4c1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangibles" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangibles"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIntangibles" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebt" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebt"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LongTermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Contingencies" xlink:type="simple" xlink:href="mrk-20200930.xsd#Contingencies"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Contingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20200930.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityRollforwardReconciliationsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlans"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansExpenseAllocationsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2478bbd9-8c39-42a2-8a1e-3bd090ab5f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_823cfb19-5ca3-4e43-93e7-ece10eeb69ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2478bbd9-8c39-42a2-8a1e-3bd090ab5f84" xlink:to="loc_us-gaap_ShareBasedCompensation_823cfb19-5ca3-4e43-93e7-ece10eeb69ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6dc73c97-8e9c-4196-a2a6-0c68cf4032ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2478bbd9-8c39-42a2-8a1e-3bd090ab5f84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6dc73c97-8e9c-4196-a2a6-0c68cf4032ed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f5336b01-6c80-461d-b197-6a9c2e11017f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f5336b01-6c80-461d-b197-6a9c2e11017f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_f72983d9-385d-40bd-ba63-6bc90df36bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_f72983d9-385d-40bd-ba63-6bc90df36bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_470fe581-4116-4ab2-ac8d-a7c4e702e236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_470fe581-4116-4ab2-ac8d-a7c4e702e236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d859af2f-2438-42e6-a2c0-13ef305be1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d859af2f-2438-42e6-a2c0-13ef305be1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_801fa8c5-79fe-422c-b244-2d312c4190b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_801fa8c5-79fe-422c-b244-2d312c4190b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_bb6fc91b-98cd-4ba6-8816-e2621cb5edab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_bb6fc91b-98cd-4ba6-8816-e2621cb5edab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_439b3da7-823e-4819-84ef-7dd8147e20c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_439b3da7-823e-4819-84ef-7dd8147e20c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4aaf832f-c66f-4655-b925-552a90decdc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_8cb8fdb5-0f5e-4343-8675-62047c82b195" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4aaf832f-c66f-4655-b925-552a90decdc8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNet"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_877d18c0-5037-4e9c-aa90-2fae87bb9d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_877d18c0-5037-4e9c-aa90-2fae87bb9d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_34efa448-789a-4c4b-80eb-35df898b972f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_us-gaap_InterestExpense_34efa448-789a-4c4b-80eb-35df898b972f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f431fce1-e992-4950-b708-c1289f61c519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f431fce1-e992-4950-b708-c1289f61c519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_9e113b1d-c21c-476a-84b0-2a69a4e2137e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_9e113b1d-c21c-476a-84b0-2a69a4e2137e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0a223f67-efee-447c-a4db-3663313b948f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0a223f67-efee-447c-a4db-3663313b948f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_52c87d18-27c6-4491-995a-981a4700e5d9" xlink:href="mrk-20200930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_88b6c6c0-4242-48d3-afab-1307cd34d1f4" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_52c87d18-27c6-4491-995a-981a4700e5d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncome"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fc4a8fa-e795-4994-8fa2-442be60a73a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_925aced6-cb49-46ca-950d-54236caf00be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fc4a8fa-e795-4994-8fa2-442be60a73a8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_925aced6-cb49-46ca-950d-54236caf00be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_078de365-bbb1-4322-a83a-9b7b85a712ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fc4a8fa-e795-4994-8fa2-442be60a73a8" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_078de365-bbb1-4322-a83a-9b7b85a712ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d344ba0d-a001-4521-98ef-d38bc44ebf74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_fda5560f-aecd-4760-9e3b-653d5a745678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d344ba0d-a001-4521-98ef-d38bc44ebf74" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_fda5560f-aecd-4760-9e3b-653d5a745678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b0c89678-df03-403b-af4f-ab74ee0a2347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d344ba0d-a001-4521-98ef-d38bc44ebf74" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b0c89678-df03-403b-af4f-ab74ee0a2347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_62ecc2ad-777c-4d26-86f9-5268884c9760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_7f9d636d-d4b9-4b9c-824f-03a8b812fa14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_62ecc2ad-777c-4d26-86f9-5268884c9760" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_7f9d636d-d4b9-4b9c-824f-03a8b812fa14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_79e10797-c0c0-44e3-ae75-0ac44d7997b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_62ecc2ad-777c-4d26-86f9-5268884c9760" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_79e10797-c0c0-44e3-ae75-0ac44d7997b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_68b4b1f0-a07f-4b61-8db9-cbf133999984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f94e5b78-ad95-4f9b-8a47-ccc884e7451a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_68b4b1f0-a07f-4b61-8db9-cbf133999984" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_f94e5b78-ad95-4f9b-8a47-ccc884e7451a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_db1f0a10-5ff8-4a93-962a-0944b4cf3312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_68b4b1f0-a07f-4b61-8db9-cbf133999984" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_db1f0a10-5ff8-4a93-962a-0944b4cf3312" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReporting"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingTables"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingRevenuesbyGeographicAreaDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingProfitstoIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mrk-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="i4402c56905714f3797a6310f57d15cf7_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1eb1c192-081b-4eb5-ba03-c24d55ee3f98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentType_1eb1c192-081b-4eb5-ba03-c24d55ee3f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e0dd040b-540d-4cae-87f5-9d826b016672" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentQuarterlyReport_e0dd040b-540d-4cae-87f5-9d826b016672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_990d09ec-9b4a-49f7-a7db-6bb350ecea09" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentPeriodEndDate_990d09ec-9b4a-49f7-a7db-6bb350ecea09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f4306c5b-28bd-465a-8462-8314bb4676c1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentTransitionReport_f4306c5b-28bd-465a-8462-8314bb4676c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8083f4bf-1d95-48ad-a3d0-2c4cb4aa47fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityFileNumber_8083f4bf-1d95-48ad-a3d0-2c4cb4aa47fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_875cccdf-cff2-417e-81c2-1061c09ffb7c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityRegistrantName_875cccdf-cff2-417e-81c2-1061c09ffb7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fc8c025d-deea-4e3b-b5ba-27e0231bee6b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fc8c025d-deea-4e3b-b5ba-27e0231bee6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d4877a43-855a-4ff0-a232-bf3eb3d15111" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityTaxIdentificationNumber_d4877a43-855a-4ff0-a232-bf3eb3d15111" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_49532f90-80f3-4663-b2ff-1f210101c771" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressAddressLine1_49532f90-80f3-4663-b2ff-1f210101c771" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91fc0b70-36b7-4eda-85d5-a92fc1c46f44" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressCityOrTown_91fc0b70-36b7-4eda-85d5-a92fc1c46f44" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a9113bfa-e70a-458d-98f4-1e0bf3678061" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressStateOrProvince_a9113bfa-e70a-458d-98f4-1e0bf3678061" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ef2f3c5d-3e51-4fc7-95ba-a5e31222812b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressPostalZipCode_ef2f3c5d-3e51-4fc7-95ba-a5e31222812b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f5f9e663-0fa8-441c-94fd-ac0b09652998" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_CityAreaCode_f5f9e663-0fa8-441c-94fd-ac0b09652998" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6ead383b-0cf8-42d4-b9bb-d0c35687dc12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_LocalPhoneNumber_6ead383b-0cf8-42d4-b9bb-d0c35687dc12" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7c6e244d-4d47-416a-b568-45d891b0128d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCurrentReportingStatus_7c6e244d-4d47-416a-b568-45d891b0128d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9e571246-17ac-4fdd-9131-683896d61f05" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityInteractiveDataCurrent_9e571246-17ac-4fdd-9131-683896d61f05" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1510f923-5556-4f4a-9aa7-ba6064d1286b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityFilerCategory_1510f923-5556-4f4a-9aa7-ba6064d1286b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e40e95dc-d097-4050-8da3-558949fc3aaf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntitySmallBusiness_e40e95dc-d097-4050-8da3-558949fc3aaf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5e9703d6-df47-4bc3-a540-e4669fd65eb5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityEmergingGrowthCompany_5e9703d6-df47-4bc3-a540-e4669fd65eb5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e8a27060-220e-41d1-8e57-4073a0c45596" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityShellCompany_e8a27060-220e-41d1-8e57-4073a0c45596" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8f4c99ae-7f35-499d-a4d8-f9a48b039e0d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_Security12bTitle_8f4c99ae-7f35-499d-a4d8-f9a48b039e0d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4589a606-4c42-4b8f-aa6d-8c26d3ec2979" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_TradingSymbol_4589a606-4c42-4b8f-aa6d-8c26d3ec2979" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bceced6a-5166-46da-90e8-5f7ff3d75d1a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_SecurityExchangeName_bceced6a-5166-46da-90e8-5f7ff3d75d1a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bdbb8cbf-4839-456f-9948-4445b66ee5c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bdbb8cbf-4839-456f-9948-4445b66ee5c6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e3e26e6e-d33f-4fc6-aac3-b87828789732" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_AmendmentFlag_e3e26e6e-d33f-4fc6-aac3-b87828789732" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_adcd26a0-edba-4d5d-8ed6-95b7d42955bd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentFiscalYearFocus_adcd26a0-edba-4d5d-8ed6-95b7d42955bd" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57ddc8b7-3fc6-49b7-b1c7-a01bf773da59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57ddc8b7-3fc6-49b7-b1c7-a01bf773da59" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_867feb35-50e4-4e1f-a645-dd31d0828d2c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCentralIndexKey_867feb35-50e4-4e1f-a645-dd31d0828d2c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c9f54cbd-3cab-4dfe-8165-3e3f21a72c12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_CurrentFiscalYearEndDate_c9f54cbd-3cab-4dfe-8165-3e3f21a72c12" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa9a39aa-de8d-42b4-9902-6951d6ece8a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:to="loc_us-gaap_ClassOfStockDomain_aa9a39aa-de8d-42b4-9902-6951d6ece8a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:to="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a6cc5a5-29de-4555-a830-62b0ace5c3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_us-gaap_CommonStockMember_6a6cc5a5-29de-4555-a830-62b0ace5c3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member_88ee9971-bac0-4c9e-8011-fc3327f4919d" xlink:href="mrk-20200930.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.125Notesdue2021Member_88ee9971-bac0-4c9e-8011-fc3327f4919d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_bd30f473-0875-4f1f-8c1d-e180a3c815a8" xlink:href="mrk-20200930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A0.500Notesdue2024Member_bd30f473-0875-4f1f-8c1d-e180a3c815a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_2d40e0b5-a893-4623-9b0c-bb9c6b63715c" xlink:href="mrk-20200930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.875Notesdue2026Member_2d40e0b5-a893-4623-9b0c-bb9c6b63715c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_1622ed33-3dd5-45c8-b8ac-3e81d4bd9e52" xlink:href="mrk-20200930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A2.500Notesdue2034Member_1622ed33-3dd5-45c8-b8ac-3e81d4bd9e52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_a2dd6f41-15be-42b8-b0af-7ad59e38a041" xlink:href="mrk-20200930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.375Notesdue2036Member_a2dd6f41-15be-42b8-b0af-7ad59e38a041" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended" id="i0506d61967154e2ea78c6b6dff427510_CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended" id="idc256ad7e9154116940755aaa62ce118_CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended" id="i38701bfb16fc4cb5b423facdbafdb9bf_CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="extended" id="ic9286beb6ab243bf8f05ff7d50767d4d_CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended" id="i08f85f95c5ce476481a86f33f9013539_CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="extended" id="i1f9636fd32394b16b606773cecb89784_CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/BasisofPresentation" xlink:type="extended" id="i6aa566bae4ff456f87d87e4345af3b47_BasisofPresentation"/>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="extended" id="i4114c6d1135e4a79b636357cc04a7300_BasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended" id="i4343853f8221454db7f8d0fd32f09cbd_AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended" id="i4e5cf4ae1a3a4f85acd9a8a13c3746be_AcquisitionsResearchCollaborationsandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="extended" id="i034e33e4280d4ea48684da11cbfb306d_AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0cf2b066-7c5d-46c3-b28a-df790f072b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0cf2b066-7c5d-46c3-b28a-df790f072b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ed95040d-f997-4acf-870c-8d770b691c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ed95040d-f997-4acf-870c-8d770b691c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a5d88f7a-6f83-4035-a818-53537eb0a90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a5d88f7a-6f83-4035-a818-53537eb0a90f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a91a8d6-5b0f-493f-95ff-239cc36e9f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a91a8d6-5b0f-493f-95ff-239cc36e9f5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2648c314-6eb2-44ea-9bf4-d147d3e360af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2648c314-6eb2-44ea-9bf4-d147d3e360af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_888957c6-417e-45f1-815f-2e293dcf6ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_888957c6-417e-45f1-815f-2e293dcf6ceb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_0b44536a-ef5c-497b-aad1-eeb8aa7b7842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_0b44536a-ef5c-497b-aad1-eeb8aa7b7842" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_86e741e6-0939-4eb7-8d3c-edc9a8fa7369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_86e741e6-0939-4eb7-8d3c-edc9a8fa7369" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbc7e1c-9f94-4e6d-bba3-fcecca4c53dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbc7e1c-9f94-4e6d-bba3-fcecca4c53dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1d8d6951-ee29-48b1-bea4-f4002306c095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1d8d6951-ee29-48b1-bea4-f4002306c095" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4702f761-5046-4560-8a47-342091eede66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_Goodwill_4702f761-5046-4560-8a47-342091eede66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_34d45715-d6f2-48f2-b37b-03b3aa2bd250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_34d45715-d6f2-48f2-b37b-03b3aa2bd250" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8986afe9-d543-4d24-a0e8-860107cdea71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8986afe9-d543-4d24-a0e8-860107cdea71" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_17dbbea2-3375-4963-a964-a3c313fd3c22" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_17dbbea2-3375-4963-a964-a3c313fd3c22" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_a30a23e4-cb22-4896-9648-04935a150edb" xlink:href="mrk-20200930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_a30a23e4-cb22-4896-9648-04935a150edb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7513e806-326a-4427-ada1-1245744bee96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_SharePrice_7513e806-326a-4427-ada1-1245744bee96" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_42a26833-44dc-4961-877c-c99221bc024c" xlink:href="mrk-20200930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_42a26833-44dc-4961-877c-c99221bc024c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4c988af4-dfd5-4ce1-a83d-c69322b892af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4c988af4-dfd5-4ce1-a83d-c69322b892af" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7b01b801-c45a-47e5-9832-a13ce32d9f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7b01b801-c45a-47e5-9832-a13ce32d9f91" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_813d1a8b-2a6f-4ba9-99b6-b048b39eebf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_InventoryNet_813d1a8b-2a6f-4ba9-99b6-b048b39eebf0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1e41d883-c592-484f-9a94-85528ebab152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1e41d883-c592-484f-9a94-85528ebab152" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8988b7a9-d389-472e-9155-4996d39bd47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8988b7a9-d389-472e-9155-4996d39bd47a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6d7c5c82-afff-4388-8adb-5b47cb105f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6d7c5c82-afff-4388-8adb-5b47cb105f14" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9568354e-6a30-4647-af75-07a49467c6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9568354e-6a30-4647-af75-07a49467c6d6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_57d9f101-269d-40f5-9b52-e7a757db1d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_57d9f101-269d-40f5-9b52-e7a757db1d33" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_310bd4b0-5df8-4fe1-858e-5c3053fa4054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_310bd4b0-5df8-4fe1-858e-5c3053fa4054" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_69524e93-c9cc-49b1-b13a-dea362724d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_69524e93-c9cc-49b1-b13a-dea362724d07" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_41dc4b36-de9b-483c-a516-25d92949a8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_41dc4b36-de9b-483c-a516-25d92949a8a6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_bd960021-e46b-4754-b865-fe4b2135b07d" xlink:href="mrk-20200930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_RoyaltyRatePercentage_bd960021-e46b-4754-b865-fe4b2135b07d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3d6eaec1-7b57-45b4-8341-7edb6badeb22_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3d6eaec1-7b57-45b4-8341-7edb6badeb22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0a1d2af3-0480-4683-b663-ee3bf920f5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0a1d2af3-0480-4683-b663-ee3bf920f5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2fe8b38-bb36-45c1-89af-db2c8a47c055_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c2fe8b38-bb36-45c1-89af-db2c8a47c055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_c49645b0-d691-4db8-badc-8b2e8d53c85a" xlink:href="mrk-20200930.xsd#mrk_SeagenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:to="loc_mrk_SeagenMember_c49645b0-d691-4db8-badc-8b2e8d53c85a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_34d470a8-b41b-4450-af20-afce0d56f8c4" xlink:href="mrk-20200930.xsd#mrk_IAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:to="loc_mrk_IAVIMember_34d470a8-b41b-4450-af20-afce0d56f8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_9618b77a-3b3d-4467-9571-c0e6cde12367_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_9618b77a-3b3d-4467-9571-c0e6cde12367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_f4f62006-562c-4f76-9c18-694bec00fb57" xlink:href="mrk-20200930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_DevelopmentMilestonesMember_f4f62006-562c-4f76-9c18-694bec00fb57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_f6b63635-d2ec-4390-9598-24ee4fcb6058" xlink:href="mrk-20200930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_SalesBasedMilestonesMember_f6b63635-d2ec-4390-9598-24ee4fcb6058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_69f0523e-a73e-45d4-93b3-0128426a2140" xlink:href="mrk-20200930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_RegulatoryMilestonesMember_69f0523e-a73e-45d4-93b3-0128426a2140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialMilestoneMember_0f547b2b-a2dc-40b7-8ea6-e010831fc619" xlink:href="mrk-20200930.xsd#mrk_CommercialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_CommercialMilestoneMember_0f547b2b-a2dc-40b7-8ea6-e010831fc619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5cb84551-c18a-437a-9bff-2395f3aacd45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5cb84551-c18a-437a-9bff-2395f3aacd45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_622a6160-1edf-4f95-986c-cd0e507b24ef" xlink:href="mrk-20200930.xsd#mrk_DunboyneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_DunboyneMember_622a6160-1edf-4f95-986c-cd0e507b24ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_c912bbf7-eead-4865-bacb-c17cf5bb6501" xlink:href="mrk-20200930.xsd#mrk_ThemisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ThemisMember_c912bbf7-eead-4865-bacb-c17cf5bb6501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_91d8cd17-2167-4d41-96ee-fda1c15cd2d7" xlink:href="mrk-20200930.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ArQuleMember_91d8cd17-2167-4d41-96ee-fda1c15cd2d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_51f038b9-6275-4842-bc92-03012644035a" xlink:href="mrk-20200930.xsd#mrk_PelotonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_PelotonMember_51f038b9-6275-4842-bc92-03012644035a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_0e3b720d-9cb4-46a2-a707-f19a66a76bcf" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_AntelliqMember_0e3b720d-9cb4-46a2-a707-f19a66a76bcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_796497e4-3e63-4bfb-8e25-77037004ca71" xlink:href="mrk-20200930.xsd#mrk_ImmuneDesignMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ImmuneDesignMember_796497e4-3e63-4bfb-8e25-77037004ca71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_fa18f253-f275-476b-ba88-69ef4ff5d84e" xlink:href="mrk-20200930.xsd#mrk_VelosBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_VelosBioMember_fa18f253-f275-476b-ba88-69ef4ff5d84e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4ffad6a-2c3d-4099-9e39-ac58b732deb1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:to="loc_srt_ProductsAndServicesDomain_c4ffad6a-2c3d-4099-9e39-ac58b732deb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:to="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_0ae92259-a84f-4c17-991f-767818d70d79" xlink:href="mrk-20200930.xsd#mrk_TukysaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:to="loc_mrk_TukysaMember_0ae92259-a84f-4c17-991f-767818d70d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_92cc5a78-7409-4de8-8c2b-305c468b8bde" xlink:href="mrk-20200930.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:to="loc_mrk_SentinelMember_92cc5a78-7409-4de8-8c2b-305c468b8bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_f72d4dec-a43d-4920-b1db-1e9beb553d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:to="loc_us-gaap_ForwardContractsMember_f72d4dec-a43d-4920-b1db-1e9beb553d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a32d4254-21df-4c92-9918-2eb37f828aba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a32d4254-21df-4c92-9918-2eb37f828aba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f475cdcc-0c42-46b8-b20b-2d8edb703274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f475cdcc-0c42-46b8-b20b-2d8edb703274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1e664a3d-791e-4f75-9f2c-eef17eae6d30_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1e664a3d-791e-4f75-9f2c-eef17eae6d30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4576fdb4-97fb-45e6-91b2-e89cc361bd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:to="loc_us-gaap_SubsequentEventMember_4576fdb4-97fb-45e6-91b2-e89cc361bd03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd90c8c5-1be5-435c-b996-034cbb5aacdd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:to="loc_srt_RangeMember_bd90c8c5-1be5-435c-b996-034cbb5aacdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:to="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa10430-9edd-49f1-ba26-0421bcc8e40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:to="loc_srt_MinimumMember_7aa10430-9edd-49f1-ba26-0421bcc8e40e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cd4cec0-6535-4db2-bcab-66d75724b2e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:to="loc_srt_MaximumMember_7cd4cec0-6535-4db2-bcab-66d75724b2e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_743ab166-eb14-4848-90d1-12effa33d63a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_743ab166-eb14-4848-90d1-12effa33d63a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_463bf272-5150-46fb-aba4-0fc65adfe456" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:to="loc_srt_ScenarioForecastMember_463bf272-5150-46fb-aba4-0fc65adfe456" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i5ff9dca862cf459ca2d4733597298b3b_AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca6e689f-2b3b-4035-bcb3-046ba9f1784a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca6e689f-2b3b-4035-bcb3-046ba9f1784a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9826b9d3-5e38-48a2-87af-550aff6c18bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9826b9d3-5e38-48a2-87af-550aff6c18bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_671ece3c-0540-40ba-8bca-28a0317f3860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_671ece3c-0540-40ba-8bca-28a0317f3860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_880745ff-ca22-4c31-8371-4aac80d46531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_880745ff-ca22-4c31-8371-4aac80d46531" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_134cb4f7-f3f2-4164-b10d-f081329a7823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_134cb4f7-f3f2-4164-b10d-f081329a7823" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46a00843-0ada-4837-8fc8-b051ffba7b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46a00843-0ada-4837-8fc8-b051ffba7b8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24c6347c-8a78-454d-9e24-8aa80726f29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24c6347c-8a78-454d-9e24-8aa80726f29b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_3518eee1-2a1a-4c50-a300-2a1332e976d3" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_3518eee1-2a1a-4c50-a300-2a1332e976d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e2b76f0-0cca-435a-90d1-52781c77fa3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e2b76f0-0cca-435a-90d1-52781c77fa3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1b0034bd-2bdc-490d-ad60-25eb3d5e50ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_Goodwill_1b0034bd-2bdc-490d-ad60-25eb3d5e50ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_00484e73-b55f-4696-912c-70a263bdd59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_00484e73-b55f-4696-912c-70a263bdd59d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_20017596-fce8-4b10-a3ac-53b9aa69dff7" xlink:href="mrk-20200930.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_20017596-fce8-4b10-a3ac-53b9aa69dff7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_acabc737-c3ff-4d2e-9049-c0e6e6d6cd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_acabc737-c3ff-4d2e-9049-c0e6e6d6cd68" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e17f1ca6-06b0-4551-a4a3-a076a844881e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e17f1ca6-06b0-4551-a4a3-a076a844881e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_34d741c2-0e1e-4ba0-803e-eaa12e0ac562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_34d741c2-0e1e-4ba0-803e-eaa12e0ac562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9d72c40-d72b-4060-998c-9d656109b36c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a9d72c40-d72b-4060-998c-9d656109b36c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_519bbd60-b600-407a-991c-15501e9dbaf7" xlink:href="mrk-20200930.xsd#mrk_ArQuleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:to="loc_mrk_ArQuleMember_519bbd60-b600-407a-991c-15501e9dbaf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_24bde692-1e4a-4049-a9f9-0321dda3f166" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:to="loc_mrk_AntelliqMember_24bde692-1e4a-4049-a9f9-0321dda3f166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611a0531-dace-4a3c-9636-2de7cf256f31_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_611a0531-dace-4a3c-9636-2de7cf256f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_9d6a0574-ab59-4b40-8224-3d09dbf8ad4d" xlink:href="mrk-20200930.xsd#mrk_SentinelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:to="loc_mrk_SentinelMember_9d6a0574-ab59-4b40-8224-3d09dbf8ad4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_7596b5fe-18a0-4275-91d0-3210d5f966ba" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:to="loc_mrk_AntelliqMember_7596b5fe-18a0-4275-91d0-3210d5f966ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc89cbb2-387f-4313-8d8f-4e8e140264da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc89cbb2-387f-4313-8d8f-4e8e140264da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_47a2270a-1ad3-4475-96eb-e28d9ec73bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_47a2270a-1ad3-4475-96eb-e28d9ec73bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83df4fbb-f95e-431c-8cbe-9126f72c81f2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:to="loc_srt_RangeMember_83df4fbb-f95e-431c-8cbe-9126f72c81f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:to="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ee4e552-f86c-4e56-9a70-eb3e11ab45df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:to="loc_srt_MinimumMember_9ee4e552-f86c-4e56-9a70-eb3e11ab45df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80ce661c-24f0-4c92-9c9c-c9b97428baec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:to="loc_srt_MaximumMember_80ce661c-24f0-4c92-9c9c-c9b97428baec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangements"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended" id="i730f921fdec64b04bde6cd9cebc28a59_CollaborativeArrangements"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended" id="iebcdde656a4749daad758491ea9bf2eb_CollaborativeArrangementsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="i83b76a90ef264535bf99d3e9e95b3788_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f64fc543-99cd-4055-a4ae-9b3edd78b3a7" xlink:href="mrk-20200930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f64fc543-99cd-4055-a4ae-9b3edd78b3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_65073d9c-0500-4b9c-a374-1ab696dc643e" xlink:href="mrk-20200930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_65073d9c-0500-4b9c-a374-1ab696dc643e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6e304ad-b6f9-42f9-ac91-032ed1455a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6e304ad-b6f9-42f9-ac91-032ed1455a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_a9bd51f8-cbfa-47e3-855a-c81063151296" xlink:href="mrk-20200930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_a9bd51f8-cbfa-47e3-855a-c81063151296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6af84636-b584-4901-a5cd-a43fd13ea76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_Liabilities_6af84636-b584-4901-a5cd-a43fd13ea76f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_2f21cdad-72f9-41ac-8957-8623879b95af" xlink:href="mrk-20200930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_2f21cdad-72f9-41ac-8957-8623879b95af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_bde49cbd-13d0-4996-9c1e-9a49f831665f" xlink:href="mrk-20200930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_bde49cbd-13d0-4996-9c1e-9a49f831665f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a320bae6-30c4-412c-8656-c0efcaeea730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a320bae6-30c4-412c-8656-c0efcaeea730" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_892b236d-0385-4ae5-bb92-b9f83633608d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_892b236d-0385-4ae5-bb92-b9f83633608d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4984b7a-32e4-467f-905b-758b36b30982_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4984b7a-32e4-467f-905b-758b36b30982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_afb39c61-1483-470e-8658-96064577c46a" xlink:href="mrk-20200930.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_AstraZenecaMember_afb39c61-1483-470e-8658-96064577c46a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_75d1c39b-b248-4b74-a748-803e965512a6" xlink:href="mrk-20200930.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_EisaiMember_75d1c39b-b248-4b74-a748-803e965512a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_b5e81c29-24ef-4882-9a6a-c52df0f38eec" xlink:href="mrk-20200930.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_BayerAGMember_b5e81c29-24ef-4882-9a6a-c52df0f38eec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74874e57-1c89-449c-a123-4950ef369004_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74874e57-1c89-449c-a123-4950ef369004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_57d15b96-0410-4661-a003-6d5cb20fe4d5" xlink:href="mrk-20200930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:to="loc_mrk_SalesBasedMilestonesMember_57d15b96-0410-4661-a003-6d5cb20fe4d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_4a3c76f2-3145-4545-95c2-149e484df354" xlink:href="mrk-20200930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:to="loc_mrk_RegulatoryMilestonesMember_4a3c76f2-3145-4545-95c2-149e484df354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c88e02be-3cb0-44ec-90ac-d9dc12bf9689_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:to="loc_srt_ProductsAndServicesDomain_c88e02be-3cb0-44ec-90ac-d9dc12bf9689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:to="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d85c64a0-1f65-47a8-841c-88ce34dbf089" xlink:href="mrk-20200930.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_LynparzaMember_d85c64a0-1f65-47a8-841c-88ce34dbf089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_480d24f6-2385-4647-b47e-2eef7fb7bf88" xlink:href="mrk-20200930.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_LenvimaMember_480d24f6-2385-4647-b47e-2eef7fb7bf88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_6ee25db0-070a-4880-8ca3-478b4617ed5d" xlink:href="mrk-20200930.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_AdempasMember_6ee25db0-070a-4880-8ca3-478b4617ed5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8d8b99df-0fe4-487d-af7b-980872d681d0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8d8b99df-0fe4-487d-af7b-980872d681d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_87fbe0da-298f-4beb-9af0-f2e13fd75361" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:to="loc_srt_ScenarioForecastMember_87fbe0da-298f-4beb-9af0-f2e13fd75361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d7c72320-59e5-4af7-bf15-53fb0aaf4e23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d7c72320-59e5-4af7-bf15-53fb0aaf4e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ae90de03-01b2-419b-96cf-7ff5ef63a909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ae90de03-01b2-419b-96cf-7ff5ef63a909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_bd7c9512-809c-4008-bac4-f6133fb32b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_bd7c9512-809c-4008-bac4-f6133fb32b7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsScheduleofTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="extended" id="i59f8d9d02fcb4d8b8a69122052b55256_CollaborativeArrangementsScheduleofTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_a98258e9-170c-4d98-a9f2-bb0d84893c7e" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_a98258e9-170c-4d98-a9f2-bb0d84893c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_313184d0-3f48-438f-b035-4f899680961c" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_313184d0-3f48-438f-b035-4f899680961c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5e22076-8945-45bf-bfdf-6aa421e89c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_Revenues_f5e22076-8945-45bf-bfdf-6aa421e89c75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_28caa1ac-4a5c-4b03-bcd2-21a4ec6d3508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_28caa1ac-4a5c-4b03-bcd2-21a4ec6d3508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d54b5d28-aceb-4102-b5de-62019395d87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d54b5d28-aceb-4102-b5de-62019395d87c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_267659d2-e169-4c3c-b2b2-0819abfb5093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_267659d2-e169-4c3c-b2b2-0819abfb5093" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_65811282-ca35-4b4a-95ca-5dd21314b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_ReceivablesNetCurrent_65811282-ca35-4b4a-95ca-5dd21314b225" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f819c718-b1e8-41f8-9426-dd78a7c4110d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_LiabilitiesCurrent_f819c718-b1e8-41f8-9426-dd78a7c4110d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e53dd74c-815f-4d7f-b2b7-96558cf4ef9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e53dd74c-815f-4d7f-b2b7-96558cf4ef9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1837de22-540e-48a3-9619-79bcf1a09a98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1837de22-540e-48a3-9619-79bcf1a09a98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1b15efdb-3979-4261-a78d-983837d0ada0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_SalesMember_1b15efdb-3979-4261-a78d-983837d0ada0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9598b07e-dbf8-4891-bd24-22ce0a47d04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_CostOfSalesMember_9598b07e-dbf8-4891-bd24-22ce0a47d04f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9bbf38d-6862-4902-b137-4735e7379c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9bbf38d-6862-4902-b137-4735e7379c1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b4462be-bd24-40cb-82c8-21b6dc5988ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b4462be-bd24-40cb-82c8-21b6dc5988ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c6b8f124-082e-4237-8c4a-b6fda02131a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c6b8f124-082e-4237-8c4a-b6fda02131a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_e84cf9cd-c61f-4793-8dc8-d54424d8093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_e84cf9cd-c61f-4793-8dc8-d54424d8093c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_950a0d16-127c-4e41-8339-8cd344cd4866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_950a0d16-127c-4e41-8339-8cd344cd4866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_905e1482-3828-46be-b04b-e537d09b24f1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_905e1482-3828-46be-b04b-e537d09b24f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_08d771c2-5c81-42bc-9b5a-f52e350a5f9f" xlink:href="mrk-20200930.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_AstraZenecaMember_08d771c2-5c81-42bc-9b5a-f52e350a5f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_054ab896-2cda-4dd7-9b27-dc4e1d86971d" xlink:href="mrk-20200930.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_EisaiMember_054ab896-2cda-4dd7-9b27-dc4e1d86971d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_b953de05-22a8-44b3-97dc-16a9a7e4166b" xlink:href="mrk-20200930.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_BayerAGMember_b953de05-22a8-44b3-97dc-16a9a7e4166b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7cf61f35-7a72-4a0f-a045-1da2a694f776_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7cf61f35-7a72-4a0f-a045-1da2a694f776_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d26293ef-5479-47a7-a965-09624874a5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d26293ef-5479-47a7-a965-09624874a5a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22672a8d-2bd4-422b-9229-33cb7b3ec6b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:to="loc_srt_ProductsAndServicesDomain_22672a8d-2bd4-422b-9229-33cb7b3ec6b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:to="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_5f622f00-61c7-4ee5-ada5-44a04e8c8b04" xlink:href="mrk-20200930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_5f622f00-61c7-4ee5-ada5-44a04e8c8b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_2880602f-f719-46da-a30c-9c209953ed81" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_2880602f-f719-46da-a30c-9c209953ed81" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20200930.xsd#Restructuring"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended" id="i4021997d00bb465491123027d9e77e47_Restructuring"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended" id="ifdb63b84a94442008bca800e20139e14_RestructuringTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i88c0cd11bafe457abca897517f3654e4_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_bae885c7-badd-4194-8379-857143a15417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_bae885c7-badd-4194-8379-857143a15417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_296bd5cc-169e-4bb7-9449-39fb14e0e99d" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_296bd5cc-169e-4bb7-9449-39fb14e0e99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_7fe02084-e6de-4a00-a317-9ae35f9e4d17" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_7fe02084-e6de-4a00-a317-9ae35f9e4d17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_983191f9-c476-4b27-95af-cb74c21418ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_983191f9-c476-4b27-95af-cb74c21418ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_400e2f39-d1b2-4ca2-957d-f12223004382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_400e2f39-d1b2-4ca2-957d-f12223004382" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:to="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0d80a7ff-6889-4af2-b0bb-7f3b9d6fcbe8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:to="loc_srt_ScenarioForecastMember_0d80a7ff-6889-4af2-b0bb-7f3b9d6fcbe8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended" id="ia17e88d5276041748c564815f16107f9_RestructuringChargesActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e6bb4122-e821-4209-83a6-2ffa60c47aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e6bb4122-e821-4209-83a6-2ffa60c47aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_14d7a7a7-58c5-4987-aaab-929421336178_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_14d7a7a7-58c5-4987-aaab-929421336178_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a961c2a7-b0e3-4a69-a9c2-543d6a0e573d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_CostOfSalesMember_a961c2a7-b0e3-4a69-a9c2-543d6a0e573d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68cd5388-36b3-417f-9739-7ca67540d948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68cd5388-36b3-417f-9739-7ca67540d948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0f53453-bb10-45ab-9734-c4d312c57f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0f53453-bb10-45ab-9734-c4d312c57f97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_98d19ed0-3c9c-4b06-bfa3-cb5e4b445957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_RestructuringChargesMember_98d19ed0-3c9c-4b06-bfa3-cb5e4b445957" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e0a7967c-ef28-428d-b0e1-9d6399edc799_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e0a7967c-ef28-428d-b0e1-9d6399edc799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_be581883-058d-43f5-be41-529dae37cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_be581883-058d-43f5-be41-529dae37cb85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_2b553fd1-af21-4092-a89c-e59b9be6b7c7" xlink:href="mrk-20200930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_mrk_AcceleratedDepreciationMember_2b553fd1-af21-4092-a89c-e59b9be6b7c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2ba4126d-f423-42c3-81f3-0daff178202b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_us-gaap_OtherRestructuringMember_2ba4126d-f423-42c3-81f3-0daff178202b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended" id="i196bf1560988421dbf30697302d2dcf5_RestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:to="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5196c736-bb0e-40d5-92ed-c18a4a1589a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_RestructuringReserve_5196c736-bb0e-40d5-92ed-c18a4a1589a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2f253857-2ab5-420d-927f-bccbd8d238a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2f253857-2ab5-420d-927f-bccbd8d238a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3d467a57-e8bd-41dd-b017-92c671bfcab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_PaymentsForRestructuring_3d467a57-e8bd-41dd-b017-92c671bfcab3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity_648546fe-dca7-4be7-8ade-09070a22885d" xlink:href="mrk-20200930.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_mrk_RestructuringReserveNoncashActivity_648546fe-dca7-4be7-8ade-09070a22885d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_705a7e45-6d51-4823-85da-72413845b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_555fc561-0327-4573-ab72-f5386f9e74f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_555fc561-0327-4573-ab72-f5386f9e74f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_9b32c7f0-dc2e-4e8a-8195-8153a1686b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_9b32c7f0-dc2e-4e8a-8195-8153a1686b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_c9f0dba4-8f56-4201-825c-4ea283200ac2" xlink:href="mrk-20200930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_mrk_AcceleratedDepreciationMember_c9f0dba4-8f56-4201-825c-4ea283200ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a96f9b09-0444-46a8-8264-29bd86885e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_us-gaap_OtherRestructuringMember_a96f9b09-0444-46a8-8264-29bd86885e18" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended" id="i96acdc7d59c34d68ae5cbdc518d4fb51_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i60a5b907044b4b2d9183e9fee76fd5c0_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ib425aed4c80849dfb17f56a4ab1322fe_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_e305952e-9bca-48b1-b7e6-590cdf1771ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_e305952e-9bca-48b1-b7e6-590cdf1771ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_a7e43785-d3d5-4e85-9a5f-52a656c56b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_a7e43785-d3d5-4e85-9a5f-52a656c56b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_7d1c889f-5f58-4343-b53b-7700de4d5788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_7d1c889f-5f58-4343-b53b-7700de4d5788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f1c5676-886e-461a-973e-5663b7484c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f1c5676-886e-461a-973e-5663b7484c79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_28410cfc-9820-47d9-851c-cf4690175f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_28410cfc-9820-47d9-851c-cf4690175f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_a945635b-1518-4014-82ea-0fd4a8d7b937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_a945635b-1518-4014-82ea-0fd4a8d7b937" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_86ab55ab-fd0f-4313-a9bb-512d5651c55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_86ab55ab-fd0f-4313-a9bb-512d5651c55c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_1b134ff4-9f4b-4829-b78c-d9a505bcd2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_1b134ff4-9f4b-4829-b78c-d9a505bcd2c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b62e0f22-6ea1-4f73-90d2-b71b24a13342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b62e0f22-6ea1-4f73-90d2-b71b24a13342" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3d7098ce-5bb3-4082-b480-4c27ca36b248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3d7098ce-5bb3-4082-b480-4c27ca36b248" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_fda7f5f4-23fb-43a0-bbc3-5039f06513ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_fda7f5f4-23fb-43a0-bbc3-5039f06513ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_1da64d19-1680-443e-ac33-e57a456030f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_1da64d19-1680-443e-ac33-e57a456030f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_6aa5a953-c7de-40ac-a254-bc81f751c5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_AccountsReceivableSale_6aa5a953-c7de-40ac-a254-bc81f751c5ea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5524c62f-94f2-4bc6-b98b-1ebddce62186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5524c62f-94f2-4bc6-b98b-1ebddce62186" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d6a2e3d8-4693-4b67-aa2d-96c746c76158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d6a2e3d8-4693-4b67-aa2d-96c746c76158" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e5c313ac-0824-4700-9431-d52a2141a234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e5c313ac-0824-4700-9431-d52a2141a234" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f5982b15-51ea-4684-baf8-4291758c0bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f5982b15-51ea-4684-baf8-4291758c0bfd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa271c24-0181-4b8b-ae4b-3a3b68fdbf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa271c24-0181-4b8b-ae4b-3a3b68fdbf24" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2a781006-6ba0-40fc-a226-1fe1704655cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2a781006-6ba0-40fc-a226-1fe1704655cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_37b76314-6829-41de-baf5-7303be8f1fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:to="loc_us-gaap_InterestRateSwapMember_37b76314-6829-41de-baf5-7303be8f1fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8612e95f-949b-40be-883b-8be6e774e376_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8612e95f-949b-40be-883b-8be6e774e376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member_75cd0fb2-28da-4154-8b49-1b146cd26a73" xlink:href="mrk-20200930.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:to="loc_mrk_A1.85NotesDue2020Member_75cd0fb2-28da-4154-8b49-1b146cd26a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_36c48459-4a07-410e-9412-7c5b363ed07c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:to="loc_us-gaap_HedgingDesignationDomain_36c48459-4a07-410e-9412-7c5b363ed07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:to="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87a0916d-7014-4edd-a119-d6fd4645cd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87a0916d-7014-4edd-a119-d6fd4645cd4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dd4f75d3-f6e2-45df-8b13-bb037d6545ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:to="loc_us-gaap_NondesignatedMember_dd4f75d3-f6e2-45df-8b13-bb037d6545ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d910c61c-69bc-4357-ab54-91446bf8d79a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:to="loc_srt_RangeMember_d910c61c-69bc-4357-ab54-91446bf8d79a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:to="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df2b765e-9c02-4118-bbec-d5de31cf0fc5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:to="loc_srt_MaximumMember_df2b765e-9c02-4118-bbec-d5de31cf0fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e16154d-381a-4e58-92e0-847ca10a129f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5e16154d-381a-4e58-92e0-847ca10a129f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c59c689-5aad-4a26-8227-6cbe17f8e0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c59c689-5aad-4a26-8227-6cbe17f8e0a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="ib9d72ee20b444a068302a98f407fc164_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c9b17de0-ee94-4de4-a122-5e8e94eeca74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c9b17de0-ee94-4de4-a122-5e8e94eeca74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_eba8ecf4-c20d-4a9a-b0cf-4f91ccc16911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_eba8ecf4-c20d-4a9a-b0cf-4f91ccc16911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4bc96461-d924-485c-b767-890ab57d9215_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4bc96461-d924-485c-b767-890ab57d9215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e7b501db-f625-4e9f-a78f-9c36246f1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e7b501db-f625-4e9f-a78f-9c36246f1e79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_0430f094-0473-4798-bb52-7dd1f8133c48" xlink:href="mrk-20200930.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:to="loc_mrk_EurodominatedNotesMember_0430f094-0473-4798-bb52-7dd1f8133c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9a6fd6e9-da2a-48ef-9e6d-4ff167e1d058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9a6fd6e9-da2a-48ef-9e6d-4ff167e1d058" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="extended" id="ie2c534fa9c15435c9d5471a8fe8055de_FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e746c26-b129-4227-9a54-610d6cca504d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e746c26-b129-4227-9a54-610d6cca504d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6bca2090-4c2c-4fe3-baa3-32bd8507551a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6bca2090-4c2c-4fe3-baa3-32bd8507551a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_630e7644-1eee-44aa-98d3-c310a0297228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_630e7644-1eee-44aa-98d3-c310a0297228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_bc2025b0-064d-405c-ac4f-78476bff7395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_bc2025b0-064d-405c-ac4f-78476bff7395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2214f2f9-76db-478d-84bd-6b60a071af65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2214f2f9-76db-478d-84bd-6b60a071af65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_25c753aa-d8f1-4dec-b250-303b84fe9f76" xlink:href="mrk-20200930.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A3.875NotesDue2021Member_25c753aa-d8f1-4dec-b250-303b84fe9f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_6674870e-caad-43a4-b1f4-dc517fbefa22" xlink:href="mrk-20200930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A2.40NotesDue2022Member_6674870e-caad-43a4-b1f4-dc517fbefa22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_595358ce-f155-4225-8845-d635fc7cdce8" xlink:href="mrk-20200930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A2.35NotesDue2022Member_595358ce-f155-4225-8845-d635fc7cdce8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_21253333-572c-4d56-ad7c-7a13188acf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:to="loc_us-gaap_InterestRateSwapMember_21253333-572c-4d56-ad7c-7a13188acf0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="extended" id="iacc02bd8476d45ba8210ff53c36a5c9c_FinancialInstrumentsFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_bf4fd38d-8ee9-416b-80e4-cbea127506b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_bf4fd38d-8ee9-416b-80e4-cbea127506b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f332d752-69ed-431c-ba32-22e04a7d05de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f332d752-69ed-431c-ba32-22e04a7d05de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_a1094f4b-66e6-42c1-95c6-ccbe971cceea" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_a1094f4b-66e6-42c1-95c6-ccbe971cceea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_4dd3efd5-39f6-402c-9ad1-5d092e7c2ace" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_4dd3efd5-39f6-402c-9ad1-5d092e7c2ace" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="ibb807fb732474a518b6141b89be3684c_FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b6f9904f-27bc-4400-bafe-15a7bdb3ae56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeAssets_b6f9904f-27bc-4400-bafe-15a7bdb3ae56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d1bbcdc-54ba-434e-a39c-30dbbea4236a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeLiabilities_1d1bbcdc-54ba-434e-a39c-30dbbea4236a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6d3a524d-5438-487f-be38-d0e24f5b014e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6d3a524d-5438-487f-be38-d0e24f5b014e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e0d3cbc-62a7-4a70-b165-74f7673e0be5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e0d3cbc-62a7-4a70-b165-74f7673e0be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_1d84d8af-c716-4c1b-b5ca-8d33113fff1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_InterestRateContractMember_1d84d8af-c716-4c1b-b5ca-8d33113fff1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ebf40f3a-e627-475e-bf7b-362ea3e0e601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ebf40f3a-e627-475e-bf7b-362ea3e0e601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_04b6b2b0-8d8b-49b4-916b-461c8e0be158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_ForwardContractsMember_04b6b2b0-8d8b-49b4-916b-461c8e0be158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_34fbad67-70c2-42d8-84a6-80388b9dc041_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:to="loc_us-gaap_HedgingDesignationDomain_34fbad67-70c2-42d8-84a6-80388b9dc041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:to="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e9ba8e34-f4bc-4c58-b35a-d548a331c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e9ba8e34-f4bc-4c58-b35a-d548a331c4d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c4f72ff0-caf9-49f6-b5fd-92e006dbafa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:to="loc_us-gaap_NondesignatedMember_c4f72ff0-caf9-49f6-b5fd-92e006dbafa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b38e299f-13ac-4462-9ced-c101e694ed62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b38e299f-13ac-4462-9ced-c101e694ed62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_607513a9-8cd2-4fad-9908-8cea53fb6831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_607513a9-8cd2-4fad-9908-8cea53fb6831" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_1a078abe-d3a8-4291-bb2b-169d41c13c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherAssetsMember_1a078abe-d3a8-4291-bb2b-169d41c13c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_32aabb5b-2d6f-41ee-821f-b859e1bb58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_32aabb5b-2d6f-41ee-821f-b859e1bb58a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c1b4ed62-ce05-4ce0-a505-69c539a488ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c1b4ed62-ce05-4ce0-a505-69c539a488ef" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended" id="i8e1b4e2ed17b413f9f68ebc037888d20_FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended" id="i0ed28e7f3ae44ba8ad194a85061c1be4_FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ecc5987b-bb83-4f65-866f-84a116504958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_Revenues_ecc5987b-bb83-4f65-866f-84a116504958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25de9ddc-f05c-4409-88c9-82f541a023bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25de9ddc-f05c-4409-88c9-82f541a023bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_06f4ef00-e0cf-4bca-ba69-186d3b7affb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_06f4ef00-e0cf-4bca-ba69-186d3b7affb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_7a39de49-d0ae-4822-ae3c-a74c6c059b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_7a39de49-d0ae-4822-ae3c-a74c6c059b23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3ec899d9-1796-4ad7-b724-4c45d8806e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3ec899d9-1796-4ad7-b724-4c45d8806e32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_2766149f-356a-4657-aee5-b0b8eb62fbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_2766149f-356a-4657-aee5-b0b8eb62fbd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_09d05b7e-80c6-4fc5-8ec9-b2b636e34e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_09d05b7e-80c6-4fc5-8ec9-b2b636e34e1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c51ac148-bf4c-4a09-a6fb-976b507684d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c51ac148-bf4c-4a09-a6fb-976b507684d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_47078de7-daf4-40dc-8845-e794c3962fc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_47078de7-daf4-40dc-8845-e794c3962fc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b21e9433-9d77-42a8-877e-f519652a1b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:to="loc_us-gaap_InterestRateSwapMember_b21e9433-9d77-42a8-877e-f519652a1b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_54877d64-3b35-457a-85cc-bf55934b01d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:to="loc_us-gaap_ForeignExchangeContractMember_54877d64-3b35-457a-85cc-bf55934b01d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2ddd635b-da21-4b2b-ae82-174d9c3419e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2ddd635b-da21-4b2b-ae82-174d9c3419e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_523e67de-2187-44e2-aa4c-5a2a7fe19933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_523e67de-2187-44e2-aa4c-5a2a7fe19933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b84a618-56c9-41e1-b7a0-24aa3483dd3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:to="loc_us-gaap_EquityComponentDomain_9b84a618-56c9-41e1-b7a0-24aa3483dd3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:to="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37f7132f-8059-4f62-919e-415e97b4bebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37f7132f-8059-4f62-919e-415e97b4bebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_93cda9d8-39be-47cb-a7a7-3d93988761d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_93cda9d8-39be-47cb-a7a7-3d93988761d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e68871d4-840c-42f9-b91c-26ebe2fe66dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e68871d4-840c-42f9-b91c-26ebe2fe66dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i7abc59b98220433689d05b2a4ab9a04a_FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cb8f7eba-9b0e-42e2-9922-4f719603c8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cb8f7eba-9b0e-42e2-9922-4f719603c8ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0a9bfb42-d33b-4d26-869d-946c8a8494b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0a9bfb42-d33b-4d26-869d-946c8a8494b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_292c5260-d607-45f4-9c05-4b3dc66e934e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_CurrencySwapMember_292c5260-d607-45f4-9c05-4b3dc66e934e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_f03acd5e-9f21-4ce2-ab69-3e1a77e12186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_f03acd5e-9f21-4ce2-ab69-3e1a77e12186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_8cf3706f-0565-492a-bf96-1296ce803d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_TreasuryLockMember_8cf3706f-0565-492a-bf96-1296ce803d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_ef43efa8-13d0-4db7-a95b-5e7dafde7c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_ForwardContractsMember_ef43efa8-13d0-4db7-a95b-5e7dafde7c2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3ecccb77-c041-4a8f-b87c-5414c61b41a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3ecccb77-c041-4a8f-b87c-5414c61b41a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a5c470e1-2945-4053-acc9-d67f7da872d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a5c470e1-2945-4053-acc9-d67f7da872d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5c224adc-0b69-4d87-a02b-28fa2e62b83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_SalesMember_5c224adc-0b69-4d87-a02b-28fa2e62b83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a267654-2f5f-4fd6-b531-ade6d6a6c6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a267654-2f5f-4fd6-b531-ade6d6a6c6eb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended" id="if689de2694da49e6b1a82962e6fcf16e_FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbfd5c1b-0f2f-4a52-9a99-a6358f035cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbfd5c1b-0f2f-4a52-9a99-a6358f035cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_209af63c-7435-4ab3-8f18-58c73b894ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_209af63c-7435-4ab3-8f18-58c73b894ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_103f5618-ec5d-4600-bc4a-79232fe21b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_103f5618-ec5d-4600-bc4a-79232fe21b31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb1ddaaa-ad6b-407e-9dcb-66c62bf92946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb1ddaaa-ad6b-407e-9dcb-66c62bf92946" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_325933ee-a227-4e3d-bd3b-7e81fe44df82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_325933ee-a227-4e3d-bd3b-7e81fe44df82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f767795a-becd-496a-be2c-06ea951eaf2b" xlink:href="mrk-20200930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f767795a-becd-496a-be2c-06ea951eaf2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8065b3a1-8a97-492d-b235-008a3b780f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8065b3a1-8a97-492d-b235-008a3b780f7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8513eae-8065-4528-ab00-e79d777c2504_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8513eae-8065-4528-ab00-e79d777c2504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3071c7d5-6cfe-4d01-b910-a08d6d8e6371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3071c7d5-6cfe-4d01-b910-a08d6d8e6371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b911f131-6e0b-4648-920a-359131257ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b911f131-6e0b-4648-920a-359131257ac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79932602-c95b-4fd3-8e09-e9c0cc457efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_CommercialPaperMember_79932602-c95b-4fd3-8e09-e9c0cc457efd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4a0547d6-4dc7-4ed3-8f08-0731674f7e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4a0547d6-4dc7-4ed3-8f08-0731674f7e49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_72dfbc20-a5c4-4c05-82f9-4681a9624536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_72dfbc20-a5c4-4c05-82f9-4681a9624536" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i0c6ba92d7d3540d9a92f0cb2c286661f_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5df6e28a-3e72-4562-8f61-13c42377dd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5df6e28a-3e72-4562-8f61-13c42377dd36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9e2338c3-32dc-40f3-9dfe-0bcdee714942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9e2338c3-32dc-40f3-9dfe-0bcdee714942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_ee3796aa-029c-416b-9e98-27dbd5bf7ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_TradingSecurities_ee3796aa-029c-416b-9e98-27dbd5bf7ee3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aa2d23a2-b0a1-4405-857d-819e38ead183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aa2d23a2-b0a1-4405-857d-819e38ead183" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2fbfca6b-d9e9-4241-8824-e902aa34bfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_DerivativeAssets_2fbfca6b-d9e9-4241-8824-e902aa34bfbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a16a09f0-c5b4-430b-a101-c51dc820a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a16a09f0-c5b4-430b-a101-c51dc820a8be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35822ad3-e116-4512-8dd5-13ccb8b0051c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35822ad3-e116-4512-8dd5-13ccb8b0051c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f2f02c1b-bc31-4a49-b65e-ef3513f00025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_DerivativeLiabilities_f2f02c1b-bc31-4a49-b65e-ef3513f00025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_72245f1f-a378-4f37-9679-1221f749656c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_72245f1f-a378-4f37-9679-1221f749656c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_cdbd6d7e-4217-45e0-82d4-e69f21d57486" xlink:href="mrk-20200930.xsd#mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_cdbd6d7e-4217-45e0-82d4-e69f21d57486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_32a38d30-4092-4c45-86fe-0569d355ae93_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_32a38d30-4092-4c45-86fe-0569d355ae93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_403fdf87-8e99-4105-9187-6b240ccfcb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_403fdf87-8e99-4105-9187-6b240ccfcb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7450b50c-a297-4afb-a8b7-9ff46763d599_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7450b50c-a297-4afb-a8b7-9ff46763d599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_c9531983-b2ac-44fc-816c-80fbe8da13d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_c9531983-b2ac-44fc-816c-80fbe8da13d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_248e374d-88c0-45b3-b8df-39bd02bb4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_248e374d-88c0-45b3-b8df-39bd02bb4ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_102aca86-0012-4c8f-81e1-ac7aceafa60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_CommercialPaperMember_102aca86-0012-4c8f-81e1-ac7aceafa60b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b1217051-07c7-4aa2-99fa-6921c70041d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b1217051-07c7-4aa2-99fa-6921c70041d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6b805bb6-b7e2-467a-87eb-1f24d6c8eb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6b805bb6-b7e2-467a-87eb-1f24d6c8eb59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b867de89-4d85-4d60-929c-a544471020e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_EquitySecuritiesMember_b867de89-4d85-4d60-929c-a544471020e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc403258-68a3-434c-a964-0ff0594466bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc403258-68a3-434c-a964-0ff0594466bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f13af46a-988f-4b74-8380-f11a23f5f145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f13af46a-988f-4b74-8380-f11a23f5f145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_314c7de2-bbf0-432e-bc3e-96d0e80ea454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_314c7de2-bbf0-432e-bc3e-96d0e80ea454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75e2e6e2-9ba4-4317-b36f-61a1157da95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75e2e6e2-9ba4-4317-b36f-61a1157da95e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f2ba14b8-0705-42e7-af84-9f18a44e9c65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f2ba14b8-0705-42e7-af84-9f18a44e9c65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_15b6c3f9-c7f5-4d3f-a408-796cf1f0bf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForeignExchangeContractMember_15b6c3f9-c7f5-4d3f-a408-796cf1f0bf15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_765983cf-98d4-4ebc-82bc-e1766b321d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_InterestRateSwapMember_765983cf-98d4-4ebc-82bc-e1766b321d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_8c95fbb2-adda-4009-833f-3461e0bdb6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_8c95fbb2-adda-4009-833f-3461e0bdb6a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a45b59c4-1b42-44f0-8e4c-9a4110363c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_InterestRateContractMember_a45b59c4-1b42-44f0-8e4c-9a4110363c88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_56aeb98a-974b-4a85-b629-5ddcf481dfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForwardContractsMember_56aeb98a-974b-4a85-b629-5ddcf481dfca" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i4928109a3d2b4f598df2874b2198ae9c_FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8dce45b3-2aaf-4048-a9a8-7b61654811c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8dce45b3-2aaf-4048-a9a8-7b61654811c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3623c163-e14d-49d8-aa61-1bc72124065c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3623c163-e14d-49d8-aa61-1bc72124065c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5848fcff-e54f-407a-9a23-d33d4f624ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5848fcff-e54f-407a-9a23-d33d4f624ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4801e791-50dd-432e-8db0-2e7a0ad4054f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4801e791-50dd-432e-8db0-2e7a0ad4054f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ad180fb2-cfee-4783-93ba-38aa82d1fb33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_309bf2d2-3431-4964-a84d-1bfa4fd1e873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_309bf2d2-3431-4964-a84d-1bfa4fd1e873" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_210640de-fe93-4724-ae77-38a7677a39b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1990d29e-3bdf-480e-b2a9-a742ab093e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1990d29e-3bdf-480e-b2a9-a742ab093e2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_490e0590-2966-4678-9a41-91fa47f4a3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_490e0590-2966-4678-9a41-91fa47f4a3c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_570c4f6f-624c-48d7-ba25-8380d894a588_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_570c4f6f-624c-48d7-ba25-8380d894a588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_916eae42-f183-4bb8-a052-67bd332431d5" xlink:href="mrk-20200930.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:to="loc_mrk_SanofiPasteurMember_916eae42-f183-4bb8-a052-67bd332431d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20200930.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended" id="ica29bb8feb5a4288a81f2874ad76796b_Inventories"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended" id="i9203b820a1cb4c7f8285166d530dc91c_InventoriesTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended" id="ica3e3a884d754da6b423c4e26c687100_InventoriesInventoriesDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i000b39b269d244079e43233b21a4ef93_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d88fbd29-032b-4e92-8d13-0f5b2b63602e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:to="loc_us-gaap_InventoryNoncurrent_d88fbd29-032b-4e92-8d13-0f5b2b63602e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:href="mrk-20200930.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:to="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e99faf4-60ac-4e44-a282-b0c3bec2d32a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e99faf4-60ac-4e44-a282-b0c3bec2d32a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ccd52f23-f429-4fe4-b9c6-97a583f645d8" xlink:href="mrk-20200930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ccd52f23-f429-4fe4-b9c6-97a583f645d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02df81e9-47ba-474f-8a65-80938a126f58" xlink:href="mrk-20200930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02df81e9-47ba-474f-8a65-80938a126f58" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangibles" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangibles"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIntangibles" xlink:type="extended" id="iac41901c2a43432195f17298f0a1050b_OtherIntangibles"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="extended" id="i26f88e46b4bb425f83df6159e45d861c_OtherIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d4cc6915-583f-4c4f-b38f-6dfce2bbb294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d4cc6915-583f-4c4f-b38f-6dfce2bbb294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:to="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c83956d8-3986-48e9-8ee6-74db1d0d8f8c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:to="loc_srt_ProductsAndServicesDomain_c83956d8-3986-48e9-8ee6-74db1d0d8f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:to="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_44264117-c43e-4eee-a72e-aad6bd16503b" xlink:href="mrk-20200930.xsd#mrk_SivextroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:to="loc_mrk_SivextroMember_44264117-c43e-4eee-a72e-aad6bd16503b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebt" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebt"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LongTermDebt" xlink:type="extended" id="ib244552ccc15435984b8a584b7816d32_LongTermDebt"/>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="extended" id="i62228481220049758bb4bf9a66db0942_LongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cbc85821-6cae-40e7-8971-2e73aae1b9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cbc85821-6cae-40e7-8971-2e73aae1b9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b03846-5000-4f51-ae66-28cf9fc3f96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b03846-5000-4f51-ae66-28cf9fc3f96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:to="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e579814-0a6c-4801-ae05-c245b2597031_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e579814-0a6c-4801-ae05-c245b2597031_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member_390c242f-1507-4be2-811c-e8cc1f3d9392" xlink:href="mrk-20200930.xsd#mrk_A0.75notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A0.75notesdue2026Member_390c242f-1507-4be2-811c-e8cc1f3d9392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member_41874a01-56c2-493a-823b-dac370a172f7" xlink:href="mrk-20200930.xsd#mrk_A1.45notesdue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A1.45notesdue2030Member_41874a01-56c2-493a-823b-dac370a172f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member_78a0459d-154b-4c0e-99e6-fa42f782c6a4" xlink:href="mrk-20200930.xsd#mrk_A2.35notesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A2.35notesdue2040Member_78a0459d-154b-4c0e-99e6-fa42f782c6a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member_7eac00f9-0ee4-43d7-8d29-d6e54a0fcd83" xlink:href="mrk-20200930.xsd#mrk_A2.45notesdue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A2.45notesdue2050Member_7eac00f9-0ee4-43d7-8d29-d6e54a0fcd83" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Contingencies" xlink:type="simple" xlink:href="mrk-20200930.xsd#Contingencies"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Contingencies" xlink:type="extended" id="i304714cfdbe74e3e898cbeabab0839f4_Contingencies"/>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="extended" id="ia5f3323f7a264b2ca808bb7be2ec64c3_ContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b570d4d1-8c33-4ed8-86b6-8b017f6f6103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b570d4d1-8c33-4ed8-86b6-8b017f6f6103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_7489c210-a93a-4f73-9a07-b458b649dd85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_7489c210-a93a-4f73-9a07-b458b649dd85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_203baa0b-fd26-4b99-91c8-b2643a6f9f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_203baa0b-fd26-4b99-91c8-b2643a6f9f32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_9d5aed8c-7361-4a4b-a558-50da3e9923e5" xlink:href="mrk-20200930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_9d5aed8c-7361-4a4b-a558-50da3e9923e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_63fb2a6f-cac6-4f8b-9da4-2fd5e12a523c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LitigationReserve_63fb2a6f-cac6-4f8b-9da4-2fd5e12a523c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_414a11cd-4de8-446b-b8ce-9ca26d711e97_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:to="loc_srt_ProductsAndServicesDomain_414a11cd-4de8-446b-b8ce-9ca26d711e97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:to="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_3589aefd-bc6f-4152-a7e5-a2a474215cfc" xlink:href="mrk-20200930.xsd#mrk_FosamaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:to="loc_mrk_FosamaxMember_3589aefd-bc6f-4152-a7e5-a2a474215cfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_5ea382ef-25b9-42b4-a886-0ed1643e2584" xlink:href="mrk-20200930.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:to="loc_mrk_JanuviaMember_5ea382ef-25b9-42b4-a886-0ed1643e2584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b08f6643-c803-4af4-8e45-52feb8a3f30f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b08f6643-c803-4af4-8e45-52feb8a3f30f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember_802ff7b1-90d2-4147-a48b-6fbf637b93c7" xlink:href="mrk-20200930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:to="loc_mrk_FemurFractureLitigationMember_802ff7b1-90d2-4147-a48b-6fbf637b93c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8cf319c0-959f-4911-b351-cce04bd8edf8" xlink:href="mrk-20200930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8cf319c0-959f-4911-b351-cce04bd8edf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8c151ff5-1feb-4bcd-917f-414c7369cc60_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:to="loc_srt_LitigationCaseTypeDomain_8c151ff5-1feb-4bcd-917f-414c7369cc60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:to="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_a57939e2-f2a2-44f4-a8f9-200d77851c2b" xlink:href="mrk-20200930.xsd#mrk_FederalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_FederalMember_a57939e2-f2a2-44f4-a8f9-200d77851c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember_6b817e01-1490-4c4b-871c-571ddec4aab2" xlink:href="mrk-20200930.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_NewJerseyStateCourtMember_6b817e01-1490-4c4b-871c-571ddec4aab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember_e7bab5f1-f78e-437a-917a-41be1810feab" xlink:href="mrk-20200930.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_CaliforniaStateCourtMember_e7bab5f1-f78e-437a-917a-41be1810feab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_48d8a1cc-a526-46e6-81aa-b1c82dfe990c" xlink:href="mrk-20200930.xsd#mrk_OtherStateCourtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_OtherStateCourtMember_48d8a1cc-a526-46e6-81aa-b1c82dfe990c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_f1007b65-d760-45b3-ade0-3adf1d84d042" xlink:href="mrk-20200930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_f1007b65-d760-45b3-ade0-3adf1d84d042" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a0d35b38-2fe8-4223-9ccc-e68e947fa98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_us-gaap_PatentsMember_a0d35b38-2fe8-4223-9ccc-e68e947fa98d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e3013b5d-e53c-4cf3-bd81-f824278de3b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e3013b5d-e53c-4cf3-bd81-f824278de3b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_87369e09-87ca-4f55-bc11-419471e47c9c" xlink:href="mrk-20200930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:to="loc_mrk_LegalDefenseCostsMember_87369e09-87ca-4f55-bc11-419471e47c9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20200930.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended" id="i2fd46844d6f74478a2c09bb6fcd6365b_Equity"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended" id="i64c4bed7fe214f14af0d8dd3d7083103_EquityTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityRollforwardReconciliationsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="extended" id="ia4e0f70a3d0c4233a142cadac0ca5e37_EquityRollforwardReconciliationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a975927d-6174-4410-8f99-f4cab18db9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_CommonStockSharesIssued_a975927d-6174-4410-8f99-f4cab18db9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3dc2f586-22f3-4b50-b907-f46eac934c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3dc2f586-22f3-4b50-b907-f46eac934c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d49fcdd1-f27f-43b8-9a6f-3d4cdfd8e153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_NetIncomeLoss_d49fcdd1-f27f-43b8-9a6f-3d4cdfd8e153" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05d6765-55cb-4608-8d54-62e6bfeebcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05d6765-55cb-4608-8d54-62e6bfeebcd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_e13b3518-4eea-4364-b619-dcf00f50b76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_DividendsCommonStockCash_e13b3518-4eea-4364-b619-dcf00f50b76c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f377a8bf-5afb-4cac-b9c7-0b1a308b173b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f377a8bf-5afb-4cac-b9c7-0b1a308b173b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5c466acd-86e5-497c-9e75-4f893b2c67fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5c466acd-86e5-497c-9e75-4f893b2c67fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_59f7b651-4d3a-4ddc-8f8f-9ea4d42e3f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_59f7b651-4d3a-4ddc-8f8f-9ea4d42e3f53" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_386c168c-8a97-4953-a4bf-45bd6bd69a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityOther_386c168c-8a97-4953-a4bf-45bd6bd69a81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a257619d-568c-49d2-ae87-89a1f4edfccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a257619d-568c-49d2-ae87-89a1f4edfccd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d6c9ae7a-1147-466b-a68f-2538528d84bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d6c9ae7a-1147-466b-a68f-2538528d84bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a6ec51a5-a7ea-4490-b280-494d44e9852a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b322a2d-dbb8-4853-93a3-6a72d8d24a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b90c74f6-036d-4b5f-8daa-ec27c3a8b880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b90c74f6-036d-4b5f-8daa-ec27c3a8b880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:to="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a93da48-7583-4a1f-bd47-9bb7a62b93dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:to="loc_us-gaap_EquityComponentDomain_1a93da48-7583-4a1f-bd47-9bb7a62b93dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:to="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eac25ba2-5f05-407e-8d29-5efba87a57ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_CommonStockMember_eac25ba2-5f05-407e-8d29-5efba87a57ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_45764e98-93b0-4914-a5a4-44b4da516302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_45764e98-93b0-4914-a5a4-44b4da516302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5393dc68-bd68-4422-9084-d30aff26db13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_RetainedEarningsMember_5393dc68-bd68-4422-9084-d30aff26db13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ba58a5af-3e78-41b6-8236-bfe7b60bb479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ba58a5af-3e78-41b6-8236-bfe7b60bb479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_6049ee12-25eb-4e3a-bf64-9326c7b3b4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_TreasuryStockMember_6049ee12-25eb-4e3a-bf64-9326c7b3b4e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_48ae0ed0-0b4c-47e2-959f-27e000dff940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_NoncontrollingInterestMember_48ae0ed0-0b4c-47e2-959f-27e000dff940" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlans"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended" id="i0ddabbbbd5b44c0999ffcd9261180371_ShareBasedCompensationPlans"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended" id="i429af8bbf53249ef822faac58609bfbe_ShareBasedCompensationPlansTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansExpenseAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="extended" id="iabe164d191324a48b8839a65b65202f2_ShareBasedCompensationPlansExpenseAllocationsDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="id6cbed2d55fd4a31a09c46ce95a3ad8e_ShareBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1259be14-cab0-4a0c-9171-4ad5ebdfb196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1259be14-cab0-4a0c-9171-4ad5ebdfb196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b5aec3e-f72b-4b98-a71b-cadb32cf3ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b5aec3e-f72b-4b98-a71b-cadb32cf3ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c88f79c9-8c2e-47c7-a10d-fb1648ff2ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c88f79c9-8c2e-47c7-a10d-fb1648ff2ef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21aad2ba-d211-4e22-82d7-6fe74637bbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21aad2ba-d211-4e22-82d7-6fe74637bbf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa2c9563-7fd4-4a90-a6fa-8500db942172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa2c9563-7fd4-4a90-a6fa-8500db942172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba61f0a1-78e0-456f-871e-f4f611573c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba61f0a1-78e0-456f-871e-f4f611573c69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c42b577-65a1-4cfa-b677-a8e1e5ad6e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c42b577-65a1-4cfa-b677-a8e1e5ad6e4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:to="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77ed1e56-3005-45e4-9ddc-4875336f3a84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77ed1e56-3005-45e4-9ddc-4875336f3a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ba4e05c1-2b5e-4e9d-85c7-d8e50f4316bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ba4e05c1-2b5e-4e9d-85c7-d8e50f4316bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_31e0acbf-8cd9-47ca-98d0-96ab7a11d973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:to="loc_us-gaap_PerformanceSharesMember_31e0acbf-8cd9-47ca-98d0-96ab7a11d973" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="extended" id="i03934c54614449fda684254a70eb3d4a_ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended" id="id46b6fd34c284d4c93fb6630d1b2a45f_PensionandOtherPostretirementBenefitPlans"/>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended" id="ib7382e29e91d47c79e1fb5b83a953513_PensionandOtherPostretirementBenefitPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e97856cb-ae88-4061-92da-7aa3ea1df83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e97856cb-ae88-4061-92da-7aa3ea1df83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2522d5c1-90da-4ab1-8658-de57c53c6aac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2522d5c1-90da-4ab1-8658-de57c53c6aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_53a13858-dc53-4d3e-b9c7-3e3f3e520411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_53a13858-dc53-4d3e-b9c7-3e3f3e520411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f31d143f-0bf6-4216-88e3-8a1d39553cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f31d143f-0bf6-4216-88e3-8a1d39553cd7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="extended" id="idbb79b354c9741b0a073bfc89a993ca5_PensionandOtherPostretirementBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c7492736-a48a-4942-8697-45044dc22bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c7492736-a48a-4942-8697-45044dc22bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_434a5950-1c9d-478f-b0e1-5b79b55ec6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_434a5950-1c9d-478f-b0e1-5b79b55ec6aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9c27f9cf-fc4d-4c73-9db3-4a05e2300cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9c27f9cf-fc4d-4c73-9db3-4a05e2300cbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_97852f1f-f551-4828-9864-ef9ba696c59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_97852f1f-f551-4828-9864-ef9ba696c59a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8b6625b3-f068-47f2-b608-2ab3d50d42f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8b6625b3-f068-47f2-b608-2ab3d50d42f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a8e40c5a-5db0-4b97-aa25-9dcb817a011c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a8e40c5a-5db0-4b97-aa25-9dcb817a011c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_070a4138-be34-4cba-824b-878f07a05766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_070a4138-be34-4cba-824b-878f07a05766" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a7f85d39-af66-4f75-9703-7c04d124430d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a7f85d39-af66-4f75-9703-7c04d124430d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b1628dfb-be8b-4121-9455-b6880c35611c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b1628dfb-be8b-4121-9455-b6880c35611c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ef555585-5bb3-4018-b8c3-42ba6fca5583_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ef555585-5bb3-4018-b8c3-42ba6fca5583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69f71717-7168-40b2-b355-f9411d5df682" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:to="loc_country_US_69f71717-7168-40b2-b355-f9411d5df682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_94f90af9-aced-4f95-94f7-416bb4a6b14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:to="loc_us-gaap_ForeignPlanMember_94f90af9-aced-4f95-94f7-416bb4a6b14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f70be11a-6cc0-4dcb-89cc-2e73449c3760_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f70be11a-6cc0-4dcb-89cc-2e73449c3760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2559d320-56f2-4c65-aada-e1d64c7778e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2559d320-56f2-4c65-aada-e1d64c7778e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ff428aad-86f9-4593-a1e4-7d509736b3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ff428aad-86f9-4593-a1e4-7d509736b3c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended" id="i0823e201c56641bebb21cc59f096332d_PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_2e9af417-bf06-40d5-a2bb-c8b92b2ed108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_2e9af417-bf06-40d5-a2bb-c8b92b2ed108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_40ac814a-8e49-4c25-9a58-a1a943bcef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_40ac814a-8e49-4c25-9a58-a1a943bcef3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_652a3910-58de-4fdc-928e-e5af766f08af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:to="loc_us-gaap_ForeignPlanMember_652a3910-58de-4fdc-928e-e5af766f08af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f58b4972-87c8-46c2-a731-292d9a6bbd40" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:to="loc_country_US_f58b4972-87c8-46c2-a731-292d9a6bbd40" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNet"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended" id="i60060dff4a61443385fae59ba33406d9_OtherIncomeExpenseNet"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended" id="ib5944749fed645ccb8e5f5c956dbe757_OtherIncomeExpenseNetTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended" id="i71585d3fa8c34aa9b36f6ed9cce8c4bf_OtherIncomeExpenseNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bbd6238d-e76a-4a83-a858-cff856c0ffb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bbd6238d-e76a-4a83-a858-cff856c0ffb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a10051e2-c2e3-4268-9dc3-3127b37be059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_InterestExpense_a10051e2-c2e3-4268-9dc3-3127b37be059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbf1dfc6-74e2-4312-ae6c-8628d33d44f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbf1dfc6-74e2-4312-ae6c-8628d33d44f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_784a1783-c4c3-44a9-8da5-80d85b480d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_784a1783-c4c3-44a9-8da5-80d85b480d1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0b3e6080-644e-432d-b0de-8d1bc1cfa76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0b3e6080-644e-432d-b0de-8d1bc1cfa76f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_854fb561-02c4-4724-a824-f0c1ce6a2ae2" xlink:href="mrk-20200930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_854fb561-02c4-4724-a824-f0c1ce6a2ae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fcc5d4f8-2cf8-4091-9c6e-d8e2fe9486c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fcc5d4f8-2cf8-4091-9c6e-d8e2fe9486c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:to="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7801e7d8-15b5-4d23-ab58-ef99d544d734_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7801e7d8-15b5-4d23-ab58-ef99d544d734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:to="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f84a846c-b592-44af-8b9b-e0ae381b1b25" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:to="loc_srt_ScenarioForecastMember_f84a846c-b592-44af-8b9b-e0ae381b1b25" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="extended" id="i5b018de8963044a89067073b75db85e6_OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7d7ba1a6-3385-41f1-a8b0-8dd7cf8148ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7d7ba1a6-3385-41f1-a8b0-8dd7cf8148ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_e5c192bf-c493-4b92-ae9b-84b9ea630895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:to="loc_us-gaap_InterestPaid_e5c192bf-c493-4b92-ae9b-84b9ea630895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9303ce0f-7025-4f50-b444-66cb4d8b9911_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:to="loc_us-gaap_SegmentDomain_9303ce0f-7025-4f50-b444-66cb4d8b9911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:to="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_fca6fda6-6bbf-4821-bd9f-2426d330cffb" xlink:href="mrk-20200930.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:to="loc_mrk_HealthcareServicesSegmentMember_fca6fda6-6bbf-4821-bd9f-2426d330cffb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncome"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended" id="i9c3feddec1e440d5a57525b873ff1874_TaxesonIncome"/>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended" id="i9dffcb1c221240c39de89aaf3d7a703a_TaxesonIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ee74f31-ead7-4d49-97b6-b35fe1ab70bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ee74f31-ead7-4d49-97b6-b35fe1ab70bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48409e6b-156a-42cc-8a69-6a55a2b075aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48409e6b-156a-42cc-8a69-6a55a2b075aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_326a5ed3-5fea-432a-9083-ce4704cc012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_IncomeTaxesPaid_326a5ed3-5fea-432a-9083-ce4704cc012c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6c24a559-aff5-4f0e-9161-90b3e146a5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6c24a559-aff5-4f0e-9161-90b3e146a5d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cb3b9eaf-8561-4daa-8d3d-48948196aa43_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cb3b9eaf-8561-4daa-8d3d-48948196aa43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_949faf13-0f60-4bb1-bc01-46e1242bff56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:to="loc_us-gaap_DomesticCountryMember_949faf13-0f60-4bb1-bc01-46e1242bff56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsPerShare" xlink:type="extended" id="i058500ad666943f9b8c7f3f6c997605d_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsPerShareTables" xlink:type="extended" id="iec07f5ff0a6c4cd28d0cad91da37b62f_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="extended" id="i36e13b4c83eb4a6b8b9e0804e2ddf5ae_EarningsPerShareDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended" id="i9d455d8a74bb4577a7f3e4316321e0a1_OtherComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended" id="i6bb67a30dc9445ba82712fc917bf8d42_OtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i60325abab2d549118f7ed9d397304e94_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab9f005c-a318-462e-9a1a-f6ff85641857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab9f005c-a318-462e-9a1a-f6ff85641857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_c9b618d4-fd2c-4839-8524-bc0891b228b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_c9b618d4-fd2c-4839-8524-bc0891b228b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_39a45137-b13e-46a2-99c5-64809a67457f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_39a45137-b13e-46a2-99c5-64809a67457f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6e1f7be7-ec84-40ad-b809-8c143876ddcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6e1f7be7-ec84-40ad-b809-8c143876ddcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c41541c8-936d-4100-b465-d09beaa64dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c41541c8-936d-4100-b465-d09beaa64dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_05c705c1-6642-4b9b-817b-2f36065eae1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_05c705c1-6642-4b9b-817b-2f36065eae1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_78558b01-fcca-4bde-a9c6-613c8520c7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_78558b01-fcca-4bde-a9c6-613c8520c7ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_836f6f54-fa91-4c70-bf2d-27b0af90571a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_836f6f54-fa91-4c70-bf2d-27b0af90571a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c9d6641-cd97-4a09-832b-2c4d1bb8f35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_306a5896-f3dd-44e7-9739-2e08fbf8ba23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:to="loc_us-gaap_EquityComponentDomain_306a5896-f3dd-44e7-9739-2e08fbf8ba23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:to="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e05db331-e0aa-47c5-b747-9e55c8e7e94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e05db331-e0aa-47c5-b747-9e55c8e7e94f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_630daf6f-dc88-4507-b447-46cfbb89f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_630daf6f-dc88-4507-b447-46cfbb89f50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1a31e849-5e51-4091-8df9-6cfde27d09e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1a31e849-5e51-4091-8df9-6cfde27d09e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501456ea-f54c-4f7b-939e-cb7faa33ab18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501456ea-f54c-4f7b-939e-cb7faa33ab18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_23307731-5acf-40f9-a002-62ea33be1d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_23307731-5acf-40f9-a002-62ea33be1d58" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReporting"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended" id="i8b3d9cc0d4f640598c5d06c03bc9c7ae_SegmentReporting"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended" id="ib25e903355c141bf89d3a7f75ead3a35_SegmentReportingTables"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended" id="i0655f4514f0545d9af3afbffaa90b73d_SegmentReportingNarrativeDetails"/>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended" id="ic4d06a7c091347a98686c00d98d1e0c4_SegmentReportingSalesofCompanysProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_15fa941d-cef3-4ac5-83d0-8ff62c26d454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:to="loc_us-gaap_Revenues_15fa941d-cef3-4ac5-83d0-8ff62c26d454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_90a562b8-02f1-4adc-a496-352e97c0b174_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:to="loc_us-gaap_SegmentDomain_90a562b8-02f1-4adc-a496-352e97c0b174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:to="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_bea80679-774c-4eca-9f20-91ab0a666a29" xlink:href="mrk-20200930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_mrk_PharmaceuticalsegmentMember_bea80679-774c-4eca-9f20-91ab0a666a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3fd168e7-cece-480c-8a76-de9d6be5b9f2" xlink:href="mrk-20200930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_mrk_AnimalHealthsegmentMember_3fd168e7-cece-480c-8a76-de9d6be5b9f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_d0d44818-77d7-488f-9a81-03fef29a8c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_us-gaap_AllOtherSegmentsMember_d0d44818-77d7-488f-9a81-03fef29a8c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_64f91a52-3f51-4b71-b24b-65ff517ec8fc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:to="loc_srt_SegmentGeographicalDomain_64f91a52-3f51-4b71-b24b-65ff517ec8fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:to="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_75fa7d35-34ec-42d9-be4e-3babbd80dac5" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:to="loc_country_US_75fa7d35-34ec-42d9-be4e-3babbd80dac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_95ccf964-3336-45ea-97ab-7a916d804f7b" xlink:href="mrk-20200930.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:to="loc_mrk_InternationalMember_95ccf964-3336-45ea-97ab-7a916d804f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2280f716-09fc-4b20-aa27-b5770bd78dc4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:to="loc_srt_ConsolidationItemsDomain_2280f716-09fc-4b20-aa27-b5770bd78dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:to="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8ce9790a-705b-4d80-970b-a779b54d7753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:to="loc_us-gaap_OperatingSegmentsMember_8ce9790a-705b-4d80-970b-a779b54d7753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e24294c1-10fc-4ccd-b154-b0a837367d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e24294c1-10fc-4ccd-b154-b0a837367d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7534038e-ac11-43cd-84ea-57b47a1563a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:to="loc_srt_ProductsAndServicesDomain_7534038e-ac11-43cd-84ea-57b47a1563a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:to="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_a0447cbe-d4b5-4f4e-94ce-72c0f84458ca" xlink:href="mrk-20200930.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_KeytrudaMember_a0447cbe-d4b5-4f4e-94ce-72c0f84458ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_c5880a07-ca01-457d-a3a2-8d6ebafcedb0" xlink:href="mrk-20200930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_c5880a07-ca01-457d-a3a2-8d6ebafcedb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_3f85a2e0-8683-4f23-b89c-2b070da6c1ce" xlink:href="mrk-20200930.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_LenvimaMember_3f85a2e0-8683-4f23-b89c-2b070da6c1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember_14026a0f-c244-4ec9-a5b3-e36551ff81de" xlink:href="mrk-20200930.xsd#mrk_EmendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_EmendMember_14026a0f-c244-4ec9-a5b3-e36551ff81de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_83747c05-48ca-4ef1-abac-8b24c2e5e968" xlink:href="mrk-20200930.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_GardasilGardasil9Member_83747c05-48ca-4ef1-abac-8b24c2e5e968" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_7e6e01de-d0f0-4a68-9a9c-9aea4c831c84" xlink:href="mrk-20200930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_7e6e01de-d0f0-4a68-9a9c-9aea4c831c84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_50e0321b-6530-425b-bcd5-63123a503d48" xlink:href="mrk-20200930.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_Pneumovax23Member_50e0321b-6530-425b-bcd5-63123a503d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_6d871692-07fc-405d-97c2-61791a209f58" xlink:href="mrk-20200930.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_RotateqMember_6d871692-07fc-405d-97c2-61791a209f58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_016acf86-90d4-4368-b930-9e762bdc1f09" xlink:href="mrk-20200930.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_VaqtaMember_016acf86-90d4-4368-b930-9e762bdc1f09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_b24e63c7-c3f8-4b33-99bf-d7799a7d7c27" xlink:href="mrk-20200930.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_BridionMember_b24e63c7-c3f8-4b33-99bf-d7799a7d7c27" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_6a9d676d-ca02-4d5b-a17e-a10e3c7ae0b6" xlink:href="mrk-20200930.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NoxafilMember_6a9d676d-ca02-4d5b-a17e-a10e3c7ae0b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_04784d4f-8c9c-4010-ac65-47aff06368d8" xlink:href="mrk-20200930.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_PrevymisMember_04784d4f-8c9c-4010-ac65-47aff06368d8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_346ee483-87cf-4f3e-82d6-a34aaf5deef4" xlink:href="mrk-20200930.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_PrimaxinMember_346ee483-87cf-4f3e-82d6-a34aaf5deef4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_9ac8ded9-5016-42ff-b83d-6acebb30e09e" xlink:href="mrk-20200930.xsd#mrk_InvanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_InvanzMember_9ac8ded9-5016-42ff-b83d-6acebb30e09e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_11e2ba64-3d5f-44b8-ae09-b51c58906b23" xlink:href="mrk-20200930.xsd#mrk_CancidasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CancidasMember_11e2ba64-3d5f-44b8-ae09-b51c58906b23" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember_6d9416a5-1995-41c3-a4ad-54e91466ebfd" xlink:href="mrk-20200930.xsd#mrk_CubicinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CubicinMember_6d9416a5-1995-41c3-a4ad-54e91466ebfd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_0b13fe92-e8fc-49e8-853f-b651dd13a3f6" xlink:href="mrk-20200930.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZerbaxaMember_0b13fe92-e8fc-49e8-853f-b651dd13a3f6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_2552697d-6d99-47ce-957f-46414301a3a4" xlink:href="mrk-20200930.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_SimponiMember_2552697d-6d99-47ce-957f-46414301a3a4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_6582706b-a224-45f9-8318-d000f4bbb483" xlink:href="mrk-20200930.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_RemicadeMember_6582706b-a224-45f9-8318-d000f4bbb483" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_c41b53b9-5e3a-45d8-b81d-a4ec76e6e7b5" xlink:href="mrk-20200930.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_BelsomraMember_c41b53b9-5e3a-45d8-b81d-a4ec76e6e7b5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_6ac997ac-b96e-4b97-bafa-c8efc0f69045" xlink:href="mrk-20200930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_IsentressIsentressHDMember_6ac997ac-b96e-4b97-bafa-c8efc0f69045" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember_eea460b1-d2e4-4de1-96d7-2bc3012ceda7" xlink:href="mrk-20200930.xsd#mrk_ZepatierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZepatierMember_eea460b1-d2e4-4de1-96d7-2bc3012ceda7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember_dcd4aa9c-a88f-45c8-b9b6-b2ec14520487" xlink:href="mrk-20200930.xsd#mrk_ZetiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZetiaMember_dcd4aa9c-a88f-45c8-b9b6-b2ec14520487" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember_b991ce10-cf55-483a-a34b-750a96b97f45" xlink:href="mrk-20200930.xsd#mrk_VytorinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_VytorinMember_b991ce10-cf55-483a-a34b-750a96b97f45" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember_a32c711d-8852-421e-b39c-a72895fe75a5" xlink:href="mrk-20200930.xsd#mrk_AtozetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AtozetMember_a32c711d-8852-421e-b39c-a72895fe75a5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember_c43e76bc-537a-42f3-968d-49747deca7b2" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AllianceRevenueAdempasMember_c43e76bc-537a-42f3-968d-49747deca7b2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_4708c213-c2ec-481d-9106-e3549ef759ee" xlink:href="mrk-20200930.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AdempasMember_4708c213-c2ec-481d-9106-e3549ef759ee" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_d30da3b0-7267-47e1-ac05-448db7352ddb" xlink:href="mrk-20200930.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_JanuviaMember_d30da3b0-7267-47e1-ac05-448db7352ddb" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_9057e150-3674-4c11-ad42-64ec27fbcafe" xlink:href="mrk-20200930.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_JanumetMember_9057e150-3674-4c11-ad42-64ec27fbcafe" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_b064209b-ff4f-4d78-b57f-a10cfb46b9de" xlink:href="mrk-20200930.xsd#mrk_ImplanonNexplanonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ImplanonNexplanonMember_b064209b-ff4f-4d78-b57f-a10cfb46b9de" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember_b6658dc7-53b7-4a8c-b7ee-1f3011c52c1f" xlink:href="mrk-20200930.xsd#mrk_NuvaringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NuvaringMember_b6658dc7-53b7-4a8c-b7ee-1f3011c52c1f" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember_f0f88c1c-2319-45ea-a9b6-8b3f9dfb30cb" xlink:href="mrk-20200930.xsd#mrk_SingulairMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_SingulairMember_f0f88c1c-2319-45ea-a9b6-8b3f9dfb30cb" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember_488b3e36-51f6-4a2b-a340-ced213b2a834" xlink:href="mrk-20200930.xsd#mrk_NasonexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NasonexMember_488b3e36-51f6-4a2b-a340-ced213b2a834" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember_d1f8c557-db62-4b7c-a8ae-0ea132f84cbc" xlink:href="mrk-20200930.xsd#mrk_ArcoxiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ArcoxiaMember_d1f8c557-db62-4b7c-a8ae-0ea132f84cbc" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember_70787500-6fed-4f3f-8518-5f95c7482014" xlink:href="mrk-20200930.xsd#mrk_CozaarHyzaarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CozaarHyzaarMember_70787500-6fed-4f3f-8518-5f95c7482014" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember_b651e557-b219-4bbd-8813-a6bbc89c938d" xlink:href="mrk-20200930.xsd#mrk_FollistimAqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_FollistimAqMember_b651e557-b219-4bbd-8813-a6bbc89c938d" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_701bdfcf-82bc-4388-9558-b556260414a0" xlink:href="mrk-20200930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_OtherPharmaceuticalMember_701bdfcf-82bc-4388-9558-b556260414a0" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_83e9cfb2-26cc-44e0-a639-55e5602a86b6" xlink:href="mrk-20200930.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_LivestockMember_83e9cfb2-26cc-44e0-a639-55e5602a86b6" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_dd731dfb-d7ef-4b27-a3fe-04e8079dfcc8" xlink:href="mrk-20200930.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CompanionAnimalsMember_dd731dfb-d7ef-4b27-a3fe-04e8079dfcc8" xlink:type="arc" order="38"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingRevenuesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="extended" id="i575b932ea5d0438f85bfc14315b443c8_SegmentReportingRevenuesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f497c40a-460a-44fb-a479-7083b5d7227a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:to="loc_us-gaap_Revenues_f497c40a-460a-44fb-a479-7083b5d7227a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:to="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_039dab7b-f0eb-441c-84cd-cc9a52c0a075_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:to="loc_srt_SegmentGeographicalDomain_039dab7b-f0eb-441c-84cd-cc9a52c0a075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:to="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_81031c85-7bb6-469a-8931-3d0eef289b85" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_US_81031c85-7bb6-469a-8931-3d0eef289b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_c00d2272-e07a-4619-8120-731851c54fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_us-gaap_EMEAMember_c00d2272-e07a-4619-8120-731851c54fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ecb21738-41ce-4eb6-bec8-036ef87e981a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_CN_ecb21738-41ce-4eb6-bec8-036ef87e981a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f1c824fe-8d1a-4a71-8174-001a5a6e0882" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_JP_f1c824fe-8d1a-4a71-8174-001a5a6e0882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_e4408151-f75d-4131-be2c-e3cd42bae06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_srt_AsiaPacificMember_e4408151-f75d-4131-be2c-e3cd42bae06f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_779428c1-0e02-44ab-9430-66903b238903" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_srt_LatinAmericaMember_779428c1-0e02-44ab-9430-66903b238903" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_281ce894-07bb-4d02-a73d-dda6d0e5a56f" xlink:href="mrk-20200930.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_mrk_OtherCountriesMember_281ce894-07bb-4d02-a73d-dda6d0e5a56f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingProfitstoIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="extended" id="ia25d6ace032942acaac81d7608835f95_SegmentReportingProfitstoIncomeBeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86cc06c4-7419-4ce9-a4fb-10e0e1d06f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86cc06c4-7419-4ce9-a4fb-10e0e1d06f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5d975d99-20f1-4f1b-938f-e21aff2b0eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5d975d99-20f1-4f1b-938f-e21aff2b0eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3da54ac4-d39c-4b4c-82f6-ee6a1d89d0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_InterestExpense_3da54ac4-d39c-4b4c-82f6-ee6a1d89d0d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7064dc82-a6e5-4c05-9d84-2197e916b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7064dc82-a6e5-4c05-9d84-2197e916b77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8c381a12-fd51-4aa0-bf6f-77d92e721140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8c381a12-fd51-4aa0-bf6f-77d92e721140" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_cbe2edaf-d971-496a-a94e-81581a7238d5" xlink:href="mrk-20200930.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_cbe2edaf-d971-496a-a94e-81581a7238d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_213c3007-bde5-4f89-97cf-dbde77c16e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_RestructuringCharges_213c3007-bde5-4f89-97cf-dbde77c16e20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_4b1c092a-ff8f-44b2-97f5-f6112cabcf5c" xlink:href="mrk-20200930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_4b1c092a-ff8f-44b2-97f5-f6112cabcf5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:to="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_17a0d357-ddab-4831-a58f-a602d4fe7a3f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:to="loc_srt_ConsolidationItemsDomain_17a0d357-ddab-4831-a58f-a602d4fe7a3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:to="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_62d9ffcf-c32e-4c9a-8ab3-8e05b080f92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_OperatingSegmentsMember_62d9ffcf-c32e-4c9a-8ab3-8e05b080f92f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4ec745c8-fa96-4a00-8bc8-c8e21a8c7467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4ec745c8-fa96-4a00-8bc8-c8e21a8c7467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_57be3407-7309-4f15-8243-1bade835776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_57be3407-7309-4f15-8243-1bade835776c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:to="loc_us-gaap_SegmentDomain_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:to="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_8f6c4102-9a91-4d5d-ae12-7e798748d92f" xlink:href="mrk-20200930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_8f6c4102-9a91-4d5d-ae12-7e798748d92f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_4b738df1-e186-4ff2-9ed1-1e261381fecc" xlink:href="mrk-20200930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_mrk_AnimalHealthsegmentMember_4b738df1-e186-4ff2-9ed1-1e261381fecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_30a938a5-2041-4980-a3d3-1863c6011021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_30a938a5-2041-4980-a3d3-1863c6011021" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mrk-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f056d16-5bd2-41de-9fae-e3cfd4358fbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3923552d-c8e9-4a60-851c-a1541570ab52_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1fd825de-b93c-49b6-bfb5-201aad9c1d67_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_323f9d24-8bf2-48ab-a1a9-1140646c28a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_bc71b482-4c7a-4c88-a273-aa6570caf87a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_44613e8f-5c99-46c5-825b-cd216be817c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e2861b6c-fa36-416d-a2da-13bb0392684f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_b0180aba-be5c-44d3-82b9-01b49838439d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_112ac898-5293-4752-b150-72ce82417290_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d71d9553-1aa6-4d7c-a629-2d0ca793d3ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImplanonNexplanonMember_c2453195-d025-4735-8d3b-b1611212f6cb_terseLabel_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon</link:label>
    <link:label id="lab_mrk_ImplanonNexplanonMember_label_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon [Member]</link:label>
    <link:label id="lab_mrk_ImplanonNexplanonMember_documentation_en-US" xlink:label="lab_mrk_ImplanonNexplanonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implanon/Nexplanon [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember" xlink:href="mrk-20200930.xsd#mrk_ImplanonNexplanonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImplanonNexplanonMember" xlink:to="lab_mrk_ImplanonNexplanonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_23826063-a638-4d73-a7ae-be1c22ec5429_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fa58832f-3e71-4097-8c63-ea929d124da6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e72966d4-54f7-4c77-bb28-d9b866b488da_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_8c842ba7-44c5-47d9-bf5f-543b30241bdd_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1f67d4d9-4277-4b05-8ee7-924a7f3ce915_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_10529ec5-ca69-4a05-80c6-2da993ad4722_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d05c83c1-452b-4873-b30e-15a2f1a05ab9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d0516b78-3753-4b2b-afd5-5f219656c968_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_456a9b6c-e02f-4870-9d64-3c85aff5f06a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_5fb73dc7-5bfa-4c88-89b4-3ad0485f5574_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_6eb0edac-9dd3-4683-a5db-dcc1fc8481a6_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_6f51d22d-a75e-411c-8ccb-5d605aac7d99_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a7bd2e75-2bf3-4cf3-9cad-5a9f5c3ba6a2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_60f0a0de-3dee-49a7-a432-ecbfe24599ce_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3c3fbb-9c72-4ea1-bd77-3e28e591455e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d6f8845e-ff90-46c6-be9c-9734f2199d98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_b716440e-ff2e-4fd8-823c-669d39b49760_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_4ac65c2e-4560-4bd9-9eab-23b39d1f01af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_25960edb-2fad-41a3-97b6-3f7ab8670d97_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2f41163-c148-4a7e-96cc-5294b240d7de_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9cabb39e-53db-44bb-bb86-8a85e60a3bfa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a41add7c-f42d-4de6-9129-9ee4e4c1baac_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_43f03ea1-6666-441c-aedc-a72e83d706a6_terseLabel_en-US" xlink:label="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary weighted average life of collateral</link:label>
    <link:label id="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_label_en-US" xlink:label="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Primary Weighted Average Life of Collateral</link:label>
    <link:label id="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_documentation_en-US" xlink:label="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Primary Weighted Average Life of Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:href="mrk-20200930.xsd#mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:to="lab_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_38704520-034b-42a4-af19-e98641103fcd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2051836f-2bde-4067-9436-5eaec4aa4d31_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables, current</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_edc0efd3-3ea2-4f42-8272-f905ed838f1e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_43efda81-5a9f-4922-84ad-bc9dc3649234_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_f5e98222-9386-4995-b091-1b2002d47d19_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_d94e30fb-a597-4315-8a6f-344eea562361_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units (PSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ab1e6bc6-2dab-46a1-953e-75978fd3c938_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_371537ff-605d-4f47-8502-a36a84b7fcef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_681a245d-c473-49d8-87aa-53b8cb83476f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_05e44030-5b47-498f-afb9-9662aab49073_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20200930.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a63f5a20-e83b-4f97-b58c-a4f2b66e58b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of ArQule, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f8eabe14-c1e6-479d-82d7-a1f9df601abc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a2f6b250-bf18-43c6-b784-75d99a084788_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8539323e-c62e-4da5-8fa7-d488cf94ef04_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9f730a98-a3bb-49b1-a197-03acd9543d15_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_c229de8c-e849-4eeb-88ae-186813886680_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_96c90698-11cd-4a1f-9127-e47c27a0e647_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_e07e2638-9fd1-4ece-b32a-205b7cf3433b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life of acquired finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArQuleMember_e7a2df84-7f80-4b60-82c4-1aea46ab1be3_terseLabel_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule</link:label>
    <link:label id="lab_mrk_ArQuleMember_label_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:label id="lab_mrk_ArQuleMember_documentation_en-US" xlink:label="lab_mrk_ArQuleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ArQule [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember" xlink:href="mrk-20200930.xsd#mrk_ArQuleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArQuleMember" xlink:to="lab_mrk_ArQuleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6a674533-007b-480e-9d13-b15e0738655f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_37ec2cc7-ee43-4caf-9372-fdc18e054cd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_09bd57d4-cc50-4e9f-9f7f-f64a5c0b8ddd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_a847369c-fa63-4fab-86cc-04ec98663b04_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecasted transactions</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Future [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeFutureMember" xlink:to="lab_us-gaap_ForeignExchangeFutureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_98931809-ec8e-4940-a961-3de4cc589133_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_78053d56-1b92-4e95-9c4f-f5375494601b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_f2988bd7-8445-4255-9934-74198a720304_terseLabel_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_label_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed ToToll Statute Of Limitations [Member]</link:label>
    <link:label id="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_documentation_en-US" xlink:label="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cases Company Agreed To Toll Statute Of Limitations[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:href="mrk-20200930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:to="lab_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_6ab3f909-7fa6-4b6c-8e54-31182f1e836d_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20200930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_bf7a2a7e-8c6b-46e0-890c-2e47d549d610_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_5c6d86f1-d65a-4a61-921a-46604faba1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c4161bb0-2fa8-4486-b721-88dfe28b30a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_24c85f56-e4a6-42e3-bfb4-dbb0389e0cf5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a3c7af9f-35c8-4453-a297-0b844476abcc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_935c1824-7ac2-4671-a716-b3bd56360a49_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5c3d88a8-bbf6-457c-a37f-6e2eac9b145e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_06b6d1e0-633b-418e-8578-0b7c183de24f_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20200930.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d19dc3ff-6616-488a-8d70-9a7d194b4737_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_134e6ad0-0214-40f5-88cc-ea26a3e48d3c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AntelliqMember_2bb269c8-8d7e-4d96-9716-10597988ad03_terseLabel_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq</link:label>
    <link:label id="lab_mrk_AntelliqMember_label_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:label id="lab_mrk_AntelliqMember_documentation_en-US" xlink:label="lab_mrk_AntelliqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antelliq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AntelliqMember" xlink:to="lab_mrk_AntelliqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0ad23c8a-ff18-4e0a-9ea3-879999d5effa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_502cce7f-7a31-4d3e-a65a-be391ed1e8ba_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_0cdeb6ed-2578-4aff-97cc-64db65afcefe_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20200930.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00e07aab-767a-4f7f-a893-9948abebd1f6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_d697d39d-3fca-4f8e-b243-e4796a37c506_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ab9bd84b-d955-4517-91d5-d0f0f53a567f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note&#160;6)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d8e8dd21-1a37-421f-b4c1-345dcedc6f48_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_425d3d62-068b-44e8-afde-8afbd4b876ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_2f98cda2-feda-4d2a-96c0-86074728bff8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_a5da427e-cb6e-4040-8440-cc62c1e84c9d_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_16f1b8d5-a6ca-44f8-9227-58a3acbf57ad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f1cc8c17-7d23-4961-af65-26f81ee25e6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5d5becc3-97e9-4b1f-bdf6-59a7c092c8ba_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_d15b4e2b-45a7-4a36-8fba-9715b7be4640_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_050150a5-ff7e-4efa-9120-99e98475fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_c021ec89-a2c2-43f6-99bd-17ce00602b54_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e51b1618-d539-48d3-822a-e3bb58bb7c2a_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_227702ab-df3b-41bd-8de1-a9b44b225852_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_353c89b1-9725-4e24-b308-f2318c47689c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_34aa9e16-fe54-4d61-aa78-04f75e54f11a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c5b6f61c-656f-45a0-bae2-8c42dc8ff532_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b280ef99-7dc0-4d88-8f93-db5a24fe979c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_b129c47b-d984-43f7-9c8b-f0aafbf1f2ba_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Animal Health segment sales</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_442b7a6f-870e-4b1e-ac4f-4525098195c9_verboseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20200930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a3b22175-7b25-493f-a07b-ed4705d0ec16_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_fbe484f7-bddd-479d-a50c-37b990943b3f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_2c823416-dc88-41e5-945c-ad27130320a0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a6e6d296-6509-478d-9ee0-b56712533b12_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_4acd517e-c9f7-41ec-8d2a-b3fc413714c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_e64be45f-a8dd-48d1-ab53-1fb157bc53c2_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2cc5f71b-2b1f-4081-85c7-ff367d0b08fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_276e3e22-1d92-4f71-8b83-85eb7476042a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_b9bef635-e94b-433b-9a41-d0482fadf3cd_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_90c35e25-e364-45be-94bb-eb78dcf1769d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_b42bfa17-f5de-453c-9105-ae082461d862_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_38cb78bc-2335-4e7d-9cdc-0664897a3b33_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_c7f3c3c6-7f40-489f-88cc-46b5f3e25abe_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas (2)</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Adempas [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Adempas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasMember" xlink:to="lab_mrk_AllianceRevenueAdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_80b4ede9-525a-4657-b036-bbe994e34ebe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_d3141621-fbcc-450e-9a3c-820a17388fd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b7d3b464-c34d-496c-8569-1fdbb4ae7c45_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d37f649f-a341-4c54-af52-66443bcde10e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_beeeb72a-12e7-4c0e-8888-5d8c6a65acff_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_6d628e81-f615-4737-b95a-0eb3f56871df_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_956611cf-5408-4e2c-bff4-a929711fb94e_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_683edb28-a286-4095-8437-e732cedda4fa_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fdab3485-b3b3-453d-b2bb-e59fee0d187c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_a77c13d8-84cc-4fa4-b120-e559066df458_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation payments attributable to precombination service</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbc4de02-3545-4ef8-b013-b7d2c936d9d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_ec9c25de-3a07-4d60-b1d8-d5bfe66e2545_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_f7796f33-6598-4641-861e-5733a9943fd6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_d25ec82f-9c55-4f48-9cde-cd30ec2eb0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0f566055-0346-40e3-aeb6-da15983d10d2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_72cf07bd-241d-4998-b081-50894933a0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_6f206e6c-eec0-4d8e-b103-6214fa854093_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_fc5b5188-ac56-4d9e-abd5-e1a9114f3503_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other profits</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_97a3ede3-9321-49e2-942d-11bfff01327f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_82cbacbb-b658-46f9-8ea1-c897182f9036_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments made to collaborative partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20200930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_08bc8327-a131-4728-8b7b-acf286199993_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_00ab3361-dbc0-4286-99f7-0d37dd171d9a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_469705cf-9ba1-4361-a230-08ea77886bc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in Sales as a result of AOCI reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_b90ee684-40ce-4266-b4cb-af474fc184f2_terseLabel_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value discount rate</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_mrk_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_mrk_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput" xlink:href="mrk-20200930.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IntangibleAssetMeasurementInput" xlink:to="lab_mrk_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_c7397bbd-206f-4d6f-94c5-503363cfc860_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20200930.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ada4b1c4-4ac2-492f-bfb1-96193ac14450_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_77897f9f-38da-4a7c-b384-1303e1a2914f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b8fdd2e8-b30a-46b4-a6e8-66251c16d049_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_17323cdd-b23b-4df6-b006-567eb63954b1_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20200930.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_37280448-eba5-4695-a89d-dbd8415bfca9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e1d41b71-3b48-44e7-97e4-1856c10d309d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SentinelMember_bee45319-4c2f-4a9f-b7aa-5576d4046bd9_terseLabel_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel</link:label>
    <link:label id="lab_mrk_SentinelMember_label_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:label id="lab_mrk_SentinelMember_documentation_en-US" xlink:label="lab_mrk_SentinelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sentinel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember" xlink:href="mrk-20200930.xsd#mrk_SentinelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SentinelMember" xlink:to="lab_mrk_SentinelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3dd5d35f-9918-49df-b2a4-30888a48112d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc90eec4-b45b-4ab4-b0ad-00c4eb3c8f45_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_81d64c8a-0187-4779-a073-a74f5a93edc9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_5a63988a-8152-4c95-9a54-6ae595086688_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - profit sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_f0863917-e0cf-440f-8848-537e5ca47905_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_1517f057-238a-4606-9a9c-3d2c12e02924_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_d1584068-f07b-4cb2-a762-a7500d84cbcb_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0f7bd261-d573-4aa6-8b2b-9b81e0caf718_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_2460ff3b-a3dd-4c17-9448-5cb7a0c5ff6e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b64f1e8e-ec3e-4f46-a76d-0d2cd5c10d35_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherStateCourtMember_90d0bfe9-6410-41af-8852-9b89337b3fb6_terseLabel_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other state courts</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_label_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other State Court [Member]</link:label>
    <link:label id="lab_mrk_OtherStateCourtMember_documentation_en-US" xlink:label="lab_mrk_OtherStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other state court.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember" xlink:href="mrk-20200930.xsd#mrk_OtherStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherStateCourtMember" xlink:to="lab_mrk_OtherStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_68fd6a0b-698e-4066-81c1-a21fba094f07_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_7ee18260-e01c-47aa-9706-baec17e652db_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9226ca4-5d17-4359-b609-e54c9e9acee1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69d95575-9389-4c18-9689-3d86551d1c94_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1875158e-77f2-4c20-92e3-c307d3ed8847_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_5ab4c9ca-b438-4cb7-b384-34641cde876f_terseLabel_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.40NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.40NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.40% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member" xlink:href="mrk-20200930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.40NotesDue2022Member" xlink:to="lab_mrk_A2.40NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_0c45744f-4ffd-4052-a82d-c0556861938e_terseLabel_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services Segment</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_label_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services Segment [Member]</link:label>
    <link:label id="lab_mrk_HealthcareServicesSegmentMember_documentation_en-US" xlink:label="lab_mrk_HealthcareServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Services segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember" xlink:href="mrk-20200930.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_HealthcareServicesSegmentMember" xlink:to="lab_mrk_HealthcareServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1d785356-9196-4985-a257-3d7740c35c4f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (1)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_3fdb338d-4169-49c6-a389-6d46ae8bd358_verboseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_d295a7e8-8caf-417b-987a-d71d7aa18f1a_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20200930.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a0133ba3-37a3-436c-8b02-637e84dc6183_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of Company's products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b75017c8-1a4f-497b-944e-02357a713e24_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ba0d6690-f17a-406b-9670-4981c614f413_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3b4b2e7f-1498-4fb7-b21a-58c05d695efd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_d0cb1ebb-e28c-4d05-a7fb-91133fb61c41_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_7e837b6c-6864-4377-b84d-5d0a49f0546d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d261cb7c-9801-4f62-b3bb-31ed33b6853a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_0e576fad-204b-4cf5-a56b-1a29a0470cbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_4f87c199-1773-469c-8aa1-aa1cc0f05119_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_e553e932-c6df-4d1a-bd16-878c589e6035_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total swap notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_e943f692-ef67-4d70-9867-430b1b3232f9_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Dollar Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_c67bd5ad-1de5-4d0a-9c4c-4cbccef62bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated revenues by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_4e088019-6fe4-4921-84bb-7472c8b2ef96_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f8d79557-becc-4433-bfd7-8400f575ecc7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_ba56a129-2773-4af6-8a5a-2c8cd8acdb72_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical (3)</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20200930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryLockMember_490603a3-5f38-4c7e-839d-5250d185ffb8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury lock</link:label>
    <link:label id="lab_us-gaap_TreasuryLockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryLockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Lock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryLockMember" xlink:to="lab_us-gaap_TreasuryLockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c69b71b8-b8b4-43ca-ac42-e5293666bebf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_e11c14b5-4c2c-45ac-b7ff-ba1888311199_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_690cbe50-c927-4a6c-9c2e-0317f0557c4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Antelliq Corporation, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Three, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NuvaringMember_6e6aba95-d148-4c53-bb5c-344003cc89fa_terseLabel_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NuvaRing</link:label>
    <link:label id="lab_mrk_NuvaringMember_label_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuvaring [Member]</link:label>
    <link:label id="lab_mrk_NuvaringMember_documentation_en-US" xlink:label="lab_mrk_NuvaringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NuvaRing [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember" xlink:href="mrk-20200930.xsd#mrk_NuvaringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NuvaringMember" xlink:to="lab_mrk_NuvaringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_bd6de3c0-b1fa-411a-8f65-f08b261c4c52_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_d80c8bd9-9b80-4473-b133-988f1e530c3c_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Excluding Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtExcludingCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b3db9b20-f03e-4650-8e73-c8454c1a1251_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_646cb62c-911d-4459-a924-756bd2f1d902_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_14c9917e-e814-40b2-b6ab-980941b735b1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_cdd69255-f51a-48ea-9710-bb9ab6b271c6_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_7c5e9a0f-3334-4753-bddd-0ac273cee6f8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_50faba39-27a7-434c-87c6-482cba5bbc98_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2b44e8eb-4696-4141-a976-e2016d450c8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_49679aeb-e2d2-49be-a8c8-2abd50c66dbd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_a2ce3992-5654-47e2-821e-9a165a6a7d3a_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20200930.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_2f44bb1a-2c44-4225-bcff-98558f620c30_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from investments in equity securities, net (1)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_68643b57-8621-41a9-b6f5-b90430a3d77c_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20200930.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_d26e0fc4-639b-4411-8c7b-63e738a1f6a1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7ead927f-a22f-4be3-be11-183ef51c9c95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a6037da3-6de6-4365-9479-7f8da1bb141c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_10ad1b8e-bb33-4f55-91f7-80a9ff2e3c42_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4213eb79-8f70-46a1-9773-805b7ec38f4d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_de419ecf-303e-4088-a8f2-541c482aa61a_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20200930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6e4d098c-3942-4cd4-93a3-6cc0c4f14502_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_5a753b51-7272-40c4-aefb-fe870e0f8fa2_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_25a34ab4-b776-4217-a251-6fc6af9c64b0_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima (1)</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20200930.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_49ff081e-db65-4797-b5b7-9426fc5be7df_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_cedbbfbf-5e89-4f62-959c-7ca61fcad3f9_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_48c9742d-b687-4708-b086-00e5b487b038_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0ab9892f-15b5-4855-8ae0-95dda132b081_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7278f219-738f-4a9b-94a7-87b7eed84f21_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_a459e73c-b5cb-4f8a-95e5-a2ed6d0bec45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_72a2907f-c235-4318-87cd-310028f74934_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_cd17e621-5a14-44fc-8cf3-fe8c7cf22c8c_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3b1e3174-5dd1-4635-86e6-0d527642fa67_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_730f9cdf-8b03-4bec-8164-ffb15feb5384_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net losses (gains)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_837f28fb-6666-43cc-9e40-0d2de437945e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_56e35986-f518-4d6f-b2d5-551521f1051d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CubicinMember_337010d1-6537-4358-aa99-8a17b9db80c0_terseLabel_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin</link:label>
    <link:label id="lab_mrk_CubicinMember_label_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin [Member]</link:label>
    <link:label id="lab_mrk_CubicinMember_documentation_en-US" xlink:label="lab_mrk_CubicinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cubicin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember" xlink:href="mrk-20200930.xsd#mrk_CubicinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CubicinMember" xlink:to="lab_mrk_CubicinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_bfc78ef9-07bb-4dbe-8fc0-7f63510342f4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9ea3f750-3c8b-4bff-9dea-379411b57463_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6cccf0fb-e650-4806-8b2d-d1d57d7840fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_5ba35ea3-cbde-424c-ba7b-d649f9f4ec7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_4c2b17fd-e9d9-4c8e-94e2-dc09e50f9a8a_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20200930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SingulairMember_e2c81c51-aa2f-4271-a9fa-4ec82106ce4a_terseLabel_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair</link:label>
    <link:label id="lab_mrk_SingulairMember_label_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair [Member]</link:label>
    <link:label id="lab_mrk_SingulairMember_documentation_en-US" xlink:label="lab_mrk_SingulairMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singulair [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember" xlink:href="mrk-20200930.xsd#mrk_SingulairMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SingulairMember" xlink:to="lab_mrk_SingulairMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_23574b60-6dba-4e7c-9d70-f96a7bc08e00_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_8b787905-a904-48e5-9adf-ad442d377096_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityLineItems_a979d1df-1ed3-4e90-9696-cb470070de10_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_label_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityLineItems" xlink:to="lab_mrk_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_08524236-d5e1-47a0-8513-5b80664b1fb3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EmendMember_b9038b37-aa64-4dbf-8df1-935c6e1c7424_terseLabel_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend</link:label>
    <link:label id="lab_mrk_EmendMember_label_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend [Member]</link:label>
    <link:label id="lab_mrk_EmendMember_documentation_en-US" xlink:label="lab_mrk_EmendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emend [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember" xlink:href="mrk-20200930.xsd#mrk_EmendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EmendMember" xlink:to="lab_mrk_EmendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a346b806-505e-4d77-9c87-45b822ee41ca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_c8336d35-e9ec-4fa5-8221-407357f62053_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c75afa88-ecbd-4484-b327-58b267c7a923_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_e1b3e641-305a-4af7-9e4f-966c65c5d5e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_80212077-1e47-4423-92cb-69d9b62ca1ee_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segment sales (4)</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_59e1cfd4-efd1-48f1-82de-b5e3ceecaec4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other segment</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZepatierMember_83726b39-b607-47bc-aa95-b42818f7c6ad_terseLabel_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier</link:label>
    <link:label id="lab_mrk_ZepatierMember_label_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier [Member]</link:label>
    <link:label id="lab_mrk_ZepatierMember_documentation_en-US" xlink:label="lab_mrk_ZepatierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zepatier [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember" xlink:href="mrk-20200930.xsd#mrk_ZepatierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZepatierMember" xlink:to="lab_mrk_ZepatierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_d3323fcb-229c-4c53-aab3-20b141b05a3e_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims on appeal, number (in legal matters)</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_label_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:label id="lab_mrk_LossContingencyClaimsonAppealNumber_documentation_en-US" xlink:label="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims on Appeal, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:href="mrk-20200930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyClaimsonAppealNumber" xlink:to="lab_mrk_LossContingencyClaimsonAppealNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.45notesdue2050Member_c81d32dd-59f3-4627-bd9b-48fdf648b846_terseLabel_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050</link:label>
    <link:label id="lab_mrk_A2.45notesdue2050Member_label_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050 [Member]</link:label>
    <link:label id="lab_mrk_A2.45notesdue2050Member_documentation_en-US" xlink:label="lab_mrk_A2.45notesdue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% notes due 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member" xlink:href="mrk-20200930.xsd#mrk_A2.45notesdue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.45notesdue2050Member" xlink:to="lab_mrk_A2.45notesdue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_7add1200-8bb2-4902-bf6d-19b8802fde33_terseLabel_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable contingent payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20200930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c78f0df6-42f6-471b-af90-3edb36f50f77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a0e2f60e-23ed-44b8-b2c4-490c4de71c32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_eb92383f-1cd1-4fde-b1df-29aa84f0763f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of (loss) gain recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_2ca17413-c278-4a72-93f9-577537b16dc4_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ce1a1891-408b-4d08-9d48-c3057c913558_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f8db3b7a-93c8-4dd3-9460-36c9b84f0409_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_5d430e57-00e4-4206-a4f2-fa02674bdb89_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20200930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_807586e2-8e71-455d-b1c9-9ae5084ef3ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImmuneDesignMember_92900412-6ecc-43c7-bea9-ebeb3cb8b79d_terseLabel_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_label_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:label id="lab_mrk_ImmuneDesignMember_documentation_en-US" xlink:label="lab_mrk_ImmuneDesignMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immune Design [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember" xlink:href="mrk-20200930.xsd#mrk_ImmuneDesignMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImmuneDesignMember" xlink:to="lab_mrk_ImmuneDesignMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_adb4ec9c-a89b-4e9b-8e31-fcd5450f9c1a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_373c1762-4ab7-4a0c-8b0e-17b356ae95cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AtozetMember_42fff63e-625a-4fc7-8bef-36aaf167c9bf_terseLabel_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet</link:label>
    <link:label id="lab_mrk_AtozetMember_label_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet [Member]</link:label>
    <link:label id="lab_mrk_AtozetMember_documentation_en-US" xlink:label="lab_mrk_AtozetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Atozet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember" xlink:href="mrk-20200930.xsd#mrk_AtozetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AtozetMember" xlink:to="lab_mrk_AtozetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_9050947a-9fdb-4d66-98eb-4ccb122f6c44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_356f4427-233f-4ae7-b2eb-e665c8e45369_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20200930.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_ae55b63e-b07c-4ea4-b06a-de0e6dfe0edb_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_de3b9bcf-7bd6-46d1-a70d-c62a94f77aca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_f4ac9c68-3e97-4b43-be63-f84cbac17c34_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total segment profits</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_0571dc14-9f86-4a5f-87ef-86abaf84344d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_6e5508dd-1be1-41ee-b563-7fad609bc1d2_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9244f897-2033-4ca7-9023-1da0514786bd_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_02f21922-d913-4921-9398-343e1e999f9f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5c293ed7-e348-491a-8275-82e6e3f56995_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_991a9b23-df60-4232-a2e8-aafbe8fddc96_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_686b6e75-a769-4566-af38-bae9695dc13c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_91a49178-d855-473f-950b-560b950db3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_17783c0d-51d2-4708-ba90-8e803bd06d98_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_480eaf19-a399-4dc6-8815-9c2d13201dd3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5bd480e6-1db0-4a69-8d89-d03e760f4702_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on investments, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b479fe6a-c0cb-40c5-ac8a-95b5f5629686_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_c3838a06-347f-4916-81dd-94fa20060b73_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20200930.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_f0b2cdd2-4661-4574-8bfd-f1d602c8caf7_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_95c63acf-c3fe-4385-a724-1a05cf7b8c24_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_75f73185-abf9-4018-b207-e41f33a74d7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_b9fe00f8-e278-4636-a617-b77135a02d08_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_1362681f-5cf6-4fd7-a7a1-ef0c56a26ce3_negatedTerseLabel_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_label_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:label id="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_documentation_en-US" xlink:label="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Four, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:href="mrk-20200930.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:to="lab_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_35f48d5b-0171-4eaa-a1e1-dc84e1ac03bb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a60774df-c55b-46bd-af3e-48832e1c5af2_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_4fc9dece-5ba5-4bef-9363-41232c92ad83_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20200930.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_5f224f7a-b71a-4c34-96b0-546762a89e61_terseLabel_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_label_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:label id="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_documentation_en-US" xlink:label="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License option payment related to collaborative arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:href="mrk-20200930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:to="lab_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_5b8eca56-2a2e-4308-bae7-03d07034863f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt assumed and paid</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_550f7240-a951-4ca4-b062-054190a7d096_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_64179794-edf8-456e-9bb5-74ce5238fd1c_terseLabel_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to partner as part of collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="mrk-20200930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5fef3564-d259-4bbd-9da1-ab14e0699439_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_30aea876-6eb4-444a-b424-accddac91bd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8e2fcb58-824d-4d58-9f25-e241303a3004_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_c32fa7ba-c600-41d1-8d34-07d829184b91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6cea09b8-4d40-4bd7-837d-11b9b99cb863_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_53717d87-3a49-4066-a77c-47e5840c5e60_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_91d43232-c80c-41c1-9934-95e7c9ca7266_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20200930.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_62dd51c3-3f4e-42f3-8cd6-b2b43884be9a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_80347544-6e5a-4bc7-bcb5-5a3b8aa77732_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_404df2ae-6be6-4587-910d-43be290740c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5e9455a2-4133-4423-b36e-1531f54998af_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fb1a8c1c-f68e-4151-b85f-f34bb5d72012_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8a23a811-8598-4989-82ef-baaf3e7c8bd9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_add9844a-a6f7-4f8b-9903-c580fc5f110d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea966232-54ff-464c-9e77-5c96932d6b96_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cf0fd269-c111-42c6-868b-fbd86675b2f3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_63109f65-353e-405c-9b08-70856534824c_terseLabel_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_mrk_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_mrk_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember" xlink:href="mrk-20200930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DevelopmentMilestonesMember" xlink:to="lab_mrk_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_fba9d29b-7c82-416f-ba38-428dc75b9158_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20200930.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f663f2ea-d8df-4f0e-afe6-c7c070551582_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d099252b-f5b5-4536-b91b-6ef6f3503589_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_aa060be0-19e2-4d5e-998b-5ad721649313_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ef9b2ed6-7400-4ad5-87c4-3238ae4d5644_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_901dcd7a-27db-4644-a008-8aae05451b8a_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_724942c5-12b8-409b-8cb6-3e9e466b93f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6bb3ee64-eb68-44e7-a39b-f312bd599146_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_605efb78-88db-4d7f-ba1d-7fa9c1e75b02_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3b71c1af-f628-4fc6-8ea6-d77965f08d6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_988ccc7a-4e76-4d20-b07f-80a49f926ca5_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_7bae1e40-3143-4b70-a76f-cf9fdd273f2a_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20200930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_19e30a9b-8f78-4dc7-9752-14a3ed80fdac_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SivextroMember_6546352c-3889-404d-80af-1d4f099fb0fb_terseLabel_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:label id="lab_mrk_SivextroMember_label_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro [Member]</link:label>
    <link:label id="lab_mrk_SivextroMember_documentation_en-US" xlink:label="lab_mrk_SivextroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sivextro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember" xlink:href="mrk-20200930.xsd#mrk_SivextroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SivextroMember" xlink:to="lab_mrk_SivextroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_015af7a6-c0bf-4ae4-a05d-52213fbff942_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_db2f2c95-5f12-41df-a64e-51ea1809f6a7_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_fa31ac01-cc1f-4acf-ad5e-493c1b5e6bd6_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_389110f3-5e71-4b38-b909-26113404da83_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_affb113f-256b-4114-baea-f2cdb7f42448_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_f5608d26-2d68-4290-9ea9-0e7bbc6c5f9e_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20200930.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_652e63e3-74ae-4acd-a590-e15b09014e5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_26b33a87-bce9-4f58-a32c-c6f0f76f8e2b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cb2c93e4-223e-4386-b4dc-61c1ad0adb71_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_3c627fc7-99fb-4423-bcd2-40e7e37bbead_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d739019f-29e8-4f1c-954b-d8e0b26703f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_b77d305c-26ad-4f68-a246-69dda9350422_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_9c2a3103-1e77-42fa-adbe-3cd99cbc56ab_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20200930.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_46a704ee-89af-44df-84fe-17327f846617_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20200930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a47b9508-1c94-46bf-a327-2f51b5b5092f_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_94c7dc04-0158-49a7-9655-b69bf1472497_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b0b447ca-8373-4f52-8721-fdbb939bf806_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_0f1b7aba-6ce0-474a-a9e9-2a2113fbf9f2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_c09e4cfa-bada-44ac-8f5b-a4ccd26ab449_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c3efe6b8-8265-4cf6-a6c2-916c73d89cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_cac10546-24c7-4b1c-b4e6-5ab52c7badf2_terseLabel_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_label_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:label id="lab_mrk_LongTermDebtCurrentMaturitiesMember_documentation_en-US" xlink:label="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Current Maturities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LongTermDebtCurrentMaturitiesMember" xlink:to="lab_mrk_LongTermDebtCurrentMaturitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30cd7041-c75c-4fb0-b057-c6b3cdb5ded4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_68978712-dd3b-4432-b797-b6bb718abc0d_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CozaarHyzaarMember_a06aeff1-3474-46f9-add6-e6689222fa0e_terseLabel_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex</link:label>
    <link:label id="lab_mrk_CozaarHyzaarMember_label_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar Hyzaar [Member]</link:label>
    <link:label id="lab_mrk_CozaarHyzaarMember_documentation_en-US" xlink:label="lab_mrk_CozaarHyzaarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar/Hyzaar [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember" xlink:href="mrk-20200930.xsd#mrk_CozaarHyzaarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CozaarHyzaarMember" xlink:to="lab_mrk_CozaarHyzaarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_ae6d5132-b9d7-4ecc-a5e0-60284fa13de6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_93eb1b0b-c946-49f4-9e10-bec24ad4a238_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f07ebc2c-cb51-4364-9023-227ac847a1fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_aeb62858-ae34-441c-9ba3-84a7c22cd753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8635899c-c0fc-463d-b488-2a855ef6b3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_aef2a39b-93c5-44d0-80c8-b1ea4b413eb7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_e2522b5e-6f39-4e85-8401-65aa4c28be9d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_05a2f09b-34b1-4ae6-a82d-05f9c471d389_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_ebff96aa-aca9-4dd2-ad85-4b3967f7317b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FosamaxMember_d503fd66-fad8-4848-8b3a-12439c7d453d_terseLabel_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax</link:label>
    <link:label id="lab_mrk_FosamaxMember_label_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member]</link:label>
    <link:label id="lab_mrk_FosamaxMember_documentation_en-US" xlink:label="lab_mrk_FosamaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosamax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember" xlink:href="mrk-20200930.xsd#mrk_FosamaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FosamaxMember" xlink:to="lab_mrk_FosamaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_00906a55-5c70-4629-a000-ab3e085980f6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims dismissed, number (in legal matters)</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_57da82c7-e5fe-4e78-ab92-30f791510229_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_f05c1fb4-b717-42cf-a36a-fec8c9cb156a_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20200930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e0fff0de-f257-44f5-a3d2-f422c8c0ec8b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_12ebbd61-50b7-4dce-b29c-83855c892890_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_93925e95-635c-401c-b108-8c8976fd1aad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories classified in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_44b05d97-bb51-441f-9b50-65f1c5dbe66d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3d086540-e42a-4476-946d-1e28369abebb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_511635bd-e465-4ac0-b08b-a58e3c863d44_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_3feace5d-95ae-4f9c-898b-8f4019d04a1a_negatedTerseLabel_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity" xlink:href="mrk-20200930.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveNoncashActivity" xlink:to="lab_mrk_RestructuringReserveNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_f8bff1db-b83b-4d5b-8725-cd55879a1de5_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized losses on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_e20ea6b0-75a3-4b53-8218-0dc40f45dff6_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20200930.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0b9a28aa-55bd-4129-b40e-588ea0da1634_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_5cb5beb2-3729-4e4f-9b6c-8671a6298f9a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90f8932b-34d6-4473-a2a0-20184cfb7e90_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_877c46fc-d134-4ccb-86a0-17478c9a2dca_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum average period of maturities of contracts in years (less than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_754a6106-23ad-4127-b5bb-00aba1534ef9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_79077341-6882-4759-a720-8767891e4220_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_bce972eb-a280-4bf6-99ea-686df171cb38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a94dcbd9-56ad-4e8c-a78c-9cb8a014f818_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d4800b2f-44ea-4939-babf-4c823a4e07a7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_96c61a9d-3e71-4050-babb-0c812f0ab1d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b8286ee-9542-47bc-90d5-f1465116a1a4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4a9f289b-9030-42d1-8980-f869b286e3a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5ebd87bf-eb82-4940-8d07-7039363886a0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_1b6e7e09-06eb-4cda-8a3c-f2f1d2e1dc38_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims, number (in legal matters)</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_dab74b0d-5cdd-4459-a3fc-9a55271802a8_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20200930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_2c58be93-933c-42fb-b79a-e138b6807ec2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ba69401b-4430-4ae2-9813-baff71f6dc8b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5e21d5f8-f981-4a60-a3b4-1030c2f6e1d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1a754dd1-21ae-44d6-a647-48a652696d89_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_e609f4f9-f726-42bc-bd4d-61589df13be5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_b22e6daa-a068-4d5b-9de8-fb8d919ab55e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_9f489e7c-59f9-4df0-98be-412e5e8c82ef_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_499e598f-6775-4fc4-afa9-faa632b70baa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ThemisMember_0a5d213d-c392-4ab2-9147-b8aea4fca4b7_terseLabel_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis</link:label>
    <link:label id="lab_mrk_ThemisMember_label_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:label id="lab_mrk_ThemisMember_documentation_en-US" xlink:label="lab_mrk_ThemisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Themis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember" xlink:href="mrk-20200930.xsd#mrk_ThemisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ThemisMember" xlink:to="lab_mrk_ThemisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8f28478d-7983-4b6a-a19d-5e200a4a85b6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income (Loss) Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93d56cb1-1372-4dd6-904b-c3d495b5ad3b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_a858afc4-7304-4849-93d5-ef1d42fad065_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Amount of Pretax (Gains) Losses of Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_241d8a14-0df4-42ce-a8ec-622cf3dcc1fb_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e4fcd2dd-016a-4408-bd24-eba5b4dc7273_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b1239d3a-6c78-49df-b8cc-1a4c6d83df23_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_25daa387-f3b2-46b7-b57d-d0624d79ddad_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_958e38b6-ea7c-4f60-b6f1-9fa24f6d248f_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e46b8d4a-6a7c-4dd3-b448-7ed8b08559f8_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_aaa6b972-4fc1-49ac-b29e-52f4d7f58c64_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_8b56d6fd-7798-4f6f-9c41-6f3f08731710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_23000cc4-e956-46f6-9ad0-0130ec91c35f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cad4a9e0-8cc8-4d28-82d6-2d5c4e0cc69c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_a99429b8-a306-40bd-8f73-8676643bb7c9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other (in shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_ed7024ff-c4ba-4607-945b-ee570383e1c3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_b2eabef6-e391-46b9-8ac5-5c0ef951a8bc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_8307ff35-f66e-40f7-8e3d-5ded7181e17f_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IAVIMember_78c549bc-1e62-4cd2-b0da-c172f4077287_terseLabel_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI</link:label>
    <link:label id="lab_mrk_IAVIMember_label_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:label id="lab_mrk_IAVIMember_documentation_en-US" xlink:label="lab_mrk_IAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember" xlink:href="mrk-20200930.xsd#mrk_IAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IAVIMember" xlink:to="lab_mrk_IAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_8cacc598-1fd4-462d-bf77-de5ce7dc826a_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20200930.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_669a8fd6-574c-4094-8fde-dd32a61b7908_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9cc43a71-7239-4403-9a01-1c67c53eee52_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_556535d6-5830-4dee-bf67-b0185406a4fb_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20200930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_e9b1c0bb-314e-48bd-a8ab-d0bfe4465c61_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b01c1763-e493-40dd-8077-706c3b181a79_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a602cb0e-fbdc-4e1f-9e2e-d6576ac7503f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_502d41a2-3ff0-46b3-bf70-ee281f8b0a64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_30c27f83-7624-4590-9a36-8aa78197a8ad_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of segment profits to income before taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_39375fc1-c5dc-4fe6-a3be-fa12da352936_terseLabel_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_label_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_documentation_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember" xlink:href="mrk-20200930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaantitrustlitigationMember" xlink:to="lab_mrk_ZetiaantitrustlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_607c9f94-2200-4459-aa0d-a85688b0406f_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Research Collaborations and License Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, divestitures, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20200930.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76de4ea9-f97f-4c7c-8622-38d986241119_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_7a8bead3-5f62-41fa-99a1-8e1762583ad8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_a10a8625-8b10-4cfc-a31b-68add283d7f0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_b74b01ef-243d-4cd4-a95c-6e5eba24ce0d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_f5044d32-1b8e-47a3-a3c6-8861d763df18_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20200930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_bab77918-b07b-4926-9d10-076cdbb647ac_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_e3b00d34-fda9-43a0-ad54-04692d134eb1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_531b64c8-6792-4240-9dec-3ac2f68c4cfe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_783015d0-ea71-4261-8267-46fdde5652ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractsMember_b5305ca1-a487-4954-9520-5bf1087665fc_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts</link:label>
    <link:label id="lab_us-gaap_ForwardContractsMember_label_en-US" xlink:label="lab_us-gaap_ForwardContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractsMember" xlink:to="lab_us-gaap_ForwardContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_b7200e0f-472f-42b1-b825-d4c6dbecbb43_terseLabel_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020</link:label>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_label_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020 [Member]</link:label>
    <link:label id="lab_mrk_A1.85NotesDue2020Member_documentation_en-US" xlink:label="lab_mrk_A1.85NotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.85% Notes Due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member" xlink:href="mrk-20200930.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.85NotesDue2020Member" xlink:to="lab_mrk_A1.85NotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_6b6aa270-f387-4d43-ae5b-0d7c5702ff71_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_fc65f1ef-e783-472c-9572-3a99a5303f9d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_8d89888a-ba56-4365-846d-4752a331fd7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_cdbb1c51-76c5-4aba-8196-ed0f3a5bec39_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_13a7d309-9108-41b6-b2d8-f0e2f8e4929a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_1eb7234f-94a8-4187-8d7e-29ef36d7d7ec_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_0dfeb1c3-23f0-421d-b32b-747bbef98287_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_a9ffc28b-2622-4347-b6ab-7ee8322e7972_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_1e5bb94d-e380-45b9-9260-c1c6e329c101_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_8a599e1c-a5d5-42a0-b6c6-7984fd7d7ed7_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_562874c7-165e-41d7-ba14-388b8f3ddf38_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CancidasMember_d7c8d925-6c83-4b11-9dd3-545fd7471b21_terseLabel_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas</link:label>
    <link:label id="lab_mrk_CancidasMember_label_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member]</link:label>
    <link:label id="lab_mrk_CancidasMember_documentation_en-US" xlink:label="lab_mrk_CancidasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancidas [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember" xlink:href="mrk-20200930.xsd#mrk_CancidasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CancidasMember" xlink:to="lab_mrk_CancidasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_51bad989-6c68-4197-aaf0-c5a0caaa63b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PelotonMember_3f6745df-8fa0-4419-9b6e-6fc8ada3ead6_terseLabel_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton</link:label>
    <link:label id="lab_mrk_PelotonMember_label_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton [Member]</link:label>
    <link:label id="lab_mrk_PelotonMember_documentation_en-US" xlink:label="lab_mrk_PelotonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peloton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember" xlink:href="mrk-20200930.xsd#mrk_PelotonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PelotonMember" xlink:to="lab_mrk_PelotonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_c9148e34-777d-484f-9544-5f6f0acbf044_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_44f3095d-4cb2-4fc1-a85e-556b7f517882_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4f9fd0af-8888-488c-a773-102b84324b68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_90fee93a-d775-4e62-b1a4-06c60750e6b5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9dc6e85e-d93e-478d-91ae-6a6595f085cd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_edfe02f3-88bb-4344-b0e1-55ad31a4e171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ff2ae5b6-96ef-41cc-bd79-ba1a7707ae9f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6f3b3f09-eca9-4100-91c3-15cb9f2370d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_1ec7427f-2f7e-4b97-b096-a6a8bf14b59f_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Costs, Expenses and Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20200930.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_728fab8d-0245-49e1-9578-f5e1804ce50e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_58b3ce06-ec88-44f2-9128-8bcd9cfde0aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77566e7e-2d1f-44ab-9afb-571a7b6c4137_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_d10de21e-4ae8-4f4b-9b05-9177f75c92bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_0dbfcc62-6bd8-461c-9f90-bd27209c5286_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20200930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_118781b3-6300-4ef6-89f0-84c2f462801e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c17a749b-b901-4dd4-aeff-d5ae831b72ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_351b041d-5c92-40d9-897e-43ec0afbdf3f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par Value of Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_456f974e-8310-4d6b-933a-d14357f9ccbe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_73c84239-da1b-45a6-a5f2-189253243ce2_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20200930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_51819b54-4790-4743-80a0-a01eaba9afbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate (as percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d8960a97-90a2-4b0d-9202-9b65028d37a4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DunboyneMember_72afeb0b-d02b-4b9b-8a7f-56db3e65cc8a_terseLabel_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:label id="lab_mrk_DunboyneMember_label_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne [Member]</link:label>
    <link:label id="lab_mrk_DunboyneMember_documentation_en-US" xlink:label="lab_mrk_DunboyneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dunboyne</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember" xlink:href="mrk-20200930.xsd#mrk_DunboyneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DunboyneMember" xlink:to="lab_mrk_DunboyneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_d20a70bd-c820-4ac3-8058-d3e10b59653b_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_7fc38672-b3dc-4d29-baea-9479852076b5_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_95d0adc3-1b98-45ac-b919-ea32cc21349a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a171ba8a-c616-45b2-8aed-492f0ca76e7d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_94933d6c-83ba-4af1-b32a-2525918f719c_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FemurFractureLitigationMember_1196f9e4-a09b-4e01-bea8-468dfa12a8d3_terseLabel_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture Litigation</link:label>
    <link:label id="lab_mrk_FemurFractureLitigationMember_label_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture Litigation [Member]</link:label>
    <link:label id="lab_mrk_FemurFractureLitigationMember_documentation_en-US" xlink:label="lab_mrk_FemurFractureLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Femur Fracture litigation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember" xlink:href="mrk-20200930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FemurFractureLitigationMember" xlink:to="lab_mrk_FemurFractureLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_1cc85b06-4c25-40de-96eb-2bb7a5ddda80_terseLabel_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021</link:label>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_label_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A1.125Notesdue2021Member_documentation_en-US" xlink:label="lab_mrk_A1.125Notesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member" xlink:href="mrk-20200930.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.125Notesdue2021Member" xlink:to="lab_mrk_A1.125Notesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fdf07549-0972-469e-835e-0c372f3d623b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9f830864-184d-404a-b3e7-02c8867e91a9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe58a267-c006-46a2-8782-48924eac2757_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_27d4f012-6c60-40a9-8048-3f87fae41ff9_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_11370238-5d7d-4c61-b29d-be5d65c57d62_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f8f2f4c3-2206-4e05-9420-a54733ad7b22_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_0eb4cd6d-4316-4e78-88c9-c9209a8706b4_terseLabel_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contract, shares</link:label>
    <link:label id="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_label_en-US" xlink:label="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Contract Indexed to Issuer's Equity, Indexed Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:to="lab_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_11b0ef90-c9f9-4679-8241-c67ad00e3704_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_66bd6839-818f-4957-a38e-06208da0d894_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_7451606d-9c82-4383-9af3-9456894aa482_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20200930.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_3506a890-4b99-4770-9734-01b5466bba13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f77939de-d31f-4b99-ba77-c2492021ef06_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7bb7d734-69cd-440d-91c2-ac80fa8085d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_8774a59b-6643-4ce5-af49-00808228231e_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_21282318-7d63-4599-bc1c-69b420adda01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_9d6ac87d-9a65-43a2-a218-453f3df2c754_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_a017359e-f834-4bda-a4ff-9500b49f1b11_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_b906f7d8-5ba4-4fc8-b9ca-fae2015efe9b_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_baf6b17f-9fa9-4f28-968b-491544f9b868_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired rights</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_14e010eb-9954-4de4-b2ae-90dc65212522_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c5dfb6e0-ed8a-4236-a30b-407800255e0c_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_903573ec-cce5-4199-a302-bb47a2dc8a67_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1c192c8d-a654-4026-8749-cbcc6128341a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NasonexMember_263f010d-c625-49ae-96ab-5c172108a73c_terseLabel_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cozaar/Hyzaar</link:label>
    <link:label id="lab_mrk_NasonexMember_label_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex [Member]</link:label>
    <link:label id="lab_mrk_NasonexMember_documentation_en-US" xlink:label="lab_mrk_NasonexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nasonex [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember" xlink:href="mrk-20200930.xsd#mrk_NasonexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NasonexMember" xlink:to="lab_mrk_NasonexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b6582aa8-04e1-4816-b09c-d5b84fa3f983_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f41820e5-6dd1-43b9-ba52-ac00096f11de_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5f8950ad-549f-4849-ba16-d497d5ec446e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7028e239-19c4-43ee-826f-a34c70a7acf6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_239d4782-3bb5-4b71-986c-8c85b91d494b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_f4751280-4e15-4aa6-a841-3ef38682c7f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VelosBioMember_dda800c1-28a8-4686-ad33-d0d8b9aa08f0_terseLabel_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio [Member]</link:label>
    <link:label id="lab_mrk_VelosBioMember_label_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio [Member]</link:label>
    <link:label id="lab_mrk_VelosBioMember_documentation_en-US" xlink:label="lab_mrk_VelosBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VelosBio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember" xlink:href="mrk-20200930.xsd#mrk_VelosBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VelosBioMember" xlink:to="lab_mrk_VelosBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_13962263-3ab1-4b2c-b38c-796d9c3201d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d99c4afa-a022-44fe-85fc-83fa1faa16f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3d2ef696-effb-44b1-9ba4-14fd025c161a_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_defabc2b-a03c-4f8e-8fc4-1fef9ac62ffd_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized on investments in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_21f23b05-d594-4a2a-bf82-28370ee02755_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognized related to settlement</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_44fcf783-0f98-4332-9105-477f8a96511b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_2a82b6c5-b6c0-4cea-ab2f-551bd00946af_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring and related cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_7c2f2d70-0279-4116-ba3d-70c2051303eb_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_b85ffbb6-fb5c-4024-a997-cf41ecfc870d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_95de0106-5c45-4623-81d7-66ba669f6400_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_a47c5c23-5a9f-4cba-8d1f-98e16d6d55cb_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20200930.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_236d8836-c3fc-44c7-8ffb-a728018abeaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3b6e37e5-91c0-4847-ba63-a46d9edecdc5_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_4266ec70-ee99-4bdf-b234-019a3350bfe7_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6fa6d777-a9f3-4fcf-bab2-5d8660864abb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per share granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6d01ecfa-105e-486d-a26f-64a86e56c407_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6e097eab-2b61-42ff-aedd-7d00778fd1e2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5764389c-1510-4aa5-9a97-2dc3054860ad_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_751a666f-e141-4145-8073-0549a3159f2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_11900336-c05c-43d7-b15f-5405791d252d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c852bf1e-5995-47a3-a6f4-45f982ca11da_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1b5c983-ed8e-41cf-8aff-a260e49ac781_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FederalMember_fb5feb68-22ce-42db-b02d-dfae9f158181_terseLabel_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_mrk_FederalMember_label_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_mrk_FederalMember_documentation_en-US" xlink:label="lab_mrk_FederalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember" xlink:href="mrk-20200930.xsd#mrk_FederalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FederalMember" xlink:to="lab_mrk_FederalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_aded14b1-f7d2-49d7-a850-27702dc720c7_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_7bce8fb7-62e0-4a16-a596-107aa6ef510c_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20200930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_918b45a3-4e3a-48c7-9174-c598536afb5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VytorinMember_df576286-fc19-48be-bd81-2bdc7a17553d_terseLabel_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin</link:label>
    <link:label id="lab_mrk_VytorinMember_label_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin [Member]</link:label>
    <link:label id="lab_mrk_VytorinMember_documentation_en-US" xlink:label="lab_mrk_VytorinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vytorin [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember" xlink:href="mrk-20200930.xsd#mrk_VytorinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VytorinMember" xlink:to="lab_mrk_VytorinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_673e94e2-e0ba-494d-ab64-ffb5ac1abd66_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c2745da8-944b-4586-801c-a454ac2e396f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.75notesdue2026Member_5bfc27b7-859a-4200-9441-25d6c520ab97_terseLabel_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:label id="lab_mrk_A0.75notesdue2026Member_label_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A0.75notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A0.75notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% notes due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member" xlink:href="mrk-20200930.xsd#mrk_A0.75notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.75notesdue2026Member" xlink:to="lab_mrk_A0.75notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1f9c5d3e-6c46-48e7-b280-2adb27ad2f8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_915980ae-af65-4a5a-abf8-934729f30ee1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_092dcaf4-8ee8-4ba2-b66e-a3e4201a08ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_9f72e223-72d7-4906-b3b2-90efda615973_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6bf4e6ed-66bf-4cd8-9620-050a54d53411_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_87b879ba-ca50-4f42-b3e6-1baacb6886f7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14740792-8204-4332-bd06-e27e2e5e3e86_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8a5815d9-154b-44dc-aa94-9171f9fa8396_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_1f976f81-2082-47ac-a624-e33209f7b888_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables, Noncurrent</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ba25b70-8cbe-49b7-b546-ee57c79d56eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6604ed34-ddde-4479-8194-0aafd0a12c24_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_2c536d2d-5d09-415c-8d6f-434eae1079ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Rate Swaps Held</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c2acd13e-cfc1-4311-99c8-f906b61531a8_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_3a54b2f1-1e7f-4c9b-9ed9-48261645a05a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_22321539-2e8a-424c-86b8-959a9347758b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e8707ba9-7620-4f69-9f98-f1eb06b679de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38d68582-ec42-4630-a205-3918a66af6ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ef751dc6-8c13-4780-9925-8774a49b1f97_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_6a578796-5d55-4d71-a20a-46af73c07f1b_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20200930.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_f9ba2cfa-a853-4403-858f-b5b1a16975b4_terseLabel_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California state court</link:label>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_label_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California State Court [Member]</link:label>
    <link:label id="lab_mrk_CaliforniaStateCourtMember_documentation_en-US" xlink:label="lab_mrk_CaliforniaStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California state court.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember" xlink:href="mrk-20200930.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CaliforniaStateCourtMember" xlink:to="lab_mrk_CaliforniaStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_61072da2-a424-4419-936b-d4e652d2501f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_79ec7d44-2856-4009-9fc8-8bf39a9a1d5e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_feb3a172-41a1-4b5f-b881-37167d1a81ec_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for acquisition of Peloton Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_02f243ed-da15-42ea-b7d4-efcf76b6b8c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_2725e317-a7cc-4b2d-845f-ff007df93057_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e6e60372-610a-4321-9679-de469c32dff6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_1fe6c874-c658-455e-8829-ceb44309496e_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20200930.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6efc19a3-2e7f-4bb2-868f-385d258c07f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_ed4e8f08-d5a4-4534-910f-8bc781f19b9b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_55824403-f91b-48ef-9613-48cb2d766b0b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_916944e8-a0a0-4d76-b430-dfb47d67ad0b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c53f873f-3257-4502-850e-7e074bb428bb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1eb5f49b-3204-46e4-b8a4-b7c4cded7211_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_87a01eb4-b646-4ae7-b9b0-99655061f0af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_d73cb45e-4a96-4b5b-9324-a2e3524836d7_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20200930.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ef09c74b-f898-4f97-b15c-0e8886e58b15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_471c77eb-0825-40db-af6c-41fc5d7a6fa7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_6245e8c5-9e35-4a15-8d64-6f0e92421f6d_terseLabel_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:label id="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:to="lab_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SeagenMember_f952612b-8619-4fbf-bc99-d37c5795a75b_terseLabel_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:label id="lab_mrk_SeagenMember_label_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen [Member]</link:label>
    <link:label id="lab_mrk_SeagenMember_documentation_en-US" xlink:label="lab_mrk_SeagenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seagen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember" xlink:href="mrk-20200930.xsd#mrk_SeagenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SeagenMember" xlink:to="lab_mrk_SeagenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_0793f393-9847-4629-9f2b-a23679601b6d_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20200930.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1e3029b4-f3f6-45f4-8dcc-7469bf3dacd7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5f20470e-d266-4d7a-a662-d52ecf9df2d5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_f8067e4d-37fc-4633-8b46-cd4feeb6f54c_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held (in interest rate swaps)</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_619ca426-81af-49e6-83ad-0fbe88c42efd_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Swaps Held (in interest rate swaps)</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_4b6c273f-ef33-40c5-9c00-753f6ddad4b3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_dcefb9d0-0191-4ca3-940c-a4aff8c35b5c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_ed5fe196-8ea7-4f67-8856-77870c3b14eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_8e6f263d-e7a0-4b8a-b364-b2784518082c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_739cb959-ccec-43cf-a890-2218d9f5686c_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FollistimAqMember_94971501-8a05-4bba-9746-22cf785cc10b_terseLabel_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim AQ</link:label>
    <link:label id="lab_mrk_FollistimAqMember_label_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim Aq [Member]</link:label>
    <link:label id="lab_mrk_FollistimAqMember_documentation_en-US" xlink:label="lab_mrk_FollistimAqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follistim AQ [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember" xlink:href="mrk-20200930.xsd#mrk_FollistimAqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FollistimAqMember" xlink:to="lab_mrk_FollistimAqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_0c796fe2-6100-4c67-b225-aa406214da10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1df93c08-532b-4573-ae64-590a8dc72bb8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_fa5cd08f-7f6f-4205-a695-69c01a5545af_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_d12af156-30f1-42a9-a46c-15cd85ae9e5c_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Pharmaceutical segment sales</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_ad26d52a-588c-43e3-b598-9c631f82c5a5_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20200930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_20d5d9c0-dc4d-4555-80b7-8496d3c04d01_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_218303f3-654a-4563-8e9e-2ff6c793aebf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f3507385-cb44-4af7-b974-08a2afb742df_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_a2bd9e34-5a44-4841-8fb2-178bb3788a0d_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology Rights</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e67ff360-09b0-4be8-82d0-7b1200e8a148_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c09c191d-6cb8-4928-89df-9ada9367790d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_d77cab89-5a17-4773-8aee-885e69b5e943_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_fd3ce08f-d259-4286-9562-49dcf6e0f4fd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net gain and prior service credit, net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a5b27a16-6f65-4347-b992-6f2fbb1d884a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_9379fa8b-ebcb-45d7-98cf-d8a45fb1fa61_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by employer</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0b33e3d4-0cf9-47d2-b786-de693df4b83b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1a5c1519-a2b8-4047-9758-b5301ffd6466_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative costs since program inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_e0ce8b84-f5fa-448b-b0dd-3df806e07d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0046057a-99b3-469c-86ed-c26de0dc6d55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4cea22e5-bcf0-4ed9-827c-54dd4e4ddb3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;&#160; Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_d2d731b1-b520-468b-8acc-2264bc5d92f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0d1fdf19-e726-41ee-a995-43de20f9976c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_cfaa9cc4-c04d-4d3c-8951-e2b7021f9470_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_70120aeb-8fc2-41fa-9e82-3eb45cf976ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_089f8b87-74c0-4dc6-b327-a58e80ffc2e5_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20200930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_86bda8c8-aa03-4615-a144-085078509b9d_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaMember_3f246c82-55b2-4911-9677-bd25ddd604d9_terseLabel_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia</link:label>
    <link:label id="lab_mrk_ZetiaMember_label_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia [Member]</link:label>
    <link:label id="lab_mrk_ZetiaMember_documentation_en-US" xlink:label="lab_mrk_ZetiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember" xlink:href="mrk-20200930.xsd#mrk_ZetiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaMember" xlink:to="lab_mrk_ZetiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_ea1261a2-3667-49f5-be48-62173c32bf90_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on investments in equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_39ab67f7-c874-4d9d-ac50-01040b18f063_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20200930.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_b1740c00-c504-4cab-8863-98725e20022b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_c553f3c5-85b6-4227-b6db-402831f651fb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future employer contributions, current fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e3a2acf5-e92b-48e8-b818-e12fcd9cc7df_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_72a808fc-425a-4dae-98dc-0e558a5713d7_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_749b2936-9ba4-43c9-a74d-10db52270fdf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_190b7073-5567-4e6e-b460-625da90ea287_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20200930.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_28ced88f-494c-4e25-9ca6-b9b8edf98590_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityTable_6c5b1aac-e2c4-42b2-9c1e-68ea42a00cde_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_label_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityTable" xlink:to="lab_mrk_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dfd8fcb1-65a0-43ba-a4d8-3461f550c679_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Decrease in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_aa0150e2-a010-428f-ba71-960b2058cec0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_300beaa4-4d86-4fb4-bc10-10725c1dce24_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20200930.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_63c6a9ca-ca9f-4e75-9ac2-0b0d3dee0f1f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1275d524-120f-4b10-9dcf-605ab3162610_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_a719457e-f6d4-4d73-b817-fe57217d18de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_002ca534-bfdf-45eb-a64f-23d5227a6edc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e511ebb1-33ed-42eb-b28b-3606ddc36412_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_58fa6795-776f-4ff3-9c58-c4175a0b1be7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_09acebd0-b593-4e59-acbf-4d190cee38e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recorded on Balance Sheet Related to Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_7575adfb-9d6c-465f-9055-03fe82d253df_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35notesdue2040Member_fd7a9813-559d-4197-b07b-68f315b8c0a6_terseLabel_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040</link:label>
    <link:label id="lab_mrk_A2.35notesdue2040Member_label_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040 [Member]</link:label>
    <link:label id="lab_mrk_A2.35notesdue2040Member_documentation_en-US" xlink:label="lab_mrk_A2.35notesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member" xlink:href="mrk-20200930.xsd#mrk_A2.35notesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35notesdue2040Member" xlink:to="lab_mrk_A2.35notesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_57d2b386-2b80-4b4f-8131-7c6095aa9a64_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20200930.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_10414bb6-3a55-4fd1-ada1-0b0ec3c5c9d0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_ac961e82-61cf-41ee-9235-0f09002ef3f5_terseLabel_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_label_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of Other Income / Expense of Nonoperating [Line Items]</link:label>
    <link:label id="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_documentation_en-US" xlink:label="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:to="lab_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_80c3027a-3974-4ece-b63f-1eb92db75c3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_ef4c43a5-2611-4dcd-a984-5abd79931d77_negatedLabel_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of purchase accounting adjustments</link:label>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Purchase Accounting Adjustments</link:label>
    <link:label id="lab_mrk_AmortizationOfPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of purchase accounting adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:href="mrk-20200930.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:to="lab_mrk_AmortizationOfPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_78c95a15-c45e-445b-8e04-dcf2913878cf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TukysaMember_52e41ec1-78ec-4e5e-a8be-d346cd3195d1_terseLabel_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:label id="lab_mrk_TukysaMember_label_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa [Member]</link:label>
    <link:label id="lab_mrk_TukysaMember_documentation_en-US" xlink:label="lab_mrk_TukysaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tukysa</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember" xlink:href="mrk-20200930.xsd#mrk_TukysaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TukysaMember" xlink:to="lab_mrk_TukysaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc28e4ba-d5ca-40f8-8406-c80e0d7f04c1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6266908b-f291-4953-b2dd-748d96cf1552_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_663057bd-d1b5-4d28-96c2-1cd0a12046c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_5c6135ab-8cd8-481b-9261-58192249f9c7_terseLabel_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey state court</link:label>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_label_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey State Court [Member]</link:label>
    <link:label id="lab_mrk_NewJerseyStateCourtMember_documentation_en-US" xlink:label="lab_mrk_NewJerseyStateCourtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey state court member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember" xlink:href="mrk-20200930.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NewJerseyStateCourtMember" xlink:to="lab_mrk_NewJerseyStateCourtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f1ad57c3-680c-40cf-9d08-2d47975c4782_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_54cc1196-8ff7-46cc-90ca-0a2db5309960_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7a8f68bc-5460-4e43-a4db-269fa095c3e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1f67a19f-aee9-4167-90d8-e290f423a634_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_0a14054c-43e4-4522-9f16-f0fd15700450_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20200930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_71da17c8-bf72-4722-a15c-3746503ece44_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20200930.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c99adde6-0cc1-4938-85a4-da026ad9e5c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d265ae0-0459-4699-8fb3-652d20eb4f7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_07d3041a-588b-435d-8e6b-d5ceb3b433e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_c2c035fc-cbfc-43df-b77b-23a27cd0f886_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_e66eb59a-9c95-41e0-b356-a252f8f3e2dd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8b9bcaf5-af56-4016-8a77-33fde0d951fe_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Assuming Dilution Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_981829dc-912a-4638-b89c-57a635218f04_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_81916913-9001-4cdf-b96b-2ab378f68236_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza (1)</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20200930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_87f3cab9-8923-4fd6-ba7f-383adb3d43d7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_382801b4-2500-4fc1-a30b-0c962e16551e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_accac201-a565-4000-a3c7-8b2118c81755_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20200930.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e1f44f59-424c-4819-97a6-88344f24993d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_423dbd43-1849-409d-bc6f-6069f42bdfce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a226f307-8c30-4d59-bedd-722880d7a6d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information About the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_90184aff-ca10-4018-bd70-a4276b9c984c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_2426079f-0856-4067-ba3e-31c287076144_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20200930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CommercialMilestoneMember_be281314-1c5c-449b-acb4-aaf2856193cf_terseLabel_en-US" xlink:label="lab_mrk_CommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone</link:label>
    <link:label id="lab_mrk_CommercialMilestoneMember_label_en-US" xlink:label="lab_mrk_CommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone [Member]</link:label>
    <link:label id="lab_mrk_CommercialMilestoneMember_documentation_en-US" xlink:label="lab_mrk_CommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialMilestoneMember" xlink:href="mrk-20200930.xsd#mrk_CommercialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CommercialMilestoneMember" xlink:to="lab_mrk_CommercialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_73422f10-798e-4d07-9fd0-bf46f402e28e_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20200930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1903fd03-9503-4909-83bc-fd416107f771_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of taxes</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4b594dc5-3b1a-43ee-90ed-8fbb45577bd4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6fa6b33e-faf4-44cc-b707-54a0d27283fe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, maximum</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7d49bef1-07fb-4c27-9fde-f9554b5ccdfa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_a2429da5-fe20-4e21-a38c-19b4e355b246_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_23fc44bd-2d8d-405b-b516-5440aa60939a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bd6d9e68-5dff-4d8f-9769-ca622aa5d8ec_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_34d9a179-1380-4a44-a0ec-5e9248232ba2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_12c561f5-5607-4821-b6aa-0b02b64fd522_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_d24f46c6-f8e2-485e-a785-1920ca2a9bb2_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_317e4c7f-5787-44b0-8641-b1f4bc84b7aa_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_ec7a4d59-888d-4fa5-917b-20dd5953486a_terseLabel_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% notes due 2022</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_label_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_mrk_A2.35NotesDue2022Member_documentation_en-US" xlink:label="lab_mrk_A2.35NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member" xlink:href="mrk-20200930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.35NotesDue2022Member" xlink:to="lab_mrk_A2.35NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_34b3c169-36c0-423f-9ccd-87f1fdd650cd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate (as percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_73c01e4b-0a3f-4aff-a550-9affec3b616f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net cost of defined benefit plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68201d61-a05f-4456-af42-c64be1b0247b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_186d2f7d-f735-408f-a0f4-00c720df73fc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d692cb6-277a-4530-86f1-ae99525adc44_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0636780d-a572-4b50-b4da-38c25c5c9923_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26e3e4aa-b848-41c8-978d-b3a7a97aadd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_86148538-9b7e-49f8-a674-30f812466698_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_b573842b-1c12-4390-a84e-17475ee8c04d_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20200930.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2789cdd6-d241-49fe-b735-a15a82014bb3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_147997ad-7dea-4f76-9c62-adf53d50b0bd_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_134ea484-703c-4136-88e2-e4c624a0e20e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.45notesdue2030Member_fdad1d60-1058-4a3e-a182-2e91467275fc_terseLabel_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030</link:label>
    <link:label id="lab_mrk_A1.45notesdue2030Member_label_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030 [Member]</link:label>
    <link:label id="lab_mrk_A1.45notesdue2030Member_documentation_en-US" xlink:label="lab_mrk_A1.45notesdue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.45% notes due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member" xlink:href="mrk-20200930.xsd#mrk_A1.45notesdue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.45notesdue2030Member" xlink:to="lab_mrk_A1.45notesdue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_be7c188b-b0ac-4a74-8117-282e7eac2c7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_0dc704a5-0df3-4e70-8483-6fda15422e72_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_83d0a698-9357-47b2-90ea-ca9cafae2286_terseLabel_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payments collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20200930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_87211c55-6ca3-4b4f-8e74-ea6b4d722685_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InvanzMember_20f64b35-0f11-4fe4-95f1-bb99fa77ef12_terseLabel_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz</link:label>
    <link:label id="lab_mrk_InvanzMember_label_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member]</link:label>
    <link:label id="lab_mrk_InvanzMember_documentation_en-US" xlink:label="lab_mrk_InvanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invanz [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember" xlink:href="mrk-20200930.xsd#mrk_InvanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InvanzMember" xlink:to="lab_mrk_InvanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_8c08cb8c-c47d-497f-9c7e-22bc1cad85ee_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_abda19f9-58c0-4010-bc21-6ddc43e016de_terseLabel_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% notes due 2021</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_label_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021 [Member]</link:label>
    <link:label id="lab_mrk_A3.875NotesDue2021Member_documentation_en-US" xlink:label="lab_mrk_A3.875NotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member" xlink:href="mrk-20200930.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A3.875NotesDue2021Member" xlink:to="lab_mrk_A3.875NotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_401c20de-e8ce-49cd-87a4-301a579e975c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_48fd7045-1b93-4b56-8fb3-70d310036d5e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_52d2880b-4121-4c51-8722-b85119534386_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral advanced to counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_3a878c0e-db34-470e-ad03-5fdec980a4b1_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fd16145-581e-4e62-a0d8-334ada613cda_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6b287401-f2e0-4822-8f1a-2bd86bdf9aa1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract_73700ec2-1359-4873-958e-9c81de8512c3_terseLabel_en-US" xlink:label="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]</link:label>
    <link:label id="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract_label_en-US" xlink:label="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]</link:label>
    <link:label id="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract_documentation_en-US" xlink:label="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:href="mrk-20200930.xsd#mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:to="lab_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d03352db-bcd2-4daa-a265-73c106c76066_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_f8aebfec-19d6-48dc-960c-fdb359c07035_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ArcoxiaMember_d5e0cf78-e6fb-4fbd-8087-cbce51761bf3_terseLabel_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia</link:label>
    <link:label id="lab_mrk_ArcoxiaMember_label_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia [Member]</link:label>
    <link:label id="lab_mrk_ArcoxiaMember_documentation_en-US" xlink:label="lab_mrk_ArcoxiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcoxia [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember" xlink:href="mrk-20200930.xsd#mrk_ArcoxiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ArcoxiaMember" xlink:to="lab_mrk_ArcoxiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b97d914a-36b7-492f-94e6-b4b2d73fd184_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_b56f4b4d-5a10-4b1e-92cc-15a86a059dcd_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_30e07299-3efa-477c-9273-aac72b73c08e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9f0011fe-0627-43cf-a1a2-d10a4e9a66b7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_936dcce0-d828-49d2-9a46-347c81ff1ad2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mrk-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a3b4f571-9208-4d1b-9315-c47a6036bcc7,g:1cfae7b8-71a0-4b7e-8fe6-d77942560c08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_abc28f9c-4a27-4387-813a-9b5b6fb24142" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abc28f9c-4a27-4387-813a-9b5b6fb24142" xlink:to="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa9a39aa-de8d-42b4-9902-6951d6ece8a3" xlink:to="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a6cc5a5-29de-4555-a830-62b0ace5c3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_us-gaap_CommonStockMember_6a6cc5a5-29de-4555-a830-62b0ace5c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.125Notesdue2021Member_88ee9971-bac0-4c9e-8011-fc3327f4919d" xlink:href="mrk-20200930.xsd#mrk_A1.125Notesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.125Notesdue2021Member_88ee9971-bac0-4c9e-8011-fc3327f4919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_bd30f473-0875-4f1f-8c1d-e180a3c815a8" xlink:href="mrk-20200930.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A0.500Notesdue2024Member_bd30f473-0875-4f1f-8c1d-e180a3c815a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_2d40e0b5-a893-4623-9b0c-bb9c6b63715c" xlink:href="mrk-20200930.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.875Notesdue2026Member_2d40e0b5-a893-4623-9b0c-bb9c6b63715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_1622ed33-3dd5-45c8-b8ac-3e81d4bd9e52" xlink:href="mrk-20200930.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A2.500Notesdue2034Member_1622ed33-3dd5-45c8-b8ac-3e81d4bd9e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_a2dd6f41-15be-42b8-b0af-7ad59e38a041" xlink:href="mrk-20200930.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bf66cae6-1827-4b5c-96f9-4d60313d4753" xlink:to="loc_mrk_A1.375Notesdue2036Member_a2dd6f41-15be-42b8-b0af-7ad59e38a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4a8f7f6f-d422-4e84-990e-4cec91778dca" xlink:to="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1eb1c192-081b-4eb5-ba03-c24d55ee3f98" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentType_1eb1c192-081b-4eb5-ba03-c24d55ee3f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e0dd040b-540d-4cae-87f5-9d826b016672" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentQuarterlyReport_e0dd040b-540d-4cae-87f5-9d826b016672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_990d09ec-9b4a-49f7-a7db-6bb350ecea09" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentPeriodEndDate_990d09ec-9b4a-49f7-a7db-6bb350ecea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f4306c5b-28bd-465a-8462-8314bb4676c1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentTransitionReport_f4306c5b-28bd-465a-8462-8314bb4676c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8083f4bf-1d95-48ad-a3d0-2c4cb4aa47fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityFileNumber_8083f4bf-1d95-48ad-a3d0-2c4cb4aa47fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_875cccdf-cff2-417e-81c2-1061c09ffb7c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityRegistrantName_875cccdf-cff2-417e-81c2-1061c09ffb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fc8c025d-deea-4e3b-b5ba-27e0231bee6b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fc8c025d-deea-4e3b-b5ba-27e0231bee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d4877a43-855a-4ff0-a232-bf3eb3d15111" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityTaxIdentificationNumber_d4877a43-855a-4ff0-a232-bf3eb3d15111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_49532f90-80f3-4663-b2ff-1f210101c771" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressAddressLine1_49532f90-80f3-4663-b2ff-1f210101c771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_91fc0b70-36b7-4eda-85d5-a92fc1c46f44" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressCityOrTown_91fc0b70-36b7-4eda-85d5-a92fc1c46f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a9113bfa-e70a-458d-98f4-1e0bf3678061" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressStateOrProvince_a9113bfa-e70a-458d-98f4-1e0bf3678061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ef2f3c5d-3e51-4fc7-95ba-a5e31222812b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityAddressPostalZipCode_ef2f3c5d-3e51-4fc7-95ba-a5e31222812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f5f9e663-0fa8-441c-94fd-ac0b09652998" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_CityAreaCode_f5f9e663-0fa8-441c-94fd-ac0b09652998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6ead383b-0cf8-42d4-b9bb-d0c35687dc12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_LocalPhoneNumber_6ead383b-0cf8-42d4-b9bb-d0c35687dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7c6e244d-4d47-416a-b568-45d891b0128d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCurrentReportingStatus_7c6e244d-4d47-416a-b568-45d891b0128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9e571246-17ac-4fdd-9131-683896d61f05" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityInteractiveDataCurrent_9e571246-17ac-4fdd-9131-683896d61f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1510f923-5556-4f4a-9aa7-ba6064d1286b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityFilerCategory_1510f923-5556-4f4a-9aa7-ba6064d1286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e40e95dc-d097-4050-8da3-558949fc3aaf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntitySmallBusiness_e40e95dc-d097-4050-8da3-558949fc3aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5e9703d6-df47-4bc3-a540-e4669fd65eb5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityEmergingGrowthCompany_5e9703d6-df47-4bc3-a540-e4669fd65eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e8a27060-220e-41d1-8e57-4073a0c45596" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityShellCompany_e8a27060-220e-41d1-8e57-4073a0c45596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8f4c99ae-7f35-499d-a4d8-f9a48b039e0d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_Security12bTitle_8f4c99ae-7f35-499d-a4d8-f9a48b039e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4589a606-4c42-4b8f-aa6d-8c26d3ec2979" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_TradingSymbol_4589a606-4c42-4b8f-aa6d-8c26d3ec2979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bceced6a-5166-46da-90e8-5f7ff3d75d1a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_SecurityExchangeName_bceced6a-5166-46da-90e8-5f7ff3d75d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bdbb8cbf-4839-456f-9948-4445b66ee5c6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bdbb8cbf-4839-456f-9948-4445b66ee5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e3e26e6e-d33f-4fc6-aac3-b87828789732" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_AmendmentFlag_e3e26e6e-d33f-4fc6-aac3-b87828789732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_adcd26a0-edba-4d5d-8ed6-95b7d42955bd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentFiscalYearFocus_adcd26a0-edba-4d5d-8ed6-95b7d42955bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57ddc8b7-3fc6-49b7-b1c7-a01bf773da59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57ddc8b7-3fc6-49b7-b1c7-a01bf773da59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_867feb35-50e4-4e1f-a645-dd31d0828d2c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_EntityCentralIndexKey_867feb35-50e4-4e1f-a645-dd31d0828d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c9f54cbd-3cab-4dfe-8165-3e3f21a72c12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_9d19e7ec-17a3-4cf9-a3ac-fa8da221a6f6" xlink:to="loc_dei_CurrentFiscalYearEndDate_c9f54cbd-3cab-4dfe-8165-3e3f21a72c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9e0022cf-52f6-4c33-8ed0-ec2030892731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_Revenues_9e0022cf-52f6-4c33-8ed0-ec2030892731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5f182493-b786-40e8-87ee-feadc5904aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5f182493-b786-40e8-87ee-feadc5904aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02cb61c7-fad9-42bf-a77e-0de3886ecd0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_02cb61c7-fad9-42bf-a77e-0de3886ecd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6a60fd80-b934-41c4-bcbe-db00353b066d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6a60fd80-b934-41c4-bcbe-db00353b066d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_28bc00a2-5a75-47ef-8f9f-b2ca9aa3b650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_us-gaap_RestructuringCharges_28bc00a2-5a75-47ef-8f9f-b2ca9aa3b650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_135635dd-dfb7-41e5-a7aa-c803ad4e9362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_135635dd-dfb7-41e5-a7aa-c803ad4e9362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_c636074c-af2e-47bd-ba13-6398e2620004" xlink:href="mrk-20200930.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_31cdd6ab-39e9-4d2b-baab-2bdff84566ea" xlink:to="loc_mrk_CostsExpensesAndOther_c636074c-af2e-47bd-ba13-6398e2620004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f916128a-a2bb-453d-99a4-dcb339c904fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f916128a-a2bb-453d-99a4-dcb339c904fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1655b8a5-23b9-4e69-90bd-094b90c2dee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1655b8a5-23b9-4e69-90bd-094b90c2dee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a13a69a1-ec85-40f9-909b-ca51053e6572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_ProfitLoss_a13a69a1-ec85-40f9-909b-ca51053e6572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b194a87e-534b-4d46-a9b3-6f82b4e05020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b194a87e-534b-4d46-a9b3-6f82b4e05020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_68ab67fa-c8e8-4444-80f5-b92b27d08ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_NetIncomeLoss_68ab67fa-c8e8-4444-80f5-b92b27d08ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1bfda376-7419-4f07-95b6-4f4b167e498b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_EarningsPerShareBasic_1bfda376-7419-4f07-95b6-4f4b167e498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dd2ecf52-3f82-4b6b-8cec-3defce4ca828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e78e0dbe-f8b4-4c36-9e53-5bccb423b95a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dd2ecf52-3f82-4b6b-8cec-3defce4ca828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a3df6773-f358-4577-a61b-a6e2fb83a1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d21e2910-e8b3-431e-8703-cdd3fe8e4237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a3df6773-f358-4577-a61b-a6e2fb83a1d2" xlink:to="loc_us-gaap_NetIncomeLoss_d21e2910-e8b3-431e-8703-cdd3fe8e4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a3df6773-f358-4577-a61b-a6e2fb83a1d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_a704a7c0-c68a-4d58-9442-7a6e3f1516de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_a704a7c0-c68a-4d58-9442-7a6e3f1516de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_926a946b-b5b6-4241-9cca-f4d01652a5f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_926a946b-b5b6-4241-9cca-f4d01652a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_5d6bb702-01af-422c-af5a-5954069072a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_5d6bb702-01af-422c-af5a-5954069072a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9953f87c-9dde-4b33-a87d-79e13b53fc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9953f87c-9dde-4b33-a87d-79e13b53fc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_271ff68e-20f7-4f95-8a70-eb92218d6f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b43e3c2d-c3cf-4423-b22d-6eaf9f25f79d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_271ff68e-20f7-4f95-8a70-eb92218d6f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_973eeb0a-bdaf-44a2-a56f-d78b32ec8411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a3df6773-f358-4577-a61b-a6e2fb83a1d2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_973eeb0a-bdaf-44a2-a56f-d78b32ec8411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bd80937e-898a-435c-b187-ebfdc15214ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bd80937e-898a-435c-b187-ebfdc15214ce" xlink:to="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d953084-9036-407f-a177-d049d2dc0d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d953084-9036-407f-a177-d049d2dc0d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1c9d7e41-24fe-4e36-a9aa-70ae0c37c8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1c9d7e41-24fe-4e36-a9aa-70ae0c37c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_694170ba-182a-4018-8211-f93fea1ca3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_694170ba-182a-4018-8211-f93fea1ca3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_63ac6919-59a0-44aa-898e-f52b60390135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_InventoryNet_63ac6919-59a0-44aa-898e-f52b60390135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_afd22f32-3f6a-4042-845f-9f79217218c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_afd22f32-3f6a-4042-845f-9f79217218c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d82c796e-3a75-443f-978d-a09734d7a2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2f3bac50-9c27-4dd5-9a7f-ed0910c4b438" xlink:to="loc_us-gaap_AssetsCurrent_d82c796e-3a75-443f-978d-a09734d7a2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_f0e600a8-fc9d-4038-b663-dbb57967e031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_f0e600a8-fc9d-4038-b663-dbb57967e031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4ddca57e-b26c-4ba9-adbd-75b477bcdafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4ddca57e-b26c-4ba9-adbd-75b477bcdafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a9850601-d2c9-4f7e-b7ba-2fbbc079cdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_Goodwill_a9850601-d2c9-4f7e-b7ba-2fbbc079cdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14c6bb70-73ea-4884-aa2e-2b35144f21d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14c6bb70-73ea-4884-aa2e-2b35144f21d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8b7f2e25-4c18-4d01-9003-574af034e534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8b7f2e25-4c18-4d01-9003-574af034e534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c003bb90-585d-4336-87f5-756ab78ae74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_71d10f28-85f1-439d-a87d-5a63f5de6018" xlink:to="loc_us-gaap_Assets_c003bb90-585d-4336-87f5-756ab78ae74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bd80937e-898a-435c-b187-ebfdc15214ce" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_06f6150a-e683-4aa0-b762-f12af95e1779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_DebtCurrent_06f6150a-e683-4aa0-b762-f12af95e1779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8f2329b3-8043-4d91-b52f-b81792f278ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_AccountsPayableCurrent_8f2329b3-8043-4d91-b52f-b81792f278ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d5dc7da5-41b2-40f5-8a75-2311ca2eaffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d5dc7da5-41b2-40f5-8a75-2311ca2eaffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_375aa380-f9dd-46bf-be2b-62845a7ef094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_375aa380-f9dd-46bf-be2b-62845a7ef094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_a7c571bb-58df-4ff2-9ece-a287b06c80a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_DividendsPayableCurrent_a7c571bb-58df-4ff2-9ece-a287b06c80a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d423f80-d9ee-410b-8bb5-0a1dfb283229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_888ada99-1894-489b-923c-d468c74e411f" xlink:to="loc_us-gaap_LiabilitiesCurrent_5d423f80-d9ee-410b-8bb5-0a1dfb283229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f3f4d322-afe5-4ca4-9c15-f95ffacbded9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f3f4d322-afe5-4ca4-9c15-f95ffacbded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_785a79f4-7fe7-4b49-b839-4e9543393109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_785a79f4-7fe7-4b49-b839-4e9543393109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_14596902-8a37-493f-b0ce-6394d717fc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_14596902-8a37-493f-b0ce-6394d717fc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_326862c7-0fd3-4056-b529-ccfae3f78cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_CommonStockValue_326862c7-0fd3-4056-b529-ccfae3f78cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f83a2d10-6c69-4a6f-b20f-a7086fe15a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f83a2d10-6c69-4a6f-b20f-a7086fe15a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ad65d92-e94b-4751-8eb0-d6fd83569f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ad65d92-e94b-4751-8eb0-d6fd83569f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51617f05-9c9a-40d5-a532-c9b6f9abcf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51617f05-9c9a-40d5-a532-c9b6f9abcf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_662a2071-61b8-4c48-a25a-383d3e1807d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_662a2071-61b8-4c48-a25a-383d3e1807d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0d86c4a2-8619-44d0-baf0-d28780899098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_TreasuryStockValue_0d86c4a2-8619-44d0-baf0-d28780899098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82fa2b36-7906-4cb2-b258-06a351bb2c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_StockholdersEquity_82fa2b36-7906-4cb2-b258-06a351bb2c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a229f4c6-9f30-4e81-99a4-260a888364cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_MinorityInterest_a229f4c6-9f30-4e81-99a4-260a888364cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fbd8629d-e15d-4c4f-b6ed-ced776f8daab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_81f45ef2-86e4-4b76-ba31-2aa9f9c2644b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fbd8629d-e15d-4c4f-b6ed-ced776f8daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b63fbbaa-00d9-4ccb-90af-a2bedf1b096d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc2172ea-dfad-4b1f-bb2f-d71d69bccc4a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b63fbbaa-00d9-4ccb-90af-a2bedf1b096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b7d9c499-a418-4c47-8446-8f03b18b7ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b7d9c499-a418-4c47-8446-8f03b18b7ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_14d0106d-70ca-4983-94cd-7de7648d0f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_InventoryNoncurrent_14d0106d-70ca-4983-94cd-7de7648d0f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb7a6d92-70c0-407a-9788-dbf174b7f7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fb7a6d92-70c0-407a-9788-dbf174b7f7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f5af3dd-7042-475f-8d91-713fc3ebc837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2f5af3dd-7042-475f-8d91-713fc3ebc837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8d0946a-8763-4ef7-9d74-5977e5c37397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8d0946a-8763-4ef7-9d74-5977e5c37397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_566e51c7-384d-4b2d-8ab3-3388242d2244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_CommonStockSharesIssued_566e51c7-384d-4b2d-8ab3-3388242d2244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_0a5ca1f5-706a-4996-95c6-ae8056df3c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d1160a7-e990-4b59-8a1a-4bca8508899f" xlink:to="loc_us-gaap_TreasuryStockShares_0a5ca1f5-706a-4996-95c6-ae8056df3c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e70e721e-0722-49ca-9c05-03d1ab1ae5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e70e721e-0722-49ca-9c05-03d1ab1ae5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd6fd228-1919-49f8-8e36-64ac6ce8a6d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e70e721e-0722-49ca-9c05-03d1ab1ae5fc" xlink:to="loc_us-gaap_ProfitLoss_cd6fd228-1919-49f8-8e36-64ac6ce8a6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e70e721e-0722-49ca-9c05-03d1ab1ae5fc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d756f5c8-63f4-426e-a242-4d8bb2a9ace1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d756f5c8-63f4-426e-a242-4d8bb2a9ace1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cc2b1874-6112-4d62-8ca1-08f60f2421b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_cc2b1874-6112-4d62-8ca1-08f60f2421b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7e8f4c44-9858-4c2b-a2d9-3baf83339648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7e8f4c44-9858-4c2b-a2d9-3baf83339648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bdb7a9b7-8efa-424d-8c99-5460494072eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bdb7a9b7-8efa-424d-8c99-5460494072eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_99b5609e-0f0a-472a-beb5-0a9a7caab4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_ShareBasedCompensation_99b5609e-0f0a-472a-beb5-0a9a7caab4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f1d2ca95-6a3c-432a-b9d9-0350909ecc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f1d2ca95-6a3c-432a-b9d9-0350909ecc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_58e6ed96-f424-4fa3-aa3a-7d4241587d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4db99801-1655-491c-8077-e4efbb7b54de" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_58e6ed96-f424-4fa3-aa3a-7d4241587d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfa12d5b-4134-49c4-b1bc-ddfae329146c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e70e721e-0722-49ca-9c05-03d1ab1ae5fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cfa12d5b-4134-49c4-b1bc-ddfae329146c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_7722ae75-6016-4ef1-a4d9-011d67510a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_7722ae75-6016-4ef1-a4d9-011d67510a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6929dc8f-2c1e-4c7b-888a-1bafcdcd1d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6929dc8f-2c1e-4c7b-888a-1bafcdcd1d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_298cd726-31ee-4240-9821-5704b1cddffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_298cd726-31ee-4240-9821-5704b1cddffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_e8df43d6-8a16-4625-9ecf-bcc170aab36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_e8df43d6-8a16-4625-9ecf-bcc170aab36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_7a9ae81d-f768-4102-8db6-13254e55c0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired_7a9ae81d-f768-4102-8db6-13254e55c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_a3e3dd94-e4ff-4e13-863e-9b370cdb997d" xlink:href="mrk-20200930.xsd#mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired_a3e3dd94-e4ff-4e13-863e-9b370cdb997d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c1765938-c3d0-47f6-9238-43f6ffaa4ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c1765938-c3d0-47f6-9238-43f6ffaa4ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ace36074-f224-4d41-b786-109736e984c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ace36074-f224-4d41-b786-109736e984c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba9e5769-6c7c-4058-9827-818d11b077ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88c9fb10-c111-49e8-95a4-a15214cad68a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba9e5769-6c7c-4058-9827-818d11b077ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_e2bc3aae-29dc-4195-b09d-c11553c615dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_e2bc3aae-29dc-4195-b09d-c11553c615dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6c576d65-c879-476d-8356-e338cfc80d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6c576d65-c879-476d-8356-e338cfc80d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9597a97d-5c4c-4153-9424-40749e63bd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9597a97d-5c4c-4153-9424-40749e63bd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30418b1e-c3a2-4449-9bb4-71be894be194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_30418b1e-c3a2-4449-9bb4-71be894be194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_8922b67f-1ff6-4319-8d2b-b1de23f49d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_8922b67f-1ff6-4319-8d2b-b1de23f49d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_509d4528-647e-449b-83ad-e80699353f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_509d4528-647e-449b-83ad-e80699353f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_77fdb1e1-02bb-4bd4-88d5-9a71fcf4e22e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_77fdb1e1-02bb-4bd4-88d5-9a71fcf4e22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d90c480c-19df-49b8-96d0-ea6375f81b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33f4c0b6-c21c-4a64-be06-c39811cc6bd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d90c480c-19df-49b8-96d0-ea6375f81b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0812aa-24f5-45d8-8ddd-55098b1ee2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc0812aa-24f5-45d8-8ddd-55098b1ee2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1499b543-f362-424f-8b73-59094fb7d033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1499b543-f362-424f-8b73-59094fb7d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33306d7d-4b27-4d3f-a88c-a0b284bd339c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33306d7d-4b27-4d3f-a88c-a0b284bd339c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb1eed08-2fd7-4a21-8ef7-7f4d0b7d6d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d88c8b0b-0f9a-4c59-b587-7fc688c9d955" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb1eed08-2fd7-4a21-8ef7-7f4d0b7d6d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="mrk-20200930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3153bdfe-e525-44d3-a9c3-e301c2839357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_af63ce3c-2648-4c0c-a605-a152c803b96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3153bdfe-e525-44d3-a9c3-e301c2839357" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_af63ce3c-2648-4c0c-a605-a152c803b96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ceb2388-dea5-4d76-812a-edd390c25fda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7f2495d0-b4d5-41bc-860b-648166c6e437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ceb2388-dea5-4d76-812a-edd390c25fda" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_7f2495d0-b4d5-41bc-860b-648166c6e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mrk-20200930.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e950ad33-d036-4b8e-998d-49a0230a18c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f234d094-a747-46a6-bdc7-b098c200b17f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e950ad33-d036-4b8e-998d-49a0230a18c2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f234d094-a747-46a6-bdc7-b098c200b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf734e97-c36b-454c-aeca-b98a03a4d912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e950ad33-d036-4b8e-998d-49a0230a18c2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf734e97-c36b-454c-aeca-b98a03a4d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_de204654-4fba-4893-b765-3b56fa258721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e950ad33-d036-4b8e-998d-49a0230a18c2" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_de204654-4fba-4893-b765-3b56fa258721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1d00e14a-8861-4c72-be4f-4258124b44c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_008806ee-f71d-4a8b-bcb7-e9bb60b661bc" xlink:href="mrk-20200930.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1d00e14a-8861-4c72-be4f-4258124b44c4" xlink:to="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_008806ee-f71d-4a8b-bcb7-e9bb60b661bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a8f6121b-50f2-4d48-910e-0a6a1aa00dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a26ab991-4683-4cd0-84f8-84fe42c8e981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a8f6121b-50f2-4d48-910e-0a6a1aa00dd4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a26ab991-4683-4cd0-84f8-84fe42c8e981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_58675645-8140-4208-aa43-2571a9b75e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_58675645-8140-4208-aa43-2571a9b75e99" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3d6eaec1-7b57-45b4-8341-7edb6badeb22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0a1d2af3-0480-4683-b663-ee3bf920f5fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d96e528a-665c-4706-a913-040f6d7160db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0a1d2af3-0480-4683-b663-ee3bf920f5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c2fe8b38-bb36-45c1-89af-db2c8a47c055" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SeagenMember_c49645b0-d691-4db8-badc-8b2e8d53c85a" xlink:href="mrk-20200930.xsd#mrk_SeagenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:to="loc_mrk_SeagenMember_c49645b0-d691-4db8-badc-8b2e8d53c85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IAVIMember_34d470a8-b41b-4450-af20-afce0d56f8c4" xlink:href="mrk-20200930.xsd#mrk_IAVIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8db08c7a-723c-48ca-9b48-8afbe79440e5" xlink:to="loc_mrk_IAVIMember_34d470a8-b41b-4450-af20-afce0d56f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_9618b77a-3b3d-4467-9571-c0e6cde12367" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DevelopmentMilestonesMember_f4f62006-562c-4f76-9c18-694bec00fb57" xlink:href="mrk-20200930.xsd#mrk_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_DevelopmentMilestonesMember_f4f62006-562c-4f76-9c18-694bec00fb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_f6b63635-d2ec-4390-9598-24ee4fcb6058" xlink:href="mrk-20200930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_SalesBasedMilestonesMember_f6b63635-d2ec-4390-9598-24ee4fcb6058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_69f0523e-a73e-45d4-93b3-0128426a2140" xlink:href="mrk-20200930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_RegulatoryMilestonesMember_69f0523e-a73e-45d4-93b3-0128426a2140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CommercialMilestoneMember_0f547b2b-a2dc-40b7-8ea6-e010831fc619" xlink:href="mrk-20200930.xsd#mrk_CommercialMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2f9a0f6b-19b2-4c82-b63c-2972e40f98eb" xlink:to="loc_mrk_CommercialMilestoneMember_0f547b2b-a2dc-40b7-8ea6-e010831fc619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5cb84551-c18a-437a-9bff-2395f3aacd45" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DunboyneMember_622a6160-1edf-4f95-986c-cd0e507b24ef" xlink:href="mrk-20200930.xsd#mrk_DunboyneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_DunboyneMember_622a6160-1edf-4f95-986c-cd0e507b24ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ThemisMember_c912bbf7-eead-4865-bacb-c17cf5bb6501" xlink:href="mrk-20200930.xsd#mrk_ThemisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ThemisMember_c912bbf7-eead-4865-bacb-c17cf5bb6501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_91d8cd17-2167-4d41-96ee-fda1c15cd2d7" xlink:href="mrk-20200930.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ArQuleMember_91d8cd17-2167-4d41-96ee-fda1c15cd2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PelotonMember_51f038b9-6275-4842-bc92-03012644035a" xlink:href="mrk-20200930.xsd#mrk_PelotonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_PelotonMember_51f038b9-6275-4842-bc92-03012644035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_0e3b720d-9cb4-46a2-a707-f19a66a76bcf" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_AntelliqMember_0e3b720d-9cb4-46a2-a707-f19a66a76bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImmuneDesignMember_796497e4-3e63-4bfb-8e25-77037004ca71" xlink:href="mrk-20200930.xsd#mrk_ImmuneDesignMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_ImmuneDesignMember_796497e4-3e63-4bfb-8e25-77037004ca71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VelosBioMember_fa18f253-f275-476b-ba88-69ef4ff5d84e" xlink:href="mrk-20200930.xsd#mrk_VelosBioMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c06d648-a5b7-4b94-9eaf-50e60674dc33" xlink:to="loc_mrk_VelosBioMember_fa18f253-f275-476b-ba88-69ef4ff5d84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c4ffad6a-2c3d-4099-9e39-ac58b732deb1" xlink:to="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TukysaMember_0ae92259-a84f-4c17-991f-767818d70d79" xlink:href="mrk-20200930.xsd#mrk_TukysaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:to="loc_mrk_TukysaMember_0ae92259-a84f-4c17-991f-767818d70d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_92cc5a78-7409-4de8-8c2b-305c468b8bde" xlink:href="mrk-20200930.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_668303eb-d62f-46f2-86c3-db8aaccba8f7" xlink:to="loc_mrk_SentinelMember_92cc5a78-7409-4de8-8c2b-305c468b8bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7ddf5187-2f17-4b6b-a5a3-fc1cd52883b6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_f72d4dec-a43d-4920-b1db-1e9beb553d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bb3eaae1-ee12-4f57-812d-4fa09ae333ed" xlink:to="loc_us-gaap_ForwardContractsMember_f72d4dec-a43d-4920-b1db-1e9beb553d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a32d4254-21df-4c92-9918-2eb37f828aba" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f475cdcc-0c42-46b8-b20b-2d8edb703274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_24044912-33e6-46e5-9bed-72e535c23126" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f475cdcc-0c42-46b8-b20b-2d8edb703274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1e664a3d-791e-4f75-9f2c-eef17eae6d30" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4576fdb4-97fb-45e6-91b2-e89cc361bd03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b75e1fca-1238-4157-a7a8-1847000397fa" xlink:to="loc_us-gaap_SubsequentEventMember_4576fdb4-97fb-45e6-91b2-e89cc361bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bd90c8c5-1be5-435c-b996-034cbb5aacdd" xlink:to="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7aa10430-9edd-49f1-ba26-0421bcc8e40e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:to="loc_srt_MinimumMember_7aa10430-9edd-49f1-ba26-0421bcc8e40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cd4cec0-6535-4db2-bcab-66d75724b2e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_95549b19-5005-4927-b8ff-a66422f5a458" xlink:to="loc_srt_MaximumMember_7cd4cec0-6535-4db2-bcab-66d75724b2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_743ab166-eb14-4848-90d1-12effa33d63a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_463bf272-5150-46fb-aba4-0fc65adfe456" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_d7ca3934-81d7-41c3-aad4-8f443cb3644f" xlink:to="loc_srt_ScenarioForecastMember_463bf272-5150-46fb-aba4-0fc65adfe456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_375e2597-218b-498a-986a-b278722eb151" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0cf2b066-7c5d-46c3-b28a-df790f072b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_0cf2b066-7c5d-46c3-b28a-df790f072b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ed95040d-f997-4acf-870c-8d770b691c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ed95040d-f997-4acf-870c-8d770b691c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a5d88f7a-6f83-4035-a818-53537eb0a90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a5d88f7a-6f83-4035-a818-53537eb0a90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a91a8d6-5b0f-493f-95ff-239cc36e9f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7a91a8d6-5b0f-493f-95ff-239cc36e9f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2648c314-6eb2-44ea-9bf4-d147d3e360af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2648c314-6eb2-44ea-9bf4-d147d3e360af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_888957c6-417e-45f1-815f-2e293dcf6ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed_888957c6-417e-45f1-815f-2e293dcf6ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_0b44536a-ef5c-497b-aad1-eeb8aa7b7842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_0b44536a-ef5c-497b-aad1-eeb8aa7b7842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_86e741e6-0939-4eb7-8d3c-edc9a8fa7369" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_86e741e6-0939-4eb7-8d3c-edc9a8fa7369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbc7e1c-9f94-4e6d-bba3-fcecca4c53dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbc7e1c-9f94-4e6d-bba3-fcecca4c53dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1d8d6951-ee29-48b1-bea4-f4002306c095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_1d8d6951-ee29-48b1-bea4-f4002306c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4702f761-5046-4560-8a47-342091eede66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_Goodwill_4702f761-5046-4560-8a47-342091eede66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_34d45715-d6f2-48f2-b37b-03b3aa2bd250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_34d45715-d6f2-48f2-b37b-03b3aa2bd250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8986afe9-d543-4d24-a0e8-860107cdea71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_8986afe9-d543-4d24-a0e8-860107cdea71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_17dbbea2-3375-4963-a964-a3c313fd3c22" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_17dbbea2-3375-4963-a964-a3c313fd3c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_a30a23e4-cb22-4896-9648-04935a150edb" xlink:href="mrk-20200930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_a30a23e4-cb22-4896-9648-04935a150edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7513e806-326a-4427-ada1-1245744bee96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_SharePrice_7513e806-326a-4427-ada1-1245744bee96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_42a26833-44dc-4961-877c-c99221bc024c" xlink:href="mrk-20200930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_42a26833-44dc-4961-877c-c99221bc024c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4c988af4-dfd5-4ce1-a83d-c69322b892af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4c988af4-dfd5-4ce1-a83d-c69322b892af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7b01b801-c45a-47e5-9832-a13ce32d9f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7b01b801-c45a-47e5-9832-a13ce32d9f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_813d1a8b-2a6f-4ba9-99b6-b048b39eebf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_InventoryNet_813d1a8b-2a6f-4ba9-99b6-b048b39eebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1e41d883-c592-484f-9a94-85528ebab152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1e41d883-c592-484f-9a94-85528ebab152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8988b7a9-d389-472e-9155-4996d39bd47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8988b7a9-d389-472e-9155-4996d39bd47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6d7c5c82-afff-4388-8adb-5b47cb105f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6d7c5c82-afff-4388-8adb-5b47cb105f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9568354e-6a30-4647-af75-07a49467c6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9568354e-6a30-4647-af75-07a49467c6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_57d9f101-269d-40f5-9b52-e7a757db1d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares_57d9f101-269d-40f5-9b52-e7a757db1d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_310bd4b0-5df8-4fe1-858e-5c3053fa4054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_310bd4b0-5df8-4fe1-858e-5c3053fa4054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_69524e93-c9cc-49b1-b13a-dea362724d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_69524e93-c9cc-49b1-b13a-dea362724d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_41dc4b36-de9b-483c-a516-25d92949a8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_41dc4b36-de9b-483c-a516-25d92949a8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_bd960021-e46b-4754-b865-fe4b2135b07d" xlink:href="mrk-20200930.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36eecd84-e562-40dd-907c-e809b8bb7fcf" xlink:to="loc_mrk_RoyaltyRatePercentage_bd960021-e46b-4754-b865-fe4b2135b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1e22d76d-7229-4b43-9b3d-2d5ba0feae63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1e22d76d-7229-4b43-9b3d-2d5ba0feae63" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e17f1ca6-06b0-4551-a4a3-a076a844881e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_34d741c2-0e1e-4ba0-803e-eaa12e0ac562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7530f20d-68ec-4df7-806f-5a902699f697" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_34d741c2-0e1e-4ba0-803e-eaa12e0ac562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a9d72c40-d72b-4060-998c-9d656109b36c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArQuleMember_519bbd60-b600-407a-991c-15501e9dbaf7" xlink:href="mrk-20200930.xsd#mrk_ArQuleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:to="loc_mrk_ArQuleMember_519bbd60-b600-407a-991c-15501e9dbaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_24bde692-1e4a-4049-a9f9-0321dda3f166" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1752a667-c14f-40f1-b9d9-8f1bea90b805" xlink:to="loc_mrk_AntelliqMember_24bde692-1e4a-4049-a9f9-0321dda3f166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_611a0531-dace-4a3c-9636-2de7cf256f31" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SentinelMember_9d6a0574-ab59-4b40-8224-3d09dbf8ad4d" xlink:href="mrk-20200930.xsd#mrk_SentinelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:to="loc_mrk_SentinelMember_9d6a0574-ab59-4b40-8224-3d09dbf8ad4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AntelliqMember_7596b5fe-18a0-4275-91d0-3210d5f966ba" xlink:href="mrk-20200930.xsd#mrk_AntelliqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b9b19d-15d3-4f39-9f25-4a7d4fbce8bd" xlink:to="loc_mrk_AntelliqMember_7596b5fe-18a0-4275-91d0-3210d5f966ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc89cbb2-387f-4313-8d8f-4e8e140264da" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_47a2270a-1ad3-4475-96eb-e28d9ec73bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84505295-c1c1-463d-9005-d12510bf475f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_47a2270a-1ad3-4475-96eb-e28d9ec73bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83df4fbb-f95e-431c-8cbe-9126f72c81f2" xlink:to="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ee4e552-f86c-4e56-9a70-eb3e11ab45df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:to="loc_srt_MinimumMember_9ee4e552-f86c-4e56-9a70-eb3e11ab45df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80ce661c-24f0-4c92-9c9c-c9b97428baec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9403a577-d506-461f-bba8-8fee3122b73d" xlink:to="loc_srt_MaximumMember_80ce661c-24f0-4c92-9c9c-c9b97428baec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69f180f1-5882-4208-bf34-86e99200fc31" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca6e689f-2b3b-4035-bcb3-046ba9f1784a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ca6e689f-2b3b-4035-bcb3-046ba9f1784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9826b9d3-5e38-48a2-87af-550aff6c18bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9826b9d3-5e38-48a2-87af-550aff6c18bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_671ece3c-0540-40ba-8bca-28a0317f3860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_671ece3c-0540-40ba-8bca-28a0317f3860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_880745ff-ca22-4c31-8371-4aac80d46531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_880745ff-ca22-4c31-8371-4aac80d46531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_134cb4f7-f3f2-4164-b10d-f081329a7823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_134cb4f7-f3f2-4164-b10d-f081329a7823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46a00843-0ada-4837-8fc8-b051ffba7b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_46a00843-0ada-4837-8fc8-b051ffba7b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24c6347c-8a78-454d-9e24-8aa80726f29b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_24c6347c-8a78-454d-9e24-8aa80726f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_3518eee1-2a1a-4c50-a300-2a1332e976d3" xlink:href="mrk-20200930.xsd#mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet_3518eee1-2a1a-4c50-a300-2a1332e976d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e2b76f0-0cca-435a-90d1-52781c77fa3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e2b76f0-0cca-435a-90d1-52781c77fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1b0034bd-2bdc-490d-ad60-25eb3d5e50ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_Goodwill_1b0034bd-2bdc-490d-ad60-25eb3d5e50ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_00484e73-b55f-4696-912c-70a263bdd59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_00484e73-b55f-4696-912c-70a263bdd59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IntangibleAssetMeasurementInput_20017596-fce8-4b10-a3ac-53b9aa69dff7" xlink:href="mrk-20200930.xsd#mrk_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_mrk_IntangibleAssetMeasurementInput_20017596-fce8-4b10-a3ac-53b9aa69dff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_acabc737-c3ff-4d2e-9049-c0e6e6d6cd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_083c0959-7358-419b-b992-6b8f325ec2f4" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_acabc737-c3ff-4d2e-9049-c0e6e6d6cd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_74feee29-1c7a-4590-8580-6c12a8cc62d1" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9df0c734-5d88-48e3-8cca-a0b9b5f7fa00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_74feee29-1c7a-4590-8580-6c12a8cc62d1" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9df0c734-5d88-48e3-8cca-a0b9b5f7fa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_e4dcebf3-9039-4a8b-827b-698c857a2def" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a16758ed-ec50-436b-8316-5956265d74a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_e4dcebf3-9039-4a8b-827b-698c857a2def" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a16758ed-ec50-436b-8316-5956265d74a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_5cd66e5a-cd81-49bd-8cc5-3859c7bd80a5" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_5cd66e5a-cd81-49bd-8cc5-3859c7bd80a5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d4984b7a-32e4-467f-905b-758b36b30982" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_afb39c61-1483-470e-8658-96064577c46a" xlink:href="mrk-20200930.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_AstraZenecaMember_afb39c61-1483-470e-8658-96064577c46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_75d1c39b-b248-4b74-a748-803e965512a6" xlink:href="mrk-20200930.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_EisaiMember_75d1c39b-b248-4b74-a748-803e965512a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_b5e81c29-24ef-4882-9a6a-c52df0f38eec" xlink:href="mrk-20200930.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f67d3b23-03d7-45c0-827b-8f241b970641" xlink:to="loc_mrk_BayerAGMember_b5e81c29-24ef-4882-9a6a-c52df0f38eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74874e57-1c89-449c-a123-4950ef369004" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_57d15b96-0410-4661-a003-6d5cb20fe4d5" xlink:href="mrk-20200930.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:to="loc_mrk_SalesBasedMilestonesMember_57d15b96-0410-4661-a003-6d5cb20fe4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_4a3c76f2-3145-4545-95c2-149e484df354" xlink:href="mrk-20200930.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_030fd077-c0e2-40b5-a905-da45f226f286" xlink:to="loc_mrk_RegulatoryMilestonesMember_4a3c76f2-3145-4545-95c2-149e484df354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c88e02be-3cb0-44ec-90ac-d9dc12bf9689" xlink:to="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_d85c64a0-1f65-47a8-841c-88ce34dbf089" xlink:href="mrk-20200930.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_LynparzaMember_d85c64a0-1f65-47a8-841c-88ce34dbf089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_480d24f6-2385-4647-b47e-2eef7fb7bf88" xlink:href="mrk-20200930.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_LenvimaMember_480d24f6-2385-4647-b47e-2eef7fb7bf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_6ee25db0-070a-4880-8ca3-478b4617ed5d" xlink:href="mrk-20200930.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5972d904-718c-423d-be05-255efa70f946" xlink:to="loc_mrk_AdempasMember_6ee25db0-070a-4880-8ca3-478b4617ed5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8d8b99df-0fe4-487d-af7b-980872d681d0" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_87fbe0da-298f-4beb-9af0-f2e13fd75361" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e58151b7-f46f-460b-989a-9e866fdb0e53" xlink:to="loc_srt_ScenarioForecastMember_87fbe0da-298f-4beb-9af0-f2e13fd75361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d7c72320-59e5-4af7-bf15-53fb0aaf4e23" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_ae90de03-01b2-419b-96cf-7ff5ef63a909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_ae90de03-01b2-419b-96cf-7ff5ef63a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_bd7c9512-809c-4008-bac4-f6133fb32b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5c59d1ec-b091-49b5-a85c-143379ba44e7" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_bd7c9512-809c-4008-bac4-f6133fb32b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21241eec-3331-4c0c-87e7-31361520fc1d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f64fc543-99cd-4055-a4ae-9b3edd78b3a7" xlink:href="mrk-20200930.xsd#mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_f64fc543-99cd-4055-a4ae-9b3edd78b3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_65073d9c-0500-4b9c-a374-1ab696dc643e" xlink:href="mrk-20200930.xsd#mrk_Licenseoptionpaymentrelatedtocollaborativearrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement_65073d9c-0500-4b9c-a374-1ab696dc643e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b6e304ad-b6f9-42f9-ac91-032ed1455a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b6e304ad-b6f9-42f9-ac91-032ed1455a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_a9bd51f8-cbfa-47e3-855a-c81063151296" xlink:href="mrk-20200930.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_a9bd51f8-cbfa-47e3-855a-c81063151296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6af84636-b584-4901-a5cd-a43fd13ea76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_Liabilities_6af84636-b584-4901-a5cd-a43fd13ea76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_2f21cdad-72f9-41ac-8957-8623879b95af" xlink:href="mrk-20200930.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_2f21cdad-72f9-41ac-8957-8623879b95af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentPaymentsCollaborativeArrangement_bde49cbd-13d0-4996-9c1e-9a49f831665f" xlink:href="mrk-20200930.xsd#mrk_ContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_mrk_ContingentPaymentsCollaborativeArrangement_bde49cbd-13d0-4996-9c1e-9a49f831665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a320bae6-30c4-412c-8656-c0efcaeea730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a320bae6-30c4-412c-8656-c0efcaeea730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_892b236d-0385-4ae5-bb92-b9f83633608d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f5987eb-acfd-4e6d-aaec-3e25ce3829d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_892b236d-0385-4ae5-bb92-b9f83633608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#CollaborativeArrangementsScheduleofTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_8ef7c4f1-a6e6-42a3-9cd0-060da01e3af5" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_8ef7c4f1-a6e6-42a3-9cd0-060da01e3af5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1837de22-540e-48a3-9619-79bcf1a09a98" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_1b15efdb-3979-4261-a78d-983837d0ada0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_SalesMember_1b15efdb-3979-4261-a78d-983837d0ada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9598b07e-dbf8-4891-bd24-22ce0a47d04f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_CostOfSalesMember_9598b07e-dbf8-4891-bd24-22ce0a47d04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9bbf38d-6862-4902-b137-4735e7379c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b9bbf38d-6862-4902-b137-4735e7379c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b4462be-bd24-40cb-82c8-21b6dc5988ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_53890b0d-51e9-4526-b1fc-98967f6ec40b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b4462be-bd24-40cb-82c8-21b6dc5988ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e3748bd-a3eb-4b59-bcc7-7adbac8eb9cc" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_c6b8f124-082e-4237-8c4a-b6fda02131a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_c6b8f124-082e-4237-8c4a-b6fda02131a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_e84cf9cd-c61f-4793-8dc8-d54424d8093c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_e84cf9cd-c61f-4793-8dc8-d54424d8093c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_950a0d16-127c-4e41-8339-8cd344cd4866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf5b211a-58d0-4193-91cb-e02ebe9443c2" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_950a0d16-127c-4e41-8339-8cd344cd4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_905e1482-3828-46be-b04b-e537d09b24f1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_08d771c2-5c81-42bc-9b5a-f52e350a5f9f" xlink:href="mrk-20200930.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_AstraZenecaMember_08d771c2-5c81-42bc-9b5a-f52e350a5f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_054ab896-2cda-4dd7-9b27-dc4e1d86971d" xlink:href="mrk-20200930.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_EisaiMember_054ab896-2cda-4dd7-9b27-dc4e1d86971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_b953de05-22a8-44b3-97dc-16a9a7e4166b" xlink:href="mrk-20200930.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71f44399-5578-4817-b452-aa6e64035292" xlink:to="loc_mrk_BayerAGMember_b953de05-22a8-44b3-97dc-16a9a7e4166b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7cf61f35-7a72-4a0f-a045-1da2a694f776" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d26293ef-5479-47a7-a965-09624874a5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa3a1a61-5168-4ee1-ac19-7bcc1d6ed795" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d26293ef-5479-47a7-a965-09624874a5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_22672a8d-2bd4-422b-9229-33cb7b3ec6b8" xlink:to="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_5f622f00-61c7-4ee5-ada5-44a04e8c8b04" xlink:href="mrk-20200930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_5f622f00-61c7-4ee5-ada5-44a04e8c8b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_2880602f-f719-46da-a30c-9c209953ed81" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b86bfaf0-c26b-4141-bc92-56054c03dd5a" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_2880602f-f719-46da-a30c-9c209953ed81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1cfc67b-5c21-43f2-a5c7-8273251ec99c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_a98258e9-170c-4d98-a9f2-bb0d84893c7e" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_a98258e9-170c-4d98-a9f2-bb0d84893c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_313184d0-3f48-438f-b035-4f899680961c" xlink:href="mrk-20200930.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_313184d0-3f48-438f-b035-4f899680961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5e22076-8945-45bf-bfdf-6aa421e89c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_Revenues_f5e22076-8945-45bf-bfdf-6aa421e89c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_28caa1ac-4a5c-4b03-bcd2-21a4ec6d3508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_28caa1ac-4a5c-4b03-bcd2-21a4ec6d3508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d54b5d28-aceb-4102-b5de-62019395d87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d54b5d28-aceb-4102-b5de-62019395d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_267659d2-e169-4c3c-b2b2-0819abfb5093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_267659d2-e169-4c3c-b2b2-0819abfb5093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_65811282-ca35-4b4a-95ca-5dd21314b225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_ReceivablesNetCurrent_65811282-ca35-4b4a-95ca-5dd21314b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f819c718-b1e8-41f8-9426-dd78a7c4110d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_LiabilitiesCurrent_f819c718-b1e8-41f8-9426-dd78a7c4110d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e53dd74c-815f-4d7f-b2b7-96558cf4ef9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_311b3bcd-ea17-49e1-bc58-d9cc765a7b38" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e53dd74c-815f-4d7f-b2b7-96558cf4ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20200930.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee6263bd-ca20-4d49-9d8e-3ff4cbc6758f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_13b52eb7-13f8-480c-a4ab-77bd47a69169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee6263bd-ca20-4d49-9d8e-3ff4cbc6758f" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_13b52eb7-13f8-480c-a4ab-77bd47a69169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_24d322ff-c8d9-4941-9072-0c7059cbec42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1f404f5e-5fb2-43be-8948-b7d7c5302e07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_24d322ff-c8d9-4941-9072-0c7059cbec42" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1f404f5e-5fb2-43be-8948-b7d7c5302e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_618fe049-6907-436d-a591-d79d41cc9927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_24d322ff-c8d9-4941-9072-0c7059cbec42" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_618fe049-6907-436d-a591-d79d41cc9927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5932ecb1-af43-484e-b11a-d1de3348edb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5932ecb1-af43-484e-b11a-d1de3348edb6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:to="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e1bdb5c8-8219-4e90-b5f5-490e9cc3fa2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_0d80a7ff-6889-4af2-b0bb-7f3b9d6fcbe8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3c7d65e5-4403-4549-934c-1fc3fefe6a50" xlink:to="loc_srt_ScenarioForecastMember_0d80a7ff-6889-4af2-b0bb-7f3b9d6fcbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0b65fea0-d8e8-4a21-8c5c-4fb804508486" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_bae885c7-badd-4194-8379-857143a15417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_bae885c7-badd-4194-8379-857143a15417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_296bd5cc-169e-4bb7-9449-39fb14e0e99d" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_296bd5cc-169e-4bb7-9449-39fb14e0e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_7fe02084-e6de-4a00-a317-9ae35f9e4d17" xlink:href="mrk-20200930.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_7fe02084-e6de-4a00-a317-9ae35f9e4d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_983191f9-c476-4b27-95af-cb74c21418ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_983191f9-c476-4b27-95af-cb74c21418ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_400e2f39-d1b2-4ca2-957d-f12223004382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_4fba4cb0-239a-41c4-8508-69fd118b0f9a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_400e2f39-d1b2-4ca2-957d-f12223004382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d7aa8e1-d13d-4133-ad93-897e6af4134b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d7aa8e1-d13d-4133-ad93-897e6af4134b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_14d7a7a7-58c5-4987-aaab-929421336178" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a961c2a7-b0e3-4a69-a9c2-543d6a0e573d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_CostOfSalesMember_a961c2a7-b0e3-4a69-a9c2-543d6a0e573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68cd5388-36b3-417f-9739-7ca67540d948" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68cd5388-36b3-417f-9739-7ca67540d948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0f53453-bb10-45ab-9734-c4d312c57f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c0f53453-bb10-45ab-9734-c4d312c57f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_98d19ed0-3c9c-4b06-bfa3-cb5e4b445957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8954e3e1-5cf8-46a7-b1e6-63d7797f242f" xlink:to="loc_us-gaap_RestructuringChargesMember_98d19ed0-3c9c-4b06-bfa3-cb5e4b445957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_e0a7967c-ef28-428d-b0e1-9d6399edc799" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_be581883-058d-43f5-be41-529dae37cb85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_be581883-058d-43f5-be41-529dae37cb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_2b553fd1-af21-4092-a89c-e59b9be6b7c7" xlink:href="mrk-20200930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_mrk_AcceleratedDepreciationMember_2b553fd1-af21-4092-a89c-e59b9be6b7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_2ba4126d-f423-42c3-81f3-0daff178202b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_814bad86-37f9-42cb-8fc9-610d554b3b82" xlink:to="loc_us-gaap_OtherRestructuringMember_2ba4126d-f423-42c3-81f3-0daff178202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1dc03eaf-e1d7-4ecc-8f79-bec607270515" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e6bb4122-e821-4209-83a6-2ffa60c47aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5e8f8e8a-3894-47a5-95f3-2a3fe3de02ab" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_e6bb4122-e821-4209-83a6-2ffa60c47aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_74a00532-5491-4c4c-b942-6706e81b83e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_74a00532-5491-4c4c-b942-6706e81b83e7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_555fc561-0327-4573-ab72-f5386f9e74f1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_9b32c7f0-dc2e-4e8a-8195-8153a1686b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_9b32c7f0-dc2e-4e8a-8195-8153a1686b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_c9f0dba4-8f56-4201-825c-4ea283200ac2" xlink:href="mrk-20200930.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_mrk_AcceleratedDepreciationMember_c9f0dba4-8f56-4201-825c-4ea283200ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_a96f9b09-0444-46a8-8264-29bd86885e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4bb7134a-c544-4f84-806f-9c91a7445008" xlink:to="loc_us-gaap_OtherRestructuringMember_a96f9b09-0444-46a8-8264-29bd86885e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_24188bb1-d2d5-4466-a6ef-77d202768c4c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0016ad83-cf55-4b20-9184-ccbabe7c4251" xlink:to="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5196c736-bb0e-40d5-92ed-c18a4a1589a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_RestructuringReserve_5196c736-bb0e-40d5-92ed-c18a4a1589a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2f253857-2ab5-420d-927f-bccbd8d238a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_2f253857-2ab5-420d-927f-bccbd8d238a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_3d467a57-e8bd-41dd-b017-92c671bfcab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_PaymentsForRestructuring_3d467a57-e8bd-41dd-b017-92c671bfcab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveNoncashActivity_648546fe-dca7-4be7-8ade-09070a22885d" xlink:href="mrk-20200930.xsd#mrk_RestructuringReserveNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_mrk_RestructuringReserveNoncashActivity_648546fe-dca7-4be7-8ade-09070a22885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_705a7e45-6d51-4823-85da-72413845b8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_da6d65ea-ca95-452f-abe8-fd1177c272b7" xlink:to="loc_us-gaap_RestructuringReserve_705a7e45-6d51-4823-85da-72413845b8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_88f17b2d-b414-43e0-ae70-1a31dad70d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c2b0825a-a85f-485d-8003-81517d6c758f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_88f17b2d-b414-43e0-ae70-1a31dad70d5d" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c2b0825a-a85f-485d-8003-81517d6c758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_844c63de-d4c3-4acb-ad8a-ad8eaad3b06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_844c63de-d4c3-4acb-ad8a-ad8eaad3b06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_8ca07c1d-8cf3-434e-963b-b19478b57730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_8ca07c1d-8cf3-434e-963b-b19478b57730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c7e31783-219d-4a34-8530-b8e3538f799a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c7e31783-219d-4a34-8530-b8e3538f799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1b8048fa-6f30-4681-a79c-999f3308b396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1b8048fa-6f30-4681-a79c-999f3308b396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_b3c77f43-1076-4d4c-a8f7-1dee40dc4741" xlink:href="mrk-20200930.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_b3c77f43-1076-4d4c-a8f7-1dee40dc4741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_57d03206-49cf-4522-8dd9-e217b2a4ecf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_57d03206-49cf-4522-8dd9-e217b2a4ecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_71273c0d-1f2b-4662-8f14-c26d505e5c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_71273c0d-1f2b-4662-8f14-c26d505e5c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3a197c3a-34db-47fc-86e4-d72cc506f35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3a197c3a-34db-47fc-86e4-d72cc506f35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_64c83f79-039b-4a05-ba75-9ab230e79f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_64c83f79-039b-4a05-ba75-9ab230e79f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d3f69bb3-f275-4d92-9fa1-b297da4f22ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_df5236f6-6da9-4535-9682-dee9c8922e7b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d3f69bb3-f275-4d92-9fa1-b297da4f22ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d73e89e6-2962-4e3e-9375-d375d9d3860a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d73e89e6-2962-4e3e-9375-d375d9d3860a" xlink:to="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a781006-6ba0-40fc-a226-1fe1704655cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_37b76314-6829-41de-baf5-7303be8f1fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_009babfc-e6ea-44a5-9007-02875d3c6315" xlink:to="loc_us-gaap_InterestRateSwapMember_37b76314-6829-41de-baf5-7303be8f1fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8612e95f-949b-40be-883b-8be6e774e376" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.85NotesDue2020Member_75cd0fb2-28da-4154-8b49-1b146cd26a73" xlink:href="mrk-20200930.xsd#mrk_A1.85NotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b6bce6bc-3a66-4bbe-a744-065894cf93f6" xlink:to="loc_mrk_A1.85NotesDue2020Member_75cd0fb2-28da-4154-8b49-1b146cd26a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_36c48459-4a07-410e-9412-7c5b363ed07c" xlink:to="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87a0916d-7014-4edd-a119-d6fd4645cd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_87a0916d-7014-4edd-a119-d6fd4645cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_dd4f75d3-f6e2-45df-8b13-bb037d6545ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_353effeb-1e12-414d-8625-06a33ffcc82d" xlink:to="loc_us-gaap_NondesignatedMember_dd4f75d3-f6e2-45df-8b13-bb037d6545ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d910c61c-69bc-4357-ab54-91446bf8d79a" xlink:to="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df2b765e-9c02-4118-bbec-d5de31cf0fc5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_758412ca-2776-4274-9133-9b9ccca8df8f" xlink:to="loc_srt_MaximumMember_df2b765e-9c02-4118-bbec-d5de31cf0fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5e16154d-381a-4e58-92e0-847ca10a129f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c59c689-5aad-4a26-8227-6cbe17f8e0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86c488b9-1ac3-47c8-8128-7ab0eeef4e4d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c59c689-5aad-4a26-8227-6cbe17f8e0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4386d82d-1b77-47b3-b74b-d3e1ff72fcff" xlink:to="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_e305952e-9bca-48b1-b7e6-590cdf1771ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_e305952e-9bca-48b1-b7e6-590cdf1771ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_a7e43785-d3d5-4e85-9a5f-52a656c56b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_a7e43785-d3d5-4e85-9a5f-52a656c56b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_7d1c889f-5f58-4343-b53b-7700de4d5788" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_7d1c889f-5f58-4343-b53b-7700de4d5788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f1c5676-886e-461a-973e-5663b7484c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9f1c5676-886e-461a-973e-5663b7484c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_28410cfc-9820-47d9-851c-cf4690175f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_28410cfc-9820-47d9-851c-cf4690175f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_a945635b-1518-4014-82ea-0fd4a8d7b937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_a945635b-1518-4014-82ea-0fd4a8d7b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_86ab55ab-fd0f-4313-a9bb-512d5651c55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_86ab55ab-fd0f-4313-a9bb-512d5651c55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_1b134ff4-9f4b-4829-b78c-d9a505bcd2c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_1b134ff4-9f4b-4829-b78c-d9a505bcd2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b62e0f22-6ea1-4f73-90d2-b71b24a13342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b62e0f22-6ea1-4f73-90d2-b71b24a13342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3d7098ce-5bb3-4082-b480-4c27ca36b248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3d7098ce-5bb3-4082-b480-4c27ca36b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_fda7f5f4-23fb-43a0-bbc3-5039f06513ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_fda7f5f4-23fb-43a0-bbc3-5039f06513ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_1da64d19-1680-443e-ac33-e57a456030f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_1da64d19-1680-443e-ac33-e57a456030f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_6aa5a953-c7de-40ac-a254-bc81f751c5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_AccountsReceivableSale_6aa5a953-c7de-40ac-a254-bc81f751c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5524c62f-94f2-4bc6-b98b-1ebddce62186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_5524c62f-94f2-4bc6-b98b-1ebddce62186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d6a2e3d8-4693-4b67-aa2d-96c746c76158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d6a2e3d8-4693-4b67-aa2d-96c746c76158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e5c313ac-0824-4700-9431-d52a2141a234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e5c313ac-0824-4700-9431-d52a2141a234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f5982b15-51ea-4684-baf8-4291758c0bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f5982b15-51ea-4684-baf8-4291758c0bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa271c24-0181-4b8b-ae4b-3a3b68fdbf24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_4fe46747-15df-427a-a6ef-9918f72a6f8b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fa271c24-0181-4b8b-ae4b-3a3b68fdbf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce7f3af2-2dae-4dee-b0c9-51abe09d59eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ce7f3af2-2dae-4dee-b0c9-51abe09d59eb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4bc96461-d924-485c-b767-890ab57d9215" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e7b501db-f625-4e9f-a78f-9c36246f1e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e7b501db-f625-4e9f-a78f-9c36246f1e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_0430f094-0473-4798-bb52-7dd1f8133c48" xlink:href="mrk-20200930.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_554470ad-77cb-4df8-b751-961b8f45c5d1" xlink:to="loc_mrk_EurodominatedNotesMember_0430f094-0473-4798-bb52-7dd1f8133c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_18b8b1ef-074f-43f9-9a8a-add9f2f65ae7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9a6fd6e9-da2a-48ef-9e6d-4ff167e1d058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca3183ef-5ccf-473c-b3c0-45178195e007" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9a6fd6e9-da2a-48ef-9e6d-4ff167e1d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f861d7cd-b12c-4d7f-b499-4d94425ace97" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c9b17de0-ee94-4de4-a122-5e8e94eeca74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_c9b17de0-ee94-4de4-a122-5e8e94eeca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_eba8ecf4-c20d-4a9a-b0cf-4f91ccc16911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_464f976f-7265-439e-b394-2f3bce10d7ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_eba8ecf4-c20d-4a9a-b0cf-4f91ccc16911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_949a1fde-8e62-4dd7-86e4-1e3894000b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_949a1fde-8e62-4dd7-86e4-1e3894000b1c" xlink:to="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2214f2f9-76db-478d-84bd-6b60a071af65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A3.875NotesDue2021Member_25c753aa-d8f1-4dec-b250-303b84fe9f76" xlink:href="mrk-20200930.xsd#mrk_A3.875NotesDue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A3.875NotesDue2021Member_25c753aa-d8f1-4dec-b250-303b84fe9f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.40NotesDue2022Member_6674870e-caad-43a4-b1f4-dc517fbefa22" xlink:href="mrk-20200930.xsd#mrk_A2.40NotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A2.40NotesDue2022Member_6674870e-caad-43a4-b1f4-dc517fbefa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35NotesDue2022Member_595358ce-f155-4225-8845-d635fc7cdce8" xlink:href="mrk-20200930.xsd#mrk_A2.35NotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97ad2876-9ddd-4b62-8f57-a3d6a9bac7e6" xlink:to="loc_mrk_A2.35NotesDue2022Member_595358ce-f155-4225-8845-d635fc7cdce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_447e6f72-ca3f-4d6f-ab52-cb65b8b4d93c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_21253333-572c-4d56-ad7c-7a13188acf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99c1b756-20fc-4ab2-873b-9c4082023df3" xlink:to="loc_us-gaap_InterestRateSwapMember_21253333-572c-4d56-ad7c-7a13188acf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_a791d3fc-6ff8-43ca-98ea-3dd921ad0a11" xlink:to="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e746c26-b129-4227-9a54-610d6cca504d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e746c26-b129-4227-9a54-610d6cca504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6bca2090-4c2c-4fe3-baa3-32bd8507551a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6bca2090-4c2c-4fe3-baa3-32bd8507551a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_630e7644-1eee-44aa-98d3-c310a0297228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_630e7644-1eee-44aa-98d3-c310a0297228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_bc2025b0-064d-405c-ac4f-78476bff7395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_11b41351-7041-4a2f-9767-165a49bcb5f9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_bc2025b0-064d-405c-ac4f-78476bff7395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_16ff625c-ee00-471d-8123-5752dcc8b260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_16ff625c-ee00-471d-8123-5752dcc8b260" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4b34f62-1b5d-45ef-b4e9-dfed587c9b00" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtCurrentMaturitiesMember_a1094f4b-66e6-42c1-95c6-ccbe971cceea" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtCurrentMaturitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:to="loc_mrk_LongTermDebtCurrentMaturitiesMember_a1094f4b-66e6-42c1-95c6-ccbe971cceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_4dd3efd5-39f6-402c-9ad1-5d092e7c2ace" xlink:href="mrk-20200930.xsd#mrk_LongTermDebtExcludingCurrentMaturitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b28360d0-f565-47e4-8026-ba98e7e6ca67" xlink:to="loc_mrk_LongTermDebtExcludingCurrentMaturitiesMember_4dd3efd5-39f6-402c-9ad1-5d092e7c2ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_1cfcfe20-ebb1-4ad9-9372-4d6c2fc9ad55" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_bf4fd38d-8ee9-416b-80e4-cbea127506b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_bf4fd38d-8ee9-416b-80e4-cbea127506b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f332d752-69ed-431c-ba32-22e04a7d05de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_ebf640dd-0dbf-464e-bd4a-ecc9797bfc1b" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f332d752-69ed-431c-ba32-22e04a7d05de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4ca0438-9a5c-41c8-bf8a-01511f7c7b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f4ca0438-9a5c-41c8-bf8a-01511f7c7b0a" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e0d3cbc-62a7-4a70-b165-74f7673e0be5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_1d84d8af-c716-4c1b-b5ca-8d33113fff1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_InterestRateContractMember_1d84d8af-c716-4c1b-b5ca-8d33113fff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ebf40f3a-e627-475e-bf7b-362ea3e0e601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ebf40f3a-e627-475e-bf7b-362ea3e0e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_04b6b2b0-8d8b-49b4-916b-461c8e0be158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6d886814-97c1-453b-b15e-a2765bcc380c" xlink:to="loc_us-gaap_ForwardContractsMember_04b6b2b0-8d8b-49b4-916b-461c8e0be158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_34fbad67-70c2-42d8-84a6-80388b9dc041" xlink:to="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e9ba8e34-f4bc-4c58-b35a-d548a331c4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e9ba8e34-f4bc-4c58-b35a-d548a331c4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c4f72ff0-caf9-49f6-b5fd-92e006dbafa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_738b0687-2ebd-419b-bd02-b2c1d291b17e" xlink:to="loc_us-gaap_NondesignatedMember_c4f72ff0-caf9-49f6-b5fd-92e006dbafa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b38e299f-13ac-4462-9ced-c101e694ed62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_607513a9-8cd2-4fad-9908-8cea53fb6831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_607513a9-8cd2-4fad-9908-8cea53fb6831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_1a078abe-d3a8-4291-bb2b-169d41c13c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherAssetsMember_1a078abe-d3a8-4291-bb2b-169d41c13c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_32aabb5b-2d6f-41ee-821f-b859e1bb58a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_32aabb5b-2d6f-41ee-821f-b859e1bb58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c1b4ed62-ce05-4ce0-a505-69c539a488ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2deeaa13-fe54-4e50-a3f0-b2b68de50d1b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c1b4ed62-ce05-4ce0-a505-69c539a488ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c95fb156-6fa8-4ccb-9d62-ba6e4056963b" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b6f9904f-27bc-4400-bafe-15a7bdb3ae56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeAssets_b6f9904f-27bc-4400-bafe-15a7bdb3ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d1bbcdc-54ba-434e-a39c-30dbbea4236a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeLiabilities_1d1bbcdc-54ba-434e-a39c-30dbbea4236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_6d3a524d-5438-487f-be38-d0e24f5b014e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_cde757f0-003b-4d03-8a61-d7d5b0755299" xlink:to="loc_us-gaap_DerivativeNotionalAmount_6d3a524d-5438-487f-be38-d0e24f5b014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_999dc5b5-c99e-458f-9cdd-9554fd928fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeAssets_999dc5b5-c99e-458f-9cdd-9554fd928fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_710a6776-bbda-4ade-a763-5717119e58f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_710a6776-bbda-4ade-a763-5717119e58f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_349990ae-b59a-46bc-9885-8ca7eab839dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_349990ae-b59a-46bc-9885-8ca7eab839dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7ff465b2-193f-49bd-b332-18a054a89ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_7ff465b2-193f-49bd-b332-18a054a89ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_b7df5898-68aa-4adb-b827-0a3689a529cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeLiabilities_b7df5898-68aa-4adb-b827-0a3689a529cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_f8a459f8-522b-40e4-84b3-ddf4cde1e4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_f8a459f8-522b-40e4-84b3-ddf4cde1e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d73039a1-7c2f-4bb3-add7-83b24f3a057e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_d73039a1-7c2f-4bb3-add7-83b24f3a057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e78ba47b-b96f-4ad8-a145-275e30c7b428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_357e8dc2-c1fa-41bd-b476-e241011d6853" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_e78ba47b-b96f-4ad8-a145-275e30c7b428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78cd641c-24cf-45d4-ab90-3fbbbeb46f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_78cd641c-24cf-45d4-ab90-3fbbbeb46f24" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_47078de7-daf4-40dc-8845-e794c3962fc2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b21e9433-9d77-42a8-877e-f519652a1b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:to="loc_us-gaap_InterestRateSwapMember_b21e9433-9d77-42a8-877e-f519652a1b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_54877d64-3b35-457a-85cc-bf55934b01d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_421cb25a-c9b5-4db5-8618-7dc81b068fce" xlink:to="loc_us-gaap_ForeignExchangeContractMember_54877d64-3b35-457a-85cc-bf55934b01d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_2ddd635b-da21-4b2b-ae82-174d9c3419e3" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_523e67de-2187-44e2-aa4c-5a2a7fe19933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0f44c294-53b4-4eb5-aef5-9cbfa3b0c220" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_523e67de-2187-44e2-aa4c-5a2a7fe19933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b84a618-56c9-41e1-b7a0-24aa3483dd3f" xlink:to="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37f7132f-8059-4f62-919e-415e97b4bebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_227771b7-bbcc-41d1-9e1b-420689158207" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_37f7132f-8059-4f62-919e-415e97b4bebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_93cda9d8-39be-47cb-a7a7-3d93988761d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e68871d4-840c-42f9-b91c-26ebe2fe66dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0b6da156-6066-4217-8c88-5701bd443443" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_e68871d4-840c-42f9-b91c-26ebe2fe66dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e257f709-3ea2-46b1-a662-7e1875e54f79" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ecc5987b-bb83-4f65-866f-84a116504958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_Revenues_ecc5987b-bb83-4f65-866f-84a116504958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25de9ddc-f05c-4409-88c9-82f541a023bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25de9ddc-f05c-4409-88c9-82f541a023bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_06f4ef00-e0cf-4bca-ba69-186d3b7affb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_06f4ef00-e0cf-4bca-ba69-186d3b7affb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_7a39de49-d0ae-4822-ae3c-a74c6c059b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_7a39de49-d0ae-4822-ae3c-a74c6c059b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3ec899d9-1796-4ad7-b724-4c45d8806e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3ec899d9-1796-4ad7-b724-4c45d8806e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_2766149f-356a-4657-aee5-b0b8eb62fbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_2766149f-356a-4657-aee5-b0b8eb62fbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_09d05b7e-80c6-4fc5-8ec9-b2b636e34e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_09d05b7e-80c6-4fc5-8ec9-b2b636e34e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c51ac148-bf4c-4a09-a6fb-976b507684d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_b5cf6541-38ee-419b-92a4-55602f344169" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c51ac148-bf4c-4a09-a6fb-976b507684d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_67a00b43-21dd-4640-89a9-ee55265ed10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_67a00b43-21dd-4640-89a9-ee55265ed10b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0a9bfb42-d33b-4d26-869d-946c8a8494b0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_292c5260-d607-45f4-9c05-4b3dc66e934e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_CurrencySwapMember_292c5260-d607-45f4-9c05-4b3dc66e934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_f03acd5e-9f21-4ce2-ab69-3e1a77e12186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_f03acd5e-9f21-4ce2-ab69-3e1a77e12186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryLockMember_8cf3706f-0565-492a-bf96-1296ce803d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryLockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_TreasuryLockMember_8cf3706f-0565-492a-bf96-1296ce803d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_ef43efa8-13d0-4db7-a95b-5e7dafde7c2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_928416ee-4119-479d-939b-3f1b25763a08" xlink:to="loc_us-gaap_ForwardContractsMember_ef43efa8-13d0-4db7-a95b-5e7dafde7c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3ecccb77-c041-4a8f-b87c-5414c61b41a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a5c470e1-2945-4053-acc9-d67f7da872d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_a5c470e1-2945-4053-acc9-d67f7da872d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5c224adc-0b69-4d87-a02b-28fa2e62b83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_SalesMember_5c224adc-0b69-4d87-a02b-28fa2e62b83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a267654-2f5f-4fd6-b531-ade6d6a6c6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_19fd09a6-6a3f-4f20-b60a-3025fa9a45a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a267654-2f5f-4fd6-b531-ade6d6a6c6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0313afce-2231-4845-8b5a-33bcee800a28" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cb8f7eba-9b0e-42e2-9922-4f719603c8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_91e3fe3f-64c7-475d-91cb-74c97d38520b" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_cb8f7eba-9b0e-42e2-9922-4f719603c8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c433410-a73f-4313-8765-decc31171473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c433410-a73f-4313-8765-decc31171473" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8513eae-8065-4528-ab00-e79d777c2504" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3071c7d5-6cfe-4d01-b910-a08d6d8e6371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3071c7d5-6cfe-4d01-b910-a08d6d8e6371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b911f131-6e0b-4648-920a-359131257ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_b911f131-6e0b-4648-920a-359131257ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79932602-c95b-4fd3-8e09-e9c0cc457efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_CommercialPaperMember_79932602-c95b-4fd3-8e09-e9c0cc457efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4a0547d6-4dc7-4ed3-8f08-0731674f7e49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4a0547d6-4dc7-4ed3-8f08-0731674f7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_72dfbc20-a5c4-4c05-82f9-4681a9624536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a0e50cb-a5ff-4e0f-98e3-5bde5d70a802" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_72dfbc20-a5c4-4c05-82f9-4681a9624536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_32fb3d23-9a6c-43c1-9656-d8a9e7d852af" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbfd5c1b-0f2f-4a52-9a99-a6358f035cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbfd5c1b-0f2f-4a52-9a99-a6358f035cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_209af63c-7435-4ab3-8f18-58c73b894ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_209af63c-7435-4ab3-8f18-58c73b894ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_103f5618-ec5d-4600-bc4a-79232fe21b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_103f5618-ec5d-4600-bc4a-79232fe21b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb1ddaaa-ad6b-407e-9dcb-66c62bf92946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cb1ddaaa-ad6b-407e-9dcb-66c62bf92946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_325933ee-a227-4e3d-bd3b-7e81fe44df82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_325933ee-a227-4e3d-bd3b-7e81fe44df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f767795a-becd-496a-be2c-06ea951eaf2b" xlink:href="mrk-20200930.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_f767795a-becd-496a-be2c-06ea951eaf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8065b3a1-8a97-492d-b235-008a3b780f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42a34633-8ad4-4c81-8375-6fb04ccc689c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8065b3a1-8a97-492d-b235-008a3b780f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d4938c4-2ad9-49aa-8b3a-6cab9086dcbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d4938c4-2ad9-49aa-8b3a-6cab9086dcbb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32a38d30-4092-4c45-86fe-0569d355ae93" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_403fdf87-8e99-4105-9187-6b240ccfcb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1af3b42a-749c-486c-b05e-73300211aeb1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_403fdf87-8e99-4105-9187-6b240ccfcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7450b50c-a297-4afb-a8b7-9ff46763d599" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_c9531983-b2ac-44fc-816c-80fbe8da13d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_c9531983-b2ac-44fc-816c-80fbe8da13d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_248e374d-88c0-45b3-b8df-39bd02bb4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_248e374d-88c0-45b3-b8df-39bd02bb4ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_102aca86-0012-4c8f-81e1-ac7aceafa60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_CommercialPaperMember_102aca86-0012-4c8f-81e1-ac7aceafa60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b1217051-07c7-4aa2-99fa-6921c70041d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b1217051-07c7-4aa2-99fa-6921c70041d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6b805bb6-b7e2-467a-87eb-1f24d6c8eb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6b805bb6-b7e2-467a-87eb-1f24d6c8eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b867de89-4d85-4d60-929c-a544471020e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a891fe01-4674-4e38-8999-14ed04955a58" xlink:to="loc_us-gaap_EquitySecuritiesMember_b867de89-4d85-4d60-929c-a544471020e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc403258-68a3-434c-a964-0ff0594466bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f13af46a-988f-4b74-8380-f11a23f5f145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f13af46a-988f-4b74-8380-f11a23f5f145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_314c7de2-bbf0-432e-bc3e-96d0e80ea454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_314c7de2-bbf0-432e-bc3e-96d0e80ea454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_75e2e6e2-9ba4-4317-b36f-61a1157da95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_14f8c211-319c-4db5-91e5-d61010f9b237" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_75e2e6e2-9ba4-4317-b36f-61a1157da95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f2ba14b8-0705-42e7-af84-9f18a44e9c65" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_15b6c3f9-c7f5-4d3f-a408-796cf1f0bf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForeignExchangeContractMember_15b6c3f9-c7f5-4d3f-a408-796cf1f0bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_765983cf-98d4-4ebc-82bc-e1766b321d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_InterestRateSwapMember_765983cf-98d4-4ebc-82bc-e1766b321d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_8c95fbb2-adda-4009-833f-3461e0bdb6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_8c95fbb2-adda-4009-833f-3461e0bdb6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_a45b59c4-1b42-44f0-8e4c-9a4110363c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_InterestRateContractMember_a45b59c4-1b42-44f0-8e4c-9a4110363c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForwardContractsMember_56aeb98a-974b-4a85-b629-5ddcf481dfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForwardContractsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_915b185b-9891-491e-8a03-9f95453214ed" xlink:to="loc_us-gaap_ForwardContractsMember_56aeb98a-974b-4a85-b629-5ddcf481dfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d7e4e826-e992-4651-a302-7d645f5134be" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5df6e28a-3e72-4562-8f61-13c42377dd36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5df6e28a-3e72-4562-8f61-13c42377dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9e2338c3-32dc-40f3-9dfe-0bcdee714942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9e2338c3-32dc-40f3-9dfe-0bcdee714942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_ee3796aa-029c-416b-9e98-27dbd5bf7ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_TradingSecurities_ee3796aa-029c-416b-9e98-27dbd5bf7ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aa2d23a2-b0a1-4405-857d-819e38ead183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_aa2d23a2-b0a1-4405-857d-819e38ead183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2fbfca6b-d9e9-4241-8824-e902aa34bfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_DerivativeAssets_2fbfca6b-d9e9-4241-8824-e902aa34bfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a16a09f0-c5b4-430b-a101-c51dc820a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e680e92d-333d-451b-8100-3b8bbe08d604" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a16a09f0-c5b4-430b-a101-c51dc820a8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35822ad3-e116-4512-8dd5-13ccb8b0051c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_35822ad3-e116-4512-8dd5-13ccb8b0051c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f2f02c1b-bc31-4a49-b65e-ef3513f00025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_DerivativeLiabilities_f2f02c1b-bc31-4a49-b65e-ef3513f00025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_72245f1f-a378-4f37-9679-1221f749656c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_840392d5-fe86-4d56-82ec-24ef4aea8b1b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_72245f1f-a378-4f37-9679-1221f749656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_cdbd6d7e-4217-45e0-82d4-e69f21d57486" xlink:href="mrk-20200930.xsd#mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_20c0c3b4-c341-438b-8f09-b7790edfaa53" xlink:to="loc_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral_cdbd6d7e-4217-45e0-82d4-e69f21d57486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f796d22-d311-487a-a500-17f35aa64f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f796d22-d311-487a-a500-17f35aa64f19" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_cc67e147-7ce2-4d28-b52d-fa6fb3e3f0a7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_490e0590-2966-4678-9a41-91fa47f4a3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ec7adfad-eac2-4007-b278-7f294b11fab7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_490e0590-2966-4678-9a41-91fa47f4a3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_570c4f6f-624c-48d7-ba25-8380d894a588" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_916eae42-f183-4bb8-a052-67bd332431d5" xlink:href="mrk-20200930.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_fc084891-f74a-47c7-96b3-88e0fcfbf6e8" xlink:to="loc_mrk_SanofiPasteurMember_916eae42-f183-4bb8-a052-67bd332431d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_fa502125-d857-4c2a-96fa-0eaf301939fd" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b49c90b2-265f-4729-84e4-43f1d2a1d24d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8dce45b3-2aaf-4048-a9a8-7b61654811c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8dce45b3-2aaf-4048-a9a8-7b61654811c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3623c163-e14d-49d8-aa61-1bc72124065c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3623c163-e14d-49d8-aa61-1bc72124065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5848fcff-e54f-407a-9a23-d33d4f624ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5848fcff-e54f-407a-9a23-d33d4f624ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4801e791-50dd-432e-8db0-2e7a0ad4054f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4801e791-50dd-432e-8db0-2e7a0ad4054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ad180fb2-cfee-4783-93ba-38aa82d1fb33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ad180fb2-cfee-4783-93ba-38aa82d1fb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_309bf2d2-3431-4964-a84d-1bfa4fd1e873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_309bf2d2-3431-4964-a84d-1bfa4fd1e873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_210640de-fe93-4724-ae77-38a7677a39b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_210640de-fe93-4724-ae77-38a7677a39b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1990d29e-3bdf-480e-b2a9-a742ab093e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_030784e0-70ca-4a85-860c-2f2f0b12448c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1990d29e-3bdf-480e-b2a9-a742ab093e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20200930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_19768062-5135-4870-b461-6eaa0f7cb6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_2b110d1c-076e-4ca8-9bf1-53860297ee69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_19768062-5135-4870-b461-6eaa0f7cb6a1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_2b110d1c-076e-4ca8-9bf1-53860297ee69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_64ce3531-9bf9-4001-a4fc-6edd870a6d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fd91217c-a9a7-430d-ad0a-3ccde208c4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64ce3531-9bf9-4001-a4fc-6edd870a6d70" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_fd91217c-a9a7-430d-ad0a-3ccde208c4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_10b0c706-222f-470b-a555-b57fd170a288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_us-gaap_InventoryFinishedGoods_10b0c706-222f-470b-a555-b57fd170a288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_3c28ac6e-d73a-4aed-9eb4-7332c386391f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_3c28ac6e-d73a-4aed-9eb4-7332c386391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_73e09bb0-e5ea-42e8-8110-c0cde13d3f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_us-gaap_OtherInventorySupplies_73e09bb0-e5ea-42e8-8110-c0cde13d3f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0b01811a-5f75-4859-8dcf-cefe4afb791d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_us-gaap_InventoryGross_0b01811a-5f75-4859-8dcf-cefe4afb791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_318515ad-e1ee-4e9f-819c-59844a083a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_us-gaap_InventoryLIFOReserve_318515ad-e1ee-4e9f-819c-59844a083a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_a2d850e0-7f95-48c5-942b-bde79498d3c0" xlink:href="mrk-20200930.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_a2d850e0-7f95-48c5-942b-bde79498d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_aa34e323-bf4e-4c82-bbc7-4040500d6472" xlink:href="mrk-20200930.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6e728790-a3c0-46e2-b99d-8e2410c9dacd" xlink:to="loc_mrk_RecognizedAsAbstract_aa34e323-bf4e-4c82-bbc7-4040500d6472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2fcfeee9-b70c-4de3-a18c-9327ff351285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_aa34e323-bf4e-4c82-bbc7-4040500d6472" xlink:to="loc_us-gaap_InventoryNet_2fcfeee9-b70c-4de3-a18c-9327ff351285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f8f1c75e-7ec8-425b-a9ff-45f11af2d38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_aa34e323-bf4e-4c82-bbc7-4040500d6472" xlink:to="loc_us-gaap_InventoryNoncurrent_f8f1c75e-7ec8-425b-a9ff-45f11af2d38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_721f25a7-255e-4171-b810-38e8dc098d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:href="mrk-20200930.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_721f25a7-255e-4171-b810-38e8dc098d93" xlink:to="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_6e99faf4-60ac-4e44-a282-b0c3bec2d32a" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ccd52f23-f429-4fe4-b9c6-97a583f645d8" xlink:href="mrk-20200930.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_ccd52f23-f429-4fe4-b9c6-97a583f645d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02df81e9-47ba-474f-8a65-80938a126f58" xlink:href="mrk-20200930.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1eb22e89-34b5-4bce-9614-c2a3bd498063" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_02df81e9-47ba-474f-8a65-80938a126f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_c29aaf6d-c624-46a6-bf54-fcdb0160ed31" xlink:to="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_d88fbd29-032b-4e92-8d13-0f5b2b63602e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_4da9b701-ab2a-4f84-a058-e74cb9a281c6" xlink:to="loc_us-gaap_InventoryNoncurrent_d88fbd29-032b-4e92-8d13-0f5b2b63602e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangibles" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangibles"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIntangibles" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75aa0f09-d511-4e4c-a933-f458e045f797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_7d061fd5-f27c-4f6e-ab6f-be6fbd6cb3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75aa0f09-d511-4e4c-a933-f458e045f797" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_7d061fd5-f27c-4f6e-ab6f-be6fbd6cb3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b58f73e3-2757-457d-813a-9dcfe08cf546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b58f73e3-2757-457d-813a-9dcfe08cf546" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:to="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c83956d8-3986-48e9-8ee6-74db1d0d8f8c" xlink:to="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SivextroMember_44264117-c43e-4eee-a72e-aad6bd16503b" xlink:href="mrk-20200930.xsd#mrk_SivextroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_18ec2053-656c-47a7-848d-eac07dcec729" xlink:to="loc_mrk_SivextroMember_44264117-c43e-4eee-a72e-aad6bd16503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_05c253c8-729e-45fa-98f1-53c60932ce68" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d4cc6915-583f-4c4f-b38f-6dfce2bbb294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_86c174d5-14a1-4dec-884c-caf1ebea6fb0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d4cc6915-583f-4c4f-b38f-6dfce2bbb294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebt" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8145aba-87ef-4a20-b876-34a1c2e92140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_51884758-6b34-473b-b019-c4e712f9dd4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8145aba-87ef-4a20-b876-34a1c2e92140" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_51884758-6b34-473b-b019-c4e712f9dd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#LongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/LongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bee00d23-9868-4291-9337-e38da6baacfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bee00d23-9868-4291-9337-e38da6baacfa" xlink:to="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e579814-0a6c-4801-ae05-c245b2597031" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.75notesdue2026Member_390c242f-1507-4be2-811c-e8cc1f3d9392" xlink:href="mrk-20200930.xsd#mrk_A0.75notesdue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A0.75notesdue2026Member_390c242f-1507-4be2-811c-e8cc1f3d9392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.45notesdue2030Member_41874a01-56c2-493a-823b-dac370a172f7" xlink:href="mrk-20200930.xsd#mrk_A1.45notesdue2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A1.45notesdue2030Member_41874a01-56c2-493a-823b-dac370a172f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.35notesdue2040Member_78a0459d-154b-4c0e-99e6-fa42f782c6a4" xlink:href="mrk-20200930.xsd#mrk_A2.35notesdue2040Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A2.35notesdue2040Member_78a0459d-154b-4c0e-99e6-fa42f782c6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.45notesdue2050Member_7eac00f9-0ee4-43d7-8d29-d6e54a0fcd83" xlink:href="mrk-20200930.xsd#mrk_A2.45notesdue2050Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a32d4db3-72b3-40f4-9daf-42f335e86882" xlink:to="loc_mrk_A2.45notesdue2050Member_7eac00f9-0ee4-43d7-8d29-d6e54a0fcd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dbe0f236-c147-4354-a80a-a76876b5d5a8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cbc85821-6cae-40e7-8971-2e73aae1b9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cbc85821-6cae-40e7-8971-2e73aae1b9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b03846-5000-4f51-ae66-28cf9fc3f96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_492e04e1-7d1b-4fa9-824e-cfcc8e0643b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b03846-5000-4f51-ae66-28cf9fc3f96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Contingencies" xlink:type="simple" xlink:href="mrk-20200930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03fb1dd9-a25b-4db3-aee0-8fab4edebb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5485bc5f-c476-4d71-9219-f0fba13dc417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03fb1dd9-a25b-4db3-aee0-8fab4edebb05" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5485bc5f-c476-4d71-9219-f0fba13dc417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_674ae8f1-27e2-48c3-86f4-3145305fa4db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_674ae8f1-27e2-48c3-86f4-3145305fa4db" xlink:to="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_414a11cd-4de8-446b-b8ce-9ca26d711e97" xlink:to="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FosamaxMember_3589aefd-bc6f-4152-a7e5-a2a474215cfc" xlink:href="mrk-20200930.xsd#mrk_FosamaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:to="loc_mrk_FosamaxMember_3589aefd-bc6f-4152-a7e5-a2a474215cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_5ea382ef-25b9-42b4-a886-0ed1643e2584" xlink:href="mrk-20200930.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab1104d2-f4c0-4646-82f3-a0d1dfd62634" xlink:to="loc_mrk_JanuviaMember_5ea382ef-25b9-42b4-a886-0ed1643e2584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b08f6643-c803-4af4-8e45-52feb8a3f30f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FemurFractureLitigationMember_802ff7b1-90d2-4147-a48b-6fbf637b93c7" xlink:href="mrk-20200930.xsd#mrk_FemurFractureLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:to="loc_mrk_FemurFractureLitigationMember_802ff7b1-90d2-4147-a48b-6fbf637b93c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8cf319c0-959f-4911-b351-cce04bd8edf8" xlink:href="mrk-20200930.xsd#mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_a0a28b26-0b45-489a-91a1-e6a6af01ba51" xlink:to="loc_mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember_8cf319c0-959f-4911-b351-cce04bd8edf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_8c151ff5-1feb-4bcd-917f-414c7369cc60" xlink:to="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FederalMember_a57939e2-f2a2-44f4-a8f9-200d77851c2b" xlink:href="mrk-20200930.xsd#mrk_FederalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_FederalMember_a57939e2-f2a2-44f4-a8f9-200d77851c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NewJerseyStateCourtMember_6b817e01-1490-4c4b-871c-571ddec4aab2" xlink:href="mrk-20200930.xsd#mrk_NewJerseyStateCourtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_NewJerseyStateCourtMember_6b817e01-1490-4c4b-871c-571ddec4aab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CaliforniaStateCourtMember_e7bab5f1-f78e-437a-917a-41be1810feab" xlink:href="mrk-20200930.xsd#mrk_CaliforniaStateCourtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_CaliforniaStateCourtMember_e7bab5f1-f78e-437a-917a-41be1810feab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherStateCourtMember_48d8a1cc-a526-46e6-81aa-b1c82dfe990c" xlink:href="mrk-20200930.xsd#mrk_OtherStateCourtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_OtherStateCourtMember_48d8a1cc-a526-46e6-81aa-b1c82dfe990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_f1007b65-d760-45b3-ade0-3adf1d84d042" xlink:href="mrk-20200930.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_f1007b65-d760-45b3-ade0-3adf1d84d042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a0d35b38-2fe8-4223-9ccc-e68e947fa98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_40e7f2ba-7beb-47ca-9947-251a1cf0705f" xlink:to="loc_us-gaap_PatentsMember_a0d35b38-2fe8-4223-9ccc-e68e947fa98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e3013b5d-e53c-4cf3-bd81-f824278de3b8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_87369e09-87ca-4f55-bc11-419471e47c9c" xlink:href="mrk-20200930.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_211b2f79-e47e-4623-9edb-18cdb76eca62" xlink:to="loc_mrk_LegalDefenseCostsMember_87369e09-87ca-4f55-bc11-419471e47c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1d6e34c7-30be-4663-af11-8b8c7695f384" xlink:to="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b570d4d1-8c33-4ed8-86b6-8b017f6f6103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b570d4d1-8c33-4ed8-86b6-8b017f6f6103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_7489c210-a93a-4f73-9a07-b458b649dd85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_7489c210-a93a-4f73-9a07-b458b649dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_203baa0b-fd26-4b99-91c8-b2643a6f9f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_203baa0b-fd26-4b99-91c8-b2643a6f9f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyClaimsonAppealNumber_9d5aed8c-7361-4a4b-a558-50da3e9923e5" xlink:href="mrk-20200930.xsd#mrk_LossContingencyClaimsonAppealNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_mrk_LossContingencyClaimsonAppealNumber_9d5aed8c-7361-4a4b-a558-50da3e9923e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_63fb2a6f-cac6-4f8b-9da4-2fd5e12a523c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_80d2a465-e4d9-4afe-ae63-17697f2163fa" xlink:to="loc_us-gaap_LitigationReserve_63fb2a6f-cac6-4f8b-9da4-2fd5e12a523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20200930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_492c14db-457d-402b-95e8-6c2bb028fa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5c4716a2-9d14-4828-9ea2-fc98ec3d60d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_492c14db-457d-402b-95e8-6c2bb028fa7f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5c4716a2-9d14-4828-9ea2-fc98ec3d60d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_07fc107e-1d9a-44af-a0c5-d87638de2f3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_d491191e-4237-462f-b712-caee57d0adac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_07fc107e-1d9a-44af-a0c5-d87638de2f3d" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_d491191e-4237-462f-b712-caee57d0adac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EquityRollforwardReconciliationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityRollforwardReconciliationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bd50eb39-9723-4a3f-9de8-39f9852f08d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bd50eb39-9723-4a3f-9de8-39f9852f08d1" xlink:to="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a93da48-7583-4a1f-bd47-9bb7a62b93dc" xlink:to="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eac25ba2-5f05-407e-8d29-5efba87a57ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_CommonStockMember_eac25ba2-5f05-407e-8d29-5efba87a57ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_45764e98-93b0-4914-a5a4-44b4da516302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_45764e98-93b0-4914-a5a4-44b4da516302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5393dc68-bd68-4422-9084-d30aff26db13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_RetainedEarningsMember_5393dc68-bd68-4422-9084-d30aff26db13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ba58a5af-3e78-41b6-8236-bfe7b60bb479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ba58a5af-3e78-41b6-8236-bfe7b60bb479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_6049ee12-25eb-4e3a-bf64-9326c7b3b4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_TreasuryStockMember_6049ee12-25eb-4e3a-bf64-9326c7b3b4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_48ae0ed0-0b4c-47e2-959f-27e000dff940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1525bd75-0424-468e-833f-8f47da2515ce" xlink:to="loc_us-gaap_NoncontrollingInterestMember_48ae0ed0-0b4c-47e2-959f-27e000dff940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:href="mrk-20200930.xsd#mrk_StockholdersEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_1e8ed78e-8046-43b6-b2f9-afa12c3ce818" xlink:to="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a975927d-6174-4410-8f99-f4cab18db9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_CommonStockSharesIssued_a975927d-6174-4410-8f99-f4cab18db9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3dc2f586-22f3-4b50-b907-f46eac934c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3dc2f586-22f3-4b50-b907-f46eac934c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d49fcdd1-f27f-43b8-9a6f-3d4cdfd8e153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_NetIncomeLoss_d49fcdd1-f27f-43b8-9a6f-3d4cdfd8e153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05d6765-55cb-4608-8d54-62e6bfeebcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a05d6765-55cb-4608-8d54-62e6bfeebcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_e13b3518-4eea-4364-b619-dcf00f50b76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_DividendsCommonStockCash_e13b3518-4eea-4364-b619-dcf00f50b76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f377a8bf-5afb-4cac-b9c7-0b1a308b173b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f377a8bf-5afb-4cac-b9c7-0b1a308b173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5c466acd-86e5-497c-9e75-4f893b2c67fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5c466acd-86e5-497c-9e75-4f893b2c67fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_59f7b651-4d3a-4ddc-8f8f-9ea4d42e3f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_59f7b651-4d3a-4ddc-8f8f-9ea4d42e3f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_386c168c-8a97-4953-a4bf-45bd6bd69a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityOther_386c168c-8a97-4953-a4bf-45bd6bd69a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a257619d-568c-49d2-ae87-89a1f4edfccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a257619d-568c-49d2-ae87-89a1f4edfccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d6c9ae7a-1147-466b-a68f-2538528d84bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d6c9ae7a-1147-466b-a68f-2538528d84bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a6ec51a5-a7ea-4490-b280-494d44e9852a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_CommonStockSharesIssued_a6ec51a5-a7ea-4490-b280-494d44e9852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b322a2d-dbb8-4853-93a3-6a72d8d24a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_89970ef2-78dd-4926-8f6d-16f92a5c0e75" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b322a2d-dbb8-4853-93a3-6a72d8d24a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b90c74f6-036d-4b5f-8daa-ec27c3a8b880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_619867b0-0713-488e-ac14-414397b9674b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b90c74f6-036d-4b5f-8daa-ec27c3a8b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4844b9ce-9720-4944-a5e8-a4e5313392f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3cb2877-0544-4365-85fa-9e98eb75f916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4844b9ce-9720-4944-a5e8-a4e5313392f8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3cb2877-0544-4365-85fa-9e98eb75f916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c2600c6-6259-452b-8f0a-2b317d5c0475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_afa3a41c-3286-46a7-b3ec-fb4c283fbe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c2600c6-6259-452b-8f0a-2b317d5c0475" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_afa3a41c-3286-46a7-b3ec-fb4c283fbe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0f8700f-9729-4b45-bcbf-554b735a5243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c2600c6-6259-452b-8f0a-2b317d5c0475" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0f8700f-9729-4b45-bcbf-554b735a5243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansExpenseAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeec79d0-018f-46dd-b413-3bb4c0dfe4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9fc5d29c-8f4c-4779-9b45-2379a7e38744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeec79d0-018f-46dd-b413-3bb4c0dfe4c2" xlink:to="loc_us-gaap_ShareBasedCompensation_9fc5d29c-8f4c-4779-9b45-2379a7e38744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_7b550d5c-fe98-4373-9e08-7e613c2d3bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeec79d0-018f-46dd-b413-3bb4c0dfe4c2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_7b550d5c-fe98-4373-9e08-7e613c2d3bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_135c005c-73d6-4726-9b12-1b5298efd0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aeec79d0-018f-46dd-b413-3bb4c0dfe4c2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_135c005c-73d6-4726-9b12-1b5298efd0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_087befe8-0be0-4011-8ce2-7bd32c92deb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_087befe8-0be0-4011-8ce2-7bd32c92deb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:to="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_77ed1e56-3005-45e4-9ddc-4875336f3a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ba4e05c1-2b5e-4e9d-85c7-d8e50f4316bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ba4e05c1-2b5e-4e9d-85c7-d8e50f4316bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_31e0acbf-8cd9-47ca-98d0-96ab7a11d973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd0efa5-abf7-4238-9b85-2209f70b5125" xlink:to="loc_us-gaap_PerformanceSharesMember_31e0acbf-8cd9-47ca-98d0-96ab7a11d973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd5f98b1-5bed-40fe-9fee-3ba7990e5dc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1259be14-cab0-4a0c-9171-4ad5ebdfb196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1259be14-cab0-4a0c-9171-4ad5ebdfb196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b5aec3e-f72b-4b98-a71b-cadb32cf3ae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b5aec3e-f72b-4b98-a71b-cadb32cf3ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c88f79c9-8c2e-47c7-a10d-fb1648ff2ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c88f79c9-8c2e-47c7-a10d-fb1648ff2ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21aad2ba-d211-4e22-82d7-6fe74637bbf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21aad2ba-d211-4e22-82d7-6fe74637bbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa2c9563-7fd4-4a90-a6fa-8500db942172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa2c9563-7fd4-4a90-a6fa-8500db942172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba61f0a1-78e0-456f-871e-f4f611573c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba61f0a1-78e0-456f-871e-f4f611573c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c42b577-65a1-4cfa-b677-a8e1e5ad6e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5c9f7095-9b7f-4556-8b4f-d31747f4123b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c42b577-65a1-4cfa-b677-a8e1e5ad6e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08fb1c3d-931a-49fd-85c5-0ef52df58260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e2a48c66-5286-4790-b3d5-810f47d20894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08fb1c3d-931a-49fd-85c5-0ef52df58260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e2a48c66-5286-4790-b3d5-810f47d20894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7c034b5-a112-4fc4-96e7-6a2879caf54c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08fb1c3d-931a-49fd-85c5-0ef52df58260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7c034b5-a112-4fc4-96e7-6a2879caf54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4a857c4e-a30b-4c27-a914-1373f737cbbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08fb1c3d-931a-49fd-85c5-0ef52df58260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4a857c4e-a30b-4c27-a914-1373f737cbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b826ad15-eae6-4e60-b277-9439b67f3223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08fb1c3d-931a-49fd-85c5-0ef52df58260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b826ad15-eae6-4e60-b277-9439b67f3223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd3d005f-2237-42d0-8427-6fb5e2141183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_dc9b04cb-4e44-4cfe-bbcf-9a84b2e6d3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd3d005f-2237-42d0-8427-6fb5e2141183" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_dc9b04cb-4e44-4cfe-bbcf-9a84b2e6d3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6cda2027-c211-4df4-aab8-86be994f46d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6cda2027-c211-4df4-aab8-86be994f46d7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2522d5c1-90da-4ab1-8658-de57c53c6aac" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_53a13858-dc53-4d3e-b9c7-3e3f3e520411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_53a13858-dc53-4d3e-b9c7-3e3f3e520411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f31d143f-0bf6-4216-88e3-8a1d39553cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1e5f3cb7-04e2-496c-bd86-d525e09569c8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f31d143f-0bf6-4216-88e3-8a1d39553cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b992a27f-fda0-4fa1-907b-ffaec47a2ec1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e97856cb-ae88-4061-92da-7aa3ea1df83d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_76538ff4-9ad5-4ce1-88f9-bb3f89396981" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_e97856cb-ae88-4061-92da-7aa3ea1df83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da542339-de90-4b09-807a-cf688b12a48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da542339-de90-4b09-807a-cf688b12a48e" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_ef555585-5bb3-4018-b8c3-42ba6fca5583" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69f71717-7168-40b2-b355-f9411d5df682" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:to="loc_country_US_69f71717-7168-40b2-b355-f9411d5df682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_94f90af9-aced-4f95-94f7-416bb4a6b14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_aa8fe4bd-29d4-4150-a275-a2652f75c90c" xlink:to="loc_us-gaap_ForeignPlanMember_94f90af9-aced-4f95-94f7-416bb4a6b14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f70be11a-6cc0-4dcb-89cc-2e73449c3760" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2559d320-56f2-4c65-aada-e1d64c7778e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2559d320-56f2-4c65-aada-e1d64c7778e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ff428aad-86f9-4593-a1e4-7d509736b3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1470673e-2e35-4411-938e-fd64b16744be" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_ff428aad-86f9-4593-a1e4-7d509736b3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_aeb62006-44fa-4b53-9770-8c055dcf1ec2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c7492736-a48a-4942-8697-45044dc22bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c7492736-a48a-4942-8697-45044dc22bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_434a5950-1c9d-478f-b0e1-5b79b55ec6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_434a5950-1c9d-478f-b0e1-5b79b55ec6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9c27f9cf-fc4d-4c73-9db3-4a05e2300cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_9c27f9cf-fc4d-4c73-9db3-4a05e2300cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_97852f1f-f551-4828-9864-ef9ba696c59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_97852f1f-f551-4828-9864-ef9ba696c59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8b6625b3-f068-47f2-b608-2ab3d50d42f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_8b6625b3-f068-47f2-b608-2ab3d50d42f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a8e40c5a-5db0-4b97-aa25-9dcb817a011c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_a8e40c5a-5db0-4b97-aa25-9dcb817a011c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_070a4138-be34-4cba-824b-878f07a05766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_070a4138-be34-4cba-824b-878f07a05766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a7f85d39-af66-4f75-9703-7c04d124430d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a7f85d39-af66-4f75-9703-7c04d124430d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b1628dfb-be8b-4121-9455-b6880c35611c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_213aeca7-da5d-40c1-92c8-32eb769e5895" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b1628dfb-be8b-4121-9455-b6880c35611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract_51677dc3-fdd5-40ca-b13c-a9681d7013bb" xlink:href="mrk-20200930.xsd#mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract_51677dc3-fdd5-40ca-b13c-a9681d7013bb" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0c2a278e-491f-4093-aa8c-4cfc8e71b0a6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_652a3910-58de-4fdc-928e-e5af766f08af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:to="loc_us-gaap_ForeignPlanMember_652a3910-58de-4fdc-928e-e5af766f08af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f58b4972-87c8-46c2-a731-292d9a6bbd40" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0ff15619-ce3a-46ea-872c-3d098493cb2a" xlink:to="loc_country_US_f58b4972-87c8-46c2-a731-292d9a6bbd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4175b8b3-4c9b-4d73-aea4-660e04cdfeef" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_2e9af417-bf06-40d5-a2bb-c8b92b2ed108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear_2e9af417-bf06-40d5-a2bb-c8b92b2ed108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_40ac814a-8e49-4c25-9a58-a1a943bcef3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1d4fed9c-b996-4015-8f94-12be44d1fa56" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_40ac814a-8e49-4c25-9a58-a1a943bcef3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_c189ed15-6f3b-4024-a437-b852a8f2adde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_91ba02e5-6cf3-4bb9-8ad9-8f1ede55bcdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_c189ed15-6f3b-4024-a437-b852a8f2adde" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_91ba02e5-6cf3-4bb9-8ad9-8f1ede55bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_523a067d-53a1-4f1e-9294-5aa8703ef63b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_98a61ce3-67fd-454f-bc7d-76f4ef23bcca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_523a067d-53a1-4f1e-9294-5aa8703ef63b" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_98a61ce3-67fd-454f-bc7d-76f4ef23bcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_a07fdb0f-a570-476b-8d53-fcbc8109755d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_a07fdb0f-a570-476b-8d53-fcbc8109755d" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:to="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7801e7d8-15b5-4d23-ab58-ef99d544d734" xlink:to="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f84a846c-b592-44af-8b9b-e0ae381b1b25" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_167ab94b-88d2-4b6b-8647-e049b7628091" xlink:to="loc_srt_ScenarioForecastMember_f84a846c-b592-44af-8b9b-e0ae381b1b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_b83fa298-6c6c-425e-928e-7111b0400d6b" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_bbd6238d-e76a-4a83-a858-cff856c0ffb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_InvestmentIncomeInterest_bbd6238d-e76a-4a83-a858-cff856c0ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a10051e2-c2e3-4268-9dc3-3127b37be059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_InterestExpense_a10051e2-c2e3-4268-9dc3-3127b37be059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbf1dfc6-74e2-4312-ae6c-8628d33d44f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cbf1dfc6-74e2-4312-ae6c-8628d33d44f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_784a1783-c4c3-44a9-8da5-80d85b480d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_784a1783-c4c3-44a9-8da5-80d85b480d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0b3e6080-644e-432d-b0de-8d1bc1cfa76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_0b3e6080-644e-432d-b0de-8d1bc1cfa76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_854fb561-02c4-4724-a824-f0c1ce6a2ae2" xlink:href="mrk-20200930.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_854fb561-02c4-4724-a824-f0c1ce6a2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fcc5d4f8-2cf8-4091-9c6e-d8e2fe9486c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_e9ce5ed1-6089-4919-a5c4-ece320106594" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fcc5d4f8-2cf8-4091-9c6e-d8e2fe9486c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_99fb0cc6-4204-4ed6-9c2a-51aa882f12d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_99fb0cc6-4204-4ed6-9c2a-51aa882f12d4" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_9303ce0f-7025-4f50-b444-66cb4d8b9911" xlink:to="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_HealthcareServicesSegmentMember_fca6fda6-6bbf-4821-bd9f-2426d330cffb" xlink:href="mrk-20200930.xsd#mrk_HealthcareServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af93daf9-7c79-45a8-9211-5d09e84d7d4f" xlink:to="loc_mrk_HealthcareServicesSegmentMember_fca6fda6-6bbf-4821-bd9f-2426d330cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:href="mrk-20200930.xsd#mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingTable_5df85e57-de34-4058-be31-e51688cba691" xlink:to="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7d7ba1a6-3385-41f1-a8b0-8dd7cf8148ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7d7ba1a6-3385-41f1-a8b0-8dd7cf8148ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_e5c192bf-c493-4b92-ae9b-84b9ea630895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems_7ad22b33-60e0-4f26-bb7c-a2c31a3bc430" xlink:to="loc_us-gaap_InterestPaid_e5c192bf-c493-4b92-ae9b-84b9ea630895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1f02344-f9d9-4489-beb5-eaa955529145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_45e25dd4-d7cf-4785-ad9b-14e744aa086a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1f02344-f9d9-4489-beb5-eaa955529145" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_45e25dd4-d7cf-4785-ad9b-14e744aa086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#TaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9f17775c-4df2-4591-8403-f9f39a6db2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9f17775c-4df2-4591-8403-f9f39a6db2cc" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_e5dee7b1-39c0-4b96-aeac-5ebe145e6b12" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6c24a559-aff5-4f0e-9161-90b3e146a5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0d0db3d9-6c18-4665-81b7-57481002ce8a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6c24a559-aff5-4f0e-9161-90b3e146a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cb3b9eaf-8561-4daa-8d3d-48948196aa43" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_949faf13-0f60-4bb1-bc01-46e1242bff56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_813fed0a-aa13-4b67-926a-8ec879d2cd68" xlink:to="loc_us-gaap_DomesticCountryMember_949faf13-0f60-4bb1-bc01-46e1242bff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1b561cfc-d9fb-4785-a770-aa266830b331" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ee74f31-ead7-4d49-97b6-b35fe1ab70bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ee74f31-ead7-4d49-97b6-b35fe1ab70bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48409e6b-156a-42cc-8a69-6a55a2b075aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_48409e6b-156a-42cc-8a69-6a55a2b075aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_326a5ed3-5fea-432a-9083-ce4704cc012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_4428dbca-7b7f-4f08-a329-6049fdc852ee" xlink:to="loc_us-gaap_IncomeTaxesPaid_326a5ed3-5fea-432a-9083-ce4704cc012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c376f5b-a81a-4c1b-898b-e9f7a1668df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_942cb275-4806-4fb5-acc7-f1369c3b3ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c376f5b-a81a-4c1b-898b-e9f7a1668df7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_942cb275-4806-4fb5-acc7-f1369c3b3ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bf09dce3-a410-42d2-a492-2140f7781d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0d9980c-21b8-429d-8d3e-50ad5b15a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bf09dce3-a410-42d2-a492-2140f7781d81" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a0d9980c-21b8-429d-8d3e-50ad5b15a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cc5647a-4559-42f6-8cd1-812b4a946a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_NetIncomeLoss_3cc5647a-4559-42f6-8cd1-812b4a946a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbf0e40e-a726-4494-87c1-baa58dac9c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbf0e40e-a726-4494-87c1-baa58dac9c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c55d1c6-b602-476f-8923-637ca6d6fdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c55d1c6-b602-476f-8923-637ca6d6fdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1e8283-2e2b-455b-a562-22e64a95d69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f1e8283-2e2b-455b-a562-22e64a95d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_24c64324-8b87-4c45-887e-daf10ccc7a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_EarningsPerShareBasic_24c64324-8b87-4c45-887e-daf10ccc7a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7b7e43c5-c943-440b-8e50-d17710cfdff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7b7e43c5-c943-440b-8e50-d17710cfdff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01ff8648-e65f-4e37-813c-b59542d8c022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_065befe3-bb16-4c76-926d-1d2770f62cbb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_01ff8648-e65f-4e37-813c-b59542d8c022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2f0fb164-375a-4b3c-958c-57fac243392e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_028e512f-0606-4a21-a2b6-f38bf4f13e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f0fb164-375a-4b3c-958c-57fac243392e" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_028e512f-0606-4a21-a2b6-f38bf4f13e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_25466302-4e1c-4443-ac32-1cb263fac71c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1913d75c-4611-47c1-8f85-ee55114b0f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25466302-4e1c-4443-ac32-1cb263fac71c" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1913d75c-4611-47c1-8f85-ee55114b0f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ef3d83e4-3d1f-4862-9a01-d339338a6f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef3d83e4-3d1f-4862-9a01-d339338a6f7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_306a5896-f3dd-44e7-9739-2e08fbf8ba23" xlink:to="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e05db331-e0aa-47c5-b747-9e55c8e7e94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_e05db331-e0aa-47c5-b747-9e55c8e7e94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_630daf6f-dc88-4507-b447-46cfbb89f50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_630daf6f-dc88-4507-b447-46cfbb89f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1a31e849-5e51-4091-8df9-6cfde27d09e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_1a31e849-5e51-4091-8df9-6cfde27d09e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501456ea-f54c-4f7b-939e-cb7faa33ab18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_501456ea-f54c-4f7b-939e-cb7faa33ab18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_23307731-5acf-40f9-a002-62ea33be1d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_55eb1b85-bc3b-4cf0-95b1-6b277942dc11" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_23307731-5acf-40f9-a002-62ea33be1d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_da6b3164-2727-4681-830c-737c49c1d5d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_3c2c2299-4a5f-4f63-b101-7d60c7ccc5c2" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab9f005c-a318-462e-9a1a-f6ff85641857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ab9f005c-a318-462e-9a1a-f6ff85641857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_c9b618d4-fd2c-4839-8524-bc0891b228b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_c9b618d4-fd2c-4839-8524-bc0891b228b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_39a45137-b13e-46a2-99c5-64809a67457f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_39a45137-b13e-46a2-99c5-64809a67457f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6e1f7be7-ec84-40ad-b809-8c143876ddcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6e1f7be7-ec84-40ad-b809-8c143876ddcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c41541c8-936d-4100-b465-d09beaa64dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_c41541c8-936d-4100-b465-d09beaa64dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_05c705c1-6642-4b9b-817b-2f36065eae1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_05c705c1-6642-4b9b-817b-2f36065eae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_78558b01-fcca-4bde-a9c6-613c8520c7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_78558b01-fcca-4bde-a9c6-613c8520c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_836f6f54-fa91-4c70-bf2d-27b0af90571a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_836f6f54-fa91-4c70-bf2d-27b0af90571a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c9d6641-cd97-4a09-832b-2c4d1bb8f35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_96bd3f3e-41a6-4654-905d-64a6ef894589" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9c9d6641-cd97-4a09-832b-2c4d1bb8f35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4c08bd92-c9d8-4e9f-b84b-eb18ca01d729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7234c452-f92c-4999-bb27-4123e92519d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4c08bd92-c9d8-4e9f-b84b-eb18ca01d729" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7234c452-f92c-4999-bb27-4123e92519d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_91c93d57-f916-4b6e-8646-47b1c0174e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_bce8da1d-4ddb-4206-8c00-2e7f22f48074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_91c93d57-f916-4b6e-8646-47b1c0174e9b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_bce8da1d-4ddb-4206-8c00-2e7f22f48074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_337e5544-d1e1-4fdc-a7c5-5ebc9a8d3148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_91c93d57-f916-4b6e-8646-47b1c0174e9b" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_337e5544-d1e1-4fdc-a7c5-5ebc9a8d3148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_e0dffb0e-f4c7-4e8c-a9ee-b0e84dbabcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_91c93d57-f916-4b6e-8646-47b1c0174e9b" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_e0dffb0e-f4c7-4e8c-a9ee-b0e84dbabcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0b2cd537-ec82-4f86-a5d2-44f33502db30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d01cae9e-a255-4196-a802-f54d66bf7e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b2cd537-ec82-4f86-a5d2-44f33502db30" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d01cae9e-a255-4196-a802-f54d66bf7e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_21dd7e48-8d38-48fc-b994-d700f9d39398" xlink:href="mrk-20200930.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b2cd537-ec82-4f86-a5d2-44f33502db30" xlink:to="loc_mrk_SalesDiscounts_21dd7e48-8d38-48fc-b994-d700f9d39398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingSalesofCompanysProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_66fa51b9-0257-4906-a363-9dede5a867d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_66fa51b9-0257-4906-a363-9dede5a867d5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_90a562b8-02f1-4adc-a496-352e97c0b174" xlink:to="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_bea80679-774c-4eca-9f20-91ab0a666a29" xlink:href="mrk-20200930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_mrk_PharmaceuticalsegmentMember_bea80679-774c-4eca-9f20-91ab0a666a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_3fd168e7-cece-480c-8a76-de9d6be5b9f2" xlink:href="mrk-20200930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_mrk_AnimalHealthsegmentMember_3fd168e7-cece-480c-8a76-de9d6be5b9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_d0d44818-77d7-488f-9a81-03fef29a8c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0dfc4844-98d1-4bf8-b03d-91cfc7111835" xlink:to="loc_us-gaap_AllOtherSegmentsMember_d0d44818-77d7-488f-9a81-03fef29a8c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_64f91a52-3f51-4b71-b24b-65ff517ec8fc" xlink:to="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_75fa7d35-34ec-42d9-be4e-3babbd80dac5" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:to="loc_country_US_75fa7d35-34ec-42d9-be4e-3babbd80dac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_95ccf964-3336-45ea-97ab-7a916d804f7b" xlink:href="mrk-20200930.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_25bd6ade-c3bb-466d-bd90-376492e6dfbc" xlink:to="loc_mrk_InternationalMember_95ccf964-3336-45ea-97ab-7a916d804f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2280f716-09fc-4b20-aa27-b5770bd78dc4" xlink:to="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8ce9790a-705b-4d80-970b-a779b54d7753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:to="loc_us-gaap_OperatingSegmentsMember_8ce9790a-705b-4d80-970b-a779b54d7753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e24294c1-10fc-4ccd-b154-b0a837367d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ca4e2211-398a-4016-93d8-635ff678ddc5" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e24294c1-10fc-4ccd-b154-b0a837367d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7534038e-ac11-43cd-84ea-57b47a1563a3" xlink:to="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_a0447cbe-d4b5-4f4e-94ce-72c0f84458ca" xlink:href="mrk-20200930.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_KeytrudaMember_a0447cbe-d4b5-4f4e-94ce-72c0f84458ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_c5880a07-ca01-457d-a3a2-8d6ebafcedb0" xlink:href="mrk-20200930.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_c5880a07-ca01-457d-a3a2-8d6ebafcedb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_3f85a2e0-8683-4f23-b89c-2b070da6c1ce" xlink:href="mrk-20200930.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_LenvimaMember_3f85a2e0-8683-4f23-b89c-2b070da6c1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EmendMember_14026a0f-c244-4ec9-a5b3-e36551ff81de" xlink:href="mrk-20200930.xsd#mrk_EmendMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_EmendMember_14026a0f-c244-4ec9-a5b3-e36551ff81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_83747c05-48ca-4ef1-abac-8b24c2e5e968" xlink:href="mrk-20200930.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_GardasilGardasil9Member_83747c05-48ca-4ef1-abac-8b24c2e5e968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_7e6e01de-d0f0-4a68-9a9c-9aea4c831c84" xlink:href="mrk-20200930.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_7e6e01de-d0f0-4a68-9a9c-9aea4c831c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_50e0321b-6530-425b-bcd5-63123a503d48" xlink:href="mrk-20200930.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_Pneumovax23Member_50e0321b-6530-425b-bcd5-63123a503d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_6d871692-07fc-405d-97c2-61791a209f58" xlink:href="mrk-20200930.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_RotateqMember_6d871692-07fc-405d-97c2-61791a209f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_016acf86-90d4-4368-b930-9e762bdc1f09" xlink:href="mrk-20200930.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_VaqtaMember_016acf86-90d4-4368-b930-9e762bdc1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_b24e63c7-c3f8-4b33-99bf-d7799a7d7c27" xlink:href="mrk-20200930.xsd#mrk_BridionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_BridionMember_b24e63c7-c3f8-4b33-99bf-d7799a7d7c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_6a9d676d-ca02-4d5b-a17e-a10e3c7ae0b6" xlink:href="mrk-20200930.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NoxafilMember_6a9d676d-ca02-4d5b-a17e-a10e3c7ae0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_04784d4f-8c9c-4010-ac65-47aff06368d8" xlink:href="mrk-20200930.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_PrevymisMember_04784d4f-8c9c-4010-ac65-47aff06368d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_346ee483-87cf-4f3e-82d6-a34aaf5deef4" xlink:href="mrk-20200930.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_PrimaxinMember_346ee483-87cf-4f3e-82d6-a34aaf5deef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InvanzMember_9ac8ded9-5016-42ff-b83d-6acebb30e09e" xlink:href="mrk-20200930.xsd#mrk_InvanzMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_InvanzMember_9ac8ded9-5016-42ff-b83d-6acebb30e09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CancidasMember_11e2ba64-3d5f-44b8-ae09-b51c58906b23" xlink:href="mrk-20200930.xsd#mrk_CancidasMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CancidasMember_11e2ba64-3d5f-44b8-ae09-b51c58906b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CubicinMember_6d9416a5-1995-41c3-a4ad-54e91466ebfd" xlink:href="mrk-20200930.xsd#mrk_CubicinMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CubicinMember_6d9416a5-1995-41c3-a4ad-54e91466ebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_0b13fe92-e8fc-49e8-853f-b651dd13a3f6" xlink:href="mrk-20200930.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZerbaxaMember_0b13fe92-e8fc-49e8-853f-b651dd13a3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_2552697d-6d99-47ce-957f-46414301a3a4" xlink:href="mrk-20200930.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_SimponiMember_2552697d-6d99-47ce-957f-46414301a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_6582706b-a224-45f9-8318-d000f4bbb483" xlink:href="mrk-20200930.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_RemicadeMember_6582706b-a224-45f9-8318-d000f4bbb483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_c41b53b9-5e3a-45d8-b81d-a4ec76e6e7b5" xlink:href="mrk-20200930.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_BelsomraMember_c41b53b9-5e3a-45d8-b81d-a4ec76e6e7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_6ac997ac-b96e-4b97-bafa-c8efc0f69045" xlink:href="mrk-20200930.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_IsentressIsentressHDMember_6ac997ac-b96e-4b97-bafa-c8efc0f69045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZepatierMember_eea460b1-d2e4-4de1-96d7-2bc3012ceda7" xlink:href="mrk-20200930.xsd#mrk_ZepatierMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZepatierMember_eea460b1-d2e4-4de1-96d7-2bc3012ceda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaMember_dcd4aa9c-a88f-45c8-b9b6-b2ec14520487" xlink:href="mrk-20200930.xsd#mrk_ZetiaMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ZetiaMember_dcd4aa9c-a88f-45c8-b9b6-b2ec14520487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VytorinMember_b991ce10-cf55-483a-a34b-750a96b97f45" xlink:href="mrk-20200930.xsd#mrk_VytorinMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_VytorinMember_b991ce10-cf55-483a-a34b-750a96b97f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AtozetMember_a32c711d-8852-421e-b39c-a72895fe75a5" xlink:href="mrk-20200930.xsd#mrk_AtozetMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AtozetMember_a32c711d-8852-421e-b39c-a72895fe75a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasMember_c43e76bc-537a-42f3-968d-49747deca7b2" xlink:href="mrk-20200930.xsd#mrk_AllianceRevenueAdempasMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AllianceRevenueAdempasMember_c43e76bc-537a-42f3-968d-49747deca7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_4708c213-c2ec-481d-9106-e3549ef759ee" xlink:href="mrk-20200930.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_AdempasMember_4708c213-c2ec-481d-9106-e3549ef759ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_d30da3b0-7267-47e1-ac05-448db7352ddb" xlink:href="mrk-20200930.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_JanuviaMember_d30da3b0-7267-47e1-ac05-448db7352ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_9057e150-3674-4c11-ad42-64ec27fbcafe" xlink:href="mrk-20200930.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_JanumetMember_9057e150-3674-4c11-ad42-64ec27fbcafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImplanonNexplanonMember_b064209b-ff4f-4d78-b57f-a10cfb46b9de" xlink:href="mrk-20200930.xsd#mrk_ImplanonNexplanonMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ImplanonNexplanonMember_b064209b-ff4f-4d78-b57f-a10cfb46b9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NuvaringMember_b6658dc7-53b7-4a8c-b7ee-1f3011c52c1f" xlink:href="mrk-20200930.xsd#mrk_NuvaringMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NuvaringMember_b6658dc7-53b7-4a8c-b7ee-1f3011c52c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SingulairMember_f0f88c1c-2319-45ea-a9b6-8b3f9dfb30cb" xlink:href="mrk-20200930.xsd#mrk_SingulairMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_SingulairMember_f0f88c1c-2319-45ea-a9b6-8b3f9dfb30cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NasonexMember_488b3e36-51f6-4a2b-a340-ced213b2a834" xlink:href="mrk-20200930.xsd#mrk_NasonexMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_NasonexMember_488b3e36-51f6-4a2b-a340-ced213b2a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ArcoxiaMember_d1f8c557-db62-4b7c-a8ae-0ea132f84cbc" xlink:href="mrk-20200930.xsd#mrk_ArcoxiaMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_ArcoxiaMember_d1f8c557-db62-4b7c-a8ae-0ea132f84cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CozaarHyzaarMember_70787500-6fed-4f3f-8518-5f95c7482014" xlink:href="mrk-20200930.xsd#mrk_CozaarHyzaarMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CozaarHyzaarMember_70787500-6fed-4f3f-8518-5f95c7482014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FollistimAqMember_b651e557-b219-4bbd-8813-a6bbc89c938d" xlink:href="mrk-20200930.xsd#mrk_FollistimAqMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_FollistimAqMember_b651e557-b219-4bbd-8813-a6bbc89c938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_701bdfcf-82bc-4388-9558-b556260414a0" xlink:href="mrk-20200930.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_OtherPharmaceuticalMember_701bdfcf-82bc-4388-9558-b556260414a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_83e9cfb2-26cc-44e0-a639-55e5602a86b6" xlink:href="mrk-20200930.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_LivestockMember_83e9cfb2-26cc-44e0-a639-55e5602a86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_dd731dfb-d7ef-4b27-a3fe-04e8079dfcc8" xlink:href="mrk-20200930.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c701587-c1e5-4055-b506-d28b04614404" xlink:to="loc_mrk_CompanionAnimalsMember_dd731dfb-d7ef-4b27-a3fe-04e8079dfcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0ba4dd3e-3898-4c95-8fc1-628b1637a8be" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_15fa941d-cef3-4ac5-83d0-8ff62c26d454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_578cf690-1871-4e73-b911-4f3235053ba5" xlink:to="loc_us-gaap_Revenues_15fa941d-cef3-4ac5-83d0-8ff62c26d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingRevenuesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_23c34d6c-50b5-43a6-a86d-e4a44f56f335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_23c34d6c-50b5-43a6-a86d-e4a44f56f335" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:to="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_039dab7b-f0eb-441c-84cd-cc9a52c0a075" xlink:to="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_81031c85-7bb6-469a-8931-3d0eef289b85" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_US_81031c85-7bb6-469a-8931-3d0eef289b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_c00d2272-e07a-4619-8120-731851c54fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_us-gaap_EMEAMember_c00d2272-e07a-4619-8120-731851c54fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ecb21738-41ce-4eb6-bec8-036ef87e981a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_CN_ecb21738-41ce-4eb6-bec8-036ef87e981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f1c824fe-8d1a-4a71-8174-001a5a6e0882" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_country_JP_f1c824fe-8d1a-4a71-8174-001a5a6e0882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_e4408151-f75d-4131-be2c-e3cd42bae06f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_srt_AsiaPacificMember_e4408151-f75d-4131-be2c-e3cd42bae06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_779428c1-0e02-44ab-9430-66903b238903" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_srt_LatinAmericaMember_779428c1-0e02-44ab-9430-66903b238903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_281ce894-07bb-4d02-a73d-dda6d0e5a56f" xlink:href="mrk-20200930.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2cea2ee8-514f-4045-92ab-c73b616adfc8" xlink:to="loc_mrk_OtherCountriesMember_281ce894-07bb-4d02-a73d-dda6d0e5a56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_aa6a636f-c5dc-41dd-9add-23ec712cbdd1" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f497c40a-460a-44fb-a479-7083b5d7227a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cfb43eb5-a5b3-4dfb-b42d-c8fba65cac84" xlink:to="loc_us-gaap_Revenues_f497c40a-460a-44fb-a479-7083b5d7227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20200930.xsd#SegmentReportingProfitstoIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6da666ac-48b2-4709-9795-65445092f16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6da666ac-48b2-4709-9795-65445092f16d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:to="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_17a0d357-ddab-4831-a58f-a602d4fe7a3f" xlink:to="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_62d9ffcf-c32e-4c9a-8ab3-8e05b080f92f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_OperatingSegmentsMember_62d9ffcf-c32e-4c9a-8ab3-8e05b080f92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4ec745c8-fa96-4a00-8bc8-c8e21a8c7467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4ec745c8-fa96-4a00-8bc8-c8e21a8c7467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_57be3407-7309-4f15-8243-1bade835776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6011adbb-c2ff-4f20-aeeb-aec500cd0a0c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_57be3407-7309-4f15-8243-1bade835776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_60af72cc-a91e-4135-80a2-c0d0c6c3e0f4" xlink:to="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_8f6c4102-9a91-4d5d-ae12-7e798748d92f" xlink:href="mrk-20200930.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_mrk_PharmaceuticalsegmentMember_8f6c4102-9a91-4d5d-ae12-7e798748d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_4b738df1-e186-4ff2-9ed1-1e261381fecc" xlink:href="mrk-20200930.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_mrk_AnimalHealthsegmentMember_4b738df1-e186-4ff2-9ed1-1e261381fecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_30a938a5-2041-4980-a3d3-1863c6011021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36d016c1-eb80-4a12-ad51-af0f0cdccd0c" xlink:to="loc_us-gaap_AllOtherSegmentsMember_30a938a5-2041-4980-a3d3-1863c6011021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c2120248-2cf8-4e5b-8705-f0822886a4bf" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86cc06c4-7419-4ce9-a4fb-10e0e1d06f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86cc06c4-7419-4ce9-a4fb-10e0e1d06f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5d975d99-20f1-4f1b-938f-e21aff2b0eec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5d975d99-20f1-4f1b-938f-e21aff2b0eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3da54ac4-d39c-4b4c-82f6-ee6a1d89d0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_InterestExpense_3da54ac4-d39c-4b4c-82f6-ee6a1d89d0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7064dc82-a6e5-4c05-9d84-2197e916b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7064dc82-a6e5-4c05-9d84-2197e916b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8c381a12-fd51-4aa0-bf6f-77d92e721140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8c381a12-fd51-4aa0-bf6f-77d92e721140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_cbe2edaf-d971-496a-a94e-81581a7238d5" xlink:href="mrk-20200930.xsd#mrk_AmortizationOfPurchaseAccountingAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_mrk_AmortizationOfPurchaseAccountingAdjustments_cbe2edaf-d971-496a-a94e-81581a7238d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_213c3007-bde5-4f89-97cf-dbde77c16e20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_us-gaap_RestructuringCharges_213c3007-bde5-4f89-97cf-dbde77c16e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_4b1c092a-ff8f-44b2-97f5-f6112cabcf5c" xlink:href="mrk-20200930.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4c1455ec-ef4e-4b4c-86d8-c8d301ed2639" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_4b1c092a-ff8f-44b2-97f5-f6112cabcf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>mrk-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrk-20200930.xsd" xlink:type="simple"/>
    <context id="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50285e1c6dd24576944ec0497f734115_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.125Notesdue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i268c7fc26945402f9b563336318cd610_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2b50aa67803469bbee45c3c944121ea_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1cde861334fc459fa80a684680fc7c3f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i953cc45283754d089c0fca74403dda73_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0969664a04674af0b31c49bed8cbef6b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia308feb215e043c1ac8a269b649d7e2c_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:VelosBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia583d33831214bf4866a5542b0ff6a64_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i320a221119db4c07bc18a27ee248eb45_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ib49be4558c154020a76d8aa7b2e8040b_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8fca4df4602b4b828121637976fc9b3f_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0ae7c8f36d1429f92d0302a0bd467cc_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79f0266f7336448ca453ec3742701279_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i414ba63dcbe44cb0aabfd3725361a92d_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6780cf4bc91a4f248379b2621aca7281_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SeagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:TukysaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i735e835c710c461daa6baff4b2c9daa6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:DunboyneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0898439e84514304bb0e2daef6e908ba_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ic7d789d97e6442d686b9da78d5403190_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i5c4f7a3740f64b7abcdfd5b44d05ccef_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SentinelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i414e40bb67fd4c20b343d703df377db1_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic43ede995e004eca8e478b1619a43970_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie31320a95b2645eeaad75930b67cd813_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8a2237c4c6b34455a09bda4fbaa26b43_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c438f84c119401f80abdd10e94d725d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ThemisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:IAVIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i81e81ff682db48488ca54b8292137c0f_D20200116-20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-16</startDate>
            <endDate>2020-01-16</endDate>
        </period>
    </context>
    <context id="id17fd71a693f4aabb61654a6f056a503_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="ia1a7e2f30fbf4abfa7df8669c678d554_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ArQuleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="i9187aade515d4b17a57839461a710a17_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i5ae34a9825984630b66dd918d954fcfc_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i0baac3ebe43444669dc909ad981c9377_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:CommercialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i5659ac2efe6a47eebd65404c8699603d_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i84fda59fee3946e2ab4d84541f28495e_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:PelotonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="iea36cb2c86ec4304acd066b3b746ee37_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i4c6ddf69451d477ab002e15190237eae_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="iaca125e93e984f7b91c7a53947611a63_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="i1f9c5cc14b4a4bd59f6fd4bca8f78bcb_D20190401-20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="icd675ee00e0c4fdda383d5adb62f0478_I20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:AntelliqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="i074bf99e14004c60960bce1f01d121b3_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ic574c26e06ba4bc7a5089ddc4873458d_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrk:ImmuneDesignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="id8dd786e26d1477aa8bd45ad2b6f3c5e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i96b4efb9755a49cfbb3e9ad58fc1264f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if0cbbe2696d440b882b0f472d8d42ccd_D20170801-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36b53eb43aee4f21bc681f524ea62b7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i20b40407b64e47609c2aa82a3959404e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i65572a08fd174295982fa8fbf05e5d45_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if4fc5d236d7843638ab3281a103c93b7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iee9da70429aa4ac0ba5c6fc6bbe4b20c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i39a12f6da7654fefa46f0e8502eba97b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4306e1310aea4c4e8219428ac7a74614_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26a49639fd9e44fc80d9d728cf4248ad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0af7869909e242429c04502cbac1701d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib89e4869799c4eddbb76087e4856f6e1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffbf0955eb8b4c4d98918582883b0e4a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id6d48c63441f485a81bc70510125df4a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idcc67ca1d79b4a9d9c65fbadafe2ed03_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id8682bf21cbf4722b662136970328362_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8418200bd3474a8989d1feeaac0927f6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8baff54113d34962926404de668611aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b54f758421c483abea6109fc48d1294_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i672e14c8326e49119792c5a739d15560_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idff28471372f43c4aeca73d2b047bf8a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i08e7fffaaeaa473495ffacd2ac50867f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id915e0532c914695b005384447c665a1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98a1dd31df764266bc67364b6f1a7916_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3121da41fc0647a98833a789f5fdd4ec_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6fe6accc36045aca588c404c0b2cd07_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic40f44394c1e4c1bac21ea2a06244edd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d8f3b8efe9043f9aacc552835d92b46_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea90d2039c7141dca1496ccaa589ecc1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i203c7a3ab0ea46d4a6dc810ea5880354_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i452c7b783504434287bc42a63fca472f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if4812ae09bfa4ee1a36daa5fabe59052_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97f1dbf8ba2e4ace97a8ff751592fe5d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0dc77ff7d3d2418fa16f24a6c043ef75_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i09080dd93c834c57b9ebff1a5663ec83_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i09aa6a0b51c94fd996e7402de95de2be_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if30c830280f947a689d5b271c94dc69a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i93a278d539314213bd6e5766dd997779_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i355c8a370ea34624aebfc74a71246fae_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i5ef5983f652b4f678745213cc80d39a2_D20180301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia70a1af19330475d88753e88f14c38c2_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8da39f245c784880b54370510f8d89b1_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icba8f4a74d444bcd8400c0863cd3c92b_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if9f4566b3c6f4506b767bc5d2b892db8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if5f82b5879934498baf8420915f61a2a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if3fbe331c8084a23bccb932806d23825_D20180401-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5002ac2a1b5410cb178591c19cc6f15_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i245fd78ff94042f9bc0ed66ef072aafd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d59f0ea051148e99f9ddbfbb6a91314_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0f502109a8d408591929847e1ec04c1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia08506df034040a0a6bc566e66e0b025_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ff8630eade846b29dfa54f515c419a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i34ce8a9c45264255b55253efdffbee5a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cd5ed28ae9c4290ae150fb16d9466fd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i05babc5db48d458d8839840a56d0a9c1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d38eaf8021744fe8f4dfab94a5015fa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie29d30b68df740dfbc20eaab83dc5e38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e7336913b5b4a20a439157fdc51f46f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifc67bccad40d470c9949756b7eb748bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb427d5a13434a21a6ed491a4dd0e763_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic9bee3c7f7024b5281e40456c78625e3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82ff54672a98446994645788d1f59463_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida9b2e380dc5459f818bd1f423bdd1c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i23ab39e6826f45b7a3da069eaebd2a39_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i734edac95cf34e8d8c5aa9e71b9f85ea_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f3d3057a1b74664bfffcee79d494ca8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i47f27f8096b5447d8aa97005ecfa5902_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3debc0d591324b7ea043d28f9093108a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3240881da60142e5953a1ec3857fb0d4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia949281fca194d51bc2b1de185ec698d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4715d086fff4408be90ea9d32249068_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i84ce31a9d972414f87e8b9b510ffd15f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f3cda8bb28a46d5bcadf58cfcbba40b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id9bdb7de8f0e4a9593cf268c8664a7ab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idedcac7eb55940d8bf55d7f495fee349_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i08b439500c8b4e4db9be5c2fef7ba050_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i43c3eb857ced458dafba143b0afe517e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i496aa343ecfe4651b28bd840131d00b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16c74758a3e84c32b5a4934acd2a2e76_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3150bde02fd14893b33da1eeac0249de_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8461e98ecef64dbebc07597db5b84152_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id073b72dfd8d4b199dcc27df47315e69_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a955d765ba34e32bc493ef244feee8f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1082a8df5454aa3ad070d4a15057c2b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5e2f7775e904a7b98b34ad10b77040a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i991fd53b18024cf78c8d36aca923947e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if9ea86431ecd4511a44c25d8a18f135f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfdc92bf6c724ec79c32415e7d58a9c8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1b86f1b1c991406c8b65e857fd90f944_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieaef7e6bfd9d488cb6176aec4c7b915e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia602b90ebc2445e0b159157c4045d0a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i416b15a8a7a9405fa9afdca4905b3480_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b2305d63e914c5a801615d0a836fd82_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e55f5c070a64f55b6535d792904a04d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03df5735331c425896e06f66d7b5f298_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5366f568814c48f7b7b07bc4f56ba7d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8e35b84854a44c8979089fcdc6b2904_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60ef15a431a448c983ceb5183ff67376_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf78bc89101f49d49da83f8937116a1c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica4a5bb3156148598a1e1f9ae18ef04f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe562f89249d4b43afbae31ab4ce846c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e10375bb6d64e70929401d584732bef_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6fecd12fd431414ab4ca6f2ad011b352_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i690cdcbbd385411cbf1ba1c4cd5fdb4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb0c8a5aab924e72ab1c5b49254dc12d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaed7648249e34fcc824408b9de77708f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib983a94ca97d45f787f3cb16f067a659_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i195c75449a61434aa05bc8da3256a067_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08999a59917842e88f521971cba054c2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3bebe903b23d4dcbba8ed1365bd1e791_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc3ad757a3474d31b0358ffd8bcf1d49_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf9d1ae3982047b5add76445bf5210fc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia027800bf45f44df94cb3963582a6506_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i070cc173e6a448f3a98d517737a45927_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55afe91875264dccbe9dfa4dc20872fa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae06c8a7ac2342d19a9a90933b904d07_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib375dc6a1ba24c1881cabe25f15d7706_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i45d0d80e338f41339faf6f80cc02c591_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i991711e49c2d4dd69b0c61a892af6fbe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a8018c802ee402783f4d35dc51c8a4b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17880d14005f4047b6465ac23055841e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b8c757f331f461eab0d5987f837a626_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i900f54b60fd94491a712d08a359324a3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13e78a92e49843fbb9317beadc1eba25_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea5d2c7cc4af4df5910fd6327736a5b6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54e8aaa546894b88aacd797ac4581098_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82edc63f8c3749d78bc298cec6f0f96d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f385b2ccdba4576aedf43c72125dbbf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39ee7a7c59a64fea97d7f02763d319bc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac6098e7148348ea895e9410942d889e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia11d46afe5bb4d4dbe9c00eaac1c3492_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i472cfcc469764447a0758f2c876c9790_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3e3c8924793a4372a8741bdcfca35bf5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id249057c9eac47108ca7d3ebbb591f6f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5ae315aed51b4ef5ab252fc43e7d39c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3ad00d781aca4014ad7705b32c5aab4c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2eda964c1d12432095177f2a403fe8bd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee2cc47f55874d4da7e7cb748a8de516_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice5ff6ca1aa444b5b1aca886da4f6507_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib88c550ca65b41a2a95b1c07df1dfee2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae5f714e7bf04709ab68bb6d0c04368c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i57b2c9576daf42aaa97debb74c377ea1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4115454e07d24a8e9ac482d5f838c14d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5971c370c69444c08c083e89b5e5cd63_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i46aa77d775fd4917ac86fb7ae4074f65_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iabf0c00a539540ffb0ff76746fc77f47_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i461e55ad36644dcd801b1bc34ca7c5f5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i527fd9fd337149e19c3b0dcd8fab028a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9575da987aca4e06b7d8e7d64abdb71f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i403aaeb86ea846378114a6861f297986_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd6a58d8069f4937a5073e16850b6b61_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie2f29939fb6a4adc8144a86a1f1fa0a4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i925511a1d07c420bb943ffad4efc7f06_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6a15758d4a2849bb9a55611f14fff157_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i78ce36018a4a4b87beac4699cee74ff0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i54180e23c792425c947ae0b2a21aed19_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i23df0efd04e04b098e88861100d3586f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa78a4b6d7eb4b8cb4b91c89c4da9930_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37617f3467a144fb952951327ab34f7e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f1dbaeb50ad4a1eac4d94e2a65c9d04_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i839190f80323464f9bf5f1c57c708e99_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0622c35f09b249ecb7e04d44c43f9a29_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id39f12905a33428bb5c546d1a6abec0d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie882429bc0d748c8a0b03fb32a34139c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i34a1493f82274c09859007cd79eacd11_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i600eb20f2b2d4307b840f143cdefa814_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i09cb0595ddce45a290d0d525d2a81f01_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iba0a355198574cf8a0944647df846e14_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i051031ffd19a4ba6b66f4482f9b16121_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8cbdc10b57a2408d87748c99f6cc8658_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a928a5e815d4cabb958c8a84b7958ae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic8c0393b19a348d7aa690741b65c628e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i309613a945a243f8881020b1a11c44c6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia319b8cd1cf240fc8cf6a6cf572ed109_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i082ff741b7854aa59ffd11f6af0439fa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3cffc90ec6148909d3599ea1d9df327_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b807ee322bd4ee9958bad75b8677e25_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7fa29d8b186047fc9548a924b7455a42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice720ee19510470cb2be22bfa752c7b3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8d2767b71a8465d8afd845a2deff157_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48bafb9af91b4c66810b2658a0fb8100_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief51f272bb714d06bb4d146033290b24_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie9862822be464d7590cac38e8a733045_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie877415544764c93a0e92480717fd720_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1ac34bac82349ec87abc769df473091_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i102e8398b68443efb7c670be371e221d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7f7ee9e6e6f4549b1c06a6e2ee15ae2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8db34a980b2470aaaff3a2d9dc09883_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i174087d9f6454aebb32d8415fd4b71d8_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.85NotesDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ibd638b943ba14bbaa99c094906c46496_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A3.875NotesDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia515ed5a6863469596b5d8b9a986ea6f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib089735791f34e7e946205004d6a744f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1cd8cd4de38943e2b14074d9417f6715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7ef73b3681a741db8a0d3055eb532b01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtExcludingCurrentMaturitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if78266c2751d45698fdfe199e03b129d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id1023089c2c54a80a18259c1511f87c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa826dff4de743c7acb6d521bd66ea9f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i63ec13cee627454ebf66f0d6ed39894a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21967f622cdb45cebad35ad052ece1de_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i08b48c75e8014c2382f84a5d33f0efe2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i66d507c1385a4984b104b15b14ad0b87_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibebb8d0e743c4bc3aef276f00d195299_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i62d19d97eade44b698ef4d90c18cfb52_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3cb0bacacaba494588fdc16bec7aad2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a28e0e89eaa4a0381eb181749135076_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i56b722555bf44b6282741eb433c205bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c4627226ed34963af481b31b209e7d1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i01c1b766e702403daadda490393c9ef9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4207f99483f4b8f940795c3f462096f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i77b4c081c7234c27a717225ff5066862_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i009ad414b39545bcb9714e42490d7cfe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f62a4056afb402185c1fd095207abdb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5b237fa0466c445994cb3f605edb9744_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf0afe3813f94b848a3beb92819435d7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf7c81a6717548f3a8cb066f1d5113f1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i68ba62239ca44acebbb3f35490c6701e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd3ca1373fb24ba68251d0301a10a20d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1ea9d32cf204b73801d5f9d1325e43e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8a5e4820eed4496988270e13e3b094d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib552830a5da14067a97f6a37503c4784_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e7e123c95db456a843cb9b4ea2ee304_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie6199f48889a49748506a4b635c3bb86_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieae423a542494b8d9adff25f3bf634fd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34c5e6efb1434480a3a0aac64deb74fc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2fd5010fab09451c946ea37d93a410e6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e626082878b47229b64aad4223936be_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i84727b70c6dd4761b253ea527ddd0887_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i812ca05ea4394a4dac627795b29c49aa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5e39e07079d24f1d97851dd0941257a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0874acdea1b94c23a104b3d79fa7bc54_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i924cd3c5889b4fa5a227f02451269580_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa5f04d36a4044a793fc61d278bd3322_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i46bd265492f54f4c8caf95f9c471e390_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6804bab188cb4e53b4fdd152aab4cfbf_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:TreasuryLockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9334afd80f1c4e62b06c088ba45904e4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if9bcef7dcc6d49e88feb6e96d724788d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfcc3a06092c43dba855fc359441f405_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifca8bb4bb8164a2a8869dee454cc4519_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i49af6e85df0d44aab61037549d8b7ec7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie85db4eee737467d84fa784c0406b915_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f31c0e3c79745898f6a563992c13494_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c141fe83ea54eb294e21e30b6d5921d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f79830cca114e6ba2294c2eb4be7851_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36602f32e5a74d8a81439836a90cda02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ed394545474492aa72d62f2775bca14_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8b74dc13822409f9caf279f6c6efb79_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0910059a35fa4db3a4f1688038846dcd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8bcc86aa77164a2c9e420f79d5512eab_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i460148134f8548f3b116acd07b6f4262_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1c548bb51d534758a5b6a6644bb57312_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f28d45aab574360b168ce04f39ca7e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifffe4cec0a0a437daa7a6c75edf5f759_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8ab343a960448718c962d4ff1664ca7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50cee26c0cb24582a4fa7a23dab93ff8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0b962ca0878246aea2caaba1e5068597_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i12865349bba54bec9a0bc339687682cd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f9c2404403b4dd19bf073d3fc40b18e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i084046817ad547f0bf33554533117419_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3126ac40e55147ecad0cf2d7e7171a71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie381b020bc2d4cf48eefd6af3e63740a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0edd3a5e5dbd40979d86029cf03f258d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id993747e094b4fd79654920246348cca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99eaa11a9d134c84aa9cfca643e17d0b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4d4c8e65bbc04387a96c107b13853bc9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i809e8cb34704419bbc81bc11c64fce2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8bfd28bc6e0f42aaa81be96e54b6f594_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia932f1a4fb0744bc9993e55668e12ee7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic21417c5ce10444faed848f53271d30e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26f12d40a4894778869023a3c016eeb5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied7a998c6b5342efb1a584d95ce95eda_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i084814a830464e63ba5b40197d05e746_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7a334d2c7f7f4c7ba7103637d1ec075c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8349cad8fb23464c808e9dda6e139864_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6faceee075314917b67b95d162851967_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1addd4cf0a714a1bb6df0443bd656292_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2ab410ffa984d74b8491ca6135d2f49_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4220ee3541742be9a6a5b1189b6144f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4608091360a94197892bd6a3625a1eaf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i295721b3731942a08da7676215878345_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id54942bdb7d14f95b3cee4e66d8055b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1949445e84e744f29823c34223e1e913_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia7932b106c7448daa2a3a55d1da0adfd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i729ae19583c44de3bea4894565e3326e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9b2c6ae9105493882fd7968a705b503_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c3a6c594db44074808bec17ed6ec8b9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6bd21a1a7d51489a86f20b38a1d20755_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2583cf01e284ddcb2320ca55728a506_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if7816629b0334d2aa6b53dc07c4e8faf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc955b1af87545599fdfcd8990fdedbd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia58a28f0d346460685afcc652227a9c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a1cbc1130ff48c682a122fa35090632_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if9929f95c47e484fa82d3e06b0f0c945_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i349b9790bbe54e36b0de77f50529bd5b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if9014bc2ec9f4abeafcff803b0a03584_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i096da5da4b9648cbb2c2a7e18c11065c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i80ad7583f26b437581d137910e409b27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i727ab934d22c4cfcbcec767507b45eeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1755cafcd4254c2e8aeb93f416956e53_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i67e30aabe97d4272be3e7e97eeff7de4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i827bb071fabb4cd1816ed87eba65624d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f5a8e02f1b1415090e676b983a40e37_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i534176133b5e46268b75e8ee4783ef0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2257904af3c45abbfbf463b398101d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i675ac0a159cc4cc691060e09552724bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfdd387cfc074b9f95912bc5b38d09b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f98a00d9cb1469381ff2b85052e050d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id735af80d7e943a7b6cbff2ff9825cca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i554c0786877949ee8178f77e6daab0f3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie26963a2ac324ba4a14e6c9468186690_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iea2c0faf9f814cdca31718d64e210291_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9553bd5ca6744da1b5727a32a9c9263b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8904871bd9ff4926abbade9d25474108_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5cb5301d76a4873b15a1335479d3c2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e635dc42c1b49bb99f084c0f6584807_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i91862fa2efc447e29c59e61b626857ed_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i81090f7e16204c969f9a89fd1d33cc95_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5599e985c1df48b8af48f1564e7b9e6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2df4c3c188454c12a12d6adf310f9ac9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie262f30b95734e43832d8a9407f94eb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43f22f3a8e434723aa4c8e677adcb774_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i82319f76c8e24d55ad16cfbcb26dd55b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie1b391a9730b4cf68a103be0f154b323_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i92ed48ae16f7483ab2c12115e9b3b1f8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic318e672eaab447c8135df89f679f16b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i26fad08fdba44d0b82362dc57e0d7f8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b6898b1302e46f2b14f135b0cf9ad8f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7943709a46a24d76a5bb3f5bcdd1ef43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForwardContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc02a58f23874914ab829313aab4a522_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i77b04eea3e5b4a1b849d4967371f9b86_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie7573baa67fd4165af6f52acfff81eb1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e96a20a877543ee9ce8338ad2ef622f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i59cb59c697544159a4a94b077d73ed46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifcb4503c9509423bbee8e6c29bd5e78e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bf8d0cc1ac8422fb6018bd01c7ffaa6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57f17a0fdf894d27bdd29405d396934e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe06cede262f48698bafa7ad43037553_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c1a6f29c939482d8e9f901e3e75b9db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20dc5a545bbb43b5b42188e27def9036_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i575af78c5c07443093cc857d1c99b8ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7f10c43e33c64fccbb6f541ca846b3ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15622ac81bf64b6d8a631c6e28692012_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i95e09f3059bd4468a374ad7a474b31ec_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica983717d6fb4ff095964b0c590cae02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib6fe871055ff4f2c8a6464ebc3c894da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie31e25b750ad407bbfe538ce6e4d1eba_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfc8aed4c32f4ba9bb8680a335959dec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice5e55028bcf49d98bb89ed4e93e01ae_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SivextroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i41f558a03fc74d9786822fef7d1da9ac_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia564edcd14034ec790ba4a71ee6a8622_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A0.75notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic940ded1777647d7b1ecbaaef52763f0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A1.45notesdue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i111bb73a24814a3c8fff74bfc915fedd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35notesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i037b1090dc53410598ac31bbb1af0ed8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.45notesdue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2c65f9d30293433985417442b5f323df_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iab048735a64c498682a6136168824f23_D20140301-20140331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-03-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="i17584faa284b4b578d5ddb79fabaf164_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa614806e2ba4145bc4bcb5eccb090e5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:NewJerseyStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i41c548a060bf47df90e49186c4d38865_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:CaliforniaStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i17f4cd39dcfa47ef9b2f783ce64bf95a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0c76a997e6b436ba14ab8377850ad0d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8ed7a5d6344d40cb8f2f177240990f6b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i954b3ee345d542df871f572d67e9eb31_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i42fde4910e9b464480e8f2e6cbb3d025_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6549f2bd3da3405297ab00a3e9493624_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5e3c82a44a84c4d9e95b408e7440546_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie3bda94820614e02831a1a380b925d56_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i76ba186142fb49e1be6e39777874b85e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie94d9d12af0d4d57bd9f39eda31326c2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8b1ea5618fc74137a1dd7d0a99fdc553_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i661be48d847543a8a32ba2358107f61c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i2f65949371d5466d8d9c0005d5ea3e86_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i05f6eb6801e94b6aa490cf8461ca344d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i83b341ae138f41489d101f0152d09d24_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i20ac31ed97124e86a01cbe0bb15a0082_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6fddb49b39a14e4c87423206f85f6bee_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia61d77e3b21045fc893756b66fd2684b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i206b5fb493434864b42f3461b9ec4325_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i532639a15db54349b73094a5ac53f994_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0577848ca68a405a9fd06758b4987ebe_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia3eaa864f094450daf59663572c42e5f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i58eff3e8192a44b392d66978e46f4f8e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i729eb54219b048ff818ad6a1ac398d7c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ida404da98be84835bb1bca80aa637c1e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib55a6686f5d84014aaa7f5e1f1a99b12_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie36f2245e6244cac86b52c10ca135b22_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2024d90064f04b119d58d93d92e8236d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f7b18662e9547c19e8db82d3b49ad03_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i68eb834fd2ba4689a131fc785fe1664a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2dbce2023d24bf7b14295815dc63340_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i24296881407c49c4b8c78ad66fa3ad49_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1515e466edac46189d255abcb1355fd9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4b0d790716bd451a9a48dc70ee90327e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2aadea4a29ba4b14bb25f94d3779239f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i242db40746324acea9058b979850563c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifda54616745e475d9c94ff06081355b2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45834c2505094eeeb4eda66b2b373ec9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa8db1c4585543f3813c30fd6dae8d64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6df4e6fd9a51492ca873f16e901201f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice9dc335efad486f8e04c605de2f04aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28d6e7a2db2f477998a358afa23a3447_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8adcb6d851f94dc3a3fdea895e2d7460_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib13c6933c3674a5181dbe15e12aaee8c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7179c9a592ed4b02a3c776ff0dd331b9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iac567bcc7ca2418f86edba65970f34af_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if9ad3599c3a84146ad4a9b8040fa9260_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i69fee893e6cb48f090068514eaf1dca8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id990f16dcd334b06840813dd8a39b138_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b089353a48f43fbaced08dd69103993_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb29bc6824544a9092c890ad56549217_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c25fddd196848148931730be86e9b3b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaa3ff69e58674e75915bf501c2c193e4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:HealthcareServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9db841c072d54fa6888133ec10cf2cc4_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6591fbc20c114de39653e3b19a29f103_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id1a6af2de3ce4f4a8efd8359eaeeb7bd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9c230d35c63044149c73c8bb256576c8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ibc822dde06b54f21808c01d97156591e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c779292425f4b18beae2abca895aff5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02201bf8615043028576af77f1b90ca3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e8f30eb9789429a962564babf142645_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i16aedbdec871407ea66e24efd83da330_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1878ab8ba71c4e20a87cd62012ad996e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie7ebcbbb713742d698719f2cb0caa991_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i25f69cc39ada42e0b2aac3d80fa1092e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id791a906551f4c699ba3f0a28a87d3ae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i93df020249f849fca4ee19c9749a68c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifec46d9b67b440a8843d54b6ee61db1a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i105d158e3f10426186dd470f87d1581d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i065889e51dbb442688e6ff3173a1e969_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8cf5449d143444ea99ebf110cf6c87e2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i454ba9cd9d334299a099d995c578d97c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia333381aeda74595900b302e6c11c47a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia99ed860505e4c2a85a20cf2fdc2edef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic97b428654714aed9ddab64e466a889f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i20d4c840c395453fa62ce23262d48529_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ed1325b520746ccbe6a911296faf7db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a46df96ea1b4b7db6f00fbe6c57fae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i217cd2a0efd84c7a9c2ef838da08a751_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31769e108011463f815d560721783429_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i734875f415f6427894327094cfdf75b7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i306fdc3327c343139058a1e912ec7a34_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e1a45620d5740ef84279eefcdd52471_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b41de768cca43ae86a2b620ab7fd37a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf926c3546c74014b7e2f8860b5e44c2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i63f0231c8a1941c9a7f095b2dae733ac_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i317ddaf4b00343c591e8949ca7d910a4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3eff4fa2263b449ba4ad1953be6ba8f5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i547f0c973ddf4d25a0edb9aa55b1c990_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic8c49eca89b64ce683fdef4e64585ef6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib22b6772278549d3a7dc5725de45a549_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3906b3ace9b64befaf73a1adc407ae5b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iccc25861951e409b9bcaedf62ff4b291_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if94fd4d2613b4279b09a4b269c9fa2e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1958e912e6ac404ab8549a9c645d5cc6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2a4c78ade6e465c8ac9352f2745678f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ea751a267ca49428fd752d3d82441bc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7dc329ef53f6466f8fd7202d74ce0a3c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7327daaa39b444129ac7963593aaf968_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i93971dcba04a4a31bdce5505e25d2fe7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcfca5975a1840b695feea389585ff70_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib56ff7b0e8a54c8a8d4dfa5d57d82641_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ec9add45dc0469788010c549ccbdb76_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia51ef3c4eb03413ab36423e2fd771da8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf99264c8dcb454ea5e90380b2400b9e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2ca7a266855d4254a95f8178169a039e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2dc9b994e7da4fd19c71b16dd69ea18f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8717ca08a9d4379806fdd058d2feee8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i733c87bbcdae43878560a4ef5bdac803_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i23398778be554bbf9ea4cac06d6173a0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibe040aeeb11e449b8c5c18407e83aa44_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie1453f6542194317be39084f21e53aed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icef3169c86e54fc5ae677a048dc4eb96_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a6829456a78436f98f59cc9fc651fee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i553c60428afd4395aca8a65dc4d3d90c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i92959775580548159c5b7ea24a92ea98_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if56024565ddb4465ab8bf341e3dd84c4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ddf16367e464e79a9f9c63e9ab32ce1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00ecfc38e80742e18efb7ff88f14c004_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78f067784d5e422c8ab4af07a2f8bcb9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i172b683fbef54b37a292f3dfae49f813_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c3c6f85819c4714b9885f8013fa08b1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i393c1adee8e84595bfe0acc21bf97c3d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia217fa4e279b4536b6b3f04c7fe81688_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c0887d9184c47dfac2ce9c7bf039dec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5359f26b034c4f8b839c6f0b2177c80a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife80c9a9053e41bca34e6b7e6d9d4efa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9223587952c44aa0931adbd426c4f5e9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i82e280b6f3ee4222b4211f6c6344e7ce_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:EmendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea870736ba5b42dd970e1c2e8cecd0a2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67048c78dc0b441b984b5eb1a80d4918_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i708250723a2049d9b4354763f848521b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i979e50a4991d42aabb587279a1630515_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i87fdab53c5ca4fc7afb34303af488fe7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icefe099ec9f9447d89313fe5d966d097_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i686f3ec310f8431aa70f7a29632549dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39a7371dce5a4c7381c1ee54f2af4bba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66daa9001fc14740a44d38a81090f3aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icce3f31aab04474a85482e57d7fe3b96_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i414cc671cdbd4152bd1583dc67a4d839_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i59138a1df4c34c0b8f31017c314ed9f4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3925c7ab1c44ef58b807944198fc32e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i862f90ba138c4b01a609bfaec7fe9442_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7bf560762c004da7ab56bb4c5d6f3276_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44944b71a8804ac88c5e1188334b304d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icac08e29232648c58d4d3e2b32573921_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70e8855545fd4a67b2906f59348cf1cf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c793f46d7434d639f4b9af5a81dda9a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifae37299fa8e429c88f31b01349409ac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44abdfd9ef2340be84e53509a2ad1217_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if38bc46dc41e4806b8a366f7c6a66444_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i844c2dd9fe0b4d59b864cfc9dbeac1fd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0aaf14c7fbad4e81b02ee7ede86f6740_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifb1757a74efe45beab35e7c434a837d1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb7e9b25563d433abdc2de1fcc1cf790_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62b874688aab4e3691b20bcb3c5dbeba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33106e55798a48b699ea798ff3d9c2c9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcb60f686f644588a89cc8c7b689dd91_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic8b7cc10d3a44053975f929842e5c6f4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i03d7485ea0d844afb437a33a9c0c373b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3468a4ec91e4e0299f5e9d0627e20c0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia14d6de6abd24d9487ccef62b379ddb5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63f20dcd0d3d4ee4add22bc0f3b7b2b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c865283192843a8b5c2910e9b0530bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i13e9b7bed9404b7fb7a2473c47829169_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i67e3e6fb55fb4477bd2e4344ba69226f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i29681f0938a8432486e7449f7854b7b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc1cba7975734d45833cda2fa2563bd7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0f730dabc2740699bd827d675b983b2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i27eb3d476c694f68abd9f5e5db26dcde_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i66c2064d607f4f06b74136bd86690a51_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i178d9b4b6cf34d169a02c96fa38dbaac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i235ae291edd64816acba0905d28cc37c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71afa28afc2b4c3bbe764e1563f8598f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d9440d8597143a1b91e48f43b4b0bd4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia3da5777cebc48a1ab0eb78234e6c524_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6a0f69efec34219b126a5a5473b1670_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c189c6b947a49aa97d6dce2f79c6151_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4345b97e7f84437e9ba2ed7305654d4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4db3706ed6884db480687fa6df343826_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82f4b0c199f44ad6bda16bdc1c99307b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98ae2ba3b636440dbf51084099ea4e14_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50b04d71a9794cad9297feb729f927f0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id7ef7e87f1f6403786c8243b16effa57_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3da6673eab644f5ac8940187a307ab9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2737dd0c1b8c4fd6be8f3eb432e38a55_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea5abdf92066496d90d2e3ed8f83f10c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf624a2fc58f4b8db74dc7ff1193332a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i694a4dfc7d4f41fc9459a5328750c279_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieb6e1314672d458c80a6ea2181ccfefa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5204d5450def457b9bddb35e60c60d82_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d941127ebee46c6b3ca083a457c564a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i367f009328af4f81970cfce2c888d476_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2772e763e8334f6a84b55704b593c8a1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0b806fa3c4004464a6b42dc860d39e09_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3ac62401b132462a9e7d3e00f737696c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie80b7f42ff4d40feb2b2ffee0f6914df_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i72fdde8bfc914ac389b6d2024c9b1b2f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i351299226c1643e7ba68239fe2ba57a1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8aee6fbf35747b39ce2ad1ed1d54893_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icec21e115e3a40838a098aa0894c0609_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i417799794c1e4e23ae2b7e19043fcc61_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31a7bde573a847948f09da2562a0a446_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74d9612c858e4a19b3a9c1ecc6f502a9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia84a9822d9b040e1876a2c6879d001aa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73623d962db34390a9676bda7471397c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd9ef0920dbc496fbc1ef7fff281f68c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i59a9379092fd4fa5b67eb0c0899dc62d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc60755989b24bf88af02e4825aa9c3e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib8062908fcb748948fa4b9408f90ea88_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i341ee46b776246b09ef1d6d67599e9e2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i47edc2dbd975482da465c5ac979419dd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i19e6a07eb2aa4e858f46dbb14ef8ced6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94548af382c74ea191084b248c9f2fa2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62d18847d0eb4080984a7f92642b9c3f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8dca799bf08b420b80463a36fb534945_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a1bc6f405f84099ab6dfd1b166d4a30_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i702d3186e41442f7a78d814e62d3bd65_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9a9f2da00d04e34a495294f13d301e8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie33c89ea2353410a992159fd79ba7b27_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7537a2642ad14cc1b29e3fc7e39efdd1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i708c24fc9863489497166c927cd80e26_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic5ac91c09eb64ca48bdfe2203abf90da_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i49b4250d2788459e8b5e2a862644234c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia61152773c82437db2127adab1053a23_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie1d1e6a2e75a4c8eaff7e19133a84fe5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie2671e945dfd43ed804f379d6b30ac92_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ac2ca8f7efa4e3e8df4117cad2b06ed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87fbe25f948d434ea8c2d71514c905b2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idba671a135e142189f057be3fd5355bd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if7426bb60d684ecc97eb4c32ab073460_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib178b02bf26e48b68748d2a55b2657c7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77e7d2bc3a714126b66d4718cfa4a689_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39019f71db724d0388921c330404ac9d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if399ecbab7c147ff8c533bd49e5029dc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa9c994a82754ec3bb4d67db85d4338a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i279d66dabd8340e4afb06b61ff1106da_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae82259b4751461ca0624752a35bce09_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib77110243471455e93528fb60c32e34a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63b27d7fd3224ed7a7515432a72d21c5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad3d9fbef4a14ad188dd6c702f303d81_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icd56b11ec30f439db004563892878a44_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7574915e7f9f45adb507296bad2d8acf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i68c4b2e42e50440983fdf402f1a3318b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6f0d8c1ce2404f1eb1853fea7819c9a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48a812f083634c0c918b8e40ac83a158_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c7a2fc3636d4744a1e68680dd160a7d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ieaf89995052242baaefbffc9a6c3d93f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9f03323d756c4aaebedf7365c0c5f115_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb6f397f156d434ba8c705812199c7b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b09565c92894fccad03d9a3f77269e3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i776d8cffb24042c6bb2c4c3d914dff0a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i143736d83dd84805ba380c77aff27679_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i427aaa6059414501938b90f49d23d83f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia54c2cf432c2492e881936280bb904f8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if7f165c4787b42588723ff48d0b6cf98_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7e895a82c3e4ef3852770005b410b0b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06056e3d1fdd450fbaea2f8910ecf385_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13ee3bcbe2894ccdb9103ea6acf2dc54_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaf3c12dc7fb64612938cc2e9c4345cca_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i953896ac43dd4a4492bb05e6f55f1f63_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iebc471aad3c94e04a06f0fee9bd88cf3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d2dc4f551874bdea08cc8b480c809b3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifbf3e6bdecc74c8db16756ad0211654b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea020ccf4a554e1b82196c6dd3816009_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i81eb3b266055401489cbcc9e71b1b590_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1eaeca1be734efd9e7311afed56e4fd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia5a53f2d7fad41e399de72c840dc300a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id54a4864f2fc40e2af2de994c8aa8ab5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10c982e709794dd68acadc44141524cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33aa602ccb9e44e7a7efcad8055fafa2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id881511a6cc84e72acb24c070e6797f5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3880d04cc6c346cbbb1fbaec73165ce3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iabe91553b040477b9005ed581ecac9d9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff55a2b1e45f483b908fa739760c0534_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6b5e5f802c454eb59aeab6da3df4da1d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id827b82628ce40ed984d4a930de9a590_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ideb446c3d46c4a828db42c890a42b26e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4bebfe0a869441d786bd3a8fd4c62b20_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i361cbe5c451845abb30a9a8f4f2e6455_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1e8ccd8cde3495f9af0b571d95d1d00_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb936fd1c99f4c35801a4495e91bec73_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i76fe9b60ce0f449a99363f745dca6e96_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1acb4cddc5604c7eb880aaa49a3e16f6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i17701907ca0e47ba8fd1a971d48c2457_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73faba95052145acb3c26e84d3a4b602_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie736913c7dc4408abb11d1fbef1ce474_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec058f1ae0fc472090afafbd68d47461_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i989cab976f6448758df4479ff64c1fc5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i261c4ce6a02a4800a83a51be1c99da21_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2bf9eb755fc44eafa35a8b13e484061d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52ba00bb057b41f5a6855415133e2535_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia73eb6d53bbd4f5ba331d317ac2a8489_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac01653e21d0445aa0eee236c7ba741f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5d4102e12044f109f6a5e7816007905_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i242aa19f5d014d05a2d3f4cd08cd39ba_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36ff90a270f74713b7bcc28d52341906_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5a7c01c0be3e49b5915a0dac164db1e4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7972da26546c42ac99a76ed6a9fd9ec2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bb7005b439e4d31aef9325c0babf90e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i993dd102bdca4431a2a35bc582ce9394_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3485a40e14d749c98847179c09c2bf32_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4acb7f674c0e47aa9e58edfff2e3dbb9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2cf0a90d670947f2be36e5211d88cb00_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a7f87c772bb46ba90ef0bd0821eca8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04909af50dc845da9f9a8569bcf5eccb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia26152f7f7b440fbb4cb9d200d2e7f77_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0931102ba1674080bf90d3330f7955d1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7670dc70afcd4b09937d261583e363d3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id20fe0f50a9b4260b6c07bfa057998d1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i858538797815486f80a7414cb57358de_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87a8339ae25046d28c34fe065d7fa146_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57ff7e9937ea4f4d82b65c6fa6926786_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied1700dc6b374b3aa45edfd416e35917_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9928d769c694dc2b2adfc1fb517f81b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibe0a0fa75bd64a7b8e10d99ff43623d5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b1825f1272940bba1d0662fbbebe361_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a4523ccacdb4f7f9000657e8e4309a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57c9e9493f5641b8a375c87f2e0f240e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1e423505d49f437db0eea268f1caec94_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5b1c51d2fbf4f78a7e2768a8d38f881_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaa4fa96062de49de83a4eec95e5f1c59_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iebff762cc1db43248ab6ce27128b3ea1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie35113cc0f784ea18a9ab80c7456f72f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd0b5f18d0c94b499db52d87cb762e66_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i623c2805c097460f9a7582db63744702_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i96bb9a967fac42b0959e471029dd753d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i24b59bcf248242288925f9d29334b8a4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83851ea51a8b4f348c297fe9674a70b9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i374d9072818a4be49130b74a30fab649_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaeb66d45ea6d43f891ac8d34790f596a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4d20159069f44586beb2bd4d53b486fa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic1589f85930c4c2490dbcd2bc2471fba_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i01d2b1a5d4e445afb22b111f115751ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a2782b98a704284ac75156aa7888225_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic28c15341c614ec3ab5f080633c0f9e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7892ccc679854d0f856e0d492c1d0dc2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i454932685d7e4ec2b3f324fd851227e8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a6b957265c64b67b737a553dc147e91_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if87992e546f14efb895456eb6a74307a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i713d3719b5024faca7719a158e89109b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic9b7b30d595b4b568bf5d47c20418641_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3a2b13d213f4580ade960efd7096274_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idb922157dde34ceab969c20d2c593243_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i05e831ddc4674ba7a0e1d0b61409a910_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZepatierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c7c5a8d8197420585dca57047243f97_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i938196e4279e4040b004c3a0e20fb083_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if79705fd98c64c8e83345f5d01da64f7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1f7c0c892af4ff1a708a6271afe4da7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i93f14a0f1d8c4abb8f6a1d03da5e0eae_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iadd47e42c1944c9c8213aa8f8808165f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i04d650ce0abb457d9453531cb7e334c7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c32b81ac1784ecf9a98aba06ce43e61_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2de38a6154464d5695596fd542cd49e0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3ab7aff39d449dcb43df1642f85616e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifcbac2ba02f245f2bf19de7c0dda76b7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie9f6f5e968c5474488f0b232fe0e77e0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZetiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icdd98423d8c14073b9a11bd36db51615_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15d20ffb278846169ca7fdcd9df043c4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id028f116dd7b43eaa20b6e06ed2df1ac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50456612190942a080739275f8173a2e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib0c087cfa4f64c55b828f161589a223b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8b39be43599c4cb7bf9bd31828ef9002_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99bcb57eb48d4c5598c716226714d7a3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i05834b1651a949dc8f02f619c612749e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7da82df886634a4fa849605c59fae2bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i716c7e7fa0504751a650112eca041f5e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i318576a512024c6c81441fd12fd57fa1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8cbee4cd8d004afe9a3ad3ed1829964e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VytorinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i334447130bb944a993957aeaa20c39eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b78ab8426f34f24a032ff8f5061739f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8977d72497b74b1086d865c0aaaac8e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea630f933a7446e9a808f75d1870113b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie5c211102c3f46678a682f40f99d407a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee0d607a7351455a9f45abc4f86f952f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia279e76e54074dcaa5ac97de34e18efb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12096c3c413a49c898ae87d73a81726d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58002f53d69a46229000ce6d3360542b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14e7b9d13ce74df1b09ad0cf151c9851_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib92db4be05ab40318a94c027967ef6ad_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a231f98c7d149a490b785bad71e4496_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AtozetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id303f0dee3b74b50b4a15ee325ebafa3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie44bd2933ec84060aee7e36859962375_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i617676e5fd5247fa822d36489d37e0e4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d72700287de4fd4abc770a532f25f9c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie0c6b30dcffd403bb85af19b9d4165b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i296ad230a93245ddbc5fd02cba30cc53_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i88917ca1de89409e9f4b5b2c0fa57485_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iebfa044147144425859e25282f0ef9bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i003abe7634514241b3a8d6350da515dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i618a9be04c62409099b81b9ef1c5344d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2a2abc9a0e534088b5e0fd5437f763c4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if0be09895f8143679533f9a333f5a993_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i93521f60ff59466495549fc41c457899_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5952b34144c141cda9875d2d182b3881_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5caa54b167f3434b80a36e8e76d7c6f5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i651c70a05142434cbfb538a617b89007_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2fcc4708c8eb4156b83f9055e325dac6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i740e22d8434f4b8183f077a8a007e956_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i640d595c82ce42e7a7c0fc6c0583bf14_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i44f141f8261348bca533b4aa5e20e68f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e53e8331413497ab9874b05911c0437_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if68cf832a35a46ff8bdde3920247bd39_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1f48e3aedc24f50b0808a4b79b5dc6f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icd6b9e3b829c4249bb4c0dd15118296b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4d275d442cff4f52b27f27fd2a721187_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b693b792e3f4432bb82f7c6052c3ade_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i226ad6cf1abd49039985c8760bfc48d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2c690705a704872bb3bf8a6745a536b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i95ca2e5a714e482f8fdd4c3d12841689_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3da7b1a0beca4bd29d8c4620041e50ef_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idab88e6cb5824e4ea0470b131ece9e3d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f6c90ac04b148ab96bd8f595258f46c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9f486eea8904e70b20acef9a91c8270_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ae7aa49415340d9869b132435677a23_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idb42bbe4a18548f4a03796d68320493e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib2e9ec73128f4b998b320a2ff73af17e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c91d7cd6e084ae696ac51575ba5006a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13bbe57c7ef04ccab0073746177c2e21_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b0ecfa83ad149c5ad28f2a5c2bcba9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86aab60a014a46da930b6b4e9e51c7b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i101456f617a34e8f91f201fe318d9a1d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic39e3340b0e647debae7f510c822e44a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6009d7735cd3433f9a820af8fb018481_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0257c158246c4e4dacbd738eee948877_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ae95c10fc15484eb3969d05a0a65b4c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i047053376fd540a295e977bc6188ab36_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id09da9da15f049f18535de414de6ca38_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic9106c5caf2b40498beb6bd13c71325c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42088e2a28144cd7873c943696f37b29_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0baa103cf7c4cac90311107a935dc92_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd842388eed64b3da555ffae75b7899f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idda57adf0dc14c4d897dfd88fd256191_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c35e7bef0f74b0e9f2ad280b8c9d79a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iffe3d788155d4dcfa6d1bcf0849a7908_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf13f6a3f0b24f4692421a7f681056e2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i823b7acf4af043c7bcfc682b9ea59b03_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i250b5ff269ea46b4bd2e15044f7e9e39_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i816a6164517c4476bbb9046b7465a255_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1bdf582fe7f04b6e84f53a13fdf085fd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iabcb5052939546a08171746b38d9a959_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ImplanonNexplanonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1e1e1cd1ea5f45cb8b0d49ab5e325e7a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00ee2df0e4d24ac49cecaf2f8612ac56_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie8da3de0a1d54bb19a95bf565424fd8f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib197c58857094217ae70f45c5bba1512_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i65bf34d7c3de4b76b99865acb7b377fb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5ec190b0d42f42ba87646a7397218a62_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id87932775cd94b648c1cddd6c945029d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida18cbb39b744ce7a0792eb9db392c68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida7a1d7200fb43eaac711c3fce8929b7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5936f316e3b42a5bc7edc460c3d44d7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iec2c7223374443ddb83cddcd93f11059_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia2fc1591a9274ddf8df88b43546a8090_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e354e7391d543ed99baad3fb5dab811_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79cbc9acc32f44e2806b5ff08ab4fe23_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida4ad108871045beb3935eec15ecb68e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i564e295cbae1431ea1342d1a6aeb2d66_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia4cffe9e90bd459eaf7ef8497c5e3424_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0d690c97e9cd4f4d9c35a892caaecac6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i649cbc3cd44646e9a198d32f7491aaf6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cc84657eb0946a79cc4a2c2d53f5f7c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0c935c934b3455584cb3ada0f1e5c0b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id80cc24848e04d269a3e8ae9c377edad_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib77eee53991d46b5909d9edb93e5b74d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b7f6840d5e34b2faca6d72b25845338_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SingulairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id320e1dcac42446cbc9350d2c429f55c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0f8b81383774d52a52223b7869349aa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3b8498ad9774b9d82c1c33f73ed1085_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4d53f4525194a86a9fea6c036af1d55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0c38480569ad43bf8a8faaefe258752f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib2661c49a72f4fa4b82bfea2d5eeafcf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ba0bdb0d16143e98878115551e164fa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i33caa9debafc499f9f035c363252e664_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i70254c5658804d7db8c93d35ca1b2469_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f17b6e17a35418e8016b026c1f452a9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaaf07528158c400fb9045d2904828cdc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7c6e2064c3ec4ee7bc561d67868ea2c2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NasonexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if29c1b123d68491cbc79c7aa181a889e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba270aaa589748cd947e1be8c444099d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia59bc2566f18462695b19da2c7e8857d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14f8fcbabb864499b102a4d91eb12390_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icab058ed790442cf887ada3d278a7abe_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8878e9ea7e44254a65607e3a621ad36_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c96ed92bdc54f6dae73012eb2b0161a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib8cfb19850424c50b34394d1394866d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice8b9c2751764e1f8d74e88aaa332b62_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a3220d799974f0eb91ea6a92667c1d5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8875e8b3d4847bf905c685aef59e0b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b57a142ee3a4ce9a28e2129619938b4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ArcoxiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6fcc4f2c591d42c2a24736d2c11c3061_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i972845bfd88640bea722b70626571964_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icbe81fbfea644f74bfae5c97dafab313_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied38158acb5748a0a9a535f78ea93b3c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i631b85d3d7a44f58b74177a695ee880f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i80e80c1e64b24bea81b052f8f6a31353_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1bb093533b64c6c9ff9dafcf60f4ee1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe47ce5722b844be8d813eb70e594427_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i85247bb365e149738ac7c734ad073fcb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iccdda557d4de4ed7b963da933bc6d89c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a45b54cb929479b91a5036c365ad2d1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf194fe2ef394a6d8fb6776943995e44_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CozaarHyzaarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5cd2fbab6f9043ddb7f5562393c06341_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1930b8b6109e4cea903f59042c7e749b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifed7a671edaf49edad215de41a079a58_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75a4a0980d7e40e4be58e702f91aab82_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief202939785e4d1fbd2e37bcca814959_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iba9f4d9097a44d18897c5e28a6e2be16_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic824da0674df49ef92b0f0f79ed94902_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1ddc6db0368f41c29f507c8f2fe146ad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58d21dbdf0f84c0d8dcbb85d77cda350_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb259bf8f6774eab95195ce94daa4d29_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i60073e1f170740a18f008719f2754f25_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5bdf03e64d0c4fddbadaa8c893893a20_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:FollistimAqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b602e80983f48678ff06480b5a96fc6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i319f3974785d4167937eccdebe28675c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i636d30541f2d41c1b70a178f58cf65e9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3add7668e892473ebd440941e4e6ff61_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2b4f8e164ae7418cb04b0ea9679efe3e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iebb109d299f6434dba3b52e63f9ea583_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibfd5b2fc3a6c4e7487aa809e527b4eb1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i819e259a8f8545249f0f53c7bf645645_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id642fa8a9a20492f96aadcfe08e8c96b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99a0a14797f94d938261561386085f3e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5e0134b6331943ce82d4a3f44a0afd52_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1618964a1d4460d94d2b4f7ca640620_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1b3af3901704424498cbb93a1bd47e45_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib69b42b66ea64f81bc571b5e136a6b1e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58a38b0abb2d475ea621d0cb55cade32_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibf8ba8b236c94262b8730ba51f7dc42a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9728acb79d00420087a90f15524df617_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id57045208e33461c96ad659d41f00462_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba969a5c23b6451cbeefa5426f1e393f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc5946b43768450782f6246b122b119f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia5473f1dea7542f691d2d95c97cad854_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8aaf2b2de2044518a3ec564ba88f75e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic94420b005aa4e66b856a2ff67bf8c89_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i699b95b4f1f44764b9ba3bd58279cc61_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6dc35669ee24101a2c1185b33f55579_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia1ba7ff21103477bbabb92b26c7b3364_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i96a279b2b6514d2192430c67323a7e85_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4b5f9cabdb9941e7a863c97299c00368_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a57f86aa38f484f8aafcb6f09735cfe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8eff7b7cb796442c9f4d72037c21fc95_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6983c97c98d42fb96684499a02a239b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i754f6fc9ad27497fa0cd1510ac8e8907_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i342f3ee0e5454000a23a20f0cd994598_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i652d6027f193497da031fa27687560ae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d49a9dabac54fc597f022af9277e212_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia3a784d71f1c4eefad36065887fc2930_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic534fa3517b64854a0401aca08abad91_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i11cc9e5ed0ff4a02b7d86616c322d0aa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibe9c7f8333b0450f87749a200192587e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45a6c4a6b6894cda952479c46d393577_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a3207dac346430d8a41e7dc3467d758_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd61a490327b40cfb9292092cfdc5ac4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifeeb2222d43c4f96aa888a009b82082d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6aa7236576c74fcfb7383ec2acb28be4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibe85f304c00147af96a365f14c8d9c30_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e40ead15e764c9889121bf33547189b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id0e37194dc584ce0b830f6a8b322858e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14106dbbbd7f48158d4a3e3068314a55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae4011fe77ab4e7eaa38d98a880134fb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02d0ea546af24a87a6255e69c9be826a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icdba0b24408b477dbd1da28288ef0b28_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e1ada048a5848499745516122810eab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc62432f3542449c81953affd9de22e1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0bdebf9d8834484a80089286c5c652a8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice0e6a497660484fb717730ec1682382_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6047455c7c64d9f874b87a52288b80e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7dbedce779e14d0aa2f39e6a7b145b9d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i898e69e9e3184245a88cddf0a47d6dc5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic000af4b0c4c4a2fadd5664d561dafbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia09c33cccd764e8993469adf4635a214_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2365ecc7f5a942f28ba80cc309ae1981_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id893aa0127934f2d91eecbde06753def_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8e15c24b2824478a886c6474a727dd9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2268e80ec95d4d869afeccbe9a5d42b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8a5dbad6f9e4534bd2dae1d741c29b0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2c2d0f03f76040508bfb37e1f86e3a44_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie5d1cf04d3654121bb1372860aad23cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71294026dc2b41a6b110370ac311ccef_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf593e2d5525476f9946cba41a11778a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8dc8d4c2f684a0daf26c38edd0fc54e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie753576e2fbc401991ed4e99717613ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide9e8a73d73d4f3a9142b2330c6f27fe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e4500010fb54d02ae13949698b9b8c4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70a40509dbf045e4ada553d6fac4e6eb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i581246c6bfe2404db7120fbc4f4dee00_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89fb5894e97f4df3bc23850e83b77053_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1463025af91424094e317c427bd8c0a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0766d9bdbbc4e00bec07a37b42563bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie6eae77f55e94cc2b2c83b0c7dc60c51_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4c2c4a4b7be4001b1d581d890f1c1bc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3be56294e35345518657c9cb1c795a55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie5373290982d4d9790e6f6de2c301cb7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bd74fd1d348488a9909e5be2e21240e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5968a3319d5e411c8e90433cc1e6dfee_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba8a8038d02e4f88a246aa02f656695a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i13f058de6b2243f9becd32481d9afbbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia932a81be775481f98c6d46c74fc889e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0fb50c2f22f44b9c87ff52bc490d1857_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id85051d25a924f2190907c50f47325ec_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i313cf220e7c04c1a8ad44c9b6fdcbed0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82a2befecfbb4aa5bc67a5cf1e38775f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3b97ea09a131441e902cb9300382361f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d79fe35117f4651b248b578edc99dce_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifd022943eb58411bbd1ed2c225198ac6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36c4d3fc287a432a9fd94239cf8da2e4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a1349039c214a1ab7b78b435fbbdb71_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a68094581a24c318a5e928a8ef2586d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc9d51c6c5d64a0ba83ede5553c4da40_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a6360f4861f46ebbb62566ea24fd0ea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i100e2f176d6e43288c7996c8bb790ee0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7dcfda74e184dd19aa1034852473ac0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i71cc45c9f8b14d8195ccd2d6963f6085_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b1d1ba55c914a7b8e44658d9480b9dd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8eee42c966664f4e9a6f8dda9caa4b70_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5c9af3f42bbe446f8bc0971d7ea5b622_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3c2156786fb46cfa1e5ff1a41f7d595_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if2a87acce6704921ba325076af735562_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96580d74a79a47a099c051438f4b7638_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="case">
        <measure>mrk:Case</measure>
    </unit>
    <unit id="claim">
        <measure>mrk:Claim</measure>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM18zLTEtMS0xLTA_1db248f9-9364-4139-8ee7-d782b8b95bf2">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM180LTEtMS0xLTA_d28f6272-adc1-42dd-975a-e641db8399ec">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM181LTEtMS0xLTA_27361bd4-d0c7-4d97-9006-d9463f61c762">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM182LTEtMS0xLTA_669c10a8-98b1-482d-9759-f76a0bfb8a6a">0000310158</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80L2ZyYWc6OGEwNDU0ZTEyMDc4NDE5MjkxM2JkZWE3ODViNjk4MGQvdGFibGU6YmQ1MWU0YzdlMTc2NDYzMmJkMWY3M2E3Mjg4MDAxYzMvdGFibGVyYW5nZTpiZDUxZTRjN2UxNzY0NjMyYmQxZjczYTcyODgwMDFjM183LTEtMS0xLTA_44c11b16-8771-44f8-a45d-e1a6d647b1e4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk0_9ee9068b-48c8-4a95-b106-57fe5f00e0f6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6NWJmNTcyZDdkYzY0NDdmODliNDRmYTAzZDNhOGY0OWMvdGFibGVyYW5nZTo1YmY1NzJkN2RjNjQ0N2Y4OWI0NGZhMDNkM2E4ZjQ5Y18wLTAtMS0xLTA_72c52771-307f-4b3f-9cf7-1444b114ece8">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xNDE_2cd645e3-6a9d-4484-85c7-edc246bc1a4e">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6OWY3OTdhYzc3MDRhNDUwYzk1NGMxYTExNWM1N2YyMjgvdGFibGVyYW5nZTo5Zjc5N2FjNzcwNGE0NTBjOTU0YzFhMTE1YzU3ZjIyOF8wLTAtMS0xLTA_b7d2dcc3-521a-4cda-a296-412f849edbad">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk1_0e42add0-1904-45e8-8d46-56125760a4d1">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk2_3e26cced-cf7a-43d4-b75e-302050750547">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8wLTAtMS0xLTA_f7398a7f-fa88-4c1e-8ab2-2d4e5b358e8a">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8wLTEtMS0xLTA_6e3221a8-f7e0-4ade-84db-0382c283a17d">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl8zLTAtMS0xLTA_6542fe7b-246d-4741-a3e5-bea4bef8fc8f">2000 Galloping Hill Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTAtMS0xLTA_41f85777-f2f8-40dc-ae3a-66bc67ae6ec5">Kenilworth</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTEtMS0xLTA_20b0ac7a-9640-46ed-92b1-f71deebef475">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZGNlY2MxNTJiZTc1NDdmMWE3YWRjOTY1Y2NkZGU0OWIvdGFibGVyYW5nZTpkY2VjYzE1MmJlNzU0N2YxYTdhZGM5NjVjY2RkZTQ5Yl80LTItMS0xLTA_ce0b63f7-e63d-4d72-afb3-bea6c70af550">07033</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk3_6f57a33f-938e-480c-be51-ea9cf39d9bb4">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk4_23a1b457-4d84-418a-b27c-6ece3141f249">740-4000</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODk5_91a487db-f02f-449a-9dd0-05e5540be77f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODky_974b9fc2-1c9e-428d-b559-9941771126f6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl8wLTAtMS0xLTA_90c2fa45-04e6-407b-9e58-1bf5c3cf4f76">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl8yLTMtMS0xLTA_30aa511c-408c-4837-8494-7332abfa3029">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6N2ZjZmE3NTAxNmQxNGNlMmExNDM0MmEwMGU0NDkyMmIvdGFibGVyYW5nZTo3ZmNmYTc1MDE2ZDE0Y2UyYTE0MzQyYTAwZTQ0OTIyYl80LTMtMS0xLTA_1776075a-51c1-4a4f-8640-900e1321124f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODkz_9d5f98f3-1e67-4681-a915-06e05c04869e">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTAtMS0xLTA_5c132516-3527-49f2-9b60-e04dbc11c84f">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTEtMS0xLTA_4175d09d-7c04-4ae5-8e98-2f2772383a3f">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i50285e1c6dd24576944ec0497f734115_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8yLTItMS0xLTA_fd1ee212-40a6-4656-9109-d87ef4b0a5bf">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTAtMS0xLTA_984ab766-33df-4689-b00a-ba95d5787a0a">1.125% Notes due 2021</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTEtMS0xLTA_04bc0d78-b62f-468a-8cd4-88f0d3256269">MRK/21</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ide08910d57a04101a47af3bf283a3ce0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl8zLTItMS0xLTA_4a8d0c17-f2d1-4f15-b43f-a7b799e1ff4a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTAtMS0xLTA_10d9be51-6253-49b0-a9da-1f577f051c51">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTEtMS0xLTA_436cebcb-ecf9-4ac0-948b-4e4780baca3a">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i268c7fc26945402f9b563336318cd610_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl80LTItMS0xLTA_1fcb7e31-91e7-4f3b-b4f9-7b26aaa28775">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTAtMS0xLTA_fb946643-0969-4347-ac28-b27eddae1e14">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTEtMS0xLTA_2c1299f7-5206-4adf-84da-f141554c7880">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i354b9fcd628140f49a4449cfac66a58a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl81LTItMS0xLTA_da5c4a56-b21e-4b86-9a57-ffbf15007c94">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTAtMS0xLTA_c23a1794-59dd-4954-98e9-ca63071d1465">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTEtMS0xLTA_997922f1-5f73-4e8b-96cb-e93221034c63">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i78b015cf27dd469aa145a6a1a2a76085_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl82LTItMS0xLTA_0b534477-e05c-4133-8654-9bdcfbfae27d">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTAtMS0xLTA_0a36a174-3053-4002-881e-13a93384c7d6">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTEtMS0xLTA_ffcff42e-be65-4feb-aac7-c36fafb13851">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0e13498580ad4c6da6d59bcb449f7f1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGFibGU6ZWM0MTU1YjM3YzNhNDExZDk3OGNjOWRhYWYzZTFmOGIvdGFibGVyYW5nZTplYzQxNTViMzdjM2E0MTFkOTc4Y2M5ZGFhZjNlMWY4Yl83LTItMS0xLTA_0ccb3e18-aff0-4724-a93a-74e9f5d392c1">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if2b50aa67803469bbee45c3c944121ea_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xL2ZyYWc6YzM1ODEyNzM5NDdjNDE0MWFkOWYxNjAyMzIyZmQ0MDUvdGV4dHJlZ2lvbjpjMzU4MTI3Mzk0N2M0MTQxYWQ5ZjE2MDIzMjJmZDQwNV8xODg4_692eda74-ac78-457f-af28-b2e528c04a0e"
      unitRef="shares">2530034437</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi0xLTEtMS0w_ed85604e-117e-4fd2-8523-1f6252bd9e23"
      unitRef="usd">12551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi0zLTEtMS0w_4d31f31c-fd68-4e14-b5cf-f8f924b82e37"
      unitRef="usd">12397000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi01LTEtMS0w_c1689e55-137a-488f-8e8d-55d3fc63136b"
      unitRef="usd">35479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMi03LTEtMS0w_e52688da-558c-48e0-8697-48b123dea50a"
      unitRef="usd">34972000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC0xLTEtMS0w_712037f7-8f9e-4c06-a585-8ea19ccbd2ea"
      unitRef="usd">3481000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC0zLTEtMS0w_44e85034-7b8f-4a81-935e-bb40460a71da"
      unitRef="usd">3990000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC01LTEtMS0w_449a7c8d-76b8-4571-aa4d-a4b2b4d3c305"
      unitRef="usd">9952000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNC03LTEtMS0w_55b3e07c-2c6e-417c-aef7-d10863bd911d"
      unitRef="usd">10443000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS0xLTEtMS0w_37adb5cc-d380-4ff7-9afe-f7e089b31fbe"
      unitRef="usd">2450000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS0zLTEtMS0w_c4eee595-055c-4bfd-b9ad-fc2131972201"
      unitRef="usd">2589000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS01LTEtMS0w_99ffad27-6fe9-4234-8b7d-47b58a45e7ec"
      unitRef="usd">7383000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNS03LTEtMS0w_15bc7fcf-415b-49b6-9de8-24f99d893445"
      unitRef="usd">7726000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi0xLTEtMS0w_a4177cd6-9d4b-4f29-90c6-b3502d8abdfd"
      unitRef="usd">3390000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi0zLTEtMS0w_06997abf-5ec9-4617-9133-ea855f939d63"
      unitRef="usd">3204000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi01LTEtMS0w_15f0f30f-8990-44fc-b71d-e868d0bed995"
      unitRef="usd">7721000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNi03LTEtMS0w_923d0c60-1487-4aef-84a4-6de2f8dae295"
      unitRef="usd">7324000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy0xLTEtMS0w_66dbd908-df75-49d6-b64b-709ebe314da8"
      unitRef="usd">114000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy0zLTEtMS0w_5aad937a-6413-4378-b7d2-1c7a67d4d0e5"
      unitRef="usd">232000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy01LTEtMS0w_5ffb0676-3a39-4b76-b707-20fc88a4f5d7"
      unitRef="usd">269000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfNy03LTEtMS0w_d61849a5-b520-4ee0-bb3d-f56e4bbc35da"
      unitRef="usd">444000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC0xLTEtMS0w_1ca7dab9-4229-4303-868b-ed6178ff538c"
      unitRef="usd">312000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC0zLTEtMS0w_0ebb5f88-477b-49e8-95f1-9f64109edde9"
      unitRef="usd">-35000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC01LTEtMS0w_22773d74-b9cb-4558-8fda-f853aacc6ad0"
      unitRef="usd">630000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOC03LTEtMS0w_612a0cfe-3837-48fb-bf2b-943f9233c441"
      unitRef="usd">-362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS0xLTEtMS0w_e32f338c-f89d-4c13-852d-ca4fb3187411"
      unitRef="usd">9123000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS0zLTEtMS0w_1952261c-41a2-4b1b-ad34-5c6b315b8936"
      unitRef="usd">10050000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS01LTEtMS0w_0946ac5a-c923-4b97-9fad-4178d3da3717"
      unitRef="usd">24695000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfOS03LTEtMS0w_0895201c-7c19-43e2-b8ff-004f430d752b"
      unitRef="usd">26299000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtMS0xLTEtMA_d5d64c5d-cc71-4924-a954-cdfbe956f952"
      unitRef="usd">3428000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtMy0xLTEtMA_b467d7a2-e307-4774-8aee-266daa348380"
      unitRef="usd">2347000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtNS0xLTEtMA_d17af8d3-98d0-43c6-bb50-afe7cd8dee34"
      unitRef="usd">10784000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTAtNy0xLTEtMA_5c044e34-9100-499c-8430-0a42d42abfff"
      unitRef="usd">8673000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtMS0xLTEtMA_62169a99-4841-43bc-98ac-07dbefcb23ae"
      unitRef="usd">483000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtMy0xLTEtMA_b697756f-f373-4f54-a92f-745907c8e19f"
      unitRef="usd">440000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtNS0xLTEtMA_38afc057-cf10-424b-bdba-66e823813883"
      unitRef="usd">1611000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTEtNy0xLTEtMA_0656763b-96d7-4610-a4c2-d128b010107e"
      unitRef="usd">1259000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItMS0xLTEtMA_e9d08eae-d6b5-4423-81fb-c6edd00dbe68"
      unitRef="usd">2945000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItMy0xLTEtMA_ab03fd9f-7a77-4e74-9983-454e229df189"
      unitRef="usd">1907000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItNS0xLTEtMA_4ae7d4ed-5fad-48ae-994c-bb6c1d324d0a"
      unitRef="usd">9173000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTItNy0xLTEtMA_8045cbc1-c5b8-4a07-8304-2f8015628261"
      unitRef="usd">7414000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtMS0xLTEtMA_88655bfb-c4f1-47e7-8a8b-ad1405cb4a5a"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtMy0xLTEtMA_f106d29f-006e-4fb9-bde3-b1c2185857ae"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtNS0xLTEtMA_2b2c323a-059e-4452-ae19-af347cdb433f"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTMtNy0xLTEtMA_203fa466-5666-40bd-a83d-98bb315ece52"
      unitRef="usd">-73000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtMS0xLTEtMA_02623fc4-35bc-4848-a2a4-fa538594b78c"
      unitRef="usd">2941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtMy0xLTEtMA_22b4e31d-a11f-4a40-a139-94cac1df8572"
      unitRef="usd">1901000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtNS0xLTEtMA_491c293b-e36f-4adc-af4b-05b1eb074a87"
      unitRef="usd">9161000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTQtNy0xLTEtMA_b0297bdc-5c94-42e8-acc1-9431415420a6"
      unitRef="usd">7487000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtMS0xLTEtMA_5aad267c-6997-4738-9b6f-ad0443578f79"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtMy0xLTEtMA_8076d4ad-0b24-439b-b6ae-1fe98bd63025"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtNS0xLTEtMA_8dbcc411-0715-48c4-920c-47f23eb476d2"
      unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTUtNy0xLTEtMA_133d6867-4eb5-42d5-aabd-5ea9c3e26553"
      unitRef="usdPerShare">2.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtMS0xLTEtMA_6fc00e23-da7a-40e5-b501-3fe39fe5a68d"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtMy0xLTEtMA_a851888a-77e5-4742-aaa5-395a6b85dfb3"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtNS0xLTEtMA_b1040d4e-8c72-4902-809a-daea6c2d6c92"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xNi9mcmFnOjM0YzUwZDQxMzkyZjQ2NzJiMDI4YjhiMTkzODFkZmJkL3RhYmxlOmU3NDZhYzhjOWQ5MDRiZDVhNDNiNjM2ZjFhOTVkOWZkL3RhYmxlcmFuZ2U6ZTc0NmFjOGM5ZDkwNGJkNWE0M2I2MzZmMWE5NWQ5ZmRfMTYtNy0xLTEtMA_733ee47a-4e27-4218-b779-cc55e3b86bf8"
      unitRef="usdPerShare">2.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi0xLTEtMS0w_da639635-4cf1-45a8-bced-5e47b49e37fa"
      unitRef="usd">2941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi0zLTEtMS0w_e2b26c54-10ff-4a5e-b8b1-520dab8d6489"
      unitRef="usd">1901000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi01LTEtMS0w_37991659-ec58-495c-8cb9-922e5e68faa1"
      unitRef="usd">9161000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfMi03LTEtMS0w_7b77d21b-d6c4-4463-8eac-954574ac86da"
      unitRef="usd">7487000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC0xLTEtMS0w_2a6b70ac-4973-40f0-b224-a19f3909e53d"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC0zLTEtMS0w_4ffb2fec-022f-447c-8d9d-aa764118ee05"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC01LTEtMS0w_ed29f38e-1815-44e4-94cf-8ba9904f51ce"
      unitRef="usd">-153000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNC03LTEtMS0w_cab06857-041c-485f-8c60-16c56f9f0e86"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS0xLTEtMS0w_2b78c226-8f1a-49fc-8524-90e99a82bbce"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS0zLTEtMS0w_9719f9c1-137f-457f-bfb8-d2fd17903348"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS01LTEtMS0w_f676bdbd-2b82-4873-ae50-aadada7eeff7"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNS03LTEtMS0w_b44f8c25-7a10-40bc-bd5e-30051065d1e5"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi0xLTEtMS0w_28445e26-2f58-41bf-a0b8-39aa0469bded"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi0zLTEtMS0w_31b91b08-2219-44e1-a8b1-cef10f5b4125"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi01LTEtMS0w_a901c26a-7002-4881-aea9-a425fae6c7ec"
      unitRef="usd">-161000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNi03LTEtMS0w_07f8d12a-b3d4-4377-999b-2b454e341d54"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy0xLTEtMS0w_6c28e73b-e4f8-4645-9c86-9c4e711a3202"
      unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy0zLTEtMS0w_ce1a4494-a392-4779-b0ec-b671f813123c"
      unitRef="usd">-117000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy01LTEtMS0w_c9f4c18f-ff49-4d90-b68f-8294ff2103b3"
      unitRef="usd">-180000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfNy03LTEtMS0w_4a23dc8c-39cf-4933-9a8f-775917fc40d8"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC0xLTEtMS0w_3ee0f61a-119a-4e07-aab4-8b0e5c38fb6f"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC0zLTEtMS0w_f7480f06-e35b-4742-a6e8-f2686cbe75fe"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC01LTEtMS0w_68ab0fa1-c299-4ff5-a1e5-e2cc396f81c1"
      unitRef="usd">-190000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOC03LTEtMS0w_0c4f4124-bd51-477a-a6f4-8a304f53b89d"
      unitRef="usd">155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS0xLTEtMS0w_ac78967d-1d4f-428b-b88b-72a29b6484aa"
      unitRef="usd">2951000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS0zLTEtMS0w_ef77b8b7-922a-447e-9e22-3a1733b3d1df"
      unitRef="usd">1873000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS01LTEtMS0w_6a9aeeec-61b3-455e-b6e6-f3658074c9d9"
      unitRef="usd">8971000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xOS9mcmFnOmE2ODg1NzE2M2ExOTQ4NGE5ZGViZjA2YjQxMDA5MWVmL3RhYmxlOmNiNGIwZDdiZDZlMTRlMDM4YTFhYjUxM2Y5Y2U4YzA0L3RhYmxlcmFuZ2U6Y2I0YjBkN2JkNmUxNGUwMzhhMWFiNTEzZjljZThjMDRfOS03LTEtMS0w_2a4dd5a4-afd2-4757-8481-fd5202729d6f"
      unitRef="usd">7642000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMy0xLTEtMS0w_3361c358-983c-41cc-be29-5c92ba652205"
      unitRef="usd">7356000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMy0zLTEtMS0w_408073f9-3661-4c8e-97d7-c8d92566d449"
      unitRef="usd">9676000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNC0xLTEtMS0w_fc56a083-380f-4edd-8728-76a610a687aa"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNC0zLTEtMS0w_77fff40b-6226-45dd-9065-e528735b895f"
      unitRef="usd">774000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0wLTEtMS0wL3RleHRyZWdpb246NjcxYTVjM2NlODg1NDdiZjg4YmIwNWIxOGVjNzZhZWRfMjE5OTAyMzI1NTg1OQ_2db3eef0-02b4-4701-b8b3-56f1e669d673"
      unitRef="usd">89000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0wLTEtMS0wL3RleHRyZWdpb246NjcxYTVjM2NlODg1NDdiZjg4YmIwNWIxOGVjNzZhZWRfMjE5OTAyMzI1NTg3NQ_b4113599-2f23-4973-b6bb-8602b043aa16"
      unitRef="usd">86000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0xLTEtMS0w_b06fb974-e8ca-4db7-88a8-e5504214de4d"
      unitRef="usd">8422000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNS0zLTEtMS0w_66baf9aa-1a93-4dca-b9a7-2c5d46a31f1b"
      unitRef="usd">6778000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0wLTEtMS0wL3RleHRyZWdpb246Mzg5M2E1MzYzYmQyNDEzNDk0Njg2MGNhNzU4ZjMyNjdfMjE5OTAyMzI1NTY5NA_b699de2c-84f0-4c80-b05d-600dfb8b59fc"
      unitRef="usd">2081000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0wLTEtMS0wL3RleHRyZWdpb246Mzg5M2E1MzYzYmQyNDEzNDk0Njg2MGNhNzU4ZjMyNjdfMjE5OTAyMzI1NTY4OA_6ee4213d-806e-48cb-82fc-7f6ac1c64dd6"
      unitRef="usd">1480000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0xLTEtMS0w_6b1ea8d4-fe80-4972-84d2-50042eea08f6"
      unitRef="usd">6128000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNi0zLTEtMS0w_861656cc-c54b-4459-a019-777f31eb8f69"
      unitRef="usd">5978000000</us-gaap:InventoryNet>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNy0xLTEtMS0w_05760fde-c74f-4554-8b7a-d6cbf2241fe2"
      unitRef="usd">4671000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfNy0zLTEtMS0w_06bbefc0-48e3-4679-b47c-ec5f151b9cf9"
      unitRef="usd">4277000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOC0xLTEtMS0w_5b8a63e5-08d0-47a2-bde4-d3b68769cb59"
      unitRef="usd">26577000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOC0zLTEtMS0w_728edfe3-37f3-49d9-a4dc-fdd6600617ea"
      unitRef="usd">27483000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOS0xLTEtMS0w_bc0329f9-8f6e-40af-a0fb-d13022078bb8"
      unitRef="usd">1372000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfOS0zLTEtMS0w_a6718b78-af6e-4ffd-8665-4679231aca93"
      unitRef="usd">1469000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjM2ODg4ZGVkMWE2NTQyOTBhYmMwNGU3ZmM5NDg1NzY1XzIxOTkwMjMyNTU2OTc_fac30a97-7e8a-4e99-b0e3-139f0d6686f9"
      unitRef="usd">18572000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjM2ODg4ZGVkMWE2NTQyOTBhYmMwNGU3ZmM5NDg1NzY1XzIxOTkwMjMyNTU2OTI_025a504a-351c-458e-95d5-58ff651e5b27"
      unitRef="usd">17686000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMS0xLTEtMA_bd9e329b-b064-4149-9081-fc1e55d24247"
      unitRef="usd">16919000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTAtMy0xLTEtMA_49333215-0c3f-4018-8eea-8de2ee3c518a"
      unitRef="usd">15053000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTEtMS0xLTEtMA_45719962-78ba-4db9-8c8d-18dc66f72e02"
      unitRef="usd">20248000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTEtMy0xLTEtMA_5566a877-30f1-4832-9a4a-50d5a0eaf768"
      unitRef="usd">19425000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTItMS0xLTEtMA_6c9d6a15-86f6-4281-bb46-27c540583fd8"
      unitRef="usd">16677000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTItMy0xLTEtMA_6b5dc6e4-43a6-42f0-8189-a864b610b1de"
      unitRef="usd">14196000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTMtMS0xLTEtMA_7211219f-3d61-4f01-9636-fc142d228d6d"
      unitRef="usd">8007000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTMtMy0xLTEtMA_2c378a05-19a1-462c-a2dd-a0d29a7f7da0"
      unitRef="usd">6771000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTQtMS0xLTEtMA_70daadad-3bae-4268-9f08-3411b5d360bd"
      unitRef="usd">89800000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTQtMy0xLTEtMA_28e77943-7cc0-42e5-bdf1-c647a4dc9d28"
      unitRef="usd">84397000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTctMS0xLTEtMA_6af2f9fe-44bb-442a-bb4a-452229864a14"
      unitRef="usd">2420000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTctMy0xLTEtMA_03a5555e-0a50-46f6-8ef2-b9e206c66d0b"
      unitRef="usd">3610000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTgtMS0xLTEtMA_82b91c06-664d-43af-ba4f-c85b604e9271"
      unitRef="usd">3744000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTgtMy0xLTEtMA_8a306f9b-bf40-4611-a133-03fd8bf0de88"
      unitRef="usd">3738000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTktMS0xLTEtMA_0ec617bf-82fa-4826-89f2-811a9a99d8ff"
      unitRef="usd">11690000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMTktMy0xLTEtMA_cb90dd0b-a52d-4fa6-ae58-dd52bb026164"
      unitRef="usd">12549000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjAtMS0xLTEtMA_b3075df8-476e-456f-a02f-5bf90bb7c0b2"
      unitRef="usd">984000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjAtMy0xLTEtMA_cbc8b6e0-881e-475b-8578-df5da09f21a3"
      unitRef="usd">736000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjEtMS0xLTEtMA_d5b777ea-6627-4952-9944-cfe73be861f3"
      unitRef="usd">1567000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjEtMy0xLTEtMA_253b92c1-60c3-4919-90fc-e7558afbe059"
      unitRef="usd">1587000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjItMS0xLTEtMA_13ed3e88-b517-468f-922d-8b7f8f8dcb0e"
      unitRef="usd">20405000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjItMy0xLTEtMA_f446232c-c6e4-4c55-81a5-90a46b231590"
      unitRef="usd">22220000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjMtMS0xLTEtMA_76bbd25a-6df0-4a28-bc56-70621e81faef"
      unitRef="usd">26321000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjMtMy0xLTEtMA_6cd683de-1f24-4f8c-8dd2-3500af3d8360"
      unitRef="usd">22736000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjQtMS0xLTEtMA_1a402e1d-b925-4897-ac08-3ff05253417f"
      unitRef="usd">1777000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjQtMy0xLTEtMA_68aa41cb-8127-43bb-9852-b9e371db13f0"
      unitRef="usd">1470000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjUtMS0xLTEtMA_1430817b-7b46-4cf4-b698-9e3ca6ae2fff"
      unitRef="usd">12027000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjUtMy0xLTEtMA_c0743511-809d-4991-bf28-8dac0a0e2569"
      unitRef="usd">11970000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2NzI_88f01d58-0c3b-448c-9f02-8a3b9755ba94"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2NzI_ab7d7c2f-73ef-4ab0-bac1-b52cf815f34e"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2OTE_3177a118-537a-4595-b3f5-e46db8f34875"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU2OTE_e466ac5c-bcc2-493f-9945-0cbedbd3b876"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU3MDc_68870392-6230-408d-a4cb-36a01e4de746"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOmU0MjgzYmQzMjI5ODQ2N2JhMmViOWM5NDZhZDFiNDBkXzIxOTkwMjMyNTU3MDc_b8277376-7fe0-4e87-b9bd-e2819f0311a9"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMS0xLTEtMA_1328d8ff-7b5c-4787-875a-6720797a99c3"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjctMy0xLTEtMA_5695f6ea-172d-400e-8191-40f69c5168a7"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjgtMS0xLTEtMA_43905fb4-a695-41d3-a44a-938606d8c4ae"
      unitRef="usd">39489000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjgtMy0xLTEtMA_bed4486d-1ed4-4b42-8413-6ad51d027dce"
      unitRef="usd">39660000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjktMS0xLTEtMA_73daea13-b38c-44d4-a554-990f15cee6c6"
      unitRef="usd">51107000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMjktMy0xLTEtMA_300a0625-b3fe-4b77-85a0-58b8d4cb1e61"
      unitRef="usd">46602000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzAtMS0xLTEtMA_e985e81f-c235-4d49-9ff2-6bab74c9c43e"
      unitRef="usd">-6383000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzAtMy0xLTEtMA_4a3fa19b-bcbb-455a-a002-4770432d9c25"
      unitRef="usd">-6193000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzEtMS0xLTEtMA_ad94d5d0-78f4-48b2-82ba-0777e9a35843"
      unitRef="usd">86001000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzEtMy0xLTEtMA_ad1c0b3b-4280-4292-a8f3-a708ad59b914"
      unitRef="usd">81857000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmQ4ZGQxMWQ4ZGM3MTRlMTJiNTIwN2VmOTdmZmQwNDc3XzIxOTkwMjMyNTU3NTk_d01ffa77-4ac7-4e2c-93e9-07e2734a474e"
      unitRef="shares">1047343390</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmQ4ZGQxMWQ4ZGM3MTRlMTJiNTIwN2VmOTdmZmQwNDc3XzIxOTkwMjMyNTU3NzU_ab10cb83-f73a-4990-a7d0-0cd46723c7df"
      unitRef="shares">1038087496</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMS0xLTEtMA_8f71fd54-c737-4111-9cce-39a0df502818"
      unitRef="usd">56815000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzItMy0xLTEtMA_348d8d67-0d40-490b-9348-f2f2e81f7c3a"
      unitRef="usd">55950000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzMtMS0xLTEtMA_4ee808ab-6e8a-4b37-b9c2-b4eb0e113a04"
      unitRef="usd">29186000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzMtMy0xLTEtMA_d3bb6f6c-c49c-42d1-a2cd-af3e9167a9ff"
      unitRef="usd">25907000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzQtMS0xLTEtMA_836ff8f4-1fa2-4c0a-bbee-88ac7547aa5e"
      unitRef="usd">84000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzQtMy0xLTEtMA_9f2606b6-ff96-4657-b24a-a19e3c378023"
      unitRef="usd">94000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzUtMS0xLTEtMA_9576d43d-b8cc-4d92-86c2-2239e13a9e14"
      unitRef="usd">29270000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzUtMy0xLTEtMA_6e62b257-fd1a-493f-8268-d744c086f0ec"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzYtMS0xLTEtMA_d7ab91c5-802b-4f0c-a905-be0c00475809"
      unitRef="usd">89800000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yMi9mcmFnOjQyZGYxYTExMGJmYjQ3NWViYTc0YTQzZjMxNTMxN2ZjL3RhYmxlOmIwZmUwY2Q5MzBmOTQ3Mjk4ZGMyNjA4YzAwZGYyMDFkL3RhYmxlcmFuZ2U6YjBmZTBjZDkzMGY5NDcyOThkYzI2MDhjMDBkZjIwMWRfMzYtMy0xLTEtMA_473bcc54-edb7-4a90-9417-07d973698f43"
      unitRef="usd">84397000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMy0xLTEtMS0w_7eb2758b-128e-4ad0-84bc-0a6bedac97ff"
      unitRef="usd">9173000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMy0zLTEtMS0w_d7dcb3a6-afdb-422a-8e4a-24a4f92e1bc4"
      unitRef="usd">7414000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNS0xLTEtMS0w_181a99bd-bf4f-4c16-a691-f21a6d786e7b"
      unitRef="usd">2721000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNS0zLTEtMS0w_8b239bcd-da09-4ddd-b620-7d221334ed8c"
      unitRef="usd">2716000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNi0xLTEtMS0w_08e8dc7b-8b3d-441e-b6df-0c3942f6db5b"
      unitRef="usd">35000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNi0zLTEtMS0w_cd527c7f-75f6-42e1-bef4-68cc59ebf7dc"
      unitRef="usd">864000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0xLTEtMS0xMDQ0_5ad2651b-c2e3-4d67-9429-d736e40f7dfb"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0zLTEtMS0xMDQ0_11569774-f8fb-4a36-a3bc-b2dfa711b6f0"
      unitRef="usd">982000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0xLTEtMS0w_9b600dbd-77f2-411e-80c2-be6a60c1c731"
      unitRef="usd">47000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfNy0zLTEtMS0w_3aab500c-78ae-4c14-8522-3627b848d549"
      unitRef="usd">-386000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOC0xLTEtMS0w_15438552-0455-4ae7-8314-47417f755e31"
      unitRef="usd">354000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOC0zLTEtMS0w_d419ba42-3a25-42d9-a7e1-40ae25db277d"
      unitRef="usd">306000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOS0xLTEtMS0w_ad1b8ef1-badf-4c4e-bb6f-70e94aa1b511"
      unitRef="usd">445000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfOS0zLTEtMS0w_6c9aa356-f244-472b-be63-e0107df24c67"
      unitRef="usd">-219000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTAtMS0xLTEtMA_e30aa00c-c26b-425b-9579-0e3c3140e707"
      unitRef="usd">5638000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTAtMy0xLTEtMA_c094d06b-c30f-47d8-876e-a537768d3bbb"
      unitRef="usd">3469000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTEtMS0xLTEtMA_9a39bdb4-8201-47b7-9435-3d9546b635be"
      unitRef="usd">6247000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTEtMy0xLTEtMA_2ef27be1-8583-4b08-ab47-538333fa3d53"
      unitRef="usd">8646000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTMtMS0xLTEtMA_f7fd725b-bfd3-4ed2-8c31-590884432b0f"
      unitRef="usd">3170000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTMtMy0xLTEtMA_5bc17e3c-dcd0-4a77-91cc-ced8a4081b82"
      unitRef="usd">2336000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTQtMS0xLTEtMA_20802a68-fa39-4dea-a4ef-2cce291e1248"
      unitRef="usd">78000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTQtMy0xLTEtMA_aa9b3b0a-facd-4f25-b5cc-acd9cd3c8fc4"
      unitRef="usd">2380000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTUtMS0xLTEtMA_dc470111-407e-482e-95e1-acc1b0ffa82f"
      unitRef="usd">1894000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTUtMy0xLTEtMA_442bd991-d72d-40be-aa8a-1d69a4ba6921"
      unitRef="usd">7459000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTYtMS0xLTEtMA_72dae676-6193-4930-a3dc-4cd651229b3b"
      unitRef="usd">2545000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTYtMy0xLTEtMA_4ae1a900-142d-49d8-a503-cfdbf967a8ad"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTctMS0xLTEtMA_4c87778d-403f-4d8b-94ca-8c71d8315e00"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTctMy0xLTEtMA_8e6be62f-e55d-49f3-999b-fcf0d69e530b"
      unitRef="usd">3620000000</us-gaap:PaymentsToAcquireBusinessThreeNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMS0xLTEtMTA1MQ_604b6333-7611-4ffd-96a9-ea244be0da52"
      unitRef="usd">0</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMy0xLTEtMTA1MQ_9558e96c-216b-463c-ae78-48c7cbb93368"
      unitRef="usd">1040000000</mrk:PaymentsToAcquireBusinessFourNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTgtMS0xLTEtMA_f652c4e1-cbde-4389-8a71-4a32a6b865d2"
      unitRef="usd">907000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTgtMy0xLTEtMA_9a9240d9-a182-49de-8c81-c94cf6ed7748"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMS0xLTEtMA_1accf3cb-2192-4276-8ed3-f3f0e6f27047"
      unitRef="usd">-141000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMTktMy0xLTEtMA_b7658380-1e18-473d-8a93-bd5685be1794"
      unitRef="usd">-320000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjAtMS0xLTEtMA_f061f4ed-4d64-4c3d-b03e-1fa36853b170"
      unitRef="usd">-4665000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjAtMy0xLTEtMA_fe04fb3a-319b-43db-8a42-349478b43b8f"
      unitRef="usd">-1866000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjItMS0xLTEtMA_00db15b1-f71d-4477-a0b5-80a2ac937fb2"
      unitRef="usd">-311000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjItMy0xLTEtMA_849e25e9-73df-4ace-af25-b1f9d6e8ff4a"
      unitRef="usd">-3892000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjMtMS0xLTEtMA_6b82126a-86da-4978-ad13-f678a790e5a0"
      unitRef="usd">1954000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjMtMy0xLTEtMA_eb9f3223-e062-405c-a483-bf5c00418ada"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjQtMS0xLTEtMA_16786b10-2359-41db-856f-26508d8a730b"
      unitRef="usd">4419000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjQtMy0xLTEtMA_ea32884d-8d86-422a-bd5b-bce119706976"
      unitRef="usd">4958000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjUtMS0xLTEtMA_e6364eb0-bfe7-49bb-a4b6-34d8e974ec05"
      unitRef="usd">1281000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjUtMy0xLTEtMA_7a260b82-8893-43df-beb2-8ede71c62714"
      unitRef="usd">3730000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjYtMS0xLTEtMA_fed17fc3-dc08-4b46-8e87-8083778f69ea"
      unitRef="usd">4673000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjYtMy0xLTEtMA_ea1f63b2-313b-45b6-9d01-fd525c00b844"
      unitRef="usd">4290000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjctMS0xLTEtMA_8a0e3e24-d8e8-43e5-bd86-46afbc6cc35e"
      unitRef="usd">68000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjctMy0xLTEtMA_16eef22a-a7c6-418c-a806-d9ac83b5b7aa"
      unitRef="usd">344000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjgtMS0xLTEtMA_ebb5164b-b5a8-4cc1-a4dd-06cd3014d897"
      unitRef="usd">-472000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjgtMy0xLTEtMA_4c2ff995-b286-4000-b744-5a84a334e3a1"
      unitRef="usd">-240000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjktMS0xLTEtMA_91831937-3963-448b-92af-d48d2d562269"
      unitRef="usd">-4204000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMjktMy0xLTEtMA_5a8648ee-840e-435f-ba00-7946dea9550c"
      unitRef="usd">-6850000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzAtMS0xLTEtMA_27b32802-b2b3-43cf-b7f4-5e3108e543a9"
      unitRef="usd">89000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzAtMy0xLTEtMA_e2f8e5bf-e85d-4e06-9706-673ac63b0fe1"
      unitRef="usd">-26000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzEtMS0xLTEtMA_23fbd30b-a34e-4831-8b2c-c56e65163013"
      unitRef="usd">-2533000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzEtMy0xLTEtMA_51a10ed1-f9e5-4fc5-87d1-50509291b369"
      unitRef="usd">-96000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjJjYzlhMjRhODU3NjRjNjhhMGNkZGQ0NzZiMzYyMzlkXzI3NDg3NzkwNjk2MjE_d649fb31-6c8c-4400-83bf-1641c9b56921"
      unitRef="usd">258000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMS0xLTEtMA_ae0cbfbb-0a36-46d4-8fe4-f20863b6733e"
      unitRef="usd">9934000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzItMy0xLTEtMA_38b7e6bd-8e0e-4628-92a3-cfa65cc0c889"
      unitRef="usd">7967000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjUyMWVjMjUzNTljMDQxYWQ4NzcxNDUzNmJkMmE3M2RiXzIxOTkwMjMyNTU3NDU_aeecbea0-bd91-45c4-89bc-663b0d09efa5"
      unitRef="usd">45000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMS0xLTEtMA_59193a2e-08ad-47d0-a60d-11bf84d22911"
      unitRef="usd">7401000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8yOC9mcmFnOmNjNmE2YWM3MDIxNTQ3ZmZiMzA4OTU5Mzc2NzRlOTcxL3RhYmxlOmQxYWM5ZWNhMWU1MjQyMzNhZTlhZGI2NDZhYWRmY2ZjL3RhYmxlcmFuZ2U6ZDFhYzllY2ExZTUyNDIzM2FlOWFkYjY0NmFhZGZjZmNfMzMtMy0xLTEtMA_2042738d-009e-434f-9350-ae90e2ec30be"
      unitRef="usd">7871000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU3Ng_cb3ccc5b-25ff-404c-8db3-8d42999b08a1">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;26, 2020.The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU4NQ_78548442-2f5c-4be0-9dad-6fc759324ec9">Basis of Presentation&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;26, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Planned Spin-Off of Women&#x2019;s Health, Biosimilars and Established Brands into New Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, Merck announced its intention to spin-off products from its women&#x2019;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp;amp; Co. (Organon) through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ezetimibe) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vytorin &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ezetimibe and simvastatin), as well as the rest of Merck&#x2019;s diversified brands franchise. Merck&#x2019;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#x2019;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#x2019;s collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8zNy9mcmFnOmJlZTM1M2VjNjA3ZjRmZGJiZWVhNmQ1YjhmOTY5OWM1L3RleHRyZWdpb246YmVlMzUzZWM2MDdmNGZkYmJlZWE2ZDViOGY5Njk5YzVfNTU2Mg_f66e58fb-e587-4f5b-9fe4-d3b7126374da">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#x2019;s consolidated financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#x2019;s collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTYwMQ_693a8572-17e8-4aa5-bda5-a378873edc0e">Acquisitions, Research Collaborations and License Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75&#160;billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio&#x2019;s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase&#160;1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#x2019;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $622&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22&#160;million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $6&#160;million reduction to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#x2019;s territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#x20ac;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments of up to $740 million, including up to $80 million for development milestones, up to $260 million for regulatory approval milestones, and up to $400 million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase&#160;1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&amp;amp;D) of $136 million, cash of $59 million, deferred tax assets of $71 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $229 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties&#x2019; commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck&#x2019;s approved Ebola Zaire virus vaccine, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ervebo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments of up to $100 million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the first nine months of 2020. ArQule&#x2019;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#x2019;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D MK-1026 (formerly ARQ 531) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible asset related to IPR&amp;amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#x3b1; (HIF-2&#x3b1;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#x2019;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#x3b1; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50&#160;million upon U.S. regulatory approval, $50&#160;million upon first commercial sale in the United States, and up to $1.05&#160;billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $64 million, and other net liabilities of $6 million at the acquisition date and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses of $982 million in the third quarter and first nine months of 2019 related to the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#x2019;s debt. The transaction was accounted for as an acquisition of a business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses in the first nine months of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approaches to enable the body&#x2019;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 &lt;/span&gt;&lt;/div&gt;million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.</mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ia308feb215e043c1ac8a269b649d7e2c_D20201101-20201130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwNTYxNg_58b3628c-4358-4d7f-9cc8-7fc5bc1ebb63"
      unitRef="usd">2750000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTY4NQ_b518682a-7d9d-4a25-987e-858e86de0b0b"
      unitRef="usd">600000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTcwNA_a993be34-121e-4c68-8a26-7a5c83fba235"
      unitRef="usd">1000000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares
      contextRef="ia583d33831214bf4866a5542b0ff6a64_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTcyMg_c5910466-cdca-41b8-8bb8-71e740ada762"
      unitRef="shares">5000000</us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares>
    <us-gaap:SharePrice
      contextRef="ia583d33831214bf4866a5542b0ff6a64_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTczMw_dc598bb2-a8f3-4484-ba07-c8ce98420b85"
      unitRef="usdPerShare">200</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjMzNQ_c55f52ea-1e3b-4cc5-9508-409016082cd5"
      unitRef="usd">622000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjI3OA_b81d4d26-f4fe-4347-9c1b-65670f848a9b"
      unitRef="usd">-22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i320a221119db4c07bc18a27ee248eb45_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjI5MQ_3907dd07-1733-4857-badd-4933ab3d6619"
      unitRef="usd">6000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ia3699f0144a742659ebab39ca8e93166_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc1MQ_d9d41f48-d8bb-41f6-8b66-f8d38e202235"
      unitRef="usd">2600000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ib49be4558c154020a76d8aa7b2e8040b_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc2Ng_f0c9f9db-983e-46f1-8b17-cceab207bc18"
      unitRef="usd">850000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i8fca4df4602b4b828121637976fc9b3f_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTc4Mg_7c430e92-4c08-45ff-b1cd-d9cd87055c52"
      unitRef="usd">1750000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ib0ae7c8f36d1429f92d0302a0bd467cc_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTgxMA_414d8d00-d7f7-4a42-96c0-0b74fd207263"
      unitRef="usd">210000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i79f0266f7336448ca453ec3742701279_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NTgyNA_66af8d38-94b0-4d48-b68b-be7c0b20561b"
      unitRef="usd">65000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:RoyaltyRatePercentage
      contextRef="i414ba63dcbe44cb0aabfd3725361a92d_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjM0OQ_585f40fe-c50b-4c99-9070-647cc4790c21"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i6780cf4bc91a4f248379b2621aca7281_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzMwMjM1NA_f21c03f3-bf5c-4184-88e6-433a71e3e539"
      unitRef="number">0.33</mrk:RoyaltyRatePercentage>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODI5OQ_726af914-4558-4482-8a15-d860b5635a28"
      unitRef="eur">256000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i21c3aeef902d4e72891e4a111440586c_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk3MA_723d61ad-8f23-4a05-a80a-868c5dfa686d"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i735e835c710c461daa6baff4b2c9daa6_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk0Mw_25120c77-0ca9-45f0-96d7-270a68b7bfad"
      unitRef="usd">289000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i735e835c710c461daa6baff4b2c9daa6_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODk1Nw_76d720f2-e5e9-45a2-b53f-8bd9168fe569"
      unitRef="usd">13000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0898439e84514304bb0e2daef6e908ba_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMTEwMQ_3aacfe17-c137-4e96-ba9b-14656734b5c7"
      unitRef="usd">410000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ic7d789d97e6442d686b9da78d5403190_D20200701-20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI5MDAzNA_b1be7c15-17ad-45ed-a0f9-d8fabf2d22cd"
      unitRef="usd">401000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i5c4f7a3740f64b7abcdfd5b44d05ccef_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NjEzMg_8c344d13-76a0-4e2a-bbce-1e76fd4438ff"
      unitRef="usd">9000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI5MDA0MA_5e9ea53b-4d05-45e9-b2f3-fdc88caed6cc">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i414e40bb67fd4c20b343d703df377db1_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjM5MA_617ea163-115c-4f55-970e-caf669ab8604"
      unitRef="usd">366000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjQ1Nw_d6be6a1e-c3c8-45c7-aeb7-e04b9f7d3890"
      unitRef="usd">740000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ie31320a95b2645eeaad75930b67cd813_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjQ3Nw_314978ce-ab80-433e-89c6-e7ee7bdca1ba"
      unitRef="usd">80000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i8a2237c4c6b34455a09bda4fbaa26b43_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjUxNA_44b953ce-73d0-4310-b438-a603942c1ef5"
      unitRef="usd">260000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i9c438f84c119401f80abdd10e94d725d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjU2Mw_4d4b15e9-3634-455d-891f-ec6b0111f0bf"
      unitRef="usd">400000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzM2Nw_4b419222-4c48-410a-8081-1eb7ac0fea1a"
      unitRef="usd">97000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzYzNg_d4659047-4321-4cd9-9d5b-8296ddb3388e"
      unitRef="usd">136000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzY0OA_077b3f06-f2e4-4bd6-9753-42ddf59bf986"
      unitRef="usd">59000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzY3NQ_94949fef-b2ae-43ad-a291-d6f1d9db7393"
      unitRef="usd">71000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzcwNw_e64263b7-490b-4220-8e69-780422081b3e"
      unitRef="usd">-32000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:Goodwill
      contextRef="ic43ede995e004eca8e478b1619a43970_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMzgwMQ_83934c47-9ee8-41a5-a538-a82ed29df163"
      unitRef="usd">229000000</us-gaap:Goodwill>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNTA5Mg_f7f70679-4194-440c-b0ae-755289bf8d11"
      unitRef="usd">6500000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i34d7f570c4d94099a32cd0221f40aa75_D20200501-20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNTE0OA_2960e3c5-9b6b-4cb3-acbd-8b5e4ca45bdb"
      unitRef="usd">100000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i81e81ff682db48488ca54b8292137c0f_D20200116-20200116"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjIzNA_857969b5-cfcd-4784-a5c7-1d5c371c8f35"
      unitRef="usd">2700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjI0Ng_de94cef6-7372-400d-9c64-31960bc3bbaf"
      unitRef="usd">138000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNjQyNw_81ba330b-4811-4a4e-a036-813fdc254f58"
      unitRef="usd">95000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTYxOQ_45744391-1527-4141-bec1-a58352b74dff">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D MK-1026 (formerly ARQ 531) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing arrangement for ARQ 087&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair value of the identifiable intangible asset related to IPR&amp;amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets (useful lives ranging from 18-24 years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets and liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMi0xLTEtMS0w_49eba494-b74b-4731-aec4-41df9cbc136d"
      unitRef="usd">145000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMy0xLTEtMS0w_0aea5984-9169-4a63-aa91-ff5b7687856e"
      unitRef="usd">2280000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNS0xLTEtMS0w_6e3b6920-1ec1-49ad-ba17-df3d12d0c034"
      unitRef="usd">80000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNi0xLTEtMS0w_ebc8521f-bc22-4503-ac03-43e0d25230ed"
      unitRef="usd">389000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfNy0xLTEtMS0w_425b9ddd-eabb-4dcc-abb4-007ab29b165f"
      unitRef="usd">34000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfOC0xLTEtMS0w_83647a94-64de-4246-bf32-a969a9037b62"
      unitRef="usd">2150000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfOS0xLTEtMS0w_69383923-6923-45c2-8f93-4ab8419dd048"
      unitRef="usd">540000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id17fd71a693f4aabb61654a6f056a503_I20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjdhYzAyYzk3MjdiZjQwNDBhN2Q0NTEwZWRlMTVkNGZhL3RhYmxlcmFuZ2U6N2FjMDJjOTcyN2JmNDA0MGE3ZDQ1MTBlZGUxNWQ0ZmFfMTAtMS0xLTEtMA_cd158cd9-8b4c-4694-8930-06cec1f45d43"
      unitRef="usd">2690000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="ia1a7e2f30fbf4abfa7df8669c678d554_I20200116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzI4OQ_daf4e9ec-381e-40b1-8afc-499465ca318c"
      unitRef="number">0.125</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9187aade515d4b17a57839461a710a17_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkxMg_cd26bb50-e846-45ad-ad39-7d94195420b0"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i5ae34a9825984630b66dd918d954fcfc_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkyMw_ff32b1a4-6e58-4f73-ab62-172b8cffa5b4"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i0baac3ebe43444669dc909ad981c9377_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4NzkzNg_e50bc0c4-24ac-4c8c-875f-f71f1fd51188"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i5659ac2efe6a47eebd65404c8699603d_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk0OQ_0f619edd-78ac-47c5-bc1a-aa1e3b8e9d85"
      unitRef="usd">1050000000.00</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk3Ng_ec75f6ba-4f13-4172-8bf8-5b883f77004d"
      unitRef="usd">157000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODA2Ng_7af72bce-5c1b-47d3-a68e-db6f505518c0"
      unitRef="usd">64000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i84fda59fee3946e2ab4d84541f28495e_I20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4ODA3OQ_47db99ba-5f97-4d33-9198-6207254c16d2"
      unitRef="usd">6000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9187aade515d4b17a57839461a710a17_D20190701-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfMjE5OTAyMzI4Nzk5MQ_9f39a261-4962-44f4-8988-4ae2080cb669"
      unitRef="usd">982000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iea36cb2c86ec4304acd066b3b746ee37_D20190401-20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzc2Nw_ec5360b4-b675-45fa-ad64-96a4f4cb4b9b"
      unitRef="usd">2300000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfNzgyNg_fafba0b6-de4f-4c63-a05a-cfcce597da70"
      unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMi0xLTEtMS0w_a4ab11fb-d4f5-409f-a3d3-b3a9007ce3b1"
      unitRef="usd">31000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMy0xLTEtMS0w_29f14165-6248-41e4-a1c1-df2fe4eea6b4"
      unitRef="usd">73000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNC0xLTEtMS0w_bbb4a3c4-e5fd-4b77-9bd5-698f995a3d8b"
      unitRef="usd">93000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNS0xLTEtMS0w_8d4a1148-69be-4bda-9c4d-ae011f01d712"
      unitRef="usd">60000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="iaca125e93e984f7b91c7a53947611a63_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0wLTEtMS0wL3RleHRyZWdpb246MWFkMWYwMmJkMjE3NDdlNGFkMzgwOTQxYzEyMzE0NmFfMjE5OTAyMzI1NTYzMw_3390e690-1cee-416b-90bb-d2eb90452eae">P18Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1f9c5cc14b4a4bd59f6fd4bca8f78bcb_D20190401-20190401"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0wLTEtMS0wL3RleHRyZWdpb246MWFkMWYwMmJkMjE3NDdlNGFkMzgwOTQxYzEyMzE0NmFfMjE5OTAyMzI1NTYzOQ_f775b383-0650-451b-a161-cb61190d0f5c">P24Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNi0xLTEtMS0w_4f20b510-b803-4350-8cf1-fa28c3f7e3e6"
      unitRef="usd">2689000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfNy0xLTEtMS0w_77fc9eb6-03af-48b9-9ae6-b653b4220c27"
      unitRef="usd">589000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfOC0xLTEtMS0w_bef8194f-0e47-4d12-be49-b8f37a147a5d"
      unitRef="usd">-82000000</mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfOS0xLTEtMS0w_c931fa19-7545-437b-b336-28d25dac186c"
      unitRef="usd">2275000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMTAtMS0xLTEtMA_c4d044d7-e718-4cca-a025-801733032617"
      unitRef="usd">1376000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RhYmxlOjRiOGY0MDY2NGFmMDRiZWI4NmNiMzFiZGM2MzFkZDlhL3RhYmxlcmFuZ2U6NGI4ZjQwNjY0YWYwNGJlYjg2Y2IzMWJkYzYzMWRkOWFfMTEtMS0xLTEtMA_7246c37a-6fcb-46af-af11-9e7443554318"
      unitRef="usd">3651000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mrk:IntangibleAssetMeasurementInput
      contextRef="icd675ee00e0c4fdda383d5adb62f0478_I20190401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfODI1Mg_f64c0b3e-b459-4085-ae12-794de02006cd"
      unitRef="number">0.115</mrk:IntangibleAssetMeasurementInput>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="i4c6ddf69451d477ab002e15190237eae_I20190401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfODY1Ng_c680db17-4827-4e8d-af59-88bb5d82d7f5"
      unitRef="usd">47000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i074bf99e14004c60960bce1f01d121b3_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTA1Mw_6bf9e47f-d751-4013-8996-3e4fda58f5b4"
      unitRef="usd">301000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTE3MA_16d694c6-6006-4b00-a898-d764c72115a8"
      unitRef="usd">156000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTE4Mg_3fb7278e-03f3-417a-a5c0-5299147b1a3d"
      unitRef="usd">83000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTIwOQ_07c34679-02ac-4ae3-9066-1dc15a35cc34"
      unitRef="usd">42000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="ic574c26e06ba4bc7a5089ddc4873458d_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80MC9mcmFnOjU4MzZhZjhkNGQxMjRmZmY5Yzc2N2ViNWYwZTczMGFjL3RleHRyZWdpb246NTgzNmFmOGQ0ZDEyNGZmZjljNzY3ZWI1ZjBlNzMwYWNfOTMwMw_eaedb1f0-ce37-41c8-880c-477f0fb61108"
      unitRef="usd">20000000</us-gaap:Goodwill>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTg3MQ_3f4bde70-7a4f-44b7-9a13-07f9823ecb1e">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca&#x2019;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $400 million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million&#160;and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $135 million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at September&#160;30, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $370 million from Merck to Eisai. Accordingly, Merck recorded a $370 million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million. Of these amounts, $50 million&#160;was paid to Eisai in 2019 and an additional $500 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at September&#160;30, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#x2019;s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck&#x2019;s share of profits from the sale of Adempas in Bayer&#x2019;s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, Merck accrued&#160;$725 million&#160;of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that&#160;has not yet been accrued as it is not deemed by the Company to be probable at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $838 million at September&#160;30, 2020 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMjc2Mg_3248d3fc-b237-4aad-848c-e6b789d64cca"
      unitRef="usd">1600000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMjc5NA_2e51b875-5955-4f7a-a9d4-7ee509a4062b"
      unitRef="usd">750000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="id8dd786e26d1477aa8bd45ad2b6f3c5e_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzE0Mw_8fb88c0b-adb6-4201-97d6-43d3b5bd65d9"
      unitRef="usd">400000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="i96b4efb9755a49cfbb3e9ad58fc1264f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzIzNw_4211c389-b3c6-4ab0-8af3-f5a86c730a5c"
      unitRef="usd">400000000</us-gaap:Liabilities>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="if0cbbe2696d440b882b0f472d8d42ccd_D20170801-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzM5Ng_bc79b1ba-55c3-40c3-b3a9-160301852bf3"
      unitRef="usd">1000000000.0</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i36b53eb43aee4f21bc681f524ea62b7f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQyOQ_7e07a524-2ba9-439c-b348-74408af5ab73"
      unitRef="usd">200000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i20b40407b64e47609c2aa82a3959404e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQzNg_9bbaa068-b357-4afe-988e-caf2b8d40fa7"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i65572a08fd174295982fa8fbf05e5d45_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzQ5OQ_95a7a97a-a4ca-4956-9513-1539f706adf2"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="if4fc5d236d7843638ab3281a103c93b7_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzU5NA_9a99d31e-9c41-48eb-86c4-85b3fb67a13f"
      unitRef="usd">2700000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="iee9da70429aa4ac0ba5c6fc6bbe4b20c_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzgwNQ_4f52e4e7-3284-47f8-a2a9-c66a08b79100"
      unitRef="usd">135000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i39a12f6da7654fefa46f0e8502eba97b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzkzNw_8b1e0541-f195-4314-af45-ab7eb1d0a34f"
      unitRef="usd">60000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i4306e1310aea4c4e8219428ac7a74614_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfMzk0NA_b0a8c520-d958-4b63-b548-0ec5c87f88ab"
      unitRef="usd">140000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i26a49639fd9e44fc80d9d728cf4248ad_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNDA1Ng_8c38a3d6-ee99-4271-a383-ccf0a6c011ec"
      unitRef="usd">1400000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0af7869909e242429c04502cbac1701d_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNDIxNQ_55470778-6bc2-4a4a-9fae-94f0f0bd8fda"
      unitRef="usd">1300000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTg3NQ_5f12b1d1-6c65-45f0-88e9-e4fcae112071">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone and future option payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents accrued milestone payment.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ib89e4869799c4eddbb76087e4856f6e1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi0xLTEtMS0w_f61a2fba-938f-4855-996a-51aa71a2a52b"
      unitRef="usd">196000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="iffbf0955eb8b4c4d98918582883b0e4a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi0zLTEtMS0w_335ae0c3-96ce-4041-8eb7-a77d7138772b"
      unitRef="usd">123000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id6d48c63441f485a81bc70510125df4a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi01LTEtMS0w_933e8cda-4f78-481e-9754-99584e4ef34d"
      unitRef="usd">519000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="idcc67ca1d79b4a9d9c65fbadafe2ed03_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMi03LTEtMS0w_d3070641-e82d-4080-882c-18e841cfc945"
      unitRef="usd">313000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id8682bf21cbf4722b662136970328362_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy0xLTEtMS0xNzY2_a07b09e5-3654-4062-ba6b-51befd0d86d4"
      unitRef="usd">3000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i8418200bd3474a8989d1feeaac0927f6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy0zLTEtMS0xNzY2_f77c0835-c7fd-4165-aff6-1b3bcade5b86"
      unitRef="usd">0</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i8baff54113d34962926404de668611aa_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy01LTEtMS0xNzY2_c490a06d-26cb-485e-8788-237874308b00"
      unitRef="usd">3000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i1b54f758421c483abea6109fc48d1294_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMy03LTEtMS0xNzY2_a93ca814-c651-4e62-9464-9f4709bfa8bc"
      unitRef="usd">0</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i672e14c8326e49119792c5a739d15560_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0xLTEtMS01Njg3_5286bf21-0e8e-4f5f-bce9-b4752c8e688a"
      unitRef="usd">199000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="idff28471372f43c4aeca73d2b047bf8a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0zLTEtMS01Njg3_b55b9fe1-48dc-4b9c-bf64-9e1ee7c5a5ba"
      unitRef="usd">123000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i08e7fffaaeaa473495ffacd2ac50867f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC01LTEtMS01Njg3_71a5419a-fa63-4cba-8ffa-3c9bc043d25c"
      unitRef="usd">522000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="id915e0532c914695b005384447c665a1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC03LTEtMS01Njg3_0f2ff944-58d0-48a7-8d46-3cab28306b15"
      unitRef="usd">313000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i98a1dd31df764266bc67364b6f1a7916_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0xLTEtMS0w_07930633-7cac-4134-8d35-6bf30ef39e06"
      unitRef="usd">41000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3121da41fc0647a98833a789f5fdd4ec_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC0zLTEtMS0w_12071b2d-cdde-4a9c-961a-c49dd66495db"
      unitRef="usd">28000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia6fe6accc36045aca588c404c0b2cd07_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC01LTEtMS0w_076d12ff-f909-4fdd-a08e-aee9f9815ca7"
      unitRef="usd">205000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic40f44394c1e4c1bac21ea2a06244edd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNC03LTEtMS0w_fb2eaf86-49d6-491c-b674-ce58a499e18f"
      unitRef="usd">120000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0d8f3b8efe9043f9aacc552835d92b46_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS0xLTEtMS0w_20008ee2-7859-48ef-9a21-6160a707095a"
      unitRef="usd">40000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iea90d2039c7141dca1496ccaa589ecc1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS0zLTEtMS0w_a06bb909-0da4-4e23-b4a1-2ebd0b0da5e3"
      unitRef="usd">36000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i203c7a3ab0ea46d4a6dc810ea5880354_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS01LTEtMS0w_338cb977-2521-453d-854d-ed59416b8189"
      unitRef="usd">112000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i452c7b783504434287bc42a63fca472f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNS03LTEtMS0w_56252b2a-2290-41d0-ae51-483e7843d023"
      unitRef="usd">96000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if4812ae09bfa4ee1a36daa5fabe59052_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi0xLTEtMS0w_5f93ccc9-4511-47b3-8caf-af125263d8e8"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i97f1dbf8ba2e4ace97a8ff751592fe5d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi0zLTEtMS0w_02fa446d-c501-4662-877a-415a6ead5e84"
      unitRef="usd">44000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0dc77ff7d3d2418fa16f24a6c043ef75_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi01LTEtMS0w_369c2e10-a4b1-46f3-8f87-7cc2451d2896"
      unitRef="usd">93000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09080dd93c834c57b9ebff1a5663ec83_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfNi03LTEtMS0w_89ebbd00-cac6-4c22-a21b-da001ba1236b"
      unitRef="usd">122000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i09aa6a0b51c94fd996e7402de95de2be_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfOS01LTEtMS0w_98958f2f-59a2-460a-bb34-8076a0d5f6d8"
      unitRef="usd">197000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if30c830280f947a689d5b271c94dc69a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfOS03LTEtMS0w_d764b6cf-b71e-47b5-b0e7-d19b0dfcc4a6"
      unitRef="usd">128000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTAtNS0xLTEtMA_92582369-2a9a-4c65-b8b4-6ddec25a20b6"
      unitRef="usd">309000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i93a278d539314213bd6e5766dd997779_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTAtNy0xLTEtMA_b6b0df51-f4d2-409e-8e13-34b8211138bd"
      unitRef="usd">577000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i39a24ffb9e8140e9b8ffcd8c63a774de_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTEtNS0xLTEtMA_ebb77af5-de1c-42a1-a2f6-bce35d5c42d7"
      unitRef="usd">400000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i93a278d539314213bd6e5766dd997779_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjM4MDkyYWRiMWM2NDQ1ZTFiM2JiYTAwNTc2YTVhMjAwL3RhYmxlcmFuZ2U6MzgwOTJhZGIxYzY0NDVlMWIzYmJhMDA1NzZhNWEyMDBfMTEtNy0xLTEtMA_754f8f56-2a33-4152-b408-4261af2ffbf0"
      unitRef="usd">0</us-gaap:LiabilitiesNoncurrent>
    <mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i355c8a370ea34624aebfc74a71246fae_D20180301-20180331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTgyMg_7afa4f8d-fab7-4494-ad96-4d3a9f93ac90"
      unitRef="usd">750000000</mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="i5ef5983f652b4f678745213cc80d39a2_D20180301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTg2Mg_11c4495c-1136-4dc4-b733-16ea5a7ef4b0"
      unitRef="usd">650000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="ia70a1af19330475d88753e88f14c38c2_D20190301-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTkxNA_70ffba83-bb84-406f-a7a8-6c493cc81c9d"
      unitRef="usd">325000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="i8da39f245c784880b54370510f8d89b1_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTk0MQ_8542a9a6-1fa0-4dcb-8a2b-7fc081e8c68c"
      unitRef="usd">200000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
      contextRef="icba8f4a74d444bcd8400c0863cd3c92b_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNTk3MQ_2cd36c30-9620-4445-9eb6-998e68e9c44a"
      unitRef="usd">125000000</mrk:Licenseoptionpaymentrelatedtocollaborativearrangement>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="if9f4566b3c6f4506b767bc5d2b892db8_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjM0Mg_21833d65-ac23-4007-a42a-4edc1840432c"
      unitRef="usd">370000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="if5f82b5879934498baf8420915f61a2a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjM5Ng_d1fd80d5-861b-47e8-89c5-d1697afb161a"
      unitRef="usd">370000000</us-gaap:Liabilities>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="if3fbe331c8084a23bccb932806d23825_D20180401-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjU1NA_df270193-c5b7-4ef1-b1bb-260bac9b9d03"
      unitRef="usd">950000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="id5002ac2a1b5410cb178591c19cc6f15_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjU3Ng_69de8e87-d8cc-4c9e-a029-db4387e635ff"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i245fd78ff94042f9bc0ed66ef072aafd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjYyMw_ab12bd4e-db4c-4c96-bdef-2110ba74356e"
      unitRef="usd">500000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i7d59f0ea051148e99f9ddbfbb6a91314_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjcxOA_fee9972b-9876-481e-be0c-d04482c9d16a"
      unitRef="usd">2700000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="id0f502109a8d408591929847e1ec04c1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjkwNg_1964960a-445c-4c96-af63-c542aa4649bb"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="ia08506df034040a0a6bc566e66e0b025_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNjk5Nw_2053cb68-b734-4a45-8a1a-c3210f2343b6"
      unitRef="usd">135000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0ff8630eade846b29dfa54f515c419a7_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfNzE1NQ_d1a7e246-3428-470d-8cc0-abfa92b37921"
      unitRef="usd">1100000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i34ce8a9c45264255b55253efdffbee5a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi0xLTEtMS0w_a3361e0a-7394-4630-b597-9d66531f329a"
      unitRef="usd">142000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i7cd5ed28ae9c4290ae150fb16d9466fd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi0zLTEtMS0w_1be8c3a5-3406-4141-a002-6438017e22e5"
      unitRef="usd">109000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i05babc5db48d458d8839840a56d0a9c1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi01LTEtMS0w_1320311b-c913-4314-9906-cf90f898298e"
      unitRef="usd">421000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i1d38eaf8021744fe8f4dfab94a5015fa_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMi03LTEtMS0w_8a880dc3-990b-40b5-9f49-33c76142a993"
      unitRef="usd">280000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie29d30b68df740dfbc20eaab83dc5e38_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC0xLTEtMS0w_99e03be5-9e99-40ae-8585-470e8a395de8"
      unitRef="usd">46000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e7336913b5b4a20a439157fdc51f46f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC0zLTEtMS0w_eb81cf71-b5aa-4104-a22a-c600a928f695"
      unitRef="usd">23000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifc67bccad40d470c9949756b7eb748bc_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC01LTEtMS0w_1ef8f84b-732d-455c-b934-a490b1d376c7"
      unitRef="usd">215000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibb427d5a13434a21a6ed491a4dd0e763_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNC03LTEtMS0w_d5363df5-e052-4cc5-be28-6dc7414711ec"
      unitRef="usd">97000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic9bee3c7f7024b5281e40456c78625e3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS0xLTEtMS0w_8cd0db59-9459-4c5d-8ad5-4a4e731ad4a3"
      unitRef="usd">18000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i82ff54672a98446994645788d1f59463_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS0zLTEtMS0w_478ecab8-63e9-4422-8eb6-a9d6c258c8ef"
      unitRef="usd">21000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ida9b2e380dc5459f818bd1f423bdd1c2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS01LTEtMS0w_4741426e-ec62-4f7c-b4b9-3a0ea2418a50"
      unitRef="usd">48000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i23ab39e6826f45b7a3da069eaebd2a39_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNS03LTEtMS0w_099af6e2-23b8-4223-bffa-a64734a30de0"
      unitRef="usd">59000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i734edac95cf34e8d8c5aa9e71b9f85ea_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi0xLTEtMS0w_129e97a9-d877-4f15-8d05-31602db570cb"
      unitRef="usd">48000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4f3d3057a1b74664bfffcee79d494ca8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi0zLTEtMS0w_26fa53b2-a803-458e-8b4c-368d06459c12"
      unitRef="usd">37000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i47f27f8096b5447d8aa97005ecfa5902_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi01LTEtMS0w_9bbdff76-c637-412d-9abc-3768786f135d"
      unitRef="usd">168000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3debc0d591324b7ea043d28f9093108a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfNi03LTEtMS0w_1d51e378-668c-4010-8ff0-9dc3f6afa074"
      unitRef="usd">146000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3240881da60142e5953a1ec3857fb0d4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfOS01LTEtMS0w_10fecbc0-3cc4-4fe3-b8f3-fb648e02dc66"
      unitRef="usd">170000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia949281fca194d51bc2b1de185ec698d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfOS03LTEtMS0w_f68f6279-6d73-4ee7-b97c-e4e361e4ae8b"
      unitRef="usd">150000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic4715d086fff4408be90ea9d32249068_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTAtNS0xLTEtMA_b6278e58-d0f2-4e62-bda5-46f5bd481ac3"
      unitRef="usd">325000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i84ce31a9d972414f87e8b9b510ffd15f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTAtNy0xLTEtMA_a8ba839c-4db7-41c5-94b2-b129ff2d68eb"
      unitRef="usd">700000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5f3cda8bb28a46d5bcadf58cfcbba40b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTEtNS0xLTEtMA_42c05789-0d7e-436e-aabc-85130bdc9e69"
      unitRef="usd">570000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id9bdb7de8f0e4a9593cf268c8664a7ab_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjc4ZjVhNjczNTAwYzRlMDliZTBlYjMyMzI4OWNkZWYxL3RhYmxlcmFuZ2U6NzhmNWE2NzM1MDBjNGUwOWJlMGViMzIzMjg5Y2RlZjFfMTEtNy0xLTEtMA_991f5db2-b121-4591-a12b-38582020eb1f"
      unitRef="usd">525000000</us-gaap:LiabilitiesNoncurrent>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="idedcac7eb55940d8bf55d7f495fee349_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTAyMw_79e63b1a-09c6-4e06-992b-04e63dce0909"
      unitRef="usd">725000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i08b439500c8b4e4db9be5c2fef7ba050_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTA5Mw_db132591-340c-4efe-a5a4-2358d2aa0c55"
      unitRef="usd">350000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:ContingentPaymentsCollaborativeArrangement
      contextRef="i43c3eb857ced458dafba143b0afe517e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTE0Ng_6bff8867-688c-40df-a53c-6ad8858e3064"
      unitRef="usd">400000000</mrk:ContingentPaymentsCollaborativeArrangement>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i496aa343ecfe4651b28bd840131d00b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RleHRyZWdpb246MjA0ZDllNzBjYjdhNGE0MWJlNjIxYmNiYjk0Mzk1NDVfOTQ2Mw_6ad2fa9f-e99e-4781-8081-69a1475a8aae"
      unitRef="usd">838000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi0xLTEtMS0w_b3082246-3e30-4590-9a34-5b0a9efba5ce"
      unitRef="usd">83000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi0zLTEtMS0w_29369201-9213-4a99-861b-313ef8a06ea9"
      unitRef="usd">50000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi01LTEtMS0w_e9617b70-f3c4-4b19-a9b6-c1f64b70276a"
      unitRef="usd">216000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMi03LTEtMS0w_9cd1cd39-5c04-4a10-b427-cccba8c9cf5e"
      unitRef="usd">144000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy0xLTEtMS0w_1a1b0728-80bf-4ddb-aee1-0d720acf9092"
      unitRef="usd">55000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy0zLTEtMS0w_48c7c382-730c-4131-8a29-f906f7aae061"
      unitRef="usd">57000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy01LTEtMS0w_c75c1269-4336-44ac-a7d0-0c47b2885f38"
      unitRef="usd">167000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMy03LTEtMS0w_ff0f390c-291d-4552-91d5-96fd121f54c4"
      unitRef="usd">158000000</mrk:CollaborativeArrangementSalesNet>
    <us-gaap:Revenues
      contextRef="ied845fda2cb0436a9f62074d2ed4cf60_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC0xLTEtMS0w_29a7b169-829a-4b98-b6ef-3bbb1c58a573"
      unitRef="usd">138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibec2639001bc4ae886e04558d95b692e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC0zLTEtMS0w_deac5859-b1a0-4ad9-aa80-7683d27aa81f"
      unitRef="usd">107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic25b9d165e3a4b9cba3541a9271c712b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC01LTEtMS0w_ff554bbf-730c-4050-87f3-de1a24a0fe3a"
      unitRef="usd">383000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b8302693ae949728e07cd6d7dc96277_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNC03LTEtMS0w_037a57f6-e7c2-4c71-87c6-63f4f13e62ab"
      unitRef="usd">302000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i16c74758a3e84c32b5a4934acd2a2e76_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi0xLTEtMS0w_d893c0bb-5d66-4b9e-beab-40b2a5723fe6"
      unitRef="usd">29000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3150bde02fd14893b33da1eeac0249de_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi0zLTEtMS0w_af1ad37d-e0f8-419d-b9ca-1db18810f34e"
      unitRef="usd">28000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8461e98ecef64dbebc07597db5b84152_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi01LTEtMS0w_c17cf2eb-44e3-46b0-9ee5-29083f0e86f2"
      unitRef="usd">85000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id073b72dfd8d4b199dcc27df47315e69_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNi03LTEtMS0w_498cacd9-e5ab-4109-b34f-fa33f5149b76"
      unitRef="usd">86000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3a955d765ba34e32bc493ef244feee8f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy0xLTEtMS0w_c899081f-fa60-4eae-925f-f3817b3f5733"
      unitRef="usd">19000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic1082a8df5454aa3ad070d4a15057c2b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy0zLTEtMS0w_2894d60a-7979-4650-8022-a2ced57c66fe"
      unitRef="usd">12000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id5e2f7775e904a7b98b34ad10b77040a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy01LTEtMS0w_6b72d925-b4f4-4c22-aef9-83d67caf9c29"
      unitRef="usd">42000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i991fd53b18024cf78c8d36aca923947e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfNy03LTEtMS0w_9faa96d7-1113-40e0-8937-b22e29bd52b3"
      unitRef="usd">31000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9ea86431ecd4511a44c25d8a18f135f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC0xLTEtMS0w_0232f5ed-df4e-4d37-91bd-25527e3f7b6e"
      unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idfdc92bf6c724ec79c32415e7d58a9c8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC0zLTEtMS0w_dc22a0b7-4cfe-442c-9cf3-51c22f97d69d"
      unitRef="usd">31000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1b86f1b1c991406c8b65e857fd90f944_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC01LTEtMS0w_6dedf595-b278-4d0f-8f1c-f7ff3ddac7a4"
      unitRef="usd">53000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ieaef7e6bfd9d488cb6176aec4c7b915e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfOC03LTEtMS0w_c44489a4-9638-4a88-900a-0f2001082308"
      unitRef="usd">94000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ia602b90ebc2445e0b159157c4045d0a6_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTEtNS0xLTEtMA_6eb64e61-648c-468c-a8ee-1b9d8cbdcfc1"
      unitRef="usd">70000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i416b15a8a7a9405fa9afdca4905b3480_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTEtNy0xLTEtMA_13878d81-8645-470a-9340-8f653824cff5"
      unitRef="usd">49000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i4b2305d63e914c5a801615d0a836fd82_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTItNS0xLTEtMA_6d38e9fe-181f-49c8-866e-64b0b08b40a6"
      unitRef="usd">375000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i4e55f5c070a64f55b6535d792904a04d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80My9mcmFnOjIwNGQ5ZTcwY2I3YTRhNDFiZTYyMWJjYmI5NDM5NTQ1L3RhYmxlOjcyNzdjNzUwMjg2YzQwYmY4MGVjNmYwMzg5Zjg1NzNmL3RhYmxlcmFuZ2U6NzI3N2M3NTAyODZjNDBiZjgwZWM2ZjAzODlmODU3M2ZfMTItNy0xLTEtMA_3934e57e-5144-4d79-950f-8b0ada78f400"
      unitRef="usd">375000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzcxMg_42276795-58f8-4ea2-a137-4015ea08eb90">Restructuring&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#x2019;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2020, Merck has recorded total pretax accumulated costs of approximately $1.4 billion. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves September 30, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfOTI5_3e3f704b-121d-4d53-be1e-958054752a7a"
      unitRef="usd">2500000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfOTc0_0600b708-4fd6-426e-a4e3-847b26b2550f"
      unitRef="number">0.60</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTEzMA_9a2a6f36-9dfe-487d-b47a-e92a55af3c12"
      unitRef="number">0.40</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i03df5735331c425896e06f66d7b5f298_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTMyOA_28dcc437-530a-4237-b0e8-ca1ca180e389"
      unitRef="usd">800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTUwNg_392ddbca-8c6d-4303-a106-bc13729fa5a7"
      unitRef="usd">186000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTUxMw_0b538ff8-246d-4882-a7fb-7ab3e339f903"
      unitRef="usd">296000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTU2Ng_e9f28ddb-3c23-4216-a47f-964eae820e0e"
      unitRef="usd">504000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTU3Mw_d5e81c36-db80-4caa-964c-ee62185263e1"
      unitRef="usd">642000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMTgwMQ_4753b5d0-d233-4735-8b1a-3b03b2595d7f"
      unitRef="usd">1400000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzczNw_59f08bb9-2daf-47ac-ae89-c4662bcdd3a8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5366f568814c48f7b7b07bc4f56ba7d6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xLTEtMS0w_33bf4439-5822-41e0-a1f4-92cbb8a40cb6"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie8e35b84854a44c8979089fcdc6b2904_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0zLTEtMS0w_ee469ff8-987d-4056-9aa2-dfb232137961"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i60ef15a431a448c983ceb5183ff67376_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi01LTEtMS0w_cd22a2c2-94b8-44ce-877d-bb771b5a48a6"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi03LTEtMS0w_667ce273-fb20-4438-a5a9-afbcd378d667"
      unitRef="usd">38000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibf78bc89101f49d49da83f8937116a1c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi05LTEtMS0w_09d41b67-e9db-4289-9e04-0b8ba45f1851"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ica4a5bb3156148598a1e1f9ae18ef04f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xMS0xLTEtMA_d08a267d-6c4b-4539-a5b6-e73c418c9dc4"
      unitRef="usd">89000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibe562f89249d4b43afbae31ab4ce846c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xMy0xLTEtMA_64e4b8b5-10eb-4b24-9e4b-46899b69294d"
      unitRef="usd">42000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0e10375bb6d64e70929401d584732bef_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMi0xNS0xLTEtMA_af5572d5-18a4-4de1-b04c-37287da4dae7"
      unitRef="usd">131000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6fecd12fd431414ab4ca6f2ad011b352_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xLTEtMS0w_a1788581-6846-4059-a91d-9f4b8156f1d9"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i690cdcbbd385411cbf1ba1c4cd5fdb4a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0zLTEtMS0w_e7433926-d8f4-4298-8546-e1b56577cc75"
      unitRef="usd">15000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifb0c8a5aab924e72ab1c5b49254dc12d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy01LTEtMS0w_d01efc7f-fa8b-47f9-be13-2a73cd4aa16b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaed7648249e34fcc824408b9de77708f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy03LTEtMS0w_d337e990-cf06-4631-afe3-3418ac5aad42"
      unitRef="usd">15000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib983a94ca97d45f787f3cb16f067a659_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy05LTEtMS0w_623437e9-3870-4ddf-9c74-eed089719ddc"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i195c75449a61434aa05bc8da3256a067_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xMS0xLTEtMA_9d9318b1-3e90-42f1-8aaf-c556a010b585"
      unitRef="usd">37000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i08999a59917842e88f521971cba054c2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xMy0xLTEtMA_bac2dd1b-f551-400f-a7b3-3a17f6ff7eae"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3bebe903b23d4dcbba8ed1365bd1e791_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfMy0xNS0xLTEtMA_95b3b392-3370-411a-80a3-019c526511ad"
      unitRef="usd">37000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idc3ad757a3474d31b0358ffd8bcf1d49_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xLTEtMS0w_b9da0f28-a3fd-4761-afed-e30f86566638"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idf9d1ae3982047b5add76445bf5210fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0zLTEtMS0w_975336a6-06c0-4c25-96b0-6f9814beb248"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia027800bf45f44df94cb3963582a6506_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC01LTEtMS0w_1d838c0b-b8cf-4ae0-bd3a-f084af8672a5"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i070cc173e6a448f3a98d517737a45927_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC03LTEtMS0w_ca770487-051d-4770-b98d-7001ad795a82"
      unitRef="usd">19000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i55afe91875264dccbe9dfa4dc20872fa_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC05LTEtMS0w_583fe504-e1b9-4421-8e76-2c007596b9d6"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iae06c8a7ac2342d19a9a90933b904d07_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xMS0xLTEtMA_34049407-1583-488b-8ead-d69de2e75ea1"
      unitRef="usd">66000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib375dc6a1ba24c1881cabe25f15d7706_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xMy0xLTEtMA_8b5e12d1-c356-43b5-8ceb-4d7a98d4470d"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i45d0d80e338f41339faf6f80cc02c591_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNC0xNS0xLTEtMA_638311bc-1b71-4a8a-b0a8-8220e017d248"
      unitRef="usd">67000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i991711e49c2d4dd69b0c61a892af6fbe_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xLTEtMS0w_541d75e8-eac0-4e70-ab61-360aaa4cc770"
      unitRef="usd">61000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5a8018c802ee402783f4d35dc51c8a4b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0zLTEtMS0w_0372de24-d2b2-469b-a0a5-aaf784ba7e15"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i17880d14005f4047b6465ac23055841e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS01LTEtMS0w_332ed2f1-a6e7-4c1f-ad65-11f6cee8f8f5"
      unitRef="usd">53000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9b8c757f331f461eab0d5987f837a626_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS03LTEtMS0w_b53fc92c-e817-460f-8341-6813921c6e22"
      unitRef="usd">114000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i900f54b60fd94491a712d08a359324a3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS05LTEtMS0w_cbe89a58-3207-401d-923f-4741bba86b25"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i13e78a92e49843fbb9317beadc1eba25_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xMS0xLTEtMA_b057e401-eaeb-4947-9362-b6c19a086f69"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iea5d2c7cc4af4df5910fd6327736a5b6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xMy0xLTEtMA_49c23ea6-ffae-4ae3-b341-f4e02e1e2193"
      unitRef="usd">126000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i54e8aaa546894b88aacd797ac4581098_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNS0xNS0xLTEtMA_e168cd3e-a643-4d19-ba60-7b0aa940b799"
      unitRef="usd">269000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i82edc63f8c3749d78bc298cec6f0f96d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xLTEtMS0w_4f888323-67eb-412d-bcf2-54ac8b83e474"
      unitRef="usd">61000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2f385b2ccdba4576aedf43c72125dbbf_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0zLTEtMS0w_cedb0ea9-40b5-4bed-814a-a9b716cc0a1f"
      unitRef="usd">66000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i39ee7a7c59a64fea97d7f02763d319bc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi01LTEtMS0w_b74d1fda-2f8a-4b8b-9582-6f0f5e61c050"
      unitRef="usd">59000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi03LTEtMS0w_2983ad8a-992c-4e92-883d-af0ace0621af"
      unitRef="usd">186000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi05LTEtMS0w_1253d582-3f75-49d4-a364-74f8335fb52f"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xMS0xLTEtMA_f0aab30d-8b04-4d05-8500-64ef91093197"
      unitRef="usd">192000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xMy0xLTEtMA_ac7e836b-c25b-4850-90a5-ec6ae398e1b0"
      unitRef="usd">169000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjA5YTdiMmVhNWQzMzRiZGE4OTJiYjcyNWIzNTI5YzdiL3RhYmxlcmFuZ2U6MDlhN2IyZWE1ZDMzNGJkYTg5MmJiNzI1YjM1MjljN2JfNi0xNS0xLTEtMA_b8218a44-63b7-46cf-b03c-64c9805985f0"
      unitRef="usd">504000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iac6098e7148348ea895e9410942d889e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xLTEtMS0w_0f8e6214-c89b-4eb6-beb9-8c109d6bd47b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia11d46afe5bb4d4dbe9c00eaac1c3492_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0zLTEtMS0w_d8776eed-ab96-4cee-8d2f-ce247dc14e76"
      unitRef="usd">41000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i472cfcc469764447a0758f2c876c9790_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi01LTEtMS0w_c9999a82-bf41-4f3a-a96c-f791d0834932"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3e3c8924793a4372a8741bdcfca35bf5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi03LTEtMS0w_7fa60e78-d123-425c-aa03-046d0c569626"
      unitRef="usd">62000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id249057c9eac47108ca7d3ebbb591f6f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi05LTEtMS0w_ed330841-a39e-45bb-9a27-276d6e813679"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5ae315aed51b4ef5ab252fc43e7d39c8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xMS0xLTEtMA_d7234b51-c5a8-499d-b511-8edc6fb29f20"
      unitRef="usd">139000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3ad00d781aca4014ad7705b32c5aab4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xMy0xLTEtMA_e56af9d5-a765-4459-92d4-22c21baef6be"
      unitRef="usd">22000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2eda964c1d12432095177f2a403fe8bd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMi0xNS0xLTEtMA_1b41bbe7-0614-4eed-9e80-314c11eb0c2e"
      unitRef="usd">161000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iee2cc47f55874d4da7e7cb748a8de516_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xLTEtMS0w_ed8a4c68-9817-4516-8cb4-aedf4d76d2b8"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ice5ff6ca1aa444b5b1aca886da4f6507_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0zLTEtMS0w_75aded07-4afd-46d3-8289-33a65d1389ca"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ib88c550ca65b41a2a95b1c07df1dfee2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy01LTEtMS0w_77412aa7-88fc-474d-b75c-cd381e68e665"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iae5f714e7bf04709ab68bb6d0c04368c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy03LTEtMS0w_2888e192-de6a-4474-9eb7-b9b1abcfd44f"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i57b2c9576daf42aaa97debb74c377ea1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy05LTEtMS0w_a3f717d1-6b16-436e-a813-8daf7ae77e85"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4115454e07d24a8e9ac482d5f838c14d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xMS0xLTEtMA_437f397a-be47-4b51-b362-fbb27f15ae9f"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i5971c370c69444c08c083e89b5e5cd63_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xMy0xLTEtMA_594612f7-1f96-4d70-be42-14fe7214fc99"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i46aa77d775fd4917ac86fb7ae4074f65_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfMy0xNS0xLTEtMA_83037c64-26c6-4492-8be5-e67a5d2f427a"
      unitRef="usd">33000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iabf0c00a539540ffb0ff76746fc77f47_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xLTEtMS0w_e8548952-31a2-4747-9033-7e44d288fc34"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i461e55ad36644dcd801b1bc34ca7c5f5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0zLTEtMS0w_717cd8e1-0c94-4752-af5a-0730c5c823ac"
      unitRef="usd">-1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i527fd9fd337149e19c3b0dcd8fab028a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC01LTEtMS0w_ec9988ad-2205-472d-ae29-a3cc702bca6c"
      unitRef="usd">2000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9575da987aca4e06b7d8e7d64abdb71f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC03LTEtMS0w_3fdcd4e5-10d4-4866-8fd9-bb157e5bd9f8"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i403aaeb86ea846378114a6861f297986_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC05LTEtMS0w_4d2daa4f-9c41-4b1c-b9ad-32af2d7682f4"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibd6a58d8069f4937a5073e16850b6b61_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xMS0xLTEtMA_6be54221-972f-414e-a13a-0c2ef891268f"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie2f29939fb6a4adc8144a86a1f1fa0a4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xMy0xLTEtMA_f9ac1ce6-11a6-4a45-9e77-fae1883ea7e6"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i925511a1d07c420bb943ffad4efc7f06_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNC0xNS0xLTEtMA_c79df1ce-de58-48d3-ba43-ca8dfaaf4d08"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6a15758d4a2849bb9a55611f14fff157_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xLTEtMS0w_a69c2e58-df79-42fc-a3c2-ef8483d8ddf8"
      unitRef="usd">205000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i78ce36018a4a4b87beac4699cee74ff0_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0zLTEtMS0w_d07ebfbc-f4fe-43ea-b550-3c47bd14655e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i54180e23c792425c947ae0b2a21aed19_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS01LTEtMS0w_7db608d2-17da-46f7-88bf-46d840fda83b"
      unitRef="usd">27000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i23df0efd04e04b098e88861100d3586f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS03LTEtMS0w_554f8252-f237-4767-85aa-e646e783c04a"
      unitRef="usd">232000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifa78a4b6d7eb4b8cb4b91c89c4da9930_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS05LTEtMS0w_954cdf75-ae24-41c3-8628-13824a346bb7"
      unitRef="usd">358000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i37617f3467a144fb952951327ab34f7e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xMS0xLTEtMA_004f8690-ad0d-4853-94a1-76a4d6e3f138"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3f1dbaeb50ad4a1eac4d94e2a65c9d04_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xMy0xLTEtMA_72bcac81-e50d-4bdc-8800-727a48eab15d"
      unitRef="usd">86000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i839190f80323464f9bf5f1c57c708e99_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNS0xNS0xLTEtMA_2ac9f457-7bc2-4b9a-8faa-424fdc32566e"
      unitRef="usd">444000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0622c35f09b249ecb7e04d44c43f9a29_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xLTEtMS0w_9dfe8447-32d9-42c9-a039-56bd8fb59904"
      unitRef="usd">205000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id39f12905a33428bb5c546d1a6abec0d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0zLTEtMS0w_8ee0909f-53ce-4cc2-917a-fdf8cb99f023"
      unitRef="usd">41000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie882429bc0d748c8a0b03fb32a34139c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi01LTEtMS0w_0faf35c7-85f1-4263-bb91-e276f6c89c0a"
      unitRef="usd">50000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi03LTEtMS0w_8f3f8d24-f410-4a85-b43b-4cd5f89313cf"
      unitRef="usd">296000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i34a1493f82274c09859007cd79eacd11_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi05LTEtMS0w_66417fae-9fce-4432-b49c-3100de2f6cdb"
      unitRef="usd">358000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i600eb20f2b2d4307b840f143cdefa814_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xMS0xLTEtMA_3fe7d6b2-e4d5-47bb-863a-a46dc9d77a3d"
      unitRef="usd">173000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i09cb0595ddce45a290d0d525d2a81f01_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xMy0xLTEtMA_998a5a70-47c3-4804-bfda-113f2fd3b5d4"
      unitRef="usd">111000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOmY0YjhmNzE4NzY0NTQ5YzNiMGZkYTMxZmI3ZGRiMWU5L3RhYmxlcmFuZ2U6ZjRiOGY3MTg3NjQ1NDljM2IwZmRhMzFmYjdkZGIxZTlfNi0xNS0xLTEtMA_b59e7f6b-7250-4079-b63a-bc2f80a5ce3d"
      unitRef="usd">642000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RleHRyZWdpb246M2Y5MDIxYjY5NjNkNDVhMTg2MTgyNDkyZmViMGJlOTZfMzcxNQ_72c24008-f901-4e1a-90f6-148cca040619">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserves September 30, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="iba0a355198574cf8a0944647df846e14_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS0xLTEtMS0w_57edbd3f-d9c2-40ef-902e-84337757e6a3"
      unitRef="usd">690000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i051031ffd19a4ba6b66f4482f9b16121_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS0zLTEtMS0w_71e3777e-bdb4-4766-b4aa-cced9a40719e"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8cbdc10b57a2408d87748c99f6cc8658_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS01LTEtMS0w_78e13b32-9d11-4e1a-903a-caa725563b42"
      unitRef="usd">69000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMS03LTEtMS0w_ccd1b7a8-9fff-4671-a045-9682d2e8ac57"
      unitRef="usd">759000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi0xLTEtMS0w_0af8eb3d-6f13-443b-b83b-a8f2de0ab3d6"
      unitRef="usd">143000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi0zLTEtMS0w_ceacb71d-cb20-4214-9436-fb4f2fa70337"
      unitRef="usd">192000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi01LTEtMS0w_3b247626-9366-4301-8f16-62732c82f38e"
      unitRef="usd">169000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMi03LTEtMS0w_1406fc56-56f3-4a13-902b-b3a2eb04eace"
      unitRef="usd">504000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy0xLTEtMS0w_b2aef363-84e9-4c54-a3a7-e0a487840ac2"
      unitRef="usd">395000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy0zLTEtMS0w_57140155-92c0-4311-ac78-d8a22172cdf5"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy01LTEtMS0w_18080372-6d1a-49e0-8265-acaf69f2fbf6"
      unitRef="usd">237000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfMy03LTEtMS0w_32d54cf8-9a5a-4b04-ab69-eb8d26231123"
      unitRef="usd">632000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i84e22e70278b4fcab4bffb6525179244_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC0xLTEtMS0w_fc3704d9-6db3-499f-90d4-810352e3fcc9"
      unitRef="usd">0</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i48c42dab24ed4e869ac374c0e1bbd0e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC0zLTEtMS0w_12863d56-6406-4207-862e-237feb0692fa"
      unitRef="usd">192000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i8af44f4db2f44cecb5d755c9e23a65b2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC01LTEtMS0w_90bd895e-ab65-49df-b702-71fc9ba9ffbf"
      unitRef="usd">-39000000</mrk:RestructuringReserveNoncashActivity>
    <mrk:RestructuringReserveNoncashActivity
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNC03LTEtMS0w_235bc90e-9596-4716-bd61-93da31b476bc"
      unitRef="usd">153000000</mrk:RestructuringReserveNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i8a928a5e815d4cabb958c8a84b7958ae_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS0xLTEtMS0w_d44baf66-e6d6-43f6-9cbd-7b95ca4dfdf1"
      unitRef="usd">438000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic8c0393b19a348d7aa690741b65c628e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS0zLTEtMS0w_5bacd04e-5dee-4d7a-a8dd-9b11c29723bd"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i309613a945a243f8881020b1a11c44c6_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS01LTEtMS0w_eee1bdbe-baa7-492e-bf80-1920cb9bd00f"
      unitRef="usd">40000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80Ni9mcmFnOjNmOTAyMWI2OTYzZDQ1YTE4NjE4MjQ5MmZlYjBiZTk2L3RhYmxlOjlkMjFlZGI1ZTZiNDQ5YjJhYTUzYzRmYjQxZTk1M2NhL3RhYmxlcmFuZ2U6OWQyMWVkYjVlNmI0NDliMmFhNTNjNGZiNDFlOTUzY2FfNS03LTEtMS0w_32366073-d53f-4fc7-82dd-8fd15935992a"
      unitRef="usd">478000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2OTU_388eec1b-eda3-4400-be0a-8f12750749ce">Financial Instruments&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#x2019;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCI into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020,&#160;five&#160;interest rate swaps with notional amounts of&#160;$250 million&#160;each matured. These swaps effectively converted the Company&#x2019;s&#160;$1.25 billion,&#160;1.85%&#160;fixed-rate notes due 2020 to variable rate debt.&#160;At September&#160;30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the Company estimates $155 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net (gains) losses recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at September&#160;30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at September&#160;30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020 and September&#160;30, 2019, the Company also had $508 million and $393 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $21 million and unrealized losses of $3 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to these equity investments held at September&#160;30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $4 million and unrealized losses of $12 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to these investments held at September&#160;30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2020 were $128 million and $24 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Quoted prices (unadjusted) in active markets for identical assets or liabilities; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily all of the asset-backed securities were highly rated (Standard&#160;&amp;amp; Poor&#x2019;s rating of AAA and Moody&#x2019;s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included $6.6 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value September 30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Balance at September&#160;30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At September&#160;30, 2020 and December&#160;31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2020, was $32.6 billion compared with a carrying value of $28.7 billion and at December&#160;31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $34 million at December&#160;31, 2019. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. No cash collateral was advanced by the Company to counterparties as of September&#160;30, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="ia319b8cd1cf240fc8cf6a6cf572ed109_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ4MQ_2b219f98-0cba-409c-9b10-9495c632a724">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i082ff741b7854aa59ffd11f6af0439fa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNTAxMg_ff026d29-4570-4281-8ad9-425c153f7cd1">P1Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NjQ_21e3237e-3b80-4f49-b0b7-9b45a270c244">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; No amounts were reclassified from AOCI into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xLTEtMS0w_cf387c16-0748-4f02-b114-df1b174a722f"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0zLTEtMS0w_d2220b78-fa16-4da5-ab63-ab5edca45f0e"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC01LTEtMS0w_dbe0a796-6417-46c7-ab8e-85f101d923dc"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC03LTEtMS0w_90071c73-01c5-4e97-a8d8-80c0598b8253"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="if3cffc90ec6148909d3599ea1d9df327_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC05LTEtMS0w_82972282-b507-4fdc-a2a1-8120f47b3919"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i4b807ee322bd4ee9958bad75b8677e25_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xMS0xLTEtMA_2dbb3dd1-a406-4617-9fb2-585bd9aae343"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i7fa29d8b186047fc9548a924b7455a42_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xMy0xLTEtMA_05e68b2d-f873-4772-9c10-07c73c1fa1b7"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ice720ee19510470cb2be22bfa752c7b3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNC0xNS0xLTEtMA_ab29cc30-9a58-4f1e-9436-f0bb9d617e42"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if8d2767b71a8465d8afd845a2deff157_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xLTEtMS0w_5be1733b-f7de-4758-853d-99cb9c58280c"
      unitRef="usd">-162000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i48bafb9af91b4c66810b2658a0fb8100_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0zLTEtMS0w_5b5a04f6-8562-4af4-bbf9-ca04a3940f28"
      unitRef="usd">150000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ief51f272bb714d06bb4d146033290b24_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS01LTEtMS0w_a1079143-6974-4777-b232-c0154a65d989"
      unitRef="usd">-182000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie9862822be464d7590cac38e8a733045_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS03LTEtMS0w_97f37f7e-bf0d-4441-bbdf-1e31dbfe1e9f"
      unitRef="usd">152000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ie877415544764c93a0e92480717fd720_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS05LTEtMS0w_b3a0222d-491d-47c8-ba4f-37a374c373f7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ic1ac34bac82349ec87abc769df473091_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xMS0xLTEtMA_c793e09a-2743-4210-b3dd-bf979c80bd1d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i102e8398b68443efb7c670be371e221d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xMy0xLTEtMA_d9fd5a56-0dec-46c3-a932-463ac17040ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="id7f7ee9e6e6f4549b1c06a6e2ee15ae2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmUwNWM1NDIzZTg1YjQ3NDBhNWZhNjc1MGY4OWE0N2E2L3RhYmxlcmFuZ2U6ZTA1YzU0MjNlODViNDc0MGE1ZmE2NzUwZjg5YTQ3YTZfNS0xNS0xLTEtMA_1e644d7e-c278-4f8b-a722-bcb9d2404025"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ie8db34a980b2470aaaff3a2d9dc09883_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzA4Nw_93df0738-f35a-4de2-807c-6f92aac61b58"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie8db34a980b2470aaaff3a2d9dc09883_I20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzEzNQ_ec202b68-2a0c-483b-87bd-d9a051d54c05"
      unitRef="usd">250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i174087d9f6454aebb32d8415fd4b71d8_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzIwMA_5203146a-ee73-48bf-adaf-2d599e8ceed8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i174087d9f6454aebb32d8415fd4b71d8_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzIwNA_d3f9b8ed-b7eb-41fc-814c-61cb90ab5cee"
      unitRef="number">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NDI_d0b8b5bf-4e78-4535-8ba8-f0bb6ef4f27a">At September&#160;30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par Value of Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Number of Interest Rate Swaps Held&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Swap Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.875% notes due 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.40% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.35% notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ibd638b943ba14bbaa99c094906c46496_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfNzI5MA_d67f6b80-a687-4e34-8274-32ba0d68e43a"
      unitRef="interest_rate_swap">14</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0wLTEtMS0wL3RleHRyZWdpb246ZGQxZmI1ZGNiMDEyNDA1ZWFjZWVjZjI1M2YxY2NkOTNfMjE5OTAyMzI1NTU4Mw_b17e9853-8625-46ac-9af2-016c1e790ca9"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0xLTEtMS0w_08749588-4737-4a5e-bd01-9657409390f9"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi0zLTEtMS0w_0536d06a-da88-4551-a182-119537b0586d"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMi01LTEtMS0w_095401ff-1202-48df-934c-6c97f984a5a5"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0wLTEtMS0wL3RleHRyZWdpb246MDAzZTIzYWJiNDNkNGEyY2E1ZGZlMWUyM2Y5NTJkMjlfMjE5OTAyMzI1NTU4MQ_15d83318-b027-4a66-bf7e-4412fd2a3e7b"
      unitRef="number">0.0240</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0xLTEtMS0w_68f1c600-9ed1-43b1-a400-082f05d7062d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy0zLTEtMS0w_08522ffa-9f1f-442b-8e31-d2b5a45a2d92"
      unitRef="interest_rate_swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia515ed5a6863469596b5d8b9a986ea6f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfMy01LTEtMS0w_c96615b1-c9a0-4332-b9dc-f93401c27e39"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib089735791f34e7e946205004d6a744f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0wLTEtMS0wL3RleHRyZWdpb246YzVkNjI1NDdjZTdjNDdkMmI1YmE1Mzg2Y2ZjZTc0Y2RfMjE5OTAyMzI1NTU4MQ_3884f3a8-3671-461c-9a5c-f034df7a95ce"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib089735791f34e7e946205004d6a744f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0xLTEtMS0w_ca46ee7b-0795-4372-bb0b-c47a3d0e9689"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="ib089735791f34e7e946205004d6a744f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC0zLTEtMS0w_a9841832-ec2c-458d-b35e-9c4ffce60edf"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib089735791f34e7e946205004d6a744f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjIxMTc1NTBhZDE0ZjQ4N2I5NWY1ZTBiOGMxMDYyMTliL3RhYmxlcmFuZ2U6MjExNzU1MGFkMTRmNDg3Yjk1ZjVlMGI4YzEwNjIxOWJfNC01LTEtMS0w_e9ee9835-a0c9-4586-abee-8187e9cb8c4d"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NzI_f6548899-5669-48a3-92e1-508a178869f3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Line Item in which Hedged Item is Included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loans payable and current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-Term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy0xLTEtMS0w_bdc1fe1b-48ca-41ed-8ec7-544f22851b21"
      unitRef="usd">1155000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i1cd8cd4de38943e2b14074d9417f6715_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy0zLTEtMS0w_556fcbf6-6d8b-4d51-87f3-f3b192d2fb91"
      unitRef="usd">1249000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i2dbc854f67d845b19f16eeb52ee6dd09_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy01LTEtMS0w_d6228664-b101-4bef-8b45-25b2a69b2a46"
      unitRef="usd">5000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i1cd8cd4de38943e2b14074d9417f6715_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfMy03LTEtMS0w_a250223e-e5e4-49cc-8936-4d1abdaf679e"
      unitRef="usd">-1000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC0xLTEtMS0w_50ec4dd6-978d-4d69-bcdb-ffdfdb60b3b5"
      unitRef="usd">2309000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i7ef73b3681a741db8a0d3055eb532b01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC0zLTEtMS0w_468cdca1-def1-4af6-b7c3-0537cc5ee499"
      unitRef="usd">3409000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ie8c3f04e2dfb47e5833c3f837fccb320_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC01LTEtMS0w_b5e078d7-a21b-4cda-8ab5-fe0e76ada5a0"
      unitRef="usd">62000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i7ef73b3681a741db8a0d3055eb532b01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjJjZTRiNDIxZWIwNDRlZGM5YmRiYWYzZjAwM2QzNzdhL3RhYmxlcmFuZ2U6MmNlNGI0MjFlYjA0NGVkYzliZGJhZjNmMDAzZDM3N2FfNC03LTEtMS0w_9ae05f96-461f-45c0-bccb-9f7477e24269"
      unitRef="usd">14000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NzQ_42261f15-556e-4e8e-8cde-75660085ec77">&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.301%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="if78266c2751d45698fdfe199e03b129d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC0yLTEtMS0w_88cdf284-0fd2-4355-bdc3-4e6233464ae2"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if78266c2751d45698fdfe199e03b129d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC02LTEtMS0w_d19b25b7-1597-4a5a-a250-7aec288ed84a"
      unitRef="usd">1150000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="id1023089c2c54a80a18259c1511f87c3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC04LTEtMS0w_f816ca8c-8940-4b4b-a072-4e0f066cb42d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id1023089c2c54a80a18259c1511f87c3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNC0xMi0xLTEtMA_06b231db-5480-4864-a410-427150a6f8ee"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iaa826dff4de743c7acb6d521bd66ea9f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS0yLTEtMS0w_33e7c33c-d22a-4b96-abe6-1ac8629eefe3"
      unitRef="usd">63000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaa826dff4de743c7acb6d521bd66ea9f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS02LTEtMS0w_5e5684ff-0cda-471b-8f37-1e05a741fef3"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i63ec13cee627454ebf66f0d6ed39894a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS04LTEtMS0w_8435231a-dfd0-4db5-ae4b-f2b19c4e2ca9"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i63ec13cee627454ebf66f0d6ed39894a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNS0xMi0xLTEtMA_f4d5606f-74e0-485c-b9a9-68bf57df14c7"
      unitRef="usd">3400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i21967f622cdb45cebad35ad052ece1de_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi00LTEtMS0w_c6428f2b-0285-453c-9367-0367e81b6b32"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i21967f622cdb45cebad35ad052ece1de_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi02LTEtMS0w_e91d5066-0eef-4890-89d2-89deb7622b2e"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i08b48c75e8014c2382f84a5d33f0efe2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi0xMC0xLTEtMA_ab3c9473-7062-4be0-aa2d-2a683e16c697"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i08b48c75e8014c2382f84a5d33f0efe2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNi0xMi0xLTEtMA_ba573339-4453-4522-9204-1d134da314d4"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i66d507c1385a4984b104b15b14ad0b87_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy0yLTEtMS0w_31d9456c-596f-4cb3-b226-0578922fee57"
      unitRef="usd">30000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i66d507c1385a4984b104b15b14ad0b87_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy02LTEtMS0w_346e686d-6e93-4efc-8d90-9b3f8687a091"
      unitRef="usd">4120000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ibebb8d0e743c4bc3aef276f00d195299_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy04LTEtMS0w_a0dc5bb9-37cf-4e6e-a910-05098bcd9646"
      unitRef="usd">152000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibebb8d0e743c4bc3aef276f00d195299_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfNy0xMi0xLTEtMA_e138a279-673e-40ca-965e-a2cfc2ec6fce"
      unitRef="usd">6117000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i62d19d97eade44b698ef4d90c18cfb52_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC0yLTEtMS0w_e0db0845-0058-4427-bf12-e586d9bf5b62"
      unitRef="usd">59000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i62d19d97eade44b698ef4d90c18cfb52_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC02LTEtMS0w_bf7bf5ae-5aa4-46d5-ae02-f493b974b3ee"
      unitRef="usd">1881000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i3cb0bacacaba494588fdc16bec7aad2b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC04LTEtMS0w_236e46d7-6ed4-4ca2-97f9-aeb544a0fe40"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3cb0bacacaba494588fdc16bec7aad2b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOC0xMi0xLTEtMA_36ca8070-47d3-4bb4-97ac-4d41c5440982"
      unitRef="usd">2160000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i0a28e0e89eaa4a0381eb181749135076_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS00LTEtMS0w_38b7bf64-41bd-4a5b-a275-b3ebe4d850e0"
      unitRef="usd">104000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i0a28e0e89eaa4a0381eb181749135076_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS02LTEtMS0w_755ce991-fb95-4ab8-ab8a-320e411cbd45"
      unitRef="usd">3096000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i56b722555bf44b6282741eb433c205bf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS0xMC0xLTEtMA_1c7827df-ee4a-4c09-9749-eddd933e1c60"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i56b722555bf44b6282741eb433c205bf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfOS0xMi0xLTEtMA_e0eef132-466f-4a8f-8678-0adf822f5707"
      unitRef="usd">1748000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i1c4627226ed34963af481b31b209e7d1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtNC0xLTEtMA_fee39e62-51dc-4ecb-8f07-39059b93ef8e"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1c4627226ed34963af481b31b209e7d1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtNi0xLTEtMA_a5a364e7-a1db-4af9-88d8-b6d1df546b4c"
      unitRef="usd">157000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i01c1b766e702403daadda490393c9ef9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtMTAtMS0xLTA_1ffb09ee-8fc6-41cc-a80a-ca2fabb67244"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i01c1b766e702403daadda490393c9ef9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTAtMTItMS0xLTA_41d19ad7-8096-4861-9de6-1497e86950f6"
      unitRef="usd">53000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMi0xLTEtMA_5b5ab74c-f379-4b9d-b1ad-b2683e16b2c6"
      unitRef="usd">158000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtNC0xLTEtMA_db08962d-7b7e-4f7a-b7d8-e2de7b2f61d4"
      unitRef="usd">105000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib4207f99483f4b8f940795c3f462096f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtNi0xLTEtMA_f037d46c-975b-4ee8-9e90-9ca712235ef1"
      unitRef="usd">12654000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i77b4c081c7234c27a717225ff5066862_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtOC0xLTEtMA_d9d7056c-c404-4308-834e-b900bfc8a71b"
      unitRef="usd">222000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i77b4c081c7234c27a717225ff5066862_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMTAtMS0xLTA_0682e6e4-b0d8-4f71-a8c0-003a8c62f5a3"
      unitRef="usd">24000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i77b4c081c7234c27a717225ff5066862_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTEtMTItMS0xLTA_5cc269cb-dd7f-4780-b983-3c29e7f8640b"
      unitRef="usd">14728000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtMi0xLTEtMA_9ea6e315-2b10-4679-b231-20a172272fb9"
      unitRef="usd">81000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i49aafffb24cc4abfbccf696a2d12e2c4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtNi0xLTEtMA_4319e297-e9e9-471c-a9ad-44b4a2f60fb4"
      unitRef="usd">5455000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i009ad414b39545bcb9714e42490d7cfe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtOC0xLTEtMA_6effcc2a-4307-473a-bb08-14a957f610f5"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i009ad414b39545bcb9714e42490d7cfe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTMtMTItMS0xLTA_796527e6-95c6-4f77-a4a5-8a323e1be034"
      unitRef="usd">7245000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i5f62a4056afb402185c1fd095207abdb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtNC0xLTEtMA_ff6ef8c2-160a-46ce-bc2e-43a021f5b2f4"
      unitRef="usd">171000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5f62a4056afb402185c1fd095207abdb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtNi0xLTEtMA_f671a3b7-e14f-4b2b-b535-ef91f31ce942"
      unitRef="usd">8042000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i5b237fa0466c445994cb3f605edb9744_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtMTAtMS0xLTA_80c9b522-4f31-4424-b402-18e35008d889"
      unitRef="usd">73000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5b237fa0466c445994cb3f605edb9744_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTQtMTItMS0xLTA_db03db3b-1786-4e53-a4d5-a87b3620d3be"
      unitRef="usd">8693000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="icf0afe3813f94b848a3beb92819435d7_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNC0xLTEtNDc4NQ_13e84c55-46a7-44b6-a9d8-c33e5a11a51c"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icf0afe3813f94b848a3beb92819435d7_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNi0xLTEtNDgyNQ_a180f513-be98-4bf0-a6f1-fcc6542bb6a9"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTAtMS0xLTQ3ODU_33f49db4-57b3-4b0b-adef-02d385a0f35a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic19eb7f120354c2a93d7d4c926cd7bab_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTItMS0xLTQ3ODU_f3cef186-1724-4965-b3d0-a2a193476182"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMi0xLTEtMA_302de65d-1d6d-4cdc-925c-f33698df8896"
      unitRef="usd">81000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNC0xLTEtMA_251c4d0a-601d-4a52-aae3-f8f0469e53ac"
      unitRef="usd">193000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icf7c81a6717548f3a8cb066f1d5113f1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtNi0xLTEtMA_1a9940d4-38fa-44d7-b680-2a86e8b0ef28"
      unitRef="usd">14497000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtOC0xLTEtMA_464a358f-98c8-4fe4-8991-83aaa4bdd3e1"
      unitRef="usd">66000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTAtMS0xLTA_98719d03-5215-4118-9218-a4649182eda1"
      unitRef="usd">73000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i68ba62239ca44acebbb3f35490c6701e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTUtMTItMS0xLTA_cdbc5790-4b23-45d8-926f-8a40f370838b"
      unitRef="usd">15938000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMi0xLTEtMA_f27b34f3-b292-4196-9742-d6be2846cd22"
      unitRef="usd">239000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtNC0xLTEtMA_ca650909-2eee-4ad1-a27e-55743663cb52"
      unitRef="usd">298000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtNi0xLTEtMA_be559448-14ad-473f-9ffa-2fa1c6f8d277"
      unitRef="usd">27151000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtOC0xLTEtMA_b07a8e97-61ae-4d9f-ada2-aba6d602ef40"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMTAtMS0xLTA_f8d03d74-8ca0-4124-867a-3538a4832cb4"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjMyMGYwMDk0MDVlODRlODZiMjY4MTc4OGE2Y2Q2OWRjL3RhYmxlcmFuZ2U6MzIwZjAwOTQwNWU4NGU4NmIyNjgxNzg4YTZjZDY5ZGNfMTYtMTItMS0xLTA_a501dbf0-43b3-4859-bba5-e876c07a99b7"
      unitRef="usd">30666000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NDU_0a82f0aa-f5c1-4c05-9801-b1a00a7a33ac">The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi0xLTEtMS0w_a3f59a9d-ad27-40fc-837e-418401f9e1ef"
      unitRef="usd">239000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi0zLTEtMS0w_d4f432ba-fb18-4cc1-ad48-2c5e59cd0cb3"
      unitRef="usd">298000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi01LTEtMS0w_74f11f9b-c623-4eec-96bb-fde008c71f0b"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMi03LTEtMS0w_4d2a7f8b-b54a-4167-9404-34f6fb52e5aa"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy0xLTEtMS0w_3a5dc671-b20e-4c20-8efb-e92ec587a428"
      unitRef="usd">140000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy0zLTEtMS0w_abd0e2aa-d529-47dc-b6c5-43d1051c565a"
      unitRef="usd">140000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy01LTEtMS0w_7c0a0427-b6dd-44b9-a328-4705c26b7232"
      unitRef="usd">84000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfMy03LTEtMS0w_b9dcf4e3-ed29-4174-bd15-3c988d82480f"
      unitRef="usd">84000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC0xLTEtMS0w_b817e4ed-0295-482c-9035-bb89fe4b1604"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC0zLTEtMS0w_f90f6d7e-0821-407e-b844-d6394eb61c51"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC01LTEtMS0w_4b7bd622-7429-467d-9a07-acdd3a330f8e"
      unitRef="usd">34000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNC03LTEtMS0w_f2259e19-341f-4e8b-ab38-ba0c4cd9de7b"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS0xLTEtMS0w_2ab8d516-0fd9-40d0-9107-c88700c335ca"
      unitRef="usd">99000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS0zLTEtMS0w_8c9fea14-55b8-4c46-a66a-a16d23ee85b0"
      unitRef="usd">158000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS01LTEtMS0w_e80e73a3-2098-4614-a1e3-84b835a0dab1"
      unitRef="usd">170000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjlmZGYwYjU3NTVhYzQ5N2M5YzQ2OGFkODY0ZDdmOTE4L3RhYmxlcmFuZ2U6OWZkZjBiNTc1NWFjNDk3YzljNDY4YWQ4NjRkN2Y5MThfNS03LTEtMS0w_3f47536a-cd6a-4591-a43e-cbd9ad897ce5"
      unitRef="usd">13000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NTg_1e747659-ffb5-4f91-92f8-950f88b8b1a3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.686%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xLTEtMS0w_ed85604e-117e-4fd2-8523-1f6252bd9e23"
      unitRef="usd">12551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0zLTEtMS0w_4d31f31c-fd68-4e14-b5cf-f8f924b82e37"
      unitRef="usd">12397000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy01LTEtMS0w_1ca7dab9-4229-4303-868b-ed6178ff538c"
      unitRef="usd">312000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy03LTEtMS0w_0ebb5f88-477b-49e8-95f1-9f64109edde9"
      unitRef="usd">-35000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy05LTEtMS0w_b3ae5699-819b-4d18-ba07-bcc92f43a019"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xMS0xLTEtMA_ab72d760-36aa-4f98-95cb-562f4c4e3ef6"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:Revenues
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xMy0xLTEtMA_c1689e55-137a-488f-8e8d-55d3fc63136b"
      unitRef="usd">35479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xNS0xLTEtMA_e52688da-558c-48e0-8697-48b123dea50a"
      unitRef="usd">34972000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xNy0xLTEtMA_22773d74-b9cb-4558-8fda-f853aacc6ad0"
      unitRef="usd">630000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0xOS0xLTEtMA_612a0cfe-3837-48fb-bf2b-943f9233c441"
      unitRef="usd">-362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0yMS0xLTEtMA_68ab0fa1-c299-4ff5-a1e5-e2cc396f81c1"
      unitRef="usd">-190000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMy0yMy0xLTEtMA_0c4f4124-bd51-477a-a6f4-8a304f53b89d"
      unitRef="usd">155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi01LTEtMS0w_27e2efc5-7eb4-4cf8-b4cd-b339955d2faa"
      unitRef="usd">14000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi03LTEtMS0w_e131f0c9-853b-49c8-bbe3-b6e60cfefec5"
      unitRef="usd">-13000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi0xNy0xLTEtMA_d008b3c2-fe3e-485a-8851-c84fd38a3682"
      unitRef="usd">-54000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNi0xOS0xLTEtMA_300aa064-caed-468b-88ca-eb45c3b8529e"
      unitRef="usd">-101000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy01LTEtMS0w_e28fda62-6054-4892-b8e2-6e50d546cc4a"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy03LTEtMS0w_ec59e1ce-ed1c-4af1-aef6-cac68c62971d"
      unitRef="usd">6000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy0xNy0xLTEtMA_0d2d9b13-872a-47e3-8b26-2f9fe07f7e24"
      unitRef="usd">76000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfNy0xOS0xLTEtMA_77315abd-b999-43f5-a98c-984ba07ebb32"
      unitRef="usd">74000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtOS0xLTEtMA_617e9534-6bb3-4097-a1bb-bbe80124cf4a"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMTEtMS0xLTA_198943de-2adf-4935-ab78-098882d7b42b"
      unitRef="usd">186000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMjEtMS0xLTA_986ee591-4ff7-4663-a46f-497eea62293e"
      unitRef="usd">-126000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTAtMjMtMS0xLTA_2df73eed-b323-4626-bb8c-5c0881be92cb"
      unitRef="usd">183000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="ibd3ca1373fb24ba68251d0301a10a20d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMS0xLTEtMA_ba8831c2-f42d-487a-9338-e3d8780d113e"
      unitRef="usd">-23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1ea9d32cf204b73801d5f9d1325e43e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMy0xLTEtMA_fceadae5-781f-4a39-acd2-e5dbc0e94c07"
      unitRef="usd">70000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtOS0xLTEtMA_cb6c44b7-b444-4c1c-b05d-41b36e3ff2f3"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i06682e1e48c1497faf0efc64c8952be9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTEtMS0xLTA_adb4f772-5fe0-4996-9403-af72c2e3f368"
      unitRef="usd">-70000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:Revenues
      contextRef="i8a5e4820eed4496988270e13e3b094d0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTMtMS0xLTA_50e262ec-a562-41f4-b5ee-b532074f9953"
      unitRef="usd">65000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib552830a5da14067a97f6a37503c4784_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMTUtMS0xLTA_023428f5-6a0d-4411-bbaa-5714627b5cb2"
      unitRef="usd">189000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ia70fdd79b5f74c7ab0d84b82565740cf_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMjEtMS0xLTA_474a030a-28e7-4342-b9c9-e9fd1400be8b"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic48bb41c2342444d9e9158fa4052a16f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTEtMjMtMS0xLTA_d2dbbc72-abdd-4b01-8c49-1e71983a2c7d"
      unitRef="usd">-189000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ide0d752aef624394872e15d539a1b6e7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtNS0xLTEtMA_dea86df9-e5c7-4426-aa2f-1b2a54516a74"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i75f70a0d4d9b4cf380af1efd26bd86c4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtNy0xLTEtMA_900ff081-0d44-4aba-821e-fdd514ac9b09"
      unitRef="usd">-1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i0b43b454063948cb89981a3cbc7b0b98_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtMTctMS0xLTA_682f9b63-f5dc-4317-be3a-cc7c30564361"
      unitRef="usd">-3000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i53f2df04743c4c51be6cd38f4035ed95_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTMtMTktMS0xLTA_a31f3caa-127c-47eb-a250-144203472c68"
      unitRef="usd">-3000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtOS0xLTEtMA_5ef644d4-61a9-4296-8f4e-110b40ef805c"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i7e7e123c95db456a843cb9b4ea2ee304_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMTEtMS0xLTA_bc27ffbf-622e-4356-8f42-628abe7c4889"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie6199f48889a49748506a4b635c3bb86_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMjEtMS0xLTA_030e5f7b-36e9-4e68-98ce-6c1ce744e640"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ieae423a542494b8d9adff25f3bf634fd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjU1YjBkMDQwY2IwYjQ2ZjA4NjJjNzE4MWE2MzRkM2VmL3RhYmxlcmFuZ2U6NTViMGQwNDBjYjBiNDZmMDg2MmM3MTgxYTYzNGQzZWZfMTQtMjMtMS0xLTA_31a0b6b9-a1ac-4d27-bc40-3f9fb2b72662"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2ODU_86f06323-46ff-4879-ad57-a63c1aa51843">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivative contracts serve as economic hedges of forecasted transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; These derivatives serve as economic hedges against rising treasury rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC0zLTEtMS0w_c7671841-7352-460d-89e7-0da70ff38441"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i34c5e6efb1434480a3a0aac64deb74fc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC01LTEtMS0w_17c85079-f592-4684-94b4-3d6d61565689"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i2fd5010fab09451c946ea37d93a410e6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC03LTEtMS0w_d9728889-e3d1-4116-ba52-3e0d2f0ab93b"
      unitRef="usd">138000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i7e626082878b47229b64aad4223936be_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNC05LTEtMS0w_3e93e764-3a19-47f3-9cf2-2ada2e4e0d1c"
      unitRef="usd">-112000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i84727b70c6dd4761b253ea527ddd0887_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS0zLTEtMS0w_62cf77a0-62b4-4d3c-b7b6-a20ed7d3a540"
      unitRef="usd">-7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i812ca05ea4394a4dac627795b29c49aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS01LTEtMS0w_84f16add-e8c0-4173-8cbd-ae72cbc1b6ef"
      unitRef="usd">11000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5e39e07079d24f1d97851dd0941257a9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS03LTEtMS0w_d5d05f39-61b1-4dab-8033-71998af5683c"
      unitRef="usd">-4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0874acdea1b94c23a104b3d79fa7bc54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNS05LTEtMS0w_1fcdcd5f-b566-4029-95d6-62beb6532e99"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i924cd3c5889b4fa5a227f02451269580_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi0zLTEtMS0w_7c980e3a-cbf3-4337-a26c-4b612294afeb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iaa5f04d36a4044a793fc61d278bd3322_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi01LTEtMS0w_3961da5b-c7a5-4227-b986-3efe806e7bbc"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i46bd265492f54f4c8caf95f9c471e390_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi03LTEtMS0w_ea6930ed-8a1b-4b53-b744-512aec260173"
      unitRef="usd">-9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6804bab188cb4e53b4fdd152aab4cfbf_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNi05LTEtMS0w_fdf23704-234c-40cb-befd-593fc0abac99"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8de1818a4f884cb384c99b6554fafaaa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy0zLTEtMS00ODAz_13530a0e-22fc-4acf-8215-5c19b04e3b36"
      unitRef="usd">-22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i9334afd80f1c4e62b06c088ba45904e4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy01LTEtMS00ODAz_b08b4cfc-8651-4291-b030-530b9a6fe861"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="if9bcef7dcc6d49e88feb6e96d724788d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy03LTEtMS00ODAz_e2b10062-4753-437f-b58f-3583dc1ddfd1"
      unitRef="usd">-22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="idfcc3a06092c43dba855fc359441f405_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjNhYTFhYjZmZTMyNTRhMWJiYzY0OTU4YzM1OGExZTNhL3RhYmxlcmFuZ2U6M2FhMWFiNmZlMzI1NGExYmJjNjQ5NThjMzU4YTFlM2FfNy05LTEtMS00ODAz_1ad11ae0-0285-4776-a382-23d32422700f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfOTcxMw_42c947cc-08f8-4d40-bc92-51d531f393bf"
      unitRef="usd">-155000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg3MTU_2c8402aa-a688-4dba-b222-71f8de0dbaea">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net (gains) losses recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at September&#160;30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; on equity securities still held at September&#160;30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xLTEtMS0w_bbcbc0cf-ed91-4d8d-bfef-7554441e41d0"
      unitRef="usd">74000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0zLTEtMS0w_09eb3346-b16d-4b36-af66-d01ce6a9bcd3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy01LTEtMS0w_3faca50d-64b3-460e-9339-9666e1c76098"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifca8bb4bb8164a2a8869dee454cc4519_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy03LTEtMS0w_48f93b04-4600-495a-9954-9f68ce676d1c"
      unitRef="usd">74000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy05LTEtMS0w_6879a916-e76a-4c93-a4bf-db724925446f"
      unitRef="usd">266000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xMS0xLTEtMA_cf39d91e-25db-43f2-bb6e-caeda963f810"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xMy0xLTEtMA_2a5ce312-31c8-4376-a9d2-0da898f88f31"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49af6e85df0d44aab61037549d8b7ec7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMy0xNS0xLTEtMA_4d8b3e02-0887-4ca4-b564-482fe3907667"
      unitRef="usd">269000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie85db4eee737467d84fa784c0406b915_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xLTEtMS0w_22deca63-2044-492a-9a77-a14904d51e1d"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie85db4eee737467d84fa784c0406b915_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0zLTEtMS0w_6ca1c2fe-7177-44c6-b6b8-40889888b812"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie85db4eee737467d84fa784c0406b915_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC01LTEtMS0w_4446aee5-d2f5-4892-a03e-c7219da5b707"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie85db4eee737467d84fa784c0406b915_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC03LTEtMS0w_1d0d62b5-f772-4456-9f41-e559996ff8cd"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC05LTEtMS0w_b9dac7c7-1237-406f-917f-309f8170b5bc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xMS0xLTEtMA_29c4d1f3-0ed3-4703-9b22-7f0222f3b935"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xMy0xLTEtMA_3b199a1a-2bd1-453e-ab60-1f902a4641e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f31c0e3c79745898f6a563992c13494_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNC0xNS0xLTEtMA_23185d7e-2e14-40e9-a1f1-32239eb1f2c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xLTEtMS0w_8c2058da-d669-4e9c-8612-f1864d2ceea9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0zLTEtMS0w_9724e735-34df-4751-8614-f99442f278dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS01LTEtMS0w_0ca0a38a-5399-443e-8777-25cd1a676408"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c141fe83ea54eb294e21e30b6d5921d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS03LTEtMS0w_10dd3c8b-0422-4e73-a4e1-07b72e4e4c6f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS05LTEtMS0w_7dc1cd13-ff42-408a-9a9d-85344d1b9cd5"
      unitRef="usd">668000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xMS0xLTEtMA_8c277058-0bd2-4e8f-849a-608f18d7f4c6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xMy0xLTEtMA_147dc27e-aa4f-4316-9dce-d6d67526a2e3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f79830cca114e6ba2294c2eb4be7851_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNS0xNS0xLTEtMA_e6837c66-4f07-4779-9d3b-8d6834bc8e84"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xLTEtMS0w_d85c2b5b-0667-4133-9ac1-74e7387fca56"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0zLTEtMS0w_7cd46d6a-3e8e-45e0-9f97-92738eb11bea"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi01LTEtMS0w_c3f784e4-ef50-4713-982d-0248c72a310e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36602f32e5a74d8a81439836a90cda02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi03LTEtMS0w_531a5847-1559-4951-b0cc-81e831a77709"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi05LTEtMS0w_550c9b2e-f023-4955-96e1-ef1b87053ded"
      unitRef="usd">608000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xMS0xLTEtMA_525f2b67-98bb-4d1f-92b7-64c68bae60c4"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xMy0xLTEtMA_0c6b01da-418a-4ecf-95db-69ebdeec23e6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf4c9b157f5c45a0a74b8b08bebb4842_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNi0xNS0xLTEtMA_c9ad6348-548f-4ecd-a215-4bf33afdc358"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0ed394545474492aa72d62f2775bca14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xLTEtMS0w_489e42d1-c5ae-4706-8b16-3751ca3e9e1f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0ed394545474492aa72d62f2775bca14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0zLTEtMS0w_9b1e1221-3534-43be-9a5e-a54b9ba58f09"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0ed394545474492aa72d62f2775bca14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy01LTEtMS0w_3d72881a-e237-4977-862c-aa9093e61d73"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ed394545474492aa72d62f2775bca14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy03LTEtMS0w_f0157f8c-a0b7-4436-8d94-7d5669d09e27"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy05LTEtMS0w_7a5aae2d-3302-4527-ba16-02ecb59d16c3"
      unitRef="usd">226000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xMS0xLTEtMA_30c2cc14-aa4c-402c-8543-99c1d15167c6"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xMy0xLTEtMA_2ca595ca-454a-4fb7-847a-153001a4448e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i118e80b2fde04adcab0ec33fc8b50cb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfNy0xNS0xLTEtMA_295d4f04-0000-4f5a-a6f1-2ba3f2ac8256"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xLTEtMS0w_b3185fe0-6a41-4875-8045-baf85753cd56"
      unitRef="usd">76000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0zLTEtMS0w_5b47b69a-f778-4b68-a159-0d730efe07b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC01LTEtMS0w_db29d2d8-f498-4c8c-a5c9-fe08f2bbdf92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC03LTEtMS0w_e83bb22c-dcd4-445e-82be-e3ebb1f2ac27"
      unitRef="usd">76000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC05LTEtMS0w_e01ffab8-b4da-47f7-9e9d-5f4a4ca979a5"
      unitRef="usd">1768000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xMS0xLTEtMA_27531bb7-9078-4c2b-9418-aa4633d85178"
      unitRef="usd">17000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xMy0xLTEtMA_7f5813e1-a04b-49b6-a86b-0c16dba138a7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOC0xNS0xLTEtMA_63236252-9651-4df9-9678-9ef026d3650c"
      unitRef="usd">1785000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOS03LTEtMS0w_e8c5b9ef-9a28-4ae9-9848-5a43342858ad"
      unitRef="usd">1477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfOS0xNS0xLTEtMA_5d728b21-16a5-4454-a48e-3dcf69e1a7f8"
      unitRef="usd">838000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMTAtNy0xLTEtMA_2e44ee0d-bada-4e6c-b651-1279101ef43d"
      unitRef="usd">1553000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOjFjM2IzM2U0ZmI3NDRiNzI4NTU3MWJjYWNiYTVhYzZiL3RhYmxlcmFuZ2U6MWMzYjMzZTRmYjc0NGI3Mjg1NTcxYmNhY2JhNWFjNmJfMTAtMTUtMS0xLTA_b1f2a6bd-aab8-4444-8496-a406af7102b9"
      unitRef="usd">2623000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTAzMjI_c4d1aef3-9a1a-478e-8fba-3d853b127265"
      unitRef="usd">43000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTAzMjk_196b4dec-5482-47a8-8c02-2a4d89fe3d8c"
      unitRef="usd">512000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA1MDY_6c94bc65-c935-4209-9f40-636e93399e46"
      unitRef="usd">-25000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA1MTM_60939121-fc1a-4749-b6e8-fc87a58d5098"
      unitRef="usd">41000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA2MTA_84521a11-e639-45cb-82c4-14835b496631"
      unitRef="usd">508000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTA2MTc_316f3d39-568a-4a8a-91b6-476adfbd514d"
      unitRef="usd">393000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEwNjQ_2940ed4f-cad3-4fda-99cf-19a8e8f0d9c6"
      unitRef="usd">21000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEwOTI_199a15a0-3fe2-4596-82fc-d19aaa19fc3c"
      unitRef="usd">3000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEyNTE_d47aacf1-739d-42a8-8ecc-3c34804ff2fa"
      unitRef="usd">4000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTEyNzk_37f0d070-1b80-46fc-abcb-48e611cdaed2"
      unitRef="usd">12000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTE1NTE_32425edf-ce84-4138-8834-81bc306ae277"
      unitRef="usd">128000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTE1NTg_65c80b08-b533-4bbf-b7a7-7aa4f459cc14"
      unitRef="usd">24000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2OTg_b3147c3a-21d6-4b25-9f0f-96d6dfb5c2fb">&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contract related to Seagen common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily all of the asset-backed securities were highly rated (Standard&#160;&amp;amp; Poor&#x2019;s rating of AAA and Moody&#x2019;s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8b74dc13822409f9caf279f6c6efb79_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xLTEtMS0w_affb003e-01b0-4cb8-b5e6-adbf92f141a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0910059a35fa4db3a4f1688038846dcd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0zLTEtMS0w_8fd55415-cb8b-41bb-99d3-a446081ee9f8"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bcc86aa77164a2c9e420f79d5512eab_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS01LTEtMS0w_4a271ef4-ea4c-48e0-a559-c0d8c2f270cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i460148134f8548f3b116acd07b6f4262_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS03LTEtMS0w_3c1fd79c-f48e-46ae-b456-2f23a48b383c"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c548bb51d534758a5b6a6644bb57312_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS05LTEtMS0w_007c03ee-8a29-4136-a667-0d77546ca501"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f28d45aab574360b168ce04f39ca7e5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xMS0xLTEtMA_e6fcebf5-965d-493f-abed-12932641f8df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifffe4cec0a0a437daa7a6c75edf5f759_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xMy0xLTEtMA_cc3ac52a-665c-4bba-ac7e-e0e8c9bf3300"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8ab343a960448718c962d4ff1664ca7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNS0xNS0xLTEtMA_8b0d7d2a-e9a6-4bb2-b1e5-7096e92a0a9e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50cee26c0cb24582a4fa7a23dab93ff8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xLTEtMS0w_99f1b585-5a77-4a78-ab58-9a26eaa649da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b962ca0878246aea2caaba1e5068597_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0zLTEtMS0w_1fd9deb2-d171-4b9e-aab2-f79eb9849d10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12865349bba54bec9a0bc339687682cd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi01LTEtMS0w_3f604a49-6ddd-4e1e-b7de-21beeb73aafc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f9c2404403b4dd19bf073d3fc40b18e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi03LTEtMS0w_5d46b165-44da-4696-be06-b85cd9bfff85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i084046817ad547f0bf33554533117419_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi05LTEtMS0w_28249556-1aca-4771-9ab4-b8803e68c6ed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3126ac40e55147ecad0cf2d7e7171a71_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xMS0xLTEtMA_3a0a0f8d-a48e-4c6a-b4c5-d58f922411fd"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie381b020bc2d4cf48eefd6af3e63740a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xMy0xLTEtMA_65257a60-08cf-434f-bb29-5f5a02590cfa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0edd3a5e5dbd40979d86029cf03f258d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNi0xNS0xLTEtMA_1f937cb0-4b15-424b-95b3-1d2817cb47b6"
      unitRef="usd">668000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id993747e094b4fd79654920246348cca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xLTEtMS0w_783787eb-94cc-49c3-98b5-c4a163951c84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i99eaa11a9d134c84aa9cfca643e17d0b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0zLTEtMS0w_c00d8f2e-0983-4634-a10f-4c03d84398dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d4c8e65bbc04387a96c107b13853bc9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy01LTEtMS0w_836e303b-3cba-485e-95af-b009247e76c9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i809e8cb34704419bbc81bc11c64fce2d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy03LTEtMS0w_b4ccc02b-7987-48b2-84f3-dffacc4505ca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bfd28bc6e0f42aaa81be96e54b6f594_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy05LTEtMS0w_f1da1dfa-f462-45b1-bf1d-3ea1b328dc21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia932f1a4fb0744bc9993e55668e12ee7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xMS0xLTEtMA_77be8fb2-ad6c-45ea-9968-3177b0db777f"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic21417c5ce10444faed848f53271d30e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xMy0xLTEtMA_b20ca0e4-1211-4230-8a44-e9ef6915d323"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26f12d40a4894778869023a3c016eeb5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfNy0xNS0xLTEtMA_bfcbce2f-2d56-40bc-8ee4-a7a91239bf50"
      unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied7a998c6b5342efb1a584d95ce95eda_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xLTEtMS0w_59a19d0d-df42-4f87-a3a8-4c6b3bfacbb0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i084814a830464e63ba5b40197d05e746_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0zLTEtMS0w_7dc7f158-5e47-4356-a2cc-0b48b4a2e5df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a334d2c7f7f4c7ba7103637d1ec075c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC01LTEtMS0w_d0c27b0e-445b-4bce-8b00-05d2eb01e9ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8349cad8fb23464c808e9dda6e139864_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC03LTEtMS0w_84720740-29fe-48c8-9901-f17b2259adec"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6faceee075314917b67b95d162851967_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC05LTEtMS0w_6bca55ae-ffef-4679-985b-98f3fe29c537"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1addd4cf0a714a1bb6df0443bd656292_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xMS0xLTEtMA_3edf2bce-2ed3-48b0-a348-1fcc32a0a981"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2ab410ffa984d74b8491ca6135d2f49_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xMy0xLTEtMA_79b47484-dfb7-4571-910b-7f919db55da6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4220ee3541742be9a6a5b1189b6144f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOC0xNS0xLTEtMA_e68b9337-cee3-423d-a46b-263ff96bf76d"
      unitRef="usd">227000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4608091360a94197892bd6a3625a1eaf_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xLTEtMS0w_c87fb246-0e0a-447b-89e0-81111e49fb1b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i295721b3731942a08da7676215878345_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0zLTEtMS0w_4e358fc3-fea1-4cc3-b64c-4c6582676d08"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id54942bdb7d14f95b3cee4e66d8055b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS01LTEtMS0w_f178aa26-18d6-4905-b0f6-ac0651ee2a4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1949445e84e744f29823c34223e1e913_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS03LTEtMS0w_9ddf45ea-b552-4bba-8c88-05fc61fcf26d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7932b106c7448daa2a3a55d1da0adfd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS05LTEtMS0w_4d45c86a-9086-443b-b94f-1e575d895a80"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xMS0xLTEtMA_2527dc3d-09a4-43be-9d24-b6eee76399b3"
      unitRef="usd">209000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i729ae19583c44de3bea4894565e3326e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xMy0xLTEtMA_4c0d8e5c-6530-4ff1-af4e-dcdae3ada01b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9b2c6ae9105493882fd7968a705b503_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfOS0xNS0xLTEtMA_7e29148d-7892-483e-8bd0-289c47457f94"
      unitRef="usd">209000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMS0xLTEtMA_9310229e-a72f-47d3-a6e1-5c87b9175acf"
      unitRef="usd">1370000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0c3a6c594db44074808bec17ed6ec8b9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMy0xLTEtMA_7d790117-3b53-48df-baf0-f238a8a72cf8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6bd21a1a7d51489a86f20b38a1d20755_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtNS0xLTEtMA_f77bfb51-40fb-494c-b79c-06956fa69daa"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if2583cf01e284ddcb2320ca55728a506_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtNy0xLTEtMA_7ca26656-f352-49a7-87fe-6cdbcf96536e"
      unitRef="usd">1370000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if7816629b0334d2aa6b53dc07c4e8faf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtOS0xLTEtMA_ccca170d-a655-499f-a6be-be4129b7ea59"
      unitRef="usd">518000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idc955b1af87545599fdfcd8990fdedbd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTEtMS0xLTA_89823ee0-b38b-483a-82ea-4663c7acb3fd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia58a28f0d346460685afcc652227a9c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTMtMS0xLTA_2e0de33a-076d-4244-bd16-2edb079d0579"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTAtMTUtMS0xLTA_831cfa84-9c36-4691-8cdb-9a4a2ec2cfe7"
      unitRef="usd">518000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMS0xLTEtMA_d63183ea-6dff-4770-be9a-23563a6d3382"
      unitRef="usd">1370000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMy0xLTEtMA_12f6d789-33a1-4b51-a934-f9aa905bbc25"
      unitRef="usd">2000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtNS0xLTEtMA_5e2abf48-6bd3-422f-a0b5-55a97d214878"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtNy0xLTEtMA_d28f8a3a-88fd-4d16-b528-0f7276e0f946"
      unitRef="usd">1372000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtOS0xLTEtMA_fd9d5739-4787-422b-bd0d-14febdebec71"
      unitRef="usd">518000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTEtMS0xLTA_9a7f746e-bbc5-4b18-97ea-db51ca89312a"
      unitRef="usd">1725000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTMtMS0xLTA_085b4835-c76c-40c3-a896-87bb99c416c5"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTEtMTUtMS0xLTA_8dcd47b7-0fde-4655-87d1-557f274327d7"
      unitRef="usd">2243000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4608091360a94197892bd6a3625a1eaf_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMS0xLTEtMA_2ddeab0d-93bc-4f19-ae41-017a590cc9c8"
      unitRef="usd">74000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i295721b3731942a08da7676215878345_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMy0xLTEtMA_ae39ce50-bdc8-4891-8d88-ca7ea3b56b83"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id54942bdb7d14f95b3cee4e66d8055b5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtNS0xLTEtMA_6befd683-76b3-4563-98f7-b9f99f770532"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1949445e84e744f29823c34223e1e913_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtNy0xLTEtMA_73f5779c-3b81-441c-80d1-b58934ea8a8e"
      unitRef="usd">74000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia7932b106c7448daa2a3a55d1da0adfd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtOS0xLTEtMA_7a9effa7-61b2-4f0f-8c84-8696b513612d"
      unitRef="usd">60000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i96d8d90e701e4ad1b605a5a83fc37f49_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTEtMS0xLTA_b8c63101-9ce8-451c-b14c-ea59c9a5af11"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i729ae19583c44de3bea4894565e3326e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTMtMS0xLTA_23961dc0-1e12-4ba6-a04d-e01a492c7538"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib9b2c6ae9105493882fd7968a705b503_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTMtMTUtMS0xLTA_f884a20c-3b55-456f-bc07-46a215889f32"
      unitRef="usd">60000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i46ca3c84e4fa4c03b95fb4e99d1c782b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMS0xLTEtMA_a445e5b1-2a0c-43b5-907c-53c0543f3fba"
      unitRef="usd">107000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0c3a6c594db44074808bec17ed6ec8b9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMy0xLTEtMA_02ea12d2-d88d-4f27-8af0-e1b4114ef66b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6bd21a1a7d51489a86f20b38a1d20755_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtNS0xLTEtMA_da7c83e0-c2ff-4030-b71e-86bd177fab4a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if2583cf01e284ddcb2320ca55728a506_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtNy0xLTEtMA_4b7ea03f-be59-4adf-9679-f94ebae117c3"
      unitRef="usd">107000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if7816629b0334d2aa6b53dc07c4e8faf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtOS0xLTEtMA_d3b22e4d-8fa2-413c-8d7f-a9acaea6377c"
      unitRef="usd">320000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idc955b1af87545599fdfcd8990fdedbd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTEtMS0xLTA_55828db2-8679-4d03-9dec-eed3a903bafc"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia58a28f0d346460685afcc652227a9c5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTMtMS0xLTA_b291da1b-3442-4f4c-b80b-25c8d345f375"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7a10b9fefc0e4a96b82eb6cb791398f6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTQtMTUtMS0xLTA_a23720dd-d429-47c6-bf13-d269a81f72f3"
      unitRef="usd">320000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMS0xLTEtMA_276cbf40-f50f-484d-ae11-84c526f088ae"
      unitRef="usd">181000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMy0xLTEtMA_9f2ef168-98e5-4b06-9d89-6b2978521d82"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtNS0xLTEtMA_95bf1ec8-94d2-4485-8109-2c77c9d5567a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtNy0xLTEtMA_c60bd584-5ee7-4164-bb50-6a65dacc7036"
      unitRef="usd">181000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtOS0xLTEtMA_a2d947b5-ac97-4f0c-a12e-38c68ee9e5e6"
      unitRef="usd">380000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTEtMS0xLTA_f1124a53-be3a-4750-afd4-10191d0b5a3a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTMtMS0xLTA_27be1fd3-6e8e-48c6-a51c-eac754cfc64b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTUtMTUtMS0xLTA_66698dd3-d34f-4ef7-b277-7a11c6e598e9"
      unitRef="usd">380000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i1755cafcd4254c2e8aeb93f416956e53_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMS0xLTEtMA_6fd313fe-b6aa-4340-ab03-b4fbe9b2a6c8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i67e30aabe97d4272be3e7e97eeff7de4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMy0xLTEtMA_a6438d03-da53-486e-9622-fe7c0f333634"
      unitRef="usd">116000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i827bb071fabb4cd1816ed87eba65624d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctNS0xLTEtMA_6ddfa8e4-ca60-4a70-9a95-d63b9e1e62b6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6f5a8e02f1b1415090e676b983a40e37_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctNy0xLTEtMA_8b68afb5-ebd8-487c-9839-0c824b82d0a4"
      unitRef="usd">116000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i534176133b5e46268b75e8ee4783ef0b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctOS0xLTEtMA_7b5d80d8-3499-4c54-9b14-2857b1011cac"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic2257904af3c45abbfbf463b398101d9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTEtMS0xLTA_2921e534-47fe-4e47-b7de-515135179b95"
      unitRef="usd">169000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i675ac0a159cc4cc691060e09552724bf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTMtMS0xLTA_4924144e-4a1b-4172-a810-71218c07ea32"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="icfdd387cfc074b9f95912bc5b38d09b3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTctMTUtMS0xLTA_092dc509-8007-48cd-b6b3-0a6bb73b717f"
      unitRef="usd">169000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4f98a00d9cb1469381ff2b85052e050d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMS0xLTEtMzIzMA_1fdce328-cf21-45fb-89ce-4e6539d0e696"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id735af80d7e943a7b6cbff2ff9825cca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMy0xLTEtMzIzMA_d01748bc-1d73-4f97-95bd-bd9413574fde"
      unitRef="usd">69000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i554c0786877949ee8178f77e6daab0f3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNS0xLTEtMzIzMA_b5705e19-640b-468f-8aa8-864c475922cb"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie26963a2ac324ba4a14e6c9468186690_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNy0xLTEtMzIzMA_4497e6a8-8f66-4c0f-a870-27fc22fefa26"
      unitRef="usd">69000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iea2c0faf9f814cdca31718d64e210291_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtOS0xLTEtMzIzMA_dc4ff84c-6585-408d-b737-37af216e5065"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9553bd5ca6744da1b5727a32a9c9263b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTEtMS0xLTMyMzA_303645e2-d499-4e55-bc8e-174721a14590"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8904871bd9ff4926abbade9d25474108_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTMtMS0xLTMyMzA_d88c69cc-a8cb-4022-aab9-8d2c4d711ba9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia5cb5301d76a4873b15a1335479d3c2a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTUtMS0xLTMyMzA_adcfd24a-2bc4-410c-bfb5-c88ee020e493"
      unitRef="usd">15000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4e635dc42c1b49bb99f084c0f6584807_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMS0xLTEtMA_63ef88ef-14f1-4ea6-922c-ab8dfd942bb7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMy0xLTEtMA_fdd1e5f3-9a83-41a0-ab53-d5a8180d18fb"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNS0xLTEtMA_7ca73bb8-a27a-4ba0-8225-695cf0283fa2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i91862fa2efc447e29c59e61b626857ed_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtNy0xLTEtMA_33188090-8394-4177-9a61-b3cf4275db68"
      unitRef="usd">54000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i81090f7e16204c969f9a89fd1d33cc95_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtOS0xLTEtMA_137e3fc8-2847-45aa-b8d4-50b1b03661d5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5599e985c1df48b8af48f1564e7b9e6d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTEtMS0xLTA_2941df57-57c8-4e56-bff0-4624dea3773f"
      unitRef="usd">104000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2df4c3c188454c12a12d6adf310f9ac9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTMtMS0xLTA_673c345b-c30e-445f-bb70-c60407b8a6cc"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie262f30b95734e43832d8a9407f94eb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMTgtMTUtMS0xLTA_b331f99c-826a-40e7-b449-73f950075d36"
      unitRef="usd">104000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMS0xLTEtMA_79b8028e-9950-4a14-9150-b40adc5887c8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMy0xLTEtMA_b8ea3702-088f-451a-b23d-4fcf8e158630"
      unitRef="usd">239000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtNS0xLTEtMA_d54976ac-2247-4128-9241-5294be73c02e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtNy0xLTEtMA_f9f8e744-4567-4e29-9194-4e5eee6704db"
      unitRef="usd">239000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtOS0xLTEtMA_94393098-16e4-43ca-b672-dadb8bc88981"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTEtMS0xLTA_e99a703a-42ca-45a3-8d67-4926bbee4c52"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTMtMS0xLTA_a82e3d62-209b-4406-884a-5e63fbac5380"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjAtMTUtMS0xLTA_979c7dc3-56d0-4e0d-affe-fe3b9a8c3acf"
      unitRef="usd">288000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMS0xLTEtMA_a9c6381d-10c5-42ee-b7cf-cb6b531ab834"
      unitRef="usd">1551000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMy0xLTEtMA_dbee66e1-1923-4b85-b7ad-2902598a5695"
      unitRef="usd">241000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtNS0xLTEtMA_5471874e-83b7-4e1c-bd85-e28dd8a8d2d3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtNy0xLTEtMA_07beea63-c085-45d5-8410-332ca0165016"
      unitRef="usd">1792000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtOS0xLTEtMA_360b0e95-f38a-408a-9d18-39fcb51a90ff"
      unitRef="usd">898000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTEtMS0xLTA_0793048a-c4f4-4a6c-b159-90a4a6cc6c48"
      unitRef="usd">2013000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTMtMS0xLTA_19dd85d2-1924-4cf9-aa9b-4c150ad0af54"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjEtMTUtMS0xLTA_74645250-f8d7-4ad3-b0ed-24bcb2c89385"
      unitRef="usd">2911000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMS0xLTEtMA_8f9795bd-a4a3-4ecc-9613-544f859055e8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMy0xLTEtMA_068a1b60-e423-4377-8dbd-7ccea5ed43e1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtNS0xLTEtMA_69baf17b-74e9-4299-aad2-b70012879391"
      unitRef="usd">829000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtNy0xLTEtMA_0ef2c76e-23e1-4b20-9572-421f0525ea48"
      unitRef="usd">829000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtOS0xLTEtMA_7a44ad3c-4341-4c6f-8485-ca0c340739ca"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTEtMS0xLTA_f779d6f6-1fb1-485b-ad3d-700cd99cb833"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTMtMS0xLTA_88838856-7c2a-4a17-b9a6-ec668a3a3d23"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjQtMTUtMS0xLTA_7b20ff03-2d79-404b-9ab2-2418495d7b34"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i1755cafcd4254c2e8aeb93f416956e53_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMS0xLTEtMA_2d2174da-e651-4867-aeed-4ba97fa3b39f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i67e30aabe97d4272be3e7e97eeff7de4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMy0xLTEtMA_42d50455-a71c-40da-b471-97f804d445b2"
      unitRef="usd">275000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i827bb071fabb4cd1816ed87eba65624d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtNS0xLTEtMA_f2ea9963-1e8b-4d8e-b2e8-34f0c9af8317"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6f5a8e02f1b1415090e676b983a40e37_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtNy0xLTEtMA_234c6419-fad3-4f76-ab6d-2a7da0fc67ff"
      unitRef="usd">275000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i534176133b5e46268b75e8ee4783ef0b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtOS0xLTEtMA_e01d4932-8297-43b7-85b1-b97bd5ff1f57"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic2257904af3c45abbfbf463b398101d9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTEtMS0xLTA_30246dc5-0787-42d8-8ea9-1c191a7a4e81"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i675ac0a159cc4cc691060e09552724bf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTMtMS0xLTA_a59c49c9-7762-4097-95d1-411e5bb39fe7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="icfdd387cfc074b9f95912bc5b38d09b3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjYtMTUtMS0xLTA_67ff6d6b-0be6-4c31-9b27-e504cdbb771f"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i43f22f3a8e434723aa4c8e677adcb774_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMS0xLTEtNDgxMg_35433c85-ed4a-4e5d-b8d6-44095beea184"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i82319f76c8e24d55ad16cfbcb26dd55b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMy0xLTEtNDgxMg_6993d52c-def7-411f-adbd-e478b1396873"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie1b391a9730b4cf68a103be0f154b323_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNS0xLTEtNDgxMg_777a9e45-55f6-47d8-841e-1ca8ac9fdb71"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i92ed48ae16f7483ab2c12115e9b3b1f8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNy0xLTEtNDgxMg_ce4ce63a-336f-439b-a4e4-94567c92d021"
      unitRef="usd">22000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic318e672eaab447c8135df89f679f16b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctOS0xLTEtNDgxMg_d8bd9245-990c-43b2-b47c-e7edeac6eaad"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i26fad08fdba44d0b82362dc57e0d7f8c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTEtMS0xLTQ4MTI_27775f42-4d21-4ef5-aeb1-6b28a21b7241"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1b6898b1302e46f2b14f135b0cf9ad8f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTMtMS0xLTQ4MTI_296012fc-0c4e-4e99-9a02-37be5c1635d1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7943709a46a24d76a5bb3f5bcdd1ef43_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTUtMS0xLTQ4MTI_73470396-5e94-43fb-95dc-d14c9b98cc43"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4e635dc42c1b49bb99f084c0f6584807_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMS0xLTEtMA_803621fe-5820-4287-87e1-9f10235d55b7"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if897cc85ad3e44058e00fa4e9aa8b03e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMy0xLTEtMA_ab4e20b2-a97a-4986-9308-f8bbfc04a36d"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7481f4cee7f442e08e959a40b9dcdf5c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNS0xLTEtMA_31a81d38-ad9a-468e-9591-e71455c8813d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i91862fa2efc447e29c59e61b626857ed_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctNy0xLTEtMA_68bdd203-eecb-4707-83b3-2e884e60e68d"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i81090f7e16204c969f9a89fd1d33cc95_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctOS0xLTEtMA_a044c1e0-13d6-410b-9070-c40d272586cd"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5599e985c1df48b8af48f1564e7b9e6d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTEtMS0xLTA_0f8c6257-9045-47b2-a452-cb26caac635c"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2df4c3c188454c12a12d6adf310f9ac9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTMtMS0xLTA_ab5ce7a5-8e3f-4830-9032-49ba921d2555"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie262f30b95734e43832d8a9407f94eb4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjctMTUtMS0xLTA_a1f52cbf-abae-422b-808f-f78894a7b230"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idc02a58f23874914ab829313aab4a522_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMS0xLTEtMA_0a82e1ac-2782-456a-95ad-ea4c27226452"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i77b04eea3e5b4a1b849d4967371f9b86_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMy0xLTEtMA_bd0101d7-68b1-4018-9be5-7e1f91d38b1d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie7573baa67fd4165af6f52acfff81eb1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtNS0xLTEtMA_ccc2fb1b-1e8b-4660-a86b-d04c40f90d66"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3e96a20a877543ee9ce8338ad2ef622f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtNy0xLTEtMA_a8dc0c34-9723-4666-be97-0b93be09934f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i59cb59c697544159a4a94b077d73ed46_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtOS0xLTEtMA_bf73f93f-89ce-40fb-93af-07443506451b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ifcb4503c9509423bbee8e6c29bd5e78e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTEtMS0xLTA_4cf30f85-bf96-4b8b-ae81-28e0e1aacd80"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6bf8d0cc1ac8422fb6018bd01c7ffaa6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTMtMS0xLTA_d872924e-868d-42ea-bbf2-39f4f5c5f8dd"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i57f17a0fdf894d27bdd29405d396934e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjgtMTUtMS0xLTA_fa83b1fa-2dba-4449-b033-6022a643499b"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMS0xLTEtMA_de48751c-a534-4bff-84cd-e3a3757b17f3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMy0xLTEtMA_2261c815-2f67-4bb3-a4cb-cace3c38f828"
      unitRef="usd">298000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktNS0xLTEtMA_6a8c7c8e-7c60-4d36-ae1b-9c4245d13830"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktNy0xLTEtMA_2f4b377e-93e2-4c44-9635-6e6b1b5b9446"
      unitRef="usd">298000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktOS0xLTEtMA_50568762-8beb-452e-95bb-530f5f329624"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTEtMS0xLTA_b40e4894-fe70-473f-813a-f1261ff019fc"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTMtMS0xLTA_b0fb59ed-a068-406f-a3f6-6501caea24db"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMjktMTUtMS0xLTA_bf0ea8ce-d655-4039-9e01-4182038056fc"
      unitRef="usd">97000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2a1cbc1130ff48c682a122fa35090632_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMS0xLTEtMA_fc26b786-6efd-4c8a-80c9-7460ad1ca9f6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if9929f95c47e484fa82d3e06b0f0c945_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMy0xLTEtMA_de549842-6c9d-485f-9d66-4ab0c6fd2183"
      unitRef="usd">298000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i349b9790bbe54e36b0de77f50529bd5b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtNS0xLTEtMA_1bb99810-638c-4536-94d2-2b05a88232f7"
      unitRef="usd">829000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if9014bc2ec9f4abeafcff803b0a03584_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtNy0xLTEtMA_97870dbb-1c05-42b5-b5eb-fdcb9d8e4e18"
      unitRef="usd">1127000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i096da5da4b9648cbb2c2a7e18c11065c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtOS0xLTEtMA_3a058fb3-594e-481a-a1da-746f014e8dd9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie6c9484ffb0b4a838b7bf194054ba4b1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTEtMS0xLTA_52a28cd8-9e17-4d96-ae6a-44cf440684f6"
      unitRef="usd">97000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i80ad7583f26b437581d137910e409b27_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTMtMS0xLTA_840d2337-4242-4879-8597-e3c345a306a1"
      unitRef="usd">767000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i727ab934d22c4cfcbcec767507b45eeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmQ4NDA3YzcwZTlmYzQ0YTRiNGFlYWJkNzg3MzUyZjM0L3RhYmxlcmFuZ2U6ZDg0MDdjNzBlOWZjNDRhNGI0YWVhYmQ3ODczNTJmMzRfMzAtMTUtMS0xLTA_e3eccde9-b94c-4cac-b86f-3093bb212b00"
      unitRef="usd">864000000</us-gaap:LiabilitiesFairValueDisclosure>
    <mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral
      contextRef="ibe06cede262f48698bafa7ad43037553_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM1ODM_57ddb5e8-2fd4-4c79-a0eb-e8eab0f99593">P5Y</mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8c1a6f29c939482d8e9f901e3e75b9db_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM5OTE_d0dde4a6-6119-43ed-b6c3-bf7aeec597e8"
      unitRef="usd">6600000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i20dc5a545bbb43b5b42188e27def9036_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTM5OTg_fd0dc5d4-b70d-4a25-8a0c-846c4dc983dd"
      unitRef="usd">8900000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg2NjY_aed9069b-2baf-46cd-8391-76d5495dc819">&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value September 30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;  Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Balance at September&#160;30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; At September&#160;30, 2020 and December&#160;31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMi0xLTEtMS0w_f7d6c3c6-3a3b-4061-bf85-8a48a3efff0d"
      unitRef="usd">767000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMi0zLTEtMS0w_b65c3f3d-3af3-4fde-ae4b-50635e1962b0"
      unitRef="usd">788000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMy0xLTEtMS0w_146cb649-b6c6-4294-a4e3-437f027fca74"
      unitRef="usd">97000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfMy0zLTEtMS0w_2e2a66d1-03a9-4ba1-967a-455558b12d20"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNC0xLTEtMS0w_cf2ee637-bab0-4c9a-9b8a-8878d2f06ae8"
      unitRef="usd">71000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNC0zLTEtMS0w_47371bef-c8eb-46d2-b837-3cd5b9be055a"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNS0xLTEtMS0w_549b9c00-6478-47aa-9806-0cc1796572d5"
      unitRef="usd">106000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNS0zLTEtMS0w_3ff349eb-0bfd-4fbe-bea5-f3969fb1efce"
      unitRef="usd">85000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNi0xLTEtMS0w_becafca1-0f1d-47a7-b6b7-6ea3983a7e51"
      unitRef="usd">829000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RhYmxlOmIzZTQ4NzgwZmRiYzRhNTZhNDc0NTk5NDE2OGU2ZDBjL3RhYmxlcmFuZ2U6YjNlNDg3ODBmZGJjNGE1NmE0NzQ1OTk0MTY4ZTZkMGNfNi0zLTEtMS0w_51201220-0769-44cf-944a-1edbf98a3863"
      unitRef="usd">755000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ0Mzc_efaf3d86-26c2-4c72-9a28-1a46e253a2bb"
      unitRef="usd">140000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i575af78c5c07443093cc857d1c99b8ff_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ1NTA_d45eeb05-4de7-4384-910e-ab36250c9448"
      unitRef="usd">637000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7f10c43e33c64fccbb6f541ca846b3ad_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ1NTc_5c9990ec-f232-4698-ba2b-7d43369738df"
      unitRef="usd">625000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i575af78c5c07443093cc857d1c99b8ff_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTQ3NjY_ce9e0ef5-6e77-4e26-a252-f321381a9c0c"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i15622ac81bf64b6d8a631c6e28692012_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTUwMzA_32db07fa-cc98-4524-a878-8b57d11cff84"
      unitRef="number">0.08</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU2OTA_5c0cbc90-ad0f-44e6-9f51-55565f007952"
      unitRef="usd">32600000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3Mjc_c3d73d29-eb11-48c9-a35e-2a31929b19a2"
      unitRef="usd">28700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3NDU_fefb63b7-5e25-4b67-bfc8-d67ca4918c0b"
      unitRef="usd">28800000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTU3ODI_24b21a1a-5841-4e0c-935c-9d0d1d6cd472"
      unitRef="usd">26300000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsReceivableSale
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTcxODI_19cedc35-e2f4-4368-87f6-383d15c7d5d9"
      unitRef="usd">2100000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="i95e09f3059bd4468a374ad7a474b31ec_D20191001-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTcxODk_94a9a820-994f-4def-ab2d-dd16741d4f8e"
      unitRef="usd">2700000000</us-gaap:AccountsReceivableSale>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg0MzM_142d73ce-d850-44f7-833b-b1ae2861e7d3"
      unitRef="usd">34000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg1NTk_1c6aa14c-9d06-4e30-9267-453d1fb8b754"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV80OS9mcmFnOmI5YWNjN2I1NTA2NzRiYmZiNTliZTg0ZGE5N2VmZDRhL3RleHRyZWdpb246YjlhY2M3YjU1MDY3NGJiZmI1OWJlODRkYTk3ZWZkNGFfMTg1NTk_a56ccebd-cc80-4202-a323-780132b8a3d5"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfNDIy_94b52f9b-2bcb-4130-9e1d-a587209d34c9">Inventories&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2020 and December&#160;31, 2019, these amounts included $1.8 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $288 million and $168 million at September&#160;30, 2020 and December&#160;31, 2019, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfNDM0_8dc5a792-dd28-4bac-a81d-07f48884fb23">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMS0xLTEtMS0w_1fb8531a-6311-4c55-82a8-62023242553c"
      unitRef="usd">2038000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMS0zLTEtMS0w_2d4bc6e1-f51a-4191-accd-8c295d3ebaea"
      unitRef="usd">1772000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMi0xLTEtMS0w_ff2a8479-3435-45fc-86b1-cb835450ee48"
      unitRef="usd">6073000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMi0zLTEtMS0w_2aa99040-ee7d-4005-acbf-b19f400e8e63"
      unitRef="usd">5650000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMy0xLTEtMS0w_9de31cf8-214c-4a9e-869e-34bf7f49cac3"
      unitRef="usd">197000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfMy0zLTEtMS0w_13bdfe72-e141-46da-9832-0970f3b8f2d1"
      unitRef="usd">207000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNC0xLTEtMS0w_4129902a-254a-4fd3-bf4c-dc77f2c3ab64"
      unitRef="usd">8308000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNC0zLTEtMS0w_229f6b2b-3bac-4410-8801-b24b032577bb"
      unitRef="usd">7629000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNS0xLTEtMS0w_a2302b72-c0c2-4231-8b4a-d39e7e85d266"
      unitRef="usd">99000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNS0zLTEtMS0w_859ba7bb-8aa3-4c2d-afa1-8528a7969a3e"
      unitRef="usd">171000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNi0xLTEtMS0w_62292ec0-fc44-4bce-91ba-07d39cda079d"
      unitRef="usd">8209000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfNi0zLTEtMS0w_888b63d5-beb5-49a2-a864-efe716050736"
      unitRef="usd">7458000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOC0xLTEtMS0w_42c13af4-c776-4b0e-ae04-bb5751a77fa3"
      unitRef="usd">6128000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOC0zLTEtMS0w_d3b3a3d1-4334-44e0-bf31-d460e93cdb78"
      unitRef="usd">5978000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOS0xLTEtMS0w_50d2e896-b5d2-4cb6-b405-b3452c76b29d"
      unitRef="usd">2081000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RhYmxlOmQxMzNlZTRlOWIwZjQ5Yjg4ZGI0MzdiMzRjYzIzZDRlL3RhYmxlcmFuZ2U6ZDEzM2VlNGU5YjBmNDliODhkYjQzN2IzNGNjMjNkNGVfOS0zLTEtMS0w_8c05f32b-c7ee-48d0-af2a-6d40dd50b244"
      unitRef="usd">1480000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ica983717d6fb4ff095964b0c590cae02_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMjAx_f477e356-1f37-427f-adeb-acdd6c16ddb2"
      unitRef="usd">1800000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib6fe871055ff4f2c8a6464ebc3c894da_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMjA4_d6176476-0377-459d-b15a-9b7847ab12df"
      unitRef="usd">1300000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie31e25b750ad407bbfe538ce6e4d1eba_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMzE4_be8cdf45-8371-40e3-8f2c-a88ba10a8c05"
      unitRef="usd">288000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idfc8aed4c32f4ba9bb8680a335959dec_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81NS9mcmFnOjJiMWQ1YjUyYzIyYjRjZWU4MmE5ZDAyMzgyMmRjYmVhL3RleHRyZWdpb246MmIxZDViNTJjMjJiNGNlZTgyYTlkMDIzODIyZGNiZWFfMzI1_6c0c89f3-dc5c-4941-8890-712697ddcc5f"
      unitRef="usd">168000000</us-gaap:InventoryNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTc2_ac15f1d8-7bf8-4ee6-8e99-79c82c8324f2">&lt;div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.&#160;&#160;&#160;&#160;Other Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter and first nine months of 2019, the Company recorded $612 million and $693 million, respectively, of intangible asset impairment charges related to marketed products within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. During the third quarter of 2019, the Company recorded an impairment charge of $612&#160;million related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which indicated that the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sivextro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that, when compared with its related carrying value, resulted in the impairment charge noted above.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTMy_711be0aa-bab7-43e3-a158-7ef566954233"
      unitRef="usd">612000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTQ5_b0ec7d2c-9f2a-490b-a6de-24f42e45b992"
      unitRef="usd">693000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ice5e55028bcf49d98bb89ed4e93e01ae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV8xMjk2L2ZyYWc6ODA0NjAyN2E5NjFhNDY4MDk5MjM2MmI5YjFjMTYzMjQvdGV4dHJlZ2lvbjo4MDQ2MDI3YTk2MWE0NjgwOTkyMzYyYjliMWMxNjMyNF8yMTk5MDIzMjU4OTcw_9072b7e6-296a-4d7c-bc7c-3de91c30001f"
      unitRef="usd">612000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfNDQx_0e2a1c27-ad78-417a-b43a-068e8fdd5484">Long-Term DebtIn June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i41f558a03fc74d9786822fef7d1da9ac_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfNTY_e0c190f1-6119-4bb9-a74b-89d0027f0ac6"
      unitRef="usd">4500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia564edcd14034ec790ba4a71ee6a8622_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTE2_d307fee9-0a0f-4b5e-a34f-e27be1cdd954"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia564edcd14034ec790ba4a71ee6a8622_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTIy_ec041768-ee21-4c50-a9e4-b0cdc9872f1a"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic940ded1777647d7b1ecbaaef52763f0_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTQx_a3e2fffd-88c3-41f3-adbd-f06adcb8d131"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic940ded1777647d7b1ecbaaef52763f0_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTQ3_24b12f86-10ad-41d6-8a58-50eb722846e8"
      unitRef="number">0.0145</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i111bb73a24814a3c8fff74bfc915fedd_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTY2_7f4566c7-3e91-498b-b784-f539702c5c22"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i111bb73a24814a3c8fff74bfc915fedd_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTcy_6f743638-7b7e-4c7b-a18d-13315665345e"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i037b1090dc53410598ac31bbb1af0ed8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMTk0_39864ed2-ac13-4549-a8fd-62ffb757ec81"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i037b1090dc53410598ac31bbb1af0ed8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV81OC9mcmFnOjBhYWNiMDExNTQyZjQyZjQ4MGU4Yjk5NTI0MTRiM2NkL3RleHRyZWdpb246MGFhY2IwMTE1NDJmNDJmNDgwZThiOTk1MjQxNGIzY2RfMjAw_f3f78bac-39a2-45ef-a6ec-213b16b53cb3"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTk4MjE_b6d13d6f-b2fd-4cd4-95c9-832a18fa495b">Contingencies&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Litigation). As of September&#160;30, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn v. Merck&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the jury returned a verdict in Merck&#x2019;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#x2019;s motion for judgment as a matter of law in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case and held that the plaintiff&#x2019;s failure to warn claim was preempted by federal law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#x2019;s preemption decision in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glynn&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#x2019;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#x2019;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#x2019; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, as of September&#160;30, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, approximately 2,340 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, there are four Femur Fracture cases pending in other state courts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia/Janumet&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of September&#160;30, 2020, Merck is aware of approximately 1,465 product users alleging that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the development of pancreatic cancer and other injuries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2015, the MDL and California State Court&#x2013;in separate opinions&#x2013;granted summary judgment to defendants on grounds of federal preemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;motions. Under the stipulated case management schedule, the hearings for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and summary judgment motions took place on October 20, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#x2019;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merck Sharp &amp;amp; Dohme Corp. v. Albrecht &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(relating to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fosamax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; matter discussed above). Merck filed the opinion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Albrecht&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, that preemption presents a legal question to be resolved by the court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vioxx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the Company&#x2019;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#x2019; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#x2019; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#x2019; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants&#x2019; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers&#x2019; motion for class certification and certify a class of 35 direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants&#x2019; motion for permission to appeal the district court&#x2019;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants.  The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.  All New Jersey actions against all defendants have been consolidated.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company&#x2019;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has settled with five generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Inter Partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, three additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy&#x2019;s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan&#x2019;s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. If the generic companies are successful, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; could lose market exclusivity in Germany as early as July 2022. Challenges to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;SPC have also occurred in Portugal and Finland, and could occur in other European countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2020 and December&#160;31, 2019 of approximately $255 million and $240 million, respectively, represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTk4MjY_813df34a-9769-4106-ab02-d40058b5603e">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i2c65f9d30293433985417442b5f323df_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMjQzNA_9ad613b6-ceef-4435-a610-5e4e4d766a9b"
      unitRef="case">3590</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="iab048735a64c498682a6136168824f23_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMzYzNA_0140e4c6-2ed8-4c8d-8400-12dd902c3774"
      unitRef="case">650</us-gaap:LossContingencyClaimsDismissedNumber>
    <mrk:LossContingencyClaimsonAppealNumber
      contextRef="iab048735a64c498682a6136168824f23_D20140301-20140331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMzY5NA_4dd80ca7-29fe-4d42-9ffa-4399fd4806e9"
      unitRef="case">515</mrk:LossContingencyClaimsonAppealNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i17584faa284b4b578d5ddb79fabaf164_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNDczOA_4ac3c37f-37bf-4b1f-a5fc-d3dbb9964ced"
      unitRef="case">970</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iaa614806e2ba4145bc4bcb5eccb090e5_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNDgyMA_b2bb8a7b-291c-4034-ba06-d1432d58965d"
      unitRef="case">2340</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i41c548a060bf47df90e49186c4d38865_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTEzNg_04e5cb6a-3bf5-4d07-a84b-645a898aa4f5"
      unitRef="case">275</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i17f4cd39dcfa47ef9b2f783ce64bf95a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTM5Mg_b2ca99a5-dccd-4217-a154-d85782e4d405"
      unitRef="case">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia0c76a997e6b436ba14ab8377850ad0d_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNTc3OQ_3ab62644-0c17-41d3-962b-3b0fd7ecdea5"
      unitRef="claim">1465</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8ed7a5d6344d40cb8f2f177240990f6b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfNzAyMw_7f274d3a-974e-4a46-9f89-0b727371399e"
      unitRef="claim">6</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i954b3ee345d542df871f572d67e9eb31_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfODE4Ng_ffba3a8c-8bc6-46b1-9aef-75425213a065"
      unitRef="claim">50</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i42fde4910e9b464480e8f2e6cbb3d025_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTI0MjI_9cace16b-e004-459a-a69a-365f5547b604"
      unitRef="claim">35</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i6549f2bd3da3405297ab00a3e9493624_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTY2NTE_4b0fd56a-f8fb-4e00-81a2-8487c64f7df2"
      unitRef="case">5</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic5e3c82a44a84c4d9e95b408e7440546_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTcyMzI_ee9dd72b-1343-48a3-b163-f80ad5e51add"
      unitRef="case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LitigationReserve
      contextRef="ie3bda94820614e02831a1a380b925d56_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTkxOTU_0e8b0e0c-de47-4820-8bb1-5885cc827632"
      unitRef="usd">255000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i76ba186142fb49e1be6e39777874b85e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82MS9mcmFnOmFjYTBhMDU0ZDgxNjRkYmE4NWE5ZmQzYTNmYjVhNmRmL3RleHRyZWdpb246YWNhMGEwNTRkODE2NGRiYTg1YTlmZDNhM2ZiNWE2ZGZfMTkyMDI_61bb7219-13ef-4065-b6c8-6733cf943a2b"
      unitRef="usd">240000000</us-gaap:LitigationReserve>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RleHRyZWdpb246ZTJjMjY0MGE2YmM2NDI3MmExZDM3MjdkNmIwNjVmOTdfMzg_e25846b5-c46b-47f9-8344-19aaa3c2353b">Equity&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.55 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.61 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.65 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.83 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RleHRyZWdpb246ZTJjMjY0MGE2YmM2NDI3MmExZDM3MjdkNmIwNjVmOTdfMzk_a83e84a1-7951-4f86-9e9f-25c587f7d708">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.55 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at July 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.61 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.65 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January&#160;1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(55,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($1.83 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Distributions attributable to noncontrolling&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0xLTEtMS0w_81a79cba-64fc-4ec6-bd4c-3b8bfeb38b7d"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie65ff136c6bb4d36b6a20cfff6011cd5_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0yLTEtMS0w_b20576ca-91cf-4553-a17d-c3fed4b46a49"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie94d9d12af0d4d57bd9f39eda31326c2_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy0zLTEtMS0w_f88c5f99-d829-4708-a557-273497040c14"
      unitRef="usd">39484000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b1ea5618fc74137a1dd7d0a99fdc553_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy00LTEtMS0w_51100110-41e7-4d71-b0ff-fcb482dcf097"
      unitRef="usd">45295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i661be48d847543a8a32ba2358107f61c_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy01LTEtMS0w_0774b876-4b99-41b4-adf9-0502f4e9ded1"
      unitRef="usd">-5362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2f65949371d5466d8d9c0005d5ea3e86_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy02LTEtMS0w_21b3c3d4-bd52-47c4-aff5-2d180de43cbf"
      unitRef="shares">1010000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f65949371d5466d8d9c0005d5ea3e86_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy03LTEtMS0w_2cc0c7ec-3d14-4467-89db-b81063e4d386"
      unitRef="usd">-53570000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i05f6eb6801e94b6aa490cf8461ca344d_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy04LTEtMS0w_b507ca19-1fa2-42e6-8d30-6664b63ac892"
      unitRef="usd">102000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83b341ae138f41489d101f0152d09d24_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMy05LTEtMS0w_48945593-ba83-4ce6-a14a-182e6f37ea83"
      unitRef="usd">27737000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNC00LTEtMS0w_118190cb-cb95-4daa-b8e3-3830b1dd5fb8"
      unitRef="usd">1901000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNC05LTEtMS0w_23bbd56a-8db4-4920-aa37-89f1086a03c5"
      unitRef="usd">1901000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i20ac31ed97124e86a01cbe0bb15a0082_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNS01LTEtMS0w_1a2a26c1-e73a-42da-a837-a20550ec9305"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNS05LTEtMS0w_bae23a27-bdff-4f0d-bc54-a0cf690cda00"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi0wLTEtMS0zOTY2L3RleHRyZWdpb246MWY0MmExZTkxMDI2NDI3NWIyMDc5NjQxMWNlZGZkZDNfMjE5OTAyMzI1NTYxOQ_a38b9960-71c3-4098-99be-b1d54f9037d4"
      unitRef="usdPerShare">0.55</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3cc64ecccfca479dbfc9c3521ce46019_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi00LTEtMS0w_10c20963-5431-4851-8156-04b4550d626c"
      unitRef="usd">1392000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNi05LTEtMS0w_438ad856-58b3-43a4-a648-7225b5a12de0"
      unitRef="usd">1392000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy02LTEtMS0w_33e6c712-b9d5-49d1-8656-a287c54d918b"
      unitRef="shares">17000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy03LTEtMS0w_a36f63c5-63f7-4316-9cbe-e69275d8b10a"
      unitRef="usd">1405000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfNy05LTEtMS0w_3b4d976d-38ac-4bda-9e3e-6380f6a3d821"
      unitRef="usd">1405000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i6fddb49b39a14e4c87423206f85f6bee_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC0zLTEtMS0w_6223fdc2-0f72-4c05-93b6-1f4b65243c0e"
      unitRef="usd">-77000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC02LTEtMS0w_ff59491f-3874-440d-91a7-68f0ab87451b"
      unitRef="shares">1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="id0e829183c974298b73bbc83e74b92a8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC03LTEtMS0w_fece13ed-cec6-489c-9a78-57d20e296198"
      unitRef="usd">-50000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOC05LTEtMS0w_22d03c38-68dd-4647-8f14-0a3394bc3eba"
      unitRef="usd">-127000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOS04LTEtMS0w_a90f3515-3005-4ef8-a4d0-bed9636644ab"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfOS05LTEtMS0w_3ca2052c-2b27-4669-9eaa-b2b888695833"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i340eca2e6b3f4206b4920f48aede940b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTAtOC0xLTEtMA_b4ba137f-d793-4231-a65b-645395faabe9"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTAtOS0xLTEtMA_92af2458-304c-4474-a24a-68b862a9e432"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMS0xLTEtMA_29f87f6a-3f1d-40ee-8d66-7d420b7d57e4"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMi0xLTEtMA_1305022c-e774-4eb9-908b-ce02d37ddf42"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtMy0xLTEtMA_333e997f-23c2-4972-910e-e8f6c2a702b0"
      unitRef="usd">39561000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i206b5fb493434864b42f3461b9ec4325_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNC0xLTEtMA_fd535ca5-53f5-46be-a29c-78c16c091230"
      unitRef="usd">45804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i532639a15db54349b73094a5ac53f994_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNS0xLTEtMA_182da3ba-9ee9-4cde-8d06-997cc7cbcc31"
      unitRef="usd">-5390000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNi0xLTEtMA_3e4184bd-35cb-420a-96dd-3a1740f9525f"
      unitRef="shares">1026000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtNy0xLTEtMA_45a26cd3-f2ad-487a-9ad5-721ac2fcef62"
      unitRef="usd">-54925000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtOC0xLTEtMA_87f6a539-f976-48c8-9528-f4ba144aadee"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTEtOS0xLTEtMA_ca5e0e7b-4f9c-4fe8-ad00-17bbc6e1c461"
      unitRef="usd">26925000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia3eaa864f094450daf59663572c42e5f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMS0xLTEtMA_26aeab1a-66f6-492e-85a8-d9f2534ce932"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3eaa864f094450daf59663572c42e5f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMi0xLTEtMA_f8ebadcb-3e77-4e19-854d-498271331f97"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58eff3e8192a44b392d66978e46f4f8e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItMy0xLTEtMA_9c19fc54-85f8-4792-9c83-f140771e3d15"
      unitRef="usd">39373000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i729eb54219b048ff818ad6a1ac398d7c_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNC0xLTEtMA_005114e8-a117-463d-bb7d-eeb96f64ec49"
      unitRef="usd">49724000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNS0xLTEtMA_0c3f027d-6bad-4396-8e34-de88e37602ee"
      unitRef="usd">-6393000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNi0xLTEtMA_898688cb-a095-4a9c-9552-24fbe0ac52db"
      unitRef="shares">1048000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib51a3179b9764c4cb9a718ea66d7b78d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItNy0xLTEtMA_c13966e5-c283-4d51-a29f-ac5baba3b536"
      unitRef="usd">-56850000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida404da98be84835bb1bca80aa637c1e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItOC0xLTEtMA_5393cb0a-01d9-4f91-b0ba-2ca2595f00a9"
      unitRef="usd">102000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41f558a03fc74d9786822fef7d1da9ac_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTItOS0xLTEtMA_f2e2de46-f78a-4044-9036-cb1d3b521b79"
      unitRef="usd">27744000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTMtNC0xLTEtMA_5d5bbb1f-4520-4ce1-a5c8-a7573a9bb6f6"
      unitRef="usd">2941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTMtOS0xLTEtMA_566c5d48-3ed6-4bce-97d2-602dd8e0485a"
      unitRef="usd">2941000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib55a6686f5d84014aaa7f5e1f1a99b12_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTQtNS0xLTEtMA_3394c90e-03e7-4752-86df-779d3be030b8"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTQtOS0xLTEtMA_defa963b-521f-4b3f-ae3f-57b3019cd873"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtMC0xLTEtMzk2My90ZXh0cmVnaW9uOjIxOWJkNDA4NmQxOTRhNzdhNWVjOWU0YWU2NDhiN2JmXzIxOTkwMjMyNTU2MTk_7a29e087-361d-419e-9338-ae4d4e71d48e"
      unitRef="usdPerShare">0.61</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i7d10d9126a49423abeba114bcafc9972_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtNC0xLTEtMA_f8067bbf-e688-4ad9-b115-9d1895ba2a74"
      unitRef="usd">1558000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTUtOS0xLTEtMA_0243c2cf-e5ff-48f9-bf56-2a40f2bdffda"
      unitRef="usd">1558000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockholdersEquityOther
      contextRef="ie36f2245e6244cac86b52c10ca135b22_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtMy0xLTEtMA_f074cecb-bc27-4ca5-8b66-01fb60de8d20"
      unitRef="usd">-116000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtNi0xLTEtMA_094653f7-844d-4e17-9b64-ab3a3134173b"
      unitRef="shares">1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i5209a5c0b32940d0ad2ddcf14374ac9a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtNy0xLTEtMA_3e479ff2-68aa-49cf-90f6-5c6c8b57ad6b"
      unitRef="usd">-35000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTYtOS0xLTEtMA_b02a48e7-6be2-45a0-bb46-fbd3e989004e"
      unitRef="usd">-151000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTctOC0xLTEtMA_2696161f-b309-4e3c-86f7-7fa98bf473e6"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTctOS0xLTEtMA_50003f1a-2265-4eb0-9f45-e89e6e1aa90e"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="idd95c53e752c46adab6060e5dd14d7b8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTgtOC0xLTEtMA_00449ac3-a63b-41ee-ab1e-516b27eef400"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTgtOS0xLTEtMA_eb865eca-d1df-46b7-90c2-60d79efeed8a"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMS0xLTEtMA_e800521a-25fe-4260-a0a7-cc87d32467ed"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMi0xLTEtMA_ea259b56-78d0-44a5-9364-e26901413be9"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f7b18662e9547c19e8db82d3b49ad03_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktMy0xLTEtMA_a299f4ce-285b-4341-a1ee-4093f7a5b790"
      unitRef="usd">39489000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68eb834fd2ba4689a131fc785fe1664a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNC0xLTEtMA_d2742357-6b9f-4454-926c-920d1d990c03"
      unitRef="usd">51107000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNS0xLTEtMA_59b9e109-bc3b-4c22-8be2-f0cd6254b306"
      unitRef="usd">-6383000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNi0xLTEtMA_a6d4f660-c60a-47f5-8961-5ae109cae5de"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktNy0xLTEtMA_0587a1fc-9c65-4961-804d-a9d645a0ac18"
      unitRef="usd">-56815000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktOC0xLTEtMA_7e6e6f41-a084-4492-9880-4661274e3c24"
      unitRef="usd">84000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmI3ZDQyNmViZmE0ODQ4M2NhZDBjNDExY2M4OGRkNjYyL3RhYmxlcmFuZ2U6YjdkNDI2ZWJmYTQ4NDgzY2FkMGM0MTFjYzg4ZGQ2NjJfMTktOS0xLTEtMA_99364854-9124-4e70-970a-7fe9f1e9d380"
      unitRef="usd">29270000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1515e466edac46189d255abcb1355fd9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0xLTEtMS0w_2eb6c287-f296-4d8e-9777-fdda010d02de"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1515e466edac46189d255abcb1355fd9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0yLTEtMS0w_cc7faf71-5bec-4225-9341-880535ef73b5"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b0d790716bd451a9a48dc70ee90327e_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy0zLTEtMS0w_16fce7cb-7a53-45dd-a42f-3dafd27b8679"
      unitRef="usd">38808000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2aadea4a29ba4b14bb25f94d3779239f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy00LTEtMS0w_7adae252-38b1-4e79-a694-51241c1a1adb"
      unitRef="usd">42579000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy01LTEtMS0w_8f55f206-3e0e-434a-a42f-d5bd15c6e48a"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy02LTEtMS0w_e46543fc-c92c-498a-b012-c751bedaab21"
      unitRef="shares">985000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2458ae1f4fc4645bcc30b3694823fa9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy03LTEtMS0w_088efed7-1c01-4fd7-ba53-06e810e9d584"
      unitRef="usd">-50929000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i242db40746324acea9058b979850563c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy04LTEtMS0w_6b5885b8-a9e1-4be8-ad86-ce0d07add681"
      unitRef="usd">181000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6f7c63652ac43a8a0b6410a7c55e6ae_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMy05LTEtMS0w_26dfd8c1-6109-4a0d-a78d-e3acf869548f"
      unitRef="usd">26882000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNC00LTEtMS0w_f5d85f93-54f4-4538-9803-53a1fb501ca4"
      unitRef="usd">7487000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNC05LTEtMS0w_db7df47b-ec14-4013-b4fb-cd1e265c15d3"
      unitRef="usd">7487000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifda54616745e475d9c94ff06081355b2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNS01LTEtMS0w_1caf6b73-f74c-4523-ad9c-6ad11b902889"
      unitRef="usd">155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNS05LTEtMS0w_c0461465-d315-4c87-a92c-2fdcceab5142"
      unitRef="usd">155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi0wLTEtMS0wL3RleHRyZWdpb246Y2Y2Y2FiNmEyMDJlNGExNTk0ZWJhNDgxOTliOTMyZTBfMjE5OTAyMzI1NTY4NA_4b1104ff-3a3e-440d-b645-e897ed03006d"
      unitRef="usdPerShare">1.65</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie28e474fb7064639867c16b50dbbd73f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi00LTEtMS0w_631f5e1f-b238-48be-81d3-51969dd49a1f"
      unitRef="usd">4262000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNi05LTEtMS0w_2892d12d-1b75-4878-886b-96148cb4ad7a"
      unitRef="usd">4262000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy0zLTEtMS0w_377bdd96-f662-48df-bc04-9d101073196b"
      unitRef="usd">-1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy02LTEtMS0w_692e5bba-bd76-417a-8fba-332d2d2d0ba6"
      unitRef="shares">54000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy03LTEtMS0w_a4039cd0-9c7e-446f-b97e-8d906eca59c6"
      unitRef="usd">4730000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfNy05LTEtMS0w_3e6aca1e-3993-48d6-90cc-31d58e6a3450"
      unitRef="usd">3730000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i340a1428e17048f0a0ba88b4e379c242_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC0zLTEtMS0w_d8308c9e-6f96-4df6-b12b-6e1c1b8e09ab"
      unitRef="usd">247000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC02LTEtMS0w_3989c2d2-34eb-4e08-990b-31b46b19c543"
      unitRef="shares">13000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i7599bdeed9164fb19c4299de5cbafa54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC03LTEtMS0w_21acc624-c816-4d69-9ab7-4d8ce79014f3"
      unitRef="usd">-734000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOC05LTEtMS0w_4871876a-9a84-4ff3-9966-622ac3b29cf9"
      unitRef="usd">-487000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOS04LTEtMS0w_43787fbe-f2bb-44f5-862f-19b245d2010f"
      unitRef="usd">-73000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfOS05LTEtMS0w_3b7b1a0e-bb2f-4921-b22a-b72d9b4836bd"
      unitRef="usd">-73000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic0e1e52c3a1b4cc1a95d9f0b6a5aa028_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOC0xLTEtMjk0_4f508cb4-11f9-4099-820b-27eade8a6e6f"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOS0xLTEtMTA5MA_2b45d040-11dc-4b62-ba83-887f1d83e17d"
      unitRef="usd">21000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMS0xLTEtMA_dbec383a-3381-4f84-82d2-628f4a3e6425"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia61d77e3b21045fc893756b66fd2684b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMi0xLTEtMA_ad41e5b8-8ae0-4197-a0d3-de549c1de04d"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9e9aa9e79c74d199affbfb98d1ecb3a_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtMy0xLTEtMA_caca995c-7838-45b5-948c-57f1bb6460cb"
      unitRef="usd">39561000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i206b5fb493434864b42f3461b9ec4325_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNC0xLTEtMA_392d3d98-5ded-4494-95a6-764bbaba3c79"
      unitRef="usd">45804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i532639a15db54349b73094a5ac53f994_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNS0xLTEtMA_b8ad1830-e0d2-4382-91cb-3c30ae7671bb"
      unitRef="usd">-5390000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNi0xLTEtMA_d8a35f1f-0f4f-4047-82de-51b41ffc44ba"
      unitRef="shares">1026000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0577848ca68a405a9fd06758b4987ebe_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtNy0xLTEtMA_3d52a111-3ea9-467f-a989-edf568afc422"
      unitRef="usd">-54925000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c671dba9e742ca88fefd55dd9ae0ac_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOC0xLTEtMA_c92343b8-7028-4b3f-b822-34206187823c"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0969664a04674af0b31c49bed8cbef6b_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTAtOS0xLTEtMA_961d3d78-44a7-40c0-adf5-7e45d1a7d78c"
      unitRef="usd">26925000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i45834c2505094eeeb4eda66b2b373ec9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMS0xLTEtMA_e1f28dd1-99c9-44be-b210-4ecf0cb6fa52"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45834c2505094eeeb4eda66b2b373ec9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMi0xLTEtMA_b74862ad-761a-49bd-8798-b0799d60b511"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa8db1c4585543f3813c30fd6dae8d64_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtMy0xLTEtMA_3dba8df2-e080-402e-a4a9-b8d1106a7f5b"
      unitRef="usd">39660000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6df4e6fd9a51492ca873f16e901201f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNC0xLTEtMA_a023b4c9-b864-4eff-a159-5854bb6e713f"
      unitRef="usd">46602000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice9dc335efad486f8e04c605de2f04aa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNS0xLTEtMA_9939e584-5bdd-43a3-91f4-6270d056f90d"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i28d6e7a2db2f477998a358afa23a3447_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNi0xLTEtMA_e84bbfe5-1445-4854-8755-55481f7c3b85"
      unitRef="shares">1038000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28d6e7a2db2f477998a358afa23a3447_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtNy0xLTEtMA_93877869-2264-4d2e-86cb-72bb86e01618"
      unitRef="usd">-55950000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8adcb6d851f94dc3a3fdea895e2d7460_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtOC0xLTEtMA_bc4c4fa0-49a5-47ff-b59d-c634cf815115"
      unitRef="usd">94000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i953cc45283754d089c0fca74403dda73_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTEtOS0xLTEtMA_1e84c098-f34f-4497-b42f-38ab0d8a57bc"
      unitRef="usd">26001000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTItNC0xLTEtMA_a1a67050-10bf-412c-82d4-d0063880d12c"
      unitRef="usd">9161000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTItOS0xLTEtMA_d79ab53e-4543-4547-bafd-053d7a16c44b"
      unitRef="usd">9161000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib13c6933c3674a5181dbe15e12aaee8c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTMtNS0xLTEtMA_b2875c75-6f60-4884-bca0-da6bebc9c6fa"
      unitRef="usd">-190000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTMtOS0xLTEtMA_6746f828-97d5-4a0b-8ffa-00cab656424c"
      unitRef="usd">-190000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtMC0xLTEtMzk2OS90ZXh0cmVnaW9uOjM1YWNmZmFmNmFhMTQwN2FhMzU3M2QzNDg3NmMzYjgyXzIxOTkwMjMyNTU2ODM_292a0597-3d4f-497c-82e2-3ae4b36f3059"
      unitRef="usdPerShare">1.83</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic2f968e9fb69482281d3b2ef560df95d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTQtNC0xLTEtMA_40183ff4-5aaf-4b37-bde3-1bff59b6ad42"
      unitRef="usd">4656000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTQtOS0xLTEtMA_5ffc4118-b446-4c40-b050-2d796346175a"
      unitRef="usd">4656000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtNi0xLTEtMA_aa3c24d6-acc8-478f-89ae-9e0704339844"
      unitRef="shares">16000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtNy0xLTEtMA_9a579328-24c9-4dfc-a8ba-dd39e3f5ef9d"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTUtOS0xLTEtMA_237f4683-af7c-4691-9fca-ff2a9f99b223"
      unitRef="usd">1281000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="i7179c9a592ed4b02a3c776ff0dd331b9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtMy0xLTEtMA_da4f9367-0c8c-4369-8c32-3f74ce9a2a7a"
      unitRef="usd">171000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtNi0xLTEtMA_c7192410-c0c6-48ef-a52d-6f8969909193"
      unitRef="shares">7000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i1680d4cac3f84f51a3046d2fdd4dde5c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtNy0xLTEtMA_d75107f8-5870-4c3a-ba89-3ac7d5f56e0b"
      unitRef="usd">-416000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTYtOS0xLTEtMA_013f79ed-8d2c-4705-8c93-a4b87bfe930e"
      unitRef="usd">-245000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTctOC0xLTEtMA_03cf0b26-476d-4133-9aa0-18f9bbdd38d5"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTctOS0xLTEtMA_d4d207d2-869d-4125-aebf-9e09d69cc85e"
      unitRef="usd">12000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i47981779293a4e2c945eb489c3ea47c1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTktOC0xLTEtNDA4NA_9824ebab-640c-4623-8117-fc35500bcbbf"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTktOS0xLTEtNDA5OA_b5553cb6-dc35-42b2-8dad-a168f6a8ccb5"
      unitRef="usd">22000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMS0xLTEtMA_57e33d13-5956-49d0-886c-99c45a6cb97c"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2024d90064f04b119d58d93d92e8236d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMi0xLTEtMA_336be8a6-f13b-42a3-98a8-c5b72d70b886"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f7b18662e9547c19e8db82d3b49ad03_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtMy0xLTEtMA_1d3246ee-7519-4b2e-a535-6b98701327b7"
      unitRef="usd">39489000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68eb834fd2ba4689a131fc785fe1664a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNC0xLTEtMA_f4b3a38b-4c06-48c5-bb45-f313ab4d68ff"
      unitRef="usd">51107000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNS0xLTEtMA_692bc384-3b90-414c-bae4-4b677d842ed3"
      unitRef="usd">-6383000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNi0xLTEtMA_9741447e-a976-4197-a952-cdc4121a71ea"
      unitRef="shares">1047000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i24296881407c49c4b8c78ad66fa3ad49_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtNy0xLTEtMA_1367acf4-d263-4a84-a0dd-4b4af61daef3"
      unitRef="usd">-56815000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc25c58f010b42e38af8f1e8d5f194c2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtOC0xLTEtMA_5052dab6-2209-4e4c-a3b0-e9d03cad188a"
      unitRef="usd">84000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV82NC9mcmFnOmUyYzI2NDBhNmJjNjQyNzJhMWQzNzI3ZDZiMDY1Zjk3L3RhYmxlOmIwODFkZGNjNTQ0ODQ5ZjBiYTU4NGQ5ZWI5M2Y5NGI1L3RhYmxlcmFuZ2U6YjA4MWRkY2M1NDQ4NDlmMGJhNTg0ZDllYjkzZjk0YjVfMTgtOS0xLTEtMA_a299a058-1b6e-42ca-9584-0d6ced0ba2b6"
      unitRef="usd">29270000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcwNw_418bc651-d6b3-4845-aa07-38bf4b45b3ba">Share-Based Compensation Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first nine months of 2020, the Company granted 7 million RSUs with a weighted-average grant date fair value of $77.83 per RSU and during the first nine&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months of 2019 granted 5 million&#160;RSUs with a weighted-average grant date fair value of $80.03 per RSU. During the first nine months of 2020, the Company granted 773 thousand PSUs with a weighted-average grant date fair value of $75.22 per PSU and during the first nine&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months of 2019 granted 609 thousand&#160;PSUs with a weighted-average grant date fair value of $90.50 per PSU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was $800 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcxOA_4767ff13-8aa1-40b1-8ab8-c62669b2ba43">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi0xLTEtMS0w_85d6d5bb-63e4-4398-935d-f307fbc9b488"
      unitRef="usd">126000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi0zLTEtMS0w_8ddf7c6d-c19f-40a9-8d3a-eaee6fc40c48"
      unitRef="usd">101000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi01LTEtMS0w_1e2d6aad-d4ce-4cef-a3a7-d414a0522203"
      unitRef="usd">354000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMi03LTEtMS0w_055b9c54-7118-48b3-aadb-c962b240dea6"
      unitRef="usd">306000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy0xLTEtMS0w_50e9f12d-b6ab-483e-94af-2e8145472711"
      unitRef="usd">17000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy0zLTEtMS0w_0312e845-0d1f-4167-aa13-8af8d92c9208"
      unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy01LTEtMS0w_02ee9bd4-6628-44ef-8869-5dc3c1f4f45f"
      unitRef="usd">48000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfMy03LTEtMS0w_4f95ec54-d5ec-4a2a-aafa-96b12927cdd9"
      unitRef="usd">42000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC0xLTEtMS0w_3dee6ae9-423f-4405-8745-f9a9c020a056"
      unitRef="usd">109000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC0zLTEtMS0w_afd55487-28ae-443a-adf1-3196cb17efbf"
      unitRef="usd">87000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC01LTEtMS0w_f83bb032-a8ca-4e47-b677-6909fa5581a3"
      unitRef="usd">306000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOjZhYzI5Y2Y3ZTVjYjRiNGU5YzM3YjYyZGZjOGE2NGI3L3RhYmxlcmFuZ2U6NmFjMjljZjdlNWNiNGI0ZTljMzdiNjJkZmM4YTY0YjdfNC03LTEtMS0w_1ecd7def-c8e0-48fa-b379-a2d2edd5cf12"
      unitRef="usd">264000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNTc1_fe2e26cb-9205-461d-9db6-b735873a5340"
      unitRef="shares">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic93ed2dced5b4e4687d59d691e41c7c1_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNjMy_9c62e366-36cd-43b8-acf2-fd4e410819cb"
      unitRef="usdPerShare">77.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNjg4_b9ac8e6e-2ec3-4b28-918c-770494a9c92a"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i75834e0da33b43b5bb2d08cd8b19bd75_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfNzQ1_1df1353d-b8d3-4e43-9a58-23b535035a50"
      unitRef="usdPerShare">80.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfODEx_6314cf73-0b83-4585-b18f-10ea3a1f9363"
      unitRef="shares">773000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie38e692d1e7742198e8dfa7721c4329d_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfODY4_2db68a8c-653f-417d-9005-d7e50c2dab7b"
      unitRef="usdPerShare">75.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfOTI0_8513cd63-08f7-4d98-a413-f264b59a77d6"
      unitRef="shares">609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68e2e74bb2e44c2d96a6dad54fef4fea_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfOTgx_9ff9fd46-7cc0-49bd-8237-85bff511909a"
      unitRef="usdPerShare">90.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTcyMA_d7c75d55-db44-44d1-98ed-e64afe9be1ea">During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.018%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTA1MA_08dee29b-2324-4906-a20c-b033137faa77"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTEwOQ_9e258628-cd69-4c79-bc1a-5d00e211bee4"
      unitRef="usdPerShare">77.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTE3MA_a7f9a5a3-3f34-4769-899b-9356cc0064f8"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTIyOQ_6b3492f5-e3a5-49cd-a7cc-69b3f2488a83"
      unitRef="usdPerShare">80.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTM0Mw_c3bf5a45-7fd0-447e-a632-acd3c222f948"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTM1MA_b1a4f1de-a5cc-4b2c-8d4b-97a8188b6d76"
      unitRef="usdPerShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMi0xLTEtMS0w_d70ba2d8-87bb-4597-aed0-e5aec9f1f62f"
      unitRef="number">0.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMi0zLTEtMS0w_fb686066-9148-49aa-bd1f-8a24fa61ec47"
      unitRef="number">0.032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMy0xLTEtMS0w_6052c496-4ebd-49a7-8eb3-8d833e01b8b6"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfMy0zLTEtMS0w_a3efc57f-9e81-4a70-b411-7d679709e507"
      unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNC0xLTEtMS0w_bc16345a-6d07-443b-90cb-74ab66fe9126"
      unitRef="number">0.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNC0zLTEtMS0w_022ddf7b-aac5-45aa-9f2c-f6abeb930bc4"
      unitRef="number">0.187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNS0xLTEtMS0w_56d3b029-872f-4494-b7a1-34a3e407ffc9">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RhYmxlOmE2M2MxZjhkOWEwNjQ5YTI5YTYyZTI3M2EyMGMyNDE5L3RhYmxlcmFuZ2U6YTYzYzFmOGQ5YTA2NDlhMjlhNjJlMjczYTIwYzI0MTlfNS0zLTEtMS0w_62a5afe5-1bd3-422d-b817-f0559340dbd4">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1cde861334fc459fa80a684680fc7c3f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTQ1MA_ddd42205-8590-4697-9c18-18c4663ede12"
      unitRef="usd">800000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83MC9mcmFnOjZlZmY3NDE4M2JhZTQwMWM5ZjQ2NmY1NWYxOTM3ZTUwL3RleHRyZWdpb246NmVmZjc0MTgzYmFlNDAxYzlmNDY2ZjU1ZjE5MzdlNTBfMTYxNw_92a7de3f-4611-416e-86e7-a1af0f810916">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUyNw_ce578795-87fc-402e-84f4-66c4f5bb000a">Pension and Other Postretirement Benefit Plans&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates that in 2020 it will contribute approximately&#160;$200 million&#160;and $375&#160;million to its U.S. and international pension plans, respectively, of which&#160;$184 million&#160;and $123&#160;million, respectively, was contributed in the first nine months of the year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (see Note 13), with the exception of certain amounts for termination benefits, curtailments and &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;settlements, which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.&lt;/span&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUyMg_bbd2d5ab-5642-48d8-b9fb-d746042796cb">&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xLTEtMS0w_de7597ed-4b35-4edf-9dcf-7c8ddb0591f5"
      unitRef="usd">96000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0zLTEtMS0w_bdff99b3-3d7a-4613-8ac9-2d123f87c2d8"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy01LTEtMS0w_343ca5bd-4203-4205-ab50-05c76cb86c9d"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy03LTEtMS0w_76261715-4089-4032-8225-066259a4339a"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy05LTEtMS0w_18eb3d22-9443-4b27-9c53-bc8606e5a3fd"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xMS0xLTEtMA_e330d3bc-baef-41c0-a306-eea894999043"
      unitRef="usd">225000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xMy0xLTEtMA_cea4e784-58b5-45ba-804f-fcdb16d3e58d"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMy0xNS0xLTEtMA_9a83e374-49c9-467a-a4bb-4f88d7a5f80d"
      unitRef="usd">178000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xLTEtMS0w_4f80da46-eb5e-4e8a-a4a1-7872c85e7b81"
      unitRef="usd">107000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0zLTEtMS0w_ed715080-05ad-4811-a012-c0a2b6a3f14c"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC01LTEtMS0w_47de4108-3f64-49f0-80f5-7cc9d8945992"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC03LTEtMS0w_2a039a65-3249-48c0-9adc-65daebeb5d3b"
      unitRef="usd">44000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC05LTEtMS0w_fe41fe7d-fd73-40a4-b801-ab380b172c5f"
      unitRef="usd">323000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xMS0xLTEtMA_10dd36e9-9cd4-409d-97ed-70bf477f9453"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xMy0xLTEtMA_fe174d20-a82d-4bb6-9a4d-e9b798e77bee"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNC0xNS0xLTEtMA_d57d99b4-7e31-44bd-963b-d93cf29d7115"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xLTEtMS0w_f546d859-9dfb-4e2f-bc18-9316f05ec88b"
      unitRef="usd">193000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0zLTEtMS0w_68c91a74-7f11-4ef5-8955-01f9030627a4"
      unitRef="usd">104000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS01LTEtMS0w_7533b37a-a30e-4985-860c-3696c93d78f9"
      unitRef="usd">202000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS03LTEtMS0w_a24ce3d7-4c01-4be0-8957-3b9f79ad4cf7"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS05LTEtMS0w_f1fc6b9f-6773-43eb-a06e-f964b44f74f9"
      unitRef="usd">581000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xMS0xLTEtMA_4385a7dc-8e61-4a8e-9e7b-e59f1a5f7b52"
      unitRef="usd">310000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xMy0xLTEtMA_1adeb63a-92ca-4c59-9d8c-daf156015d76"
      unitRef="usd">613000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNS0xNS0xLTEtMA_b7c4dd8c-9232-48e7-b5e0-fcbcb835332d"
      unitRef="usd">320000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xLTEtMS0w_da73cf98-6a75-42fa-afff-9640efc461cc"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0zLTEtMS0w_14661dee-2a48-46d3-b691-f25d75a267c3"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi01LTEtMS0w_06739870-35ed-4c9a-9831-1f45f712b4a5"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi03LTEtMS0w_1d689fb5-2a55-4ff7-93ab-f7f9784846b9"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi05LTEtMS0w_92586ee6-52dc-477e-9c7b-46b54bd283e4"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xMS0xLTEtMA_358254a2-ca83-4d96-a2e2-30ed8dc51c8e"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xMy0xLTEtMA_993137f6-80b4-40ec-aa50-76f5da797b0b"
      unitRef="usd">-37000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNi0xNS0xLTEtMA_14fb5caf-e603-4386-9715-bf97ac653503"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xLTEtMS0w_da5393d6-a353-4ea1-94ca-aaf4ee90f371"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0zLTEtMS0w_ae7d7c02-98a9-4244-9e60-e39efa8d2a43"
      unitRef="usd">-32000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy01LTEtMS0w_8541a63d-dc70-40dd-81a8-5fce40de6bb0"
      unitRef="usd">-43000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy03LTEtMS0w_82af2960-72ed-4484-b96c-5af4876b380e"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy05LTEtMS0w_886b23a6-df62-4066-9c7c-106e664dd7d5"
      unitRef="usd">-228000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xMS0xLTEtMA_1fbac9ec-43b6-4c5f-9cb2-e7b965432667"
      unitRef="usd">-94000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xMy0xLTEtMA_2de80ea7-be61-4acb-8fe6-462f84b39472"
      unitRef="usd">-113000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfNy0xNS0xLTEtMA_e3d138b5-5ca1-4a4e-bb96-c71ece9b8bbe"
      unitRef="usd">-47000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xLTEtMS0w_43f1b9d5-50d4-44d6-80ea-71bb951337e5"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0zLTEtMS0w_4916dc88-6f6a-45a6-9414-d38a10ecba7d"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC01LTEtMS0w_69b06cfa-756b-4243-ae7d-c3124071f31a"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC03LTEtMS0w_ba1d390d-6155-4616-8f2c-17a08a6f090c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC05LTEtMS0w_6bbb1bf8-3d3d-45a9-9f35-40177f7f2e91"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xMS0xLTEtMA_f044dbe6-77cd-4a33-a43d-19931a705270"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xMy0xLTEtMA_b386d1d2-c587-4e47-95f2-58e0f31f0417"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOC0xNS0xLTEtMA_8621e528-86c3-495b-9fd3-a8a8fbe6d4d0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xLTEtMS0w_9f017947-6517-4aee-9a21-668c8e18d21b"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0zLTEtMS0w_c4408257-c7bb-462d-8b89-8872867d235c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS01LTEtMS0w_6ba230f3-3a34-4fb0-8694-96402839db24"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS03LTEtMS0w_da21d740-ff83-4cb6-baca-70477d580d55"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS05LTEtMS0w_6961fecd-8d7f-4d60-8bbf-2ac4cfbb2265"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xMS0xLTEtMA_c9bd1cb7-9a45-49e2-a058-a81ed90a2537"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xMy0xLTEtMA_c7d575fe-a6b0-4c72-a2ed-feda7af66269"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfOS0xNS0xLTEtMA_36a47aeb-0627-4987-b5b4-fbc72155106f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMS0xLTEtMA_a264c098-be48-4bfc-b296-94fc0a957905"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMy0xLTEtMA_fbedbb91-713b-4c62-a9b1-0572508aca63"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtNS0xLTEtMA_a0869473-6893-4132-b4c8-5f24c0e1622d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtNy0xLTEtMA_96102e0f-d81b-4805-b14b-c2a35cb995cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtOS0xLTEtMA_88e18486-8b78-40af-86d6-cbf8bdce99ac"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTEtMS0xLTA_aba1718d-6609-4274-8947-70061a01fd06"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTMtMS0xLTA_932a32cf-da74-44f6-ba97-b8baea1eeda4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTAtMTUtMS0xLTA_8111f4b8-7f43-48e2-a946-16d14f79f69c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4371337fa27045bdbeffa6f4e49a7cad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMS0xLTEtMA_96d6e8d6-87c1-4635-82d5-37a2c76a7b92"
      unitRef="usd">77000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i87777f4eacfe4108bb2121938bc6fb40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMy0xLTEtMA_763cdf07-7a29-49d6-bd6a-c6eb7ce0984b"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i223966c484c34cfaa8893c9c8435cf49_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtNS0xLTEtMA_4739315f-4159-4a92-985b-6db8cd5a39bb"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4c25ff2f60564bea946c8c7729e0a990_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtNy0xLTEtMA_08c7ca43-bdd0-41eb-a5a9-b051ead134b2"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icc6986944326476e9ee45b35e42fbd44_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtOS0xLTEtMA_5aabf4e2-e9c3-45be-99a4-b247ba71a588"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7d7891edaf2a4cecb9c7a344b5732479_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTEtMS0xLTA_cfacce78-2acd-491b-9ce6-d03075f18b0e"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i132de9fef5ff46aba8cb5119095b9aee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTMtMS0xLTA_f2abd76e-894b-4a0c-9367-4dd5ec0850c3"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i70fde013ce23427885d12c7780eb56a3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmRlZWI0Y2Q2MmRlYTRlNzk5NDBhY2ZiZmJhZjMyZTBlL3RhYmxlcmFuZ2U6ZGVlYjRjZDYyZGVhNGU3OTk0MGFjZmJmYmFmMzJlMGVfMTEtMTUtMS0xLTA_102dd368-0218-4a94-addc-e07eaa67ab06"
      unitRef="usd">30000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear
      contextRef="iac567bcc7ca2418f86edba65970f34af_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMzQy_7d6e3c94-b4f0-48d7-8668-f0fe040ab0b6"
      unitRef="usd">200000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear
      contextRef="if9ad3599c3a84146ad4a9b8040fa9260_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMjE5OTAyMzI1NzM2MQ_cc457578-5e78-4f43-a0be-ee8753bba5b0"
      unitRef="usd">375000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i69fee893e6cb48f090068514eaf1dca8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMzg5_603d27c8-bcfe-43f4-b9a6-37b11587d9da"
      unitRef="usd">184000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id990f16dcd334b06840813dd8a39b138_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMjE5OTAyMzI1NzM3NQ_34494b71-7cfb-4dac-a022-d17e75281d89"
      unitRef="usd">123000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RleHRyZWdpb246Yjc4YjJjZjE4ZmU5NGM5OGIxYTNiMmMxY2JhZGFjZDlfMTUzMw_0b0cade2-ccbe-4f6e-8a78-a9acfb71b047">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi0xLTEtMS0w_bf551ede-e8d4-4eca-b6d8-c40291b29bd8"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi0zLTEtMS0w_c88b2e1e-ddec-44b8-90c5-331d793bfe16"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi01LTEtMS0w_64d03f4c-47e3-45c4-884c-deb08547fa93"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMi03LTEtMS0w_547405bf-2f1a-4e19-b4a2-bf2c8c6c82c6"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy0xLTEtMS0w_32cee2ea-4735-4560-945f-ab81cc0906c0"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy0zLTEtMS0w_15407ae0-cdb6-4c3b-8a24-af0ddce3d7bc"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy01LTEtMS0w_3705e025-87b8-477a-b696-f44c74dd672a"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfMy03LTEtMS0w_f95de4ad-e518-4432-bad4-e8f85db87770"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC0xLTEtMS0w_6abcedf1-ec81-471c-83a8-20238af382ad"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC0zLTEtMS0w_1174eb36-5fff-414f-8e7b-7e6eb04f7e8a"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC01LTEtMS0w_83bc9846-3cfe-4628-9dbe-f241665ff8dd"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNC03LTEtMS0w_d447a65a-416b-41b5-b4b8-ce172fab41e5"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS0xLTEtMS0w_21ef528d-a47d-47eb-bb61-24965d5345d5"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS0zLTEtMS0w_59464bbf-4893-4031-8cce-1721f731a25d"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS01LTEtMS0w_1dd5c037-4e18-4777-a84b-acfc9a1991f7"
      unitRef="usd">-54000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNS03LTEtMS0w_45c34aa9-e20a-47be-a8d0-62360b269c30"
      unitRef="usd">-59000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0xLTEtMS0zMzU_3d884a47-9cb8-4356-b10d-ce7ce1dc99c8"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0zLTEtMS0zMzU_be41215b-dd1a-4398-96cc-3a33a0e8ba3b"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi01LTEtMS0zMzU_cbc7a9b9-0355-4a28-8a13-663c023679a0"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi03LTEtMS0zMzU_87119675-aa2f-4281-ae4f-a720aba82b23"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0xLTEtMS0zMzk_b1bd964c-da7e-410e-8ae9-94314bad836c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0zLTEtMS0zMzk_19c82237-9282-4006-a17a-87849519ebe3"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy01LTEtMS0zMzk_9a529734-bb1b-439f-b256-e8dc111516b4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy03LTEtMS0zMzk_aecdcad2-eaa3-4931-b01b-fba8a405b8d3"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0xLTEtMS0w_6b58aef4-5b3b-4d9b-a6fa-7332929ebe09"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi0zLTEtMS0w_553c1abf-2150-44f6-b50b-6ff436dc6bcf"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi01LTEtMS0w_553317a0-05ce-4197-8b85-92b1e60e616c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNi03LTEtMS0w_2a48d23c-71a9-41d6-a949-7f1a794bb3ee"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0xLTEtMS0w_73d1931b-4051-467f-bab3-22be820bb10a"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ieb29bc6824544a9092c890ad56549217_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy0zLTEtMS0w_8400a90c-67aa-4a91-9724-43b10284a8dc"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4b089353a48f43fbaced08dd69103993_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy01LTEtMS0w_ef9a6e9d-ee9c-4e94-ae93-b7876c75115e"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9c25fddd196848148931730be86e9b3b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83My9mcmFnOmI3OGIyY2YxOGZlOTRjOThiMWEzYjJjMWNiYWRhY2Q5L3RhYmxlOmFkN2RkYTUyN2U2MDQ5Yjc5MjFmZWI2NzY2N2NiNTgyL3RhYmxlcmFuZ2U6YWQ3ZGRhNTI3ZTYwNDliNzkyMWZlYjY3NjY3Y2I1ODJfNy03LTEtMS0w_3f7a2fee-2426-4c71-9d4c-29409135f4b5"
      unitRef="usd">-35000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ2NA_0fc2ebf4-ea74-4ff0-8c4c-f494220f52ba">Other (Income) Expense, Net&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other, net (as reflected in the table above) in the first nine months of 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest paid for the nine months ended September&#160;30, 2020 and 2019 was $605 million and $629 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ4MQ_9811fb0d-dff6-4fdb-868b-a04b95971d0b">&lt;div style="margin-top:5pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi0xLTEtMS0w_69336933-989c-48b7-861f-ebfb7822b181"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi0zLTEtMS0w_cbca5c26-da67-42be-aadd-40dac05facf6"
      unitRef="usd">61000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi01LTEtMS0w_7c05d76b-6b71-4150-8d60-7e08a1264541"
      unitRef="usd">48000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMi03LTEtMS0w_7692b491-6fd6-4050-b9b4-68d8e47d8959"
      unitRef="usd">225000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy0xLTEtMS0w_58a95ea8-c62a-4c87-869f-dc0708d16092"
      unitRef="usd">203000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy0zLTEtMS0w_2146d0cc-bb35-4a5e-a9c9-92e43757e006"
      unitRef="usd">231000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy01LTEtMS0w_b46a59d1-9dce-43ff-8576-68d468a5a514"
      unitRef="usd">624000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfMy03LTEtMS0w_cbed56f2-f294-4dfa-b0e2-dbd73e3e0700"
      unitRef="usd">674000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC0xLTEtMS0w_dd8bbb6a-4042-4ae3-bc5d-e1da7ae75df5"
      unitRef="usd">-10000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC0zLTEtMS0w_b5ec6bce-3e23-4a03-b6e5-fd6e01b793c6"
      unitRef="usd">-38000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC01LTEtMS0w_13511a78-3f3e-48ac-9e42-1ec25878a6db"
      unitRef="usd">-89000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNC03LTEtMS0w_f08b3255-ed7b-4290-b8ce-b8a2196a6bf9"
      unitRef="usd">-166000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS0xLTEtMS0w_511eafdd-dadc-4439-8df1-ebf05078bee9"
      unitRef="usd">360000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS0zLTEtMS0w_9da0ed5b-f509-48c3-9e48-72f6723cac81"
      unitRef="usd">16000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS01LTEtMS0w_ee95c15f-43de-45a1-8c3d-2b4da536dd1b"
      unitRef="usd">964000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNS03LTEtMS0w_851d176c-5165-4917-9754-c5603daa0497"
      unitRef="usd">50000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi0xLTEtMS0w_4c4ecd23-634a-4053-9104-900a9d62843a"
      unitRef="usd">-88000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi0zLTEtMS0w_a496c038-ed7e-4c5c-bf37-c9d2622947b2"
      unitRef="usd">-128000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi01LTEtMS0w_f3817beb-db29-47f6-941b-7783cdd87e24"
      unitRef="usd">-259000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNi03LTEtMS0w_284d5a84-7c2f-4002-9d1c-f0bf18ddef39"
      unitRef="usd">-409000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy0xLTEtMS0w_78ff5a36-44e4-46aa-bff7-ec48ebb64d1a"
      unitRef="usd">68000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy0zLTEtMS0w_027e769a-97c5-4527-a42f-e2c088e329c7"
      unitRef="usd">29000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy01LTEtMS0w_ea13456b-21c7-4c8f-aba2-d30d8550c4a9"
      unitRef="usd">72000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfNy03LTEtMS0w_d9879b53-de4c-4fb3-b5de-a54c9bac20f2"
      unitRef="usd">-206000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC0xLTEtMS0w_6e0468d9-27f7-4a81-b132-87b9e8bf3150"
      unitRef="usd">312000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC0zLTEtMS0w_c6f52a82-4d80-4f6e-a935-d13492c6eb63"
      unitRef="usd">-35000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC01LTEtMS0w_397e46c9-e90c-4de3-89d4-5a57bd7b697e"
      unitRef="usd">630000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RhYmxlOmNhOGY5MzhjOWIwNjQ4MjBhYWM2ZmEyNjc5Y2YyZTE3L3RhYmxlcmFuZ2U6Y2E4ZjkzOGM5YjA2NDgyMGFhYzZmYTI2NzljZjJlMTdfOC03LTEtMS0w_bba9b4c1-3fbb-480f-8eb9-099a23ef79ab"
      unitRef="usd">-362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iaa3ff69e58674e75915bf501c2c193e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTI3Mw_034b3c16-814c-4209-8fd2-f7ef7c01ed40"
      unitRef="usd">162000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InterestPaid
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ0MQ_62dbadfe-735d-4e08-843d-5dcd7455b202"
      unitRef="usd">605000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83Ni9mcmFnOmIzYWFmZGE4ZTY4MjRkZDViYzI5ZWQ4NGM4YjQ1MzllL3RleHRyZWdpb246YjNhYWZkYThlNjgyNGRkNWJjMjllZDg0YzhiNDUzOWVfMTQ0OA_437e3a6d-87d0-4301-93fa-e3d3c569ac5b"
      unitRef="usd">629000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTIxOA_1b82789e-3118-4262-9ac8-fb3e80033396">Taxes on Income&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9%  and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#x2019;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company&#x2019;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNTk_b92a08f8-44fb-4f17-bbb6-843e834a772d"
      unitRef="number">0.141</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNjY_395cc74f-ef14-400e-8a9c-d5fc3a279139"
      unitRef="number">0.187</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTIw_debba452-d18f-4b5c-b2c1-992de1fc1bff"
      unitRef="number">0.149</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfMTI4_4a6a3d90-0c8d-4f0c-9a23-cd330422018b"
      unitRef="number">0.145</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNDUw_025c777e-2cdc-4d5d-8805-511dbfb2023d"
      unitRef="usd">360000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:IncomeTaxesPaid
      contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfNzQw_71705360-6b48-4cb1-89ea-16bfecacdc34"
      unitRef="usd">107000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="icde39c65b3dc463288b953c0c6fc4d94_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV83OS9mcmFnOjkxM2Q2YjgwMDExMjRmZWZiMjc0NWMyMGVlYTQ5Y2VjL3RleHRyZWdpb246OTEzZDZiODAwMTEyNGZlZmIyNzQ1YzIwZWVhNDljZWNfOTI3_025c777e-2cdc-4d5d-8805-511dbfb2023d"
      unitRef="usd">360000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfNDU1_01546a35-ea71-4e56-8caa-00882eab7215">Earnings Per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share assuming dilution attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;For the third quarter of 2020 and 2019, 5 million and 3 million, respectively, and for the first nine months of 2020 and 2019, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfNDYx_ca2e0f38-cd69-4652-86d8-40570f991e35">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share assuming dilution attributable to Merck &amp;amp; Co., Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi0xLTEtMS0w_fbf9f141-daec-4494-b054-3126a6913714"
      unitRef="usd">2941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi0zLTEtMS0w_6fcb48d5-18f5-40ad-a349-1364a5f1aa12"
      unitRef="usd">1901000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi01LTEtMS0w_69e34e63-3f9c-457f-bb91-410da2c91db8"
      unitRef="usd">9161000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMi03LTEtMS0w_41c7fd79-72d9-40d8-8ac6-6c2bbbd1ecea"
      unitRef="usd">7487000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy0xLTEtMS0w_3cb4006c-c90a-4848-829b-27cc43b855ee"
      unitRef="shares">2529000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy0zLTEtMS0w_9e9f532c-6fc1-4d39-b3d1-c775326b5113"
      unitRef="shares">2558000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy01LTEtMS0w_e264033f-1421-44e3-8e04-22620acf5fbe"
      unitRef="shares">2530000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfMy03LTEtMS0w_59009b2e-a011-4e2a-8d39-badecdf2e902"
      unitRef="shares">2572000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC0xLTEtMS0w_424aae64-855c-4f57-9cf5-0ff7e65397cc"
      unitRef="shares">9000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC0zLTEtMS0w_813eb717-c38e-4b94-a2f1-37f9008f5a6e"
      unitRef="shares">14000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC01LTEtMS0w_b61cc52b-9b1a-4bf5-9639-f4c942111301"
      unitRef="shares">11000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNC03LTEtMS0w_d7899e79-ef84-4622-92b2-4737e26067d6"
      unitRef="shares">15000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS0xLTEtMS0w_74429ead-87cc-41fb-a155-7ecf87ac08b5"
      unitRef="shares">2538000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS0zLTEtMS0w_e7869ff5-0134-4e54-a9b4-cbc2a0386a78"
      unitRef="shares">2572000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS01LTEtMS0w_f1bd8a39-3e77-4aa9-9701-28a2f4b6739f"
      unitRef="shares">2541000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNS03LTEtMS0w_e9cf312c-28c0-4910-b30a-8d38199186b6"
      unitRef="shares">2587000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi0xLTEtMS0w_5ca2075b-7de6-41de-8cbd-d4e45bb29c91"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi0zLTEtMS0w_ab8ebda0-2585-402b-9e46-6ccc74440386"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi01LTEtMS0w_199157ff-3231-4755-ac6e-e17d2a96154a"
      unitRef="usdPerShare">3.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNi03LTEtMS0w_0e7058ab-ce62-4e96-8543-051082d3d28f"
      unitRef="usdPerShare">2.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy0xLTEtMS0w_a5aaf7e8-3a0e-4651-9d27-f722caa97465"
      unitRef="usdPerShare">1.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy0zLTEtMS0w_228f0c22-a985-4b2f-9e9c-c22f7b78edbb"
      unitRef="usdPerShare">0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy01LTEtMS0w_944457b6-cffa-41bc-bdba-bf2c03963f99"
      unitRef="usdPerShare">3.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RhYmxlOjU0ZWZhOWVkMTdmYzRlNmViMGZiZTVhODA1ODA0ZWNkL3RhYmxlcmFuZ2U6NTRlZmE5ZWQxN2ZjNGU2ZWIwZmJlNWE4MDU4MDRlY2RfNy03LTEtMS0w_a2e565b6-9aa1-4e98-b424-503e7ac1ce64"
      unitRef="usdPerShare">2.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMTc2_bbe85da9-eab9-470b-a368-9e36ac958df4"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMTgz_80bf7842-9d6d-4163-80b9-939712604811"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMjc0ODc3OTA2OTk3OQ_c14f9b9e-1635-4687-9fba-c59df4611d81"
      unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84Mi9mcmFnOmQ5YjFjNTMzMzAwZjQyZmJhMzBkMTMwYzAzYWQ2NzVkL3RleHRyZWdpb246ZDliMWM1MzMzMDBmNDJmYmEzMGQxMzBjMDNhZDY3NWRfMjUy_edb657e2-8b3b-4d38-9f0f-c9e7905f9dae"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RleHRyZWdpb246N2Q2ZDUwZWI0MzYzNDg4OWI2MmFmZjRjODQxMDhjYTBfNDgy_f2081598-63df-4359-881d-367da51b3d35">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by component are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RleHRyZWdpb246N2Q2ZDUwZWI0MzYzNDg4OWI2MmFmZjRjODQxMDhjYTBfNDg5_4ee6f1d0-7b12-48bd-8afb-7ced67bea518">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by component are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance July 1, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2019, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance September 30, 2020, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AOCI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9db841c072d54fa6888133ec10cf2cc4_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi0xLTEtMS0w_d811f1fe-e0a0-4a56-b9d8-3e85b7a31436"
      unitRef="usd">66000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6591fbc20c114de39653e3b19a29f103_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi0zLTEtMS0w_30b9855d-1298-4459-9315-4cf4ba4233dd"
      unitRef="usd">48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1a6af2de3ce4f4a8efd8359eaeeb7bd_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi01LTEtMS0w_ee83934a-2620-4db3-b381-337d39d6da30"
      unitRef="usd">-3530000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c230d35c63044149c73c8bb256576c8_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi03LTEtMS0w_706009aa-e667-4b08-8be3-9b522cd5ec0c"
      unitRef="usd">-1946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i661be48d847543a8a32ba2358107f61c_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMi05LTEtMS0w_750efdb8-7a28-48b3-a23c-566c32b99990"
      unitRef="usd">-5362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy0xLTEtMS0w_95c01562-85c7-4caa-be34-45d4defc0908"
      unitRef="usd">186000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy0zLTEtMS0w_5574f2e4-e5da-477a-94c7-851fd3041d71"
      unitRef="usd">8000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy01LTEtMS0w_f13dc1c1-3d02-4e45-ba51-33cd6aa0cb71"
      unitRef="usd">-4000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy03LTEtMS0w_b9e5e0bd-69db-4233-81bb-f17d2e958a68"
      unitRef="usd">-84000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMy05LTEtMS0w_bb800d3e-4cd4-4d33-a27d-cac0377b40ca"
      unitRef="usd">106000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC0xLTEtMS0w_d464d49c-77f6-4133-bf16-43a524e819b7"
      unitRef="usd">39000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC0zLTEtMS0w_03b6f1b9-7be6-4b10-9357-883a6c0679e4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC01LTEtMS0w_4e186a9b-f62b-435d-9ac4-625472bdc89a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC03LTEtMS0w_50d6f25d-39c7-4cdd-9d8c-0f461a5692d6"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNC05LTEtMS0w_936626fb-a956-47b0-8f12-4dd11a30f1e1"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS0xLTEtMS0w_1674d66f-c525-4bc3-9121-4d6f5cdf5cf8"
      unitRef="usd">147000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS0zLTEtMS0w_24c690a2-2dc4-4833-8190-a0ecf5a465aa"
      unitRef="usd">8000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS01LTEtMS0w_73749cba-8298-4d68-a9a8-95e97ffef494"
      unitRef="usd">-4000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS03LTEtMS0w_ac009da5-c4e7-4e9f-9a67-69c415f33ee4"
      unitRef="usd">-117000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNS05LTEtMS0w_a4543012-a899-4764-b119-eb9bc8349b1c"
      unitRef="usd">34000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi0xLTEtMS0w_8eb5aab3-0991-48cd-a104-bc08c337d2be"
      unitRef="usd">71000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi0zLTEtMS0w_644582cb-ddff-499a-b202-29be1bd14c31"
      unitRef="usd">25000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi01LTEtMS0w_bb1e2919-4141-4af7-851f-e8c8bdaf3e59"
      unitRef="usd">-21000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi03LTEtMS0w_ae75801a-eccc-4d33-b31c-f5f4743f8872"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNi05LTEtMS0w_4d23460d-e5f3-4e9f-b573-10980eb76353"
      unitRef="usd">75000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy0xLTEtMS0w_52425579-022f-421f-8740-4dd81b739a9b"
      unitRef="usd">15000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy0zLTEtMS0w_96bfcd2a-355f-4186-90eb-8a99986ff738"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy01LTEtMS0w_84dce0d8-bfdd-4f38-8a07-cc32ddfef6ed"
      unitRef="usd">-2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy03LTEtMS0w_e14c4900-e940-4078-b6c6-98da24fad6cc"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfNy05LTEtMS0w_d406aaf1-3cc7-4f8b-88b6-35e8a90cc5ea"
      unitRef="usd">13000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC0xLTEtMS0w_7e47d879-876f-4de2-9fc8-2c6485fa2216"
      unitRef="usd">56000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC0zLTEtMS0w_b33b5427-69b6-4ec9-a65b-f4b332c2a354"
      unitRef="usd">25000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC01LTEtMS0w_ea9e48cb-da64-4a35-af29-f6dcd19a5290"
      unitRef="usd">-19000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC03LTEtMS0w_ee29fc3f-290b-4ece-bd93-a561a1e15d82"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOC05LTEtMS0w_90958d87-04fb-4a79-8a4d-a58a7b798821"
      unitRef="usd">62000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibc822dde06b54f21808c01d97156591e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS0xLTEtMS0w_e611b9a4-0d21-402a-8c7d-b067ef6b39c0"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5c779292425f4b18beae2abca895aff5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS0zLTEtMS0w_923e8e35-ca39-410d-9e9e-c5f05c4121ad"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i02201bf8615043028576af77f1b90ca3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS01LTEtMS0w_53caf26c-ee53-4736-b809-b763f94ff480"
      unitRef="usd">15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8e2318caad7347f5b997c0587fc38eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS03LTEtMS0w_73b59732-75f4-4515-9ec9-c2fc87ec053c"
      unitRef="usd">-117000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfOS05LTEtMS0w_beb1c55e-236c-4e9c-b20c-b790e67a3eb4"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e8f30eb9789429a962564babf142645_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtMS0xLTEtMA_c954136e-2e4f-4ec1-954c-0080c65251c8"
      unitRef="usd">157000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16aedbdec871407ea66e24efd83da330_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtMy0xLTEtMA_ab7ec0f4-e3e5-4e90-9bf4-c0aa42c8a622"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1878ab8ba71c4e20a87cd62012ad996e_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtNS0xLTEtMA_6be21df7-7745-4728-9873-1d2501885a50"
      unitRef="usd">-3515000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ebcbbb713742d698719f2cb0caa991_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtNy0xLTEtMA_a78812db-e7f8-4564-bf04-69a2a5401476"
      unitRef="usd">-2063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i532639a15db54349b73094a5ac53f994_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTAtOS0xLTEtMA_96140ef6-7fa3-4e6f-9472-1e684ce8c0ea"
      unitRef="usd">-5390000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25f69cc39ada42e0b2aac3d80fa1092e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtMS0xLTEtMA_03260e8a-b47f-4cc8-b8a4-2c00d7d57bc8"
      unitRef="usd">15000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id791a906551f4c699ba3f0a28a87d3ae_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtMy0xLTEtMA_107ea382-d5f8-4fa1-80aa-ce46c8652afa"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93df020249f849fca4ee19c9749a68c7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtNS0xLTEtMA_bf17b711-67ac-455f-86ea-40b6bb06f5e6"
      unitRef="usd">-4162000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifec46d9b67b440a8843d54b6ee61db1a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtNy0xLTEtMA_2d52288f-8bbc-4906-b201-cb7119f3a646"
      unitRef="usd">-2246000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7ea160b78c54ab3b2b467cbc1e274fe_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTEtOS0xLTEtMA_dc2adbe5-6683-4b3e-8857-48d6cf3cfdf1"
      unitRef="usd">-6393000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItMS0xLTEtMA_cd03a701-39fe-4e22-8661-47ce8887502b"
      unitRef="usd">-195000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItMy0xLTEtMA_b57ecb07-b804-4027-b68e-a1c40f110859"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItNS0xLTEtMA_d84a1536-b8ee-4cce-954f-5479ef36616d"
      unitRef="usd">2000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItNy0xLTEtMA_6cb10b70-fd1a-484b-adf4-67f1ed8f52f0"
      unitRef="usd">50000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTItOS0xLTEtMA_d3faec19-00bb-450a-8822-129bd48cc5fb"
      unitRef="usd">-143000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtMS0xLTEtMA_fe490bb1-c1c5-4886-ab35-d4cd2962c662"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtMy0xLTEtMA_98fd608f-3858-472c-861f-474b612d3fb8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtNS0xLTEtMA_6d03bde2-0737-430a-9326-2bc5b6b2e67f"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtNy0xLTEtMA_82f3bc9c-54bd-42f6-b993-a8f9d70f5ce0"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTMtOS0xLTEtMA_d11fdafa-dfe6-4f0c-bc8a-ff861b009550"
      unitRef="usd">-77000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtMS0xLTEtMA_db3040fb-b0f9-41b0-9ffd-93ba658b1e67"
      unitRef="usd">-154000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtMy0xLTEtMA_80efd1a0-c55c-4e10-b269-7fcbac59a17e"
      unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtNS0xLTEtMA_f5f24045-554a-4b57-bbac-d10e2ff46710"
      unitRef="usd">3000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtNy0xLTEtMA_3abf755c-a3c6-4de6-a146-4e3fe48eaa88"
      unitRef="usd">85000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTQtOS0xLTEtMA_fa33ba7d-58d1-45c5-9a2c-a40d05ad7932"
      unitRef="usd">-66000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtMS0xLTEtMA_18ea8dbc-5e5e-4ba1-970b-bdffafdfe3c6"
      unitRef="usd">-22000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtMy0xLTEtMA_f766530a-711d-4362-8309-b865d12f7cca"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtNS0xLTEtMA_c1ae3d96-133c-420b-a3c8-02be62c0e3bd"
      unitRef="usd">-72000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtNy0xLTEtMA_2f086194-b9fe-49b0-85ed-484cd0946572"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTUtOS0xLTEtMA_7af632b5-ed73-48f1-a85b-13423c01e0fd"
      unitRef="usd">-94000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtMS0xLTEtMA_7eb67ed9-68b1-4b76-a987-f35ab54b9428"
      unitRef="usd">-5000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtMy0xLTEtMA_c6b1beb4-1ecd-4bde-8a00-876d82956b2b"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtNS0xLTEtMA_7460a85a-09f8-4f83-b200-c2a96dd18b52"
      unitRef="usd">-13000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtNy0xLTEtMA_77698ef0-0d4a-4810-90f5-f502562ce267"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTYtOS0xLTEtMA_24e580ca-42cd-4577-b2e4-feef443ef373"
      unitRef="usd">-18000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctMS0xLTEtMA_56ee8109-bbe3-4d98-8325-096ed08df2aa"
      unitRef="usd">-17000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctMy0xLTEtMA_28d7caf1-4288-4512-8de5-4526fcb41b10"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctNS0xLTEtMA_b7ec2015-5bc8-43b8-990b-243f80e51700"
      unitRef="usd">-59000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctNy0xLTEtMA_89f0183a-654e-4796-91fc-f0719070f88e"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTctOS0xLTEtMA_1eb3b4ca-0df3-4bbf-8a0e-878917a318ca"
      unitRef="usd">-76000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic1b840794bb74a59b20cc4fdfc676b14_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtMS0xLTEtMA_efe2f068-d6a7-465d-bc30-7864fc989100"
      unitRef="usd">-137000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia5f3cdecc1764ef48af93cd962e89360_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtMy0xLTEtMA_e639016e-9a37-40f4-ae2b-076ff509813d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i105d158e3f10426186dd470f87d1581d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtNS0xLTEtMA_e0846bf8-45e2-4e92-b32c-60d59cb600e9"
      unitRef="usd">62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8b97dc90629e4fe2b041e526a56b5fab_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtNy0xLTEtMA_0a854630-9705-4ef0-911c-8d30e0a18e7c"
      unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTgtOS0xLTEtMA_c8a4c856-2306-45c6-9e41-58c8541cc2cb"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktMS0xLTEtMA_4012e411-6022-4e01-8ef4-3ac0ac7fad37"
      unitRef="usd">-122000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i065889e51dbb442688e6ff3173a1e969_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktMy0xLTEtMA_35a0195e-7863-4c9c-bb59-090615a61c3d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktNS0xLTEtMA_516585f1-589e-42e9-93a5-c33f0fa71071"
      unitRef="usd">-4100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cf5449d143444ea99ebf110cf6c87e2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktNy0xLTEtMA_904bf96f-e48e-499e-94f0-55acd413c166"
      unitRef="usd">-2161000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOmM1MWVhMTYzNmM0ZDRkZGFhOGYzNzE4MmY1OTVlNjI1L3RhYmxlcmFuZ2U6YzUxZWExNjM2YzRkNGRkYWE4ZjM3MTgyZjU5NWU2MjVfMTktOS0xLTEtMA_e3b7e2f6-32b1-4306-a479-38eb4cbdd27a"
      unitRef="usd">-6383000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i454ba9cd9d334299a099d995c578d97c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi0xLTEtMS0w_8a3b4d74-a15f-45da-9724-f1678aa31ed9"
      unitRef="usd">166000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia333381aeda74595900b302e6c11c47a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi0zLTEtMS0w_3ab23bf2-813f-4cc7-add9-9622f7def42d"
      unitRef="usd">-78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia99ed860505e4c2a85a20cf2fdc2edef_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi01LTEtMS0w_a58ab893-56a7-4a57-8db7-ceab1e800ba9"
      unitRef="usd">-3556000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic97b428654714aed9ddab64e466a889f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi03LTEtMS0w_51ecc5ea-9c4c-4da1-8072-3d8b16a078fb"
      unitRef="usd">-2077000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3b64dd57b0841dbb2b8f478c5474e4f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMi05LTEtMS0w_5fcb60c4-2915-465c-bae4-7e45180141ea"
      unitRef="usd">-5545000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy0xLTEtMS0w_d56f98c1-1b69-41f7-b18f-2ac5622ab385"
      unitRef="usd">183000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy0zLTEtMS0w_99922875-a858-4be5-8a02-5c79b589d4c3"
      unitRef="usd">139000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy01LTEtMS0w_fd508eef-ce0b-470e-8961-07f4e246a53b"
      unitRef="usd">-5000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy03LTEtMS0w_d3a1fd0f-62a9-4c59-9c9c-712a7ea6da5b"
      unitRef="usd">47000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMy05LTEtMS0w_0b4f8a37-c3ef-428e-a0f5-4b844b89017d"
      unitRef="usd">364000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC0xLTEtMS0w_e2b1e35e-9db8-4219-b469-8efc744ca3d1"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC0zLTEtMS0w_34c552b3-4824-47f6-b9da-3fb309dbb96a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC01LTEtMS0w_679ca7d2-717c-4839-96de-a264ea30b757"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC03LTEtMS0w_5f1edd8a-999d-49cc-8eb2-3723410e443f"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNC05LTEtMS0w_56c22805-7626-4ddb-b2b4-ce9155a8c40d"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS0xLTEtMS0w_27b12085-3b6e-4191-8917-5f46d116dae6"
      unitRef="usd">145000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS0zLTEtMS0w_95926f19-7d68-4bcd-8798-8b6ef16b5be6"
      unitRef="usd">139000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS01LTEtMS0w_b7f0683a-ccee-4093-978e-1d69de63b42c"
      unitRef="usd">1000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS03LTEtMS0w_683206ac-8638-4f9c-99a4-eb0e974dbf9b"
      unitRef="usd">14000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNS05LTEtMS0w_0963f890-5813-4cc7-a4c4-c78b7ff58f82"
      unitRef="usd">299000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi0xLTEtMS0w_c26ad490-ecde-47f3-af6b-1d316c6dd68e"
      unitRef="usd">195000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi0zLTEtMS0w_6af256e4-a18c-4af3-aeb2-8c57588dfc0c"
      unitRef="usd">30000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi01LTEtMS0w_5d36e1fd-76a3-4dc8-8a19-db12a32920d3"
      unitRef="usd">-49000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi03LTEtMS0w_b6564c74-fa1b-471f-ae5e-e37833a2af4e"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNi05LTEtMS0w_cf49d365-4263-45d2-902b-88cb69da4614"
      unitRef="usd">176000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy0xLTEtMS0w_bff550fd-dfdf-4caa-a244-da041a666176"
      unitRef="usd">41000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy0zLTEtMS0w_13580073-4c50-4c60-b073-35ac5a192e89"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy01LTEtMS0w_7f0e0d93-c8ed-4e36-9e4f-85bce6ac9381"
      unitRef="usd">-9000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy03LTEtMS0w_5082e2e8-accf-489c-9f82-01c4f2f181a0"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfNy05LTEtMS0w_5e180bcc-0b5b-4b23-8a6d-5cca9a6e6e0c"
      unitRef="usd">32000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC0xLTEtMS0w_cf19e4e1-1d31-4955-85c0-a961ae5fe83d"
      unitRef="usd">154000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC0zLTEtMS0w_bba42f29-9c6a-4e47-a793-cf043658a960"
      unitRef="usd">30000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC01LTEtMS0w_5303ff49-8357-4d09-bc44-f4bb117d90fa"
      unitRef="usd">-40000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC03LTEtMS0w_48d0a959-593b-498a-800d-c19c1c1f60d5"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOC05LTEtMS0w_80789eea-8e9b-4fbf-b070-b371ddde612f"
      unitRef="usd">144000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i24b831a2b20e4105ae6e722e57f1e62e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS0xLTEtMS0w_fe8cf79c-103a-4e6c-944a-0c6dfdda8226"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i55967e409ecb488dbe33c0b13d1adebc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS0zLTEtMS0w_ef473624-8592-4cbc-b9e6-695d31bda35c"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i20d4c840c395453fa62ce23262d48529_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS01LTEtMS0w_7a5ac5b8-925c-4651-8b07-bf8e54ae5a5e"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9fd2707a82c547b2801a70dcc7cfd35c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS03LTEtMS0w_6fd274c3-6255-46d3-9ab3-cc79c8f66ef3"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfOS05LTEtMS0w_c677b6cc-dc48-4618-8acb-038c1c959810"
      unitRef="usd">155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e8f30eb9789429a962564babf142645_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtMS0xLTEtMA_ffc035ae-509a-455d-9972-ce2f19fbd5f9"
      unitRef="usd">157000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16aedbdec871407ea66e24efd83da330_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtMy0xLTEtMA_0bcc4997-9b0d-4fb4-8404-70930569388c"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1878ab8ba71c4e20a87cd62012ad996e_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtNS0xLTEtMA_b62aa9b0-225b-42cb-8a05-dcef7f287b43"
      unitRef="usd">-3515000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ebcbbb713742d698719f2cb0caa991_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtNy0xLTEtMA_c8c7c431-3332-4dbf-896a-202f9651590b"
      unitRef="usd">-2063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i532639a15db54349b73094a5ac53f994_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTAtOS0xLTEtMA_7c89e1ab-6934-4804-b360-bff4ae06e250"
      unitRef="usd">-5390000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ed1325b520746ccbe6a911296faf7db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtMS0xLTEtMA_4fc3487a-f53f-4946-8f95-17a1304eed53"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a46df96ea1b4b7db6f00fbe6c57fae1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtMy0xLTEtMA_0993254b-b804-4e84-ad59-2e3a63865910"
      unitRef="usd">18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i217cd2a0efd84c7a9c2ef838da08a751_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtNS0xLTEtMA_8f59ff2b-eeef-45e4-a61c-9859b03988fd"
      unitRef="usd">-4261000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31769e108011463f815d560721783429_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtNy0xLTEtMA_b4714d90-71e6-4c64-8dc7-1487421180ab"
      unitRef="usd">-1981000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice9dc335efad486f8e04c605de2f04aa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTEtOS0xLTEtMA_67f35c1a-2915-4451-8cb9-fa9c94a98907"
      unitRef="usd">-6193000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItMS0xLTEtMA_8cb8d051-e35f-43e8-adae-5c4c8de366f5"
      unitRef="usd">-126000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItMy0xLTEtMA_726e985d-c306-44b6-a055-41c0321725a1"
      unitRef="usd">3000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItNS0xLTEtMA_3cf5a4f3-e823-4802-8fad-c1abf2e1fd25"
      unitRef="usd">-19000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItNy0xLTEtMA_58dca1fd-e8bf-4752-816b-c11c19eb7844"
      unitRef="usd">-220000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTItOS0xLTEtMA_1e03bcb1-bc9e-41e2-bd01-9374b9a0b220"
      unitRef="usd">-362000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtMS0xLTEtMA_98aa91c3-27e0-44de-86af-ef2ae7c76927"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtMy0xLTEtMA_b4d857cb-92ef-43b1-8105-5c0998fc2aa1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtNS0xLTEtMA_6220bef6-8821-4551-b280-4ff96446192e"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtNy0xLTEtMA_244263be-fca5-43cc-9295-87d23a57584f"
      unitRef="usd">-40000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTMtOS0xLTEtMA_2292b410-584c-4d66-8723-df0dc6e3a088"
      unitRef="usd">-79000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtMS0xLTEtMA_9cdf6efa-6984-4e3d-821b-0f2de8452918"
      unitRef="usd">-99000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtMy0xLTEtMA_8403b4b9-7fd8-4103-a863-a37d6b5e9e32"
      unitRef="usd">3000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtNS0xLTEtMA_decb5640-1f22-4136-8434-bdcac47bf16b"
      unitRef="usd">-7000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtNy0xLTEtMA_9bf6c71c-1f5f-43f9-9225-67d7a42d973f"
      unitRef="usd">-180000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTQtOS0xLTEtMA_f480282e-03a1-418f-bee9-70ab0a74b479"
      unitRef="usd">-283000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtMS0xLTEtMA_1db576a2-e49a-4c8f-9de0-03138af73b9d"
      unitRef="usd">68000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtMy0xLTEtMA_f3613d38-678f-4c17-9d18-c82de0fe80d0"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtNS0xLTEtMA_9cc109c5-68c5-4006-a7e4-3c3abb62f652"
      unitRef="usd">-210000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtNy0xLTEtMA_231582a2-094a-474d-8829-94d66ffa3e5c"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTUtOS0xLTEtMA_ff4569c7-8de1-4989-82fa-fcd379e11d46"
      unitRef="usd">-121000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtMS0xLTEtMA_9d1bddc9-baef-468a-a465-3e9e3262a796"
      unitRef="usd">14000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtMy0xLTEtMA_e576b7c5-7c43-4a23-b52e-8a15e083a2e2"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtNS0xLTEtMA_6c2dfd07-74a2-40c8-9435-069fd0596bf0"
      unitRef="usd">-42000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtNy0xLTEtMA_fb2f37be-cbb7-46c8-97c0-1693f9f7dd52"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTYtOS0xLTEtMA_0bd35d95-efcb-4a56-a0fb-d1997506be10"
      unitRef="usd">-28000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctMS0xLTEtMA_1e2038cb-ed90-40a3-b4b1-48c2db4b253a"
      unitRef="usd">54000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctMy0xLTEtMA_dfe06f33-a115-4f01-a892-7b9c8f3bbb9d"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctNS0xLTEtMA_932f1935-1d1f-410c-b67c-e2f74a5af5fd"
      unitRef="usd">-168000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctNy0xLTEtMA_a128b5af-1dd0-4763-8620-fdc7f88dcc13"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTctOS0xLTEtMA_7dde9569-bf0e-4fd6-a09d-4ee2ec64a701"
      unitRef="usd">-93000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i453bd43fbed3491d9f046db85eb08409_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtMS0xLTEtMA_502dad9e-8547-41c3-89ab-05f4710e7040"
      unitRef="usd">-153000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id93bb0bfb2484a6b9ad39b3bb1e68488_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtMy0xLTEtMA_f4c4dafd-7daa-4b0d-8442-f46493cc9c4c"
      unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i69e2060a2d764443a4ac323139c30b81_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtNS0xLTEtMA_3961949d-e340-461a-98ca-336989a554e8"
      unitRef="usd">161000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i734875f415f6427894327094cfdf75b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtNy0xLTEtMA_0e0f477a-1bef-47a0-acd0-4ee282f198ab"
      unitRef="usd">-180000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTgtOS0xLTEtMA_106a798a-e7ed-4609-a9f9-3173d14a67b7"
      unitRef="usd">-190000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i622f3b6a936346c0a20c86c2c0a0eb80_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktMS0xLTEtMA_97709374-e945-49c4-b3c5-e9dc06684007"
      unitRef="usd">-122000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i065889e51dbb442688e6ff3173a1e969_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktMy0xLTEtMA_e0e2edcd-393c-4fea-ad63-f03c09598204"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5cef50e6ea4143d58a328d4f70faf4c2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktNS0xLTEtMA_f4f2ffdc-5416-4e68-910a-bcbefe235f9e"
      unitRef="usd">-4100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cf5449d143444ea99ebf110cf6c87e2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktNy0xLTEtMA_8b3c5232-3b0c-4203-b5c8-6924c8b68040"
      unitRef="usd">-2161000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dbce2023d24bf7b14295815dc63340_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV84OC9mcmFnOjdkNmQ1MGViNDM2MzQ4ODliNjJhZmY0Yzg0MTA4Y2EwL3RhYmxlOjBjNDhmNGQyMGY3YTRmZmI5ODhhOWJiOWU0ZWQzNTk2L3RhYmxlcmFuZ2U6MGM0OGY0ZDIwZjdhNGZmYjk4OGE5YmI5ZTRlZDM1OTZfMTktOS0xLTEtMA_e0412b2b-63fe-433a-85df-497e3118aafd"
      unitRef="usd">-6383000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTc5Ng_95a274ba-2d00-455f-b237-baed72026d56">Segment Reporting&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cubicin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zepatier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zetia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vytorin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Atozet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Implanon/Nexplanon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;NuvaRing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diversified Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Singulair&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cozaar/Hyzaar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Arcoxia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Nasonex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Follistim AQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.4 billion and $3.0 billion for the three months ended September&#160;30, 2020 and 2019, respectively, and $9.6 billion and $8.6 billion for the nine months ended September&#160;30, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income before taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMTA4_c9733d85-b1d2-4fb9-86da-e4a69a07fd7b"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTgwNg_7928c675-3830-4575-a34e-1e6de908abea">&lt;div style="text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Emend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Invanz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cancidas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cubicin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zepatier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zetia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vytorin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Atozet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Implanon/Nexplanon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;NuvaRing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diversified Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Singulair&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cozaar/Hyzaar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Arcoxia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Nasonex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Follistim AQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other segment sales &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. &lt;/span&gt;&lt;/div&gt;(5)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="i306fdc3327c343139058a1e912ec7a34_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xLTEtMS0w_75c9fda8-fd72-4ae0-b3ad-82eb0ad02334"
      unitRef="usd">2157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e1a45620d5740ef84279eefcdd52471_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0zLTEtMS0w_1a2465fd-b658-40b6-88db-7678df4c7d5c"
      unitRef="usd">1559000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b41de768cca43ae86a2b620ab7fd37a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS01LTEtMS0w_ffbaf65d-58cd-4b76-bcb7-3253c489ec23"
      unitRef="usd">3715000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf926c3546c74014b7e2f8860b5e44c2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS03LTEtMS0w_0bae7d23-7fc1-4788-a95c-59e039748f44"
      unitRef="usd">1743000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63f0231c8a1941c9a7f095b2dae733ac_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS05LTEtMS0w_db27de1b-9d95-44d8-a874-12314ebf4a2a"
      unitRef="usd">1327000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i317ddaf4b00343c591e8949ca7d910a4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xMS0xLTEtMA_8b102988-bf39-4979-8edd-990a45ea1eb8"
      unitRef="usd">3070000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3eff4fa2263b449ba4ad1953be6ba8f5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xMy0xLTEtMA_1817680b-d2e1-4298-a87e-e7ad98a0b038"
      unitRef="usd">6106000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i547f0c973ddf4d25a0edb9aa55b1c990_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xNS0xLTEtMA_507a78e2-9b0b-4239-97d4-d32c579b1136"
      unitRef="usd">4281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8c49eca89b64ce683fdef4e64585ef6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xNy0xLTEtMA_f54524e2-9971-4c7b-b1a9-56cb7696c23b"
      unitRef="usd">10387000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib22b6772278549d3a7dc5725de45a549_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0xOS0xLTEtMA_b8335144-e704-41d7-8402-65c07ccc8eea"
      unitRef="usd">4525000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3906b3ace9b64befaf73a1adc407ae5b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0yMS0xLTEtMA_3ed6d90e-f249-46f7-a86f-e21892c0e72e"
      unitRef="usd">3448000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccc25861951e409b9bcaedf62ff4b291_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNS0yMy0xLTEtMA_97ead5ed-d871-4a76-971f-2d23fb7dc839"
      unitRef="usd">7973000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if94fd4d2613b4279b09a4b269c9fa2e8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xLTEtMS0w_9e9b1696-8878-4182-a169-6976b517300c"
      unitRef="usd">107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1958e912e6ac404ab8549a9c645d5cc6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0zLTEtMS0w_c57da9f0-9e61-43e1-9f16-00f768ada128"
      unitRef="usd">89000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2a4c78ade6e465c8ac9352f2745678f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi01LTEtMS0w_30d6f575-f500-4bed-ae6c-255c3be05d17"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6ea751a267ca49428fd752d3d82441bc_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi03LTEtMS0w_5f2d25e3-e47d-47b6-b6c0-0091189939a1"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dc329ef53f6466f8fd7202d74ce0a3c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi05LTEtMS0w_4040a6d8-0364-4fe0-bcfa-189be2b1d854"
      unitRef="usd">53000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7327daaa39b444129ac7963593aaf968_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xMS0xLTEtMA_e9755826-d57b-41c5-b746-ef626a706f40"
      unitRef="usd">123000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93971dcba04a4a31bdce5505e25d2fe7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xMy0xLTEtMA_aff62ab5-588f-46cb-9896-8a777497e23e"
      unitRef="usd">297000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcfca5975a1840b695feea389585ff70_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xNS0xLTEtMA_1d59bc5a-cb91-47ea-bce6-70f6bfcec3b9"
      unitRef="usd">223000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib56ff7b0e8a54c8a8d4dfa5d57d82641_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xNy0xLTEtMA_b85cd668-9b5b-4ad8-a128-d7621d759f1b"
      unitRef="usd">519000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ec9add45dc0469788010c549ccbdb76_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0xOS0xLTEtMA_e6f2d5b4-5ffd-4a28-a423-f9c6539c71b0"
      unitRef="usd">186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia51ef3c4eb03413ab36423e2fd771da8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0yMS0xLTEtMA_8affc4ad-fe16-4dc9-abf2-d4f5d1cf817d"
      unitRef="usd">126000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf99264c8dcb454ea5e90380b2400b9e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNi0yMy0xLTEtMA_93e9ad94-ee63-4ff4-9f43-3adba336578f"
      unitRef="usd">313000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ca7a266855d4254a95f8178169a039e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xLTEtMS0w_763c6c80-da87-40f0-ab70-166b45efea33"
      unitRef="usd">82000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dc9b994e7da4fd19c71b16dd69ea18f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0zLTEtMS0w_70d943cb-3320-47f0-9d81-6fdab379fe2f"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8717ca08a9d4379806fdd058d2feee8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy01LTEtMS0w_00844b57-e7a3-4b68-ba87-3eea1a969f0a"
      unitRef="usd">142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i733c87bbcdae43878560a4ef5bdac803_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy03LTEtMS0w_c1679217-aab1-4d84-a6a4-39896ec7c460"
      unitRef="usd">65000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23398778be554bbf9ea4cac06d6173a0_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy05LTEtMS0w_aa7779ae-c53b-4138-81a8-df46bfe28b80"
      unitRef="usd">44000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe040aeeb11e449b8c5c18407e83aa44_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xMS0xLTEtMA_23f97cd9-a314-4f69-bbe6-aa47d3e7affd"
      unitRef="usd">109000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1453f6542194317be39084f21e53aed_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xMy0xLTEtMA_0b07c731-20b0-42e6-a1a3-8c01c8861279"
      unitRef="usd">270000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icef3169c86e54fc5ae677a048dc4eb96_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xNS0xLTEtMA_1d17f567-a44b-4302-9689-5a7d2049592e"
      unitRef="usd">152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a6829456a78436f98f59cc9fc651fee_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xNy0xLTEtMA_0a7a1881-36f7-4282-9c03-8803fc7a33d3"
      unitRef="usd">421000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i553c60428afd4395aca8a65dc4d3d90c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0xOS0xLTEtMA_a3821a08-081b-424e-ab9a-26568ad4d496"
      unitRef="usd">169000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92959775580548159c5b7ea24a92ea98_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0yMS0xLTEtMA_a7b83fc0-c4bc-4c4c-94f6-f0031c2851d0"
      unitRef="usd">112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if56024565ddb4465ab8bf341e3dd84c4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNy0yMy0xLTEtMA_45e5a44a-26c2-492e-8fe7-339c7500416d"
      unitRef="usd">280000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ddf16367e464e79a9f9c63e9ab32ce1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xLTEtMS0w_419cd42d-5f25-4306-a396-505372ef531b"
      unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00ecfc38e80742e18efb7ff88f14c004_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0zLTEtMS0w_f32d065d-bb4d-4e3e-b829-b71b3b26d5a4"
      unitRef="usd">31000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78f067784d5e422c8ab4af07a2f8bcb9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC01LTEtMS0w_82d01628-4fbd-4f49-b384-68fa6f42d6a8"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i172b683fbef54b37a292f3dfae49f813_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC03LTEtMS0w_a2c49dd9-db57-48fb-81c7-c22dc89a6548"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c3c6f85819c4714b9885f8013fa08b1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC05LTEtMS0w_b9a74ae0-28d5-4cd4-8847-13f3927ade85"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i393c1adee8e84595bfe0acc21bf97c3d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xMS0xLTEtMA_9a4e8e75-687e-4654-b0d1-96acdf9cb12a"
      unitRef="usd">98000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia217fa4e279b4536b6b3f04c7fe81688_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xMy0xLTEtMA_dbb35be2-f916-4151-8c31-1ffd32b54d0e"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c0887d9184c47dfac2ce9c7bf039dec_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xNS0xLTEtMA_7953ec66-8d97-432b-86d4-3aec2a600958"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5359f26b034c4f8b839c6f0b2177c80a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xNy0xLTEtMA_7072b022-bec7-4ba5-bf62-e006c51167ca"
      unitRef="usd">115000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife80c9a9053e41bca34e6b7e6d9d4efa_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0xOS0xLTEtMA_ed21af3a-1e51-4f4e-be38-4379e4ee17c5"
      unitRef="usd">173000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9223587952c44aa0931adbd426c4f5e9_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0yMS0xLTEtMA_547625c4-fe86-4cdc-a4e7-4583931c15b7"
      unitRef="usd">163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82e280b6f3ee4222b4211f6c6344e7ce_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfOC0yMy0xLTEtMA_0f710bab-072d-4508-b096-9c68cad364d1"
      unitRef="usd">336000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea870736ba5b42dd970e1c2e8cecd0a2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMS0xLTEtMA_0983c088-af7a-40d1-8ae8-07eaa2c48882"
      unitRef="usd">579000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67048c78dc0b441b984b5eb1a80d4918_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMy0xLTEtMA_827d2182-5260-4416-8e65-f6ac257d0be5"
      unitRef="usd">608000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i708250723a2049d9b4354763f848521b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtNS0xLTEtMA_1c8595dc-f810-49a3-8830-cd6907d15a2f"
      unitRef="usd">1187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i979e50a4991d42aabb587279a1630515_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtNy0xLTEtMA_71549ca7-ab60-4e58-9c12-3e1bb5dff53f"
      unitRef="usd">761000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87fdab53c5ca4fc7afb34303af488fe7_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtOS0xLTEtMA_ee381301-e066-45ca-8616-68785755db22"
      unitRef="usd">558000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icefe099ec9f9447d89313fe5d966d097_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTEtMS0xLTA_3831a4c0-0750-427c-98e8-ad558c303fb8"
      unitRef="usd">1320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i686f3ec310f8431aa70f7a29632549dd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTMtMS0xLTA_1c1f243e-47d5-42f2-a353-811de2763d98"
      unitRef="usd">1209000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39a7371dce5a4c7381c1ee54f2af4bba_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTUtMS0xLTA_a2aed7b2-8c68-4ac5-9639-8999d3517699"
      unitRef="usd">1732000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66daa9001fc14740a44d38a81090f3aa_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTctMS0xLTA_03cd54b4-5392-4abb-941f-574563fe51e0"
      unitRef="usd">2941000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icce3f31aab04474a85482e57d7fe3b96_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMTktMS0xLTA_c20ff632-54da-4b03-be54-8bc231dc7955"
      unitRef="usd">1579000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i414cc671cdbd4152bd1583dc67a4d839_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMjEtMS0xLTA_2a924ab2-51aa-48b7-9632-156a193ba123"
      unitRef="usd">1464000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59138a1df4c34c0b8f31017c314ed9f4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTAtMjMtMS0xLTA_1334c439-3838-4348-9bb3-b9f6ed4d0a67"
      unitRef="usd">3044000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3925c7ab1c44ef58b807944198fc32e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMS0xLTEtMA_58885fd3-1a35-4498-aef6-9b06d9d8dc3a"
      unitRef="usd">437000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i862f90ba138c4b01a609bfaec7fe9442_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMy0xLTEtMA_08b78200-fb8e-4ebb-bea2-9ad1ac8851ba"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bf560762c004da7ab56bb4c5d6f3276_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtNS0xLTEtMA_d8675808-3d0d-409f-bf35-683d4a1362f4"
      unitRef="usd">576000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44944b71a8804ac88c5e1188334b304d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtNy0xLTEtMA_3ddca079-1a90-488c-b844-41bf5f9c42ed"
      unitRef="usd">482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icac08e29232648c58d4d3e2b32573921_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtOS0xLTEtMA_5ba5e5f9-ed9e-44bd-af0c-1ae2dcf3804a"
      unitRef="usd">141000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70e8855545fd4a67b2906f59348cf1cf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTEtMS0xLTA_1c56e185-3edf-43d6-b0cd-3bdcc1252df4"
      unitRef="usd">623000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c793f46d7434d639f4b9af5a81dda9a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTMtMS0xLTA_2711fc10-c413-4945-9e5f-29168c637a40"
      unitRef="usd">1033000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifae37299fa8e429c88f31b01349409ac_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTUtMS0xLTA_e76734e1-7579-4205-83cd-fcb5d8f134ff"
      unitRef="usd">356000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44abdfd9ef2340be84e53509a2ad1217_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTctMS0xLTA_1e809f0f-43ee-47c8-a0ac-df30dcdb5574"
      unitRef="usd">1390000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if38bc46dc41e4806b8a366f7c6a66444_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMTktMS0xLTA_c3b15ee3-4031-4518-bd53-b4901ac11b03"
      unitRef="usd">1325000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i844c2dd9fe0b4d59b864cfc9dbeac1fd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMjEtMS0xLTA_e575e127-f2a2-49ae-bbec-b175bf432d48"
      unitRef="usd">469000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0aaf14c7fbad4e81b02ee7ede86f6740_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTEtMjMtMS0xLTA_22099cc5-1870-44c6-b1a5-912f3561c007"
      unitRef="usd">1794000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb1757a74efe45beab35e7c434a837d1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMS0xLTEtMjI4MQ_37d220c8-3ff5-4c3f-b8de-aa26a58265a0"
      unitRef="usd">276000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb7e9b25563d433abdc2de1fcc1cf790_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMy0xLTEtMjI4MQ_c0716ab6-253e-49aa-bb7e-2e425572a80d"
      unitRef="usd">99000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62b874688aab4e3691b20bcb3c5dbeba_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNS0xLTEtMjI4MQ_a276d7ea-449e-4a27-bf5e-6bab3c64aae7"
      unitRef="usd">375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33106e55798a48b699ea798ff3d9c2c9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNy0xLTEtMjI4MQ_d4a59453-7420-4c23-a06e-aa86e49b62f9"
      unitRef="usd">179000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcb60f686f644588a89cc8c7b689dd91_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItOS0xLTEtMjI4MQ_b8250ed8-4576-4643-ac3b-80efbe0c2f3d"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8b7cc10d3a44053975f929842e5c6f4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTEtMS0xLTIyODE_e649fd2a-0384-40d4-9370-82c72a59ff73"
      unitRef="usd">237000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03d7485ea0d844afb437a33a9c0c373b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTMtMS0xLTIyODE_2af57c9b-9dcb-46d0-9cff-d78c0ac360d7"
      unitRef="usd">478000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3468a4ec91e4e0299f5e9d0627e20c0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTUtMS0xLTIyODE_ec36f877-6fb4-4866-8ac2-592af87b9e01"
      unitRef="usd">270000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia14d6de6abd24d9487ccef62b379ddb5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTctMS0xLTIyODE_5e43b736-7499-478b-9b55-09771a6ed127"
      unitRef="usd">748000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63f20dcd0d3d4ee4add22bc0f3b7b2b1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTktMS0xLTIyODE_9a5c1924-e941-4eec-8c41-91ccd543a8a6"
      unitRef="usd">428000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c865283192843a8b5c2910e9b0530bb_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjEtMS0xLTIyODE_1e76b9c4-29c1-486b-b451-150567f2975a"
      unitRef="usd">164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13e9b7bed9404b7fb7a2473c47829169_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjMtMS0xLTIyODE_f0f5d1af-e5bb-415d-85a7-d85fdd5e733d"
      unitRef="usd">592000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67e3e6fb55fb4477bd2e4344ba69226f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMS0xLTEtMA_80a586c0-69f7-417a-b253-9b598179c24c"
      unitRef="usd">114000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29681f0938a8432486e7449f7854b7b0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMy0xLTEtMA_67b92a3a-9cb7-46f7-a419-913f0444b9a9"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc1cba7975734d45833cda2fa2563bd7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNS0xLTEtMA_e4f88714-6871-4e91-9a27-a57e52d227f1"
      unitRef="usd">210000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic0f730dabc2740699bd827d675b983b2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItNy0xLTEtMA_e16721ea-dc47-4b7f-bd68-b1ba87bf72b5"
      unitRef="usd">102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27eb3d476c694f68abd9f5e5db26dcde_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItOS0xLTEtMA_33c59d94-7a0a-4680-9fc4-26193561999f"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66c2064d607f4f06b74136bd86690a51_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTEtMS0xLTA_bc6f13cd-1f27-4204-bd2b-c86f49f37d9c"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i178d9b4b6cf34d169a02c96fa38dbaac_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTMtMS0xLTA_902f6d2b-05e1-4a32-97a1-b4e697adaa18"
      unitRef="usd">355000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i235ae291edd64816acba0905d28cc37c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTUtMS0xLTA_86d4039a-aeb5-4443-a311-a169d553a04f"
      unitRef="usd">246000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71afa28afc2b4c3bbe764e1563f8598f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTctMS0xLTA_39956252-e31b-4176-87f9-a07881d1774f"
      unitRef="usd">601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d9440d8597143a1b91e48f43b4b0bd4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMTktMS0xLTA_28d8cbd3-40e6-4450-8fe0-8476bbe46c38"
      unitRef="usd">360000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3da5777cebc48a1ab0eb78234e6c524_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjEtMS0xLTA_a254abab-a364-43b1-acd8-0b87aacb8ea1"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6a0f69efec34219b126a5a5473b1670_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTItMjMtMS0xLTA_735dcfc6-5b0b-4ddc-94c6-359292869b53"
      unitRef="usd">564000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c189c6b947a49aa97d6dce2f79c6151_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMS0xLTEtMA_32c89285-4eb3-4a60-9bf3-957cb6df27a1"
      unitRef="usd">32000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4345b97e7f84437e9ba2ed7305654d4a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMy0xLTEtMA_d0b4270c-9ce8-440e-808d-a1633cb56893"
      unitRef="usd">19000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4db3706ed6884db480687fa6df343826_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtNS0xLTEtMA_49c43d4c-c8b4-4ade-a92c-84931a3a7665"
      unitRef="usd">51000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82f4b0c199f44ad6bda16bdc1c99307b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtNy0xLTEtMA_af55b42b-34e2-4c26-9ed5-2ad1f88e6c5d"
      unitRef="usd">36000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98ae2ba3b636440dbf51084099ea4e14_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtOS0xLTEtMA_fe9ffe11-c632-44ed-8d7c-3961e12099ca"
      unitRef="usd">26000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50b04d71a9794cad9297feb729f927f0_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTEtMS0xLTA_43df6cad-65c8-4ef4-8126-57d232ed7776"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7ef7e87f1f6403786c8243b16effa57_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTMtMS0xLTA_898db642-6109-48dc-8e91-885e7879b7f5"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3da6673eab644f5ac8940187a307ab9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTUtMS0xLTA_c6588f9b-314c-4b93-87e8-834a2bddab0c"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2737dd0c1b8c4fd6be8f3eb432e38a55_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTctMS0xLTA_d3c1a4be-e17c-4657-b636-2e2e8e8235b6"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea5abdf92066496d90d2e3ed8f83f10c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMTktMS0xLTA_2b0eb2ba-7830-4abe-9f79-13544a42d475"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf624a2fc58f4b8db74dc7ff1193332a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMjEtMS0xLTA_224bdfbd-0523-4636-8762-f4e0e58891dd"
      unitRef="usd">65000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i694a4dfc7d4f41fc9459a5328750c279_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTQtMjMtMS0xLTA_c5359f4f-8950-42cf-b993-198d6477d376"
      unitRef="usd">167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb6e1314672d458c80a6ea2181ccfefa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMS0xLTEtMA_5c3e47bf-3ba0-4010-babf-844972c7eac6"
      unitRef="usd">162000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5204d5450def457b9bddb35e60c60d82_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMy0xLTEtMA_8e4b416e-6c47-4343-afde-4bc47d5f8ecf"
      unitRef="usd">157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d941127ebee46c6b3ca083a457c564a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtNS0xLTEtMA_67a00c52-486b-441f-a5c8-72243a1a2a56"
      unitRef="usd">320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i367f009328af4f81970cfce2c888d476_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtNy0xLTEtMA_5b8136c2-7ee7-49af-bf9a-4d44dfd77f02"
      unitRef="usd">133000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2772e763e8334f6a84b55704b593c8a1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtOS0xLTEtMA_692fc5c6-d30b-4e22-b57e-c730af60952f"
      unitRef="usd">151000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b806fa3c4004464a6b42dc860d39e09_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTEtMS0xLTA_47220d8c-6f48-4bca-9813-68b61de2de80"
      unitRef="usd">284000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ac62401b132462a9e7d3e00f737696c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTMtMS0xLTA_5cbc97cc-a65d-4b31-8391-361aebc3e318"
      unitRef="usd">412000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie80b7f42ff4d40feb2b2ffee0f6914df_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTUtMS0xLTA_41b6bc55-38eb-4fdd-bf02-cfb3dbaa4520"
      unitRef="usd">431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72fdde8bfc914ac389b6d2024c9b1b2f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTctMS0xLTA_7b77c2d0-2878-47b0-ba75-a2764ef8c7a8"
      unitRef="usd">843000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i351299226c1643e7ba68239fe2ba57a1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMTktMS0xLTA_13bca52a-eb88-4a28-b148-a3964e128c9d"
      unitRef="usd">381000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8aee6fbf35747b39ce2ad1ed1d54893_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMjEtMS0xLTA_b259a680-b994-4703-bb1f-92489c6a5047"
      unitRef="usd">437000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icec21e115e3a40838a098aa0894c0609_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTYtMjMtMS0xLTA_9e83c475-38e8-4262-a7fe-ed66fd01bd3c"
      unitRef="usd">817000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i417799794c1e4e23ae2b7e19043fcc61_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMS0xLTEtMA_fe58c96c-3aa8-4cb7-b1f0-669a2d0d7c71"
      unitRef="usd">13000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31a7bde573a847948f09da2562a0a446_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMy0xLTEtMA_c6d2f4ac-c3b4-4f72-8cae-2e0239500f7f"
      unitRef="usd">66000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74d9612c858e4a19b3a9c1ecc6f502a9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctNS0xLTEtMA_f58a6e7d-4991-4a51-ad3c-ade2c0670ef3"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia84a9822d9b040e1876a2c6879d001aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctNy0xLTEtMA_c854374a-bb0a-483f-b1a6-6a10a7a94617"
      unitRef="usd">77000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73623d962db34390a9676bda7471397c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctOS0xLTEtMA_18e04952-aef4-4e18-acb7-6413e1ae994a"
      unitRef="usd">100000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd9ef0920dbc496fbc1ef7fff281f68c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTEtMS0xLTA_d45955b9-2002-4125-b45b-d83eca69d6c0"
      unitRef="usd">177000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59a9379092fd4fa5b67eb0c0899dc62d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTMtMS0xLTA_23538fca-652b-4de0-90d6-10181165d788"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc60755989b24bf88af02e4825aa9c3e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTUtMS0xLTA_f40b5659-1f17-4c2d-a3d8-68308b4e1534"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8062908fcb748948fa4b9408f90ea88_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTctMS0xLTA_8ccfc00d-0ad9-4e73-94ed-11f6af6603b2"
      unitRef="usd">247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i341ee46b776246b09ef1d6d67599e9e2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMTktMS0xLTA_3a5f2fdc-179f-47fe-a636-5574b2628bf1"
      unitRef="usd">268000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47edc2dbd975482da465c5ac979419dd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMjEtMS0xLTA_c201ade1-f8ae-4221-a546-f611415b263e"
      unitRef="usd">291000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i19e6a07eb2aa4e858f46dbb14ef8ced6_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTctMjMtMS0xLTA_83a5df77-e9eb-41a5-8050-68f06a413c71"
      unitRef="usd">560000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94548af382c74ea191084b248c9f2fa2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMS0xLTEtMA_65f35a10-55a3-42e8-af74-4f7e9c87c71c"
      unitRef="usd">32000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62d18847d0eb4080984a7f92642b9c3f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMy0xLTEtMA_879d08a5-0209-415f-84a8-19fd0216d01f"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8dca799bf08b420b80463a36fb534945_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtNS0xLTEtMA_bdb0e657-435d-4527-a4c9-8b35ad8fc92e"
      unitRef="usd">77000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a1bc6f405f84099ab6dfd1b166d4a30_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtNy0xLTEtMA_6bd84307-4278-42ac-8a50-042031887164"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i702d3186e41442f7a78d814e62d3bd65_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtOS0xLTEtMA_de79516e-65d0-4127-bb28-e6f30d1f1975"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9a9f2da00d04e34a495294f13d301e8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTEtMS0xLTA_febf71f6-4492-435d-97a8-49284065ee3c"
      unitRef="usd">45000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie33c89ea2353410a992159fd79ba7b27_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTMtMS0xLTA_1092bb99-6b15-41c0-ba3a-fa9912104ca8"
      unitRef="usd">87000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7537a2642ad14cc1b29e3fc7e39efdd1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTUtMS0xLTA_7f2aa3c7-2d91-45c2-a31f-e96dae9d2117"
      unitRef="usd">113000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i708c24fc9863489497166c927cd80e26_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTctMS0xLTA_f4a097b6-6a99-4d11-981e-8e7f7c9c1a0d"
      unitRef="usd">200000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5ac91c09eb64ca48bdfe2203abf90da_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMTktMS0xLTA_9edd15fc-85e1-4459-84ab-1ce347c09484"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49b4250d2788459e8b5e2a862644234c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMjEtMS0xLTA_76c3c9eb-9e3f-463f-997b-96253b1c5ef1"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia61152773c82437db2127adab1053a23_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTgtMjMtMS0xLTA_c3152e2a-1f44-4d8b-805f-1a1920ded476"
      unitRef="usd">115000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1d1e6a2e75a4c8eaff7e19133a84fe5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMS0xLTEtMA_da197635-fa9d-4889-b116-10ff1e740c97"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2671e945dfd43ed804f379d6b30ac92_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMy0xLTEtMA_920842aa-9a34-4b32-905e-9e1a58c73cb4"
      unitRef="usd">73000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ac2ca8f7efa4e3e8df4117cad2b06ed_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktNS0xLTEtMA_f2e7969f-3132-4502-b8ae-057f1cffbd87"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87fbe25f948d434ea8c2d71514c905b2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktNy0xLTEtMA_118fb620-29e7-4134-b629-620479a78da8"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idba671a135e142189f057be3fd5355bd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktOS0xLTEtMA_4af24443-a0dd-45b4-b3d8-2cf9f8edb999"
      unitRef="usd">75000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7426bb60d684ecc97eb4c32ab073460_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTEtMS0xLTA_bf2336ee-4e28-4188-b470-0bef7da4020c"
      unitRef="usd">77000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib178b02bf26e48b68748d2a55b2657c7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTMtMS0xLTA_1a9d1cee-6af7-48cd-b4c4-1e494385a85f"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77e7d2bc3a714126b66d4718cfa4a689_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTUtMS0xLTA_710aa3c7-e6a3-4454-bec7-74328de24da6"
      unitRef="usd">187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i39019f71db724d0388921c330404ac9d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTctMS0xLTA_3eacf5c5-225c-4b81-ad06-0de7cc965377"
      unitRef="usd">189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if399ecbab7c147ff8c533bd49e5029dc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMTktMS0xLTA_4d487405-f8cf-40a6-8d15-46fc980903cb"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa9c994a82754ec3bb4d67db85d4338a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMjEtMS0xLTA_f357fca1-a4b8-4129-ad3a-4c4413af2a28"
      unitRef="usd">204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i279d66dabd8340e4afb06b61ff1106da_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMTktMjMtMS0xLTA_e0f1bc68-3515-42bb-8fe9-238b8a58b647"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae82259b4751461ca0624752a35bce09_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMS0xLTEtMA_322e464b-87e1-4973-8833-3a5197233325"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib77110243471455e93528fb60c32e34a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMy0xLTEtMA_9ff4d40a-8e5e-4dd0-840e-7f8d81546406"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63b27d7fd3224ed7a7515432a72d21c5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtNS0xLTEtMA_6baec709-58cc-472a-9a8f-9b751282147f"
      unitRef="usd">51000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad3d9fbef4a14ad188dd6c702f303d81_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtNy0xLTEtMA_2d854df1-a05e-4c63-bb3a-f91020f49262"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd56b11ec30f439db004563892878a44_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtOS0xLTEtMA_3643af04-7df8-4668-a9a0-b81fe3dbee39"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7574915e7f9f45adb507296bad2d8acf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTEtMS0xLTA_e770ced1-2d52-4ea0-8a5e-8e40d3bc345c"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68c4b2e42e50440983fdf402f1a3318b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTMtMS0xLTA_9de493a7-af18-4365-a8d1-2a41237749b7"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f0d8c1ce2404f1eb1853fea7819c9a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTUtMS0xLTA_a01c481c-a4a3-4ce5-935d-0bc8beef0088"
      unitRef="usd">152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48a812f083634c0c918b8e40ac83a158_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTctMS0xLTA_b8d78458-fe39-472b-b13b-6e885899876e"
      unitRef="usd">159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c7a2fc3636d4744a1e68680dd160a7d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMTktMS0xLTA_17d8409e-f118-41ed-b61b-5c44be055d84"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieaf89995052242baaefbffc9a6c3d93f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMjEtMS0xLTA_7d2a3557-3c2f-4197-9517-de3d0429976f"
      unitRef="usd">176000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f03323d756c4aaebedf7365c0c5f115_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjAtMjMtMS0xLTA_06e4465e-a008-49de-85c8-90553c4b57ec"
      unitRef="usd">206000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb6f397f156d434ba8c705812199c7b0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMS0xLTEtMA_07fe2411-4e85-4fe6-841f-e6a868bf1f4c"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b09565c92894fccad03d9a3f77269e3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMy0xLTEtMA_c7c572b3-5322-416d-a0c0-72ef5b0fd5f3"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i776d8cffb24042c6bb2c4c3d914dff0a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtNS0xLTEtMA_7b6bb8ad-aa2d-410e-a080-739f0288bbd3"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i143736d83dd84805ba380c77aff27679_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtNy0xLTEtMA_3d3dd576-62e9-4421-8438-d57e8ac440ba"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i427aaa6059414501938b90f49d23d83f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtOS0xLTEtMA_10ba616f-7032-427a-b225-491cb033b7fe"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia54c2cf432c2492e881936280bb904f8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTEtMS0xLTA_7b4c7bc0-e939-47d3-9259-869ca1610f61"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if7f165c4787b42588723ff48d0b6cf98_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTMtMS0xLTA_bf2c14b2-848a-4737-8a12-79f375d92353"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7e895a82c3e4ef3852770005b410b0b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTUtMS0xLTA_a658c02e-0ba3-404a-a224-7dac3fc980f1"
      unitRef="usd">147000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06056e3d1fdd450fbaea2f8910ecf385_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTctMS0xLTA_949701d1-b624-4b43-ae3c-475a62a405b0"
      unitRef="usd">148000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13ee3bcbe2894ccdb9103ea6acf2dc54_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMTktMS0xLTA_0ac46d5b-3c25-47b6-85c0-5777aba5ef74"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf3c12dc7fb64612938cc2e9c4345cca_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMjEtMS0xLTA_4b14fa9e-895c-45a5-bea8-d13e1fd989bf"
      unitRef="usd">187000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i953896ac43dd4a4492bb05e6f55f1f63_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjEtMjMtMS0xLTA_9a0a3155-7d51-4c57-8a7d-6d5fb7f1598d"
      unitRef="usd">191000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebc471aad3c94e04a06f0fee9bd88cf3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMS0xLTEtMA_07d0d6ea-d389-4c4e-9818-9c5cf6619466"
      unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d2dc4f551874bdea08cc8b480c809b3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMy0xLTEtMA_3a257552-b2b5-4e65-84e5-f70d2544d921"
      unitRef="usd">28000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbf3e6bdecc74c8db16756ad0211654b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItNS0xLTEtMA_e2aff21a-215e-4cb7-b0d9-4dd7fbb04c44"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea020ccf4a554e1b82196c6dd3816009_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItNy0xLTEtMA_020f562c-5183-4a6f-b586-a0038b1b7f21"
      unitRef="usd">14000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81eb3b266055401489cbcc9e71b1b590_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItOS0xLTEtMA_a02d5db1-830d-4153-9481-baa1c7049a1f"
      unitRef="usd">38000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1eaeca1be734efd9e7311afed56e4fd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTEtMS0xLTA_c2e5bfba-8e8f-4c97-b317-a80039a0f2ef"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5a53f2d7fad41e399de72c840dc300a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTMtMS0xLTA_febc0de5-90cc-4616-95b3-d0748f911f9e"
      unitRef="usd">36000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id54a4864f2fc40e2af2de994c8aa8ab5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTUtMS0xLTA_a06f1cdf-f731-4702-9c51-d9aa02c07ec0"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10c982e709794dd68acadc44141524cd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTctMS0xLTA_51de36f4-df1d-4415-abb5-1697f70612bb"
      unitRef="usd">116000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33aa602ccb9e44e7a7efcad8055fafa2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMTktMS0xLTA_561071b1-c77d-4842-acb9-fbdf36622057"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id881511a6cc84e72acb24c070e6797f5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMjEtMS0xLTA_a5b4e232-2c47-4158-8f08-e8b63d8c82d0"
      unitRef="usd">129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3880d04cc6c346cbbb1fbaec73165ce3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjItMjMtMS0xLTA_83cf5112-fc0d-4350-88cd-f1991a45099d"
      unitRef="usd">207000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabe91553b040477b9005ed581ecac9d9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMS0xLTEtMA_dfa3ecc7-60b1-41e3-a15b-c00e54e73a6c"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff55a2b1e45f483b908fa739760c0534_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMy0xLTEtMA_fcf8bd1c-9168-43e4-b16f-f02b28749ca7"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b5e5f802c454eb59aeab6da3df4da1d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtNS0xLTEtMA_782106ed-bf3c-480c-b7e4-e1c54f637bbc"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id827b82628ce40ed984d4a930de9a590_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtNy0xLTEtMA_904fdf46-43f2-42ab-a33a-3ead26743178"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ideb446c3d46c4a828db42c890a42b26e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtOS0xLTEtMA_d55722c7-f4fc-41fe-9da4-fb3f4b0a090c"
      unitRef="usd">15000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bebfe0a869441d786bd3a8fd4c62b20_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTEtMS0xLTA_f0063dbf-1c68-4f59-8af8-69c38d0421fa"
      unitRef="usd">35000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i361cbe5c451845abb30a9a8f4f2e6455_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTMtMS0xLTA_a89da5a3-ab69-4d87-af31-683fe4b14d21"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1e8ccd8cde3495f9af0b571d95d1d00_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTUtMS0xLTA_369a6ab3-d2b7-49e9-b4e0-fad5b87f7022"
      unitRef="usd">54000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieb936fd1c99f4c35801a4495e91bec73_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTctMS0xLTA_e62230ec-c0c4-483a-825d-78e169fbb08e"
      unitRef="usd">112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76fe9b60ce0f449a99363f745dca6e96_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMTktMS0xLTA_cd755da7-5dd3-4f0c-8128-5d1b875d7362"
      unitRef="usd">45000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1acb4cddc5604c7eb880aaa49a3e16f6_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMjEtMS0xLTA_13bd5ed8-fe60-4bd2-8a75-a594a4ce6045"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17701907ca0e47ba8fd1a971d48c2457_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjMtMjMtMS0xLTA_25a72190-805f-4b20-aca4-2e15d48781fa"
      unitRef="usd">88000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73faba95052145acb3c26e84d3a4b602_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMS0xLTEtMA_c35822a1-a298-4c60-8b8a-401032ea87d2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie736913c7dc4408abb11d1fbef1ce474_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMy0xLTEtMA_53fba6c0-f880-4c14-84df-cedc08ed63ac"
      unitRef="usd">209000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec058f1ae0fc472090afafbd68d47461_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtNS0xLTEtMA_34c1753f-681b-4d1d-bf0c-a9db00716d94"
      unitRef="usd">209000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i989cab976f6448758df4479ff64c1fc5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtNy0xLTEtMA_483df49b-4af8-46db-ba7e-044944cf254c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i261c4ce6a02a4800a83a51be1c99da21_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtOS0xLTEtMA_c2c0a61d-9891-4be9-a4a6-22af6d413128"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bf9eb755fc44eafa35a8b13e484061d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTEtMS0xLTA_84fb0280-7312-47e2-8147-601febbdf5cd"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i52ba00bb057b41f5a6855415133e2535_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTMtMS0xLTA_4c4a53ff-046d-46b1-8f00-78076fc33b33"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia73eb6d53bbd4f5ba331d317ac2a8489_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTUtMS0xLTA_c01d61f2-cd29-4432-ac71-2c649a7c6ae0"
      unitRef="usd">615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac01653e21d0445aa0eee236c7ba741f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTctMS0xLTA_04a1b148-c17f-47e6-9b2a-dcc88b0f6b52"
      unitRef="usd">615000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5d4102e12044f109f6a5e7816007905_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMTktMS0xLTA_442a4683-2859-43ee-a4e0-1eb621d8fe4e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i242aa19f5d014d05a2d3f4cd08cd39ba_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMjEtMS0xLTA_a814154b-9f79-489b-887c-bce07d469666"
      unitRef="usd">625000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36ff90a270f74713b7bcc28d52341906_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjUtMjMtMS0xLTA_ddd0fcc5-9acd-450b-bb8b-5689a70916be"
      unitRef="usd">625000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a7c01c0be3e49b5915a0dac164db1e4_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMS0xLTEtMA_9902363b-1948-47ac-8388-e8b580c1dd17"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7972da26546c42ac99a76ed6a9fd9ec2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMy0xLTEtMA_0660ca0e-56b9-4dc0-9d9b-2cf3ef4cfd08"
      unitRef="usd">82000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bb7005b439e4d31aef9325c0babf90e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtNS0xLTEtMA_c0e7c497-c2d0-4369-81d1-8e0ad4c8a576"
      unitRef="usd">82000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i993dd102bdca4431a2a35bc582ce9394_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtNy0xLTEtMA_3ba1c532-1b47-4fb9-963c-7e5f86bf5838"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3485a40e14d749c98847179c09c2bf32_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtOS0xLTEtMA_29413044-0315-439f-a76a-7c343134f7e6"
      unitRef="usd">101000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4acb7f674c0e47aa9e58edfff2e3dbb9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTEtMS0xLTA_ccaaad64-156d-45c8-8309-b75e85133a95"
      unitRef="usd">101000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cf0a90d670947f2be36e5211d88cb00_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTMtMS0xLTA_179ee0b7-de9e-41b7-ae46-71200a99d170"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a7f87c772bb46ba90ef0bd0821eca8f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTUtMS0xLTA_a8dd9015-2a6c-4172-a0e5-171a1e9c52d8"
      unitRef="usd">242000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04909af50dc845da9f9a8569bcf5eccb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTctMS0xLTA_aa777281-df15-48fd-9218-de7c7f861e98"
      unitRef="usd">242000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia26152f7f7b440fbb4cb9d200d2e7f77_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMTktMS0xLTA_9a4dfa0a-911e-4dab-833e-9671230aa6c0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0931102ba1674080bf90d3330f7955d1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMjEtMS0xLTA_b54888a6-fdfc-435a-b3ca-d170f615b93a"
      unitRef="usd">322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7670dc70afcd4b09937d261583e363d3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjYtMjMtMS0xLTA_ffe84bd9-dfa0-4e67-91b4-eef17cd748ac"
      unitRef="usd">322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id20fe0f50a9b4260b6c07bfa057998d1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMS0xLTEtMA_b96a605f-66c0-457b-85c7-3a34e3573d38"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i858538797815486f80a7414cb57358de_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMy0xLTEtMA_ed0a2ee6-90cc-4e4c-ae54-ff10d6dc4456"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87a8339ae25046d28c34fe065d7fa146_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtNS0xLTEtMA_550556bb-753f-426d-88b2-bc655c7b704e"
      unitRef="usd">81000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57ff7e9937ea4f4d82b65c6fa6926786_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtNy0xLTEtMA_d2e25f1f-b136-451c-ab5b-dfb752242d92"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied1700dc6b374b3aa45edfd416e35917_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtOS0xLTEtMA_bff87fb9-17fe-47c7-9a63-75275b158862"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9928d769c694dc2b2adfc1fb517f81b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTEtMS0xLTA_127596e5-70cc-41a0-adf3-512f60c77c83"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe0a0fa75bd64a7b8e10d99ff43623d5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTMtMS0xLTA_a805a523-eda7-4ac9-b50c-ad40581dc36b"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b1825f1272940bba1d0662fbbebe361_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTUtMS0xLTA_7a2a694a-4709-4471-8d2d-b78c00fc66b8"
      unitRef="usd">177000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a4523ccacdb4f7f9000657e8e4309a8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTctMS0xLTA_4f8f8869-5397-4a0f-8854-6046aea8cc86"
      unitRef="usd">244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57c9e9493f5641b8a375c87f2e0f240e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMTktMS0xLTA_b9e03884-74d1-46f7-9572-9e88d1e56a52"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e423505d49f437db0eea268f1caec94_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMjEtMS0xLTA_e9733fbc-f98e-4ae8-891f-3e621b8803e5"
      unitRef="usd">155000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5b1c51d2fbf4f78a7e2768a8d38f881_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMjgtMjMtMS0xLTA_30b20737-ae84-4004-9afe-c7fbd3a00662"
      unitRef="usd">223000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa4fa96062de49de83a4eec95e5f1c59_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMS0xLTEtMA_56076aa3-eb7d-4f88-b698-7af704de4a44"
      unitRef="usd">92000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebff762cc1db43248ab6ce27128b3ea1_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMy0xLTEtMA_470ea067-5f67-4a65-88c6-4dc30edda1cf"
      unitRef="usd">113000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie35113cc0f784ea18a9ab80c7456f72f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtNS0xLTEtMA_6b1d4d34-d7fd-4400-97de-83c0ce4da007"
      unitRef="usd">205000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd0b5f18d0c94b499db52d87cb762e66_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtNy0xLTEtMA_0002e971-dd3f-4243-95e7-789faab90bcf"
      unitRef="usd">102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i623c2805c097460f9a7582db63744702_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtOS0xLTEtMA_6149c421-a3b7-4bbf-9760-1c8426b431a8"
      unitRef="usd">149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96bb9a967fac42b0959e471029dd753d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTEtMS0xLTA_fa0f5ab2-7ec7-49c1-80b2-367de4e7c5cf"
      unitRef="usd">250000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24b59bcf248242288925f9d29334b8a4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTMtMS0xLTA_0c6d9894-bf29-4a46-ad96-22084d2fee45"
      unitRef="usd">243000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83851ea51a8b4f348c297fe9674a70b9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTUtMS0xLTA_f9c92099-219f-47ff-9413-b084ba8420ce"
      unitRef="usd">403000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i374d9072818a4be49130b74a30fab649_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTctMS0xLTA_ef5f23dd-84da-469b-badc-6d220d4bc934"
      unitRef="usd">646000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaeb66d45ea6d43f891ac8d34790f596a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMTktMS0xLTA_ef29c3f4-b408-4e30-ac78-007811f64a22"
      unitRef="usd">304000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d20159069f44586beb2bd4d53b486fa_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMjEtMS0xLTA_886c6fcb-0225-466b-9c9b-757c3fddfa74"
      unitRef="usd">449000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1589f85930c4c2490dbcd2bc2471fba_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzAtMjMtMS0xLTA_08fc681c-dfeb-4687-a5b0-d30c18209354"
      unitRef="usd">752000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01d2b1a5d4e445afb22b111f115751ee_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMS0xLTEtMA_fcff4ad1-247e-4a4a-bf93-9a136161bf6f"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a2782b98a704284ac75156aa7888225_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMy0xLTEtMA_721a347c-eb18-4777-919d-7f5f2ed1d92f"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic28c15341c614ec3ab5f080633c0f9e8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtNS0xLTEtMA_1c6eba7e-18dc-4c89-ad43-605230894de3"
      unitRef="usd">28000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7892ccc679854d0f856e0d492c1d0dc2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtNy0xLTEtMA_7d725161-e713-42eb-8044-5f6c20ad82a9"
      unitRef="usd">24000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i454932685d7e4ec2b3f324fd851227e8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtOS0xLTEtMA_39dd675f-112e-4d51-96f3-0f66f849b6b7"
      unitRef="usd">59000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a6b957265c64b67b737a553dc147e91_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTEtMS0xLTA_d0d3f82d-45d5-418e-9ef5-d369adafd524"
      unitRef="usd">83000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if87992e546f14efb895456eb6a74307a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTMtMS0xLTA_78cd50f3-e3a9-40d1-af79-327983a11d86"
      unitRef="usd">38000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i713d3719b5024faca7719a158e89109b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTUtMS0xLTA_72259e31-49f2-409a-8744-f923bb5faf0e"
      unitRef="usd">83000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9b7b30d595b4b568bf5d47c20418641_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTctMS0xLTA_6d3ff7f4-f85d-4009-baed-462691524d7e"
      unitRef="usd">122000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3a2b13d213f4580ade960efd7096274_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMTktMS0xLTA_54496af9-8061-4138-8798-074af528ed68"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb922157dde34ceab969c20d2c593243_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMjEtMS0xLTA_8314cd56-af21-48c9-a8fb-037e6feefd43"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05e831ddc4674ba7a0e1d0b61409a910_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzEtMjMtMS0xLTA_154505fd-e3e2-4146-92fd-e3a03adb35f6"
      unitRef="usd">304000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c7c5a8d8197420585dca57047243f97_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMS0xLTEtMA_caff30f1-e8d2-4515-a25c-f645bc44a0a5"
      unitRef="usd">-1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i938196e4279e4040b004c3a0e20fb083_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMy0xLTEtMA_11a1db7e-441f-4493-b1a2-407d07aebd36"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if79705fd98c64c8e83345f5d01da64f7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtNS0xLTEtMA_db272ad1-b047-403a-a52c-b251ddfe898c"
      unitRef="usd">103000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1f7c0c892af4ff1a708a6271afe4da7_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtNy0xLTEtMA_5db7b1f6-85b3-414d-a631-dd5846195b60"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93f14a0f1d8c4abb8f6a1d03da5e0eae_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtOS0xLTEtMA_0abb6ce1-ded4-485e-a7a1-ff9800055832"
      unitRef="usd">142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadd47e42c1944c9c8213aa8f8808165f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTEtMS0xLTA_a4bc72b3-4e58-41e3-a3ea-d616cf035067"
      unitRef="usd">147000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04d650ce0abb457d9453531cb7e334c7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTMtMS0xLTA_a853ce30-61aa-454c-8d0b-e1a3418cbd6c"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c32b81ac1784ecf9a98aba06ce43e61_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTUtMS0xLTA_c0125933-6f70-4445-80c3-2a7bfcf447a3"
      unitRef="usd">389000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2de38a6154464d5695596fd542cd49e0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTctMS0xLTA_381c2fae-3a66-4fd5-89b3-4a4f928b16ff"
      unitRef="usd">384000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3ab7aff39d449dcb43df1642f85616e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMTktMS0xLTA_d7a2cdd3-d0b1-4c61-b8d4-0ffa69feeabb"
      unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifcbac2ba02f245f2bf19de7c0dda76b7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMjEtMS0xLTA_44fb9b5b-7f02-40cc-8b87-5484330853cd"
      unitRef="usd">432000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9f6f5e968c5474488f0b232fe0e77e0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzMtMjMtMS0xLTA_a71c8802-1889-4dd0-b751-93d4c641db8f"
      unitRef="usd">443000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdd98423d8c14073b9a11bd36db51615_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMS0xLTEtMA_b2cd506c-e891-414f-83aa-5956705fdcd3"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15d20ffb278846169ca7fdcd9df043c4_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMy0xLTEtMA_821c1ff9-0a8b-4cdd-9db1-c0fd8311ca23"
      unitRef="usd">44000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id028f116dd7b43eaa20b6e06ed2df1ac_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtNS0xLTEtMA_7fdb8923-99da-4cf1-a22d-8a444853a24d"
      unitRef="usd">47000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50456612190942a080739275f8173a2e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtNy0xLTEtMA_3909c590-a48e-4a94-ac32-dfa37e4ce34f"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0c087cfa4f64c55b828f161589a223b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtOS0xLTEtMA_d5e1a73b-ccb6-4524-8b5b-d752a3705917"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b39be43599c4cb7bf9bd31828ef9002_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTEtMS0xLTA_bbbd6600-b5b8-461c-94a9-0eb430f2a936"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99bcb57eb48d4c5598c716226714d7a3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTMtMS0xLTA_bc411bee-273d-4d9c-bff9-2fe378a45079"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05834b1651a949dc8f02f619c612749e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTUtMS0xLTA_53468d70-f1a6-48a3-b16c-43cfd8be426d"
      unitRef="usd">130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7da82df886634a4fa849605c59fae2bc_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTctMS0xLTA_fcd5dc68-4f36-4462-8d6c-c471f1d076c8"
      unitRef="usd">139000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i716c7e7fa0504751a650112eca041f5e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMTktMS0xLTA_1510368f-24c0-42f9-8333-fd7090d2a83b"
      unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i318576a512024c6c81441fd12fd57fa1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMjEtMS0xLTA_2760fab5-465f-451c-841d-c389d3bfed50"
      unitRef="usd">219000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cbee4cd8d004afe9a3ad3ed1829964e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzQtMjMtMS0xLTA_1bd3c3dc-142a-4902-851f-3f07dbe35458"
      unitRef="usd">231000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i334447130bb944a993957aeaa20c39eb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMS0xLTEtMA_496a67ca-195a-4af8-863a-4d1bed05b586"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b78ab8426f34f24a032ff8f5061739f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMy0xLTEtMA_e1adae83-d18e-44ba-be60-091dc0f3e04d"
      unitRef="usd">111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8977d72497b74b1086d865c0aaaac8e8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtNS0xLTEtMA_eb510b8c-ad07-45c3-92c2-a4474f320693"
      unitRef="usd">111000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea630f933a7446e9a808f75d1870113b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtNy0xLTEtMA_2ddef571-ccad-4475-8381-7e042337d4fc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5c211102c3f46678a682f40f99d407a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtOS0xLTEtMA_e328f38b-e4fa-4d99-ae3e-e546b9ec5958"
      unitRef="usd">97000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee0d607a7351455a9f45abc4f86f952f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTEtMS0xLTA_e163acf3-9998-46b1-a1a8-ee95a27c8c03"
      unitRef="usd">97000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia279e76e54074dcaa5ac97de34e18efb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTMtMS0xLTA_d4deedcc-19ff-4ebd-9f67-a0f40184f31d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12096c3c413a49c898ae87d73a81726d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTUtMS0xLTA_f3a8bf17-4067-436e-92c0-80858cc3bdb4"
      unitRef="usd">348000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58002f53d69a46229000ce6d3360542b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTctMS0xLTA_5b53a379-536d-48cb-80b0-a0ec5ef9a445"
      unitRef="usd">348000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14e7b9d13ce74df1b09ad0cf151c9851_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMTktMS0xLTA_530f8074-3ac0-409c-9c50-d6d00c3114fd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib92db4be05ab40318a94c027967ef6ad_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMjEtMS0xLTA_b9f26dc0-30dd-4205-a00f-3504a1da37ba"
      unitRef="usd">283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a231f98c7d149a490b785bad71e4496_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzUtMjMtMS0xLTA_c381a758-8950-4bb7-b444-6621aa0e381b"
      unitRef="usd">283000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id303f0dee3b74b50b4a15ee325ebafa3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMS0xLTEtMA_2f622d3c-a771-4163-8fc5-41b587c0552a"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie44bd2933ec84060aee7e36859962375_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMy0xLTEtMA_3ac0d1a9-7848-42b5-8adf-e94cc6b24f65"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i617676e5fd5247fa822d36489d37e0e4_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtNS0xLTEtMA_db6216a7-a682-4d79-a805-d1fde4ec8ecc"
      unitRef="usd">83000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d72700287de4fd4abc770a532f25f9c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtNy0xLTEtMA_6c3523c9-cce0-4a3c-bae4-405bc0f408aa"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0c6b30dcffd403bb85af19b9d4165b3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtOS0xLTEtMA_969b2fd6-1bc9-4273-bc8c-c075288b4a68"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i296ad230a93245ddbc5fd02cba30cc53_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTEtMS0xLTA_78630c68-87b5-4c96-a6b6-0a133a89cec8"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i88917ca1de89409e9f4b5b2c0fa57485_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTMtMS0xLTA_d02920f3-d2c4-415e-adf0-c16f42362692"
      unitRef="usd">200000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebfa044147144425859e25282f0ef9bb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTUtMS0xLTA_dc622d2a-1b8b-49ee-8fd3-c930e8dd2971"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i003abe7634514241b3a8d6350da515dc_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTctMS0xLTA_ee92dbf9-c228-40b4-9209-77fda8a88956"
      unitRef="usd">216000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i618a9be04c62409099b81b9ef1c5344d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMTktMS0xLTA_0adcefc5-fe93-4fe0-99d5-1c103acd5aaf"
      unitRef="usd">137000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a2abc9a0e534088b5e0fd5437f763c4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMjEtMS0xLTA_e2208944-607f-4397-b329-f81f973fd3eb"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0be09895f8143679533f9a333f5a993_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzYtMjMtMS0xLTA_3c8e56a1-4ab4-4d23-b141-23aed2884fc9"
      unitRef="usd">144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93521f60ff59466495549fc41c457899_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMS0xLTEtMA_3a5febcd-1347-48c0-97d0-1072ead9b7f5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5952b34144c141cda9875d2d182b3881_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMy0xLTEtMA_313251fa-08ba-472e-9b84-cb0b7420bbf5"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5caa54b167f3434b80a36e8e76d7c6f5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctNS0xLTEtMA_0a41222d-e3cc-4512-92d7-cb16e403e363"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i651c70a05142434cbfb538a617b89007_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctNy0xLTEtMA_93e6838e-b887-4a3b-a0a5-46ffa9897e56"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fcc4708c8eb4156b83f9055e325dac6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctOS0xLTEtMA_b700693b-f285-4c8e-af7c-f44a8aff89a2"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i740e22d8434f4b8183f077a8a007e956_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTEtMS0xLTA_2c70e80c-a88e-4164-9218-45d8aa8c6887"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i640d595c82ce42e7a7c0fc6c0583bf14_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTMtMS0xLTA_7a6d2a8e-3444-451e-ad3b-7eb4b89de579"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44f141f8261348bca533b4aa5e20e68f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTUtMS0xLTA_62ce34cd-a906-43b2-97b4-e316fd5cec83"
      unitRef="usd">167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e53e8331413497ab9874b05911c0437_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTctMS0xLTA_2af836ec-78dc-4548-bb50-f6595b994134"
      unitRef="usd">167000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if68cf832a35a46ff8bdde3920247bd39_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMTktMS0xLTA_4c5280a7-8407-416d-bc4c-00762cf726dd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1f48e3aedc24f50b0808a4b79b5dc6f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMjEtMS0xLTA_61a1e71f-3be1-46ff-b8d1-1a4bdb4238f0"
      unitRef="usd">158000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd6b9e3b829c4249bb4c0dd15118296b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzctMjMtMS0xLTA_8860f04d-c771-4df4-8369-f1e070b4caf4"
      unitRef="usd">158000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4d275d442cff4f52b27f27fd2a721187_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMS0xLTEtMA_7dbe4764-bb62-4fad-923d-c30c5338c4df"
      unitRef="usd">342000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b693b792e3f4432bb82f7c6052c3ade_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMy0xLTEtMA_10266d65-7efb-41c0-85be-abcad806cc1e"
      unitRef="usd">479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i226ad6cf1abd49039985c8760bfc48d0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktNS0xLTEtMA_451c3510-fa31-4ea4-83a5-a8606cf0bf99"
      unitRef="usd">821000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2c690705a704872bb3bf8a6745a536b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktNy0xLTEtMA_afae78cc-59c9-4b51-a54e-8d650fea073f"
      unitRef="usd">367000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95ca2e5a714e482f8fdd4c3d12841689_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktOS0xLTEtMA_e11493ad-07b1-4955-b031-c78e35be6216"
      unitRef="usd">440000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3da7b1a0beca4bd29d8c4620041e50ef_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTEtMS0xLTA_d7e85659-8405-4e4a-a9ae-d33948133c7c"
      unitRef="usd">807000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idab88e6cb5824e4ea0470b131ece9e3d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTMtMS0xLTA_4b3d6701-105a-49f2-bead-cf74350165ed"
      unitRef="usd">1110000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f6c90ac04b148ab96bd8f595258f46c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTUtMS0xLTA_d2d07d4e-881c-4474-9a0d-bfc80ac32d10"
      unitRef="usd">1339000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9f486eea8904e70b20acef9a91c8270_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTctMS0xLTA_b1ee0ec5-8b18-4ee3-94f7-b8da861992ff"
      unitRef="usd">2449000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ae7aa49415340d9869b132435677a23_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMTktMS0xLTA_2e551a46-5631-4f6d-888d-7022e861147f"
      unitRef="usd">1223000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb42bbe4a18548f4a03796d68320493e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMjEtMS0xLTA_b4e4afb0-d893-4525-af44-ee5cee162499"
      unitRef="usd">1317000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2e9ec73128f4b998b320a2ff73af17e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfMzktMjMtMS0xLTA_03c5ab1d-7da5-4be1-a013-acd550a282c0"
      unitRef="usd">2539000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c91d7cd6e084ae696ac51575ba5006a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMS0xLTEtMA_fbc57778-729b-4e54-ab68-12dfb31f28c5"
      unitRef="usd">105000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13bbe57c7ef04ccab0073746177c2e21_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMy0xLTEtMA_23400d8f-f91b-42b9-9a23-b1b5f7cd7bbc"
      unitRef="usd">400000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b0ecfa83ad149c5ad28f2a5c2bcba9a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtNS0xLTEtMA_41976bbf-98c7-443c-ac21-3ce5478e1aac"
      unitRef="usd">506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86aab60a014a46da930b6b4e9e51c7b5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtNy0xLTEtMA_0053067f-ddd8-4b19-8e8d-56f09c21e50f"
      unitRef="usd">129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i101456f617a34e8f91f201fe318d9a1d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtOS0xLTEtMA_194ca180-34d5-4124-a5fb-eed6df01519f"
      unitRef="usd">375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic39e3340b0e647debae7f510c822e44a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTEtMS0xLTA_af6ca839-38d3-43e9-9712-95c176ea3329"
      unitRef="usd">503000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6009d7735cd3433f9a820af8fb018481_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTMtMS0xLTA_a893560a-c722-4680-9a51-75c76ec35ab0"
      unitRef="usd">361000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0257c158246c4e4dacbd738eee948877_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTUtMS0xLTA_7b494c6e-467a-479d-ab41-db10a3fc6e0e"
      unitRef="usd">1138000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ae95c10fc15484eb3969d05a0a65b4c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTctMS0xLTA_4ae5a5e4-3960-4383-a4c1-81b09daf6bee"
      unitRef="usd">1499000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i047053376fd540a295e977bc6188ab36_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMTktMS0xLTA_83fbc125-7746-4cda-8199-0e95594d421e"
      unitRef="usd">462000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id09da9da15f049f18535de414de6ca38_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMjEtMS0xLTA_b6b45008-aa64-4129-bb5e-588e17615c03"
      unitRef="usd">1105000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9106c5caf2b40498beb6bd13c71325c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDAtMjMtMS0xLTA_ba730ff7-0605-47e0-b83f-7bd27bb28a6e"
      unitRef="usd">1567000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42088e2a28144cd7873c943696f37b29_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMS0xLTEtMA_73cff51e-ad6d-4cc0-84bc-9a53339fb5d1"
      unitRef="usd">137000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0baa103cf7c4cac90311107a935dc92_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMy0xLTEtMA_4b95e457-e8ce-4dba-9d96-bc21c8dd0c65"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd842388eed64b3da555ffae75b7899f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItNS0xLTEtMA_71096e07-4938-47ae-b2ca-0192e41776fb"
      unitRef="usd">189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idda57adf0dc14c4d897dfd88fd256191_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItNy0xLTEtMA_a5f79758-237a-4490-8e1b-11d3387bb72b"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c35e7bef0f74b0e9f2ad280b8c9d79a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItOS0xLTEtMA_2493bef9-c1ea-48d1-973e-e2eab4a9e60c"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffe3d788155d4dcfa6d1bcf0849a7908_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTEtMS0xLTA_e73cde14-8868-404c-8e94-8c393b3c853b"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf13f6a3f0b24f4692421a7f681056e2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTMtMS0xLTA_41273afc-a9bc-48ae-9d4e-d0d31c36ad02"
      unitRef="usd">374000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i823b7acf4af043c7bcfc682b9ea59b03_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTUtMS0xLTA_0579c030-b15f-4610-b152-6173281080f9"
      unitRef="usd">142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i250b5ff269ea46b4bd2e15044f7e9e39_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTctMS0xLTA_04bed983-b0c8-40e1-9d88-e1874501c717"
      unitRef="usd">515000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i816a6164517c4476bbb9046b7465a255_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMTktMS0xLTA_abdd9e00-fd54-487c-a8c1-9ca63fbd0068"
      unitRef="usd">421000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bdf582fe7f04b6e84f53a13fdf085fd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMjEtMS0xLTA_e1db6a71-cbde-494f-8d67-8524a8bd442f"
      unitRef="usd">160000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabcb5052939546a08171746b38d9a959_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDItMjMtMS0xLTA_7869431e-88a4-420e-b64a-027ee7a5a0d1"
      unitRef="usd">581000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e1e1cd1ea5f45cb8b0d49ab5e325e7a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMS0xLTEtMA_cba81d36-5a86-4df2-a6cc-054bd9e0ec98"
      unitRef="usd">24000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00ee2df0e4d24ac49cecaf2f8612ac56_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMy0xLTEtMA_7b1b09fa-f9a2-42e0-a6ea-4f95d803f1a9"
      unitRef="usd">34000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8da3de0a1d54bb19a95bf565424fd8f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtNS0xLTEtMA_a8180399-4b22-43cb-b693-13478593303e"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib197c58857094217ae70f45c5bba1512_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtNy0xLTEtMA_8ac96e38-e8a0-4097-8b2b-a51b4f092ba1"
      unitRef="usd">202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65bf34d7c3de4b76b99865acb7b377fb_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtOS0xLTEtMA_09561301-e9fa-448a-beb1-597b7e7e4a6d"
      unitRef="usd">39000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ec190b0d42f42ba87646a7397218a62_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTEtMS0xLTA_f1b20b20-d4d6-403e-96d4-51440e006e99"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id87932775cd94b648c1cddd6c945029d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTMtMS0xLTA_c2561251-6a0f-42f4-aa9a-392c1941dc96"
      unitRef="usd">85000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida18cbb39b744ce7a0792eb9db392c68_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTUtMS0xLTA_8f659c67-41f8-4a66-98fb-967268ed5ffa"
      unitRef="usd">98000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida7a1d7200fb43eaac711c3fce8929b7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTctMS0xLTA_3ee18bca-7749-413e-a993-4385f0bb8442"
      unitRef="usd">184000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5936f316e3b42a5bc7edc460c3d44d7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMTktMS0xLTA_7fb438e7-05c6-4733-a2d7-38f6934a5055"
      unitRef="usd">593000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec2c7223374443ddb83cddcd93f11059_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMjEtMS0xLTA_e9bfb882-843f-4d61-b003-5659fbde7364"
      unitRef="usd">107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2fc1591a9274ddf8df88b43546a8090_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDMtMjMtMS0xLTA_55ea3e6d-3d25-4363-a955-b7bbd5b4e6ec"
      unitRef="usd">700000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e354e7391d543ed99baad3fb5dab811_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMS0xLTEtMA_67fca2eb-a339-4b22-9a33-eef71c249f82"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79cbc9acc32f44e2806b5ff08ab4fe23_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMy0xLTEtMA_13c86d46-0633-4b35-88bc-44daf7b7e8de"
      unitRef="usd">78000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida4ad108871045beb3935eec15ecb68e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtNS0xLTEtMA_6a92a79f-c775-4b60-89e9-053d9f84f9ce"
      unitRef="usd">82000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i564e295cbae1431ea1342d1a6aeb2d66_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtNy0xLTEtMA_9db157d4-0ae1-4af9-b451-ed0a83659b9a"
      unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4cffe9e90bd459eaf7ef8497c5e3424_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtOS0xLTEtMA_0ff2077a-f47e-406a-baa9-dba51b789f4b"
      unitRef="usd">140000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0d690c97e9cd4f4d9c35a892caaecac6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTEtMS0xLTA_aee8cb8e-a8e9-4508-9b6b-196ca075270e"
      unitRef="usd">152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i649cbc3cd44646e9a198d32f7491aaf6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTMtMS0xLTA_14f17322-735e-477a-8857-c0a668f2f34a"
      unitRef="usd">14000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cc84657eb0946a79cc4a2c2d53f5f7c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTUtMS0xLTA_015ef5b1-b5a6-4305-8367-370ad43b7664"
      unitRef="usd">324000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0c935c934b3455584cb3ada0f1e5c0b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTctMS0xLTA_5e368aed-ecdf-4b15-81a3-3ef620de11f3"
      unitRef="usd">338000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id80cc24848e04d269a3e8ae9c377edad_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMTktMS0xLTA_81dcf365-8f5b-4563-9e6e-ccce40b8c225"
      unitRef="usd">24000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib77eee53991d46b5909d9edb93e5b74d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMjEtMS0xLTA_fd0b2e20-88fa-4a33-816b-a3d838d488c7"
      unitRef="usd">479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b7f6840d5e34b2faca6d72b25845338_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDUtMjMtMS0xLTA_bd0fdde4-6bab-4d37-bd8b-54302b47d3eb"
      unitRef="usd">503000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id320e1dcac42446cbc9350d2c429f55c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMS0xLTEtMA_d8803021-84a4-4af6-bd7f-81b1a655b7bd"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0f8b81383774d52a52223b7869349aa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMy0xLTEtMA_4f54d61c-c6ba-4896-aa57-05c5d3d76496"
      unitRef="usd">86000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3b8498ad9774b9d82c1c33f73ed1085_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtNS0xLTEtMA_b2414085-6714-4d52-95ad-810dc0bf6a6d"
      unitRef="usd">91000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4d53f4525194a86a9fea6c036af1d55_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtNy0xLTEtMA_d11ace1e-4a9c-4c32-9d9e-d8e16bee6afc"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c38480569ad43bf8a8faaefe258752f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtOS0xLTEtMA_dd2fb7a0-8086-4ce2-8a1d-bd3fdd51c2f4"
      unitRef="usd">110000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2661c49a72f4fa4b82bfea2d5eeafcf_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTEtMS0xLTA_5357bfd9-0cfa-440d-a5df-6a582cf5e07f"
      unitRef="usd">116000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ba0bdb0d16143e98878115551e164fa_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTMtMS0xLTA_e6526b1f-1939-4a6a-8d12-96b1ed2fd617"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33caa9debafc499f9f035c363252e664_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTUtMS0xLTA_0759bd31-22e1-46ec-b03a-20dea8ba39f7"
      unitRef="usd">275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70254c5658804d7db8c93d35ca1b2469_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTctMS0xLTA_6fb0f655-405c-408a-b624-c7a6a7a44df3"
      unitRef="usd">292000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f17b6e17a35418e8016b026c1f452a9_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMTktMS0xLTA_b71977b7-9d9f-4dc5-9adf-91d2f3896cf8"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaaf07528158c400fb9045d2904828cdc_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMjEtMS0xLTA_8c7e2cd2-7fcc-44af-b2e4-c1a2afb7b040"
      unitRef="usd">313000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c6e2064c3ec4ee7bc561d67868ea2c2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDYtMjMtMS0xLTA_e81701d6-3fe6-447b-ba4a-453a5cdbed9e"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if29c1b123d68491cbc79c7aa181a889e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMS0xLTEtMA_73244c09-0bd6-4e26-a8ae-774e2dcd30c8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba270aaa589748cd947e1be8c444099d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMy0xLTEtMA_1ce181d4-4c93-4051-abe6-5408b415488e"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia59bc2566f18462695b19da2c7e8857d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctNS0xLTEtMA_baa59b63-3fac-4c71-873c-22981ae7017a"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14f8fcbabb864499b102a4d91eb12390_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctNy0xLTEtMA_4bcf2d64-633c-45ae-acda-9a0aec0791fd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icab058ed790442cf887ada3d278a7abe_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctOS0xLTEtMA_b993f53f-8104-4a10-a52f-c7f4ad7317fa"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8878e9ea7e44254a65607e3a621ad36_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTEtMS0xLTA_2751177b-8d57-46e1-8b43-e378a46cacf0"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c96ed92bdc54f6dae73012eb2b0161a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTMtMS0xLTA_a2bba2e2-8a64-4322-9f2d-a6f272bca109"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8cfb19850424c50b34394d1394866d3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTUtMS0xLTA_8403a10a-0965-4f5d-b2b3-024f490df0c9"
      unitRef="usd">204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice8b9c2751764e1f8d74e88aaa332b62_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTctMS0xLTA_27fcf636-08ca-472f-bcfd-f9cbe82d4d73"
      unitRef="usd">204000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a3220d799974f0eb91ea6a92667c1d5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMTktMS0xLTA_9b895a4c-bf11-4935-b7ce-ebde72a69b12"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8875e8b3d4847bf905c685aef59e0b5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMjEtMS0xLTA_e451e73d-b58a-4d4b-940f-b070e4a43a8e"
      unitRef="usd">221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b57a142ee3a4ce9a28e2129619938b4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDctMjMtMS0xLTA_90335673-9970-4c60-b0f6-7960c02ec1de"
      unitRef="usd">221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fcc4f2c591d42c2a24736d2c11c3061_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMS0xLTEtMA_33fd9821-bfeb-4da3-936a-32fdfc15cac2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i972845bfd88640bea722b70626571964_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMy0xLTEtMA_072fddee-20ea-464b-b5e6-3038f527ef22"
      unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbe81fbfea644f74bfae5c97dafab313_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtNS0xLTEtMA_2c156b89-b475-4604-8efc-e4355af6528f"
      unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied38158acb5748a0a9a535f78ea93b3c_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtNy0xLTEtMA_47336823-e999-4ce8-93c1-3350157f1709"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i631b85d3d7a44f58b74177a695ee880f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtOS0xLTEtMA_fd4c5d63-7ab7-4148-b27a-0ca7b53d270b"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i80e80c1e64b24bea81b052f8f6a31353_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTEtMS0xLTA_20e76143-2b2d-4ec1-ab4a-44bd3492f992"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1bb093533b64c6c9ff9dafcf60f4ee1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTMtMS0xLTA_586b6705-bb7d-4acc-9953-94efa5a75192"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe47ce5722b844be8d813eb70e594427_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTUtMS0xLTA_e5abe198-beb0-4379-a769-8dffe1ce0162"
      unitRef="usd">152000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85247bb365e149738ac7c734ad073fcb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTctMS0xLTA_ccb2117e-4182-4a11-9c40-3b72ed54a6e0"
      unitRef="usd">161000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccdda557d4de4ed7b963da933bc6d89c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMTktMS0xLTA_57e015f7-982e-4e45-82e5-3e474dd5de45"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a45b54cb929479b91a5036c365ad2d1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMjEtMS0xLTA_6ef1bf12-9a96-4414-bcdd-86289be623ff"
      unitRef="usd">224000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf194fe2ef394a6d8fb6776943995e44_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDgtMjMtMS0xLTA_d2d80cad-0b33-4ca5-94c4-4c313c8bf926"
      unitRef="usd">226000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5cd2fbab6f9043ddb7f5562393c06341_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMS0xLTEtMA_d35602b1-1bf6-4089-9c7d-89c89b9c1e42"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1930b8b6109e4cea903f59042c7e749b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMy0xLTEtMA_bdd047c2-0b3a-4922-a059-ded24ea393e7"
      unitRef="usd">31000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifed7a671edaf49edad215de41a079a58_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktNS0xLTEtMA_e8ae2187-a4c3-4fdc-ba50-e6760ab85740"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i75a4a0980d7e40e4be58e702f91aab82_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktNy0xLTEtMA_6a67b379-2c5e-4345-8210-61c16518a084"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief202939785e4d1fbd2e37bcca814959_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktOS0xLTEtMA_7eb11ce3-e9c1-4a81-9625-39f292c5d056"
      unitRef="usd">35000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba9f4d9097a44d18897c5e28a6e2be16_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTEtMS0xLTA_0729d26a-a122-493b-aa9b-23526447029a"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic824da0674df49ef92b0f0f79ed94902_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTMtMS0xLTA_410c114b-3ef6-4798-be55-155e94d6b87e"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ddc6db0368f41c29f507c8f2fe146ad_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTUtMS0xLTA_7cda9a6f-4545-4326-9d34-2384e0521671"
      unitRef="usd">76000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58d21dbdf0f84c0d8dcbb85d77cda350_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTctMS0xLTA_bbf463d6-fd14-40b3-8312-9fa9be2ff1d7"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb259bf8f6774eab95195ce94daa4d29_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMTktMS0xLTA_d7b50f49-81b0-4530-8e86-52f51c5ae679"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60073e1f170740a18f008719f2754f25_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMjEtMS0xLTA_944de955-a5ea-44f4-8c4a-b15a0c1f4d5c"
      unitRef="usd">102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bdf03e64d0c4fddbadaa8c893893a20_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNDktMjMtMS0xLTA_8fe6f1f8-8ccc-48a7-acaa-94ffb858d137"
      unitRef="usd">182000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b602e80983f48678ff06480b5a96fc6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMS0xLTEtMA_c6202e5a-4add-45f4-80ef-7dfa44f7dfba"
      unitRef="usd">352000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i319f3974785d4167937eccdebe28675c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMy0xLTEtMA_3b7cc563-be5c-4fad-b894-028e3cf93096"
      unitRef="usd">834000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i636d30541f2d41c1b70a178f58cf65e9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtNS0xLTEtMA_a6cc989d-21dd-4922-82a2-c69acfdc822d"
      unitRef="usd">1186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3add7668e892473ebd440941e4e6ff61_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtNy0xLTEtMA_63347877-2263-43eb-a401-c1cf06735039"
      unitRef="usd">343000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b4f8e164ae7418cb04b0ea9679efe3e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtOS0xLTEtMA_c0e470d3-1ddf-48a0-95fc-844cbf241704"
      unitRef="usd">804000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebb109d299f6434dba3b52e63f9ea583_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTEtMS0xLTA_ce6e322c-c5e0-4da2-adcb-f3f4ce9afa10"
      unitRef="usd">1149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfd5b2fc3a6c4e7487aa809e527b4eb1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTMtMS0xLTA_f3e76621-7b0b-446e-89ab-49fed3873633"
      unitRef="usd">1144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i819e259a8f8545249f0f53c7bf645645_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTUtMS0xLTA_853a6b96-0918-4c45-82cd-ac2a3cb6de4a"
      unitRef="usd">2334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id642fa8a9a20492f96aadcfe08e8c96b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTctMS0xLTA_4754fbf4-b1ef-4f0f-b6ab-2f85f0290749"
      unitRef="usd">3478000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99a0a14797f94d938261561386085f3e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMTktMS0xLTA_c3632fbf-a7eb-4535-8e99-816f471b9bd2"
      unitRef="usd">1037000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e0134b6331943ce82d4a3f44a0afd52_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMjEtMS0xLTA_59bff052-e120-4db8-936d-9a6ee2d3c70e"
      unitRef="usd">2394000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1618964a1d4460d94d2b4f7ca640620_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTAtMjMtMS0xLTA_94bac946-4665-4de5-a344-c74f48cb9473"
      unitRef="usd">3431000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b3af3901704424498cbb93a1bd47e45_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMS0xLTEtMA_d314e0e6-2373-40a8-a82f-862ca3dfb62c"
      unitRef="usd">5218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib69b42b66ea64f81bc571b5e136a6b1e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMy0xLTEtMA_17021d8e-b82f-45e3-bb47-911af08a1560"
      unitRef="usd">6102000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtNS0xLTEtMA_174ffd37-c856-47ce-9ba4-44ad81be0b1c"
      unitRef="usd">11320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58a38b0abb2d475ea621d0cb55cade32_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtNy0xLTEtMA_6bb713a7-9ad5-484e-8438-d4aac33104ef"
      unitRef="usd">5180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf8ba8b236c94262b8730ba51f7dc42a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtOS0xLTEtMA_b37352db-5cc2-49e4-832c-cdfebd90c0e5"
      unitRef="usd">5914000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9728acb79d00420087a90f15524df617_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTEtMS0xLTA_d30aa528-8b66-479e-b524-2d10739d2ef5"
      unitRef="usd">11095000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id57045208e33461c96ad659d41f00462_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTMtMS0xLTA_9cb003b1-c49a-4e48-9f61-b7a7e8d4c946"
      unitRef="usd">14202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba969a5c23b6451cbeefa5426f1e393f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTUtMS0xLTA_2e4d5904-3b6e-452a-bc69-8e3216d60511"
      unitRef="usd">17452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTctMS0xLTA_84770b44-70bf-49a5-912e-1378a1f22bb7"
      unitRef="usd">31654000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc5946b43768450782f6246b122b119f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMTktMS0xLTA_c823fa19-9184-40fc-8d01-92f73160acf4"
      unitRef="usd">14202000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5473f1dea7542f691d2d95c97cad854_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMjEtMS0xLTA_12175fed-ddca-4552-aca6-54b8f0b6c6a6"
      unitRef="usd">17016000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTEtMjMtMS0xLTA_1a0acf3e-ac0f-475c-8da7-d066431bb4fe"
      unitRef="usd">31218000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8aaf2b2de2044518a3ec564ba88f75e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMS0xLTEtMA_3e8212af-0a4a-4b43-8e9b-4ffe3512af99"
      unitRef="usd">164000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic94420b005aa4e66b856a2ff67bf8c89_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMy0xLTEtMA_8ad08e04-b156-48da-a6f0-8549737e6d77"
      unitRef="usd">594000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i699b95b4f1f44764b9ba3bd58279cc61_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtNS0xLTEtMA_2b249f2f-7266-4bef-90b7-84acb0238e20"
      unitRef="usd">758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6dc35669ee24101a2c1185b33f55579_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtNy0xLTEtMA_cf57478a-b51b-49e5-a001-7867228d5a9c"
      unitRef="usd">144000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1ba7ff21103477bbabb92b26c7b3364_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtOS0xLTEtMA_6fe0b167-4312-4729-b786-072409653493"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96a279b2b6514d2192430c67323a7e85_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTEtMS0xLTA_87d42971-cf1b-46c7-8bce-3d33628896d3"
      unitRef="usd">726000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b5f9cabdb9941e7a863c97299c00368_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTMtMS0xLTA_d2788443-e428-4023-94be-f27674d56f2d"
      unitRef="usd">448000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a57f86aa38f484f8aafcb6f09735cfe_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTUtMS0xLTA_1be3253b-bc93-44f8-a36c-8243e9c313e9"
      unitRef="usd">1697000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eff7b7cb796442c9f4d72037c21fc95_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTctMS0xLTA_e263d73d-395b-4370-b532-baeea9e7c9f6"
      unitRef="usd">2145000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6983c97c98d42fb96684499a02a239b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMTktMS0xLTA_4c74cf73-e953-4b5f-88d5-3817a974d92e"
      unitRef="usd">406000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i754f6fc9ad27497fa0cd1510ac8e8907_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMjEtMS0xLTA_bfc7da9b-70bf-4e05-8d63-a19c1ab94e68"
      unitRef="usd">1601000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i342f3ee0e5454000a23a20f0cd994598_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTMtMjMtMS0xLTA_ee3d7884-6b66-481c-8ec4-3c264ab4debd"
      unitRef="usd">2007000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i652d6027f193497da031fa27687560ae_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMS0xLTEtMA_34cc5a98-7174-4ef8-9fc5-a054bedf992f"
      unitRef="usd">234000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d49a9dabac54fc597f022af9277e212_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMy0xLTEtMA_20067a46-39cb-47e4-bb66-85dbe3affe5c"
      unitRef="usd">228000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3a784d71f1c4eefad36065887fc2930_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtNS0xLTEtMA_792a8dfa-20f4-419f-a188-aa54560b1e96"
      unitRef="usd">462000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic534fa3517b64854a0401aca08abad91_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtNy0xLTEtMA_e6a4e01e-89cb-4eca-9af4-fa5664c4b768"
      unitRef="usd">193000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i11cc9e5ed0ff4a02b7d86616c322d0aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtOS0xLTEtMA_d4659449-6ddd-4863-a231-82e72bca4b32"
      unitRef="usd">203000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe9c7f8333b0450f87749a200192587e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTEtMS0xLTA_dbe686a7-0f6d-48e8-9d2b-f7cbf380515e"
      unitRef="usd">396000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45a6c4a6b6894cda952479c46d393577_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTMtMS0xLTA_386a091e-b7b8-42f3-9e3a-74c965b677cd"
      unitRef="usd">676000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a3207dac346430d8a41e7dc3467d758_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTUtMS0xLTA_8e762d9b-d484-4812-8a2b-620e9b2d2c90"
      unitRef="usd">714000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd61a490327b40cfb9292092cfdc5ac4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTctMS0xLTA_d922bd04-df90-4cd5-a726-3e5a69abd1a7"
      unitRef="usd">1390000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifeeb2222d43c4f96aa888a009b82082d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMTktMS0xLTA_8b6872f8-ba41-48f7-a78d-830f5a37cf85"
      unitRef="usd">560000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6aa7236576c74fcfb7383ec2acb28be4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMjEtMS0xLTA_f694e4c6-0458-479e-a24e-842e24faded6"
      unitRef="usd">704000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe85f304c00147af96a365f14c8d9c30_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTQtMjMtMS0xLTA_5766baac-620a-478f-b167-abba67fb9093"
      unitRef="usd">1264000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e40ead15e764c9889121bf33547189b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMS0xLTEtMA_856c10ce-5f0b-4ef1-987e-221ffbf44d99"
      unitRef="usd">398000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0e37194dc584ce0b830f6a8b322858e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMy0xLTEtMA_0c63db6b-163f-4eee-b61f-ed3dee4749fd"
      unitRef="usd">822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtNS0xLTEtMA_4b718314-ff60-4c3f-b7a7-caf2645c3bfd"
      unitRef="usd">1220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i14106dbbbd7f48158d4a3e3068314a55_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtNy0xLTEtMA_7db31a2e-cee0-44ec-9f5e-48f894d950a3"
      unitRef="usd">337000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae4011fe77ab4e7eaa38d98a880134fb_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtOS0xLTEtMA_11f67612-f352-4c3c-ac12-75c6ededd98e"
      unitRef="usd">785000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTEtMS0xLTA_c4087f50-560b-4b73-a722-8d8d5394f928"
      unitRef="usd">1122000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02d0ea546af24a87a6255e69c9be826a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTMtMS0xLTA_dd08fe9d-8c0b-4dfe-82c0-59a58fca27a4"
      unitRef="usd">1124000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdba0b24408b477dbd1da28288ef0b28_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTUtMS0xLTA_dc12d7fd-ff91-4a66-bf8f-41a6cfd16efe"
      unitRef="usd">2411000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e1ada048a5848499745516122810eab_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTctMS0xLTA_6f12b11c-6aaa-418f-a213-fe13dd0dd006"
      unitRef="usd">3535000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc62432f3542449c81953affd9de22e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMTktMS0xLTA_ab03b656-d254-4d91-be7c-d71cdf9b901b"
      unitRef="usd">966000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0bdebf9d8834484a80089286c5c652a8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMjEtMS0xLTA_362546a6-5fba-4c4d-bff5-982943640493"
      unitRef="usd">2305000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTUtMjMtMS0xLTA_967e4665-d405-4fa0-a14a-7fd15f2c63b1"
      unitRef="usd">3271000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice0e6a497660484fb717730ec1682382_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMS0xLTEtMA_5a0aaad9-4a39-486d-8492-b531974bdbea"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6047455c7c64d9f874b87a52288b80e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMy0xLTEtMA_7bd9256a-4708-483b-bb03-5651af3a0a30"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtNS0xLTEtMA_9e679b60-3955-4be3-95c0-2126515e2bb9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dbedce779e14d0aa2f39e6a7b145b9d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtNy0xLTEtMA_49fbc453-8bfb-4641-bfde-1e93752de38e"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i898e69e9e3184245a88cddf0a47d6dc5_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtOS0xLTEtMA_ef836a6a-162a-4603-adf9-688688da0158"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTEtMS0xLTA_2923eb81-52bf-445d-9001-fc55e8ac15ce"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic000af4b0c4c4a2fadd5664d561dafbe_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTMtMS0xLTA_975eb257-58fc-4c88-a457-d258ac10e4f6"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia09c33cccd764e8993469adf4635a214_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTUtMS0xLTA_453d6b31-419a-4589-bacd-dce470b2a87b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTctMS0xLTA_a0c88cf6-d262-4af3-a9d9-5c673e48cc38"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2365ecc7f5a942f28ba80cc309ae1981_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMTktMS0xLTA_8595d113-74ee-4e50-abf9-b03baccc5c43"
      unitRef="usd">133000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id893aa0127934f2d91eecbde06753def_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMjEtMS0xLTA_4a58c8a0-5f50-4cdb-b076-71a57c6ca263"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTYtMjMtMS0xLTA_cc400680-b4a4-4ab6-ba64-457619465843"
      unitRef="usd">133000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8e15c24b2824478a886c6474a727dd9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMS0xLTEtMA_d1298c8a-ac65-4fbe-8875-a255d043b225"
      unitRef="usd">5616000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2268e80ec95d4d869afeccbe9a5d42b5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMy0xLTEtMA_2e66778b-78bc-4780-8522-8d422729b703"
      unitRef="usd">6924000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctNS0xLTEtMA_0e1d1727-fdca-494e-93f5-9745dc0847fe"
      unitRef="usd">12540000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8a5dbad6f9e4534bd2dae1d741c29b0_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctNy0xLTEtMA_7ebf606b-f8c8-4899-b2c6-4f470ea0c771"
      unitRef="usd">5563000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c2d0f03f76040508bfb37e1f86e3a44_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctOS0xLTEtMA_7a1692b9-7460-49d6-8d9f-9b62d9fa579e"
      unitRef="usd">6699000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTEtMS0xLTA_fed8fa7a-3eff-4b29-8267-4d3c26f44608"
      unitRef="usd">12263000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5d1cf04d3654121bb1372860aad23cd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTMtMS0xLTA_8b60a443-f9b1-47ec-b1ff-87f3324f9212"
      unitRef="usd">15349000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71294026dc2b41a6b110370ac311ccef_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTUtMS0xLTA_c5abe353-0b07-44a2-8acb-3d45b8a0a82b"
      unitRef="usd">19863000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTctMS0xLTA_b7a551b4-c4a1-4f5b-857b-102a5222399b"
      unitRef="usd">35212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf593e2d5525476f9946cba41a11778a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMTktMS0xLTA_e7a9a495-b631-4aa4-b8b0-93bbd5b9d4dc"
      unitRef="usd">15301000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8dc8d4c2f684a0daf26c38edd0fc54e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMjEtMS0xLTA_30a986bb-b544-4c94-a3c4-c6b35fd34875"
      unitRef="usd">19322000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTctMjMtMS0xLTA_9b1f16c0-4b5f-4650-a1fa-07c5c8575a65"
      unitRef="usd">34622000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie753576e2fbc401991ed4e99717613ba_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMS0xLTEtMA_97511fa0-5848-42d0-a375-b64a6c79624c"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide9e8a73d73d4f3a9142b2330c6f27fe_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMy0xLTEtMA_6aa777cb-34c7-4030-ba4a-8fcfa212263d"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtNS0xLTEtMA_dbe01c1d-6342-4d17-bd6f-da46cea8f062"
      unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e4500010fb54d02ae13949698b9b8c4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtNy0xLTEtMA_3a15beca-6b8e-4827-b0e8-61b345134ce9"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70a40509dbf045e4ada553d6fac4e6eb_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtOS0xLTEtMA_e115a268-0fca-48ba-950a-e28d8dfdd7c1"
      unitRef="usd">125000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTEtMS0xLTA_c2de48e4-ef94-4c94-8c8b-6a603d5b425d"
      unitRef="usd">134000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i581246c6bfe2404db7120fbc4f4dee00_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTMtMS0xLTA_0ad8aebc-de46-422f-b8d5-50dadf1585f5"
      unitRef="usd">47000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89fb5894e97f4df3bc23850e83b77053_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTUtMS0xLTA_6bf5326a-9b73-43ae-ac87-3510fa2b5d9f"
      unitRef="usd">221000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia1463025af91424094e317c427bd8c0a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTctMS0xLTA_0bb873d9-d654-4aeb-bf4d-deaf697f801e"
      unitRef="usd">267000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0766d9bdbbc4e00bec07a37b42563bb_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMTktMS0xLTA_062a40bb-dbc4-4d50-9d17-539ed9618d5f"
      unitRef="usd">19000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6eae77f55e94cc2b2c83b0c7dc60c51_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMjEtMS0xLTA_1f499fe8-137c-4ba3-91f5-91d9e726d956"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTgtMjMtMS0xLTA_d28ad760-6981-4a19-bc8f-0b41ccd5e583"
      unitRef="usd">350000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMS0xLTEtMA_2c1d50ba-0e19-41ae-a1ba-85b98f88b206"
      unitRef="usd">5625000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4c2c4a4b7be4001b1d581d890f1c1bc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMy0xLTEtMA_ff4d3c8e-1862-487b-ac65-5bb7150558ec"
      unitRef="usd">6926000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktNS0xLTEtMA_e256ac33-007e-4e6b-a857-b514118a34f8"
      unitRef="usd">12551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3be56294e35345518657c9cb1c795a55_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktNy0xLTEtMA_cdea033a-4be9-46ad-bb8a-5624033ad6a6"
      unitRef="usd">5573000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5373290982d4d9790e6f6de2c301cb7_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktOS0xLTEtMA_1a02cf8a-21ac-4e2b-aa70-c8a3d4bf4f31"
      unitRef="usd">6824000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTEtMS0xLTA_b411f332-1170-415c-82fa-120a17ef48ec"
      unitRef="usd">12397000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTMtMS0xLTA_b4b1ce2c-fe11-438c-8fd5-57e22440b982"
      unitRef="usd">15396000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bd74fd1d348488a9909e5be2e21240e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTUtMS0xLTA_8dd88ea1-2a60-41ad-a7cf-b0eb7f4345dc"
      unitRef="usd">20084000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTctMS0xLTA_69656a90-cab1-4972-aa02-f10324f0570e"
      unitRef="usd">35479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMTktMS0xLTA_0afb6dd5-6b68-478a-bfeb-24024b67f401"
      unitRef="usd">15320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5968a3319d5e411c8e90433cc1e6dfee_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMjEtMS0xLTA_11e436b8-57dc-4971-a6c7-eb124f0a695d"
      unitRef="usd">19652000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjZmMTA5NmFkMzFiOTRlZDhhYjYwM2E5YmIzMDkwNGViL3RhYmxlcmFuZ2U6NmYxMDk2YWQzMWI5NGVkOGFiNjAzYTliYjMwOTA0ZWJfNTktMjMtMS0xLTA_18c1827f-098d-4041-ac09-67d49689162e"
      unitRef="usd">34972000000</us-gaap:Revenues>
    <mrk:SalesDiscounts
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzgyNQ_2acf2114-2be0-40ca-8919-fb275c9268d2"
      unitRef="usd">3400000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzgzMg_e8b0f0a2-256d-46a2-8ee0-8155d2cec8d1"
      unitRef="usd">3000000000.0</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzg5MQ_b1c73561-2ab2-43ca-904c-46c09b952665"
      unitRef="usd">9600000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfMzg5OA_4d5396de-f969-44e6-a117-72844ac3459c"
      unitRef="usd">8600000000</mrk:SalesDiscounts>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTc5OQ_b48886fd-b372-4642-a029-92b0810b1514">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="ic3249e565f8146e295bf627762e9b6a7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi0xLTEtMS0w_50ddb4c3-7725-4664-9e0f-9d0e200eaa8d"
      unitRef="usd">5625000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3be56294e35345518657c9cb1c795a55_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi0zLTEtMS0w_3a51cb8b-22cc-49da-9bba-36e1c06e4e52"
      unitRef="usd">5573000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2fcc19311094419683902e2fdc6ab4eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi01LTEtMS0w_7662f4bb-91da-47cf-9acb-f8884325da71"
      unitRef="usd">15396000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ad58e34200949eebcaa0b51b8a6a5a1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMi03LTEtMS0w_893362a7-de20-4f62-9626-cb8113df0660"
      unitRef="usd">15320000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy0xLTEtMS0w_47be21be-0fff-43de-b188-9235388d5601"
      unitRef="usd">3454000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba8a8038d02e4f88a246aa02f656695a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy0zLTEtMS0w_63a7b747-ac2f-470f-b946-653f9247d9eb"
      unitRef="usd">3189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13f058de6b2243f9becd32481d9afbbe_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy01LTEtMS0w_dcc2c4e3-789f-42ec-8509-ee8540201d10"
      unitRef="usd">10059000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia932a81be775481f98c6d46c74fc889e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfMy03LTEtMS0w_6cbc687d-86fd-49aa-b3d0-599595112432"
      unitRef="usd">9452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0fb50c2f22f44b9c87ff52bc490d1857_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC0xLTEtMS0w_a0903f7f-51a3-484d-a0d2-bccb11980cbe"
      unitRef="usd">1016000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id85051d25a924f2190907c50f47325ec_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC0zLTEtMS0w_5deaf5b2-9a13-4c67-8539-59de0ed3085b"
      unitRef="usd">914000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i313cf220e7c04c1a8ad44c9b6fdcbed0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC01LTEtMS0w_c3630dae-09c7-4613-8925-02655f42dd9a"
      unitRef="usd">2715000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82a2befecfbb4aa5bc67a5cf1e38775f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNC03LTEtMS0w_0165e1b2-b616-4070-82ed-638d3f6fef2c"
      unitRef="usd">2423000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b97ea09a131441e902cb9300382361f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS0xLTEtMS0w_8dbc33c1-8cf1-408c-a108-53c5cfcad278"
      unitRef="usd">828000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d79fe35117f4651b248b578edc99dce_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS0zLTEtMS0w_44d5d855-7084-4099-a715-8c9812ec7b96"
      unitRef="usd">919000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd022943eb58411bbd1ed2c225198ac6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS01LTEtMS0w_6f7f9c3e-8fb8-4eec-9a07-ccbb5e656f62"
      unitRef="usd">2506000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36c4d3fc287a432a9fd94239cf8da2e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNS03LTEtMS0w_b1d8c1d4-8fb5-4dc1-80b4-c630d14a8eb6"
      unitRef="usd">2639000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a1349039c214a1ab7b78b435fbbdb71_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi0xLTEtMS0w_c074d8fb-ed9c-4f25-81c1-43743995f953"
      unitRef="usd">735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a68094581a24c318a5e928a8ef2586d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi0zLTEtMS0w_d352dd64-d7c0-4f80-9750-31218a8b8b0a"
      unitRef="usd">756000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc9d51c6c5d64a0ba83ede5553c4da40_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi01LTEtMS0w_13130b25-b079-4e12-84ed-0d4440120547"
      unitRef="usd">2129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a6360f4861f46ebbb62566ea24fd0ea_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNi03LTEtMS0w_d32477a4-916e-421d-8394-8b2d6f7c05d9"
      unitRef="usd">2217000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i100e2f176d6e43288c7996c8bb790ee0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy0xLTEtMS0w_264f38ed-3344-42d0-94e2-4ee0131cae03"
      unitRef="usd">604000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7dcfda74e184dd19aa1034852473ac0_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy0zLTEtMS0w_92b54815-91ce-4e2f-83eb-cc5d763403ba"
      unitRef="usd">671000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71cc45c9f8b14d8195ccd2d6963f6085_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy01LTEtMS0w_f7ee51ef-c832-4dad-a4ab-294b3d9edc3f"
      unitRef="usd">1670000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b1d1ba55c914a7b8e44658d9480b9dd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfNy03LTEtMS0w_ba007942-db46-4fb2-afbd-3ce02ec9e06f"
      unitRef="usd">1889000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eee42c966664f4e9a6f8dda9caa4b70_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC0xLTEtMS0w_dad31403-3d63-4a35-aab4-8b6fa2456ea7"
      unitRef="usd">289000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c9af3f42bbe446f8bc0971d7ea5b622_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC0zLTEtMS0w_94eb4c17-1d46-4fb0-afad-d05b277d80ef"
      unitRef="usd">375000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3c2156786fb46cfa1e5ff1a41f7d595_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC01LTEtMS0w_66226a1d-fd1d-4c76-b598-ff168cfeb604"
      unitRef="usd">1004000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2a87acce6704921ba325076af735562_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOC03LTEtMS0w_0bcccb1e-d170-4a5d-ad53-e9561a526949"
      unitRef="usd">1032000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS0xLTEtMS0w_fcd771bf-69ac-4b0b-b070-152022500711"
      unitRef="usd">12551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS0zLTEtMS0w_d3f93934-1c3a-4551-8a6d-68bc2a15114a"
      unitRef="usd">12397000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS01LTEtMS0w_13a3fe6a-ad6a-41e5-a534-57fc43a61620"
      unitRef="usd">35479000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOjNjYzE2OWU1NTZmYjRjNzFiYWIxMTZlZWVkYjZjM2M1L3RhYmxlcmFuZ2U6M2NjMTY5ZTU1NmZiNGM3MWJhYjExNmVlZWRiNmMzYzVfOS03LTEtMS0w_7cdc3bc6-46e8-4015-a8e0-3943db2772e0"
      unitRef="usd">34972000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RleHRyZWdpb246OGQ5MDRhMjczYjI1NGJjYTgyM2QwYjk2ZDQ5ZmE5ZTdfNTgzMA_34593baa-178f-42c6-be67-1137c285448f">&lt;div style="margin-top:6pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income before taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,019)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i185cad50705847e8b9e1971bcb61017e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy0xLTEtMS0w_ca77c87f-7cf3-4164-a5ae-8c90d4c81b34"
      unitRef="usd">7974000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9728acb79d00420087a90f15524df617_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy0zLTEtMS0w_a635d160-98eb-4e55-94fb-d7241ab8ad7f"
      unitRef="usd">7747000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib4acef4a63c04e71a545353b01fbbc08_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy01LTEtMS0w_929b375f-ea7a-45a7-891a-042c6be43865"
      unitRef="usd">22010000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7d37acd07bca472cb57b945b07fef138_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMy03LTEtMS0w_8390832b-30b5-4337-942c-b9529b1e3b93"
      unitRef="usd">21437000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2f8cf3da09c4453ea4107a0c5bafd87e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC0xLTEtMS0w_3db362f7-03f9-4978-bee6-debd9b8a50e3"
      unitRef="usd">451000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia60f76f1769e4763bc070a7efd4ec3ba_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC0zLTEtMS0w_9be7379d-770e-4ef9-9069-e95f3144d1ee"
      unitRef="usd">423000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e1ada048a5848499745516122810eab_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC01LTEtMS0w_7b9019c8-f1e0-4a76-a6dd-8779272764e2"
      unitRef="usd">1336000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6b52afc787e546b79758571a6aa745a6_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNC03LTEtMS0w_d51d494e-3ecc-4e79-b3ad-1f803713d467"
      unitRef="usd">1243000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifaa7fbbd692f408e87393cd6f6adfee7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS0xLTEtMS0w_725dbead-9fa7-4eeb-9f7f-b0fe54adcbb0"
      unitRef="usd">-1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i956912e7586c4ed49fdb3beca134e958_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS0zLTEtMS0w_596b4d35-ec9b-41d1-97ee-8ee6a7a86caf"
      unitRef="usd">-2000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i785787ef749e4fcfa7eac5a0fde86629_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS01LTEtMS0w_6e555a35-b3dd-45ae-8749-21041904b880"
      unitRef="usd">1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i30e198a34f2d4a13a9dec267e10d6239_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNS03LTEtMS0w_323e6177-175a-40b7-9e41-fb31b4cd27b3"
      unitRef="usd">-2000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi0xLTEtMS0w_c719a1c8-9bf2-4fe7-b254-a53f0e248ffb"
      unitRef="usd">8424000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5591f31f0c034a3981aca1b9a6884bb6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi0zLTEtMS0w_804d86de-183a-40ca-b5df-6a29c63786a9"
      unitRef="usd">8168000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i567c0c7f605d44b583ba9fd891f72f32_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi01LTEtMS0w_a24fb292-6ca5-435f-af1a-143c590b8e46"
      unitRef="usd">23347000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i418d260ca16e4727b6be3eaa93850c02_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNi03LTEtMS0w_c9d57c0e-dce4-48ac-9008-e116ef6ed371"
      unitRef="usd">22678000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ife4e3c21fa0e4cd6bd81462659b1371c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy0xLTEtMS0w_d87de558-4f6f-4698-a37b-b15e674dd5f5"
      unitRef="usd">-12000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i036cb7c7a55f45d4a0e39fc329ef0520_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy0zLTEtMS0w_663bbe2c-940a-4309-816f-0338abbcde12"
      unitRef="usd">101000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia1463025af91424094e317c427bd8c0a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy01LTEtMS0w_c33ab30e-0579-4797-a5c5-c40e98ee7356"
      unitRef="usd">188000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i479ab52090fc4f0db7ba8ea3afdf4562_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfNy03LTEtMS0w_c7a8700b-6cf6-4604-825c-3764fbe49ad0"
      unitRef="usd">226000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS0xLTEtMS0w_d25fbec6-1d7d-45ef-adec-182a69f6a712"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS0zLTEtMS0w_46c79e96-6520-4f8d-80ee-7f981700f493"
      unitRef="usd">61000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS01LTEtMS0w_30ddcbae-33ea-4a20-b1eb-09e58b6bfc70"
      unitRef="usd">48000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfOS03LTEtMS0w_beace086-41b5-4b86-9ac1-a6748ad4c353"
      unitRef="usd">225000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtMS0xLTEtMA_1f4a8601-2f32-4e5f-a91e-b4ecd17e9be4"
      unitRef="usd">203000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtMy0xLTEtMA_8c20571b-c2b8-4d43-9916-59b2aef8da81"
      unitRef="usd">231000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtNS0xLTEtMA_17675f14-2dd1-466c-9f1e-0f5e3c217d7f"
      unitRef="usd">624000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTAtNy0xLTEtMA_09a8f69a-c975-4f3c-bc5d-1b56cad0d108"
      unitRef="usd">674000000</us-gaap:InterestExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtMS0xLTEtMA_5e06c582-ef5b-4cfc-b4b9-21be813e0916"
      unitRef="usd">395000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtMy0xLTEtMA_5394fcf8-c41a-4460-9856-6a413b6939e8"
      unitRef="usd">382000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtNS0xLTEtMA_6faed7d9-505a-457d-b162-1a4f528823a6"
      unitRef="usd">1173000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTEtNy0xLTEtMA_c65b9702-9d81-4c09-891e-23734c0e5c63"
      unitRef="usd">1169000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItMS0xLTEtMA_e8c2a129-e0f8-4d66-9b77-bd0676d21f87"
      unitRef="usd">3272000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItMy0xLTEtMA_0640ffb3-9361-49ee-8f77-3e09b1e951a2"
      unitRef="usd">3110000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItNS0xLTEtMA_65e64747-9ab7-4cbf-8680-d4d6c5908b86"
      unitRef="usd">7364000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTItNy0xLTEtMA_d4b091bb-9441-44a2-b9ff-2ec98042df5e"
      unitRef="usd">7045000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtMS0xLTEtMA_4217f026-b7f9-4d5a-99ce-e62406dbe60c"
      unitRef="usd">285000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtMy0xLTEtMA_73378f90-e6d1-4211-a897-a1961400c74f"
      unitRef="usd">329000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtNS0xLTEtMA_10ee3f89-52b3-4558-8e55-1a9d8317ac1e"
      unitRef="usd">879000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <mrk:AmortizationOfPurchaseAccountingAdjustments
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTMtNy0xLTEtMA_316697c1-b412-48b6-92bb-650070d6a735"
      unitRef="usd">1105000000</mrk:AmortizationOfPurchaseAccountingAdjustments>
    <us-gaap:RestructuringCharges
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtMS0xLTEtMA_7d0d4f6d-e3c0-4086-a79c-e91733c9f586"
      unitRef="usd">114000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtMy0xLTEtMA_8b0458ec-891a-42cf-9bf8-4f455d031a74"
      unitRef="usd">232000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtNS0xLTEtMA_731b1983-6301-4ff1-9184-bf7daadc7442"
      unitRef="usd">269000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTQtNy0xLTEtMA_db40f91b-909f-4845-800b-b4acafa459c8"
      unitRef="usd">444000000</us-gaap:RestructuringCharges>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="id0905c1cad7b4a69b8364dd576094923_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtMS0xLTEtMA_496c8bb3-4c3e-481d-83e2-e42a4879aed2"
      unitRef="usd">724000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="ic2d215e879d04ba9b3ae8ec180128e5e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtMy0xLTEtMA_60bb5b69-73b7-49ab-b644-8e21e1a8f671"
      unitRef="usd">1699000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i3f5ea4ae54334bb6bff42b3fe7f6fd84_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtNS0xLTEtMA_fb7903c2-4508-45bd-a6dd-de4f33aa0f5d"
      unitRef="usd">2490000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i96580d74a79a47a099c051438f4b7638_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTUtNy0xLTEtMA_ad7b1ffa-d1f0-455f-917d-3c9f76f754c6"
      unitRef="usd">4019000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i486b34b93c1f43e096e999364d31b9be_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtMS0xLTEtMA_e8252f5f-d25c-4db8-a97f-11dfac09a853"
      unitRef="usd">3428000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtMy0xLTEtMA_15e9e88b-54c6-414b-801f-4968fffb1b15"
      unitRef="usd">2347000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtNS0xLTEtMA_fd7f1c3a-7707-4621-88d9-fc4443a56c79"
      unitRef="usd">10784000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i292122eb0cf1481faf64382d4c6d2164_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY3ZWY0ZTI5ZGIzNjQzMjc4MDBlNDJhOTRlNDM0OTZhL3NlYzo2N2VmNGUyOWRiMzY0MzI3ODAwZTQyYTk0ZTQzNDk2YV85MS9mcmFnOjhkOTA0YTI3M2IyNTRiY2E4MjNkMGI5NmQ0OWZhOWU3L3RhYmxlOmUxNGQzMWU3ZmZiNzQ4NDBhM2QxZjFkZDViZGMwMzE0L3RhYmxlcmFuZ2U6ZTE0ZDMxZTdmZmI3NDg0MGEzZDFmMWRkNWJkYzAzMTRfMTYtNy0xLTEtMA_1edac6c3-fdd9-4822-be3d-e8dbb2583dbb"
      unitRef="usd">8673000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848840328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Galloping Hill Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Kenilworth<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,530,034,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">&#160;&#160; Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.125Notesdue2021Member', window );">1.125% Notes due 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.125Notesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.125Notesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156859647480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 12,551<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
<td class="nump">$ 34,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">10,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">7,383<span></span>
</td>
<td class="nump">7,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">7,721<span></span>
</td>
<td class="nump">7,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(312)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(630)<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total Costs, Expenses and Other</a></td>
<td class="nump">9,123<span></span>
</td>
<td class="nump">10,050<span></span>
</td>
<td class="nump">24,695<span></span>
</td>
<td class="nump">26,299<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
<td class="nump">10,784<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">2,945<span></span>
</td>
<td class="nump">1,907<span></span>
</td>
<td class="nump">9,173<span></span>
</td>
<td class="nump">7,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net Income (Loss) Attributable to Noncontrolling Interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,941<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 9,161<span></span>
</td>
<td class="nump">$ 7,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings per Common Share Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Common Share Assuming Dilution Attributable to Merck&#160;&amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936180232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,941<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 9,161<span></span>
</td>
<td class="nump">$ 7,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive Income (Loss) Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net unrealized (loss) gain on derivatives, net of reclassifications</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net unrealized (loss) gain on investments, net of reclassifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Benefit plan net gain and prior service credit, net of amortization</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="nump">85<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,951<span></span>
</td>
<td class="nump">$ 1,873<span></span>
</td>
<td class="nump">$ 8,971<span></span>
</td>
<td class="nump">$ 7,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156859902440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,356<span></span>
</td>
<td class="nump">$ 9,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="nump">6,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note&#160;6)</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">4,671<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">26,577<span></span>
</td>
<td class="nump">27,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019</a></td>
<td class="nump">16,919<span></span>
</td>
<td class="nump">15,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">20,248<span></span>
</td>
<td class="nump">19,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">16,677<span></span>
</td>
<td class="nump">14,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">8,007<span></span>
</td>
<td class="nump">6,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">89,800<span></span>
</td>
<td class="nump">84,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">3,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">3,744<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">11,690<span></span>
</td>
<td class="nump">12,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="nump">22,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">26,321<span></span>
</td>
<td class="nump">22,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">12,027<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">39,489<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">51,107<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,383)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">86,001<span></span>
</td>
<td class="nump">81,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019</a></td>
<td class="nump">56,815<span></span>
</td>
<td class="nump">55,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">29,186<span></span>
</td>
<td class="nump">25,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">29,270<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity</a></td>
<td class="nump">$ 89,800<span></span>
</td>
<td class="nump">$ 84,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936965320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 18,572<span></span>
</td>
<td class="nump">$ 17,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">1,047,343,390<span></span>
</td>
<td class="nump">1,038,087,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936175896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 9,173<span></span>
</td>
<td class="nump">$ 7,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,721<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible asset impairment charges</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Charge for acquisition of Peloton Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(445)<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net changes in assets and liabilities</a></td>
<td class="num">(5,638)<span></span>
</td>
<td class="num">(3,469)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">6,247<span></span>
</td>
<td class="nump">8,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(3,170)<span></span>
</td>
<td class="num">(2,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">7,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of ArQule, Inc., net of cash acquired</a></td>
<td class="num">(2,545)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired', window );">Acquisition of Antelliq Corporation, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired', window );">Acquisition of Peloton Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Other acquisitions, net of cash acquired</a></td>
<td class="num">(907)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(4,665)<span></span>
</td>
<td class="num">(1,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="num">(311)<span></span>
</td>
<td class="num">(3,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(1,954)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">4,419<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(3,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(4,673)<span></span>
</td>
<td class="num">(4,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="num">(4,204)<span></span>
</td>
<td class="num">(6,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">89<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(2,533)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)</a></td>
<td class="nump">9,934<span></span>
</td>
<td class="nump">7,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)</a></td>
<td class="nump">$ 7,401<span></span>
</td>
<td class="nump">$ 7,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Business Four, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844985608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844226808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;26, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women&#8217;s Health, Biosimilars and Established Brands into New Company </span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women&#8217;s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ezetimibe and simvastatin), as well as the rest of Merck&#8217;s diversified brands franchise. Merck&#8217;s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women&#8217;s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843119432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Research Collaborations and License Agreements</a></td>
<td class="text">Acquisitions, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75&#160;billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio&#8217;s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase&#160;1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen&#8217;s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600&#160;million and a $1.0&#160;billion equity investment in 5&#160;million shares of Seagen common stock at a price of $200 per share. Merck recorded $622&#160;million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22&#160;million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $6&#160;million reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6&#160;billion, including $850&#160;million in development milestones and $1.75&#160;billion in sales milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210&#160;million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65&#160;million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck&#8217;s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for &#8364;256&#160;million ($302&#160;million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289&#160;million and other net assets of $13&#160;million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401&#160;million related to currently marketed products and inventory of $9&#160;million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments of up to $740 million, including up to $80 million for development milestones, up to $260 million for regulatory approval milestones, and up to $400 million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase&#160;1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&amp;D) of $136 million, cash of $59 million, deferred tax assets of $71 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $229 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties&#8217; commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck&#8217;s approved Ebola Zaire virus vaccine, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ervebo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments of up to $100 million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2020. ArQule&#8217;s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2&#945; (HIF-2&#945;) for the treatment of patients with cancer and other non-oncology diseases. Peloton&#8217;s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2&#945; inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50&#160;million upon U.S. regulatory approval, $50&#160;million upon first commercial sale in the United States, and up to $1.05&#160;billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $64 million, and other net liabilities of $6 million at the acquisition date and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $982 million in the third quarter and first nine months of 2019 related to the transaction.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq&#8217;s debt. The transaction was accounted for as an acquisition of a business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approaches to enable the body&#8217;s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 </span></div>million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, divestitures, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844257544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase&#160;(PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca&#8217;s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $400 million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million&#160;and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $135 million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $370 million from Merck to Eisai. Accordingly, Merck recorded a $370 million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million. Of these amounts, $50 million&#160;was paid to Eisai in 2019 and an additional $500 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer&#8217;s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck&#8217;s share of profits from the sale of Adempas in Bayer&#8217;s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, Merck accrued&#160;$725 million&#160;of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that&#160;has not yet been accrued as it is not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $838 million at September&#160;30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156946834888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck&#160;approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;This program is a continuation of the Company&#8217;s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September&#160;30, 2020, Merck has recorded total pretax accumulated costs of approximately $1.4 billion. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936861896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary&#8217;s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020,&#160;five&#160;interest rate swaps with notional amounts of&#160;$250 million&#160;each matured. These swaps effectively converted the Company&#8217;s&#160;$1.25 billion,&#160;1.85%&#160;fixed-rate notes due 2020 to variable rate debt.&#160;At September&#160;30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:17.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company estimates $155 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net (gains) losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020 and September&#160;30, 2019, the Company also had $508 million and $393 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $21 million and unrealized losses of $3 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these equity investments held at September&#160;30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $4 million and unrealized losses of $12 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to these investments held at September&#160;30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September&#160;30, 2020 were $128 million and $24 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:20.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily all of the asset-backed securities were highly rated (Standard&#160;&amp; Poor&#8217;s rating of AAA and Moody&#8217;s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $6.6 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at September&#160;30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At September&#160;30, 2020 and December&#160;31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September&#160;30, 2020, was $32.6 billion compared with a carrying value of $28.7 billion and at December&#160;31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the United&#160;States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $34 million at December&#160;31, 2019. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No cash collateral was advanced by the Company to counterparties as of September&#160;30, 2020 or December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843042632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September&#160;30, 2020 and December&#160;31, 2019, these amounts included $1.8 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $288 million and $168 million at September&#160;30, 2020 and December&#160;31, 2019, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843133688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangibles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Other Intangibles</a></td>
<td class="text"><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Other Intangibles</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter and first nine months of 2019, the Company recorded $612 million and $693 million, respectively, of intangible asset impairment charges related to marketed products within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the third quarter of 2019, the Company recorded an impairment charge of $612&#160;million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843034264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term DebtIn June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156845017176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Litigation). As of September&#160;30, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck&#8217;s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck&#8217;s motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff&#8217;s failure to warn claim was preempted by federal law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court&#8217;s preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court&#8217;s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court&#8217;s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs&#8217; state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, as of September&#160;30, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, approximately 2,340 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are four Femur Fracture cases pending in other state courts.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of September&#160;30, 2020, Merck is aware of approximately 1,465 product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the MDL and California State Court&#8211;in separate opinions&#8211;granted summary judgment to defendants on grounds of federal preemption.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motions. Under the stipulated case management schedule, the hearings for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and summary judgment motions took place on October 20, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck&#8217;s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company&#8217;s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Antitrust Litigation</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants&#8217; motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants&#8217; motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants&#8217; motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants&#8217; motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers&#8217; motion for class certification and certify a class of 35 direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants&#8217; motion for permission to appeal the district court&#8217;s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants.  The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.  All New Jersey actions against all defendants have been consolidated.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company&#8217;s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with five generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, three additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy&#8217;s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan&#8217;s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> could lose market exclusivity in Germany as early as July 2022. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SPC have also occurred in Portugal and Finland, and could occur in other European countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September&#160;30, 2020 and December&#160;31, 2019 of approximately $255 million and $240 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844247960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,373&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,724&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,850)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,602&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,950)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.83 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843035096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation Plans</a></td>
<td class="text">Share-Based Compensation Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the Company granted 7 million RSUs with a weighted-average grant date fair value of $77.83 per RSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted 5 million&#160;RSUs with a weighted-average grant date fair value of $80.03 per RSU. During the first nine months of 2020, the Company granted 773 thousand PSUs with a weighted-average grant date fair value of $75.22 per PSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted 609 thousand&#160;PSUs with a weighted-average grant date fair value of $90.50 per PSU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $800 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844382456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text">Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that in 2020 it will contribute approximately&#160;$200 million&#160;and $375&#160;million to its U.S. and international pension plans, respectively, of which&#160;$184 million&#160;and $123&#160;million, respectively, was contributed in the first nine months of the year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 13), with the exception of certain amounts for termination benefits, curtailments and </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843091192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text">Other (Income) Expense, Net<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first nine months of 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September&#160;30, 2020 and 2019 was $605 million and $629 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156979934344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on Income<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9%  and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck&#8217;s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company&#8217;s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843025656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div>For the third quarter of 2020 and 2019, 5 million and 3 million, respectively, and for the first nine months of 2020 and 2019, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843045112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,162)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843025096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,320&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.4 billion and $3.0 billion for the three months ended September&#160;30, 2020 and 2019, respectively, and $9.6 billion and $8.6 billion for the nine months ended September&#160;30, 2020 and 2019, respectively. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156860074264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;26, 2020.The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company&#8217;s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company&#8217;s collaborative arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&#160;The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy</a></td>
<td class="text">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156842829096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Fair Value of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156842838712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843086408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844806232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Summary of Interest Rate Swaps Held</a></td>
<td class="text">At September&#160;30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Amounts Recorded on Balance Sheet Related to Fair Value Hedges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Amount of Pretax (Gains) Losses of Derivatives</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:17.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net (gains) losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September&#160;30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:20.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily all of the asset-backed securities were highly rated (Standard&#160;&amp; Poor&#8217;s rating of AAA and Moody&#8217;s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Information About the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at September&#160;30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At September&#160;30, 2020 and December&#160;31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844290040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844508424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Equity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,373&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,724&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,850)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,744&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January&#160;1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,602&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,950)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,001&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.83 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844528552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Weighted-Average Fair Value of Options Granted</a></td>
<td class="text">During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844355592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net cost of defined benefit plans</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net cost of defined benefit plans</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156864186024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844536424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156842831064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,162)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156842831064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales of Company's products</a></td>
<td class="text"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,320&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div>(5)&#160;&#160;&#160;&#160;Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated revenues by geographic area</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,972&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of segment profits to income before taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156845413864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)<br> $ / shares in Units, shares in Thousands, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829.0<span></span>
</td>
<td class="nump">$ 755.0<span></span>
</td>
<td class="nump">$ 829.0<span></span>
</td>
<td class="nump">$ 755.0<span></span>
</td>
<td class="nump">$ 767.0<span></span>
</td>
<td class="nump">$ 788.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,248.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,248.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,248.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,425.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,390.0<span></span>
</td>
<td class="nump">3,204.0<span></span>
</td>
<td class="nump">7,721.0<span></span>
</td>
<td class="nump">7,324.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,978.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,170.0<span></span>
</td>
<td class="nump">2,336.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Research and development | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SentinelMember', window );">Sentinel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember', window );">Dunboyne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to Acquire Productive Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302.0<span></span>
</td>
<td class="nump">&#8364; 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember', window );">Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="nump">$ 2,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="nump">2,280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed', window );">Share-based compensation payments attributable to precombination service</a></td>
<td class="nump">138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">145.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">540.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="nump">389.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember', window );">Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Debt assumed and paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,689.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember', window );">Immune Design</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember', window );">VelosBio [Member] | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember', window );">Development Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember', window );">Sales-Based Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Themis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember', window );">Regulatory Milestones | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialMilestoneMember', window );">Commercial Milestone | Peloton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares', window );">Forward contract, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Tukysa | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SeagenMember', window );">Seagen | Regulatory Milestones | Tukysa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_IAVIMember', window );">IAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology Rights | Sentinel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments made to partner as part of collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of issuer's shares to which the forward contract is indexed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120519210&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_DunboyneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ThemisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_PelotonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ImmuneDesignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_VelosBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_TukysaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_TukysaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_IAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_IAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156847882680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SentinelMember', window );">Sentinel | Technology Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life of acquired finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AntelliqMember', window );">Antelliq | Technology Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life of acquired finite-lived intangible assets</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AntelliqMember', window );">Antelliq | Technology Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life of acquired finite-lived intangible assets</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember', window );">ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember', window );">Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Consideration transferred</a></td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | ArQule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Antelliq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisitions Research Collaborations And License Agreements Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_IntangibleAssetMeasurementInput', window );">Present value discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SentinelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SentinelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_ArQuleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mrk_AntelliqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156849211832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1">29 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="nump">$ 7,721<span></span>
</td>
<td class="nump">$ 7,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,970<span></span>
</td>
<td class="nump">$ 11,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Sales-Based Milestones | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Regulatory Milestones | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement', window );">License option payment related to collaborative arrangement</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Sales-Based Milestones | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Regulatory Milestones | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ContingentPaymentsCollaborativeArrangement', window );">Contingent milestone payments collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_Licenseoptionpaymentrelatedtocollaborativearrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License option payment related to collaborative arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_Licenseoptionpaymentrelatedtocollaborativearrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProbableContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probable Contingent Payments Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProbableContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments made to partner as part of collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156849029304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Schedule of Transactions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 12,551<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
<td class="nump">$ 34,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">10,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">7,383<span></span>
</td>
<td class="nump">7,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">3,204<span></span>
</td>
<td class="nump">7,721<span></span>
</td>
<td class="nump">7,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables, current</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts payable and accrued liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables, current</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables, Noncurrent</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts payable and accrued liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables, current</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables, Noncurrent</a></td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables, Noncurrent</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Collaborative Arrangement, Sales, Net</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156851997352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative costs since program inception</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Estimate of cumulative pre tax costs that will result in cash outlays</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Estimate of cumulative pre tax costs that will be noncash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 504<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848878280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 504<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156849018984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expense</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RestructuringReserveNoncashActivity', window );">Non-cash activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848928568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">$ 508,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000,000<span></span>
</td>
<td class="nump">$ 393,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains recognized on investments in equity securities without readily determinable fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized losses recognized on investments in equity securities without readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized gains on investments</a></td>
<td class="nump">128,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized losses on investments</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">32,600,000,000<span></span>
</td>
<td class="nump">$ 28,800,000,000<span></span>
</td>
<td class="nump">32,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, carrying amount</a></td>
<td class="nump">28,700,000,000<span></span>
</td>
<td class="nump">26,300,000,000<span></span>
</td>
<td class="nump">28,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Accounts Receivable, Sale</a></td>
<td class="nump">2,100,000,000<span></span>
</td>
<td class="nump">2,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral advanced to counterparties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">27,151,000,000<span></span>
</td>
<td class="nump">30,666,000,000<span></span>
</td>
<td class="nump">27,151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">6,600,000,000<span></span>
</td>
<td class="nump">8,900,000,000<span></span>
</td>
<td class="nump">6,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">12,654,000,000<span></span>
</td>
<td class="nump">14,728,000,000<span></span>
</td>
<td class="nump">$ 12,654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 14,497,000,000<span></span>
</td>
<td class="nump">$ 15,938,000,000<span></span>
</td>
<td class="nump">$ 14,497,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member', window );">1.85% Notes Due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.85NotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848919832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">162<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156851764424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Interest Rate Swaps Held (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 27,151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,666,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member', window );">3.875% notes due 2021 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member', window );">2.40% notes due 2022 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member', window );">2.35% notes due 2022 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Par Value of Debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A3.875NotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.40NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mrk_A2.35NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156843249192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember', window );">Loans payable and current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="nump">$ 1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Liabilities</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_LongTermDebtExcludingCurrentMaturitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156850148632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">27,151<span></span>
</td>
<td class="nump">30,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">12,654<span></span>
</td>
<td class="nump">14,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">14,497<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">4,120<span></span>
</td>
<td class="nump">6,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">3,096<span></span>
</td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">5,455<span></span>
</td>
<td class="nump">7,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">8,042<span></span>
</td>
<td class="nump">8,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936772104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, asset</a></td>
<td class="nump">$ 239,000,000<span></span>
</td>
<td class="nump">$ 288,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</a></td>
<td class="num">(140,000,000)<span></span>
</td>
<td class="num">(84,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(34,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, asset</a></td>
<td class="nump">99,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, liability</a></td>
<td class="nump">298,000,000<span></span>
</td>
<td class="nump">97,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</a></td>
<td class="num">(140,000,000)<span></span>
</td>
<td class="num">(84,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, liability</a></td>
<td class="nump">$ 158,000,000<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848851720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 12,551<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
<td class="nump">$ 34,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(312)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(630)<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of (loss) gain recognized in OCI on derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of (loss) gain recognized in OCI on derivatives</a></td>
<td class="num">(195)<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Increase (decrease) in Sales as a result of AOCI reclassifications</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">$ (23)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156851137560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Foreign currency | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (138)<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember', window );">Forecasted transactions | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember', window );">Treasury lock | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember', window );">Forward Contracts | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_TreasuryLockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156845315736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net losses (gains)</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156846610600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral', window );">Primary weighted average life of collateral</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">2,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Forward Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Primary Weighted Average Life of Collateral</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156851727608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning balance</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning balance</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936723560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 2,038<span></span>
</td>
<td class="nump">$ 1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">6,073<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">8,308<span></span>
</td>
<td class="nump">7,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">8,209<span></span>
</td>
<td class="nump">7,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844264280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventories Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156842876728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangibles (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charges</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">$ 693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_SivextroMember', window );">Sivextro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charges</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SivextroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SivextroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156972539752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member', window );">0.75% notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member', window );">1.45% notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">1.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member', window );">2.35% notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member', window );">2.45% notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A0.75notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A1.45notesdue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.35notesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrk_A2.45notesdue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156848903096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>Case</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Case </div>
<div>Claim</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters) | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Femur Fracture Litigation | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss contingency, claims dismissed, number (in legal matters)</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_LossContingencyClaimsonAppealNumber', window );">Loss contingency, claims on appeal, number (in legal matters)</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Femur Fracture Litigation | New Jersey state court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Femur Fracture Litigation | California state court</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_FosamaxMember', window );">Fosamax | Femur Fracture Litigation | Other state courts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters) | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Other state courts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters) | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaMember', window );">Januvia | Cases Company Agreed To Toll Statute Of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims, number (in legal matters) | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyClaimsonAppealNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims on Appeal, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyClaimsonAppealNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FosamaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FosamaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_FemurFractureLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_FemurFractureLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_NewJerseyStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_NewJerseyStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_CaliforniaStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_CaliforniaStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_OtherStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_OtherStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156850395320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Rollforward Reconciliations (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 27,744<span></span>
</td>
<td class="nump">$ 27,737<span></span>
</td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 26,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,558)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
<td class="num">(4,656)<span></span>
</td>
<td class="num">(4,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,405)<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(3,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, ending balance (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 29,270<span></span>
</td>
<td class="nump">$ 26,925<span></span>
</td>
<td class="nump">$ 29,270<span></span>
</td>
<td class="nump">$ 26,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared on common stock (in dollars per share)</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">&#160;&#160; Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, beginning balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, ending balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Other Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">39,373<span></span>
</td>
<td class="nump">39,484<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
<td class="nump">38,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">39,489<span></span>
</td>
<td class="nump">39,561<span></span>
</td>
<td class="nump">39,489<span></span>
</td>
<td class="nump">39,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">49,724<span></span>
</td>
<td class="nump">45,295<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
<td class="nump">42,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,558)<span></span>
</td>
<td class="num">(1,392)<span></span>
</td>
<td class="num">(4,656)<span></span>
</td>
<td class="num">(4,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">51,107<span></span>
</td>
<td class="nump">45,804<span></span>
</td>
<td class="nump">51,107<span></span>
</td>
<td class="nump">45,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(6,393)<span></span>
</td>
<td class="num">(5,362)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (6,383)<span></span>
</td>
<td class="num">$ (5,390)<span></span>
</td>
<td class="num">$ (6,383)<span></span>
</td>
<td class="num">$ (5,390)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">&#160; Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, beginning balance (in shares)</a></td>
<td class="nump">1,048,000,000<span></span>
</td>
<td class="nump">1,010,000,000<span></span>
</td>
<td class="nump">1,038,000,000<span></span>
</td>
<td class="nump">985,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">$ (56,850)<span></span>
</td>
<td class="num">$ (53,570)<span></span>
</td>
<td class="num">$ (55,950)<span></span>
</td>
<td class="num">$ (50,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">54,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,405)<span></span>
</td>
<td class="num">$ (1,281)<span></span>
</td>
<td class="num">$ (4,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Share-based compensation plans and other (in shares)</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
<td class="num">(13,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares, ending balance (in shares)</a></td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,026,000,000<span></span>
</td>
<td class="nump">1,047,000,000<span></span>
</td>
<td class="nump">1,026,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (56,815)<span></span>
</td>
<td class="num">$ (54,925)<span></span>
</td>
<td class="num">$ (56,815)<span></span>
</td>
<td class="num">$ (54,925)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non- controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions attributable to noncontrolling interests</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156859729176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Expense Allocations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Pretax share-based compensation expense</a></td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefit</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Total share-based compensation expense, net of taxes</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936485032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 77.67<span></span>
</td>
<td class="nump">$ 80.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 9.93<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share granted (in dollars per share)</a></td>
<td class="nump">$ 77.83<span></span>
</td>
<td class="nump">$ 80.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="nump">773,000<span></span>
</td>
<td class="nump">609,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share granted (in dollars per share)</a></td>
<td class="nump">$ 75.22<span></span>
</td>
<td class="nump">$ 90.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844280904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">22.10%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156864371304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="num">(581)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net loss amortization</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Termination benefits</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156860385640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear', window );">Expected future employer contributions, current fiscal year</a></td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear', window );">Expected future employer contributions, current fiscal year</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by employer</a></td>
<td class="nump">$ 184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156860425880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Income from investments in equity securities, net (1)</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">$ (312)<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="num">$ (630)<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156844733080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember', window );">Healthcare Services Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems', window );"><strong>Component of Other Income / Expense of Nonoperating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Component of Other Income / Expense of Nonoperating [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_HealthcareServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156936022072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as percent)</a></td>
<td class="nump">14.10%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Tax benefit recognized related to settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156860244776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,941<span></span>
</td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 9,161<span></span>
</td>
<td class="nump">$ 7,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (1)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156853007800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 27,744<span></span>
</td>
<td class="nump">$ 27,737<span></span>
</td>
<td class="nump">$ 26,001<span></span>
</td>
<td class="nump">$ 26,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(143)<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">77<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(283)<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">29,270<span></span>
</td>
<td class="nump">26,925<span></span>
</td>
<td class="nump">29,270<span></span>
</td>
<td class="nump">26,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(195)<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(154)<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(137)<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(122)<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(4,162)<span></span>
</td>
<td class="num">(3,530)<span></span>
</td>
<td class="num">(4,261)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(4,100)<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Cumulative Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(2,246)<span></span>
</td>
<td class="num">(1,946)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">85<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">85<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(2,161)<span></span>
</td>
<td class="num">(2,063)<span></span>
</td>
<td class="num">(2,161)<span></span>
</td>
<td class="num">(2,063)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(6,393)<span></span>
</td>
<td class="num">(5,362)<span></span>
</td>
<td class="num">(6,193)<span></span>
</td>
<td class="num">(5,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (6,383)<span></span>
</td>
<td class="num">$ (5,390)<span></span>
</td>
<td class="num">$ (6,383)<span></span>
</td>
<td class="num">$ (5,390)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156860509128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Sales discounts | $</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156855832600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales of Company's Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 12,551<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
<td class="nump">$ 34,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12,540<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
<td class="nump">35,212<span></span>
</td>
<td class="nump">34,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">5,573<span></span>
</td>
<td class="nump">15,396<span></span>
</td>
<td class="nump">15,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,616<span></span>
</td>
<td class="nump">5,563<span></span>
</td>
<td class="nump">15,349<span></span>
</td>
<td class="nump">15,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,926<span></span>
</td>
<td class="nump">6,824<span></span>
</td>
<td class="nump">20,084<span></span>
</td>
<td class="nump">19,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,924<span></span>
</td>
<td class="nump">6,699<span></span>
</td>
<td class="nump">19,863<span></span>
</td>
<td class="nump">19,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">International | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">11,320<span></span>
</td>
<td class="nump">11,095<span></span>
</td>
<td class="nump">31,654<span></span>
</td>
<td class="nump">31,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,715<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">7,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">2,941<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">2,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
<td class="nump">3,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,218<span></span>
</td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">14,202<span></span>
</td>
<td class="nump">14,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">6,106<span></span>
</td>
<td class="nump">4,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,102<span></span>
</td>
<td class="nump">5,914<span></span>
</td>
<td class="nump">17,452<span></span>
</td>
<td class="nump">17,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Emend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Invanz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Cancidas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Cubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Zepatier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Zetia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Vytorin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Atozet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Singulair</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Nasonex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">3,535<span></span>
</td>
<td class="nump">3,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | Operating Segments | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | Operating Segments | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | United States | Operating Segments | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | United States | Operating Segments | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="nump">2,411<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | International | Operating Segments | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Total Animal Health segment sales | International | Operating Segments | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other segment sales (4) | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other segment sales (4) | United States | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other segment sales (4) | International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_EmendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_EmendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_InvanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_InvanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CancidasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CancidasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CubicinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CubicinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZepatierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZepatierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZetiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZetiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VytorinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VytorinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AtozetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AtozetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NuvaringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NuvaringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SingulairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SingulairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NasonexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NasonexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ArcoxiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ArcoxiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_FollistimAqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_FollistimAqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156864334040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenues by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 12,551<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="nump">$ 35,479<span></span>
</td>
<td class="nump">$ 34,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">5,573<span></span>
</td>
<td class="nump">15,396<span></span>
</td>
<td class="nump">15,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,454<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">10,059<span></span>
</td>
<td class="nump">9,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="nump">2,506<span></span>
</td>
<td class="nump">2,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">$ 1,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140156852993336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Profits to Income Before Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">$ 3,428<span></span>
</td>
<td class="nump">$ 2,347<span></span>
</td>
<td class="nump">$ 10,784<span></span>
</td>
<td class="nump">$ 8,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
<td class="num">(674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(3,390)<span></span>
</td>
<td class="num">(3,204)<span></span>
</td>
<td class="num">(7,721)<span></span>
</td>
<td class="num">(7,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">8,424<span></span>
</td>
<td class="nump">8,168<span></span>
</td>
<td class="nump">23,347<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">7,974<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
<td class="nump">22,010<span></span>
</td>
<td class="nump">21,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Animal Health segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Total segment profits | Other segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Unallocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
<td class="num">(674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(395)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(1,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(3,272)<span></span>
</td>
<td class="num">(3,110)<span></span>
</td>
<td class="num">(7,364)<span></span>
</td>
<td class="num">(7,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_AmortizationOfPurchaseAccountingAdjustments', window );">Amortization of purchase accounting adjustments</a></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (724)<span></span>
</td>
<td class="num">$ (1,699)<span></span>
</td>
<td class="num">$ (2,490)<span></span>
</td>
<td class="num">$ (4,019)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AmortizationOfPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AmortizationOfPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSB(N]07P^U3 :,X/= ?+MUB&_P%02P,$%     @ ^H9E4?!KYG@W!0  )A0
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M\LWT@BV]P$KO+$UY X0@2Z0,''A7,/2I@HS&5X@6D'=HE3($&0QEO+F3JZ:
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M01X^$'G?E-V-'4".2G,79$=!&+:7I<O,C\*> H\;X.'7 >^2%Q1..H<"#S?
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MO/QRU'13?LCZ0B4DD$(96T&7WH<IS)<LOPV5-UIL[.>5I=!:Y/9RS2A SAC
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M;1" ;@:^<:RJ_<PLE:4)]&9!;P1J%T#G:Z7LN^/&L'MUDC]02P,$%     @
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MGY'WBU])JS^R>U/QW-G@C*YD0H:M]MRG</RHK;2EED;<XJ8"#&,0_[PJ0O0
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MT9^GTP$'F5(X)O$ =G%L &-:/M6EFM<)J%I91HU/Q!H^O?R&IC.%%V?PM&U
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MDC'8 -YW"-N\1W/B*H*T+ ;Z[$=5^EL\;J$@RSHA&G>Z&N32EIFR15^\-!A
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MAI; 3$3Z:I>Q5T:LE;0.\PN7@4T2U^DV4Y4U<SVS!AV**1!V%"%B*%9+@](
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M9D +> ^F;L@T<'D;["*P*5)*!+$KF<BVB!U@CK@<113@E^G5/BZ!CD9])6H
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M+A=$=J''KM/!A#3@S.?P.2C$Z5]([WD8+ :CB66-^1ANS)9C',-+[+J&\DY
M<%)@/FX'6J"J9?+EB0,;K^\0WRN"A,LQ+\-D.=?4F//*#99C7+QHC 8B6M+U
M'!0 OA8M\".] NIR!J]=4V2%^*UDNS>,O86JE4KM,0=/:EIQXT#L5MQA9T&)
M$2=[16!95&J=G+.*8K[<]*1Y/:A9W9#"I<*F**DTB5TUE2!L$H%K9-+%-^"#
M9C6'UF3Y+G6N/L]51$Q6<5_*^RPEMXS[\\D<%[V1FI-"M15[".L_4UN@5.Y@
M>XYEB>RI;%^%32[PW"/G$_;&5!.=,1(G*@_ 955H4M\!EHPPRXLS4Y58[%ZT
ME.!F//)/J<6I)CIJV4BQ'4,E=@DYA_"<[F>V3IAH5;-'QP2^*L17<:[A;9O+
M4X;Q'\14KK=J$V>JBJ0X+'$YS"\]MGA?L[P/VUDB13Q$],@RH3]BGSP;F8MP
M,KK4OQ<3]>NFM2@JS$Z[":?QQ&:E,&FF\8<I+:VBGE,R;-P3$/1P,GINE#;V
MPP3*4!LG?*_RF)0YOC35)=\O=/RS5B6D;+49F>YJG=Q[J1J#CJ5#T;,]UGF&
M2%W^97!.YD*__X%3V=3O_?Y;L[%]5W8WA T_37SC9&Y^L:E[UX,N;:#*,1!'
MPA]U $I^Q92,$ER,R21=C,,(L[;CJ<[O7D0+OC&8S)'=QY/!<HY>R,5L/*)O
M9O0I7-(G#(Y4YIWZ*F71#DT[?'C<5U716T93[B:#03;#\4E7%9RG<!1V;K_N
M%Z0#$=+!C/3LC*SU'!ZZF$^Z3]Z:;2DGQ/6H:V64AI(DZGGM5CMEX2F/T[GV
MY11S\[,SGHQF^.3820ZD)CE@>A IU0E+W>2$+&7I;?(^47X"E0SF70<L&@,)
M@<MF4QAIV;,.4U3SB^5EBZ/ZZ-1'H"/ZZP3A4+WASTDRP<3PIWW?XD5"\Q<L
MW!/PF?&SM^WT'&:9;&$;D3M"H;Y,V$G#I[1_9;2;4X1TIWMF(L)2T4D=G*P&
MJAIBC^5XJJY7D*RRULF(/N7^EP9NUKSVLR_HY[E;F1O3WS",C@*-M&6?PRLP
MPH2@')(MY*5C.+1YSPKP4^.YC^"=QR5V5Q>I[JUD]N'Q*HSAG'#.E8I/A[<1
MF#:Q0RUB3GO8T<TX)YI\OZ.);$B+<F0.9_:0NV7'(:U<&^814+H!J\RX,:4D
MHCQJ#,\H>6$I=$=-A\_17]!E.^OS(K\X'5:VL<I%D/O45 5!%RK$UQJ\&5P"
ME%I*97)3T>E]7KI!!YLL8Y!CM2V#.G)7!XO,9N< :T#EOH.!HQGFC_Y[YFDL
M('-3'Y7J^G>YZ=[HCWZK&?&3;?5WQDH%IJI!;=$VNAC[2?(V4)B>ZO"CBK<N
MW1+[4>H:P?_R1X/!X!VVVC#3WOJ!>.:_F.H7!;]8V1>SBF>(D?.Y02MH\K*F
M&7/(^+OE!?)P3WW?ULS_(+J]99IY'RBSO,&5+\SN2]0XB3>'Y\%\<B!Y2U]$
ME/T9>U]$LZ71KLX *PA904%UG9N3QAJD9R=*B@?V,68.3KTPFRUZ[]W(<B_=
MHBVU)"!:)R&.%JZ[/8M"SA]<K>($^WH=DIT"%46S('0^S54-ESC))_WL$.EG
ME%B?SS@ ;^7;YXMI\*%9Y5F24Q<4;;?J<"?:A!!"FWFP&"]<%'B#VJG7<: I
MY6NCP0S]4P#G,".%OG[\_B2?LSL@:$[:+9I3,WB/,%$"Z_G%!'2ZUJLXE><7
M4XSL]"U=@L)MH\$?35Q2^@GWKV<EJ/8"/1^E0T$KLP8'H[_7S1/#]BS5[/1D
M_Z.S! 7!LXRFK3E.PF^?8KAL3['7DA&(+D:^@:.VQVT,*$U!8CP<Q\NQON&/
M-Z"=&TP*5[NB=9,-.D5QFCDZGKP'=Y.DVP;H54D.]KAVFYAUZW(/'F9CR#J^
M!^V!H\L5.@DJ89LEUG/B,KS;VP209'Z/UKK*8/IQZ<'6'<AH=OF^$'J;7@^R
MBMD,1DUQ&J=A\)J]!:JS'N;R=O9=<7&75-AS%'IKV^.QP$-CER./28+?HM:_
M"(<%_YSYM=GTU/PF9TP/G:UOG-\Y$PN70[=%H8,FE^W[OF\S29LQ*LNMLFS[
M,]\CAV>JZ#!J:89HTJ\8AFY6[QU'("HBM)DUVM2U)L\OKOP]5BP&3CL>.[.<
M[<:YQX7:\ C7^SCC%4+A)>_4A"Z/P46,+BIM:0>09J>T;>T# #ML.XS3^[BH
MP8_",TM4M[JNF)BA+%SLKE8;*7._:UJW-B@85%W"H52C/=5.+$5HRY.O[=3V
M23<'F8D2H\='E3W=Q5]!(_TI*K<OW6&6K-@W*HB#U>X^VA3=AVFK'2/FMS,1
M<B7W1M64<<"&RIQ$2;W;J*-4U+Q<U*D:]Q9? -=I&]]K<=]FFRU&Y+ 0$OUZ
M0I:?&[O/@0<.C[TT(*Z"_VZH\J@$XJ(IN*](I+2X?+*4(KZ2DQ1/D, =@RJX
M]7?3_Z!@1P#[?8<LSC8XC0*// BJ!N/Y"@RUBQ".J.U%[W@#_,Q@U1BF>\59
M%:J%(#/160ER1<XOA4C.0XK%@(5B'M?;.$-:M0&YIEX@9:^.DF ,)/B]AS<,
M@JJ>QXC NS5C6IB]<:H[#12 AM@[H&(F;-UYH-]*#W'?CPD(>1L)$A;_[F0*
M;#>@HVZH7IDZ^>>= '"IS.5&DU@O0BV2;9']@>"Y-.SL0>L1!.\8GG[DD=2V
M =4H57/XAN7^$I4R;F1U!_W<I!ONRRMU6H$V9MRN58:Q5Z;81NKJRH$TS1J[
MJ%5NP9YJ@AO?2&8Q(YF4V<HOW"? 61L0PC]Y!NX9(58"%0!"CODA\V>ECTNQ
MDW>UG-1SLUMC;:GHVD[&[35YYVPA=8M$6-_^B(XW*:I7U$OPYA1EW/VH;LFQ
MH.R^!J8:%8G3\6 \LLIJW\<AB_8[,>GQ;[7JT)I&"P<';\>__:8V1$52-U=R
M,+#W,@!'/AV[>G*@WQ?P?U^@[T;XYT3[YQ0;W%C?O3XO!7,V]-'2NSZ= @@'
MXYYB$]^=AMT4"M[C;R/OZ4A],X_<)K1H,E9>L3Z/!L+P\Z8\GW3&AENS+JYP
MZXQICN;=2<*]<=0%B/?"1;=@BO?&BY[G%R.WYJ)G.KXTN?V>^H(!&L[ZKV=+
M[[I;)K8PG$?=MZ;NY0=[W)#9=,\'#MFEG?1=8NM?WS7VN/1>+Q;>-:L>TTX7
MJJ)[- G;*:LE*HD%-\T,1F$KH3A8AJ&GU)FO7,U\(^D8/>0I?40#&Z)^C;.(
MEN9W?X9MKGX[J^L=GG3>$D?S:>_UTKM\:AVHI\03G4ZC_AODH1;%828(3UP=
MX\-3?_L@8I-4W_5R[EXR$[FT]WB#>(87,AR$D9\,7<[-6BYF$U+6'\Q!)NCE
MN/YLCW:G@!6#C)RK/&EP<0>N<8J+]?=XM_\A^"!E2>/1\9&\N0(+_-?7I-O>
M29G:ACTVI+*L8%7+>PQ.G3?B^'(0Z"V^]K@5+&<TP >YC"$\5AUQ"2* \"L\
M? 3[.>%;%=NB%XHG':"7^D!'V(KT2A]QD',3Y=H98*K.JD/W5%2JTN:71VQZ
M3;H*G;>7X!%[B:K>UG0(@GLLIPY^]_&C=N'4P2J8V,(#A,1NG\M'(0)S;%P>
M.\4YU\_J.,EN54RAV3[SE'Q3IAKMS:9#ZKR.3>5SNK#LOEZ_XQ(W\#K !NT#
M1MB?)ZYI'50QQ&Y7>.) 7K7C>PVXA\ET4:)9 R+X"_)\-ISIG7J<2ED,E^:&
M[JQQ7O7S*\&%PE<G1[3F%*GQ(KO'NYDT IY%8+7NC:=U[ZSCZW9!0+S0U.W3
M2-I!47)(E0/;R20C,23N7F%DAWN2XP2FJ!M@6V6W;^];<Y),_XP+VJ096M,
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M7ZO?#X/A?%PJ.O3&8@5J=PV7%\ E[;T0=(S-%5"1+#9;U&.EX!;+P9(X2[*
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M0>-)/@M ]VV]GUC5^E:Z598:LQ_6]!*B=@ZTOE/*GB8NP/BVKO\'4$L#!!0
M   ( /J&95&UN1>[[ ,  ,<(   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;*5637/;-A#]*QA.#^V,*LJ2G<0963/^:-,<,O'$37OH] "!*W%K$&
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MBU;L/5G>:).,*7:*.SF\WG%V]+[CX<G_A@_&>2'<1AH/"ENFQFYFX 8S&H)
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M]PV9XX>A)0_^\ 4_^R(\>T)4P(]Z0)IDH436T'%("DP#I^#ZPJJ$N,1D)B[
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M"G'.N]J<R*M?1+^?R,K+9:W=%UUY6@+$>:>-;'IFL*"I6M_RZ]X/:PPIWL)
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M@:VNY-6#-V6X!J^,ITMUF.;T%8.6!>C]VAC?/+"#]KOH\E]02P,$%     @
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M$8Z*R\[5X-/UF.VCP6^*5GYG+)C)W-I'_KC-+SM]!D2:LL 1)/Z6=$-:<R#
M>-K$[+0IV7%WO(W^2^0.+G/IZ<;JWU4>RLO.>4?D5,A&AP>[^I4V?$XY7F:U
MC[]BE6Q'HX[(&A]LM7$&@DJ9]"^?-SKL.)SW#S@,-P[#B#LEBB@_RR"G$V=7
MPK$UHO$@4HW> *<,%V46'%85_,+TBWPF+R#/K<EL19->0%!>ZF6; -<IP/!
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M'!M@O; V;#\X0?N$G/X#4$L#!!0    ( /J&95$LEQ"/^0(  "H'   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;,58;6_;-A#^*P>O&"3
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M-_#'Z5P;A;+X\Q[,:(L9.<SH*>/X'R'AO&+MDFL0+9R^/W\#\QO URO9\M8
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M2_OI;"IF8,/W$HH]=:%DTWU3(\HEJW'F@8O^!4?OM>O+EBB>@VOQ!0V\)1Z
M41TV$#@9(XS1 NTLT1MVQ43-YC5_B91>VF$\.LX-:([4A!$/9-*EP.NB[@._
MQK.YYEW,#IPJ\(!0KTO>L6.-5$9\Z3*.+%9*2#R0<W4E,/B%U#BE+>W)& M7
ML!J<$VZL]T-T<*7=J2SB"O<H68H"JZ#E"V$Z$$_C[O1.&HYB] ]N.TW-=DZH
M#5=+=P[7:+UN37=8W8YNC_JGW0EWG-[]G^ M4TO+LN8+- T.TG@"JCM[=P]&
MKMQY=RX-GI[=;<59R96=@.\7$IGV#W:![3] 3OX&4$L#!!0    ( /J&95&8
M^JYE+1(  *XK   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;+5::V_;
M2);]*P5O8^  C"V^R4PZ@.-T3S+;R622[@PPB_U0(DL2)Q2I+I*VE5^_Y]PB
M*2EQW.F>'< R);+JUGV<^ZA;?'K;VH_=QIA>W6WKIOO^;-/WNR>7EUVQ,5O=
M7;0[T^#)JK5;W>.G75]V.VMT*9.V]66P6"276UTU9\^>RKVW]MG3=NCKJC%O
MK>J&[5;;_7-3M[??G_EGTXUWU7K3\\;ELZ<[O3;O3?_+[JW%K\N92EEM3=-5
M;:.L67U_=N4_>1YQO SX4)G;[NB[HB3+MOW('Z_*[\\69,C4INA)0>-R8ZY-
M79,0V/AUI'DV+\F)Q]\GZC^*[)!EJ3MSW=;_J,I^\_U9=J9*L])#W;]K;U^:
M49Z8](JV[N2_NG5C@_Q,%4/7M]MQ,CC85HV[ZKM1#T<3LL57)@3CA$#X=@L)
MER]TKY\]M>VMLAP-:OPBHLIL,%<U-,K[WN)IA7G]L_=F#17WZIW9M;:OFO73
MRQYD^?"R&$D\=R2"KY#(U>NVZ3>=^J$I37DZ_Q+LS#P%$T_/@P<)OC>["Q4N
M/!4L@L4#],)9QE#HA=\JH_J?JV776R#B?Q\@'\WD(R$?_3LJ_)TDU,\;HZ[;
M[4XW^S_]5Q;XZ9\[!4^TFECNE+9&[6S5%-5.U_4>B&C@0J4BSO&@+8>B[PC7
M"F.;4F%D/91&]1MKS$0(RW1NX<Y3MYNJV C='DN_W6A OC!#7Q6Z]M154VUU
MK5X:7?<;H>B^%ISPWMB;JC#=3.U"V#^E(9-.R4S#YU7;!J)8T8%>UN9A>N/#
M2;1.;09H06T<[=V7B]_HHH#>9_5<J)</S)B56$#?5=>K=D4>K=[)"*&(,'@#
M%A!6%+0O:L0%8VB2KJU+M=QS4%?8:D?#>0IA5$3M$4%[X1]T'>=EU;6V-'84
M=[0^Y*SKCG,Z\Z"(,\/ !>)K!1;Z5I5V6,.V;6TZ78.V\&U-KRO^\M2F[795
MKVNRWMX8VPA/E*:HC!L]86M<MG#8:V\J\HIH3MATTU/F@=XTNBE@3KO63?7)
M0=:;^-VK)72TJOJ1\,A32^7"F%U?]8/,^,P^GYOOV#!'AMB9LM*]K0I/Z9)B
M%R(05M E(O5$AOS,>M(E(BM(&0LQ=0].]UU55%B[7:V([&^TR$3[U 0S-?&R
MV1+>T3(P/5A>#GT[:N/(%I2KK\C#E:JU71L(OMVUS8B=6=Y1QEGD25]<S;G8
M5C,"M(*_7R[>7ZAKC*/^"<H756>0W2!DT]O6><S;4:V(*A\FT3CV>E/5I34-
M;;&V>CM%#P2;U< D0-S/JQQD@0AE69$>/<23(:=*G34XLOFC*>E.Q_H@ [L:
MN!^]'R-G4?NV^+@#LD>#W1MNJ.R"Y&"!$O+5[0[?8,5AA80PV!GU]J-A;&)"
M-LKJ!IJ'OF\,5%8U*&"^)<9X=(U;B';B(H2]L((8,8P!'9.[,8X>HL1N-H!W
M%#$XMAC-!([*T7(58C\6VNI_878-7Q!UC*.I9*F"G$JZG2FJSW&-*- 2\<XE
ME;GK67S!I[JAZHU;:LU@ 5QC_0:%%4P-[8!#N(F>^(1*]+*JJW[O--DV%8#-
M=',(O5_Z4R6A:_1M&G52M/.<+UQDE,1-F:/F VEI"EH'13NMSS;H-YKP0M7%
M/&J:]6@F;[(<#%?O86PWL4 6'S/12 Y<5UNNXM+9C:X'49NP4QK:A!&&,0'*
M.F2V21$;@&1IX%<PI3-_"[*=TSSM21WRP7+HZ"4=UAR'/B"W6\,:AF82.)I\
M:\B8D 9?Y6"G!5:5163]== 61N#Z+,4NU'N))2X3?E&>S,83JIJAHD;-WSW!
M^JPZCJM$,+GKS78)XBSTWM!G'GC.U?'/SX^^G7]'V;=57=-XCURL>=7T(S^U
M^KD%5/]_;I^6'D_4WQK4W>UZK_[;['L[E%I]IP+/CU-<?2^.<UQ#+_5C^9U&
MH5S#()7[BW2!:^+YBP37R LRG\\77IBE<B,.8AD811FNJ9>GH;J"G))5)20
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M,"+/-Q>B=J%TLB%\HGZ:-TDN;</F=)B(\*$%4"U$Y#QA&06)B'?6"DS;@;<
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M+W=O<FMS:&5E=',O<VAE970R-2YX;6R]6&UO&[D1_BN$"QQLP)%D.?'E8L>
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M#\M!-Y#I#SD0"N<[HQ1+!X137 #+!2])%?")I:GQ6I HP\C6$*+%@7Q_W>M
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M3T98MXZ.&.E'.#)PRD!)70:"U8V)H&(M;'69$;)4P6X*V\8*:E-.CW>C13\
M%H*412-8:=*Q#R-T2^/)V99$=?&IBT$]]NL X]"\X><@FX P_&SW-WB1TOR$
MC7L"/I$96_/,$HX%%$[F6N;VA*N'0WT'"]ZP.9L='@BZR1TTYLXQ;4].RSK/
M<OO7_P[G;3V8KE%V#AG=+3NR\M-(@IMQ'#KMLWSK\'Y/]5<[.U!5?[H<U$_-
ME)L0H5L%P<?$[LE;0+^>Y_<"]:OH)(8IL$)(4/;9!]2'/ARV]:<Q0D]-H#]!
M1L05.&^,^1+Q .*V-N)CUM.8-#OYLZO9GRD!<]*TAH 5I&L+HHDXH:O OBZ
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M<FMS:&5E=',O<VAE970S,"YX;6R%5-MNVS ,_17"V$,"&/4E%]M!$J!I5ZS
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MW=%(1>T<Z'ZCE#T>7()N2,__ E!+ P04    " #ZAF51.PK_$2 %  "3%
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M#F&%A6,-@H8'O,"J8D7DQC^=SJ WR0>W^8WV7WWL%,N]L'BAJS]EZ9;38!Q
MB7.QJMPGO7Z/73P9ZRMT93V%=;LW&P50K*S3=7>8/*BE:D?QV.5AZ\ X?.-
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MP?[8W5:<E5S9"?A^(9%I_V 7V/Z+X_0?4$L#!!0    ( /J&95&_'&O@'@P
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MU9LL7A2_0#2)LRP.BY>/U)O1)"_ OG^(XVS])O]1H\W/MIW_'U!+ P04
M" #ZAF51V.HXNV(%  ":&0  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6S-F6U/XS@0Q[^*5:U.NQ+0V$Y"NU<JM13V."TZ#O;AQ>E>N*G;1NO$P7%:
MD.[#G^V&.-#$+=Q)VS>0IYGYCV?\LY,.UES\R)>42O"0L#0_ZRRES#YVNWFT
MI G)3WA&4W5GSD5"I#H5BVZ>"4IFQBAA7>1Y83<A<=H9#LRU&S$<\$*R.*4W
M N1%DA#Q.*:,K\\ZL/-TX39>+*6^T!T.,K*@=U1^S6Z$.NM67F9Q0M,\YBD0
M='[6&<&/E[ZG#<P3WV*ZSFO'0*<RY?R'/KF:G74\K8@R&DGM@JA_*WI.&=.>
ME([[TFFGBJD-Z\=/WB]-\BJ9*<GI.6??XYE<GG5Z'3"C<U(P><O7O]$RH4#[
MBSC+S5^P+I_U.B J<LF3TE@I2.)T\Y\\E -1,T"PQ0"5!NB% ?1;#'!I@/>-
MX)<&_KX&06D0[&L0E@:A&?O-8)F1GA!)A@/!UT#HIY4W?6#*9:S5 ,>I[JP[
M*=3=6-G)X2BZ+^(\UE7.C\ MS2D1T1*H0C$RY8*8&X"D,_ YCE1#43!:"$I5
M;\D<'(-+$@OPC;"" CX'HSRGZK+Q*>BL-"/3F*D --?WBT1=?S^ADL0L_P#>
M@3@%US%C.LR@*U5&6E<W*M6/-^I1F_I,G  /'@'DP?[7NPEX_^Y#@Y=SMY??
M"W8"L/&"O ;SB=O\CF;*W-N8MXNXV"&"I"< AKN\7+J]3&CTE$K+@'15@U1=
M@JHN0<8MWJ-+6IMDU-PD7P1)<Q)MGOGKL_(,KB1-\K\=NG"E"QM=?HNN3YS/
MUJI[FHJVL0R-I>;K:JA&UN\-NJOZ<&X_!?L^"JJGGLGR*UF^4]:=2EQ=8N ?
M\(5&RY0SOG@$AMJY(^N@<A\<5#7"2E?H3/N[P;B>]RLJU+($BIS."P98/#=X
M($]<F,=I+.DQ4VO*3 % DG013QD%Q/"C:0*[ \, /*I!<(WM:97#J=/5*)5J
ME8OOFTJGKETKY4F1. +UJD"]@RIBO]+5_TE%'+L#P][.(D+/KFK>?RHC>=A1
M1EA;0.%!%1)::$/TLTJY(S+R=]?2,AZZ(3\2?Q:,NEQ9+D/_L&IED0X#9Y+G
M)%^:_5*D#ZB2N2),QVW<203;JY;?LF9!2V_HINC5S>TO),E^G32&W-@&]>44
M];R6F):VT(W;JSV:[:+T48_=&MGB%_:<D2=T3H4P_1[QA ))'M3$J/:JC3IZ
M6SJ.<:_?HL0"%[K!]X=<4E&F;UJ@)N,(I%0V:NEO:<%^LQ)DJ8G<U/S")6$@
MGNGMRUR)4%51X1V5*?T]ZPH8M-0&6:0B^-9MW45I6@\9^&T1:_M;-[#.U:16
M>6\0 *2>ZIOV:)2 MK>68;]-@^4<VL&Y<LUR[=<MZ=!AD0Y9TJ'_CW1CM$TZ
M#%L&VH(.N4$WBB)>Z$0%C:B*/GVYNI2QMY%WBEMB6^"A7<!;J5RY:$;,&&VC
MKM\6TZ(.N5%W(WA&A7P\ ADCJ32#K\<]T^5N5+$-NK"MO2WFD!MS^Z!^C+:Q
MAL(VQ&(+-NP&V^MA/\;;:#L.6I58M&$WVMX"^S'>9MYQ#[5(L<S#;N:]EO;C
MTM_S/<!IR[X#U][AW_P2/RY-ZR$A/@U;0EHZ8O<+^FMP/RY]/6-0&+10"%L.
M8C<'KRG)"V&0"Z[2K)!'8!+GADS@EDBJ7E-V[GRQ91X.#VH]P):(V$W$&Z'4
MJ)Q7YBOB[&D(E*8F*E^4WO3[7U4.[P2V?;+!EI+83<E]ZK%[A<:6A[A_4!7Q
M+2U]-RU?5Y%QZ>UE1>#+BG1K7ZGUKQ;71"QBI9_1N;+S3D[5?!&;'P(V)Y)G
MYL/UE$O)$W.XI$1-6_V NC_G7#Z=Z&_AU<\QPW\!4$L#!!0    ( /J&95'V
MYG]3S08  /PJ   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,U:6T_C
M.!3^*U8U#S/2S#2^]8( B>M ::$"S:ZTJWTPK:'1Y-)U7!A6^^/72=.XJ1TG
M0'?4%VC2\YUS[._X\ZF3_>=8_$AFG$OP,PRBY* UDW*^UVXGDQD/6?(UGO-(
M??,0BY!)=2D>V\E<<#;-0&'01I[7:8?,CUJ'^]F]L3C<CQ<R\",^%B!9A"$3
M+\<\B)\/6K"UNG'K/\YD>J-]N#]GC_R.R^_SL5!7[<++U ]YE/AQ! 1_.&@=
MP;TQ[:2 S.(WGS\G:Y]!.I3[./Z17EQ.#UI>FA$/^$2F+ICZ]\1/>!"DGE0>
M?^=.6T7,%+C^>>7]/!N\&LP]2_A)'/SN3^7LH-5K@2E_8(M WL;/%SP?$$W]
M3>(@R?Z"Y]S6:X')(I%QF(-5!J$?+?^SG_E$K &4'SL Y0"T"2 5 )P#<%,
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M"X+7 TE/6OW)OZG_'HB0PFKOTSQ,%?]*\Z35/!G6_%CB(P:9S6:G/FUI*L
M<,7J[JN3VO&X4P+1^*A.)D=U<F!TH'G::IX.:OXL#>4VK3:KA[I=COO$3H_K
M=9H<:ET=VT2S9S;K8YMQ$!_:;(YMDCCJ#WG6ACP;#!G;!,!*,0,['@8_W[3@
M?[B*PLX;&OY'-7;9>.[F<GI4/G[G?2] [5PGIM%G)4Q]0;>S;;?WP?4XS^8O
MPO-5V#._#L\W=2_WTWW=6EY3M6-"$PY;I K.)G@<5-VMU0,C2]==W$N#O8K[
MS+'#!64-<'TKI7D:6(*V9U[^ U!+ P04    " #ZAF51JVOA=RX&  "T*
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M,V)J_6E8\X>]NC^T]@\[]W_HFONH.7TN) I,G;5_V.[_+]29Q_<AC9H\752
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;,U674_;,!3]*U:T!Y"
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M5XHGZ65("2Q@&@#O-YRKXXT.4)S:S?\%4$L#!!0    ( /J&95$<]<C+HP,
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M,<4O'2J- ;Z?"Z%?!X:@^G8:_0102P,$%     @ ^H9E4?1\S@^J!0  ?R
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M"0W>D_P)$1/*[4,S1&\5;)J^VHV=K/LDJ4+LZ#[)A$!3(><^E=#"N?M42"K
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MV=X$ES;.ECR7T%-DELY&*P:^4K9$D[+-TVD-QE"())+ $CIAL_/V']53M0J
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M$V4[Z-N-%HV=E7.A<?+:98G?1I F .\70NC'C1F_[FN;_0-02P,$%     @
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M>)@U(M>U2/2.2 QS):DP\$GFF!_ S_KQ%SWXT!;<5AWMJ[Z.>@D76)U!//@
MT6!X<<C/7\/?V(G;2X@]7_P.WRV7G/#TWOZA\\Y=P)4Q2 :>[VT^W!&6YGN/
MVGFK=N[5SM]1ZP@P)P"\K!C7]M4DR JFUWCPBFO2L2=UL^$U'0^C)'SMMNU
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M;W<^MR=6K?*]P#MEK4KSPR5GT.J[ 7!_KI1]/'$!ROWG\7=02P,$%     @
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M'F1X2.-L(4<CQ] ZX@EDXE8L;\364?/QBG+/PP[EA%S,'H$A\=V0N'5(K:K
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M17^8_53DCSR;HOU3[G?P*7?_'IFB._P[T!VNZ X?5^8?=Y$-HB+Z$?X84 B
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M?Z^D>K?DTFWD4NI/"OW79F/T%ATH$1+X @J"AA1^'7POBV9 7O%<%S)=ZB&
MF!QD0RGKE4Q[C8&?$#*^7AKVS, V+0EN$+2\;8CO.J=^Z?P<U=L]:^'NMU]>
M"4O]4N'3;G!;\YY\6]M\W4H]#6OK;HUAIZGPNMX)L/>F?+P_YN-"%X&M+@(Z
M-7/TK_C$/$UUPI1WZZEY=16T>UDO:LQT";U2,-Q37W?]1EI8[LQW-8MHOOW'
M[)M^*_M.G=IM_R39=VJC[AOZZ-NSKU/-OM"O2;ZJ7>#TKN?>J=&YS9WNA^5>
MM0N%G9;G7?*JZ6A.Z[)[VV<?]!D52W/.D=AY-DSEW[WE:GF6&ID3Q,7Z6)^Q
MS$'A%"8_H#T2L4SP"S^E"PSIM$*46N1GGGRB^-H<&^9<X2'$#%=X3J1"&^#]
M!>?J.-$/*$^>PW\!4$L#!!0    ( /J&95%BR_:PMP(  - '   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;(U5WV_:,!#^5ZQ(DSII)8GYU5: !+3;
M^E -%75[F/9@R(58=>S,-J7\]SL[(:-=R'A)[+._[^X[VW>CG=+/)@.PY#47
MTHR#S-KB)@S-.H.<F8XJ0.)*JG3.+$[U)C2%!I9X4"Y"&D6#,&=<!I.1MRWT
M9*2V5G )"TW,-L^9WL] J-TXB(.#X9%O,NL,X614L TLP3X5"XVSL&9)> [2
M<"6)AG0<3..;^=#M]QN^<]B9HS%Q2E9*/;O)?3(.(A<0"%A;Q\#P]P)S$,(1
M81B_*\Z@=NF Q^,#^V>O';6LF(&Y$C]X8K-Q<!60!%*V%?91[;Y"I:?O^-9*
M&/\ENVIO%)#UUEB55V",(.>R_+/7*@]' -H_ : 5@+X'#$X NA6@ZX66D7E9
MM\RRR4BK'=%N-[*Y@<^-1Z,:+MTI+JW&58XX.UEF3,/E#!.1D+G*\7(8YO.[
M$$P:<DFF!@^X<"9#GMPNO#GD6V7XHIFT:+NX!<NX,!]'H<6@''6XK@*8E0'0
M$P%<DP<E;6;(G4P@>8L/44RMB!X4S6@KX1**#NE&GPB-:-00S_QL>'S=$DZW
M3G#7\W5;$[SR"5ZP/3X 2Z8:\[8!/_XY71FK\3;_:G'6JYWUO+/>"6=WKP4^
M#_24\!>>@$S(GH-(FDZEG:C;B:,/3<G['XR^A[W1T:]U]%MY'KEYODPU .%X
MOS082S2ST*2CG2CJ])IUM,/HO[ W.@:UCL%YY_&B!#XKP>V^24,[":6G#J,=
M%U]UAJTJAK6*X7DJ!$^!7.R!Z>:7WD[3)QY)KDE>OOCXBB1L;YJ4G<<41P<J
MVFN@*L6&1\4Q![WQ/<.0M=I*6U:5VEJWI:FOQN_L,VQ797?Y2U/VN@>F-QS+
MH8 4*:/.$&^7+OM'.;&J\"5XI2P6=#_,L.6"=AMP/57*'B;.0=W$)W\ 4$L#
M!!0    ( /J&95&H;Q?HWP4  )H?   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8U+GAM;+V9VV[C-A"&7X4P]F(7Z$8B*9\"QT!BN>@"W398=]N+HA>*3<?"
MZN!2=)(N^O"E#I:LX8ARFB WB25_,^1/4IS?XNPQE=^RG1"*/,51DET-=DKM
M+QTG6^]$'&07Z5XD^IMM*N- Z4MY[V1[*8)-$11'#G/=D1,'83*8SXI[MW(^
M2P\J"A-Q*TEVB.- _G,CHO3Q:D 'QQM?PON=RF\X\]D^N!<KH;[N;Z6^<NHL
MFS 621:F"9%B>S6XII=+[N4!!?%[*!ZSD\\DEW*7IM_RBT^;JX&;]TA$8JWR
M%('^]R 6(HKR3+H??U=)!W6;>>#IYV/V'POQ6LQ=D(E%&OT1;M3N:C 9D(W8
M!H=(?4D??Q*5H&&>;YU&6?&7/%:L.R#K0Z;2N K6/8C#I/P?/%4#<1*@\^ !
MK I@,,#K".!5 #^W!:\*\,YM85@%%-*=4GLQ<'Z@@OE,IH]$YK3.EG\H1K^(
MUN,5)OE"62FIOPUUG)K?5G,>)!ORJ]H)26[33$FA0BGT>E#D1B1B&RIR&P5)
M1M[[0@5AE'T@'\G7E4_>O_M WI$P(9_#*-)YLIFC=*_RW,ZZZL%-V0/6T0-.
M/J>)VF5DF6S$!HGW[?%32[RC1Z,>$G8<DAMF3;@2^PO"W1\(<YF+]&=Q=CB=
M8G)>UOKR?[?>&@Q>KP]>Y/,Z\O6O"4LC7MV(5S3".QKQ=;9$;%IYB1]FZRC-
M#E*0/W_67Y-/2L397Y;FAG5S0ZNFE9 /X5J0M5:%K=<R>E1$YQOMPYSRF?-P
MN@00A+41WT3XM(TL$614(RUIHUK:R"KM4Z*$%)GJU%:&#T\[[@%M"#(&VDS$
M R.T-)$AP[6-:VUCJ[;ETUY7%[U,]$H\R(3H76N?+Y0@RX1"-YZQT8>/%,S!
M F,F0"["#$= +\9XN.!)+7AB%7P=IU*%WX.BHJ9;<DBD6*?W2?A=#\)>AJDN
M^,>E+,4F1"=\TJ]O@3#YWM,: X09@I6SQ)@I/@;3>@RFUC'X17LEO0MD)#@9
M#$SG%&D;R$00L&I]!('/_A)AQKA(ZC95V+7*_$U(7=S+F;XK=T&\E+I&XV"B
M%@A"@<K^+$MKEK;($ZM!K2(7!YF;A[R$X.)HOS@3,>808RB4AS =3RMEC3[6
MNU;W0C^7FW!]G,7.C;C*U>XE7+$HY$&]".0Q*!B!^+!#<6,.J-T=?+U879!_
MR=%$]OD!VA@"^B:.@#:6@+[,$U3AI^,W'<'9,IGQ"$Z6R;"Q\? A$.MZ_!IK
M0%_H#2A2^=TQ%(E <-WZ",09W$<QZ,1&M%4V)H&^MDN@J$V C@^CM$6'PC$;
M,#%V'X0:T2[IC5V@;^ 7*&88&!R,,R ?@_@8#H4=:H]$8QKH*[D&:A;SL;$)
MFPQTNS[",#:!6DV(=LTZ:ZP#>QWKP'I]P0)!H% $ >.U1)"."66-=6 OLP[,
MK.>&.!.!VQ:"0(N+(!T_V5CC&YC=-ZR$4I'HUF:6;O@\(@CT[PA"X;YD3=,6
MUU@$9K<(SS)%5:[6TH$%"&'@D^9CC%%_$,CKDML8%^;U%]GR:0RB9U@CUC@5
M-GP+:\0:W\#LOJ'/&C&SCIN3AKP.,";-9!@S-A?L[<2D8]8:T\#LIJ'7&C&S
M8G-8)Q#&@UX=8:AK+$P$XEUUHG$'S.X.GF^,&%;E7?BZ"*>@[\4H3J'Q12G6
M]5 V=H#9[<"K&"/6__I@<0;C8PQ\,6AGVB]R&Z/ [4;A;%/$$1L *P["4#CG
M"#.%]11AO ZWP!NWP.UNX5Q+Q/M= X+ RHH@\->WM:&VR,8U<+MKZ+-$O-<3
M+/H1'T&,ERG6-&UU)\<.=MO0XXFX6;L-<;V(CR#&S-FRM+4U'H';/<*S+%&5
MJW5( -_?(LP42C418Y->8FU!M<[)66,LY'UQR)OI[A\251XKU7?K@^3KXO@4
MW+^AEPN*W/?IY;(\)F[2EZ?6GP-Y'R89B<16-^5>C/6LR/(@N+Q0Z;XXZ;Q+
ME4KCXN-.!!LA<T!_OTU3=;S(&ZB/X^?_ 5!+ P04    " #ZAF51W)J4$Z\"
M  ".!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6R]55UKVS 4_2O"
M]*&%$CO.=TD,3=.QPKJ%AFX/8P^*?1V+RI(GR4WS[WLE.VZZ)8;!Z$NLKWO.
MN><J5].M5$\Z S#D)>="S[S,F.+*]W6<04YU1Q8@<">5*J<&IVKCZT(!35Q0
MSOTP"(9^3IGPHJE;6ZIH*DO#F8"E(KK,<ZIV<^!R._.ZWG[A@6TR8Q?\:%K0
M#:S /!9+A3._04E8#D(S*8B"=.9==Z_FW< &N!/?&6SUP9C85-92/MG)73+S
M JL(.,3&0E#\/,,-<&Z14,?O&M1K.&W@X7B/_LDEC\FLJ88;R7^PQ&0S;^R1
M!%):<O,@MY^A3FA@\6+)M?LEV_ILX)&XU$;F=3 JR)FHOO2E-N(@(.R>" CK
M@-#IKHB<R@4U-)HJN27*GD8T.W"INF@4QX2MRLHHW&489Z)E;3 5"?EF,E!D
M*;518)@"--^0.0A(F2%+3H4F_WC\_"M5BEK?+\CY @QE7%^0,\($N6><(Y*>
M^@;3L&+\N)8\KR2')R1/R+T4)M/D5B20O(_W,?W&@W#OP3QL!5Q!T2&]X)*$
M01@\KA;D_.RB!;;76-MSL/T3L'?"@!+47C[*6_#Z#5[?X?5.X"W06 ').XO)
M@NF82UTJ(#^_X#:Y,Y#K7RUT@X9NT"K_]J7 ?P[RI:6Q\) 77.ZPXC&ZK]BZ
MM(GI2[RD2MG*IZB$<K(#JH[5M"(;.C+;*IZCWF@P]9^/*!PV"H>M"F\.A9#U
MKI%XC+^"&ASP=\/><?Y1PS]JY7_LK#HM1H\;F/%'U'72T$T^LJZ3OWS%!^&X
MK]W@K2D%_Z^R-=;AU>J.^W](\ ]:9 YJXQX"C3F7PE3=LEEM'IOKJL6^':]>
MJGNJ-@QE<4@Q-.B,,'E5-?]J8F3A&NY:&FS?;ICA@PG*'L#]5$JSGUB"Y@F.
M7@%02P,$%     @ ^H9E45QX^NVZ P  9PP  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C<N>&ULI5=M;^(X$/XK5K0?0&J;5P)4@+0%3E=INU=MM7<?3O<A
M309B;6*SMH'NO[^Q$[)@#%O=?0&_///,/..),YGLN?@F2P!%WNJ*R:E7*K6Y
M]WV9EU!G\HYO@.'.BHLZ4S@5:U]N!&2%,:HK/PJ"U*\SRKS9Q*P]B]F$;U5%
M&3P+(K=UG8D?#U#Q_=0+O</"%[HNE5[P9Y--MH874%\WSP)G?L=2T!J8I)P1
M :NI]S&\7X:!-C"(/RGLY=&8:"FOG'_3D\=BZ@4Z(J@@5YHBP[\=S*&J-!/&
M\;TE]3J?VO!X?&#_S8A',:^9A#FO_J*%*J?>R",%K+)MI;[P_>_0"AIHOIQ7
MTOR2?8,=1A[)MU+QNC7&"&K*FO_LK4W$D0'RN VBUB"R#9(+!G%K$+_70](:
M)._U,&@-C'2_T6X2M\A4-IL(OB="HY%-#TSVC37FBS)=*"]*X"Y%.S7[0Y4@
M2.^1Y;R&/EF^805*N"&?L49["U 9K62?W)*O+PO2^] G'PAEY(E6%9ZRG/@*
M0]!$?MZZ>VC<11?<Q>2),U5*LF0%% [[Q77[\15['Z5W^J.#_H?H*N$+;.Y(
M'-R0*(@"1SSS=YN'8Y><_^=]^9^]GR0C[HHA-GSQ!;XYKS>< 5.$KTA3&4UA
M$/]0&7KG,V=X48E,4;8F?W]"$O*HH);_7 DAZ4)(3 C)A1 >F0(!4F&9:<>N
M"FL(4D.@[\'=[!;%[XX/S0%)PU/,PH%)1J>8I0,318,.=*)PT"D<O$\A-!EU
M26P8!D=^HR"V-#HPL:WQ')-&B:71@1DF;HEI)S&]*G'YEI<96P.IN)3@O";2
M,Z]A8 D\A\36^2S.(2.K%)8.1VGJEC?LY U_<8+FF5@)7F.9[O L\<VII+X9
MX?N6JA]$0KX55%&0-X3IFS3LNY(P/(OM-D[M-#A 86KEP8$9I_9!.T"#P)V)
M49>)T=5,Z+<$W@24%S37KV?<+L@K,!SA1I4QTLL%%%3U2<ZQY+FY4Q06!Z9(
M[&@.9MV5F]%YM"/K^.<.3!C9->( 10.[2AR@)!B[DS/NDC.^FAQS@9KS=^D;
MGWM,;7T.3&1%OG!@AI&E[AP3!1>>@3#XV3@$OY9'>K3M'.#0.5S0V[*=W*5Q
M:$4Z=Z#B@:78Q93&UF.S=#&ED27:/VJ<:A!KT[%*K,DM4\UKLUOMNN*/IA>T
MUA_"^WGH6%_H+MHT:C_IFQ;\*1-KRB2I8(6N@KLA'H]HNMIFHOC&M&VO7&$3
M:(8E?@F T #<7W&N#A/MH/NVF/T+4$L#!!0    ( /J&95$J*T>IFP(  +(&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,5574_;,!3]*U<1#R Q
MDJ9? [65:&&C$C!$Q?8P[<$DMXV%/S+;;=F_W[639H6UU=[VDMC7]QR?<QW?
M#-;:O-@"T<&K%,H.H\*Y\B*.;5:@9/9,EZAH9:Z-9(ZF9A';TB#+ TB*.$V2
M7BP95]%H$&(/9C302R>XP@<#=BDE,[_&*/1Z&+6B3>"1+PKG _%H4+(%SM ]
ME0^&9G'#DG.)RG*MP.!\&%VV+B9]GQ\2OG)<VZTQ>"?/6K_XR30?1HD7A (S
MYQD8O58X02$\$<GX67-&S98>N#W>L'\*WLG+,[,XT>(;SUTQC#Y&D..<+85[
MU.L;K/UT/5^FA0U/6->Y2039TCHM:S ID%Q5;_9:UV$+0#R[ 6D-2-\#.GL
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M.VI985C03P6-3Z#UN=9N,_$;-+^IT6]02P,$%     @ ^H9E4:%<+]/T @
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M-5++\<,5_7: <0OH^T)KW$^<0/DC,_P%4$L#!!0    ( /J&95'U5?<NZ@,
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M:+W"C6>W4;RQ\V?)E9YF=EGJ%PV%<=#G:\[5;F,"=&]D^@=02P,$%     @
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M#)]HF8_ATX*X"&A+==]0ZL?2EJ:+U?GR8C%4<^N^]-<9!*6Z+_%UHJ!4@S5
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M&N[#VK!,&40ITCYF2I2E#@<>UUMC X<H8P,'*'*^67(.865H/1-I^W3$/_T
M->/J^G*Q6J_._MI]_/S38$R#ZA6<0:LBY8LF3E2K#@<.SI!/(<KX71&J-+HR
M1#6AT;0R8U/$C?V 94XW[Q>O]J\-7FS5+CB#4D7*.TV<J%4=#CR^UH9<M)#)
M%Y@1BNQ3,$#512B%0_FU*6+8?LA4T.KMS>5B.9C]H%S5Q!DT*U)F:^)$U>IP
MX.#L 0*1F;1%*!'SM 10NN![IZ@:4<3A_8"9^/7OB\7F[*=/M_\,7G#5,#B'
MC*5\V"2I,I984:DUHRP ,C/N,X3BUM<F$4HX-,92WF^*F+\?\'2T.5]_'!Y"
M*W<V29:())V1E!R29%6ERM1F *K-S0M 7)C2C% <ZKO*^DT1[_<#^NYBNUYU
M0P8L4OYLDAPREK)<DZ3*6&)5);^A3A'([\TS!*+*-W8@%'-@Q1LIES=%;-[I
MU/YI?7FYW.Z65Y/G?QN\W*I)2 [-2AFM25(U*XG+45,$,JO?$(C$AIL!5!.8
M!"3E[::(N3N=W[LPF<GU\9'?R* ^J6S9Y'*(6,J#32Y5Q')H^5-CGH4AS!<Q
M9@@FKC8#+0@+3CDH\S=%W-\G,?ZPT#NGP_5R"%K*C4TN5=!R5ETJ=1S,@68
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MY\A>\0,D@^PSLQAABF!E:Y:2(AC5SO_2S#&N" [05+( 1Y(%1B+ZM#0E5F$
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M%     @ ^H9E49>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M/U!+ 0(4 Q0    ( /J&95$'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ^H9E45BF0=+O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ ^H9E49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #ZAF51%FM+>90&  #1(@  &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ ^H9E4?!KYG@W!0  )A0  !@              ("!V X  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( /J&95'B74;O& 0  )P-   8
M              " @444  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #ZAF515&G(*_<&  "8&@  &               @(&3&   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ^H9E44J#I4(W P
MT0@  !@              ("!P!\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( /J&95$10!2+V@8  *T;   8              " @2TC
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #ZAF51B:W8
M(2D"  "!!   &               @($]*@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ ^H9E41F\6HL0"@  FAH  !@
M ("!G"P  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /J&
M95%VYPSHBQ8  &5#   8              " @>(V  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #ZAF51PULG(9X.   (,P  &0
M        @(&C30  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( /J&95%3+I&NW@@  ,T7   9              " @7A<  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ^H9E40:-CKA 'P  I&X
M !D              ("!C64  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #ZAF51KP<_PU0#  !G!P  &0              @($$A0
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /J&95&UN1>[
M[ ,  ,<(   9              " @8^(  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ ^H9E45M=MCO/ @  '08  !D
M ("!LHP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #Z
MAF51Y'H;G#$<  "\5@  &0              @(&XCP  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /J&95'66"J[& 4  )$4   9
M          " @2"L  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#
M%     @ ^H9E49/3\'CS!   (PT  !D              ("!;[$  'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #ZAF51F>A7)\0%  #D
M#@  &0              @(&9M@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+ 0(4 Q0    ( /J&95&O#/E4E@0  /X*   9              " @92\
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ ^H9E439M
M"APX!   3@H  !D              ("!8<$  'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"% ,4    " #ZAF51+)<0C_D"   J!P  &0
M    @('0Q0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M /J&95%>\--]<@4   P1   9              " @0#)  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ ^H9E49CZKF4M$@  KBL  !D
M             ("!J<X  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #ZAF51];W3W4L(  ".%@  &0              @($-X0  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( /J&95$?"$LVL 0
M )4+   9              " @8_I  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ ^H9E4:[/[P=I!   , T  !D              ("!
M=NX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #ZAF51
M9MHMU10$   Z"P  &0              @($6\P  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( /J&95&H46#-I1   #,[   9
M      " @6'W  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ ^H9E4?2$53;/ @  L 4  !D              ("!/0@! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #ZAF51.PK_$2 %  "3%
M&0              @(%#"P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( /J&95'U['K![P,  'H)   9              " @9H0 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ^H9E46&P";>:
M!   6PP  !D              ("!P!0! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #ZAF51-#99$.P"   [!@  &0
M@(&1&0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /J&
M95$%8,S""0,  # '   9              " @;0< 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ ^H9E48<CD:][!0  [A   !D
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M=#0P+GAM;%!+ 0(4 Q0    ( /J&95$:TV'K_0<  /\V   9
M  " @;]* 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M^H9E43[IL+-5 P  /PL  !D              ("!\U(! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #ZAF51JVOA=RX&  "T*   &0
M            @(%_5@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( /J&95&?CW\D8@0  %@4   9              " @>1< 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ^H9E45(GHI*[!@
M !\  !D              ("!?6$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #ZAF51UDAF.: #  "=#0  &0              @(%O
M: $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( /J&95''
M>V%JT ,  -X1   9              " @49L 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ ^H9E4>B(G$?G @  D@@  !D
M     ("!37 ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /J&95'T?,X/J@4  '\@   9              "
M@?:% 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ ^H9E
M4:&NM'%$#@  :G,  !D              ("!UXL! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #ZAF51DSZ7(@,$   O#P  &0
M        @(%2F@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( /J&95'A3Q6;% ,  #4)   9              " @8R> 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ^H9E44_\@:"- @  >0<
M !D              ("!UZ$! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #ZAF51#*7Z#F4"  "4!@  &0              @(&;I $
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( /J&95$&74$;
MS@(  "L+   9              " @3>G 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ ^H9E45]J<EZT!   BQ8  !D
M ("!/*H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #Z
MAF51KXNV+JD(   U,0  &0              @($GKP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( /J&95&7R Y XP(  +$(   9
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M970V-BYX;6Q02P$"% ,4    " #ZAF517'CZ[;H#  !G#   &0
M    @(%3RP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M /J&95$J*T>IFP(  +(&   9              " @43/ 0!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ ^H9E4:%<+]/T @  U @  !D
M             ("!%M(! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " #ZAF51]57W+NH#  "A#0  &0              @(%!U0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( /J&95'R-V KE @
M '8X   9              " @6+9 0!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ ^H9E42)>_>J- @  +P<  !D              ("!
M+>(! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #ZAF51
M;7BBA[T<  #+ P$ &0              @('QY $ >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( /J&95' PQ96,P0  "82   9
M      " @>4! @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ ^H9E48)W?L>1!0  _QH  !D              ("!3P8" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #ZAF5129]H)5X"  !<#
M#0              @ $7# ( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /J&
M95&7BKL<P    !,"   +              "  : . @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( /J&95&&-"NKFP4  &DQ   /              "  8D/ @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #ZAF519_Q20DP"  !H+   &@
M            @ %1%0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #ZAF51AJ9C2 P"  !A*P  $P              @ '5%P( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     4P!3 +P6   2&@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1137</ContextCount>
  <ElementCount>391</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>172</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129106 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2133107 - Disclosure - Other Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIntangibles</Role>
      <ShortName>Other Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Share-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlans</Role>
      <ShortName>Share-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2160116 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2163117 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Share-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansTables</Role>
      <ShortName>Share-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/ShareBasedCompensationPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2352309 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIntangibles</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails</Role>
      <ShortName>Collaborative Arrangements - Schedule of Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Restructuring - Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails</Role>
      <ShortName>Financial Instruments - Summary of Interest Rate Swaps Held (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Information on Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2431419 - Disclosure - Inventories - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesInventoriesDetails</Role>
      <ShortName>Inventories - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2432420 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - Other Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIntangiblesDetails</Role>
      <ShortName>Other Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIntangibles</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Long-Term Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/LongTermDebtNarrativeDetails</Role>
      <ShortName>Long-Term Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesNarrativeDetails</Role>
      <ShortName>Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Equity - Rollforward Reconciliations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityRollforwardReconciliationsDetails</Role>
      <ShortName>Equity - Rollforward Reconciliations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails</Role>
      <ShortName>Share-Based Compensation Plans - Expense Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2462434 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2465435 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails</Role>
      <ShortName>Segment Reporting - Sales of Company's Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Revenues by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrk-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Profits to Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mrk-20200930.htm">mrk-20200930.htm</File>
    <File>exhibit311-rule13ax14a.htm</File>
    <File>exhibit312-rule13ax14a.htm</File>
    <File>exhibit321-section1350.htm</File>
    <File>exhibit322-section1350.htm</File>
    <File>mrk-20200930.xsd</File>
    <File>mrk-20200930_cal.xml</File>
    <File>mrk-20200930_def.xml</File>
    <File>mrk-20200930_lab.xml</File>
    <File>mrk-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "contextCount": 1137,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 650,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 25,
   "keyStandard": 366,
   "memberCustom": 94,
   "memberStandard": 72,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Collaborative Arrangements",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Restructuring",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Financial Instruments",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129106 - Disclosure - Inventories",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133107 - Disclosure - Other Intangibles",
     "role": "http://www.merck.com/role/OtherIntangibles",
     "shortName": "Other Intangibles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Long-Term Debt",
     "role": "http://www.merck.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Contingencies",
     "role": "http://www.merck.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Equity",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Share-Based Compensation Plans",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlans",
     "shortName": "Share-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:CostsExpensesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - Other (Income) Expense, Net",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Taxes on Income",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157115 - Disclosure - Earnings Per Share",
     "role": "http://www.merck.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160116 - Disclosure - Other Comprehensive Income (Loss)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163117 - Disclosure - Segment Reporting",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.merck.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables",
     "shortName": "Acquisitions, Research Collaborations and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Collaborative Arrangements (Tables)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Restructuring (Tables)",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Inventories (Tables)",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - Equity (Tables)",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Share-Based Compensation Plans (Tables)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables",
     "shortName": "Share-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352309 - Disclosure - Other (Income) Expense, Net (Tables)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.merck.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i320a221119db4c07bc18a27ee248eb45_D20201001-20201031",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731",
      "decimals": "-8",
      "lang": "en-US",
      "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details)",
     "role": "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
     "shortName": "Collaborative Arrangements - Schedule of Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "if30c830280f947a689d5b271c94dc69a_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)",
     "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Restructuring - Activities by Program (Details)",
     "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails",
     "shortName": "Financial Instruments - Summary of Interest Rate Swaps Held (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i2dbc854f67d845b19f16eeb52ee6dd09_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
     "shortName": "Financial Instruments - Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i2dbc854f67d845b19f16eeb52ee6dd09_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ib4207f99483f4b8f940795c3f462096f_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
     "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails",
     "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ibe06cede262f48698bafa7ad43037553_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431419 - Disclosure - Inventories - Inventories (Details)",
     "role": "http://www.merck.com/role/InventoriesInventoriesDetails",
     "shortName": "Inventories - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432420 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ica983717d6fb4ff095964b0c590cae02_I20200930",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - Other Intangibles (Details)",
     "role": "http://www.merck.com/role/OtherIntangiblesDetails",
     "shortName": "Other Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Long-Term Debt - Narrative (Details)",
     "role": "http://www.merck.com/role/LongTermDebtNarrativeDetails",
     "shortName": "Long-Term Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ia564edcd14034ec790ba4a71ee6a8622_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ie3bda94820614e02831a1a380b925d56_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Contingencies - Narrative (Details)",
     "role": "http://www.merck.com/role/ContingenciesNarrativeDetails",
     "shortName": "Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "ie3bda94820614e02831a1a380b925d56_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Equity - Rollforward Reconciliations (Details)",
     "role": "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
     "shortName": "Equity - Rollforward Reconciliations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails",
     "shortName": "Share-Based Compensation Plans - Expense Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails",
     "shortName": "Share-Based Compensation Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)",
     "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails",
     "shortName": "Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "if9ad3599c3a84146ad4a9b8040fa9260_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "if9ad3599c3a84146ad4a9b8040fa9260_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Other (Income) Expense, Net (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Taxes on Income (Details)",
     "role": "http://www.merck.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.merck.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462434 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465435 - Disclosure - Segment Reporting - Narrative (Details)",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details)",
     "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails",
     "shortName": "Segment Reporting - Sales of Company's Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details)",
     "role": "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Revenues by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details)",
     "role": "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
     "shortName": "Segment Reporting - Profits to Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation",
     "role": "http://www.merck.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements",
     "shortName": "Acquisitions, Research Collaborations and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20200930.htm",
      "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 172,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S.",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A0.75notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "0.75% notes due 2026",
        "label": "0.75% notes due 2026 [Member]",
        "terseLabel": "0.75% notes due 2026"
       }
      }
     },
     "localname": "A0.75notesdue2026Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.125Notesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.125% Notes due 2021 [Member]",
        "label": "1.125% Notes due 2021 [Member]",
        "terseLabel": "1.125% Notes due 2021"
       }
      }
     },
     "localname": "A1.125Notesdue2021Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.45notesdue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.45% notes due 2030 [Member]",
        "label": "1.45% notes due 2030 [Member]",
        "terseLabel": "1.45% notes due 2030"
       }
      }
     },
     "localname": "A1.45notesdue2030Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.85NotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.85% Notes Due 2020 [Member]",
        "label": "1.85% Notes Due 2020 [Member]",
        "terseLabel": "1.85% Notes Due 2020"
       }
      }
     },
     "localname": "A1.85NotesDue2020Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.35% Notes Due 2022 [Member]",
        "label": "2.35% Notes Due 2022 [Member]",
        "terseLabel": "2.35% notes due 2022"
       }
      }
     },
     "localname": "A2.35NotesDue2022Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.35notesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.35% notes due 2040 [Member]",
        "label": "2.35% notes due 2040 [Member]",
        "terseLabel": "2.35% notes due 2040"
       }
      }
     },
     "localname": "A2.35notesdue2040Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.40NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.40% Notes Due 2022 [Member]",
        "label": "2.40% Notes Due 2022 [Member]",
        "terseLabel": "2.40% notes due 2022"
       }
      }
     },
     "localname": "A2.40NotesDue2022Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.45notesdue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.45% notes due 2050 [Member]",
        "label": "2.45% notes due 2050 [Member]",
        "terseLabel": "2.45% notes due 2050"
       }
      }
     },
     "localname": "A2.45notesdue2050Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A3.875NotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "3.875% Notes Due 2021",
        "label": "3.875% Notes Due 2021 [Member]",
        "terseLabel": "3.875% notes due 2021"
       }
      }
     },
     "localname": "A3.875NotesDue2021Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.",
        "label": "Acquisitions Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Research Collaborations and License Agreements"
       }
      }
     },
     "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alliance Revenue - Adempas [Member]",
        "label": "Alliance Revenue - Adempas [Member]",
        "terseLabel": "Alliance revenue - Adempas (2)"
       }
      }
     },
     "localname": "AllianceRevenueAdempasMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza (1)"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AmortizationOfPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of purchase accounting adjustments.",
        "label": "Amortization Of Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of purchase accounting adjustments"
       }
      }
     },
     "localname": "AmortizationOfPurchaseAccountingAdjustments",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Total Animal Health segment sales",
        "verboseLabel": "Animal Health segment"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AntelliqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Antelliq [Member]",
        "label": "Antelliq [Member]",
        "terseLabel": "Antelliq"
       }
      }
     },
     "localname": "AntelliqMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArQuleMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ArQule [Member]",
        "label": "ArQule [Member]",
        "terseLabel": "ArQule"
       }
      }
     },
     "localname": "ArQuleMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ArcoxiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arcoxia [Member].",
        "label": "Arcoxia [Member]",
        "terseLabel": "Arcoxia"
       }
      }
     },
     "localname": "ArcoxiaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AtozetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Atozet [Member]",
        "label": "Atozet [Member]",
        "terseLabel": "Atozet"
       }
      }
     },
     "localname": "AtozetMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net",
        "terseLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CaliforniaStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California state court.",
        "label": "California State Court [Member]",
        "terseLabel": "California state court"
       }
      }
     },
     "localname": "CaliforniaStateCourtMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CancidasMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cancidas [Member].",
        "label": "Cancidas [Member]",
        "terseLabel": "Cancidas"
       }
      }
     },
     "localname": "CancidasMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]",
        "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]",
        "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations"
       }
      }
     },
     "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Alliance revenue - profit sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Collaborative Arrangement, Sales, Net"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20200930",
     "xbrltype": "stringItemType"
    },
    "mrk_CommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial Milestone",
        "label": "Commercial Milestone [Member]",
        "terseLabel": "Commercial Milestone"
       }
      }
     },
     "localname": "CommercialMilestoneMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Line Items]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component of Other Income / Expense of Nonoperating [Table]",
        "label": "Component of Other Income / Expense of Nonoperating [Table]",
        "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]"
       }
      }
     },
     "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Payments Collaborative Arrangement",
        "terseLabel": "Contingent milestone payments collaborative arrangement"
       }
      }
     },
     "localname": "ContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CozaarHyzaarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cozaar/Hyzaar [Member].",
        "label": "Cozaar Hyzaar [Member]",
        "terseLabel": "Nasonex"
       }
      }
     },
     "localname": "CozaarHyzaarMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CubicinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cubicin [Member]",
        "label": "Cubicin [Member]",
        "terseLabel": "Cubicin"
       }
      }
     },
     "localname": "CubicinMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DunboyneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dunboyne",
        "label": "Dunboyne [Member]",
        "terseLabel": "Dunboyne"
       }
      }
     },
     "localname": "DunboyneMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EmendMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emend [Member].",
        "label": "Emend [Member]",
        "terseLabel": "Emend"
       }
      }
     },
     "localname": "EmendMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Estimate of cumulative pre tax costs that will be noncash"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Federal.",
        "label": "Federal [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FemurFractureLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Femur Fracture litigation.",
        "label": "Femur Fracture Litigation [Member]",
        "terseLabel": "Femur Fracture Litigation"
       }
      }
     },
     "localname": "FemurFractureLitigationMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FollistimAqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Follistim AQ [Member].",
        "label": "Follistim Aq [Member]",
        "terseLabel": "Follistim AQ"
       }
      }
     },
     "localname": "FollistimAqMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FosamaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fosamax [Member].",
        "label": "Fosamax [Member]",
        "terseLabel": "Fosamax"
       }
      }
     },
     "localname": "FosamaxMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_HealthcareServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Healthcare Services segment [Member]",
        "label": "Healthcare Services Segment [Member]",
        "terseLabel": "Healthcare Services Segment"
       }
      }
     },
     "localname": "HealthcareServicesSegmentMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IAVI [Member]",
        "label": "IAVI [Member]",
        "terseLabel": "IAVI"
       }
      }
     },
     "localname": "IAVIMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImmuneDesignMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Immune Design [Member]",
        "label": "Immune Design [Member]",
        "terseLabel": "Immune Design"
       }
      }
     },
     "localname": "ImmuneDesignMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImplanonNexplanonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implanon/Nexplanon [Member].",
        "label": "Implanon/Nexplanon [Member]",
        "terseLabel": "Implanon/Nexplanon"
       }
      }
     },
     "localname": "ImplanonNexplanonMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input",
        "label": "Intangible Asset, Measurement Input",
        "terseLabel": "Present value discount rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInput",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InvanzMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Invanz [Member].",
        "label": "Invanz [Member]",
        "terseLabel": "Invanz"
       }
      }
     },
     "localname": "InvanzMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventories Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments, Primary Weighted Average Life of Collateral",
        "label": "Investments, Primary Weighted Average Life of Collateral",
        "terseLabel": "Primary weighted average life of collateral"
       }
      }
     },
     "localname": "InvestmentsPrimaryWeightedAverageLifeofCollateral",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Alliance revenue - Lenvima (1)",
        "verboseLabel": "Lenvima"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Licenseoptionpaymentrelatedtocollaborativearrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License option payment related to collaborative arrangement",
        "label": "License option payment related to collaborative arrangement",
        "terseLabel": "License option payment related to collaborative arrangement"
       }
      }
     },
     "localname": "Licenseoptionpaymentrelatedtocollaborativearrangement",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Debt, Current Maturities [Member]",
        "label": "Long Term Debt, Current Maturities [Member]",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LongTermDebtExcludingCurrentMaturitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Debt Excluding Current Maturities [Member]",
        "label": "Long Term Debt Excluding Current Maturities [Member]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtExcludingCurrentMaturitiesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LossContingencyClaimsonAppealNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Claims on Appeal, Number",
        "label": "Loss Contingency, Claims on Appeal, Number",
        "terseLabel": "Loss contingency, claims on appeal, number (in legal matters)"
       }
      }
     },
     "localname": "LossContingencyClaimsonAppealNumber",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_NasonexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nasonex [Member].",
        "label": "Nasonex [Member]",
        "terseLabel": "Cozaar/Hyzaar"
       }
      }
     },
     "localname": "NasonexMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NewJerseyStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Jersey state court member.",
        "label": "New Jersey State Court [Member]",
        "terseLabel": "New Jersey state court"
       }
      }
     },
     "localname": "NewJerseyStateCourtMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_NuvaringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NuvaRing [Member].",
        "label": "Nuvaring [Member]",
        "terseLabel": "NuvaRing"
       }
      }
     },
     "localname": "NuvaringMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical (3)"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherStateCourtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other state court.",
        "label": "Other State Court [Member]",
        "terseLabel": "Other state courts"
       }
      }
     },
     "localname": "OtherStateCourtMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments to Acquire Business Four, Net of Cash Acquired",
        "label": "Payments to Acquire Business Four, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Peloton Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PelotonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Peloton",
        "label": "Peloton [Member]",
        "terseLabel": "Peloton"
       }
      }
     },
     "localname": "PelotonMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]",
        "label": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]"
       }
      }
     },
     "localname": "PensionandOtherPostretirementBenefitPlansNarrativeAbstract",
     "nsuri": "http://www.merck.com/20200930",
     "xbrltype": "stringItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Total Pharmaceutical segment sales",
        "verboseLabel": "Pharmaceutical segment"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prevymis [Member]",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProbableContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable Contingent Payments Collaborative Arrangement",
        "label": "Probable Contingent Payments Collaborative Arrangement",
        "terseLabel": "Probable contingent payments collaborative arrangement"
       }
      }
     },
     "localname": "ProbableContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RestructuringReserveNoncashActivity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve Noncash Activity",
        "negatedTerseLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveNoncashActivity",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty Rate, Percentage"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Sales discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Seagen",
        "label": "Seagen [Member]",
        "terseLabel": "Seagen"
       }
      }
     },
     "localname": "SeagenMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SentinelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sentinel [Member]",
        "label": "Sentinel [Member]",
        "terseLabel": "Sentinel"
       }
      }
     },
     "localname": "SentinelMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SingulairMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Singulair [Member].",
        "label": "Singulair [Member]",
        "terseLabel": "Singulair"
       }
      }
     },
     "localname": "SingulairMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SivextroMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sivextro",
        "label": "Sivextro [Member]",
        "terseLabel": "Sivextro [Member]"
       }
      }
     },
     "localname": "SivextroMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Stockholders Equity [Table]",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stockholders Equity [Table]",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_ThemisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Themis [Member]",
        "label": "Themis [Member]",
        "terseLabel": "Themis"
       }
      }
     },
     "localname": "ThemisMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_TukysaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tukysa",
        "label": "Tukysa [Member]",
        "terseLabel": "Tukysa"
       }
      }
     },
     "localname": "TukysaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VelosBioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VelosBio",
        "label": "VelosBio [Member]",
        "terseLabel": "VelosBio [Member]"
       }
      }
     },
     "localname": "VelosBioMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VytorinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vytorin [Member] .",
        "label": "Vytorin [Member]",
        "terseLabel": "Vytorin"
       }
      }
     },
     "localname": "VytorinMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZepatierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zepatier [Member]",
        "label": "Zepatier [Member]",
        "terseLabel": "Zepatier"
       }
      }
     },
     "localname": "ZepatierMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zetia [Member] .",
        "label": "Zetia [Member]",
        "terseLabel": "Zetia"
       }
      }
     },
     "localname": "ZetiaMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaantitrustlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zetia antitrust litigation [Member]",
        "label": "Zetia antitrust litigation [Member]",
        "terseLabel": "Zetia antitrust litigation [Member]"
       }
      }
     },
     "localname": "ZetiaantitrustlitigationMember",
     "nsuri": "http://www.merck.com/20200930",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r201",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r181",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r201",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r70",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r400",
      "r406",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r598",
      "r641",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r400",
      "r406",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r598",
      "r641",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r208",
      "r311",
      "r312",
      "r599",
      "r640",
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/ContingenciesNarrativeDetails",
      "http://www.merck.com/role/OtherIntangiblesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r208",
      "r311",
      "r312",
      "r599",
      "r640",
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/ContingenciesNarrativeDetails",
      "http://www.merck.com/role/OtherIntangiblesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r341",
      "r400",
      "r406",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r598",
      "r641",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r341",
      "r400",
      "r406",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r598",
      "r641",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r209",
      "r210",
      "r311",
      "r313",
      "r643",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r311",
      "r313",
      "r643",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r288",
      "r401",
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Accounts Receivable, Sale"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r607",
      "r625"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r76",
      "r82",
      "r85",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r82",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r82",
      "r92",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r82",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r79",
      "r81",
      "r82",
      "r627",
      "r649",
      "r650"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r78",
      "r82",
      "r85",
      "r142",
      "r143",
      "r144",
      "r489",
      "r645",
      "r646"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r71",
      "r82",
      "r85",
      "r489",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Cumulative Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life of acquired finite-lived intangible assets"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r176",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other segment sales (4)",
        "verboseLabel": "Other segment"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Total share-based compensation expense, net of taxes"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r34",
      "r216",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r224",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r131",
      "r189",
      "r196",
      "r203",
      "r231",
      "r483",
      "r490",
      "r547",
      "r605",
      "r624"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r63",
      "r131",
      "r231",
      "r483",
      "r490",
      "r547"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r220",
      "r240"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r218",
      "r221",
      "r240",
      "r611"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, fair value",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r410",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r502",
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r396",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r396",
      "r402",
      "r457",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Acquisitions Research Collaborations And License Agreements Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r463",
      "r465",
      "r466",
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r121",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r464",
      "r467",
      "r471"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r464",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input, discount rate (as percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Debt assumed and paid"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income tax liabilities",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed",
        "terseLabel": "Share-based compensation payments attributable to precombination service"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r124"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r124",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r552"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net Decrease in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r129",
      "r131",
      "r158",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r231",
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared on common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Shares, ending balance (in shares)",
        "periodStartLabel": "Shares, beginning balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r88",
      "r90",
      "r91",
      "r98",
      "r616",
      "r635"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r97",
      "r105",
      "r615",
      "r634"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r342",
      "r390",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205",
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other profits"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r101",
      "r599"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Foreign currency"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r606",
      "r608",
      "r622"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r563",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount of debt",
        "verboseLabel": "Par Value of Debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails",
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate (as percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails",
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r134",
      "r303",
      "r304",
      "r305",
      "r306",
      "r562",
      "r563",
      "r565",
      "r621"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/LongTermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "terseLabel": "Debt, carrying amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r132",
      "r443",
      "r448",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r318",
      "r357",
      "r384",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net loss amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r318",
      "r358",
      "r385",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r334",
      "r342",
      "r344",
      "r388",
      "r390",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Contributions by employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear": {
     "auth_ref": [
      "r388",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year",
        "terseLabel": "Expected future employer contributions, current fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r318",
      "r356",
      "r383",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r318",
      "r323",
      "r355",
      "r382",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r353",
      "r380",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r319",
      "r360",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r319",
      "r360",
      "r387"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r321",
      "r354",
      "r381",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r122",
      "r184"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "negatedLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r65",
      "r69"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r64",
      "r68",
      "r546"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset",
        "terseLabel": "Derivative assets",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum average period of maturities of contracts in years (less than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r66",
      "r69",
      "r526"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedLabel": "Cash collateral received, asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r66",
      "r69",
      "r526"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "negatedLabel": "Cash collateral received, liability",
        "terseLabel": "Cash collateral advanced to counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r503",
      "r506",
      "r512",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r500",
      "r503",
      "r512",
      "r521",
      "r522",
      "r528",
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "negatedTerseLabel": "Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income",
        "terseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r64",
      "r68",
      "r546"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability",
        "terseLabel": "Derivative liabilities",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r65",
      "r69"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r497",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Total swap notional amount",
        "verboseLabel": "U.S Dollar Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r496",
      "r498",
      "r499",
      "r500",
      "r501",
      "r508",
      "r512",
      "r525",
      "r527",
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology Rights"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r47"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r99",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r156",
      "r158",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r617",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders",
        "verboseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0&amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r99",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r617",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders",
        "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck\u00a0&amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r171",
      "r232",
      "r302",
      "r307",
      "r424",
      "r425",
      "r426",
      "r444",
      "r445",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r545"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Publicly traded equity securities, fair value",
        "verboseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Income from investments in equity securities, net (1)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r230",
      "r637"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized net losses (gains)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r16",
      "r20",
      "r226",
      "r623",
      "r653",
      "r654",
      "r655"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized losses on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized gains on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r390",
      "r535",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r534",
      "r535",
      "r538",
      "r539",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r342",
      "r344",
      "r349",
      "r390",
      "r535",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r342",
      "r344",
      "r349",
      "r390",
      "r535",
      "r572"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r390",
      "r535",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r540",
      "r543"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments",
        "terseLabel": "Payments of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r390",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r502",
      "r508",
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r253",
      "r256",
      "r259",
      "r260",
      "r600",
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r253",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r259",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Acquired rights"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r551"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r342",
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeFutureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).",
        "label": "Foreign Exchange Future [Member]",
        "terseLabel": "Forecasted transactions"
       }
      }
     },
     "localname": "ForeignExchangeFutureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Currency options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r342",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r395",
      "r399",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of issuer's shares to which the forward contract is indexed.",
        "label": "Forward Contract Indexed to Issuer's Equity, Indexed Shares",
        "terseLabel": "Forward contract, shares"
       }
      }
     },
     "localname": "ForwardContractIndexedToIssuersEquityIndexedShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ForwardContractsMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.",
        "label": "Forward Contracts [Member]",
        "terseLabel": "Forward Contracts"
       }
      }
     },
     "localname": "ForwardContractsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r246",
      "r248",
      "r604"
     ],
     "calculation": {
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r122",
      "r247",
      "r249",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r500",
      "r522"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r122",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Intangible asset impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r189",
      "r195",
      "r199",
      "r202",
      "r205",
      "r602",
      "r613",
      "r619",
      "r638"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Profits",
        "totalLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r437",
      "r441",
      "r442",
      "r446",
      "r451",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r132",
      "r153",
      "r154",
      "r187",
      "r435",
      "r447",
      "r452",
      "r639"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r119",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Other Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIntangibles"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r252",
      "r257"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r93",
      "r183",
      "r561",
      "r564",
      "r618"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r342",
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap contracts",
        "verboseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r60"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note\u00a06)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventories classified in Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/InventoriesInventoriesDetails",
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product.  Includes supplies used directly or indirectly in the manufacturing or production process.  This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r103",
      "r182"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs, Policy"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r131",
      "r197",
      "r231",
      "r484",
      "r490",
      "r491",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r131",
      "r231",
      "r547",
      "r610",
      "r630"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r131",
      "r231",
      "r484",
      "r490",
      "r491",
      "r547"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Payables, current"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r22",
      "r23",
      "r131",
      "r231",
      "r484",
      "r490",
      "r491",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Payables, Noncurrent"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r52",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss contingency, claims dismissed, number (in legal matters)"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims, number (in legal matters)"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r46"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Unallocated"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r56",
      "r131",
      "r231",
      "r547",
      "r609",
      "r629"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used in Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r120",
      "r123"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r86",
      "r89",
      "r96",
      "r123",
      "r131",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r161",
      "r189",
      "r195",
      "r199",
      "r202",
      "r205",
      "r231",
      "r547",
      "r614",
      "r633"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "verboseLabel": "Net income attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareDetails",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r89",
      "r153",
      "r154",
      "r486",
      "r493"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests",
        "verboseLabel": "Net income (loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r307",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r497",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Interest Rate Swaps Held (in interest rate swaps)",
        "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r82",
      "r92"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Total segment profits"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141",
      "r155",
      "r175",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r502",
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r481",
      "r482",
      "r488"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Net unrealized (loss) gain on investments, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r77",
      "r79",
      "r481",
      "r488"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Benefit plan net gain and prior service credit, net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r481",
      "r482",
      "r488"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "verboseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r72",
      "r79",
      "r505",
      "r510",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of (loss) gain recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r79",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Increase (decrease) in Sales as a result of AOCI reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r87",
      "r90",
      "r92",
      "r97",
      "r302",
      "r553",
      "r558",
      "r559",
      "r615",
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive Income (Loss) Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r87",
      "r90",
      "r481",
      "r482",
      "r488"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r502",
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r314",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r47"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other liabilities, noncurrent"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r371",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r106",
      "r109",
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r116",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Three, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Antelliq Corporation, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r107",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Other acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to Acquire Investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures",
        "terseLabel": "Payments to Acquire Productive Assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r341",
      "r343",
      "r349",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r390",
      "r392",
      "r393",
      "r394",
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r315",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r371",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units (PSUs)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r112",
      "r115",
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r110",
      "r423"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r86",
      "r89",
      "r117",
      "r131",
      "r145",
      "r153",
      "r154",
      "r189",
      "r195",
      "r199",
      "r202",
      "r205",
      "r231",
      "r481",
      "r485",
      "r487",
      "r493",
      "r494",
      "r547",
      "r619"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net Income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r264",
      "r632"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r27",
      "r35",
      "r631",
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r82",
      "r92"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r80",
      "r84"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r195",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of segment profits to income before taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r432",
      "r666"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Charge for acquisition of Peloton Therapeutics, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r124",
      "r126",
      "r603",
      "r626"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r269",
      "r272",
      "r278",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative costs since program inception"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r269",
      "r272",
      "r278",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring and related cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r269",
      "r272",
      "r278",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Total pretax restructuring costs",
        "verboseLabel": "Expense"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r122",
      "r268",
      "r275",
      "r280"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r271",
      "r275",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r270",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r307",
      "r427",
      "r628",
      "r648",
      "r650"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r232",
      "r424",
      "r425",
      "r426",
      "r444",
      "r445",
      "r645",
      "r647"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r371",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r395",
      "r399",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r371",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r395",
      "r399",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r371",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r368",
      "r371",
      "r375",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r94",
      "r131",
      "r180",
      "r181",
      "r194",
      "r200",
      "r201",
      "r208",
      "r209",
      "r212",
      "r231",
      "r547",
      "r619"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r82",
      "r558",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails",
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r374",
      "r375",
      "r378",
      "r379",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r503",
      "r512",
      "r522"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Amount of Pretax (Gains) Losses of Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r409",
      "r419",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales of Company's products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r534",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r253",
      "r258",
      "r600"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Summary of Interest Rate Swaps Held"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net cost of defined benefit plans"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Fair Value of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r273",
      "r274",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r273",
      "r274",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r270",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r100",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated revenues by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r94",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r189",
      "r192",
      "r198",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r410",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r212",
      "r640"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r176",
      "r178",
      "r179",
      "r189",
      "r193",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Pretax share-based compensation expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per share granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r408",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r415",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r212",
      "r250",
      "r266",
      "r272",
      "r282",
      "r640"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r129",
      "r131",
      "r158",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r231",
      "r302",
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r171",
      "r232",
      "r302",
      "r307",
      "r424",
      "r425",
      "r426",
      "r444",
      "r445",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r559",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r31",
      "r32",
      "r131",
      "r217",
      "r231",
      "r547"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r131",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r231",
      "r232",
      "r307",
      "r424",
      "r425",
      "r426",
      "r444",
      "r445",
      "r479",
      "r480",
      "r492",
      "r547",
      "r553",
      "r554",
      "r559",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r307",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "negatedLabel": "Share-based compensation plans and other (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r560",
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r560",
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r560",
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryLockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
        "label": "Treasury Lock [Member]",
        "terseLabel": "Treasury lock"
       }
      }
     },
     "localname": "TreasuryLockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r53",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r53",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r26",
      "r302",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury stock shares purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r53",
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r302",
      "r307",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EquityRollforwardReconciliationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r342",
      "r620"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Tax benefit recognized related to settlement"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/ContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common shares issuable (1)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r157",
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r156",
      "r164"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r667": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r668": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r669": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r670": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r671": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r672": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0000310158-20-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000310158-20-000030-xbrl.zip
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M%=VXD+#/*SD$M$!5QE$A_KJ&;;D?Z-=2PGR/_3*/_9'OY?]ILWV.X[)K222
MX,X>[A032T+:JGISW_3.B=^Z A): E]"?#/CG\\LC\Y/ D/5GX:3WQ8&X (3
M#=T3P$[@5"T0IB#[Z%3JH8H9E#!39L@=0N6=J8AWZT.&9U^A=G?#YRA$B<9V
MJR,EY$D"2?6/NJKLUP./RWRFTADY,L_YI'IBIRM>H:Q(U8(P.I^JP"3\ ;:
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M_J=2,E-N @=M*1-O(.DM89H6<'.*88+%\_4P/",T])Z.!LE252#>E+I5?)N
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M(2L\QU+MBCSQZJN^]@UJ7L/3/P%02P,$%     @ ^H9E4:?(B3EM!   HPX
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MX^7'GB=H3!3OK:^?^ZKK+6G=FQ ?2U_(;9-G/IBJ9_GYIC\DQ_\ 4$L#!!0
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M%'N3I%3:"%P=$O.42^(RZ)/FUISCOI'AN<6Q.;"GJ^?L$&.! CX"6 )&)U;
M9*5C1HVP=Q)L;JB[87-(9:J@F5O02H.L:\#Q7W8D*5[4:EX0W%;V-'NT065N
MS5HKW8!B8\7:I;%#:),X7!#:5E/_!E$>!%E#X)*I0.A=QI]6&]2NK778NUF
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MI#98ZE3L7<G[JO%7N,[)NPJDT#H18.X@V E"HZ+C21W^=0F9_+.UTB[3"IN
M!HS:4IYJ4'.+$W7KO4QEC.L"UF!F:Z4=CB6@::MGEP2JP-)%M5>JG"PF3PK+
M'TL[K26_Q'CS>^:4Y^(\!N+8(()D*E!$A5H$AS1(B37MOGSGL<+RJF"Y0V]9
M>DU3U>[*72"DB$5CMT!E$!(6D]5;+AF6OWO.8R[>LDC*K7. 6A6@#&:LDGL-
MQ6TX3EA Y\@5EG.!Y0Z]I?; W3/&/"2:("!G<:&$D2 7VZ<,EQ]Y:^?(N#(M
M?RF#8FYXW&7_PD@NK<<4<AF*E"E;,U!*5:T)+V -=L7CM>-QI_ZQ*4:N+;8"
MV#.C2JBU1RMQ^,P%K!+L$A%S\1(5A6M*F90!6%UD<*GA,"A,10/C#9.><QDK
MYD/XE\0^%!AD FS)8[&2B:-47U(I]\5U#+C\@C_77X"VE=X"!P.;.B;VC(.Z
M1N^6JA@.5;6@ K0KOGX57]=3@C8(9($"H4[.2P6)1NC/*MHD".&"2M"N^/I-
M_W7U16A+[LEZ@+,T?2U1?(B:C!V&UG&C)57<7_'UF_[KZLO_BV7EF%N>E@H'
M0<94HH4<(L? *=B"^-<]UP,^/AYG>0ZLKT]/ONY#1)X^.CV8&/'SU8FC1X^W
M_G#Z[&3\"5MO&OV/GF57T'PY/C[[]^FXN],W'1V.I\<_$\?GO^@OO#G\\NCX
M^%,^?OCYP=&/DTR8?M3S@CA35LHT87!T<' VFIY#>@E3K8ODFQJ=R7+2GL)4
MH!3#4/V=+.94'+(OB&^NXVD=3]?.KY''L,&IJ: !4"7$U(+'[%D"@84%\>MU
M/*WCZ=KUA)22, <NQG&(UL;4>N7<2ACZHB$L2$^LXVD=3]>NGTJU6*&+Q<)3
MJB5QX"'.>Z+(!+DO2#_-411?TZ2Q-X\I*Y6I%%)EA*Q" L[)/8<E31K/T:C7
MU(ZT1J(.B$@,U !+J Q2<]$L@G5!3'*.1KVFAJ3LD#*7*8,8!(W8>D^E9^DU
M0[<%T9DY&O5Z8FI+7@R;IU(=8G+.V2-DMBJEE<P+BJF+F_-^GKVMS_8UM&?0
MXM6[Q*EC$ ;.@["Q5C"7!ET7%-I7;,V,8:1N982:SM/45(E*4(?O:D:9(09?
M$L-8L34SHM.\IAHP84.!EA))!6:#*:$M5_$%$9T56S/C6S@ U:0%K6;0:I14
MLG-)S<P"XI)R\/[0_-3GIR>GVYUAZD+POL\'EY'.?/W\"F-2#L5Y2N9DL$&M
M4FM4)-$T.<8+XE<KEJZ93Q7/Y ,JC2Q!CT8-2YS:M0U16!K3@OC4BJ5KYD\!
M&[":<Q2:*H?S5)4Y6Z/.3;0L:=UKQ=(U\R5*H):U()) Y\(IM1[2D'RI4L&P
M(+ZT."[^S=;Y^'3[;/S2'_:1/S&7'L!R90@ W"AWK='2D'V6<TH+XD\KMF;&
MIZ"*I5J 4B_005&Y4^F#F+<XJ-:2<JE6;,V,7U4<?(HE(JJ ESP"HUDLB7G:
M=B5]0?QJQ=;<^%;.P-TP]*C@-4FH&A"%H5  W[]TC,O:Z'\A9-_S8^>M/KP]
M#.9/_.#H\5EVVH6 O<BPV$G4>S/5:D".V%VJ4[66H"':@L+B"J_Y14;KJIE#
M#904L@EC*5US(8#8(2QI!]\*K_D%QZZ,(B""L0(G1JQD[E"F;-02:?[%1C[?
M'/*A;OC@%:C>M.G?[__EZ(EO#\_>>>#C6#^>FK[?=[V")N\[+$$"Q+TZ%NO!
MAKAGJ3'D-@29H337-O\2)#.WU0X+DTQF&DK&O>4&M1E"YX:@ 4(5BF4/QM6+
M*>)7!EODH"H]1PV>M5&#@H2]<JF91KB-&6@!11+G;*@=CJBF<3 >QRFW %P2
M@:?H.4P-VBE%VX,1]>G1HT>^G8[X*X\[LY@1U AS4.48A[X63FE:(_/!*GQ:
M<MV#$72%AMGAB,FUAM1S\L(-#!DCY&&IRA34."R@^>$%#+-]?+0=W'>1L4<[
M*$DLK9=!MCD,,PE*P*FY*B LH!?"' VTR_9W;IF&%BK0 "@QMV0U]=1:D>'N
M%M &X3<-=%9H_1/6']P6-WYB1,<@J9L'8%.6X)IS5Y025/:!NUVY>799R'3(
M4K"IE7E*$*B3\A@ZU*M..RC:$N86>+/]!Q^<^B?/[IXMDIQ-'7V^]7^?3AF]
M;]'L\X-?._3XWF2T[>;PP:ZFL5[[22\?_M]QD=.LU;,OISFK__"KOCA\?'IR
M?'9$W-F/F;'TV&7;$8HA%.)<.H-)9NBQ(H:,"-5T"=)C/X&<5B#_OO1J4<4Z
M:$P[F^U5<DAAR#<K9=HHN8!&)7L*Y+P"^7?F(H4(&#-T/*N1+C%65@M-:H=4
MER!M9PCDFX&=J ,R(B5:R= *<I'*M0*,UUJ.2U#=,\3.2DNO?D:\)S0HS .W
MD&N004IU*.$^-2EH7E8@K[1T$4#NO3NH:^# D)L-@LI56W'KI;>R@$;3>PKD
M&T%+=PAD1I8,F:D& &P1E6HRZ#T.?C%\\@KD%3O_<1DUJ'NJ&E02%$P\98QP
MRL9"N7=<)<W>T])EKO\'&4Y..6##!)6=QQ,6CEY"Q4(+Z.<X1^#N%BNSHK]S
M 6Y,6$L&$N$"XDH<1'.FBJUB6J?U;QQP?XONS@6XTZ;+-&WP#5G +)+TT++E
MKA DHJ_ O7[@S@4K 0=0*L;&5J#U(#WG4J#D'&.#N&KKE5;.4P_EF"H/A^:E
M1&BN;$%[LN8MMLAM"6FE,P3N@J/SI=+*76[]R!AEN'#19* =T+U;Y9Z]Y@:!
M5^#>,.!>*JW<;;:K92Y>3 P"-3*L(9'VD'LJ:"MPKQ^X<\&*$0UGUCP03+4Z
M&IT5A@D):@94Y05(D,M)75\T5J^ ULY%%Q$Y<XP\]58$16 >CDZY0O;8+"PA
M%6X%\.)HYBY3X :Y1*]%1 -D;$Q58V@2,Y8LNH3L^A7 BZ.;NTQ&#N2HDJ$%
M@$@#QT,W:8Q:H:NG)4R_WQ@ SP8STBVA:/70(3'S@(Q3]0)2>]F+W?I[@YG]
MH9V[S!"BG'IDZ!(:P C30T=Y*;6BQ^2^A RA%<"+HYV[W-29(L2F13V.L V=
MW1"PEYQ:M!Q\!? -!?!29CE3[3$9! 8D:&TJ>!92YJPA5G=90M;\C0'P7##C
M-N0UH58I&=+4_H\+@M'P@E3<EC#;N9].Y^H6T9=<)R.,"!V!,0>HX#4+%X$Q
M/IJ%X@WJ"M^Y(&9_*.<.X=LX9["DK;<.VH1;#+GF9M$UM*(K?&\D?!<SSYF!
ME V[I#S\KV) )S.N'C-A74(1J1L"W[D@IG96=Q^^+4>@V*0VH6*Q)BR1ZA(F
MB6:(F)5N7I%:BFPV9;Z%$:B!HTBU'@"R6"TUT5I@83:(V1^ZN=,93A:(H7>F
MH?&GDIS#!RO7F(NE#FO&_,V$[U+F-P52"NZY0&R0Q(GKD/LQ(DF- 'V%[US@
M.Q?$0 T8*.8:F"!20THC5'.NJ7!T[@L0*)?>5V+1X)W[^OH.I5.BTE*4W'(D
M2!S0N-56TP!<&T)\'_INK%B>,Q'=(9:MP,"PF#2+T*E(5G?P6@U#*;)B><7R
M8B9!AS<F@.((W@8)380I:QY4-7OTP3U6+,\2RW.!S]3)/$D,50=Z1DSGQ)E+
ML6@<V/H2MJ;=1/CL#T7=H=RB$;^-@K<0'=BBU%"X,.:NN2UC?FG%\I(IZBY+
MT"9BCU0P*X!Y%C]+JRNU>,ZI[D,VZ(KE.5/474Z<DB2M/-AH&,(K(Z:S?<W(
M+0RQ%?**Y5EB>2[P@:J<=>@;Z P:LE#I DYD41NF?=A0_-F_3\?O73)8]H>0
M[C(]5#-7+00F *$!3AT(-3:WZHJR#SN)5^3.AW[N,E%*+$6.W*S$P3L9:T]!
M,G*T%%K9AQG2%;GS(9L[1.Y44"EK#]$3@IE*RBDHE](2<@E+2,G??^3.!BP-
M8ZV)))PEPC-/^Y!,0U-P[+R$E([]!\O^4,M=E@E3*D4B=VP%2B'JUM60*'1S
MDWV8MU^1.Q]JN<M"#04Y80\V[=FH4R<#[JJUI)0:D^[#-N$5N?.AEKN<D^<8
MA+IW#0Y,53"Y5)5&TWZC7E?DS@"Y<P%+XJA3T:T<>@?4BN.%E#KG$BC4O#92
MW4N&MTMM0I2H4U%H#@B=,5GV4"7TH+2(A,O]!-!2YO"F!CS4*(AX <\#..:M
M]1+*$+Q6EK!NLI\ 6LQ4&H4(HLF5.K#XX.F]8\@2..2"Z_[J&=HL4#4NQB!4
M!^T029JX><1!14)]7M)AYAQU/P?]4B:6O YR,>A&ER!391N4)CT2A (R4+5V
MA]E+VK%# &%@:P5S3U4@CT?18AX2>6CF0)+6&@M[23MVFOK8ILZ\8"DI:!\J
MVK755D(3*.ZR FA^-HNM%!W\T" 5&(P1V:?FRA KE>IE";M0]G/0[ZRPRIT!
MAB=\LGGBK^8.[VV.?_C%CN&?/=6'?/C /QT8V;*>+(0\U^8Y\% ZU :06Q+/
MWL83]]Z;^2IXY@:<_2%@NRR+EII(:+&S"*A%C-4-FPM/58)@">T?5A0ODP7N
MM%1;8?20>I0(<5HT\=JJ$&:&X+FM*)X9BN<"G)(AMAISEN)04T5IQ=$=&F;O
M894/*Q5=@*#2E$JC -RS0AF1O$N'FB43#KS9$O:RS@_%>Q/$ES(76%MA#1P+
MJ8)JI1AJ\$"E#'4%LH3\VA7%RZ2BN_3%W2QCTZZA@4PY&0.RHD4R6B!9PO[5
MFX7BN0 '.B&'8*1#PU3*&'M/@E,&AH<25B5^0ZCH%P,36S\^N<<G?O]'?KP0
M)64M%^X8K#E!YC;EN@X ]X'J5);1BGP_X?M;]&^%[]E$0($1L+%B:P3DCK%A
M;\VK,4OHZYK4;!"S/ZQSA_#U5*EF3JPY3:DW'.$L-Z=BQ%HIK/"="WQG@QA.
M&CIWZAA!33G'%M$J>(HAT9JZM=+-.:LE*B6+%>7: (RCE"D3*"<FI53S.G&_
MTLTYPQ<I +8H1KW# "R+L#E9*M @!ESA.Q?$[ _=W.FV;)620[16>> X2RP<
M<Q[@)<N:>(7O7. [%\1,#6^+*22- B1"U ,.R=UK0<"P@ R-/S0'_?7CDW&2
M2W Q<P'M['>[['*+&U)3Q<*6'2 4]# 4%#@QHX3L*X9O+H:7DN_9 &,'=6\=
M(/G4!+<00Q RM;Z$+LXKAA?)/G>(88I84^?D70&:)])"7J-,^7NE^0)62F\4
MAN<"&XR!0F\>:PJ@5*D3(W6+EK,J+:"6U(V"S?Y0T!W*J*EXGQ,6C=8!!7G\
MW6.IX$V&#UQ );\5PXNDH+LL=C6@JUDC(A30.)6ZLLK6!]:&1]8%9"NO&%XD
M!=UEX8LT&&@>JJFT# X9<S)D@M Z@0NL&)X5AN<"&\@]#=PP#LA 2YD9%+VV
MQJ;2VKIG>*[\;_?#ZD?>VGF&\J6V*-_I9N$<J;<Z,)O 2F&+5;NHI&KCZ5HD
M;C:(V1_BN<N4IRB9(E,;@1NT5^08LG@8 @HDIS7'\V;"=S'3GLD-D#W6W@ S
M2QKB*<;B)%EBQQ6^<X'O7!"C.4[L,CFS #3%F(MUI%X;]5C7)+F5;LY9+:7:
MV0)V$P:P((-^UF1:F@=K'=?RI+-!S/[0S5V6N9.*A!)S2 ZU)XG0AP.6H)W8
M<-W/?C/ANY0ISD:06R"&RD/LM\I%)/<B:A:]P[J1?3;PG0MB3$/B@CUE;$ 1
M>$1LRC%/[)-+6KN8W!"Z^7J*\L+J@;4F =PY>QF8C8) !E1;;K&3X!(:@LX/
MPI>&FOVAG;N<Y6RE96&NK1O$6KC77A)K[QVC/Z_)OT+X1D)X*3.=V6F0SL#8
M6H'L3NJ8,[(E[S6EOD)X3A">"VH*J8P_E09H($Y9[4P@H35KV0V6T'%Q?JA9
MZ>=5*JBN B5DI1((4A9Q1Z]ZUH+-&_H*X3FA9G_HYRZK>$I'"ZJ1%6'$:JDA
MHEB(VGH?K'2%\(V%\%)F/DOKL7'HTU(I6&IBEJ:>9I:I4H;5"\\*PG-!C7BH
MZG:6&0Q8"84[-S;((;=2\K_NG(F68>M;LU<OO]7Y^_;QL9]\POJ#VX7;?_\!
M.PU;;$_N#"B\$ IQ_/?R/"_?>WD/[;5#7]<4Y^_\ :/BB&.U)U+*!)@,G:9&
MIU.KGR)DR\IXG"?WV*$"3,&T<($B(I"E"*2(Z*F9#ZOE97&/>5IKIV&V<&^H
M9:J4/;PDY:FX0K.H1()] ;,\MU6/3D>P_.KHQ(^_/.+#X]N']L)Y'CX8(=1'
MR),#/_YDV.X!'WQV]O._[I].G_+MX^'!GGWS[+$_M^FC[0\?W>?#H[[Y*Q^?
M^.EV(:-NL*6@D#UGK=!516HO$)41JF1>P)[$!=MQE_DJI:8T5%N47D&J(=<<
MM7H:9&9\T0*6;Z_7CA?^F:_Q[#.W_>HK_],1=S;'9U<VT>*%> 4J'JCG4$@,
MH"+G!FR-H8'DZ#K1X>$5PAD=OAKW\#L9YS2TPL48Y]NC\!T8IS)A;K%9[0*]
M!RHT1F/00D'9PP)&X5]/91SQ]Y/-P9DL^.+PR?C\T?;9JU'U\J4Q4#][^MCU
MQ.WD2/S^T8']<W/R<'/X]:%_Z[R4"#@"GF.+H93>H2<=GA,JN&C6:09A >7P
M%F*S7>[@'4XH%6DE#(D>FDCWDE&].EAT64"_@HO;;+S[U^V1G:K;YO"O6Q^!
MCJ>-O/UH^_SUDR_Y]'!<Q%(V-E@?8\P--*<.PB2"%0/G7(:[-%] 9OC2C+?+
M#DE>O)204+0#&>&P'@UC.F4/D?TY,PCM!3.8XQ \WIY\].+F?[V][]LGXZ)>
M(XV;)^-BMT>7.R$V+!+:A>G)KB;$(/92D$/NVL!HZIB14O<^9+LQ\7G]N'KY
M-OO=OJ?NQO?P5&W'U"*$#*Z-PM1OH47WREA?9KE>P1WXH[[GCLO)VS.[$VYO
MAP]:.9RTDYWZN(AZV=%@1Q91@F!NL;56H5F3(2^$V7M)K>8>%FR1^ &\9I$<
M%F*1&*-(RYP (_!@P;WWH?NZ4BS=S19LD?1!?LTBL!2+A#R&1:!I@CS#4"J$
MK'D822+WX(:+MLCK8Z3,V"*GAYOGYE ^]I?W^='SR9ZSB_ETO''^X?/7SY]/
MG_[E90^MI9/ED"A#SH0%8@-(4GI.V68\D?[K/.KSHV-^Q$\7HDE8II8.N0SM
MKT 3+^(:<XT5,4%/9^N_$V=X3FO'@_F)DUV8XT)?\N40/0_.5,P$^->^PLVW
M?+"KB=8OCXZ/IRR"S>$#/]3_S]Z[K>EQ'.>:5S3/DYO(C B?R7MYO&2-9/O
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M5V^^N&55N;FQ,D.@"Z17-JQ:I_ODD+K;(NXLV(NYGG, <<**=@QB9H>.3,<
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MB_9BCN<<2&I?/*#&,CL%%%-1&F W0%JPS#T@Z^:07%*T$Z/'3!TC%0!QN?6
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M2-Q6KQ>S..?P 2146Q;JLX,5X_68H( B1EV6@#<?M^7CDGIE0VEI2ZU'=R6
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M$NMV.><Z_]>OXE8Q!7.W,0L8AA(5$5ET]*@S-Q,W/L0OYG). @3Q\[L:DQ*
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M7LS&YN5Y>+FD?HFXHDGU((;"P0DZM%E)&0@T=N%V6Z*'0>2<6G%H2@&H@!4
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M.W8.:5;8Y=GM<LYU_J]?\@58PJ]);=8.I":C=X65OD8K,2DW$_<5[,5<SCF
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MI&!! D6 H1Z30YQI\O(X#?J8B-+V)(3M<IYO4XM"4PV02@.6KY'2D:=/ZJT
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M8 \]+=$&W'[A2T>M1A@D1A*VX=>_61(8;(/-(K11GAXV2>?4J<KGR:6R,L&
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M^?H2Q\7QO&Z2KL\?D-_)'[@V/^#[<_UM*L'7\FPK'U_+QZLQ]E*_?_[M#QP
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MV#M:%ZV=U4^MH]>?6J]:A\VC]4]E//C]8_/5&XKW.6T>?;U)UQ5[1ZVCW9W
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M[#=*BGP[?K6M=+[IWV#B)_?S]6'#QATBSS.U9'>///?WT^'AQ:HV?L*U&D:
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M\S0[1@(N*X&<)7$L29)X",*J;%A@:%C8A\1!*E4L!E7,8GBE$L2C$,25A)&
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MX"^_K?ZQVGJQWMC^S_KZSLP_Q$]O.NXDMI$TGC7^B2S3P'L<EKK]C?0I)-0
MQPFE>G_(0D>H;0;]GV^0PZD2]DUJYIRA"K2N*!XY--M'6Y"?J6RH%7'PA^ZX
MGYY?_/!K;/>/#]WI\W9G.(;AAZ[98CU'KK7+FNH"WO-=X?/+G^-Z>8CKKS3Y
MZ#4-^$EUX\MTF=WXVO<N:Y<5%?>ZZO=?D^)^5_W>6!E;1O_T5I?]P<;['3J9
M?F<W?03,R;@.MSO!L(V(3$<>(2GHLT8)OMRBX^^B3L9:"N=SP<I<,/O%7"SH
M29<?T_IP;E;[_32XN??*HV>TS><-)EH=9CJE7LK)P4'C >)QVU.AT[S&3!0S
MGF)!']??'Y8I#N6']+^3]@=W6%S ZPOY/+A@V1Q''J][Q(4)'K(0DU%,",@!
MI,W.4*<,*$-ST$'DOS<>OGV#$K;:B>7;^J6<K0Y>N%ZO!#'^<H<G:5:BAZ?-
M]GGT\.#UZ=ZKW4^[.^N?FJ]^/]H]>"U:;_]J[^X$NHOOWSMH?FKMX/_YWL%E
M]'#CX][1FX^[_+5LGOUVM+GS6C0/WL/>J^9IZV"U1 T_XC5/FVLOWW\3/3SX
M[6AOY[>#O;7W9\U7N[*U%DXW=_;?[YYM\.9:B1K^]G[O8.-C\^U6;EZM,"2$
M8D%(0ZP1@0 +@?C$+9'!<N^4Y+PTO]7/A%0S5&1M3$45*R\M*"]9*0(2$C="
M2XC4V("$Y#0 %3$Z+0HO,<NX8/\_>V_:%$>2;('^E3+>O&MJLPI-;!E+]WV8
M(:'N8:8!+4@:Z0L6*Q2JA5N+)/3KGT=D9E46BR0600'99HV@ELS("/<3QY=P
M;W%IE7"IT90;*RQ9U(@)01!W*B MO41.>4T+(3SG>FU==X5<)5Q:B>*/=T<+
MWQR.QE,$1OR@V;FS+>YX&R3JHN:<VV;\*62?XJ)+3V6DM>AT"73::18XB*X0
M!BN&&"P2XL%[I"152 HC2%H]F9+"V\::#UYWKTXT6BW]15JZX!!2@@!R;)%(
M/7!Y 5JJL2A0@/62K+!*%RDS0CZ$\DG791#-2M%W1R VG,L1P-3D.P"G3N&S
M)W73JWY_],4,74C;7L>/9G8:9_V<T)"_ A_YQZWLNLN:NU$/Z\_1>+,:5/T8
MK^=/T>KR%709=+C69;A./_SK]<G']_[84BYVCAR,^=W1-MWIYRRME'%U=, _
MP-AVWF]]W?WKW='.MX^''Y-=<?2BV-W;.('Y(#M[!V3WU3[UEH':8(2IY8BG
M(Q]6688*$4D00GLAV=JZ.ML^+\6OEX)BIZ/"IYGX'ZNA6"6@)8_M973DIG:W
M5D?NF8ZPG5?[EA/""JT1C90AKB5#5EB+E "EP9P90P3HR%GSN]01HG_KM+T)
M[]Q]?E;-=L*TU;0K:=K"_K-81*LE1T$Y@[BW$BEE%##+ G-*N _<I^,/G+:]
M!A^P_MZ"F[G5WYO3WX5E*(0U41N#B-&PMWE08JN-1-05G@O#2"1V;5UTI3Q;
M=*[U+M^18FX-/X/0C\8]N.23\-7U9QY^ZS5>O343\*?5MQ[SR<YHZ%JMO;S6
M]B[FM]O?#HIM^H+ <W[[,'AULK/Y(CT;WCDZH-M_[1SN?'O+8>PP'G^*W\(]
M-_:MT-H'ZI#B8 ARIS"RN/!(8.PC6(,@$"X5]L#J[!'&V@SLW)Y%U8K<_18Y
MOKNQ+T( =L@\4E@$Q)4#:XI&AV04QA$GN/<B%3#@YS1RJ*VJG_,\4/R4%G>&
MU*YO)I->[ 6?1IV+X75,3@CLH,XDA,[.:!K*?53\UH8'5VB7"BU67!(K&LW:
M+ E&>8YB@+V$:TEA:_$4%1ALPA ,5E$D4DG.J63<A@0?C+[>ZA;?ZNME]75A
M! *HBD(XAUS!+>* K<C RB I960D6%!7O;9>=/7UC< '$"!<$2.P)!,5KZU(
M1>MFOG,&L1EB@"7Q95&'/?,U3#:&/B]6>1*D=5E= :V:B=JXD )''Y"3J0YE
M4:1V*M(@+YR-E'(2 UU;YUUQ_8H[K<MY=77Y%MA%J\N_1I<7S ,+:T-T8"2H
MP! 7J:$KEPX%5T12$*M=U$F7J3S;TO7^N9_OVWG7\W5T;S0U_8N(QQ6,H$?<
M;N$VPMXM4%T1J)8:N156&<%"@;#R@%;24&1]X,@S*Y04VMD"@(J*;G%]I+H"
M6MQB';]?T'>E!8+;B)^W0'!U(&BD4E,5? 2RPF1,R6!>(\.]0]%[(3 61(94
M!5]VN;KAVLLKU%KEGM;ON#B:?OJ 5MLU:L5HS'G'0MJP[M7@;"E_SV%&==1(
MQ12(Q28B@Z-%GC!,*9;*VM17N\OD3>7OK0RM:=O)/01:TP+#30+#@N<8(8FR
M4B&3@2%&CY001?;1P'H99S3+&1KB[-F0%06&U7';W'PAQY_4W9?CT3$,Z*3;
M>=DWR7LS])U4M.$XT9]NQTQA8B;P2WW2S+G98-;/=6Y].!Z#"IJL\ZN77[BQ
M&.IF8Z3P>S_D[I)#OS%(C2:_Y=?KB<C3 ._-)Z%%C,L4JMC;F&[7;I+G&G_\
M[R%V@W=#\U[/=H^V4]EPN.>[3]OO7] =>,;=O6=PK^TO, ?LXV ;KIW*BG\@
M__VV]75W[].7[90QMO>6[NZY_6@<PT9+)(,RB >MD<5@=Q&F(P9;2XGD&B:J
M6YQ#37XN-XRPIW>7&K;"B9.M+CTH7=K:Q[0P!>8&L8(XQ(M40Z;P!2I4C*(@
MH;!4@B[)KOC.*;;KIR<^8B9\"SO@A6K8YD9=01-K(WECWWH=P$:VL/T(CCCA
M&FF<VDHX4)S"4TYY4A[1U>3:5+AU_3\Z9+B%_;Q%AIM$AI,Y,G#-&*.D0!@0
M''%,%%(A&*1\H"$P5Q!E4H_U+B[:6,"]B 7\-1KY+[U^OPT$K"K+J5>HQ:U+
MX=:+)J/AA21:"XJDLOG0OD;**8^(\DZ(*&G =&V=XB[E-W7J=V483>OU?PB,
MID6!JZ+ @KT4A1!&28D8C@1QQ2C2AAM48%\8'$R4(H7^=)?3XKZ@P.JX^._N
M2,C6<&J&!SW;#Y,N7'G:YF:N*I=9K%29G 6+]2)7<X!9;1'N2@BWU>0YPFDO
M#-AG2D2!.%4$6<L%HM(5'!>*1:^RYT:T29NMYV85>4Z+$+\"(18<2-@"3)[
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M,E?B:VXIS<)$&G4$TY3;5#Z8FI1F81#P;$JU$MP0GOI'<'IM\W3U"G*V^/-
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M1+%2K&%W>AC&C]+=<!D#YL8Y0I[V5 753 Y+VZ4R7%H N@P -1,SC2=6A4B
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M@X@7VG!K!"Q];KQ0/-I,ZSMIO+!<:6YC_&K6#V5MN6YNMP OYHX+IJ3MOO6
MK 8_.6U//9M-8/"3R=Z7T4Z8[L848:W>\BUN70JW/C29":"5"4(*)(AFB,.:
M(<.\0]QY4<!FE:RN9%<5USK.U?I)'@TIN:B29*O1OU2C&TS$!&(TQHCPQ$2T
M5\@4F"$7O8U:2& E?A6K2CYXA\EI+@(ZV._W_J_S?#0^'HUS580;Y"2/PJ"Z
MI2JX%V/7X3B$%KVNAUZNR4>X4U)*E4PH%A'WRB+-G4'*2>(5(T7 ^,;0J_65
MK+"Y<:?AFU;!;U;!%_1$!6&#H!&%HDCT)#*DM;8HNHB]T*%@.!_^$G1%LKT>
MFX_DXFK\K<=DI=C)8/SI8N#Z<S0;M[AU/=SZM" F>QMD^]6^P-P*QAB2(L5R
M8O1("Z-1,)1S&[ W!5U%TZKUF=Q'<M+J]Z_7[Y,E_=9%H8(6#L$26L0%<\@$
MJ1 'ZP,P7#,F5 K38MXFF=QBU;QFOZ!)ZR)9N<35&I/"I$6DZR'2P=*Y&%%0
MQP-!SOJ 8'O12!E)4L<1:H15HO# -C0^>X:\/17S(#3WQDOQMIK[*S7WI%'_
M05..4V%>HF@*P02DG )%UMQ%$;R4*?.<7JN\3>OAN&KMW<=AS=PN0[B@H&<-
M.'^.QLU\M+P>\S/Q;0V)Z_LG-O:)<2XR9\%VT8 Y5 JD@F<HLHB#B%1B+L%V
MX:3U2SQ<3?YUI7E;3;XE3\3&OI6B4$QA1 )1B$OF@?=KAJPOA"IL(%+SM75V
M3GSD_B5OW+=R+S^HD)>J(Z5ZO9>J]_((JUW=LO]BCFG7K7O5(MTUD>YHJ:IO
MQ()$'GSJ?<P1=X!T%K. 8.-B '7,$HG7UGE7B!OH)="6R'M$H'&31*@%C14
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M!B,?^OGR $^]Y!"!NRW=*5$SV&9R9=,T*B!>8+ M??^<>YK^9-1Q54FO_#6
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MLKW1,4C?P+B<%F3Z\QQ,^+?T2C5RC+*#I#>>)-U'KF^2"S[MN>,JM2@IT!3
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M_6J?:2R]!ZY$) /JI H)U,F#!:X9 PKCA2 :-LD?Z% ^AE3[1MO-\N<WRR5
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M?-CGSWK4.]VP6W9R(^ANG*36[<*#[??.Q30_U%&N]6ET^\"Q9!@[S8DHE.L
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M]H);S&LQK\6\JS#/>ZF\)4$9QZT)QDL![E.P*=(8,+N0;=]BWH-C'IMB7F#
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MVF"-HY'E?4P!T)TTT0X4EE/F0B!U*X6E//%6:>]#:<F<T@*CIS*BZ"5P_:3
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M24H166$YHDSH0*W%7HB-;;8@OW(B2<4I0'[?EF$&Q&5%:'7%G[*%S*9O"O5
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MYL9Q<<TOHQRI=**V?"C'I5X1/0&^,L_!Z!4B>O7&ZM)#J84/Q;=J6W_Y;\,
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MI%B9=OV8MHRY3Y89+;F"&()/-F:'KS@UFF=7_>;KS,KS\+4T(B=)H>1_6@+
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M5W[VI<LRMJV$OM5EO_R9%'6QCVNQ<+T%?:6D_(;=S;^Q?[BYX-/N&&\6KC/
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MW,S9;L9A_[!P^>:=']N-O6BH#0+>M!W&7A95IE2WUMU9Z)6'.3LN+@'<GOX
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MOX;OJN+46N'4V0RGJ$S*>!Y)-FC_@=:<V, HH1KMP<"R8UXO]5A5H%HC;JY
MU7JKDN8T)68E0Z"BP7.?4+G*3DL>T#:XAK>J M4Z =7>7*%RGML0!"76R9+'
MP!*Q(!3)U'L;4;]*P+=VN%@/H+ICJO6D,I]_+=NZ69M:R"U;3WAZL;3UWI6)
MU7RU^[04P=<.YV[BW3*1:Z6]9LZ DM&X'$WI719Q:YB\CG>K.N77$O+>+"1N
M29^8%L*3K&-"S0Q1ST@12>DB:(,TW- 22U3\KF[Y.T#/M]+?;KBDJWN>?(](
M<B,7E/$N>^NR91Z"4H91SY4TCF:/K^D]N: J@JP.03XO((AT%+)"W%"<@,M
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M[=SL#%8I)E'.!NLH2ES!B;<QD(S&)V6!ZR3L^DG<>^H_OV&6IZ?&:B&U95E
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ML[T/[S_M?7X/^V\//AP\W\=GWBM)96>SI#)C0LS< *$Y<@)"2N)C$ 22XD*
M I?XUHY:4?GOC27$-ZX-OI7PK:CV/:#:__?_&,[XSY7.*YUO-)W?B_2ND[_N
M6<#S>7\/9CV77A,FK2;@I".EOIYHEP(W)D4#KFU]MJJ9VA7\*OAM'OA%1KF@
MQ@8>)#A#'3-<VL D8]GH(*Y7<OLY#0?1C0ZK0;-:O(,9WF7#5'"FM P!2L"#
M)XYJ-&T2S12EEP<>9]I=1;R*>-\7XE6SIM+Y]T#G:RC9JT5S%PG_:;<[:;/S
M[!U5'D\C>B+!H(PW"H@#AJ^X1C/&J6Q2>G0R_K;Y%S6P=M56K.WSM[&S9TMC
M9C?I8[#1?0J<,US%G"$F#2)H%[R*DC,?E4K.?F'.?#6M5@>\;Q9B14(D%(<B
MD,BY0]/*-D/D%6$N&,4MDF026SM*K*@!P0,T'UE%<Y''QY2WLPGJ*6T@=%9'
M_3VCZ]Q1+Y-4!G(FM'1] LT\,5EHPA*5I5-/3EF4SI'\[H[ZRKIKR[I*I, $
M/JCB&B0DGY7*-*H4A346W'6[,U6MYVY\.7<H&Q 2M]N1F".:F-%+XA)XDKEG
M-D#BP96V2W?ND%^9LFH]]90>!#JKUG//Z+KHS$,M52JJ,M&0BC-/!N*MLT09
MGZ6.F4'0;4?<==)[[G\FYN9XZY9OQ=H^_[,0AB>EEJL?.X-S6>^]2<U=-]W.
MC7?=23-KA\IWBB*NT0R@S3ZEFXSO8E;IK#@/T8,,R;LHI(M4\A02B^EZ'H.O
MQ\#^,^>8*C-O(C.[E,XLDJ" &S0_".5&$I B$"N4)A3_2(9YY05?=?BK,NWW
MR[15U[T+W\X]?,FR**E2A*(:BIJNI<38R,L?R6L\1\]7'K:N?%M5HGI*MT%7
M:CR8H&4R%$U0+@S/!IR,0F2:<N(W]\16Y>?6(/II]Y>9P\!Y$2QH0315O$PL
MI<0Y'@EWRHC$5%!6+QL/6%FSLF;U]-T[X\X]?=Y)+82P!-!F0;N%<V(Y!<(B
M$Q"=8!"AF7N^LE*DFI=WL]Z1@R'^L]])G\*AZ[]/WV-6WI<[6M1@RS38HM"4
MT8$)(QU8 YY1_$]Z!FB >J-K=MY]X.O98G8>BQ:D"D1:A=9E\()XSM'8E-I8
MSG-*LL11UBF(4B.@-4Z](:=T+]!9M==[1M>Y[TZ 2LJH2%2RI3M.#L1$2XGU
M(AMEM*.6;>W $\8KP&XNZ_KDO8FTR:H%'X1+F6N5*8W,2FYMS<Z['[Z<9^<Y
M&H/TWA*A0RY=JQ)QEE'4>J@U/D2K0)7LO%5-3*U<6=6>>DKWBYU5[;EG>%UT
MVB744QW7EB@M$@$:'+%*(LKRD -/0>60MG;4$\;T&D'L=Y2>MV*GW2-+SKMS
M*>WW$"]1'#$V6IU<3 !>69,RH/42F G92UZ==?> JZ\7VZXF&CTU( FETA
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M;%2<2!8\@>A+G7RJB;!46F=%3";6\B\5FK- LRJLMT/G1&%%B4)!U 1+?S;
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M?8#+$Z1_GOD =UYZV/GC(Q/1@)>2@$)=\OX401L,\4)$B8RA9+YVZ:WXK&[
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M+6'[JN1U_BN&O3Q7',3F;4DP#Y?KV"YLI>_YHM;4>C^R3F,W??(9+F.!44Z
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M>?'ZKF?TW>\O)9'#)$NZEJ.JURSJ/M5]JOM4]ZGNTZKLTRQQ9$#*DS0B"*O
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MM+KB>!5Q/,G982G8$+,&$9AF69>PD>3]XR1I&YTU&<9L<39.Q?'*XIAQHZ0
MFXU<"2YZB]1Y(:PR6AG^O2R[BN/[P_$DUT6D;,XA6*)"" 0BB\3I$ EG+D:G
M!6+R%<</'\<R6<\A6_94. B!69>H%D$D#]0Q$RN.5Q''DYP1&4 YIB0!"$A
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M54/BQ:(PDD/RQA=RJGS)(BN5DK^FU'0#Z[(V?Y]M"651E>28=& 9Z! 8Q:+
M-(^"(A%C1%[>QF]#[,HB5FOOT3N=1"[@H@OT;Q': -I(%C6W+/6M;_S60[]
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MV&0F@(8(*'F4+'@;&'AG&$V"8\7%6!*'H$Q>6[^V+'B#YLI"TX(3!<AKLP5
M(G?H-?GW//J<<IEV#F\6=37VEPFP2@0GLG(L9$^ -0Y9K?YE: 5HG9P3:GD)
M\ ;;E86M%\[($B26!&!1^J0]&A'KR4AM\9P6 PV@-[>W7$6.7,Q9<L404V04
M>9/+JZ)B$IVCZ(6C<<VB/FAH.L$]+Q3F&,DA>>.+#\Z73+2M4O*ZY<CN'K +
M)Y4#!T@".2/+:1@('IGGEK,$/$LKM3.I6=1' %NMO4?O=!*Y@(LNT+]%: -H
M(YG6W Y5W<WF\;,M7EPR4EO")6@RJ35<!2U9K5%/(22C=&HF]2%C4Q(DDTJ"
M7"A-9%U%T[,)N2C!R;BF<[H(-)-Z^UO&-:VD$]J@F4-5&#C%";M*,O Q>"FR
MU%HWF_KP<8N2@E3%H]=6 8)R2F87/'!;/&"$9E/O9F.8$"J*EBD6%F) !E)&
MYK@KK%CG/ 2RL8JOEDV];96".T#6*X+.",>3WBA,L#?^&O:NMA/\&"I1<N(R
M:%>D<A:\@!"=]$JH6LL=M)0M;WW7A/-Q<2>8!R=1A,2D=>0':!.8UR$S#) H
MRI:&'/I5+$)I!61+WFZRD0-B4*@)IR(Z\!F\L<J*XJ,S#;8K -MY-CMF7MNT
M669<E7GDPC$?43.+-%UU'RJ*=M[B$< 6+7GP,01C2P9A="B&_,>0R+ES J?B
MK0VV=PO;A5WBE)(L4<191VMC. O.1)8Y).#%\VQ,@^W#AZU";X(DW\M:#0K1
M)W1*N9 E%B-E:;!= =@N5&,YBFJ2 N:M5!6VAE6!#\:CKRT?O%>P/'&7!MN5
MA:WV*=)_QA-J0=1RK. A<FNS59C!M'3WW<-V80<Y%JN*5X4YXE=RDNL!"Q4*
MXQ9 :4ZAK8@-M@\?MB5%T%PEK[D'J6)$=&B2]#%KM Y;MOM6H]B%'61(1?'B
M-(O%&P:1G.* 3C#ID*,((66WC&QWP^;*8M/$XC)/283D@#S?:+AP-;N1;"D4
MUS:3N@J(G>\@9V>EEX#,&9<92 PLQB*9\@6*3IIFLR6>'@%NM2W"!EYJ7Q[(
MTM;B6@]<9^4-A4/-IMXR0N<[R"6XVL4L,)EC8 #@6>1*,<.E# 84>!]7RZ9>
M]4!Q'(XRCEA57:^W'@]W^KEW"))EU(!<Z 8/$MXRB!23$.2=%7#)N%K:)4M0
M57W-J+:+>^>@_[RXBYL1G-4BL: 5D!]=*.:%E!FJH*RV4=BRO%8"EP7'+15]
M-3:XN0#:>UG5+!)86FA %D9FA=Q$7H4X0;=#3;>*^P4!1FE$<D(S68PEW$?%
M J3(4DBHDG+%2;>V+KUKF&^8O^06%?CHK><QH@94A/6,UA;-=9<W.Z?_?/,
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M9A5=SKZE=1L#-P9>=09>5EUEX]KEIG47"BRU#-*E[)A'81ED7\]6F=I;(14
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M'FFAJFJQ.O-F#E3><@+I)_GS3^J,%-)CZ=ATP\44][=ET_*C<I$R.B.4@I)
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MA'MAIMU=U0\/I9]WPOX@$;E<2/7C8K(60GIS)&QQT\H"DS#XV">O?NI?KIS
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MQKX\\3:5A_DGX]'E@L*]SB#]1Y6;4.S2#>S2T_-'TV>/X<=LFSYZ;:C1B(@
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MJ!*3$,?6(!V81='&*)/GV/-,=)@4HBM$5XAN>24;"]$M@NC(%=&12(.T-J#
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M4105[,<B4[-46SMF[@X@!<3K"^+51;H+B.< \3B\#<L'^K)5R U*/7B'=(H
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M!# .RCM+ C,X($GR*71)0*U/U".B+-9@QV&#_1; 78.J]UNA@<VE@274:B^
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M:XOA-3UM7[#\.%@>!]H]J--*I(BL! .:>T5SDXB $G"TLDE**LW63JECM<&
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M';;@L_2%[@K=;13=F5Q&)(1 C-1<$P[<1Q3#+FH9C6-N 3GEA>X>3'?LBNZ
MT3@6+B&:B 5CEACDN*7()5#'O?2:^IQ%ON#SDX^<);[)C:7?9Z=O[/5O]2J6
MHOI+=*:-5J(0T*P$=#'A36,4F(%&X![%!.A;$B/#14+6:>(]-EAZ#.;E=(YI
MZ8"Q,6!=@BNH@/7A8!W[@HC@6-F(D0].(NZ90]I2CFS"(?C(@G*YR]S<M<T+
M6-<7K$MP9!2P/ARL8T\&4UA$3 72RFG87E6.4QF)$N=><5@P1>W6#I\[3E7
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MGB"6G$-<XX1T= 9A8RQE,2EC7:Z,,.U:>*)J;N5[_G??NE:\JFLR>++&V0D
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MXM?<Q5#B?>=K^VJ\4Y"'ESUPLKTF[3"@D^ID<,KX\$?#2<AS4._ OMFV+VI
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M?6!1<LFDCRAB%I"4V-B6EUON-H[UFV/R27*L%W'HQK-E\TPL'+,3*#VYDR"
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MP%2@EYIL"5G5-F-7%,*]>>#[ 6"]Q(2!^]WO15NU0;E!N5.SGAOMG$<M<HP
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M#N04DPG$UZ844H-$7R#1?6W5!HEE0F(A.S347.[HF)<Z,3!:,$>.$HO%H8:
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M-Y^E!6<1<TZ>Q5!/'!L76 "CF9HD_AD9K*^\@58Y\-'J=DG5!)J:'TK-<^\
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M$:B]0R'J,\;]/!K7&VRHNS?JWBW&:S67.62/S&FPM8$S&4@^1,;),+:"H^7
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MX$\3YN,59BK>D\F:7$X1-&#0Z+ER/$JZ=/38A+DT82[D.2LD,\8#0S2*02G
M? '%5,@Q*&6T=65C6XD^^9@=]?9X[%G.>/@'2:<E.=_B[,PZXU6F8(,DKU3K
M#%)#\+HNJTX8'[B:XK7E;3TX7D\7.WT8E4QRG)'9:1GPPLGJL9P)8V@%Q()$
MV(UM)WMT@J2C4VQ-E6>J)%,W>@]H<X"2Q<0'%29GXS&(EDVY-%7.<YPM)WM'
MI<B4DIS50DW,9R>8*9F<1>L+^8H;V^81%CQLJIRILA[JLREP%WP&>N6N-M#*
M7+NZ"XWM0-#25#G/<>;< 41M:]D_<D2B<2S655,A<3)XXPNOU9"A+9:/5Y96
MJ>1LC"D'!.6LTX8'P*)C#F1&J9:WM219SG.<DS#62V%9"%$PR Y8, &8JBDB
MF&P"PVFQ?(3%8)HJSTQ812_;6A=1:XBQD.$**21NLA%6!=Y4N215SG.<0TW-
M\@%9TJKF4BK'G B.Y0(FDOWJHB-5 C15/EI51JQY[HA1"*Q5KEW2J>9N670J
M!+A)I?VFRD["/0O;7%(5;U/V+"A1SQX8SV)$0XLGV*S(LBVE;G/Q1]A6L0ES
M)DP44$\#:9#"@Q(VHO+DVQ0I4*N N65L+4V8\VTN'KE-5M4ACYR!K)H4Y&>Z
MQ$5RS@AI:RKE8^QRT81YMO^,10GCDS.HH20=T%@;.+A<DT7\3>HA-V%V(LS/
M<IR%+=J0?PE EJSBDGGC/-/!9LG!:U]K_0G=PCZ/5Y@Z&"<]:!.L V6*=T7[
ME'Q)1HN"V(2Y-&$NK)C!!N&<8*K6WP3I2)B)TXKIN"K)!J6R(A=3/L)^"$V8
M9\+4*AE.[SZ4#,KKD((+1M-ZF57V/+6,K64)<R''.2@G1>".<2=JJQ) %J(/
M3!I=*S1!!F]HQ33-QWR\PO22#"-;SU-S#4[0:JFCQ2 AD+D4?,MQ7I8P%W.<
M@XV.ED;.$L3$($%B'HIAA7,EDG1:Y'KX0#13]O$*DUP9+LF2U3E' *-#=+$H
M$*AR=C0EFC"7)LRY*0L:-;F7=8E,D@$ADKF"EJEZ(DAS#L+DC6WI^A3\Z:B2
M\U1?8B%5^6OYS@^CKULE"6]L/S_ PWQQV-M!BO.B4[D(HXQ%,(#6!U_/M]5$
M_JAD0M&REY8!F9??+V3Z@O I@\Q,%ZEK&,NPH+QAFFME9:T/5D\$W[M=13O=
MU%M1<HZI).70<0L2A<,2;2G.%0&)UI@FRB6)<I[H6Y3,G$PQ%B-D!JB012<]
MBU9$%:7)9!74LTU-E8]6E=85;JQUD#6"E,F%"*%P&V1Q,47?5+DD5<X3?1V)
M4ACI&)1(JBQ @E0.F'$EF$)KJ F.5-EJ9SQ>50HK8VU'&\DP@JA(C5X6E4M
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M^[#8=MI.CPDEAR"-#X2,['MDO4-M>V;Z YS+!]L?'MM??(MMF<4KPDIQQK;
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MF,PNV3LO7Q.P%M:R0R*EX8B/0Q\?$G-\R'QC"_ GGPYH-GWVU*)Q26@V$^]
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M+^_J ?-YP?39\VB-B;6B.I%XK@NI-A&>L Z8UX%Y\_XZ9FV]<2I>QMZ\9DG
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MG<#7SFFR/<'63A+3\X*YRJ(YC:8M0&[.XEG;*,;-BN5\P+P.S)OO%SI+E^W
MKSH2\N*DN')\6*PI;8=AK0'FJT=+#YB/"Z8R=+<RF1TG-,IE!Z6UQ46W8>*
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MSL90$0Z8EX%Y[_N%@B$S>TC+&F#2Y"3DFC*,U3T^E8;[-68^*O-YR<QMQ<?
M;&(?J#(DKV)9>]G2)G3F(?,Z,F^/?TK#EIM;6K!"91;LB>O[;R6#F$+S_B:S
M,F](YJ51R3\"5'\F7]EG7_Y:OIZ_^D?Y?G_O6PPCG&N<:YQKG&N<:_STK_&Q
MC\-\\YE\7+,P_^D/<=W/,9N04>&!-3=J-J6-C"-$L?/X '?OU_'WC:].&_XF
M;?@O[J=BIKA#]I(6673AK;0DM<WD'9M.1,FR=^O]JQ[\/Q]A_*!L_B%AA1!0
M]H5U\,*,67/&&?)KU>R:"8[Q_C(B;P;?4J28[A$U+!Y_,"0MLM_##LM#EAKT
M'>][7K\^+Y@^>.QG(TRSXZ1% -B\62XF'?U#:N8!\TW O)N(,:VC[@%2C=XE
M< 1)TNI,6ELQ\T5QMPZ8SPWF+#YFGL15'-V+C$S2ZRCB>R7".!;?R\"\5<P6
MY5*+]T1-83])MB0==CY^(^R%F_;\\N[5>RH.E@^+)8.7D"I>C":**GF/)BJ#
M25MYR3I87H7EW41,CAO1YPH.EV%":BO)D)+<F>*#TQI!W7'XQZWTO&#&WPU'
M",Q9&''RI%I 9&]LSU1Z\P/F90KS;B1&4.>HNU:N1E$P%R2!)<EZZ=,SM-S'
M)G,<,G]:9/XASV4S6F]YKGU,8QO&V*!!F3I6J,TY/L#B>Y[+OC6C-WN$4(.Y
M T1[$4G8<":RK&GMN)1"4ZV'VOS7YHCS8/91X?Q#=E5,J$I%9MD+$:>S,(E*
MCG8*8?5CO[\0R=M<S,RE-@9(W4=.B-@2Y0FIRE"?CC@$]L#:F?%^8C)M 4DO
M#;&CM<ZM<7=KT>(:\LJ'S.O(O W& )59758"Z3UAW(]$O/M;0>=*6KK[)O.1
MO(2'S#=^- NB8[_-9D-DFXI@7CK6G5M4^CHNW^O(O W&V) X&0U2]*XEX>PE
M*1FF["Z=?:U0'WN]]P'S:<'T&7_O&MUK]8K-JWIA6V-F,QE=QP'S,C#O!F,0
M75F;IN%YFPMFZ$NED1H2 N2M/BWT)9RGL\]+YF+OWA9WF@T'(I%GK5!]Y37&
M.H,Q%Y)Y]^1GE$D44!8B3FB6DXX=)P86]1.+*?E>5?%(/H,W&HSYB3J __:W
MWWSYU6=?_(<\P!_%X@TS)JQ@- OF <I2RO:QF>XHRQ.\?=$Y\U?WSE^M.WZI
MS[2S=K9KPA.!2&K<^GOSV;3]-.N!MFZ<?3AOG(??K(8.TSIH^V0Z3QG[MK-Y
M1IAXL+P,RYN9B6J9Q9U3%M(0S&:)+:3SS&X$I4RIL*O_X?)IN;1<R4OI9D,1
MEDC-VE?NRZIYD7FXO(K+._=OG(Q*7"$Q[Z6KTTN26BV18 BG!E)QZ^576R8.
MEP_+9<O8>B]U*V&LDBE:6:ZC.941]_^X#*_C\K=WN=N99^.<!&FO=6),,J$F
M<X&Q<"Y ?P/S[\'R8;'4/#.-Z8+><;:FM,MGW\L>XX0&/5A>A>6=^=?:*A)*
M/\VI/6&KF&@_;;;1:H"9&Y<=A_](2QT/EV_+)2FP+H3&/''J4&<U*$'G<L[Y
MK(^Y3E[>>7]5U7K/.06-E$+VS\11-5->H36R5^$]7MI.'_N\8#+KU#;BAI/M
M@LDT1^FU]E'0AL#Q,%T'YNVUCTXL1==*=8 E-)Y)]W.@Z@M&J,R6![^\._O)
MGY?+W A02V\E5 S;),_5>^$9FG,@K\/E=5S>7+\-L).-G+Q(=+(D.X^ASX0P
MW2@:G-KMY5V!?,A\6C*'"55SHMYA>TJ%D'MNL['+JCH/F=>1>7/]^K1FLT<7
MZQ!D8J^)+,B<.(H7RZ-/VF2>FOG$9,91/-9PR2WCB,K96]X;^*9D+-Z.Z_="
M,G]YE^U;,G3R5''FA'4'XP- >K^E(%L5@C=Q_1XP'Q9,*-1&EU:B(.*,D[CL
M/"LKU:T%KN6 >1F8=Z[?.GIVT9:P-]]Q?S,1EOA@ K&!^K*67][5<DKF\Y))
M4]?":60YH_AB 3%85J@R=SPE\T(R[^+PU6""S52P2D+.T<RVX@D\#],%#5LT
MLQ4>J69^W+F_GWSSY>_6-Q]7\.\?T@  8@@QR*J,*,S ;<A[-],$7OH!+B;_
M\JO/Y9NXUF^^^=GOUE=?FGS]]^?P>9/#YV_NK<![=U4?4U+A%F>/."7J$%]9
MT66Y:=N;6/_O_XMJJ7_Z0%,'9Q[HC1>8ZR!1PMH=T"M*ANI.WG(O ]B/\? R
M.&\&IU7$9!$DVZO+$562KIY3YF(S.ZR\C8?EC- ^,9C$8]BHR$,':LG4C7J;
M6>+_=CSP ?,J,.\<P4M;R4HSB>416GI"XCIKDFA[T*'FSG# ?&XPEW3(S@ R
M$'M(:<KDH\51'2R6#_(>GB;WA\3U5D>KV?(V2II3+.KH:(F 2AI10"O ,/1Y
MFMR/ -DV:QS*N4YP[#TZWD[5,2AFPSSDV!*O@O/.+KR@D@-I6NA;=S(G6;#2
M:MB5UVR\GW[Q"21]8BY7MA[\#6@%6Q-V;*(3G;ISJR<J^#KQ>6<77J6#3-]C
M;[SMPEJ2%*&T%C>I8]+,<,!\:C!EKX<:/8[B/-"F2)/)8V\Y7X66ZP>8GTZ/
M^X/B>GN+9&AKV9RIL'O"I9;8^TB2H\,I%+*TV&ERGY_94C/W"1,+"/(D)EDT
M;(!0&;7;,2Q>1^?-2NSQZU<O>WE4,(G0UWYBE!-E:C0GJ"F^O .D0^;3DMDH
MY^H-K+-@KY7C7VRN;@ ]-ZP?4DT/F6]$YLU*W+2!P.#4H%M"FAI0:HZZ&=IS
M>=PJ;(?,YR:SX!K*5F"NZ'.]:&:Q/+VT,IG:AS@63Y_[@_+ZR[NAG.P4<B2%
M.,U13GDFGBTGZQ;'*92"?OK<CX!9Y1H]DZ[<1#%#(6&<.01K'\N[V/$R7D;G
MG<M8V4-C!)B0+:IIS2T*:?8$+:,4BT*K\O*NTB,EF!XRW]C^)Q6*[]%R*QC]
M$V<=U%1LE(7(_9!Y'9FWYT,3J,C_9N_=>^5,<C//KR)H%P,;4/3$A0R2U8"
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M&FGLXY]]'2[OEDO/D1>U/,<**',S8]15Q&1&58/6#I>WXO+*%"U=K*[94[&
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M=NX)Z\(R4+V3O'S-)Y=]OF#VG*EYV;,W"+(67CDS%5F5$%8]TX!O!^:5^5<
MIDM4E8I[LA@L2#Q DQ74*#\73!P1,O,Y_GF^9.+.8YMWF'G FM,T8B4/EA;?
MM.9#YNW(O!S_\/*^RN+@<8P$K)1TJ":!M:+4X%G:3F;YGLA\HFG _YKA]Z<O
M.M_\_A>!ZS^__]K?OOCA:WW[K0[_\>&]O?CC!_ZD[P=^@_BSO,B__>'[=V_V
M[?#56_]&W[_YO?_V_?<_?)7J;P!^^*>?J+[S_0HO7_]%^\N?[IR'C_?T2OR3
MX>D]5^<LW!9P)UXK=^!LJ-+7Z,>.=1.Y_.^_N[8OCQZ?M6.D,''K18&Q\YCL
M*]%<>P!8_,=T/UX^[87/%\P6Q403 F*<4**B;.1C3#>O@2F. ^;-P+SXL9K1
M&-C;?G85:<S2F8P%4J[L;:RX!M*C\F^GN_#Y@ME;GRTCE%4#S%&,HOZ/N(D\
M5D>73UP#\-V/W\[OW__A]P^S3\3LE;=9^QC",E,M.YCNG@.N6M/HHF/-P;7.
M*#U>%;ZGSL-#[1.'T_C'4>_L+'MMA]L$R +%(0K3U<NQ:]T,S2M[<VN1WQ"E
M6B.F0ER5I!!78)0150@US$TBSX5VP'RV8%:#Q5XZJ!,4'I;!LD?Q2>++FQ\P
M;P7FE;]Y9 ?*LZ4(F6L?U^4DN$9B@&&K0J$,^PG7R7.?+YAN5K+,*K(Z-)BF
MS;!Z;TM<D3]FN/')<S][;7KE?1[>O=4ZTD#/>^E533J'I=76PUK$I24_)+IP
M1JP^7VQM3;2Z1HNZ!R*D,JER%L=*!FX?,_KX8/OYL;T\&EO-HS"I)9%E2P#=
M$XO&CV3M=2S4(DO^@.V)ML\76R[B%45Y,0+6N/AY81MD$7PQOAUL[P+;BV^:
M,136I*<LA1.,A];<,9..JFU8GP[Z\G5]U<YA\#/&=G:H2UE%:WY8+=$U<J[E
MF9V'](\9FWRP_?S87ES5L/UYMB!9\:ALU]X5WR/:UM#=E6O4,["/G%X!G?T@
MSQ=;$<U:@(26P)3&M1?LI7'/<1O\=.CT+YG$#K:?']N+Y7I$%ER#VZ2T%SIC
MBVCKLAW8?0$5$YM[1<&KW!X]"^-@>[?8HN?2P*(@*@)M.-<)VA9 T!QE;SW8
MW@.V5X;LW;RR,M;DI>XC*=NK*_M,HMV]SJAOLC\DR7*2Y.>+K99>6#IHF0 ]
MSPBY^ZD/#>V0^T=9L@^VGQ_;O[KJHX@;5: GZ!T#6\>D#2 -@@4\3(#:0Y+\
M^$F-3XCMSQW6;-^_G?XV;4/Q_M+OOO_FS7SQ1WX^T<S]87KS?//[/W[5/_S]
MM/_P5P5_0S^-@'[SW?3OWG^5Y$$T?@&"__OW[_6;%__/G_J^W_G??!MOZ\6[
M@.?=([S3G_K9/CO1*]9TM5 UR@ 50((;DZ;%)I#_=*!W;&*_G.C]'W\Z,KJ
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M9-AJ,G57<8HKV/=2@@)/-:7C8'M_V'H7WHGO$(ZB:)GT'@G87@Q4M3:QC_#
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MS"NS,4E5GDOC(U\1,8NL***9D^YQ?CU;<>DO7T-_M'7J@'FW8 YLL+1A(>O
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MB4<['>$]PGN$]^E6$9MCK]L;@@T"5NY(0X:508**> ;RWX/P7A+>,5US:YK
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M @.D)&'B._D'#.(,%+#V^E"+> :OGTJ:@CRALD;5(%%O@K$@H-4$9 K).E\
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M3FP!GC=!XSBV[]AAZ,:A:S][X=LJT+['<ND1+S!"QPU,8CG4-@/B\M *P-(
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M6B2D7FA&-'2=T'( UF_SS FES'NDS.=N@.GRD =!I"/>UQW3B?3 ,&/=";T
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MFBY7HC=R!.]I-5(,*+)#RUH$.R01(D]1WQ9 XF&>LXLDE>HB%V]!T<Z&"<
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MRB^;E#69WW]VHQVZ=PGW-R3J&>C.#'CUXP0&^3Z.D11_@Q+-6K)*AV6@O4Q
ML<'82"&]AS<E^I-).8*[7Q;P">I?$ 8<<@V''X;!5TT9&/Q*9-!?* "H]5<>
M%14I9AKF$AIW")8(T"9%K#L55(9Q"A\"P"6N6P[K!MB) :2M40)>=[&PC*-Z
M&:.E9>2=98SD,LZ-O%Q1 H#D @$) 'HNB#0 ) PW48!]X( @"*=RQ44$C&GO
MBR')8(#_0\:37X ;CK2#^J-#@ -%7@W!,P*@#S \B:H&7=>7M$->?D<YS8$8
M0M_*EY4 6?@H3X&; ?-_&O'%1R82.]$:DORW@D6/9P+;D^]Z7'#>>*7- Y$@
M2+KN@P46^>OHXY$6<R;<KQIFP$/0(0![S^NWKZ!EUTO!-\%4LK(.4PI4(YTT
M>## (V"SX0P].%C229(G3)N@)S;WK(7?.DF$[SF3. B\?IBA1DG!DOR<@ J$
MI9USP]P;NV=A%$]\GDR!QG0-5O_"IPG9K0'D/V ,XR3BAX*0_:+/YYEPM.][
M5->.84XAR6G)&/AKBJ[:X25/&5UJ9&2AL%H)!JT+$I3$R5P@8OA!1^ G'BU=
MR[^#+""CMK&323+A."KDYF%!QO#&1$3 )'!!X86AY1=HOSIQ%OCK(@&_L0G;
MP @GTLH=M8I)/&A$SOEBW(M,YBY(DL%/<,IF=92&H2.$_@TL)8CCPHWX=M M
M7*<S"KY5)Q0F-$I'#^5 $ V(*D9?/V(^XZ4!U,*-Z@N<'3(1@4YTNTFM<%KM
MOZ3J(AE,3/ETKGE*L/\P&-""!8!P7"LP,>9 *ZOH*VH0N VPRC<NQTQY(:)
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M(45[++5L+> _F4?UY[7VQ=%@88 DG+@=YNTNWCM7XS5OX#KAYR*4!\I&Z&+
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M55F.Q<CZC'->S"YMAUH#"%\*DS;&IP[QY%/)#O,- C*8>.0W>:*C>GYKYDZ
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MZ%VV@M0M4:6/+E=*;%NCEW%P(UNXY(L<M;Q37,2J+T"?SS>FR;))P;W?Q4?
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MX!9=LUU-7RJ4[?P[:@\IGX!:TR-@H6\ZB6' STEZ06;ELY\7#2E8T24Z+I-
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M"=CJQ5IM/*_ JHN2A$N&/]K$8BMT(F2M32]R82_ )FCXY@;027]-K<6EM;@
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MB6Q$L]\)23C-L_G^,1$RP3",'#70:"IOD"94J\N(A:7LC'F"R8:L&NLR<+(
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M+.#E;E"+F7<OJ.]RWF!UNJ+-(2RR.;KV, PY(9PO1]5 +L B"M<?AK$P-TD
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M(06#*G72>0)(&3@####<W\0!1T1@9U91>$VCWO[G_P26Z?^"_EQ>(HX P\P
MLZ?Y!%\F./5*+5)/U;&.?*P!E@ ]SYZ#<A4L.V^IBNW^.C?6:2MC?@N)2G#@
MIU??<JD5QXZ,MJ[9@:8ODJ3[[ZAMJC4!:Z'_?_;>M$F-)%D4_2MA?33'J&N
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M05^!R*.$5<D15NSRP)VG!D<UX]#Z$3Z?WIFH'UV$((6^<<L9@7T;B#&8MD?
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M;ME>?=!M[;3J^N^Z[=U6-7LU>S5[-7M]:*^#C5959;4+5Z*MMA3PA:FS#V;
M#I9^6I#"*F]!7R9S\_PA74@*YW82@)WW69H55V#?V71EF5Y7MQO5#3*+'P3/
ML_TT\.\74Y /"@%_8Y<3[HT%([A?_=)V./WSO1_ ;SW]%?WP*;!QH,3Z!4U@
M0ZL'2JO%4K?9V4#J;M@/\IEAL[FK(VLC7U&@Q7%=<-S#I3K)HOJ,+<9VEIM2
MT#M]J@-OP'S'!+CFX'EDV$$<7TN8O8GQ8Z(DPX*&!5^>!9^K9]'6,ZW+T-!H
M2Y/A']R+[QS^&O]WNCP-ZL5 6%A_^7(6UX9%AZ_V!Y]R5V,VJ^W6,W5'>,[)
M\L]1N;R3>C-\9OAL0S[;>BR]X;/G:1_P.)XK(6T='EWM TS/VO;"$/53=\LV
M1+UWHC9&CS%Z'C41MCKH/%/?K9,P>@R?&3[;!#"=:K/Q3 VF3H+/C!VVYFJR
M\^1M6XT-9@CZH,:OGC9!;]RBK]R5&O]*:R=TB7]):_O5U<Y^"YM"V.[8=694
MR52^2E!U[?7<NUJ[ARR,7L-F1GXP=3SVX=+-M:JBUD@3X<Y4\>;0]7V@O7C,
M ^9B_0T5AG [=J-0%NU$\YE@+6:K @A=][6^E16S ^=.>)F"KN%\N9C+ C'#
M'>P;!(]Z5"C$W=75750%65TN@X2E=8,2.ZE&Q3Z081PD)9&Y,K<Z^T,VU##<
M]S#WE9;?RM%;H[-)O=-MII\.EE,O%3IN2<"$%,G!*3OIZL<B!GD2WI/GT&V\
M=*^@[_6;^O*N<UV#TMYL8:XYVV'T9C-,6%8F+&0-V15!-J,#X@4&;+$*=Z.)
M'X\G+'1^U8@[V0R4(H^PP4V6_*8<*1M(U4;-%C*L%3U;V5TP-!2\?3\8B:!P
M%8:*\3(!J1D(3#M#8T* ;3$.N(=HEP6J17A#(91M8 BOX?1]KA<AG\W<.<HN
MDH;@33AV3*:!KAG7M=*T?$A)T:J/1@R/4N$PUDPK\D#!BF7E]/[#))62L'6>
M5'1+DU8[KX:PTY_ES(CUC15G%,@.E!9J0P1='C?M&IGI) E"AQIKJI\K7B?R
M!!&Q4>\(K&=_T2Z96^+C7SY(LJ0;P >! GDACF_JSH^DWM3LU>S5[-7LU=2=
M)WK3U)T?! ),W;FI.S\4^)NZ<U-W;HI>GQEPINC5U)T;%C0L>*@L^,BZ\Z.N
M*_\XG;G<\[W77\0O^=>.V7*GGG5^\%GES?/!HW+*RY8S_BRU%X;*#YW*!Z=,
MY3LDBA]/(GAWUT3P(TWT-@3WS 2W<RF-(3@$AE'5IZVJN\WN":MJ0^4G0N7G
MC^OG<MA4?M+V0;-I# 1CD;XHQ34,Q17= &].>B/ZOXU;Z1QX=/A+?,>OX1PK
MN70=$^T J@/AH^ZV76X>037/I;6WW-).8O1X*:#5V=9J,R1P9"10Z?<V5Z8O
M@_W]ZU-#>H;T#.D=,>DUSSM&\9TV"?0;#4,"ITT"E?X6=UM& 1G2>TK2VZ*A
MVZF0WI'T;%,MHTK:8V!UJN0^8%5EG(5 M*ZH!=1?; @D/J6N&EX4<$O,<"X]
M<VC34?7A\?*ZKUBF<9+L,#:<+_5!^L0C[!<QA:U;O,[27GL'@[J]=I)+<-%L
M/MS::KF355%7JN7>56F+CT"$L1MA6=0H\*>R.<O7'Q_?U9H#!J>'A1RKG@#D
M<,5'Z<EP,9R^+[EQQP&A2Z)B!G(DMK*BHM_[&Y%2O[-"9N"7*PFWBH2'#<Q@
M<7=>U=0[%AZ*#6P,.!.1@VW15G007-$1RI;]T ZBUT\9,*Y:_-C9%C_-<\)=
M$2Z&8LP)(^^$I=LZ-0=U=F%98$:AQ@%<+C1XPD9U@2,\:E#'6<!G8%WA"S+]
M79*>+[ T(=!@:@E34FXAX'3KORC3UC#7\.\8^N'\[OBA V_B06C:X&RV[*&U
MOS![-7LU>S5[-6UP$G5IVN <! ),&QS3!N=0X&_:X)@V.*8'QS,#SO3@,&UP
M# L:%CQ4%GQD&YRG&X=6AD*(M9#.Q"7W-X/TJ,LVCWY&ZR/;C)SV@%;#9(;)
M-@%,STP;WYW)=BB$/9FAL9W'=9XXT<FQAJK+C:W.MJ4;AJJ?GJJ-S6-LGD=5
M'K?ZA\?%I5$/ALL,E[U$,]S3YC)CA*T+8A\>81V=$6:H^JFI^G%-[$Z4JM>7
M[:D'.ZUZ'V]+9GY("?IO N%RK*E(<Y0Q?R[SH()F(WV$#P%R<;3ZD:6+KSV5
M\-18I\%J^33P['\G29;*C(]%;1@(_K-&8V/?</>>S\/?7N?SQAVOM@#'11#(
M@_Z=TF.*7GR(E5#I!9:NZ@D9#_0,7F%C35^VA&,6!V',L<[&9[!;/@X$#=UF
M]TXT83=\&L;>F,&J8N:$\%2]RCY%=IU5U%=G^* M[H3KSZA\P?*G4Q%8#D#G
M+W@MEI_-7"PQ$C4L"7)&#FXBW:4%#SFV+/NYC(. AI#GRTST_.!KX8U<\0OV
M47'@+^>7,^7#&A_:_ QKFS*+PIZNL;:-VR+[V[-DW'@$Y!/1.?T1317G-*!\
MY/+IE$=^,&>V$PH>BO M^^I%0?P7PJ@2!3R,XK]B?*\=1<."]WZ PV-9E9?[
M]8HW3^ [CP%H504G2,I[ /N(6[ '&LD^PS]:K/+AZKIU5I-L?2<8DG\8(? L
M58R%/V ^2#SQ"V =8H$H&\-OJ,B'?O:6?O<[0/BO.8!01-R3>\V<H.! 5QZ\
MS-T!<G7V&=;_F4P]SE(&IX(C8-[ @6=P$#QH"#D!.D.#=SCZ'0A647(=Z%%5
M]Z5;# %HP#J=KBQ8 R9X@H*UI<)+7,_EL6=-\)&4(N!5OP?\+\>E$JMX#,)
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M1$!9S@R5D?)T-D*UW&$8NTC>L APDTN*EJY)0WZ'<9^"30\RFUY&")!Y[O6
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MA"KU3]*&F8H#U-F-XZD^OKG#XX^+J1Y>X/K>6 0RV$HW;X&#=6R2#8L8M\K
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M:^%E\+Z#M>(PU/&,"X^[<VS>"K]^GP ,@T%T=TF_N19A[$;TDZ\R-">#H _
MI_9/P*7%U9431;L!61X-=J:+V!RQ.$!'5J1# H6X0^M0(=KQP"5 6RWV5'A/
MQLG#&(@K(1Z21 #6";_#NQOAH>V0?:E4\9D8V()T3'!0@*_005>YF'CJH%Y5
MX+VY0^!=*G8/_CN5:E5!A=ORC@CAB9<6F6V1M0HF&T*)K!"BO-UE:N=AF5H@
MF3;KZ7J:5^O@;!W"U?I:Q+ZT_KP6B#2P##]*QS<C[FXTP1^^-?B>A*&="F9@
M[T"?7->H%[!ZE86/D3*/D []!Z1#L[4G8$J4VL)267-OR".270@^PKFEF :[
M&31<%/BNM"^^84S!1NOZ\(VR5.5KK:NT6C4)Z\IL"8P9:66"[M;EQ!$C=O5+
M6#%UB?TZ B6IFA?([U+[0'U7)>M>W'$WENXPYC6,1O*:@^)T^2TDBE49-+$T
M>5)$S!)$2#<^)5MYC07D7V>_D\,L5:(3Z-<OWM(E[]KA7-)@@)TI"X?\+[Z]
MV[S!,='J2T!61]-I]?4NO01^3Y%XL&0RUHN#JLTC=XS>LQ)\B2\I IDOP^GE
MPJ8XAW2X>>A[? C?N<Y/#'B :%EZH/C &V]C=]G3;ARB[+F\^'[[\>N7B^M_
ML_<7E[=?KV_8[8>+6_;YXM_LXOW[J\M;]O[[[??K*W9]=?/]T^W-X6NUVTER
MM9^)XM^#21W1C3=^H>+[0=[ZI3">C!!@&"]2\;[A/!<XFO(YD1DZ5J%? S,=
MO3#J=HC'"NY!1=9<W_^I=*9:O4J_:+YE\'MD+.F/(N$/M5PI<$JM."!W [.)
MK$AY0+AW?#",AY@SA!L-G/"G_")U3"BGCMY"6R:'*% N%3QB.QB_SG*8"HZ
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M'*)42O-[I1D6:(9'WXBL?6,*G \KLFW6KC\ G@'H_LYTK"D#2XRS<\/CS/U
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MOD:8*VG\450$,F]R08, #BE3JG%(_%OL(<)1;\R0LCO5,-M2M'YP=1VU>,_
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M4#\ NJY3V&<M&P IG8'XN]8:K-0&B=X@I"#6'"2J9R,8HO_B$9#J ZD_6%5
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MHX;X$4W%*LM'>JSR5/;1\NB8X._([W%3'&$SK67S_VDAEPZ&$9(CLMWH%S#
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MG9GVCO4\MFM4YH\:MW,J,%K>VSEGV#>NRG-$MN&XQ?+M]-3[8G#(\F2V]1Y
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M/XE#R=9"25P ZLA3#RI+HH!</@"9B<S$O__'U[/)B\_0S<>SZ5]_87^FO[R
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MW1_WKX:WLXON[GJPGEL'2)#CD1()!HCW*!"'MJ6/I5:,/Y8RM/FLZP#'_B3
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M+"XZ&5F&TF0AH'-G++$Z6Z*9H4H&881K I\*&2Q/W!^C-GQJ:FJ_R9F(:6N
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M9_B^WAQXC-8A':L- =5:B_N-PEU+)3D(LXO%J].2](<<7I,@?N(>#IOEUNQ
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M*Q/1FEMVA3_L3;^K6F9#,Y1^?Y(Q3:0/I9C/EN36*,%0#EPT>C)I?2(']CC
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M<-I\CNHBW9"MZT*]/!_+E^#G\+<__2]02P,$%     @ ^H9E4>\7G_B.H0
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MA!16B6PY9U+)%$RVB9:E)5,70^KM/M7F!,XN=_='XWRXQR%SU5R7*045L_3
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MZ,K*.E3U.6M0:N@>J-= 2U/Z>2N"+G!;MJ';$._C]*AKQG]W/:M&W@'H'!H
MH$J)-JU+PKBAFGC'!*&29IT,TW0Y!O6(=.V!9GB'JFJ;<-9 Q>;A,I ^03P=
MC@:CDXL/Y>IO,F^ 0CU+W.>"QY;C82M(T%H0 !&RXS2KW*3^U .X]F_(-^7U
MSI%7/5(J5F:<C*>]%Z-SM-[&GSUZDV6VL_<E\@PV"$M"\22EPC?'.I])"CR6
MA,)(59<<87S^#07![Y:58QV H[:5JDB]8C6[@N<#?#X?QU-_HT3N,L3Y:] %
MY 9F4"<5Z8QNOT9/'2)'^V*AXF:S&5B; K71>&*XP)73QE)#3)8K^AS ."DI
M5%M-'EE5UM@LCZ@IFPB_<E/0C^!/8#C?XJ)T&@TO2I)VC,A4&J_Y%(D-'&Q2
M(EJU%"*V\A3PYC/W9S,T%/FH@KPJ=^5]_>R?K^<H2C:UH1['E@SW-ZDH\9F7
M?T6@J305B;(#:]=//#;.MI15DZ;9*^N9/K_XA ^8+39.HY%B<(XBB(0 M2%.
M&48B!1T3,"YTDTO)!Y$=M;G7AI\&!6?7 "SPYB])%X MC\ >1/@XAUZ5F>VF
M-SO2LK\%Z 90GIU'9SD0YDHQV1*P&30NM]P9#NA&.]NFV.HCZ<T#!UB/K3:;
ML%'9,KR1TW65&;XX"\DR:S0?-%&:XTZ<C28N,DNTDP$BI3DHT\'DN&>(1^AL
M7)>,47U)5C8A/WK$\ASMKG07E;[LG482!T0E'$6E=I9P"2!S#)HJV\416#O"
M,=%;28Z57]\/<'(^*+^_N(-*NTP5%T"\$:66<I+$X>J%BS*WDFO/F:0=V%T_
MPC&Q6TF.%<\"+[/WSTJGK[X?7*%:'%-G)4W@@7A>DO5I*?L*7A.@C%K!<M3,
M=2!W[0#'Q&T=*3;L*W'#N9D9&RH&*Y5"ZX*A6R.%F57ZG[6[4%EX'Y-L6A=T
M"<]WX1/6X*)AUX6;L"ZC$1=O11> +3W!!Q$^CB=8A<\..K([&0U[=ZT'*B+5
MJ91R\@H7/1D<;FK@,U'HSU!M9(IM\GP>25L>\/\>1UDVX:"VUW<^#*.+JWU0
M<^XUTY0P2!G=$U>J>.A(8J*@*.Z0$G(':^+V4P\B('@7D8^JR*NR._?I%,[Z
M"],T.L9#R(8 ^$1DB4@./@945Q.S"D$KRCKP=O.9Q\3:UK*J_+8]&_]O-&/F
M.!Q+-B96C!2-DTF2$:<!2$Z>1:9BXJG+H<K-9QX39UO+JK+K]1X&(_04YD 4
MRU38X(CFI68F^GTD1,<)%>@%:EG:'7:Y,KWUT&-B;7MI572K9NHSG,)@T/^O
MA8,'(AA.$W$Q2"+164<OGAJ2F?-:>Z/#<K/GU2_;K:<>$W$[R*NBMS.[OCT[
M.Q_"9>;I'(UQ6CH#D@C0 B>5 [KG7!%CJ#"4RGBGQ/;J*^\[3SXF!G>46\4N
M:@7-/W$AF#SOCQ8GHY[9S)4@>;82H/[@IFO+N3=DF;-*5D('!F\_]9C8VT%>
M%=N2E0"-><KNN_%'&'_IQWE0% [JD_:$QW+M19W#:0E'?%0V&,$3A"YI9)WB
MQ58!..JCIRI2K_C^WL!3RH;/$4T6<8X=0-6.-EV+9O_1I;L3=9?U2E*N'$VZ
M'IS65E !@23-T>TM73W0ZQ4DE9Z),>)*E;M$+1TB]?=$B^Z)^4V$6]D__73^
MU\7$7R5 @..XE!%?"A]*=(^)<RP3HXUE-AF:3)>;I9O/W&^D8241CRK(I_95
M?BE,,(3!PCOF,2IO+#&H?^@=E_8CD0<BJ(I2VV!#ZF)<W7[J4^=J!QDU20&[
M6V#G0W_RUVP-,2EEQ2S:#)D5FQ&-/:]FS0U93(I;*T*3:B'W@3IJ@ZLZ*PTZ
M U]C6Y0#NW$#W@5;R[N^^\ ]SC5?/2K7ZD@E'IJN+BLPAB# >RC-)1DG,BM#
M+.-HJV1/G0<A!#3*+MVWCCQPN?<X*K*)^%NDM]\N*7@5J69XPDTP$B^+V>J0
MP<!2( Q<@*"42+Q)=>C5</9_D%./LOM+.&XC[XK&X@+5ZV$<G<''J9_.$F[>
ME#]8W&U[=%(D5Q(WT'*'6<[GT8ZU!+=.8;+EUH<FJG /IN_"^*C%R5UUV;G1
MRAIH\]>C"[B6QL>]Z!['^JC&93<=V8&(!EO,_2"YI%(Z5KH,@D;_K32&"9"(
MX:"$BEPPWL2Y>00M><#^>!PEV43^#93CWJY!5TD11L44(Z%1XGZK2UXMIX'P
M9"$%0P4W32H =\"V?\ND(IN;-'#:@HH&=LK'\S"!_SHOL$H?@:NL*P9:2X^6
MDW$,2MH,3COSB 8:6NO@02?1I*'3&CS?A7U2@XN[*K)[!<R[L.;O1A=@+>V2
MM<@>QR:IPM_#.K&#\!ML-^L!!GP56(Z>,"XLD0R=.F^\)<Q*0RD5SN0F;LZ>
MM>(!&V2_2K&)S-LKPWR+D\KHG((D.#JNB0KW4<<")V!=C$*SD&B3B/>5:/9O
M7U1BZWX=V$+4E6NH?2CM;&>J'9*CT49%6$!K2:*51()SFE A8PBJ!.]W.?_L
M5NIH,>I16PC;R_<NR5OW@[P",=>U+C"J%T&['G__@2A;,K#,X0[BJUV][ 8<
MIU3I#>&(HK3TO>.&!)LS\;A-<9Z5E\L9Z0?,XCTQ)75)W$1JE<G[ R5U=GZV
M"#SUGE$I*'&0RG%W9B1XCI.1I8%XM" IU*+OULA[KF6UK>Q'-017><?\PW^[
M"20F&2%2HI50I=99"=WW@6B=C#)<!@Y=/.YN#-X<^0DRN+7@*K^#5X=&'R,,
M_;@_NKS9E,('IC7!O5R6) Q+'$T,K3S(V0N1M.CB^'1B<B6"H[>%=I?["D78
MZ5U> /ES./D,L9_[D!81"QU0U3:3UJ+9O]%4@:I1*S'77@W6@DLF>N&$))8E
M@XY>%,3[A-]F*44,0DN9GRCW]YA:^Z)^$^DVHOSWT1BBGURYX5J$S TGBJE2
MRAQ]<1^\)#1'K7S*(%67*[B-^+X-8;^;>B5N5K"]@V#76FO__NN24-[@M[-?
MS'Y>)OT!\D_EOW]^>'TEH*]?O_Y2JMG\]4L<G?TZ$\W-[6UQV?-B-$ E&5W6
MT)GXTK@LEON>J^*KD]]]?_Q//SB'4;[=Y<ROZG+V$J:^/YC<GM6D?_9Y\%"(
M\3[1_7HMO]MRG4.\I6J')$GX-H5A*N%%_?3;SWV5LTO16\UCELI%SY,T0J"-
MPIT-(O3V";1Z*9(W5XVWJ!61.N6($:H</;I0G%].-!K@@BN(/#=M#;\*U"%U
MFGSA)Z?SEH)?_*!0V(M>@[8N$XYZ0$HJ-?H9I1J9U,&CWVBL;'*?T79:!Y'2
MN9U>MNPMN2/_#6[JJ\[N?#S&/[C\)#X%<)+XEY.>LUP'EP114&XDK.?$FI),
MJZC/64=TTYH4I]W'Y'YH>CM=:%A)J\8<7P_+'=EH?-'3AN$4121425KJ#GIB
M0_2$6T\%,UE8W22NI<EL?FAT1;8K5K%I,:GUS8ZMI4:BW4K06"W%.04C5AA&
MI/?1TB2U$DT:SGZ/K:\/1<7K:$/#PJIUWN,YWZL;U/58N:B3V9 L,DZ5:4D"
MHXED:IG@SAO+FU92W,,<?ZA_<\UH6#JVSE1OS^W=]!3&GT[]\.^C4?K:'PQZ
M4GM*K41'Q"=?FMT;8G.T)%#%<@[>!!L/_S5X8)8_7H0]:$?%BC8M)OL2,J"O
MDC[Y;S=^V>,R:B%-)+94&Y!*)N* 2_S6XU[(=>;NX'W6U5/[H?2M]*!B^8!2
M^F++V=V=VNS]G7_HUM3?PK0G%+, P CW#%_E6'JK"4K+MT)P<$:G)7MG9=61
MO8 ] M4]3&(;))_6?#?+=#CP8'3&-3/&4KM;^<L;7L6-9=&8[$67V^Y'79"/
M0X4/@>$&&4E7Q@T+E H9$N&A=!%!#,0GC2^.@B"2 D5]$]/W"*W2K61:,;I\
M1U5=P%^KLI1**\$($I0J5:U<R8S@D1CJN18A)>6:%&5I-)\CTKQ#8+QF.."L
M-/!MO^P/\)/S\2P4X/7P\SDNH)0RHQ!1CH#R"JSL^#X2)8+S7KN4E^LYKJZO
M?/\P1Z DM86Y@NB=;ZH6&OG[^A.I?T'_Y'2*.^H7&/L3^',"^7SPII^AYZ,/
MT:!7'D5&+4T<<"N5;M;>$G32,>DN>1<;KTN[@#X"O=H[=RL4;^?[I8WCK;7+
MS-*,AIJUG$A.+0FY!.=I0(%1FF.;JZ)-@594,(]6VO[5JBDSJR[;?RH"2-._
MQ<%H NFWGZ?C<[C^X6@XA6_35X/9HOG;SQ,XN7NWMKGZ+2_$5[G-P$QFT6M"
M=:!DUL;)2R^(IT9[*Z6UK$LRTL9JM@[0D\F'V$@+1@W8:!#'L0K7/#BX"[*6
M]2/60WN< A)U*.R@%SO(?[\:8I2@N71%T;;T]TW9$$MU)LH[RK5S6;LN=<\/
M7C,>*"*Q;\781.Q[4(B7_4D<G0^G'_QTD3HH9#*214XHE/(9P5-$*(" ]XP#
M]5%IO@_%N MM_\9Q+2(?T(\=66@8$KO</-*[9'B4E.!_2J2NIL0Y&XE+6FE&
M71"ZZ8WX4^WBNXOY48.+AB%XZ_L'=0'XHXOO=GQNW)AU&S(:QAZO!\J,XEYK
M=/U9Z4517IK@DB,VLP"XN 9+]]8H_'"[^+95EDTXJ-RWY5:O3,5<".6*)&A:
MHHQ+KV+'(F%*408N!=_I,/?0^XIN).YU?44WD57E'BY+#1>Y# FTXX2!](A$
M.N)==H0*SE+R(C.MN[!V\ TJM^9M>WE5SK)^4<Q.&'_VX^G%6W]VZ?IHQCQ5
M@I'D(]J>7N"RHH4F/(&)F2N=.YUE=LJQ7@7@J*VZ*E*O&%X^JQP#G\_'\=3?
MR*M=AKCH8-0!9/7*9%W1[;\$Q^Y$CO;%0NT"9YW!&A-*):*$&U$21&;A2CE.
MA;!-DCE$L*%>S<+'595[*G8\DJ9L(OS*AMQRT[*D<:Y&$A^4(S*@Z6HYET0D
MBK9)MC[)U,$H>,S&;HW$?D^CMPUDUM:D*T$ 064@S'HT+DLC7\<2)6BAT*2R
MTWJYL<I!F73[86\'F;7HEK3^WOWYQ1_^/T?C%P./)LZL\V>T+H; B; &#5G!
M!+')XE=@@4G*M4QM6BAUQWC41F%KSAID8MT#]1KHC9>J"]R6AX$;XGV<H\%F
M_'?7LVKD[7=)6PG;2D45=PK]\\B(U"(15^IA)L85HZ$T"&D2+G\0NO; P>*A
MJMHFG#50L7DW&4B?()X.1X/1R<6'$J2V:'XGC>?<4$^8+[:!+)NZAD" V^0@
M&A%RDP"<!W#M_W2L*:]WFE+6(Z59;7XK4D;K,)#L%)27)!(;T<9PC.ML>+0L
M=[DW/]+:_-L>E6TGWXKIMLN5E;O .-+:_!LQL*:L^S;B:UF;7U+AE3$D*5IZ
MD+%,0O"6V P@&.?!B+H--1Z]-G\-$C>16M/:_ Y @E*<9*LCFB-*$^<-)1 $
M,.:#5*E:]=]#J<V_B>S7UN;?1'!-:_-;&D%K5$(N,YTWBXPNDNB",Y+;X*%+
M0-&3JLV_+8-;"V[M.UBO7N^-0JU?X-EX7.8[J\]Z&T.GZKKKG[5K+=R.*)<J
MUQI!L^,L)XA:!CJ[K8W)10B16Z]<KQ/@&L+\=%ENL:)(/]THX-A"L*L0+XD7
MQ9A0HDI[::1+WB>CK'0,O N90U@OWKO@:PCYK1]?_G#[^M#=G]U,\/?/8HD"
M*X+1WE'(Z,LKH4)V+@EPX%00QMKU%-P99C?W>^TXSX;I[6@8U_SZ$WXU\7'F
M?+RY2C-R63EKT _T,2?<Y'0B'E=%(H"K",)REYKD9-6<Q"YW.']^QDUH5L3N
MCSZ^)]/1$-[[BQF2/WR"3Z-;0-_[\718VN9JF:.2@C@746I4J1+XC@8BF@8I
M&1N$[Q)SM=7@^S_&>#2%NWEQU)ZHRK>#\RKLH\]% )\OH8YAX*>0IJ-;,O/7
M,NMI1=&T<:5F:(E0"_B5%T82M#>UTPDW5_'0PKKUX-^I9K4GJL$9[+W-O7M!
M@Z#2)Q)T=D1R_)>/CI5H.4A,*N5YD\2E>U%]A^I5GZV*20I%]]^/1Z$8B"]&
M):CB!$$M%M5ULNNAQ9D4RY;$D#V1!@2Q")%$RZ@63#'NND2N;C[R=Z@_>Z"H
M017>FV7QM,]6EGBM@/Y*J>?#B%>X%7LI<F("O-%-KA<?M8[AH^O-KDQ4C(4H
M*KS28INNMMAXYBPF7 Q-60<E\Y%8IPRQF@MK7'#*YP[+RP9#?H?ZT9*4BO=*
M!>8&RUY((%T,B3"1T"0KW71=9&CL>^FR%4SKY5"&E:KS8T=Z0',:45*Q*FJ'
M"_A2H\L+3H,'302-N"26\EQ6*UTJZ.3H 9=$T:0=Q_VPOD.M:L!7@TJELRJJ
M-XNGHF@NV]?TK..!"YPJ%;8$P8(B(3A.0M%R+82FMDE]O_60OF,MJL13@]*A
MUR$A%81U&33"&9<,BF2$8$1&BN^$ 8.*(C13G.;(FFA>_:GLJ^S6P>CI(VO#
M8Q?R6IORDZ2S,AA/! =<YK7)Q%$5B%$V"!T$=;9:E-AAYE8^CCX\E'VY"2^/
MEDK7!>3WGGVY$9%;Y=1MP\*CJ4S6)@DT"] H*%VB52PI9"80F_'E"<Y0+:OE
M<C^Q[,OVFK*)\&N7T9A,Q_[_PA"BGP<,^1R$BYH1)JT@TE H#H8E3B,,94R4
MNE,*W_*##S6+;R/ACVI)KO)%ZZO^Q/>O\@D3BZ+42N6R%&,N>:$&ORIUP9Q6
MBG'?Y7+BQB./C;IMI57YW7ON+V#\[.]S($&!99$[PB5D(DOXN_/:DZAXRC0+
M"\L1CJM[R]Q\Z+$1M[W$&A0V*T7^WN4;IN=LMT#=,1*4(2Q:1Z0L=^(,9RJ=
MHI"%=I0V:>N^$LUW;L778ZJ!^MP5AE\]_\5"U0%NR\38#?$^3F)L!::7R]/O
M@:8&L3&;PJ:"YD2-*>?(O/1I5L2[DG;GI<J\M&ZS^FBUZH$4V,=7JDW8J5V>
MQ0]@\ASW].N8PP4J91)3P6E"):/H&*'EZRD51"<5 Z[(()/J8+&L'V'_Y_=-
MB1E5EVIE+^(#G)P/RN\O[J J18<,3@??7ZE*:T=%G(H<71T'TLJ4A9(=N%X_
MPO%R74FJE8^&WH]'Z3Q.WXT_POA+/UX>=41K@7*T\40LQ<PEFEN.^DB22Y'Q
MD)VVKM8IT"H W[F]6H67RC7_YGC*_.>()HMB'QU U3YE7HMF_Z?*NQ-UE_5*
M4FZS5*P IYSAR5%)#+.12"X2"8!+(E<*$1F:G>QB-1XB]?><$N^)^4V$6]GH
M>W,Q_.S'_V]QL)FLBEIZ2EC6N$V9DH0J2T*XC2!D"IDN;PNK$S)N/76_9U.5
MQ#RJ(J/:638P_-(_6P"1EB8NLR9\%MZAI2%!&B <()L<3,C6=B'KYD.?/%=;
M2ZCV=4N"L\]^8?YI *X2+A>T%*61UE)BHR]7!S9(S0PDU:76Y:V'/G6JMI=0
MQ3.Z,K6/4S^=V78?(Z!GT!]=EL5(-CB7,BF.& (RB?AL G&66IRPMBQU"9?L
MM..M1/##1*[ 3,78_AF@.8X_AY//$/NY#VE1S:H#J-HV\EHT^[>1*S U:B7F
MRD;R>G"@+%,L&)*E+EV0:<'E/'%@M<ZXN($23Y3[>XSD?5&_B70;4?[[: S1
M3Z:+BBMH0P!-GG!7:A\&0$0^4Y(Y,)&34;BZU>;[-H3]V@"5N%G!]@Z";='K
MS _\,,+'4X#IF_+I18^=9*+A KE1#DI =49[,C-%E,B!>I\E\"XO^.:=B-8
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M] -,IF.<__FLZ.&M<3N5&;W]][M6#[T'S5)14$DY<\XD2D.06DG'&!>4F^3
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MXG/VQ/U\->U,7#;P9E\N4Q!?3_Z8S!"NQO_!O!;/V\FJ@UP5T>O)_?9Q8N1
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MB&W.?_KZ<*1SE;=9P'!R90W+WCBFDR0CW19@'*$H+H(*;<;4#X3_7,V>SQU
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MP <<T3[&E=>6&<XY+;^.%D)KF?2IA%(G-]@FC1>Z0WR.JC(8)0TNAN\CO1E
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MLQ5]=Y_"X]"-!KT-FBUL]=&_FLYN?JO^/3$22<MH'!V%AI:L$WW=T=(OP:-
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MZ:9/Y6_XN<8G)Q].R"[?>D3?5/+#F#;RQGVM7D^)9UVLYB;X9#*WB:N80G*
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MWP7@>[ ">PM^P!9>=_#,7TSR#:*USG<!-;01N!?-^:W _D1MLSZ0E-OL!3O
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M@:7D^A:QDF"FAB4CA S@0VK&W(([8LD+$H":Q"XX0..40;!!"F*V=DR&/*,
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M_V6'<SG!2$)KY$C05AJTM ;\";2?:S0'E>HWH%8>M+0'E?J@-/J#!H ;4$,
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M.C1MY_U6MS?K7&5WJ]??S=YM=:?>/):/^<99P@A.44(%U"PQ=JIF'!);82_
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M/+J?]HZ2/RY'5Y)Z-'%M]>"WJZ+,J^6O>+\N7ZDBNUO9V7Q;_)N2=]GJKO7
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M4QDAB&W52*:3&$:))J%24:P2I^NZ%_J9VX3=EL=NR0E^MY)ZFLKG<'5;6P=
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M0AN<7LG8,Y;R!))N*_IU^(P\IWVA\4_4?%;[0?,R'_<R;1KFLUH>95T^_^2
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MDA_L%-BFA*MT )42P&K1-\C <Y0<PPS&PW[L0(/!8?<//N@'WJ#A!YXB3!N
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M@*L7LWJ@U$&W+D\9C8,]5&H3L\]M 748TC_!?+'-;,[CIA4\26262@ERJC,
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M1@XI[A_9XQCD <;P-_C>+3;%YN6KNB]L_];%YI/Y$F:$I1DC20)(3@F E%!
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M AU;KA,WC;;#.B]P>T/5<55@7?DS1V@VU.A,]>7O[.>,*23SQ)HK5&( E1"
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M#F-.C;_>JE7QHVRHMHYVXD=L'34E@W<:>+J(76; C=MZQG5@/KL$8X]%H@(
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M6\\61MV,&J;WP%SY^Z</W]^]C;Y]O_W^[MOU!'BL8T?-_?KBBMKJ7PY9K?7
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M4$8W"'VRQ)F11B6&;FT/N>#"U4'^$U*=2+ZU)Y)IW'S[V"BC8@T@3LU_4IX
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M@VX,^N2",R.-R@3=VA[RP(6K@TT%ZWU??U5"F5TUGZM/:G-7MRY*,H9E%E-
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MYS#CO&182LE(XDJ8EP:9&E?68OX;J 4%1E)@177_YB]B>9TB8R T,#N>!2>
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MQIQ<5\?A1*9L<%_AN7C<.O2VCKMIM06MNG6P14=CT)WM-]=F.T(L[@"S,&S
M;DR!7SFJ=P#LKX?^#C%H8.-Y(9X?GZU#T48A_WVY5FQAA]C'CVQ#1W:M&E.:
M"2(A*^S..LD*2$I$H>!"%&E&<I0RGV7$5X"IK0Q[.7V[U/LB[\;Q0^(Y,&W?
M?WK[X0YT%#@,E:OCDK\H85Y^NP$S5WYG\X4M<@7U:@TKME!WX#-;VU"[^.VR
M0W&-2<3>,HS*K:$('=-E\'/\2T-]9-5JJ?YH/["LR'62)A**PG:AI=9?6# .
ML4C++$T(*W/A6A/JX,E3XZRWJ_]E;/T??WVQ?[@7/SI$JY^.;L)@:,]=(U=
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MY-;3G-*$ETF90XQMZ(PJ%.2H2&"18<EHHEA&G&R6TT=/C7>VTKF?TQU!=?T
M,QR @1EC*UC 8>41".YGE.%@C'0T>0)*I//(\XKW'$,>W3#:Z>-Y0;N'CA>N
MN+FDV3OUM%9B7D^P^7FAVASQ^T[KS<]K>]BP>;'NJHWYG0T8>:J;"V=$*$F(
MAH@BL]E2&894L )RRHF2FA+L%^X72["I,5ZWDI?L*!9<#>VV:7,SR5YC,@9F
MW^X\='6RO4I;K9JDZXY>=V"K6=.^:G-77[)3;Y#R:E$ 'Z@ VVVRO5:)MBB(
M]A1QB_-\?ROR0K'U62$P3QD34&7"[',SGAEJ3A4LB&(H8TDBI'(U)R^,,366
MO=Q)P,/*NH3G=9LS DH#T]^@ +G;HQ& &LDP#0',RT*] D6/J7KISM%LUBNB
M=XW7:Y<&EMQFU3?[?_O$[VQALR/JGCES>YQJ?U$WS>G^0^?*I@2XV>"O%:O4
M.]7\:?Z^>);SY</[/\0W6]3"GEF\UUJ)S4QJ2;3@*2PP2R#*.8,,20)S5*0:
MXT04)9UM5ANV<+-UQQ7?BZMW2@SW9=FB>%NQZV801K^V@%I'S;:SU1:$^O>>
MU<3'?4G<+.OI3OW "]#Y6;X[GN)STWYX0P,"V*( ?MCB\*,]/VZA %LLZI-D
MT* 1L>KZJ\QBU)+NXVHP;KWX5YF=DV+TKR-%V(*Z2^^IWNV+DKYAY@NV[364
MVOS2]M)X\[*_H(Y48F)C,]W?O-CZ@T:T=ZJ:/RSK:QOCD+$DQ8G*H/G3+)X9
MT9"STN:N)SQ+,!%*>#F*AA-U:IN:?=Y?!=YU:\6VVH):7;#5]\[VT=Y?![8Z
M ZNTG[$_PFOAMEQ.8[('7AI'G6?OM6[X*8BYK@TH[:AKV/"H'Z]7(XSH[^+Z
M/VQI-OO;9A]YDG#%;.R&) 5$FB/(A5E4TJ3,L$BE4!ER=6P=/'EJS-\*Y^Z9
M.<3INL,J6/N!J;"5*^"(]! !=X]4,!(C^:&.$8ET/GI6[1Z?T^'UHWF:SHK9
M]2^=OR#,"*ZK:1M",Q1F^^Q\9#8LORTJ5N2B8%0P*!C5$*D20\I$!A.>R%PJ
ME>C4*W:L9ZRID9$5%71DO0.-M($5W/I0=C,*(V$W,)6%P^9MHCD $M/&ZAMN
M5"/)0>]C*\?EEC#V>,.J>?5)WPMA:V"8YW]>+>;BI?GOOOQYFI58X@S!-$L,
MD7!COE I-"P2S'B>%EF1>FV'W8:=&J?44MM^)Y_-4[>+J!^/..+M1BGQ41R8
M778 [D6^ XVXX+?VST%JPOLA%9-V'$<>E8'\T#@F(\^[ \_*:D_AA^6^TMBV
M2<BG9=TS1'[8J,</R]W^K_['=,;*E")<*J@+:7=<96[S_TJH%2ZSM)0ID6JV
M5 ]U&SN/7K9AXCA]>K3Y]$Z$&NXS;"0&<R.R9QQ]Z+0X'C,-B/)(YT7-\<U\
M"3HE\CI-E6QQO!9]JXJ]<.]':WX3\;SG-CBC'MP$BC+N"<QM>)T<I=SXN##B
M_(>:/WPS/'+_7:W9@_KX;+>8GW3=;;SZ]+RI-FQI#V,LBXM9DF2"X1Q!KJ6Q
MZ[#BD!5(PRR7-K>(%4IZ=2WR&GUJYETK-!!-\^NJ%AJL]E+[<:7?3+@QY&#X
M#LR+6[G!%N-&<FL*-K*#CO#V",&('X\(@U"+27]^ HQ*>D'8'%-=V$,"+<-5
M57?U:0L(5?>\JIWY,X735'%NP,^5A"@S7,8SPF%>)(64(B]0FOEPV:6!ID9;
MM9Q-:1<KYCZ;S].TNX2KH^T6 :VAC3,K8A,+O\7JMZV8$?>:UY"(:E==&FM<
MP^F*QB>6T;7K ]L[6KHQ%*.D;3IIGMSTC]QW^WKSLK_D,WNI*\#:JK ["^R^
MJIX?G^H:-K_.JW_^O%:J6PQBAHEF14DQ+,O"F$M:YY *3*! :8E9PE.NO,HT
M#"[QU+C*R@BU$?*P)HUGG\?!Y]F-\B8U>P-S9ZT(Y%83T-7VH-TC?P'=ZUJ5
M0:WS77>CV]'[#EC-@57]L)!.Q(:08\U3U+:0@PL];G/(L>;@I$7D: /?VI/X
MP ]0U\G<%B2JZBI$]4_FLOF2+<6<+3ZKM5ZM'VVDBUE+]_^\JN96V&W@RU$C
MVX2:#YS+!'),<X@4II );A8SF=)$*)43SR5L7/FGMJ UM>,KVR7=SGK=_>(P
M .Y7U:1O;E8GKK[@_L;CO"J.J^!T7X"AU\16<^O%.)K:ID+Q3OVV*%S3$,5>
MO=45=#"H=R:=W[0PW.U"*$?JFCSJ- [327D<%5ZIN_*H\W.YX_*X8H0MKE]M
M L+S^J7.YVN\4;,2FZV:U!Q260B("JPA33"&2:X5R62&<[]Z6F?&F-HBM141
MU#+>M2Y7O\7G')1N"\2-  U,XI[8>/-JC_8QN>_<,*/R4X^>QQS2=ZE_L/5]
M]E..EZN-JN2SRA*4M,&T6I:,DM26IZ(2HI26D"<EAP71>8HY$0DK7,.N+XPQ
MM>_<2OEOH)83&$&!E=0]%OD2D/U?>21X!O[*SR$3$*Y]"2+WP.T(4(T4PAT&
MF5<X]Q4P>@*[+]TY6HCW%=&[P=[7+@WIK[OF[(]M#U5<RHSGI( 9)PE$'&EH
M:"^%I2@2BAFCK'#.+SEX\M3HK17.I]-L%Z?K/!:L_<#LU<H5U&NWBX!/M]U
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M]Y@VT)E1)K5K+FOYU%89N')$9$_^@M%^@P'4OF>X4!Q5I@(%<W7_(8) 2(Q
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MSVOQ=7_;-@&--V<X/Z6Y\J_SV9_+SZ]F9U_"]&*DT5LFLX%<ZI09DZ3:2S%
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M-F>ZP<3=^'. S1O(W"ZEO^+XN%9"%!E#T@Q\$C0WYZS!!UL ,_.<)45Y0X_
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M)TJ0TCFA1!9"]7*5[0%YAMZ].C:@]O!" V"ZM1UWJ<B(!9T"KTPJK#*=>F_
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M=W67)B$E2A9=44DI\*ZV2R;E:,AE#S*&XJ24WJA>5FZ>D&O@=@NM(;-++S8
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M)F($%;,"Y[(&'RPOJ2@4HI]S#[O)V>3^R3% V;4/&X#H]M8<9<^2<BP!][D
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M4%^/[C#?=4M^34\_(OWU75VN";!_Z=>&O;3M>_I%1[3L4=OXW0\&DFL9<T%
M+73MRRTA^"0!)>-)..FE[F4-I$^6\7L1Z6X<"L7(A#*!,*J2KS&:/PW3J\-S
MR3$9O>FE9^%3@C7,(+X+3C9PX77GCR;;(;P,B_%B5C[<>-8>P6K34PZ/1$_*
MUE&8>3\_#=,K7MA7L^EB-AGG<,49>_/E-_IL7"/N.\Y\PBAD;3&&@7"6K8&Z
MX &8L_0L"5UR/^Q974A_,*G80T*L?/C^E@_7MQY>XR+-QU_6Y+R7O2Y7K:8G
MXS3&Q0FY]^6D;G/:(I37F4%4F4Q;.5J<H320QAPW)AE4_70^ZU6K84/F\3%_
MC\VL&<@\E\"\UK*; 'W]M%X"]699FPK8Z#4+64K(3!I0T2%X[S(H'YB0+'"7
MQ \;L*\&V9TA=''Y\?LP*D*JVGX.@E54]YI@(.9DZWEAL@YCD=M>\LWMQ/L1
M0N@N*+P;0GMP8@-;+[_CGS<TFL^F]&FZM-IF_5*Q4J&WD*2)H+2B)!Q3I<!T
M@<G*8<1[&<B["CKL^?#AX=JK8QL [J]X&B:O9HNU.M\5R2B8,KI27\8 RGD)
MT1H-,FI3@M#.BEZ:ASPHT;#'QH>'8C>N:C)Q7-T@O^P"N5AS^5?NHA!G\]63
M%V&:?QVG2AS\XG2.EU;=(Z?<\T6'IYM=:-A1)KHN3%[-SB)!=?7R:X#RS!AR
M%< YPRN3F8"(JH B%'&AHE*IEY/[CPEU"-_)TW9_L<'NWX<68\XQ@PC%<AJF
MP46(*=;6I#%2;68,56E/8*X#,89-&CL#S$WNDV,ZY@>*>2>5>?!XD>_J=4/%
MOTW:'B,*!E<,%SR"9J4V,5(./&<(+)C 0V L]T-#TT<4O-YP2)\QGT_P?:D$
M[*?3VJC]728KC\L8\R6?ZIK)937T0AQ/+L^;+A;G9YA7SO@^ (,P(7I/8]XX
M20,_,W"J]I%4!95(#KWK)3_L6(^&0^LN*+S7^6- ;_] X?;F7[W&91A/CA=[
M-[U[J$#\I!V.$96U,U8;I<%QQ2C!8 Y"4!*$MKPV4M+H_?.-RNNWW#3URXL;
M7ZU&Y$B2FD)["X)3RJ.\"^"="1"%I3)/8.2ZY["[G: -Q]5=</1P7.W!7PVL
M![T=3\=+_'7\%>_V>"3E?@O_,9N_F@12^MMX,9+98,#$P49M0>FHP$E%7V*.
M)H:,4?2RAKF#C .?\>@5++/C>*YM4'Y7[/=PAJ]G9V$\'65O4 LRGC$Z@;+,
M0/!< E.LF&RY8;F7_H@[RCDL.'O#R_:X/-AY#6#SJM]H):1,GZ>SR>STXN/X
M]#,IAV<1YR,6>!:A5/D=N\R>HS$2$&4L7K"B2^X#BT_(U2SV#L?$O3:<W3EH
M0+PMYLO1J[H/A7.R\?*B6F<U-I,HZ*)T$&/=4M T2IT/!7*DLBPHFYC>AGR
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M[_P'38-$14\!%$,!3?D^,U;EU ]AVY.2M7%6Y"#_;X&I_9TQ='ET/HVSB^N
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MGY$&1$:;BM"F;+4LM%4'HDT"#,M1?Y0TI!/;#]T=%;^<S]/G<&/U]ZY*ZV+
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MN4A@61!&QIRUW^8XV[&BX5/Z; ?;_S;[PIVZ?\#P6).C.[7O71:5$;V/U_M
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MIVZ@BH3?2<S?5SU]=[Z)?)A_P_SY7GW$[4Z@F[=DYPJW4=#%H[@")9%!0,N
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M#7USW?;))+A05PW;K&,='T.^9=LBA"U4C8NK3H.^X?38%2C7U_]%-(4\0U5
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M08J<*/0JY#CEVN4<4T:T7'G5U_"W9GF4MK Z6?A=0.C3/&0R\G=. :*TWH0
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M2;A<7,@D7$CDJ64K:[B)&3Q&!59*D<AEDYXW>?_;B[IQ:T^:PVLPQ72 MM6
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MCD03DZWEZTPSEHVR8@]T;/OL<=]T6^#A9 GVY),0IB]$J44_6(?8L00JHX3
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M\EY__18F\SI\I';XWF=JS>]EY?<BJY2,YQKJ>PVHI"BTE*Z R26AB#$*KUJ
M;T_Z1IX./C@P'F8 &FBIRRS F]GT\R><?_T=X_*(T/_>?WYZO+^;FL&6%,?E
MMGC+<:5##. LDAH#G8SHK %)R$D"O>"JB:7?3LZI)N;^I]ZFK#0G_%OMP$2I
MZ*J7$2+CGJYLM%P4GW.;U3,[Z!E[]>_)2'AH-(:0>_=&8H#BU"<_;E@C<I;R
MU%U00F0L"TG^CJE%VYZ#E]("2I>#B2&DTJ1RKYU1N5V2O?;M<D16A#20ZG98
M)74=DLD">?Z&SDS468<F2;\MM/1I3 Y P#9C<HJ\.W!U[[.P2C$HU-:3B046
M:K3IZDLQ,@U)*!V%]I8]K&=N@9CQ<W<G:_=)M!PLZN[ \C9\O2YC"E+0_1@E
M!9#T@V)%@<]U@XXH4FJDD^6:]#GO(J@GX!RNZ"=Q<Z341\[<O6!_LWI:MYSF
M*R1EFDU*2GI&(A %N&9TGB**.@TB ;J4>)'9RX<-\EM3>#L^OB<8'*NWV;!"
M'!L'_&_J#@N27:<FN;,JT*G0IJX8]Y*<>T$^> Y)6A:X%<7N@X/M'S]N(FYX
M' P@Q+%Q(/XF[["@KEFP+C"E?28HJP@J,03OT4 ))!3K1#)![8.#[1\_[J"=
MX7$P@!#'Q\%=*.L;%NK3!BL>&*Y67V8+KI889H.:(%Y2=G(_'&S[^''GY[3
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MNIA\Q]=3BEUQPU@,VM$A*"#1NMJT4V?R2'(7"]IH6(S*[K/N_'"SM"^%XSY
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M9@ \9\A?5\#3W7.UTLJJA_/3ES#=O%?_G3YBN7@]75=M7)#U\!&Y@A3JK/;
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MPX;VKBK;B?G+^Y_\^<?[R$\*P4'M;&:Q#L-R+$(!ECR6Q(L-7'<1^^$O=(/
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M$-QF)9>WPA0(6F3R?8LB5S@18U3FQ)UB99(V:]-D9MV.@%%,D.I1M"^FC)_
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M'A%UL.)A^P?UATC*]'__K_\/4$L! A0#%     @ ^H9E41L9R?C#!P  0B$
M !H              ( !     &5X:&EB:70S,3$M<G5L93$S87@Q-&$N:'1M
M4$L! A0#%     @ ^H9E4:$]A3'*!P  L2   !H              ( !^P<
M &5X:&EB:70S,3(M<G5L93$S87@Q-&$N:'1M4$L! A0#%     @ ^H9E417/
M@$=P!   : \  !H              ( !_0\  &5X:&EB:70S,C$M<V5C=&EO
M;C$S-3 N:'1M4$L! A0#%     @ ^H9E4:?(B3EM!   HPX  !H
M     ( !I10  &5X:&EB:70S,C(M<V5C=&EO;C$S-3 N:'1M4$L! A0#%
M  @ ^H9E41/[U+P5A@0 99 ^ !               ( !2AD  &UR:RTR,#(P
M,#DS,"YH=&U02P$"% ,4    " #ZAF51("OK%'<6  #N^P  $
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I<FLM,C R,# Y,S!?<')E+GAM;%!+!08     "@ * *0"  ! ?P<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
